


WILEY-VCH

# Encyclopedia of Molecular Cell Biology and Molecular Medicine

Edited by Robert A. Meyers



Volume 16

Second Edition  
*Index*

**Encyclopedia of Molecular Cell Biology  
and Molecular Medicine**

*Edited by Robert A. Meyers*

**Volume 16  
Index**

# Encyclopedia of Molecular Cell Biology and Molecular Medicine

## Editorial Board

\*Werner Arber, Biozentrum, University of Basel, Switzerland

\*David Baltimore, California Institute of Technology, Pasadena, USA

\*Günter Blobel, The Rockefeller University, New York, USA

Martin Evans, Cardiff University, United Kingdom

\*Paul Greengard, The Rockefeller University, New York, USA

Avram Hershko, Technion, Israel Institute of Technology, Haifa, Israel

\*Robert Huber, Max Planck Institute of Biochemistry, Martinsried, Germany

\*Aaron Klug, MRC Laboratory of Molecular Biology Cambridge, United Kingdom

\*Stanley B. Prusiner, University of California, San Francisco, USA

\*Bengt Samuelsson, Karolinska Institutet, Stockholm, Sweden

\*Phillip A. Sharp, Massachusetts Institute of Technology, Cambridge, USA

Alexander Varshavsky, California Institute of Technology, Pasadena, USA

Akiyoshi Wada, RIKEN, Yokohama, Japan

Shigeyuki Yokoyama, RIKEN, Yokohama, Japan

\*Rolf M. Zinkernagel, University Hospital Zurich, Switzerland

\*Nobel Laureate

# Encyclopedia of Molecular Cell Biology and Molecular Medicine

*Edited by Robert A. Meyers*

Second Edition

**Volume 16**  
**Index**



WILEY-  
VCH

WILEY-VCH Verlag GmbH & Co. KGaA

**Editor:**

**Dr. Robert A. Meyers**  
President, Ramtech Limited  
3715 Gleneagles Drive  
Tarzana, CA 91356  
USA

This book was carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.: applied for**

**British Library Cataloguing-in-Publication**

**Data:** A catalogue record for this book is available from the British Library.

**Die Deutsche Bibliothek-CIP-Cataloguing-in-Publication Data.** A catalogue record for this publication is available from Die Deutsche Bibliothek.

©WILEY-VCH Verlag GmbH & Co. KGaA  
Weinheim, 2004

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademark, etc. used in this book, even when not specifically marked as such are not to be considered unprotected by law.

Printed in the Federal Republic of Germany.  
Printed on acid-free paper.

*Encyclopedia of Molecular Cell Biology  
and Molecular Medicine, 2nd Edition*  
Edited by Robert A. Meyers.

**Composition:** Laserwords Private Ltd,  
Chennai, India

**Printing:** Druckhaus Darmstadt GmbH,  
Darmstadt

**Bookbinding:** Buchbinderei Schaumann  
GmbH, Darmstadt

**ISBN:** 3-527-30542-4 (16 volume set),  
3-527-30543-2 (vol. 1), 3-527-30544-0 (vol. 2),  
3-527-30545-9 (vol. 3), 3-527-30546-7 (vol. 4),  
3-527-30547-5 (vol. 5), 3-527-30548-3 (vol. 6),  
3-527-30549-1 (vol. 7), 3-527-30550-5 (vol. 8),  
3-527-30551-3 (vol. 9), 3-527-30552-1 (vol. 10),  
3-527-30648-X (vol. 11), 3-527-30649-8 (vol. 12),  
3-527-30650-1 (vol. 13), 3-527-30651-X (vol. 14),  
3-527-30652-8 (vol. 15), 3-527-30653-6 (vol. 16)

## Preface

The *Encyclopedia of Molecular Cell Biology and Molecular Medicine*, which is the successor and second edition of the *Encyclopedia of Molecular Biology and Molecular Medicine* (VCH Publishers, Weinheim), covers the molecular and cellular basis of life at a university and professional researcher level. The first edition, published in 1996–97, was very successful and is being used in libraries around the world. This second edition will almost double the first edition in length and will comprise the most detailed treatment of both molecular cell biology and molecular medicine available today. The Board Members and I believe that there is a serious need for this publication, even in view of the vast amount of information available on the World Wide Web and in text books and monographs. We feel that there is no substitute for our tightly organized and integrated approach to selection of articles and authors and implementation of peer review standards for providing an authoritative single-source reference for undergraduate and graduate students, faculty, librarians, and researchers in industry and government.

Our purpose is to provide a comprehensive foundation for the expanding number of molecular biologists, cell biologists, pharmacologists, biophysicists, biotechnologists, biochemists, and physicians, as well as for those entering molecular cell biology and molecular medicine from majors or careers in physics, chemistry, mathematics, computer science, and engineering. For example, there is an unprecedented demand for physicists, chemists, and computer scientists who will work with biologists to define the genome, proteome, and interactome through experimental and computational biology.

The Board Members and I first divided the entire study of molecular cell biology and molecular medicine into primary topical categories and further defined each of these into subtopics. The following is a summary of the topics and subtopics:

- *Nucleic Acids*: amplification, disease genetics overview, DNA structure, evolution, general genetics, nucleic acid processes, oligonucleotides, RNA structure, RNA replication and transcription.
- *Structure Determination Technologies Applicable to Biomolecules*: chromatography, labeling, large structures, mapping, mass spectrometry, microscopy, magnetic resonance, sequencing, spectroscopy, X-ray diffraction.
- *Biochemistry*: carbohydrates, chirality, energetics, enzymes, biochemical genetics, inorganics, lipids, mechanisms, metabolism, neurology, vitamins.

- *Proteins, Peptides, and Amino Acids*: analysis, enzymes, folding, mechanisms, modeling, peptides, structural genomics (proteomics), structure, types.
- *Biomolecular Interactions*: cell properties, charge transfer, immunology, recognition, senses.
- *Cell Biology*: developmental cell biology, diseases, dynamics, fertilization, immunology, organelles and structures, senses, structural biology, techniques.
- *Molecular Cell Biology of Specific Organisms*: algae, amoeba, birds, fish, insects, mammals, microbes, nematodes, parasites, plants, viruses, yeasts.
- *Molecular Cell Biology of Specific Organs or Systems*: excretory, lymphatic, muscular, nervous, reproductive, skin.
- *Molecular Cell Biology of Specific Diseases*: cancer, circulatory, endocrinal, environmental stress, immune, infectious, neurological, radiational.
- *Pharmacology*: chemistry, disease therapy, gene therapy, general molecular medicine, synthesis, toxicology.
- *Biotechnology*: applications, diagnostics, gene-altered animals, bacteria and fungi, laboratory techniques, legal, materials, process engineering, nanotechnology, production of classes or specific molecules, sensors, vaccine production.

We then selected some 400 article titles and author or author teams to cover the above topics. Each article is designed as a self-contained treatment which begins with a keyword section including definitions, to assist the scientist or student who is unfamiliar with the specific subject area. The Encyclopedia includes more than 3000 key words, each defined within the context of the particular scientific field covered by the article. In addition to these definitions, the glossary of basic terms found at the back of each volume, defines the most commonly used terms in molecular cell biology. These definitions, along with the reference materials (the genetic code, the common amino acids, and the structures of the deoxyribonucleotides) printed at the back of each volume, should allow most readers to understand articles in the Encyclopedia without referring to a dictionary, textbook, or other reference work. There is, of course, a detailed subject index in Volume 16 as well as a cumulative table of contents and list of authors, as well as a list of scientists who assisted in the development of this Encyclopedia.

Each article begins with a concise definition of the subject and its importance, followed by the body of the article and extensive references for further reading. The references are divided into secondary references (books and review articles) and primary research papers. Each subject is presented on a first-principle basis, including detailed figures, tables and drawings. Because of the self-contained nature of each article, some articles on related topics overlap. Extensive cross-referencing is provided to help the reader expand his or her range of inquiry.

The articles contained in the Encyclopedia include core articles, which summarize broad areas, directing the reader to satellite articles that present additional detail and depth for each subject. The core article Brain Development is a typical example. This 45-page article spans neural induction, early patterning, differentiation, and wiring at a molecular through to cellular and tissue level. It is directly supported, and cross-referenced, by a number of molecular neurobiology satellite articles, for example, Behavior Genes, and further supported by other core presentations, for example,

Developmental Cell Biology; Genetics, Molecular Basis of, and their satellite articles. Another example is the core article on Genetic Variation and Molecular Evolution by Werner Arber. It is supported by a number of satellite articles supporting the evolutionary relatedness of genetic information, for example, Genetic Analysis of Populations.

Approximately 250 article titles from the first edition are retained, but rewritten, half by new authors and half by returning authors. Approximately 80 articles on cell biology and 70 molecular biology articles have been added covering areas that have become prominent since preparation of the first edition. Thus, we have compiled a totally updated single source treatment of the molecular and cellular basis of life.


Finally, I wish to thank the following Wiley-VCH staff for their outstanding support of this project: Andreas Sendtko, who provided project and personnel supervision from the earliest phases, and Prisca-Maryla Henheik, who served as the managing editor.

November 2003

**Robert A. Meyers**  
Editor-in-Chief




## Editor-in-Chief



**Robert A. Meyers**

Dr. Meyers earned his Ph.D. in organic chemistry from the University of California Los Angeles, was a post-doctoral fellow at California Institute of Technology and manager of chemical processes for TRW Inc. He has published in *Science*, written or edited 12 scientific books and his research has been reviewed in the *New York Times* and the *Wall Street Journal*. He is one of the most prolific science editors in the world having originated, organized and served as Editor-in-Chief of three editions of the *Encyclopedia of Physical Science and Technology*, the *Encyclopedia of Analytical Chemistry* and two editions of the present *Encyclopedia of Molecular Cell Biology and Molecular Medicine*.

## Editorial Board



**Werner Arber**

Biozentrum, University of Basel, Switzerland


*Nobel Prize in Physiology/Medicine for the discovery of restriction enzymes and their application to problems of molecular genetics*



**David Baltimore**

California Institute of Technology, Pasadena, USA


*Nobel Prize in Physiology/Medicine for the discoveries concerning the interaction between tumor viruses and the genetic material of the cell*



**Günter Blobel**

The Rockefeller University, New York, USA

*Nobel Prize in Physiology/Medicine for the discovery that proteins have intrinsic signals that govern their transport and localization in the cell*



**Martin Evans**

Cardiff University, United Kingdom

*Lasker Award for the development of a powerful technology for manipulating the mouse genome, which allows the creation of animal models of human disease*



**Paul Greengard**

The Rockefeller University, New York, USA

*Nobel Prize in Physiology/Medicine for the discoveries concerning signal transduction in the nervous system*



**Avram Hershko**

Technion – Israel Institute of Technology, Haifa, Israel

*Lasker Award for the discovery and the recognition of the significance of the ubiquitin system of regulated protein degradation*



**Robert Huber**

Max Planck Institute of Biochemistry, Martinsried, Germany

*Nobel Prize in Chemistry for the determination of the three-dimensional structure of a photosynthetic reaction centre*



**Aaron Klug**

MRC Laboratory of Molecular Biology Cambridge, United Kingdom

*Nobel Prize in Chemistry for the development of crystallographic electron microscopy and his structural elucidation of biologically important nucleic acid-protein complexes*



**Stanley B. Prusiner**

University of California, San Francisco, USA


*Nobel Prize in Physiology/Medicine for the discovery of Prions – a new biological principle of infection*



**Bengt Samuelsson**

Karolinska Institute, Stockholm, Sweden

*Nobel Prize in Physiology/Medicine for the discoveries concerning prostaglandins and related biologically active substances*



**Phillip A. Sharp**

Massachusetts Institute of Technology, Cambridge, USA  
*Nobel Prize in Physiology/Medicine for the discoveries of split genes*



**Alexander Varshavsky**

California Institute of Technology, Pasadena, USA  
*Lasker Award for the discovery and the recognition of the significance of the ubiquitin system of regulated protein degradation*



**Akiyoshi Wada**

RIKEN Yokohama Institute, Japan  
*Director of the RIKEN Genomic Science Center*



**Shigeyuki Yokoyama**

RIKEN Yokohama Institute, Japan  
*Head of the RIKEN Structural Genomics Initiative*



**Rolf M. Zinkernagel**

University Hospital Zurich, Switzerland  
*Nobel Prize in Physiology/Medicine for the discoveries concerning the specificity of the cell mediated immune defence*

## Contents

<b>Preface</b>	<i>v</i>
<b>Editor-in-Chief</b>	<i>ix</i>
<b>Editorial Board</b>	<i>xi</i>
<b>Cumulative List of Articles</b>	<i>1</i>
<b>Cumulative List of Contributors</b>	<i>33</i>
<b>Acknowledgements, Cumulative List of Reviewers</b>	<i>75</i>
<b>Cumulative Subject Index Volume 1 to Volume 15</b>	<i>83</i>
<b>Glossary of Basic Terms</b>	<i>299</i>
<b>The Twenty Amino Acids that are Combined to Form Proteins in Living Things</b>	<i>307</i>
<b>The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations</b>	<i>311</i>
<b>Complementary Strands of DNA with Base Pairing</b>	<i>313</i>

## Cumulative List of Articles

### **Volume 1**

**Preface** *v*

**Editor-in-Chief** *ix*

**Editorial Board** *xi*

**Contents** *xv*

**List of Contributors** *xvii*

**Color Plates** *xxi*

**Adipocytes** 1

*Todd Leff, James G. Granneman*

**Aggregation, Protein** 23

*Jeannine M. Yon*

**Aging and Sex, DNA Repair in** 53

*Carol Bernstein, Harris Bernstein*

**AIDS/HIV, Molecular and Cell Biology** 99

*Andrew M. L. Lever*

**Alternatively Spliced Genes** 125

*Jane Y. Wu, Liya Yuan, Necat Havlioglu*

**Alzheimer's Disease** 179

*Jun Wang, Silva Hecimovic, Alison Goate*

*Encyclopedia of Molecular Cell Biology and Molecular Medicine, 2nd Edition. Index*

Edited by Robert A. Meyers.

Copyright © 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

ISBN: 3-527-30653-6

**Animal Biotechnology and Modeling** 209

*Carl A. Pinkert, Michael H. Irwin, Robert L. Howell*

**Annexins** 241

*Carl E. Creutz*

**Anthology of Human Repetitive DNA** 251

*Vladimir V. Kapitonov, Adam Pavlicek, Jerzy Jurka*

**Anthrax (*Bacillus anthracis*), Molecular Biology of** 307

*Kathryn B. Garber*

**Antibody Molecules, Genetic Engineering of** 329

*Manuel L. Penichet, Sherie L. Morrison*

**Antigen Presenting Cells (APCs)** 353

*Harald Kropshofer, Anne B. Vogt*

**Antisense Oligonucleotides as Potential Drugs** 403

*Joachim W. Engels, Fritz Eckstein*

**Antitumor Agents: Taxol and Taxanes – Production by Yew Cell Culture** 415

*Arthur G. Fett-Neto, Hideki Aoyagi, Hideo Tanaka, Frank DiCosmo*

**Antitumor Steroids** 439

*Guy Leclercq*

**Autoantibodies and Autoimmunity** 459

*Kenneth Michael Pollard*

**Autoimmunity in Scleroderma** 481

*Yoshinao Muro, Kenji Sugimoto*

**Bacterial Cell Culture Methods** 503

*Andrew S. Ball*

**Bacterial Growth and Division** 525

*Stephen Cooper*

**Bacterial Pathogenesis, Molecular Basis of** 553

*Melanie Filiatrault, Luciano Passador*

**Bacteriorhodopsin, Molecular Biology of** 575

*Janos K. Lanyi*

**Behavior Genes** 585*Tanya Button, Peter McGuffin***Biogenesis, Structure and Function of Lysosomes** 617*James Fred Dice***Bioinorganic Chemistry** 635*R. Bruce Martin***Biological Regulation by Protein Phosphorylation** 659*Clay W. Scott, Ratan V. Bhat, Gaochao Tian***Glossary of Basic Terms** 675**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 683**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations**  
687**Complementary Strands of DNA with Base Pairing** 689**Volume 2****Preface** *v***Editor-in-Chief** *ix***Editorial Board** *xi***Contents** *xv***List of Contributors** *xvii***Color Plates** *xxi***Bioorganic Chemistry** 1*Simon H. Friedman***Bioprocess Engineering** 35*Kimberly L. Ogden***Biotransformations of Drugs and Chemicals** 51*Paul R. Ortiz de Montellano*



- Body Expression Map of Human Genome** 75  
*Shinichi Morishita, Asao Fujiyama*
- Brain Development** 87  
*Takayoshi Inoue*
- Calcium Biochemistry** 133  
*Joachim Krebs*
- Cancer Chemotherapy, Theoretical Foundations of** 171  
*Nicholas B. La Thangue*
- Cancer of the Prostate: Molecular Genetics** 191  
*Rajvir Dahiya*
- Cancer Stem Cells** 221  
*Michael F. Clarke, Andrew T. Hass*
- Carbohydrate Analysis** 243  
*Martin F. Chaplin*
- Carbohydrate Antigens** 277  
*Denong Wang*
- Cell Growth in Microgravity** 303  
*Alamelu Sundaresan, Diana Risin, Neal R. Pellis*
- Cell Junctions, Structure, Function, and Regulation** 323  
*Susan E. LaFlamme, Peter A. Vincent*
- Cell Nucleus Biogenesis, Structure and Function** 377  
*Dean A. Jackson*
- Cell Signaling During Primitive Hematopoiesis** 429  
*Devorah C. Goldman, Jan L. Christian*
- Cell-free Translation Systems** 451  
*Takuya Ueda, Akio Inoue, Yoshihiro Shimizu*
- Cellular Interactions** 463  
*Brian A. Koeneman, David G. Capco*
- Chaperones, Molecular** 487  
*Peter Lund*

**Chemiluminescence and Bioluminescence, Analysis by** 521  
*Larry J. Kricka*

**Chicken Genome** 535  
*Cheryll Tickle, David W. Burt*

**Chimpanzee Genome** 551  
*Ingo Ebersberger*

**Chirality in Biology** 579  
*Ronald Bentley*

**Chlamydomonas** 619  
*Jean-David Rochaix*

**Glossary of Basic Terms** 647

**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 655

**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations**  
659

**Complementary Strands of DNA with Base Pairing** 661

### **Volume 3**

**Preface** *v*

**Editor-in-Chief** *ix*

**Editorial Board** *xi*

**Contents** *xv*

**List of Contributors** *xvii*

**Color Plates** *xxi*

**Chromosome Organization within the Nucleus** 1  
*Wallace F. Marshall*

**Chromosome, Microdissection and Microcloning** 17  
*Nabil G. Hagag*

**Circular Dichroism in Protein Analysis** 55

*Zhijing Dang, Jonathan D. Hirst*

**Combinatorial Phage Antibody Libraries** 75

*Michael B. Zwick, R. Anthony Williamson, Dennis R. Burton*

**Cytochrome P450** 101

*Michael R. Waterman, Irina A. Pikuleva*

**Cytokines: Interleukins** 115

*Anthony Meager*

**Cytomegalovirus and Varicella–zoster Virus Vaccines** 153

*Lawrence A. Hunt*

**Denaturation of DNA** 187

*R. D. Blake*

**Dendritic Cells** 213

*Manfred B. Lutz, Thomas Berger, Erwin Schultz, Alexander Steinkasserer*

**Design and Application of Synthetic Peptides** 239

*Gregory A. Grant*

**Developmental Cell Biology** 261

*Frank John Dye*

**Diabetes Insipidus, Molecular Biology of** 301

*Alexander Oksche, Peter Pohl, Gerd Krause, Walter Rosenthal*

**Dictyostelium Discoideum: Cellular Slime Mold** 325

*Annette Müller-Taubenberger, Markus Maniak*

**DNA Damage Induced by Ultraviolet Radiation** 351

*David L. Mitchell*

**DNA Libraries** 385

*Chengcang Wu, Zhanyou Xu, Hong-Bin Zhang*

**DNA Repair in Yeast** 427

*Errol C. Friedberg, Paula L. Fischhaber*

**DNA Replication and Transcription** 449

*Yusaku Nakabeppu, Hisaji Maki, Mutsuo Sekiguchi*

**DNA Typing Analysis** 477*Chantal J. Fréreau, Rémy A. Aubin, Bruce Budowle, Ron M. Fournay***DNA, Repressor–Operator Recognition** 507*Peter G. Stockley, Simon E.V. Phillips***DNA–Protein Interactions** 531*Sylvie Rimsky, Malcolm Buckle***Down Syndrome, Molecular Genetics of** 561*Charles J. Epstein****Drosophila* Genome** 573*Robert D.C. Saunders***Drug Bioavailability, Distribution and Clearance Prediction** 595*William Bains****E. Coli* Genome** 639*Hirotsada Mori, Takashi Horiuchi***E-Cell: Computer Simulation of the Cell** 649*Pawan Dhar, Kouichi Takahashi, Yoichi Nakayama, Masaru Tomita***Glossary of Basic Terms** 667**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 675**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations**  
679**Complementary Strands of DNA with Base Pairing** 681**Volume 4****Preface** *v***Editor-in-Chief** *ix***Editorial Board** *xi***Contents** *xv***List of Contributors** *xvii*

**Color Plates** *xxi*

**Electric and Magnetic Field Reception** 1

*Eberhard Neumann*

**Electron Microscopy in Cell Biology** 21

*Gareth Griffiths*

**Electron Microscopy of Biomolecules** 89

*Claus-Thomas Bock, Susanne Franz, Hanswalter Zentgraf, John Sommerville*

**Electron Spin Resonance of Biomolecules** 115

*Betty J. Gaffney*

**Electroporation and Electrofusion** 135

*Donald C. Chang*

**Endocrinology, Molecular** 159

*Franklyn F. Bolander*

**Endocytosis** 181

*Hadiya A. Watson, Mark Von Zastrow, Beverly Wendland*

**Epidemiology, Molecular** 225

*Paul A. Schulte, Frederica P. Perera, Nathaniel Rothman*

**Epigenetic Mechanisms in Tumorigenesis** 237

*Maureen K. Bunger, Trevor K. Archer*

**Epithelial Morphogenesis** 277

*Ronit Wilk, Amanda T. Pickup, Howard D. Lipshitz*

**Exocytosis** 305

*Robert D. Burgoyne, Alan Morgan*

**Exploiting Model Organisms for Disease Intervention** 329

*Caretha L. Creasy, George P. Livi, Christine Debouck*

**Expression Systems for DNA Processes** 355

*Ka-Yiu San, George N. Bennett*

**Female Reproduction System, Molecular Biology of** 379

*Guck T. Ooi, Jock K. Findlay*

**Flow Cytometry** 415

*Michael G. Ormerod*

- Fluorescence** 439  
*David M. Jameson*
- Fluorescence Correlation Spectroscopy (FCS)** 461  
*Aladdin Pramanik, Jerker Widengren*
- Food Proteins: Interactions and Functionality** 503  
*Charles Onwulata, Phoebe X. Qi*
- Footprinting Methods to Examine the Structure and Dynamics of Nucleic Acids** 521  
*Keiji Takamoto, Mark R. Chance*
- Footprinting Methods to Examine the Structure and Dynamics of Proteins** 549  
*Jing-Qu Guan, Mark R. Chance*
- Fragile Sites** 569  
*Grant R. Sutherland, Elizabeth Baker*
- Fragile X-linked Mental Retardation** 585  
*Ilse Gantois, R. Frank Kooy, Ben A. Oostra*
- Free Radicals in Biochemistry and Medicine** 633  
*Barry Halliwell*
- FTIR of Biomolecules** 651  
*Barbara Stuart*
- Glossary of Basic Terms** 685
- The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 693
- The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 697
- Complementary Strands of DNA with Base Pairing** 699

## **Volume 5**

- Preface** *v*
- Editor-in-Chief** *ix*
- Editorial Board** *xi*
- Contents** *xv*

**List of Contributors**    *xvii*

**Color Plates**    *xxv*

**Fungal Biotechnology**    1

*Brian McNeil, Linda M. Harvey*

**Gaucher Disease, Molecular Biology of**    23

*Ernest Beutler*

**Gel Electrophoresis, 2D-difference**    33

*John F. Timms*

**Gene Distribution in the Human Genome**    53

*Yujing Zeng, Javier Garcia-Frias, Adam G. Marsh*

**Gene Expression and Replication of Picornaviruses**    93

*Christopher T. Cornell, Bert L. Semler*

**Gene Mapping and Chromosome Evolution by Fluorescence–Activated Chromosome  
Sorting**    119

*Malcolm A. Ferguson-Smith*

**Gene Mapping by Fluorescence In Situ Hybridization**    137

*Barbara G. Beatty, Henry H.Q. Heng*

**Gene Targeting**    173

*Michael M. Seidman, John H. Wilson*

**Gene Therapy and Cardiovascular Diseases**    211

*Michael E. Rosenfeld, Alan D. Attie*

**Genetic Analysis of Populations**    243

*Rus A. Hoelzel*

**Genetic Engineering of Hemoglobin**    265

*Jeremy Tame*

**Genetic Engineering of Vaccines**    293

*Tilahun D. Yilma, Leslie A. Jones, Paulo H. Verardi*

**Genetic Intelligence, Evolution of**    313

*David S. Thaler, Bradley T. Messmer*

**Genetic Variation and Molecular Evolution**    331

*Werner Arber*

- Genetics and Molecular Biology of Lung Cancer** 353  
*Jack A. Roth*
- Genetics, Molecular Basis of** 369  
*D. Peter Snustad*
- Genome Scanning Method; Restriction Landmark Genomic Scanning (RLGS)** 413  
*Hisato Okuizumi, Tomoki Matsuyama, Yoshihide Hayashizaki*
- Genomic DNA Libraries, Construction and Applications** 441  
*Eugene R. Zabarovsky*
- Genomic Imprinting, Molecular Genetics of** 469  
*Robert Feil, Yuji Goto, David Umlauf*
- Genomic Responses to Oxidative Stress** 489  
*John G. Scandalios*
- Genomic Sequencing (Core Article)** 513  
*Todd Charles Wood, Jeffrey P. Tomkins*
- Glycobiology** 537  
*Akira Kobata*
- Glycoproteins: Roles in Cellular Homeostasis and Disease** 569  
*Michael William King*
- Gonad Differentiation Genetics** 607  
*Stephen S. Wachtel*
- Growth Factors** 637  
*Antony W. Burgess*
- Glossary of Basic Terms** 657
- The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 665
- The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 669
- Complementary Strands of DNA with Base Pairing** 671



## **Volume 6**

**Preface** v

**Editor-in-Chief** ix

**Editorial Board** xi

**List of Contributors** xix

**Color Plates** xxiii

**Growth Factors and Oncogenes in Gastrointestinal Cancers** 1

*Eiichi Tahara*

**Heme Enzymes** 33

*Thomas L. Poulos*

**Hemoglobin** 67

*Gino Amiconi, Maurizio Brunori*

**Hemophilia, Molecular Genetics of** 109

*Francesco Giannelli, Peter M. Green*

**Heterochromatin and Euchromatin – Organization, Packaging, and Gene Regulation** 137

*Boris A. Leibovitch, Sarah C. R. Elgin*

**HIV Therapeutics, Biochemistry of** 155

*Raveendra Dayam, Nouri Neamati*

**Homeodomain Proteins** 179

*Thomas R. Bürglin*

**Horizontal Gene Transfer** 223

*Jack A. Heinemann, Ralph A. Bungard*

**HPLC of Peptides and Proteins** 245

*Tzong-Hsien Lee, Marie-Isabel Aguilar*

**Human and Veterinary Classical Vaccines against Bacterial Diseases** 297

*Thomas Ebensen, Claudia Link, Carlos A. Guzmán*

**Human Genetic Variation and Disease** 323

*Lynn B. Jorde*

**Immune Defence, Cell Mediated** 339*Martin F. Bachmann, Thomas M. Kundig***Immunoassays** 359*James P. Gosling***Immunologic Memory** 383*Alexander Ploss, Eric G. Pamer***Immunology** 405*Cindy Takeuchi, Paul Wentworth***Immunology of Cancer** 429*Peter R. Holman, Edward D. Ball***Immuno-PCR** 447*Takeshi Sano, Charles R. Cantor***Immunosuppressive Factors in Cancer** 465*Jeremy E. Moss, Christine N. Metz, Richard Bucala***Immunotoxins and Recombinant Immunotoxins in Cancer Therapy** 497*Yoram Reiter, Avital Lev****In vitro* Fertilization** 531*Carol A. Brenner, Hans Michael Kubisch, Barry D. Bavister***Infectious Disease Testing by LCR** 553*Max A. Chernesky, Ron L. Marshall, Astrid K. Petrich***Informatics (Computational Biology)** 567*Thomas Lengauer***Glossary of Basic Terms** 627**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 635**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 639**Complementary Strands of DNA with Base Pairing** 641

## Volume 7

**Preface** v

**Editor-in-Chief** ix

**Editorial Board** xi

**List of Contributors** xvii

**Color Plates** xxi

**Innate Immunity** 1

*Osamu Takeuchi, Shizuo Akira*

**Insulin Resistance, Diabetes and its Complications** 23

*Dominic S. Ng*

**Intracellular Fatty Acid Binding Proteins and Fatty Acid Transport** 73

*Judith Storch, Lindsay McDermott*

**Intracellular Fatty Acid Binding Proteins in Metabolic Regulation** 93

*John M. Stewart*

**Intracellular Signaling in Cancer** 113

*Chittam U. Thakore, Brian D. Lehmann, James A. McCubrey, David M. Terrian*

**Ionizing Radiation Damage to DNA** 149

*Clemens von Sonntag*

**Labeling, Biophysical** 157

*Gertz I. Likhtenshtein*

**Ligase-mediated Gene Detection** 179

*Johan Stenberg, Mats Nilsson, Ulf Landegren*

**Lipid and Lipoprotein Metabolism** 195

*Clive R. Pullinger, John P. Kane*

**Lipids, Microbial** 247

*Colin Ratledge*

**Lipoprotein Analysis** 277

*Alan T. Remaley, G. Russell Warnick*

**Liposome Gene Transfection** 297

*Nancy Smyth Templeton*

**Liver Cancer, Molecular Biology of** 323

*Mehmet Ozturk, Rengul Cetin-Atalay*

**Livestock Genomes (Bovine Genome)** 335

*John Lewis Williams*

**Living Organism (Animal) Patents** 367

*William Lesser*

**Macromolecules, X-Ray Diffraction of Biological** 391

*Albrecht Messerschmidt, Robert Huber*

**Malaria Mosquito Genome** 469

*Robert A. Holt, Frank H. Collins*

**Male Reproductive System: Testis Development and Spermatogenesis** 497

*Kate A. L. Loveland, David M. de Kretser*

**Mammalian Cell Culture Methods** 535

*Dieter F. Hülser*

**Mass Spectrometry of Proteins (Proteomics)** 557

*Hiroyuki Matsumoto, Sadamu Kurono, Masaomi Matsumoto, Naoka Komori*

**Mass Spectrometry, High Speed DNA Fragment Sizing** 587

*Chung-Hsuan Chen*

**Glossary of Basic Terms** 621

**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 629

**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations**  
633

**Complementary Strands of DNA with Base Pairing** 635

## **Volume 8**

**Preface** v

**Editor-in-Chief** ix

**Editorial Board** xi

**List of Contributors** xix

**Color Plates** xxiii

**Mass Spectrometry-based Methods of Proteome Analysis** 1

*Boris L. Zybilov, Michael P. Washburn*

**Matrix, Extracellular and Interstitial** 45

*Abebe Akalu, Peter C. Brooks*

**Medicinal Chemistry** 81

*David J. Triggle*

**Membrane Traffic: Vesicle Budding and Fusion** 119

*Michael J. Clague, Sylvie Urbé*

**Membrane Transport** 141

*Caroline Engvall, Per Lundahl*

**Metabolic Basis of Cellular Energy** 163

*Meredith F. Ross, Michael P. Murphy*

**Metabonomics and Metabolomics** 187

*David J. Grainger, Jeremy K. Nicholson*

**Metalloenzymes** 209

*Walther R. Ellis*

**Methanogens and the Archaeobacteria, Molecular Biology of** 237

*Madeline E. Rasche, James G. Ferry*

**Microarray-Based Technology: Basic Principles, Advantages and Limitations** 263

*Rumiana Bakalova, Ashraf Ewis, Yoshinobu Baba*

**Microbial Development** 289

*Paul Robert Fisher*

**Micronutrients, Trace Elements** 343

*Robert J. Cousins*

**Mitochondrial Porins, Eukaryotic** 357

*Roland Benz*

**Mobile Structures: Cilia and Flagella** 387  
*Koji Yonekura, Keiichi Namba*

**Molecular Display Technologies** 409  
*Ece Karatan, Zhaozhang Han, Brian Kay*

**Molecular Mediators: Cytokines** 431  
*Jean-Marc Cavaillon*

**Molecular Motors in Plant Cells** 461  
*Anireooy S. N. Reddy*

**Molecular Neurobiology, Single-Cell** 495  
*Jennifer Spaethling, Emily Rozak, James Eberwine*

**Molecular Systematics and Evolution** 515  
*Jeffrey H. Schwartz*

**Motor Neuron Diseases: Cellular and Animal Models** 541  
*Georg Haase*

**Motor Neuron Diseases: Molecular Mechanism, Pathophysiology, and Treatments** 559  
*Michael Sendtner*

**Motor Proteins** 575  
*Charles L. Asbury, Steven M. Block*

**Mucosal Vaccination** 601  
*W. Olszewska, Peter J. M. Openshaw*

**Mucoviscidosis (Cystic Fibrosis), Molecular Cell Biology of** 623  
*Gerd Döring, Felix Ratjen*

**Glossary of Basic Terms** 641

**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 649

**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 653

**Complementary Strands of DNA with Base Pairing** 655

## Volume 9

**Preface** v

**Editor-in-Chief** ix

**Editorial Board** xi

**List of Contributors** xix

**Color Plates** xxiii

**Mutagenesis, Malignancy and Genome Instability** 1

*Garth R. Anderson, Daniel L. Stoler, Jeremy D. Bartos*

**Nanobiotechnology** 19

*Christof M. Niemeyer*

**Nematode (*C. elegans*), Molecular Biology of** 53

*Andrew D. Chisholm*

**Nematodes, Neurobiology and Development of** 69

*Darren R. Brooks, Ian A. Hope, R. Elwyn Isaac*

**Neoplastic Disease Diagnosis, DNA in** 91

*Mukesh Verma, Jacob Kagan, Sudhir Srivastava*

**Neural Tube Defects, Molecular Biology of** 119

*Andrew J. Copp*

**Neuron Chemistry** 139

*Bonnie L. Firestein*

**Neuropeptides, Invertebrate** 167

*Edward P. Masler*

**Noncoding Tandemly Repeated DNA Sequences** 183

*Wolfgang Stephan*

**Nuclear Transfer for Cloning Animals** 203

*Andras Dinnyes, X. Cindy Tian, Jie Xu, Björn Oback*

**Nucleic Acid and Protein Sequence Analysis and Bioinformatics** 249

*Pietro Lió, Martin John Bishop*

- Nucleic Acid and Protein Single Molecule Detection and Characterization** 269  
*Karl Otto Greulich*
- Nucleic Acid Chromatography** 295  
*Douglas T. Gjerde, Christopher P. Hanna, David Hornby, Guenther Bonn*
- Nucleic Acid Hybrids, Formation and Structure of** 333  
*James G. Wetmur*
- Nucleic Acid Packaging of DNA Viruses** 351  
*Philip Serwer*
- Nucleic Acid Packaging of RNA Viruses** 363  
*Markus Jaakko Pirttimaa, Dennis Henry Bamford*
- Nucleic Acids (DNA) Damage and Repair** 379  
*Vilhelm A. Bohr*
- Nucleic Acids (DNA) Sequencing, Transcriptional** 395  
*Kazuhiro Shibata, Masaki Izawa, Yoshihide Hayashizaki*
- Oligonucleotides** 413  
*Olaf Heidenreich, Georg Sczakiel*
- Oncogenes** 435  
*Zhong-Zong Pan, Andrew K. Godwin*
- Oncology, Molecular** 497  
*Miguel H. Bronchud*
- Optimization of Proteins for Molecular and Biomolecular Electronic Devices** 549  
*Kevin J. Wise, Jason R. Hillebrecht, Jeremy F. Kosciolowski, Jeffrey A. Stuart, Robert R. Birge*
- Organic Cofactors as Coenzymes** 571  
*Donald B. McCormick*
- Glossary of Basic Terms** 589
- The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 597
- The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 601
- Complementary Strands of DNA with Base Pairing** 603



## **Volume 10**

**Preface** *v*

**Editor-in-Chief** *ix*

**Editorial Board** *xi*

**List of Contributors** *xvii*

**Color Plates** *xxi*

**Origins of Life, Molecular Basis of** *1*

*James P. Ferris*

**Pain Transduction: Gating and Modulation of Ion Channels** *29*

*Peter A. McNaughton*

**Paleontology, Molecular** *53*

*Rob DeSalle, Mary G. Egan*

**Parthenogenetic Stem Cells** *71*

*Jason D. Hipp, Josyf C. Mychaleckyj, Jose B. Cibelli, J. David Wininger, Kathleen A. Grant, Kent E. Vrana*

**Pathogens: Innate Immune Responses** *85*

*Stefan Ehlers, Silvia Bulfone-Paus*

**Pathophysiology of Stroke** *115*

*Andreas Meisel, Konstantin Prass, Tilo Wolf, Ulrich Dirnagl*

**Peptide and Non-Peptide Combinatorial Libraries** *147*

*Ruiwu Liu, Kit S. Lam*

**Phagocytosis** *177*

*Rebecca M. Henry, Joel A. Swanson*

**Pharmacogenomics and Drug Design** *197*

*Philip Dean, Paul Gane, Edward Zanders*

**Pharmacokinetics and Pharmacodynamics of Biotech Drugs** *211*

*Bernd Meibohm, Hartmut Derendorf*

**Pharmacology and Emerging Clinical Application of RNA** *241*

*Sailen Barik, Vira Bitko*

**Phospholipids** 277*Dennis E. Vance***Plant Gene Expression, Regulation of** 307*Pravendra Nath, Vidhu A. Sane, Aniruddha P. Sane, Prabodh K. Trivedi***Plant Pathology, Molecular** 359*Matt Dickinson***Plant-based Expression of Biopharmaceuticals** 385*Jörg Knäblein***Plasmids** 411*Dhruba K. Chattoraj***Pragmatic Computational Biology: Sequence Analysis and Biological Systems Description** 447*Andrzej K. Konopka***Preimplantation Mammalian Development, Regulation of Gene Expression in** 483*Melvin L. DePamphilis***Preparedness for Bioterrorism** 507*Nancy Khardori***Principles and Applications of Embryogenomics** 529*Vincent Vanburen, Minoru S. H. Ko***Prions** 557*Stanley B. Prusiner***Programmed Cell Death** 617*David L. Vaux, Andreas Strasser***Prokaryotic and Eukaryotic Cells in Biotech Production** 639*Irmgard Merfort, Stefan Pelzer, Dirk Hoffmeister, Andreas Bechthold***Glossary of Basic Terms** 667**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 675**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 679**Complementary Strands of DNA with Base Pairing** 681

## Volume 11

**Preface** v

**Editor-in-Chief** ix

**Editorial Board** xi

**List of Contributors** xix

**Color Plates** xxiii

**Proteasomes** 1  
*Martin Rechsteiner*

**Protein and Nucleic Acid Enzymes** 27  
*Daniel L. Purich*

**Protein Expression by Expansion of the Genetic Code** 45  
*Jason W. Chin, Thomas J. Magliery*

**Protein Mediated Membrane Fusion** 69  
*Reinhard Jahn*

**Protein Microarrays** 101  
*Jens R. Sydor, David S. Wilson, Steffen Nock*

**Protein Modeling** 133  
*Marian R. Zlomislic, D. Peter Tieleman*

**Protein NMR Spectroscopy** 159  
*Thomas Szyperski*

**Protein Purification** 181  
*Richard R. Burgess*

**Protein Repertoire, Evolution of** 199  
*Christine Vogel, Rajkumar Sasidharan, Emma E. Hill*

**Protein Splicing** 241  
*Kenneth V. Mills*

**Protein Structure Analysis: High-throughput Approaches** 267  
*Andrew P. Turnbull, Udo Heinemann*

- Protein Translocation Across Membranes** 287  
*Carla M. Koehler, David K. Hwang*
- Proteomics** 309  
*Paul Cutler, Israel S. Gloger, Christine Debouck*
- Proton Translocating ATPases** 333  
*Masamitsu Futai, Ge-Hong Sun-Wada, Yoh Wada*
- Pufferfish Genomes: *Takifugu* and *Tetraodon*** 361  
*Melody S. Clark, Hugues Roest Crollius*
- Quantitative Analysis of Biochemical Data** 381  
*Albert Jeltsch, Jim Hoggett, Claus Urbanke*
- Radioisotopes in Molecular Biology** 411  
*Robert James Slater*
- Rat Genome (*Rattus norvegicus*)** 433  
*Kim C. Worley, Preethi Gunaratne*
- Real-Time Quantitative PCR: Theory and Practice** 481  
*Gregory L. Shipley*
- RecA Superfamily Proteins** 525  
*Dharia A. McGrew, Kendall L. Knight*
- Receptor Biochemistry** 551  
*Tatsuya Haga, Kimihiko Kameyama*
- Receptor Targets in Drug Discovery** 593  
*Michael Williams, Christopher Mehlin, Rita Raddatz, David J. Triggle*
- Receptor, Transporter and Ion Channel Diseases** 637  
*J. Jay Gargus*
- Glossary of Basic Terms** 713
- The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 721
- The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 725
- Complementary Strands of DNA with Base Pairing** 727

## Volume 12

**Preface** *v*

**Editor-in-Chief** *ix*

**Editorial Board** *xi*

**List of Contributors** *xix*

**Color Plates** *xxiii*

**Recombination and Genome Rearrangements** 1

*Hannah L. Klein*

**Regulation of Stem Cell** 23

*Anil Kumar*

**Regulation of Stem Cell Populations** 67

*Daniela Drummond-Barbosa*

**Regulome** 99

*Miguel A. Andrade, Michael A. Rudnicki*

**Repair and Mutagenesis of DNA** 109

*Raymond Devoret*

**Repetitive Sequence and Noncoding DNA Evolution in Eukaryotes** 127

*Josep M. Comeron*

**Replication and the Cell Cycle** 139

*Helena E. Richardson, Leonie M. Quinn, Nancy Amin, Anabel Herr, Julie Secombe, Anthony M. Brumby, Kathryn M. Doyle, Patrick O. Humbert*

**Reporter Gene System: Green Fluorescent Protein** 215

*Boon Chuan Low, Zhiyuan Gong*

**Reproduction of Plants** 249

*Jaroslava Dubová, Jan Hejátko, Jiří Friml*

**Respiratory Syncytial Virus Vaccine** 297

*Edward E. Walsh*

**Restriction Endonuclease and DNA-Modification Methyltransferases** 323

*Albert Jeltsch, Richard I. Gumport*

**Retinoblastoma, Molecular Genetics of** 347*Vivette D. Brown, Brenda L. Gallie***Retinoids and the Chemical Biology of the Visual Cycle** 375*Robert R. Rando***Retrovirus Integration, Biological and Biochemical Machineries for** 399*Duane Grandgenett, Sibes Bera***Rhythmic and Temporal Processes in Biology** 413*Russell G. Foster, Stuart Peirson, David Whitmore***Ribosome, High Resolution Structure and Function** 483*Christiane Schaffitzel, Nenad Ban***Ribozymes** 513*Joyce E. Heckman***RNA Interference** 527*John G. Doench, Carl Novina***RNA Methodologies** 555*Robert E. Farrell, Jr.***RNA Secondary Structures** 581*Ivo L. Hofacker, Peter F. Stadler***RNA Three-Dimensional Structures, Computer Modeling of** 605*François Major, Philippe Thibault***Sense of Smell** 637*Robert P. Lane, Gregory S. Smutzer, Richard L. Doty***Serial Analysis of Gene Expression** 707*Jacques Marti, Jean-Marc Elalouf***Glossary of Basic Terms** 727**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 735**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations**

739

**Complementary Strands of DNA with Base Pairing** 741

## Volume 13

**Preface** v

**Editor-in-Chief** ix

**Editorial Board** xi

**List of Contributors** xix

**Color Plates** xxiii

**Sex Hormones (Male): Analogs and Antagonists** 1

*Robert W. Brueggemeier*

**Shotgun Sequencing (SGS)** 71

*Jun Yu, Gane Ka-Shu Wong, Jian Wang, Huanming Yang*

**Signaling Through JAKs and STATs: Interferons Lead the Way** 115

*Christian Schindler, Jessica Melillo*

**Signal Transduction Mediated by Heptahelical Receptors and Heterotrimeric G Proteins** 143

*Terence E. Hébert, John K. Northup, R. Victor Rebois*

**Single Nucleotide Polymorphism Blocks and Haplotypes: Human MHC Block Diversity** 191

*E. J. Yunis, J. Zuñiga, C. E. Larsen, M. Fernández-Viña, J. Granados, Z. L. Awdeh, C. A. Alper*

**Skin, Molecular Cell Biology of** 217

*Annette Wysocki, Thomas Mustoe, Gregory Schultz*

**Somatic Gene Therapy** 251

*M. Schweizer, E. Flory, C. Münk, Uwe Gottschalk, K. Cichutek*

**Spatial and Temporal Expression Patterns in Animals** 269

*Werner E. G. Müller*

**Sphingolipid and Glycolipid Biology** 311

*Anthony H. Futerman*

**Stem Cells** 327

*Stewart Sell*

**Stem Cells, Adult** 363*Jason H. Pomerantz, Helen M. Blau***Stem Cells, Embryonic** 381*Mahendra Rao***Stem Cells (Human Embryonic) and Cancer** 401*Maty Tzukerman, Karl Skorecki***Stem Cells in the Adult Brain: Their Identification and Role in Neurogenesis** 409*Arturo Alvarez-Buylla, Erica L. Jackson****Streptomyces*, Molecular Biology of** 437*Paul Herron, Emma Tilley, Iain Hunter***Stress-Induced Expression of Heat Shock Proteins and Action of the Heat Shock Protein Effectors** 463*Bernd Bukau, Elizabeth A. Craig, Richard I. Morimoto, Arthur L. Horwich***Structure-based Drug Design and NMR-based Screening** 517*David J. Craik, Richard J. Clark***Structure, Function and Biogenesis of Peroxisomes** 607*Joel M. Goodman***Superantigens** 637*Matthew D. Baker, K. Ravi Acharya***Supramolecular Protein Complexes** 653*Jianpeng Ma***Synchrotron Infrared Microspectroscopy** 671*Nebojsa S. Marinkovic, Mark R. Chance***Glossary of Basic Terms** 701**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 709**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations** 713**Complementary Strands of DNA with Base Pairing** 715



## Volume 14

Preface *v*

Editor-in-Chief *ix*

Editorial Board *xi*

List of Contributors *xix*

Color Plates *xxiii*

**Syngamy and Cell Cycle Control** 1

*Michael Whitaker*

**Synovial Mast Cells in Inflammatory Arthritis** 37

*Theoharis C. Theoharides*

**Synthesis of Peptide Mimetics and their Building Blocks** 65

*Bruce K. Cassels, Patricio Sáez*

**Synthetic Peptides: Chemistry, Biology, and Drug Design** 91

*Tomi K. Sawyer*

**Systems Biology** 123

*H. Busch, R. Eils*

**Targeted Therapy: Genomic Approaches** 151

*Anna C. Maroney, Sergey E. Ilyin*

**Targeting and Intracellular Delivery of Drugs** 163

*Ruth Duncan*

**Telomerase** 205

*Maria Antonietta Cerone, Silvia Bacchetti*

**Telomere-binding Proteins in Fission Yeast** 229

*Junko Kanoh*

**Thale Cress (*Arabidopsis thaliana*) Genome** 245

*Mark D. Curtis, Ueli Grossniklaus*

**Therapeutic Angiogenesis** 283

*Mary E. Gerritsen*

**Therapeutic Compounds in Nature as Leads for New Pharmaceuticals** 323*Antony D. Buss, Brian Cox, Roger D. Waigh***Three Dimensional Cell Culture: The Importance of Microenvironment in Regulation of Function** 383*Sophie A. Lelièvre, Mina J. Bissell***Total Analysis Systems, Micro** 421*Shigeori Takenaka***Transcription Factor NF- $\kappa$ B: Function, Structure, Regulation, Pathways, and Applications** 437*Raymond Cheong, Andre Levchenko***Transgenic Fish** 473*Pinwen Peter Chiou, Jenny Khoo, Chung Zoon Chun, Thomas T. Chen***Transgenic Mice in Biomedical Research** 505*J. Willem Voncken, Marten Hofker***Transgenic Plants for Food Use** 547*Susanne Stirn, Horst Lörz***Translation of RNA to Protein** 579*Robert Ashley Cox, Henry Rudolph Victor Arnstein***Triacylglycerol Storage and Mobilization, Regulation of** 621*Günter Müller, Stefan Petry, Aventis Pharma Germany, a member of the Sanofi Aventis group***Glossary of Basic Terms** 705**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 713**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations**

717

**Complementary Strands of DNA with Base Pairing** 719**Volume 15****Preface** v**Editor-in-Chief** ix

**Editorial Board** xi

**List of Contributors** xix

**Color Plates** xxiii

**Triplet Repeat Diseases** 1

*Stephan J. Guyenet, Albert R. La Spada*

**Two-photon Microscopy and Imaging** 61

*Patrick Theer, Bernd Kuhn, Dorine Keusters, Winfried Denk*

**Ubiquitin-Proteasome System for Controlling Cellular Protein Levels** 89

*Michael H. Glickman, Aaron Ciechanover*

**Vaccination, Genetic** 111

*Joerg Reimann, Martin Schleaf, Reinhold Schirmbeck*

**Vaccine Approaches for Protection Against HIV** 135

*Stephen M. Smith, Mahender Singh, Kuan-Teh Jeang*

**Vaccine Research and Development Methodology** 157

*Jens-Peter Gregersen*

**Variation and Conservation of the Development of Animal Bodies: Evolutionary Developmental Biology** 179

*Francoise Mazet, Sebastian M. Shimeld*

**Vascular Development and Angiogenesis** 201

*M. Luisa Iruela-Arispe*

**Vectors and Gene Therapy** 233

*Edward A. Burton, David J. Fink, Joseph C. Glorioso*

**Vector System: Plasmid DNA** 287

*Rajkumar Banerjee, Leaf Huang*

**Vector Targeting in Gene Therapy** 331

*Yosuke Kawakami, David T. Curiel*

**Vertebrate Mitochondrial DNA** 367

*Max Ingman, Ulf Gyllenstein*

**Viral Inhibitors and Immune Response Mediators: The Interferons** 387

*Anthony Meager*

**Virus-Cell Interactions** 423*Andrew J. Mouland, Nikolaus Heveker, Anne Gatignol***Virus-free Gene Transfer Systems in Somatic Gene Therapy** 485*Oliver Kayser, Albrecht F. Kiderlen***Vitamin Receptors** 505*Krishnamurti Dakshinamurti***Vitamins, Structure and Function of** 535*Donald B. McCormick***Whole Genome Human Chromosome Physical Mapping** 555*Cassandra L. Smith, Giang H. Nguyen, Denan Wang, Nickolaev Bukanov***Xenotransplantation in Pharmaceutical Biotechnology** 573*Gregory J. Brunn, Jeffrey L. Platt***Zebrafish (*Danio rerio*) Genome and Genetics** 593*Ralf Dahm, Robert Geisler, Christiane Nüsslein-Volhard***Glossary of Basic Terms** 627**The Twenty Amino Acids that are Combined to Form Proteins in Living Things** 635**The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations**

639

**Complementary Strands of DNA with Base Pairing** 641



## Cumulative List of Contributors

### **K. Ravi Acharya**

University of Bath,  
Claverton Down,  
Bath,  
UK

### **Marie-Isabel Aguilar**

Monash University,  
Clayton,  
Australia

### **Abebe Akalu**

New York University School of  
Medicine,  
New York,  
USA

### **Shizuo Akira**

Osaka University,  
Osaka,  
Japan

and

ERATO,  
Japan Science and Technology Agency,  
Osaka, Japan

### **C. A. Alper**

Harvard Medical School,  
Boston, MA,  
USA

and

The CBR Institute for Biomedical  
Research,  
Boston, MA,  
USA

### **Arturo Alvarez-Buylla**

University of California,  
San Francisco, CA,  
USA

### **Gino Amiconi**

University La Sapienza,  
Rome,  
Italy

### **Nancy Amin**

Peter MacCallum Cancer Centre,  
Melbourne,  
Australia

### **Garth R. Anderson**

Roswell Park Cancer Institute,  
Buffalo, NY,  
USA

### **Miguel A. Andrade**

Ottawa Health Research Institute,  
Ottawa,  
Canada

### **Hideki Aoyagi**

University of Tsukuba,  
Tsukuba,  
Japan

**Werner Arber**

Department of Molecular Microbiology,  
Biozentrum, University of Basel,  
Basel,  
Switzerland

**Trevor K. Archer**

Laboratory of Molecular Carcinogenesis,  
National Institutes of Health,  
Research Triangle Park, NC,  
USA

**Henry Rudolph Victor Arnstein**

National Institute for  
Medical Research,  
London, England,  
UK

**Charles L. Asbury**

Department of Biological Sciences,  
Stanford University, Stanford, CA,  
USA

and

Present Address: Department of Physiology  
and Biophysics,  
University of Washington,  
Seattle, WA,  
USA

**Alan D. Attie**

Department of Biochemistry,  
University of Wisconsin,  
Madison, WI,  
USA

**Rémy A. Aubin**

Health Canada,  
Centre for Biologics Research,  
Ottawa,  
Canada

**Aventis Pharma Germany, a member  
of the Sanofi Aventis group**

Therapeutic Department  
Metabolism,  
Frankfurt am Main,  
Germany

**Z. L. Awdeh**

The CBR Institute for Biomedical  
Research,  
Boston, MA,  
USA

**Yoshinobu Baba**

National Institute of Advanced  
Industrial Science and Technology,  
Takamatsu,  
Japan

University of Tokushima,  
Shomachi,  
Tokushima,  
Japan

and

Nagoya University,  
Nagoya,  
Japan

**Silvia Bacchetti**

Regina Elena Cancer Institute,  
Rome,  
Italy

**Martin F. Bachmann**

Cytos Biotechnology AG,  
Zürich-Schlieren,  
Switzerland

**William Bains**

Choracle Ltd.,  
Melbourn, Royston,  
UK

**Rumiana Bakalova**

National Institute of Advanced  
Industrial Science and Technology,  
Takamatsu,  
Japan

**Elizabeth Baker**

University of Adelaide,  
Department of Pediatrics,  
Adelaide,  
Australia

**Matthew D. Baker**

University of Bath,  
Claverton Down,  
Bath,  
UK

**Andrew S. Ball**

Department of Biological Sciences,  
University of Essex, Colchester,  
UK

**Edward D. Ball**

University of California,  
San Diego,  
La Jolla, CA,  
USA

**Dennis Henry Bamford**

University of Helsinki,  
Helsinki,  
Finland

**Nenad Ban**

Institute for Molecular Biology and  
Biophysics,  
Swiss Federal Institute of Technology,  
Zürich,  
Switzerland

**Rajkumar Banerjee**

Indian Institute of Chemical Technology,  
Hyderabad,  
India

**Sailen Barik**

University of South Alabama,  
Mobile, AL,  
USA

**Jeremy D. Bartos**

Roswell Park Cancer Institute,  
Buffalo, NY,  
USA

**Barry D. Bavister**

University of New Orleans,  
New Orleans, LA,  
USA

and

Tulane Institute for Reproductive  
Medicine,  
Center for Excellence in Women's  
Health,  
Tulane University Health Sciences  
Center,  
New Orleans, LA,  
USA

**Barbara G. Beatty**

Department of Pathology,  
University of Vermont,  
Burlington, VT,  
USA

**Andreas Bechthold**

Albert-Ludwigs-Universität Freiburg,  
Freiburg,  
Germany

**George N. Bennett**

Department of Biochemistry and Cell  
Biology,  
Rice University,  
Houston, TX,  
USA

**Ronald Bentley**

Department of Biological Sciences,  
University of Pittsburgh,  
Pittsburgh, PA,  
USA

**Roland Benz**

Biocenter of the University of Würzburg,  
Würzburg,  
Germany

**Sibes Bera**

Institute for Molecular Virology,  
St. Louis, MO,  
USA



**Thomas Berger**

Department of Dermatology,  
University Hospital of Erlangen,  
Erlangen,  
Germany

**Carol Bernstein**

Department of Microbiology  
and Immunology,  
University of Arizona,  
Tucson, AZ,  
USA

**Harris Bernstein**

Department of Microbiology  
and Immunology,  
University of Arizona,  
Tucson, AZ,  
USA

**Ernest Beutler**

Molecular and Experimental Medicine,  
The Scripps Research Institute,  
La Jolla, CA,  
USA

**Ratan V. Bhat**

Department of Bioscience,  
AstraZeneca R&D Södertälje,  
Huddinge,  
Sweden

**Robert R. Birge**

University of Connecticut,  
Storrs, CT,  
USA

and

Syracuse University,  
Syracuse, NY,  
USA

**Martin John Bishop**

MRC Rosalind Franklin Centre for  
Genomics Research Hinxton,  
Cambridge,  
UK

**Mina J. Bissell**

Lawrence Berkeley National Laboratory,  
Berkeley, CA,  
USA

**Vira Bitko**

University of South Alabama,  
Mobile, AL,  
USA

**R. D. Blake**

Department of Biochemistry,  
Microbiology and Molecular Biology,  
University of Maine,  
Orono, ME,  
USA

**Helen M. Blau**

Stanford University School  
of Medicine,  
Stanford, CA,  
USA

**Steven M. Block**

Department of Biological Sciences,  
Stanford University,  
Stanford, CA,  
USA

and

Department of Applied Physics,  
Stanford University,  
Stanford, CA,  
USA

**Claus-Thomas Bock**

Department of Molecular Pathology,  
University of Tübingen,  
Germany

**Vilhelm A. Bohr**

National Institute on Aging,  
NIH, Baltimore,  
MD

**Franklyn F. Bolander**

Department of Biological Sciences,  
University of South Carolina,  
Columbia,  
USA

**Guenther Bonn**

University of Innsbruck,  
Innsbruck,  
Austria

**Carol A. Brenner**

University of New Orleans,  
New Orleans, LA,  
USA

and

Tulane Institute for Reproductive Medicine,  
Center for Excellence in Women's Health,  
Tulane University Health Sciences Center,  
New Orleans, LA,  
USA

**Miguel H. Bronchud**

Hospital General of Granollers,  
Barcelona,  
Spain

**Darren R. Brooks**

School of Environment and Life Sciences,  
University of Salford, Salford,  
UK

**Peter C. Brooks**

New York University School of Medicine,  
New York,  
USA

**Vivette D. Brown**

Princess Margaret Hospital,  
Toronto,  
Canada

**Robert W. Brueggemeier**

The Ohio State University,  
Columbus, OH,  
USA

**Anthony M. Brumby**

Peter MacCallum Cancer Centre,  
Melbourne,  
Australia

**Gregory J. Brunn**

Transplantation Biology Program,  
Mayo Clinic,  
Rochester, MN,  
USA

and

Department of Pharmacology and  
Experimental Therapeutics,  
Mayo Clinic,  
Rochester, MN,  
USA

**Maurizio Brunori**

University La Sapienza,  
Rome,  
Italy

**Richard Bucala**

Yale University School of Medicine,  
New Haven, CT,  
USA

**Malcolm Buckle**

Enzymologie et Cinétique Structurale,  
CNRS,  
Cachan,  
France

**Bruce Budowle**

Federal Bureau of Investigation  
Laboratory, Quantico, VA,  
USA

**Nickolaev Bukanov**

Boston University,  
Boston, MA,  
USA

**Bernd Bukau**

University of Heidelberg,  
Heidelberg,  
Germany

**Silvia Bulfone-Paus**

Department of Immunology and  
Cell Biology,  
Parkallee, Borstel,  
Germany

**Ralph A. Burgard**

University of Canterbury,  
Christchurch,  
New Zealand

**Maureen K. Bunger**

Laboratory of Molecular Carcinogenesis,  
National Institutes of Health,  
Research Triangle Park, NC,  
USA

**Antony W. Burgess**

Ludwig Institute for Cancer Research,  
Parkville,  
Australia

**Richard R. Burgess**

University of Wisconsin,  
Madison, WI,  
USA

**Thomas R. Bürklin**

Department of Biosciences at Novum and  
CGB,  
Karolinska Institutet,  
Huddinge,  
Sweden

**Robert D. Burgoyne**

The Physiological Laboratory,  
University of Liverpool,  
Liverpool,  
UK

**David W. Burt**

Department of Genomics and  
Bioinformatics,  
Roslin Institute (Edinburgh),  
Midlothian,  
UK

**Dennis R. Burton**

Immunology Department,  
The Scripps Research Institute,  
La Jolla, CA,  
USA

**Edward A. Burton**

University of Pittsburgh,  
Pittsburgh, PA,  
USA

**H. Busch**

German Cancer Research Center,  
Heidelberg,  
Germany

**Antony D. Buss**

MerLion Pharmaceuticals Pte. Ltd,  
Science Park II,  
Singapore

**Tanya Button**

MRC Social, Genetic and Developmental  
Psychiatry Centre,  
King's College London,  
London,  
UK

**Charles R. Cantor**

Sequenom, Inc.,  
San Diego, CA,  
USA

and

Boston University,  
Boston, MA,  
USA

**David G. Capco**

School of Life Sciences Cellular  
and Molecular Biosciences Faculty,  
Arizona State University,  
Tempe, AZ,  
USA

**Bruce K. Cassels**

Department of Chemistry,  
Faculty of Sciences,  
University of Chile,  
Santiago,  
Chile

**Jean-Marc Cavaillon**

Institut Pasteur,  
Paris,  
France

**Maria Antonietta Cerone**

McGill University,  
Montreal,  
Canada

**Rengul Cetin-Atalay**

Bilkent University,  
Bilkent, Ankara,  
Turkey

**Mark R. Chance**

Department of Physiology  
and Biophysics and Center  
for Synchrotron  
Biosciences, Albert Einstein College  
of Medicine,  
Bronx, NY,  
USA

**Donald C. Chang**

Hong Kong University of Science and  
Technology,  
Kowloon,  
Hong Kong

**Martin F. Chaplin**

Food Research Centre,  
South Bank University,  
London,  
UK

**Dhruba K. Chattoraj**

Center for Cancer Research,  
NCI, NIH,  
Bethesda, MD,  
USA

**Chung-Hsuan Chen**

Oak Ridge National Laboratory,  
Oak Ridge, TN,  
USA

**Thomas T. Chen**

University of Connecticut,  
Storrs, CT,  
USA

**Raymond Cheong**

Johns Hopkins University,  
Baltimore, MD,  
USA

**Max A. Chernesky**

Department of Pathology and  
Molecular Medicine,  
Hamilton, ON,  
Canada

**Jason W. Chin**

MRC Laboratory of Molecular Biology,  
Cambridge,  
UK

**Pinwen Peter Chiou**

University of Connecticut,  
Storrs, CT,  
USA

**Andrew D. Chisholm**

University of California,  
Santa Cruz,  
California

**Jan L. Christian**

Department of Cell and Developmental  
Biology,  
Oregon Health and Science University,  
Portland, OR,  
USA

**Boon Chuan Low**

National University of Singapore,  
Singapore

**Chung Zoon Chun**

University of Connecticut,  
Storrs, CT,  
USA

**Jose B. Cibelli**

Michigan State University,  
East Lansing, MI,  
USA

**K. Cichutek**

Paul-Ehrlich-Institut,  
Langen,  
Germany

**Aaron Ciechanover**

Faculty of Medicine,  
Israel Institute of Technology, Haifa,  
Israel

**Michael J. Clague**

University of Liverpool,  
Liverpool,  
UK

**Melody S. Clark**

Biological Sciences Division,  
British Antarctic Survey Cambridge,  
UK

**Richard J. Clark**

University of Queensland,  
Brisbane,  
Australia

**Michael F. Clarke**

Department of Hematology and Oncology,  
The University of Michigan,  
Ann Arbor, Michigan,  
USA

**Frank H. Collins**

University of Notre Dame,  
Notre Dame, IN,  
USA

**Josep M. Comeron**

The University of Iowa,  
Iowa City, IA,  
USA

**Stephen Cooper**

University of Michigan Medical School,  
Ann Arbor, MI,  
USA

**Andrew J. Copp**

Institute of Child Health,  
University College London,  
London,  
UK

**Christopher T. Cornell**

Department of Microbiology and Molecular  
Genetics,  
University of California,  
Irvine, CA,  
USA

**Robert J. Cousins**

University of Florida,  
Gainesville, FL,  
USA

**Brian Cox**

Novartis Pharma Research Centre,  
Horsham,  
UK

**Robert Ashley Cox**

National Institute for Medical Research,  
London, England,  
UK

**Elizabeth A. Craig**

University of Wisconsin,  
Madison, WI,  
USA

**David J. Craik**

University of Queensland,  
Brisbane,  
Australia

**Caretha L. Creasy**

Division of Genomic and Proteomic Sciences,  
GlaxoSmithKline Pharmaceutical Research and Development,  
Collegeville, PA,  
USA

**Carl E. Creutz**

Department of Pharmacology,  
University of Virginia,  
Charlottesville, VA,  
USA

**Hugues Roest Crolius**

Laboratoire Dynamique et Organisation des Genomes (LDOG),  
Department of Biology,  
Ecole Normale Supérieure, Paris,  
France

**David T. Curiel**

University of Alabama at Birmingham,  
Birmingham, AL,  
USA

**Mark D. Curtis**

University of Zürich, Zürich,  
Switzerland

**Paul Cutler**

GlaxoSmithKline Pharmaceutical Research & Development,  
Stevenage, Hertfordshire,  
UK

**Rajvir Dahiya**

University of California San Francisco and Veterans Affairs Medical Center,  
San Francisco, CA,  
USA

**Ralf Dahm**

Max Planck Institute for Developmental Biology,  
Tübingen,  
Germany

**Krishnamurti Dakshinamurti**

University of Manitoba Winnipeg,  
MB,  
Canada

**Zhijing Dang**

School of Chemistry,  
University of Nottingham,  
Nottingham,  
UK

**Raveendra Dayam**

University of Southern California,  
Los Angeles, CA,  
USA

**Philip Dean**

DeNovo Pharmaceuticals Limited,  
Cambridge,  
UK

**Christine Debouck**

Division of Genomic and Proteomic Sciences,  
GlaxoSmithKline Pharmaceutical Research and Development,  
Collegeville, PA,  
USA

**David M. de Kretser**

Monash Institute of Reproduction and Development, Monash University,  
Clayton, Victoria, Australia

and

The Australian Research Council Centre of Excellence in Biotechnology and Development,  
Canberra,  
Australia

**Winfried Denk**

Max Planck Institute for Medical Research,  
Heidelberg,  
Germany

**Melvin L. DePamphilis**

National Institute of Child Health and Human Development Bethesda, Bethesda, MD, USA

**Hartmut Derendorf**

University of Florida, Gainesville, FL, USA

**Rob DeSalle**

Division of Invertebrates, American Museum of Natural History, New York, USA

**Raymond Devoret**

Institute Curie, Orsay, France

**Pawan Dhar**

Bioinformatics Institute, Singapore

**Matt Dickinson**

The University of Nottingham, Nottingham, UK

**Frank DiCosmo**

Cellular, Molecular and Developmental Biology, University of Toronto, Toronto, Canada

**Andras Dinnyes**

Hungarian Academy of Sciences and Szent Istvan University, Godollo, Hungary; Agricultural Biotechnology Center, Godollo, Hungary

**Ulrich Dirnagl**

Department of Experimental Neurology (Charité) Humboldt University, Berlin, Germany

**John G. Doench**

Massachusetts Institute of Technology, Cambridge, MA, USA

**Gerd Döring**

Universitätsklinikum Tübingen, Tübingen, Germany

**Richard L. Doty**

University of Pennsylvania Medical Center, Philadelphia, PA, USA

**Kathryn M. Doyle**

Peter MacCallum Cancer Centre, Melbourne, Australia

**Daniela Drummond-Barbosa**

Vanderbilt University School of Medicine, Nashville, TN, USA

**Jaroslava Dubová**

Masaryk University, Kotlářská 2, Brno, Czech Republic

**Ruth Duncan**

Welsh School of Pharmacy, Cardiff University, Cardiff, UK

**Frank John Dye**

Department of Biological and Environmental Sciences, Western Connecticut State University, Danbury, CT, USA

**Thomas Ebersen**

GBF-German Research Centre for  
Biotechnology,  
Braunschweig,  
Germany

**Ingo Ebersberger**

Institute for Bioinformatics,  
University of Düsseldorf,  
Germany

**James Eberwine**

University of Pennsylvania,  
Philadelphia, PA,  
USA

**Fritz Eckstein**

Max-Planck-Institute for Experimental  
Medicine,  
Göttingen,  
Germany

**Mary G. Egan**

Division of Invertebrates,  
American Museum of Natural History,  
New York,  
USA

**Stefan Ehlers**

Department of Immunochemistry and  
Biochemical Microbiology,  
Parkallee, Borstel,  
Germany

**R. Eils**

German Cancer Research Center,  
Heidelberg,  
Germany

**Jean-Marc Elalouf**

Commissariat à l'Energie  
Atomique/Saclay,  
France

**Sarah C. R. Elgin**

Washington University,  
St. Louis, MO,  
USA

**Walther R. Ellis**

Utah State University,  
Logan, UT,  
USA

**Joachim W. Engels**

Institute for Organic Chemistry,  
University of Frankfurt,  
Frankfurt Main,  
Germany

**Caroline Engvall**

Uppsala University,  
Uppsala,  
Sweden

**Charles J. Epstein**

Department of Pediatrics,  
University of California,  
San Francisco, CA,  
USA

**Ashraf Ewis**

National Institute of Advanced Industrial  
Science and Technology,  
Takamatsu,  
Japan

and

El-Minia University,  
El-Minia,  
Egypt

**Robert E. Farrell, Jr.**

Penn State University,  
York, PA,  
USA

**Robert Feil**

Institute of Molecular Genetics,  
CNRS,  
Montpellier,  
France



**Malcolm A. Ferguson-Smith**

Department of Clinical Veterinary  
Medicine,  
Cambridge University,  
Cambridge,  
UK

**M. Fernández-Viña**

University of Texas,  
Houston, TX,  
USA

**James P. Ferris**

Department of Chemistry and NY Center  
for Studies on the Origins of Life,  
Rensselaer Polytechnic Institute,  
Troy, NY,  
USA

**James G. Ferry**

The Pennsylvania State University,  
University Park,  
PA 16801,  
USA

**Arthur G. Fett-Neto**

Universidade Federal Do Rio Grande  
Do Sul,  
Porto Alegre,  
Brazil

**Melanie Filiatrault**

Department of Microbiology  
and Immunology,  
University of Rochester Medical Center,  
Rochester, NY,  
USA

**Jock K. Findlay**

Prince Henry's Institute of Medical  
Research,  
Victoria,  
Australia

**David J. Fink**

University of Michigan,  
Ann Arbor, MI,  
USA

**Bonnie L. Firestein**

The State University of New Jersey,  
Piscataway, NJ,  
USA

**Paula L. Fischhaber**

Department of Pathology,  
The University of Texas Southwestern  
Medical Center,  
Dallas, TX,  
USA

**Paul Robert Fisher**

La Trobe University,  
Victoria,  
Australia

**E. Flory**

Paul-Ehrlich-Institut,  
Langen,  
Germany

**Russell G. Foster**

Charing Cross Hospital,  
London,  
UK

**Ron M. Fourney**

Royal Canadian Mounted Police,  
National DNA Data Bank,  
Ottawa,  
Canada

**Susanne Franz**

German Cancer Research Center,  
Applied Tumor Virology,  
Heidelberg,  
Germany

**James Fred Dice**

Department of Physiology,  
Tufts University School  
of Medicine,  
Boston, MA,  
USA

**Chantal J. Frégeau**

Royal Canadian Mounted Police,  
National DNA Data Bank,  
Ottawa,  
Canada

**Errol C. Friedberg**

Department of Pathology,  
The University of Texas Southwestern  
Medical Center,  
Dallas, TX,  
USA

**Simon H. Friedman**

School of Pharmacy,  
University of Missouri,  
Kansas City, MO,  
USA

**Jiří Friml**

ZMBP University of Tübingen,  
Auf der Morgenstelle 3,  
Tübingen,  
Germany

**Asao Fujiyama**

RIKEN Genomic Sciences Center,  
Yokohama,  
Japan

**Masamitsu Futai**

Microbial Chemistry Research  
Foundation and CREST,  
Japan Science and Technology Agency,  
Kamiosaki, Shinagawa, Tokyo,  
Japan

**Anthony H. Futerman**

Weizmann Institute of Science,  
Rehovot,  
Israel

**Betty J. Gaffney**

Department of Biological Sciences,  
BIO Unit 1,  
Tallahassee, FL,  
USA

**Brenda L. Gallie**

Princess Margaret Hospital,  
Toronto,  
Canada

and

Hospital for Sick Children,  
Toronto,  
Canada

and

University of Toronto,  
Toronto,  
Canada

**Paul Gane**

DeNovo Pharmaceuticals Limited,  
Cambridge,  
UK

**Ilse Gantois**

Department of Medicine,  
University of Antwerp,  
Antwerp,  
Belgium

**Kathryn B. Garber**

Department of Human Genetics,  
Emory University School of Medicine,  
Atlanta, GA,  
USA

**Javier Garcia-Frias**

Department of Electrical and Computer  
Engineering,  
University of Delaware,  
Newark, DE,  
USA

**J. Jay Gargus**

University of California,  
Irvine, CA,  
USA

**Anne Gatignol**

Lady Davis Institute for Medical  
Research and McGill University,  
Montréal,  
Canada

**Robert Geisler**

Max Planck Institute for  
Developmental Biology,  
Tübingen,  
Germany

**Mary E. Gerritsen**

Exelixis,  
South San Francisco, CA,  
USA

**Francesco Giannelli**

Department of Medical and  
Molecular Genetics,  
Division of Genetics and Development,  
Guy's, King's and St. Thomas'  
School of Medicine,  
London,  
UK

**Douglas T. Gjerde**

PhyNexus, Inc.,  
San Jose, CA,  
USA

**Michael H. Glickman**

Department of Biology,  
Israel Institute of Technology,  
Haifa,  
Israel

**Israel S. Gloger**

GlaxoSmithKline Pharmaceutical  
Research & Development,  
Harlow, Essex,  
UK

**Joseph C. Glorioso**

University of Michigan,  
Ann Arbor, MI,  
USA

**Alison Goate**

Department of Psychiatry,  
Washington University School of  
Medicine,  
St. Louis, MO,  
USA

**Andrew K. Godwin**

Fox Chase Cancer Center,  
Philadelphia, PA,  
USA

**Devorah C. Goldman**

Department of Cell and Developmental  
Biology,  
Oregon Health and Science University,  
Portland, OR,  
USA

**Zhiyuan Gong**

National University of Singapore,  
Singapore

**Joel M. Goodman**

University of Texas Southwestern  
Medical Center at Dallas,  
Dallas, TX,  
USA

**James P. Gosling**

Department of Biochemistry,  
National University of Ireland,  
Galway,  
Ireland

**Yuji Goto**

Institute of Molecular Genetics,  
CNRS,  
Montpellier,  
France

**Uwe Gottschalk**

Paul-Ehrlich-Institut,  
Langen,  
Germany

**David J. Grainger**

Department of Medicine,  
University of Cambridge,  
Cambridge,  
UK

**J. Granados**

Instituto Nacional de Ciencias  
Médicas y de la Nutrición  
Salvador Zubirán,  
Mexico City,  
Mexico

**Duane Grandgenett**

Institute for Molecular Virology,  
St. Louis, MO,  
USA

**James G. Granneman**

Department of Psychiatry,  
Wayne State University School of Medicine,  
Detroit, MI,  
USA

**Gregory A. Grant**

Department of Molecular Biology and  
Pharmacology,  
Washington University School of Medicine,  
St. Louis, MO,  
USA

**Kathleen A. Grant**

Wake Forest University School of Medicine,  
Winston-Salem, NC,  
USA

**Peter M. Green**

Department of Medical and  
Molecular Genetics,  
Division of Genetics and Development,  
Guy's, King's and St. Thomas'  
School of Medicine,  
London,  
UK

**Jens-Peter Gregersen**

Chiron Vaccines,  
Chiron-Behring GmbH & Co KG,  
Marburg,  
Germany

**Karl Otto Greulich**

Institute of Molecular Biotechnology,  
Jena,  
Germany

**Gareth Griffiths**

European Molecular Biology Laboratory,  
Heidelberg,  
Germany

**Ueli Grossniklaus**

University of Zürich,  
Zürich,  
Switzerland

**Jing-Qu Guan**

Departments of Physiology and Biophysics,  
Albert Einstein College of Medicine,  
Bronx, New York,  
USA

**Richard I. Gumpert**

University of Illinois,  
Urbana, IL,  
USA

**Preethi Gunaratne**

Human Genome Sequencing Center,  
Baylor College of Medicine,  
Houston, TX,  
USA

**Stephan J. Guyenet**

University of Washington,  
Seattle, WA,  
USA

**Carlos A. Guzmán**

GBF-German Research Centre for  
Biotechnology,  
Braunschweig,  
Germany

**Ulf Gyllensten**

Uppsala University,  
Uppsala,  
Sweden

**Georg Haase**

Institut de Neurobiologie de la  
Méditerranée,  
Marseille,  
France

**Tatsuya Haga**

Gakushuin University,  
Tokyo,  
Japan

**Nabil G. Hagag**

University Medical Center,  
State University of New York,  
Stony Brook, NY,  
USA

**Barry Halliwell**

Department of Biochemistry,  
National University of Singapore,  
Singapore

**Zhaozhang Han**

Argonne National Laboratory,  
Argonne, IL,  
USA

**Christopher P. Hanna**

PhyNexus, Inc.,  
San Jose, CA,  
USA

**Linda M. Harvey**

Strathclyde University,  
Department of Bioscience  
and Biotechnology,  
Glasgow,  
UK

**Andrew T. Hass**

Cellular and Molecular Biology Program,  
The University of Michigan,  
Ann Arbor, Michigan,  
USA

**Necat Havlioglu**

Department of Pediatrics and  
Department of Molecular Biology  
and Pharmacology,  
Washington University School of  
Medicine,  
St. Louis, MO,  
USA

**Yoshihide Hayashizaki**

RIKEN Discovery and Research Institute,  
Wako,  
Japan  
and

RIKEN Genomic Sciences Center,  
Yokohama,  
Japan

and

Institute of Basic Medical Sciences,  
University of Tsukuba,  
Japan

and

RIKEN Genomic Sciences Center,  
Kanagawa,  
Japan

**Terence E. Hébert**

Université de Montréal,  
Montréal, PQ,  
Canada

**Silva Hecimovic**

Department of Psychiatry,  
Washington University School of  
Medicine,  
St. Louis, MO,  
USA

**Joyce E. Heckman**

The University of Vermont,  
Burlington, VT,  
USA

**Olaf Heidenreich**

Department of Molecular Biology,  
Institute for Cell Biology,  
University of Tübingen,  
Tübingen,  
Germany

**Jack A. Heinemann**

University of Canterbury,  
Christchurch,  
New Zealand

**Udo Heinemann**

Max Delbrück Center for Molecular  
Medicine,  
Berlin,  
Germany

**Jan Hejátko**

Masaryk University,  
Kotlářská 2,  
Brno,  
Czech Republic

and

Academy of Sciences of the  
Czech Republic,  
Institute of Biophysics,  
Brno,  
Czech Republic

**Henry H. Q. Heng**

Center for Molecular Medicine and  
Genetics,  
Wayne State University,  
Detroit, MI,  
USA

**Rebecca M. Henry**

University of Michigan Medical School,  
Ann Arbor, MI,  
USA

**Anabel Herr**

Peter MacCallum Cancer Centre,  
Melbourne,  
Australia

**Paul Herron**

University of Strathclyde,  
Glasgow,  
UK

**Nikolaus Heveker**

Centre de Recherche,  
Hôpital Sainte-Justine and  
Université de Montréal,  
Montréal,  
Canada

**Emma E. Hill**

University of California,  
Berkeley, California,  
USA

**Jason R. Hillebrecht**

University of Connecticut,  
Storrs, CT,  
USA

**Jason D. Hipp**

Wake Forest University School of Medicine,  
Winston-Salem, NC,  
USA

**Jonathan D. Hirst**

School of Chemistry,  
University of Nottingham,  
Nottingham,  
UK

**Rus A. Hoelzel**

Department of Biological Sciences,  
Durham University,  
Durham,  
UK

**Ivo L. Hofacker**

University of Vienna,  
Wien,  
Austria

**Dirk Hoffmeister**

Albert-Ludwigs-Universität Freiburg,  
Freiburg,  
Germany

**Marten Hofker**

University of Maastricht,  
Maastricht,  
The Netherlands

**Jim Hoggett**

University of York,  
York,  
UK

**Peter R. Holman**

University of California,  
San Diego,  
La Jolla, CA,  
USA

**Robert A. Holt**

Canada's Michael Smith  
Genome Science Centre,  
Vancouver, BC,  
Canada

**Ian A. Hope**

School of Biology,  
University of Leeds,  
Leeds,  
UK

**Takashi Horiuchi**

National Institute for Basic Biology,  
Okazaki,  
Japan

**David Hornby**

University of Sheffield,  
Sheffield,  
UK

**Arthur L. Horwich**

Yale School of Medicine,  
New Haven, CT and The Scripps  
Research Institute,  
La Jolla, CA,  
USA  
and

HHMI,  
Chevy Chase, MD,  
USA

**Robert L. Howell**

School of Medicine and Dentistry,  
University of Rochester,  
Rochester, NY,  
USA

**Leaf Huang**

University of Pittsburgh,  
Pittsburgh, PA,  
USA

**Robert Huber**

Max-Planck-Institut für Biochemie,  
Martinsried,  
Germany

**Dieter F. Hülser**

University of Stuttgart,  
Stuttgart,  
Germany

**Patrick O. Humbert**

Peter MacCallum Cancer Centre,  
Melbourne,  
Australia

**Lawrence A. Hunt**

University of Louisville School of Medicine,  
Department of Microbiology and  
Immunology,  
Louisville, KY,  
USA

**Iain Hunter**

University of Strathclyde,  
Glasgow,  
UK

**David K. Hwang**

University of California Los Angeles,  
Los Angeles, CA,  
USA

**Sergey E. Ilyin**

Johnson & Johnson Pharmaceutical  
Research & Development,  
Spring House, PA,  
USA

**Max Ingman**

Uppsala University,  
Uppsala,  
Sweden

**Akio Inoue**

Department of Integrated Biosciences,  
University of Tokyo,  
Kashiwa,  
Japan

**Takayoshi Inoue**

National Institute of Neuroscience,  
Tokyo,  
Japan

**M. Luisa Iruela-Arispe**

University of California,  
Los Angeles, CA,  
USA

**Michael H. Irwin**

School of Medicine and Dentistry,  
University of Rochester,  
Rochester, NY  
USA

**R. Elwyn Isaac**

School of Biology,  
University of Leeds,  
Leeds,  
UK

**Masaki Izawa**

Nippon Gene Tech. Co, Ltd.,  
Arakawa,  
Japan

**Dean A. Jackson**

Department of Biomolecular Sciences,  
University of Manchester,  
Manchester,  
UK

**Erica L. Jackson**

University of California,  
San Francisco, CA,  
USA

**Reinhard Jahn**

Max-Planck-Institute for Biophysical  
Chemistry,  
Göttingen,  
Germany

**David M. Jameson**

Department of Cell and Molecular Biology,  
University of Hawaii,  
Honolulu, HI,  
USA

**Robert James Slater**

University of Hertfordshire,  
Hatfield,  
UK

**Kuan-Teh Jeang**

Laboratory of Molecular Microbiology,  
NIAID, NIH,  
Bethesda, MD,  
USA

**Albert Jeltsch**

International University Bremen,  
Bremen,  
Germany

**Leslie A. Jones**

International Laboratory of Molecular  
Biology for Tropical Disease Agents,  
University of California,  
Davis, CA,  
USA

**Lynn B. Jorde**

University of Utah Health Sciences Center,  
Salt Lake City, Utah,  
USA

**Jerzy Jurka**

Genetic Information Research Institute,  
Mountain View, CA,  
USA



**Jacob Kagan**

Cancer Biomarkers Research Group,  
Division of Cancer Prevention,  
National Cancer Institute,  
Bethesda, MD,  
USA

**Kimihiko Kameyama**

National Institute of Advanced  
Industrial Science and Technology,  
Tsukuba,  
Japan

**John P. Kane**

University of California,  
San Francisco, CA,  
USA

**Junko Kanoh**

Graduate School of Biostudies,  
Kyoto University,  
Kyoto,  
Japan

**Vladimir V. Kapitonov**

Genetic Information Research Institute,  
Mountain View, CA,  
USA

**Ece Karatan**

Argonne National Laboratory,  
Argonne, IL,  
USA

**Yosuke Kawakami**

University of Alabama at Birmingham,  
Birmingham, AL,  
USA

**Brian Kay**

Argonne National Laboratory,  
Argonne, IL,  
USA

**Oliver Kayser**

Pharmaceutical Biology,  
Rijksuniversiteit Groningen,  
Groningen,  
The Netherlands

**Dorine Keusters**

Max Planck Institute for Medical  
Research,  
Heidelberg,  
Germany

**Nancy Khardori**

University School of Medicine,  
Springfield, IL,  
USA

**Jenny Khoo**

University of Connecticut,  
Storrs, CT,  
USA

**Albrecht F. Kiderlen**

Robert Koch-Institut,  
Berlin,  
Germany

**Michael William King**

Indiana University School of Medicine,  
Center for Regenerative Biology and  
Medicine,  
Terre Haute, IN,  
USA

**Hannah L. Klein**

New York University Medical Center,  
New York,  
USA

**Jörg Knäblein**

Schering AG,  
Berlin,  
Germany

**Kendall L. Knight**

University of Massachusetts Medical  
School,  
Worcester, MA,  
USA

**Minoru S. H. Ko**

National Institute on Aging,  
National Institutes of Health,  
Baltimore, MD,  
USA

**Akira Kobata**

Tokyo Metropolitan Institute of Gerontology,  
Tokyo,  
Japan

**Carla M. Koehler**

University of California Los Angeles,  
Los Angeles, CA,  
USA

**Brian A. Koeneman**

School of Life Sciences Cellular and Molecular Biosciences Faculty,  
Arizona State University,  
Tempe, AZ,  
USA

**Naoka Komori**

The University of Oklahoma Health Sciences Center,  
Oklahoma City, OK,  
USA

**Andrzej K. Konopka**

BioLingua Research, Inc.,  
Gaithersburg, MD,  
USA

**R. Frank Kooy**

Department of Biomedical Sciences,  
University of Antwerp,  
Antwerp,  
Belgium

**Jeremy F. Kosciielecki**

University of Connecticut,  
Storrs, CT,  
USA

**Gerd Krause**

Institute for Molecular Pharmacology,  
Berlin,  
Germany

**Joachim Krebs**

Institute of Biochemistry,  
Swiss Federal Institute of Technology,  
Zurich,  
Switzerland

**Larry J. Kricka**

Department of Pathology,  
University of Pennsylvania,  
Philadelphia, PA,  
USA

**Harald Kropshofer**

Roche Center for Medical Genomics,  
F. Hoffman-La Roche Ltd,  
Basel,  
Switzerland

**Hans Michael Kubisch**

Tulane National Primate Research Center,  
Covington, LA,  
USA

**Bernd Kuhn**

Max Planck Institute for Medical Research,  
Heidelberg,  
Germany

**Anil Kumar**

Devi Ahilya University,  
Indore, MP,  
India

**Thomas M. Kundig**

University of Zürich,  
Zürich,  
Switzerland

**Sadamu Kurono**

The University of Oklahoma Health Sciences Center,  
Oklahoma City, OK,  
USA

**Susan E. LaFlamme**

Center for Cell Biology and Cancer Research,  
Albany Medical College,  
Albany, NY,  
USA

**Kit S. Lam**

University of California Davis,  
Sacramento, CA,  
USA

**Ulf Landegren**

Department of Genetics and Pathology,  
Uppsala University,  
Sweden

**Robert P. Lane**

Wesleyan University,  
Middletown, CT,  
USA

**Janos K. Lanyi**

Department of Physiology and Biophysics,  
University of California,  
Irvine, CA,  
USA

**C. E. Larsen**

Harvard Medical School,  
Boston, MA,  
USA

and

The CBR Institute for Biomedical Research,  
Boston, MA,  
USA

**Albert R. La Spada**

University of Washington,  
Seattle, WA,  
USA

**Nicholas B. La Thangue**

Division of Biochemistry and Molecular Biology,  
University of Glasgow,  
Glasgow,  
UK

**Guy Leclercq**

Institut J. Bordet,  
Université Libre de Bruxelles,  
Brussels,  
Belgium

**Tzong-Hsien Lee**

Monash University,  
Clayton,  
Australia

**Todd Leff**

Department of Pathology,  
Wayne State University School of Medicine,  
Detroit, MI,  
USA

**Brian D. Lehmann**

The Brody School of Medicine at East Carolina University,  
Anatomy & Cell Biology,  
Greenville, NC,  
USA

**Boris A. Leibovitch**

Washington University,  
St. Louis, MO,  
USA

**Sophie A. Lelièvre**

Purdue University,  
West Lafayette, IN,  
USA

**Thomas Lengauer**

Computational Biology and Applied Algorithmics,  
Max-Planck-Institute for Informatics,  
Saarbrücken,  
Germany

**William Lesser**

Department of Applied Economics and Management,  
Cornell University,  
Ithaca, NY,  
USA

**Avital Lev**

Technion-Israel Institute of Technology,  
Haifa,  
Israel

**Andre Levchenko**

Johns Hopkins University,  
Baltimore, MD,  
USA

**Andrew M. L. Lever**

Department of Medicine,  
University of Cambridge,  
Cambridge,  
UK

**Gertz I. Likhtenshtein**

Ben-Gurion University of the Negev,  
Beer-Sheva,  
Israel

**Claudia Link**

GBF-German Research Centre for  
Biotechnology,  
Braunschweig,  
Germany

**Pietro Lió**

Computer Laboratory,  
University of Cambridge,  
Cambridge,  
UK

**Howard D. Lipshitz**

Department of Molecular and Medical  
Genetics,  
University of Toronto,  
Toronto,  
Canada

**Ruiwu Liu**

University of California Davis,  
Sacramento, CA,  
USA

**George P. Livi**

Division of Genomic and Proteomic  
Sciences,  
GlaxoSmithKline Pharmaceutical Research  
and Development,  
Collegeville, PA,  
USA

**Horst Lörz**

University of Hamburg,  
Hamburg,  
Germany

**Kate A. L. Loveland**

Monash Institute of Reproduction and  
Development,  
Monash University,  
Clayton, Victoria,  
Australia

and

The Australian Research Council Centre of  
Excellence in Biotechnology and  
Development  
Canberra  
Australia

**Peter Lund**

School of Biosciences,  
University of Birmingham,  
Birmingham,  
UK

**Per Lundahl**

Uppsala University,  
Uppsala,  
Sweden

**Manfred B. Lutz**

Department of Dermatology,  
University Hospital of Erlangen,  
Erlangen,  
Germany

**Jianpeng Ma**

Baylor College of Medicine and  
Rice University,  
Houston, TX,  
USA

**Thomas J. Magliery**

Yale University,  
New Haven, CT,  
USA

**François Major**

Université de Montréal, Montréal,  
Québec,  
Canada

**Hisaji Maki**

Graduate School of Biological Sciences,  
Nara Institute of Science and Technology,  
Ikoma,  
Japan

**Markus Maniak**

Department of Cell Biology,  
University of Kassel,  
Kassel,  
Germany

**Nebojsa S. Marinkovic**

Department of Physiology and  
Biophysics and Center for  
Synchrotron Biosciences,  
Albert Einstein College  
of Medicine,  
Bronx, NY,  
USA

**Anna C. Maroney**

Johnson & Johnson Pharmaceutical  
Research & Development,  
Spring House, PA,  
USA

**Adam G. Marsh**

Department of Marine Studies,  
University of Delaware,  
Lewes, DE,  
USA

**Ron L. Marshall**

Molecular Diagnostics,  
Abbott Park, IL,  
USA

**Wallace F. Marshall**

Department of Molecular, Cellular, and  
Developmental Biology,  
Yale University,  
New Haven, CT  
USA

**Jacques Marti**

Institut de Génétique Humaine,  
Montpellier,  
France

**R. Bruce Martin**

Chemistry Department,  
University of Virginia,  
Charlottesville, VA,  
USA

**Edward P. Masler**

Nematology Laboratory Plant Sciences  
Institute,  
Beltsville, MD,  
USA

**Hiroyuki Matsumoto**

The University of Oklahoma Health  
Sciences Center,  
Oklahoma City, OK,  
USA

**Masaomi Matsumoto**

Oklahoma Department of Agriculture,  
Oklahoma City, OK,  
USA

**Tomoki Matsuyama**

RIKEN Yokohama Institute,  
Kanagawa,  
Japan

**Francoise Mazet**

University of Reading,  
Whiteknights, Reading,  
UK

**Donald B. McCormick**

Department of Biochemistry,  
Emory University,  
Atlanta, GA,  
USA

**James A. McCubrey**

The Brody School of Medicine at East  
Carolina University,  
Microbiology & Immunology,  
Greenville, NC,  
USA

and

Leo Jenkins Cancer Center,  
Greenville, NC,  
USA

**Lindsay McDermott**

University of Glasgow,  
Glasgow,  
UK

**Dharia A. McGrew**

University of Massachusetts Medical  
School,  
Worcester, MA,  
USA

**Peter McGuffin**

MRC Social, Genetic and Developmental  
Psychiatry Centre,  
King's College London,  
London,  
UK

**Peter A. McNaughton**

University of Cambridge,  
Cambridge,  
UK

**Brian McNeil**

Department of Bioscience,  
Strathclyde University,  
Glasgow,  
UK

**Anthony Meager**

Division of Immunobiology,  
National Institute for Biological Standards  
and Control,  
Potters Bar,  
UK

and

Division of Immunology and  
Endocrinology,  
National Institute for Biological  
Standards and Control,  
South Mimms, Herts,  
UK

**Christopher Mehlin**

University of Washington,  
Seattle, WA,  
USA

**Bernd Meibohm**

The University of Tennessee Health Science  
Center,  
Memphis, TN,  
USA

**Andreas Meisel**

Department of Experimental Neurology  
(Charité) Humboldt University,  
Berlin,  
Germany

**Jessica Melillo**

Columbia University,  
New York, NY,  
USA

**Irmgard Merfort**

Albert-Ludwigs-Universität Freiburg,  
Freiburg,  
Germany

**Albrecht Messerschmidt**

Max-Planck-Institut für Biochemie,  
Martinsried,  
Germany

**Bradley T. Messmer**

Department of Experimental Immunology,  
North Shore-LIJ Research Institute,  
Manhasset, NY,  
USA

**Christine N. Metz**

North Shore-Long Island Jewish Research  
Institute,  
Manhasset, NY,  
USA

**Kenneth V. Mills**

College of the Holy Cross,  
Worcester, MA,  
USA

**David L. Mitchell**

Department of Carcinogenesis,  
University of Texas,  
Smithville, TX,  
USA

**Alan Morgan**

The Physiological Laboratory,  
University of Liverpool,  
Liverpool,  
UK

**Hirota Mori**

Research and Education Center for Genetic  
Information,  
Nara Institute of Sciences and Technology,  
Ikoma,  
Japan

**Richard I. Morimoto**

Northwestern University,  
Evanston, IL,  
USA

**Shinichi Morishita**

Department of Computational Biology,  
University of Tokyo,  
Kashiwa,  
Japan

**Sherie L. Morrison**

Department of Microbiology, Immunology,  
and Molecular Genetics,  
University of California,  
Los Angeles, CA,  
USA

**Jeremy E. Moss**

Yale University School of Medicine,  
New Haven, CT,  
USA

**Andrew J. Mouland**

Lady Davis Institute for  
Medical Research and McGill University,  
Montréal,  
Canada

**Günter Müller**

Therapeutic Department Metabolism,  
Frankfurt am Main,  
Germany

**Werner E. G. Müller**

Abteilung Angewandte  
Molekularbiologie,  
Universität Mainz,  
Mainz,  
Germany

**Annette Müller-Taubenberger**

Department for Cell Dynamics,  
Max-Planck-Institute of Biochemistry,  
Martinsried,  
Germany

**C. Münk**

Paul-Ehrlich-Institut,  
Langen,  
Germany

**Yoshinao Muro**

Nagoya Graduate University School of  
Medicine,  
Nagoya,  
Japan

**Michael P. Murphy**

MRC Dunn Human Nutrition Unit,  
Cambridge,  
UK

**Thomas Mustoe**

Northwestern University,  
Chicago, IL,  
USA

**Josyf C. Mychaleckyj**

Wake Forest University School of Medicine,  
Winston-Salem, NC,  
USA

**Yusaku Nakabeppu**

Medical Institute of Bioregulation,  
Kyushu University,  
Fukuoka,  
Japan

**Yoichi Nakayama**

Institute for Advanced Biosciences,  
Keio University,  
Tsuruoka,  
Japan

**Keiichi Namba**

Osaka University,  
Osaka,  
Japan

and

Dynamic NanoMachine Project,  
Suita, Osaka,  
Japan

**Pravendra Nath**

National Botanical Research Institute,  
Lucknow,  
India

**Nouri Neamati**

University of Southern California,  
Los Angeles, CA,  
USA

**Eberhard Neumann**

Department for Physical Chemistry and  
Biophysical Chemistry,  
University of Bielefeld,  
Bielefeld,  
Germany

**Dominic S. Ng**

University of Toronto,  
Toronto, Ontario,  
Canada

**Giang H. Nguyen**

Boston University,  
Boston, MA,  
USA

**Jeremy K. Nicholson**

Department of Biological Chemistry,  
Imperial College,  
London,  
UK

**Christof M. Niemeyer**

Universität Dortmund,  
Dortmund,  
Germany

**Mats Nilsson**

Department of Genetics and  
Pathology,  
Uppsala University,  
Sweden

**Steffen Nock**

Absalus Inc.,  
Mountain View, CA,  
USA

**John K. Northup**

National Institutes of Health,  
Rockville, MD,  
USA



**Carl Novina**

Cancer Immunology and AIDS,  
Dana-Farber Cancer Institute,  
and Department of Pathology,  
Harvard Medical School,  
Boston, MA,  
USA

**Christiane Nüsslein-Volhard**

Max Planck Institute for  
Developmental Biology,  
Tübingen,  
Germany

**Björn Oback**

AgResearch,  
Hamilton,  
New Zealand

**Kimberly L. Ogden**

Department of Chemical and  
Environmental Engineering,  
University of Arizona,  
Tucson, AZ,  
USA

**Alexander Oksche**

Institute for Pharmacology,  
Charité,  
Berlin,  
Germany

**Hisato Okuizumi**

Department of Molecular Genetics,  
National Institute of Agrobiological  
Sciences,  
Ibaraki,  
Japan

**W. Olszewska**

Imperial College,  
Paddington, London,  
UK

**Charles Onwulata**

Eastern Regional Research Center,  
U.S. Department of Agriculture,  
Wyndmoor, PA,  
USA

**Guck T. Ooi**

Prince Henry's Institute of Medical  
Research,  
Victoria,  
Australia

**Ben A. Oostra**

Department of Clinical Genetics,  
Erasmus MC,  
Rotterdam,  
The Netherlands

**Peter J. M. Openshaw**

Imperial College,  
Paddington, London,  
UK

**Michael G. Ormerod**

34 Wray Park Road,  
Reigate,  
UK

**Paul R. Ortiz de Montellano**

Department of Pharmaceutical Chemistry,  
University of California,  
San Francisco, CA,  
USA

**Mehmet Ozturk**

Bilkent University,  
Bilkent, Ankara,  
Turkey

**Eric G. Pamer**

Sloan-Kettering Institute,  
New York,  
USA

**Zhong-Zong Pan**

Fox Chase Cancer Center,  
Philadelphia, PA,  
USA

**Luciano Passador**

Department of Microbiology  
and Immunology,  
University of Rochester Medical Center,  
Rochester, NY,  
USA

**Adam Pavlicek**

Genetic Information Research Institute,  
Mountain View, CA,  
USA

**Stuart Peirson**

Charing Cross Hospital,  
London,  
UK

**Neal R. Pellis**

NASA,  
Lyndon B. Johnson Space Center,  
Houston, TX,  
USA

**Stefan Pelzer**

Combinature Biopharm AG,  
Berlin,  
Germany

**Manuel L. Penichet**

Department of Microbiology, Immunology,  
and Molecular Genetics,  
University of California,  
Los Angeles, CA,  
USA

**Frederica P. Perera**

Columbia Center for Children's  
Environmental Health,  
Columbia, NY,  
USA

**Astrid K. Petrich**

Department of Pathology and  
Molecular Medicine,  
Hamilton, ON,  
Canada

**Stefan Petry**

Therapeutic Department Metabolism,  
Frankfurt am Main,  
Germany

**Simon E. V. Phillips**

Astbury Center for Structural Molecular  
Biology,  
University of Leeds,  
Leeds,  
UK

**Amanda T. Pickup**

Program in Developmental Biology,  
The Hospital for Sick Children,  
Toronto,  
Canada

**Irina A. Pikuleva**

Department of Pharmacology and  
Toxicology,  
University of Texas Medical Branch,  
Galveston, TX,  
USA

**Carl A. Pinkert**

School of Medicine and Dentistry,  
University of Rochester,  
Rochester, NY,  
USA

**Markus Jaakko Pirttimaa**

University of Helsinki,  
Helsinki,  
Finland

**Jeffrey L. Platt**

Transplantation Biology Program,  
Mayo Clinic,  
Rochester, MN,  
USA

and

Departments of Surgery,  
Immunology and Pediatrics,  
Mayo Clinic,  
Rochester, MN,  
USA

**Alexander Ploss**

Sloan-Kettering Institute,  
New York,  
USA

and

Weill Graduate School of Medical Sciences  
of Cornell University,  
New York,  
USA

**Peter Pohl**

Institute for Molecular  
Pharmacology,  
Berlin,  
Germany

**Kenneth Michael Pollard**

Department of Molecular and Experimental  
Medicine,  
The Scripps Research Institute,  
La Jolla, CA,  
USA

**Jason H. Pomerantz**

University of California,  
San Francisco, CA,  
USA

and

Stanford University School  
of Medicine,  
Stanford, CA,  
USA

**Thomas L. Poulos**

University of California,  
Irvine, CA,  
USA

**Aladdin Pramanik**

Department of Biochemistry and  
Biophysics,  
Karolinska Institute,  
Stockholm,  
Sweden

**Konstantin Prass**

Department of Experimental Neurology  
(Charité) Humboldt University,  
Berlin,  
Germany

**Stanley B. Prusiner**

University of California,  
San Francisco, CA,  
USA

**Clive R. Pullinger**

University of California,  
San Francisco, CA,  
USA

**Daniel L. Purich**

University of Florida College of  
Medicine,  
Gainesville, FL,  
USA

**Phoebe X. Qi**

Eastern Regional Research Center,  
U.S. Department of Agriculture,  
Wyndmoor, PA,  
USA

**Leonie M. Quinn**

Peter MacCallum Cancer Centre,  
Melbourne,  
Australia

**Rita Raddatz**

Cephalon Incorporated,  
West Chester, PA,  
USA

**Robert R. Rando**

Department of Biological Chemistry and  
Molecular Pharmacology,  
Harvard Medical School,  
Boston, MA,  
USA

**Mahendra Rao**

Stem Cell Unit,  
Laboratory of Neuroscience,  
National Institute on Aging,  
NIH,  
Bethesda, MD,  
USA

**Madeline E. Rasche**

University of Florida,  
Gainesville, FL,  
USA

**Felix Ratjen**

University of Essen,  
Germany

**Colin Ratledge**

Department of Biological Sciences,  
University of Hull,  
Hull,  
UK

**Martin Rechsteiner**

Department of Biochemistry University  
of Utah,  
Salt Lake, UT,  
USA

**Anireooy S. N. Reddy**

Colorado State University,  
Fort Collins, CO,  
USA

**Joerg Reimann**

University of Ulm,  
Ulm,  
Germany

**Yoram Reiter**

Technion-Israel Institute of Technology,  
Haifa,  
Israel

**Alan T. Remaley**

National Institutes of Health,  
Bethesda, MD  
USA

**Helena E. Richardson**

Peter MacCallum Cancer Centre,  
Melbourne,  
Australia

**Sylvie Rimsky**

Enzymologie et Cinétique Structurale,  
CNRS,  
Cachan,  
France

**Diana Risin**

NASA,  
Lyndon B. Johnson Space Center,  
Houston, TX,  
USA

**Jean-David Rochaix**

Department of Molecular Biology  
and Plant Biology,  
University of Geneva,  
Geneva,  
Switzerland

**Michael E. Rosenfeld**

Department of Pathobiology,  
University of Washington,  
Seattle, WA,  
USA

**Walter Rosenthal**

Institute for Pharmacology,  
Charité,  
Berlin,  
Germany

**Meredith F. Ross**

MRC Dunn Human Nutrition Unit,  
Cambridge,  
UK

**Jack A. Roth**

The University of Texas  
M. D. Anderson Cancer Center,  
Houston, TX,  
USA

**Nathaniel Rothman**

Division of Cancer Epidemiology and Genetics,  
National Cancer Institute,  
Bethesda,  
USA

**Emily Rozak**

University of Pennsylvania,  
Philadelphia, PA,  
USA

**Michael A. Rudnicki**

Ottawa Health Research Institute,  
Ottawa,  
Canada

**Patricio Sáez**

Faculty of Medical Sciences,  
University of Santiago,  
Chile

**Ka-Yiu San**

Institute of Biosciences  
and Bioengineering,  
Rice University,  
Houston, TX,  
USA

**Aniruddha P. Sane**

National Botanical Research Institute,  
Lucknow,  
India

**Vidhu A. Sane**

National Botanical Research Institute,  
Lucknow,  
India

**Takeshi Sano**

Beth Israel Deaconess Medical Center,  
Harvard Medical School,  
Boston, MA,  
USA

**Rajkumar Sasidharan**

MRC Laboratory of Molecular Biology,  
Cambridge, MA,  
USA

**Robert D. C. Saunders**

Department of Biological Sciences,  
The Open University,  
Milton Keynes,  
UK

**Tomi K. Sawyer**

ARIAD Pharmaceuticals,  
Cambridge, MA,  
USA

**John G. Scandalios**

Department of Genetics,  
North Carolina State University,  
Raleigh, NC,  
USA

**Christiane Schaffitzel**

Institute for Molecular Biology and  
Biophysics,  
Swiss Federal Institute of Technology,  
Zürich,  
Switzerland

**Christian Schindler**

Columbia University,  
New York,  
USA

**Reinhold Schirmbeck**

University of Ulm,  
Ulm,  
Germany

**Martin Schleef**

Plasmid Factory,  
Bielefeld,  
Germany

**Paul A. Schulte**

Centers for Disease Control  
and Prevention,  
National Institute for Occupational Safety  
and Health,  
Cincinnati, OH,  
USA

**Erwin Schultz**

Department of Dermatology,  
University Hospital of Erlangen,  
Erlangen,  
Germany

**Gregory Schultz**

University of Florida,  
Gainesville, FL,  
USA

**Jeffrey H. Schwartz**

University of Pittsburgh,  
Pittsburgh, PA,  
USA

**Matthias Schweizer**

Paul-Ehrlich-Institut,  
Langen,  
Germany

**Clay W. Scott**

Lead Discovery Department,  
AstraZeneca Pharmaceuticals LP,  
Wilmington, DE,  
USA

**Georg Sczakiel**

Institute for Molecular Medicine,  
University of Lübeck,  
Lübeck,  
Germany

**Julie Secombe**

Fred Hutchinson Cancer Center,  
Seattle,  
Washington, DC,  
USA

**Michael M. Seidman**

Laboratory of Molecular Gerontology,  
National Institute on Aging,  
National Institute of Health,  
Baltimore, MD,  
USA

**Mutsuo Sekiguchi**

Biomolecular Engineering Research  
Institute,  
Osaka,  
Japan

**Stewart Sell**

New York State Health Department,  
Albany, NY,  
USA

**Bert L. Semler**

Department of Microbiology and Molecular  
Genetics,  
University of California,  
Irvine, CA,  
USA

**Michael Sendtner**

Institute of Clinical Neurobiology,  
Würzburg,  
Germany

**Philip Serwer**

The University of Texas Health Science  
Center San Antonio, TX,  
USA

**Kazuhiro Shibata**

RIKEN Discovery and Research Institute,  
Wako,  
Japan

**Sebastian M. Shimeld**

University of Oxford,  
Oxford,  
UK

**Yoshihiro Shimizu**

Department of Integrated Biosciences,  
The University of Tokyo,  
Kashiwa,  
Japan

**Gregory L. Shipley**

The University of Texas Health  
Science Center,  
Houston, TX,  
USA

**Mahender Singh**

Saint Michael's Medical Center &  
New Jersey Medical School,  
Newark, NJ,  
USA

**Karl Skorecki**

Rambam Medical Center and  
Rappaport Faculty of Medicine  
and Research Institute,  
Technion-Israel Institute  
of Technology,  
Haifa,  
Israel

**Cassandra L. Smith**

Boston University,  
Boston, MA,  
USA

**Stephen M. Smith**

Saint Michael's Medical Center &  
New Jersey Medical School,  
Newark, NJ,  
USA

**Gregory S. Smutzer**

Temple University,  
Philadelphia, PA,  
USA

and

University of Pennsylvania  
Medical Center,  
Philadelphia, PA,  
USA

**D. Peter Snustad**

Department of Plant Biology,  
University of Minnesota,  
St. Paul, MN,  
USA

**John Sommerville**

School of Biology,  
University of St. Andrews,  
St. Andrews,  
UK

**Clemens von Sonntag**

Leibniz-Institut für  
Oberflächenmodifizierung,  
Leipzig,  
Germany

**Jennifer Spaethling**

University of Pennsylvania,  
Philadelphia, PA,  
USA

**Sudhir Srivastava**

Cancer Biomarkers Research Group,  
Division of Cancer Prevention,  
National Cancer Institute,  
Bethesda, MD,  
USA

**Peter F. Stadler**

University of Vienna,  
Wien,  
Austria  
  
and

University of Leipzig,  
Leipzig,  
Germany

**Alexander Steinkasserer**

Department of Dermatology,  
University Hospital of Erlangen,  
Erlangen,  
Germany

**Johan Stenberg**

Department of Genetics and  
Pathology,  
Uppsala University,  
Sweden

**Wolfgang Stephan**

Department of Biology II,  
University of Munich,  
Munich,  
Germany

**John M. Stewart**

Mount Allison University,  
Sackville, NB,  
Canada

**Susanne Stirn**

University of Hamburg,  
Hamburg,  
Germany

**Peter G. Stockley**

Astbury Center for Structural Molecular  
Biology,  
University of Leeds,  
Leeds,  
UK

**Daniel L. Stoler**

Roswell Park Cancer Institute,  
Buffalo, NY,  
USA

**Judith Storch**

Rutgers University,  
New Brunswick, NJ,  
USA

**Andreas Strasser**

The Walter and Eliza Hall Institute of  
Medical Research,  
Royal Parade,  
Parkville, Victoria,  
Australia

**Barbara Stuart**

Department of Chemistry, Materials and  
Forensic Science,  
University of Technology,  
Sydney,  
Australia

**Jeffrey A. Stuart**

Syracuse University,  
Syracuse, NY,  
USA

**Kenji Sugimoto**

Osaka Prefecture University,  
Sakai, Osaka,  
Japan

**Alamelu Sundaresan**

Division of Space and Life Sciences,  
Universities Space Research Association  
(USRA),  
Houston, TX,  
USA

**Ge-Hong Sun-Wada**

ISIR, Osaka University,  
Ibaraki, Osaka,  
Japan

**Grant R. Sutherland**

Department of Cytogenetics and Molecular  
Genetics,  
Women's and Children's Hospital,  
Adelaide,  
Australia

**Joel A. Swanson**

University of Michigan Medical School,  
Ann Arbor, MI,  
USA

**Jens R. Sydor**

Infinity Pharmaceuticals Inc.,  
Cambridge, MA,  
USA

**Thomas Szyperski**

State University of New York,  
Buffalo, NY,  
USA

**Eiichi Tahara**

Hiroshima University,  
Hiroshima,  
Japan

**Kouichi Takahashi**

Institute for Advanced Biosciences,  
Keio University,  
Tsuruoka,  
Japan



**Keiji Takamoto**

Departments Physiology and Biophysics,  
Albert Einstein College of Medicine,  
Bronx, NY,  
USA

**Shigeori Takenaka**

Kyushu Institute of Technology,  
Kitakyushu-shi,  
Japan

**Cindy Takeuchi**

The Scripps Research Institute,  
La Jolla, CA,  
USA

**Osamu Takeuchi**

Osaka University,  
Osaka,  
Japan

and

ERATO,  
Japan Science and Technology Agency,  
Osaka,  
Japan

**Jeremy Tame**

Protein Design Laboratory,  
Yokohama City University,  
Yokohama,  
Japan

**Hideo Tanaka**

University of Tsukuba,  
Tsukuba,  
Japan

**Nancy Smyth Templeton**

Department of Molecular and  
Cellular Biology,  
Baylor College of Medicine,  
Houston, TX,  
USA

**David M. Terrian**

The Brody School of Medicine at East  
Carolina University,  
Anatomy & Cell Biology,  
Greenville, NC,  
USA

and

Leo Jenkins Cancer Center,  
Greenville, NC,  
USA

**Chittam U. Thakore**

The Brody School of Medicine at East  
Carolina University,  
Anatomy & Cell Biology,  
Greenville, NC,  
USA

**David S. Thaler**

Sachlv Laboratory of Molecular Genetics  
and Informatics,  
Rockefeller University,  
New York, NY,  
USA

**Patrick Theer**

Max Planck Institute for Medical  
Research,  
Heidelberg,  
Germany

**Theoharis C. Theoharides**

Tufts University School of Medicine,  
Boston, MA,  
USA

**Philippe Thibault**

Université de Montréal,  
Montréal,  
Québec,  
Canada

**Gaochao Tian**

Lead Discovery Department,  
AstraZeneca Pharmaceuticals LP,  
Wilmington, DE,  
USA

**X. Cindy Tian**

University of Connecticut,  
Storrs, CT,  
USA

**Cheryll Tickle**

Division of Cell and Developmental  
Biology,  
University of Dundee,  
Dundee,  
UK

**D. Peter Tieleman**

University of Calgary,  
Albeta,  
Canada

**Emma Tilley**

University of Strathclyde,  
Glasgow,  
UK

**John F. Timms**

Ludwig Institute for Cancer Research,  
UCL Branch,  
London,  
UK

**Masaru Tomita**

Institute for Advanced Biosciences,  
Keio University,  
Tsuruoka,  
Japan

**Jeffrey P. Tomkins**

Department of Genetics and Biochemistry,  
Clemson University,  
Clemson, SC,  
USA

**David J. Triggler**

State University of New York,  
Buffalo, NY,  
USA

**Prabodh K. Trivedi**

National Botanical Research Institute,  
Lucknow,  
India

**Andrew P. Turnbull**

Max Delbrück Center for Molecular  
Medicine,  
Berlin,  
Germany

**Maty Tzukerman**

Rambam Medical Center and Rappaport  
Faculty of Medicine and  
Research Institute,  
Technion-Israel Institute  
of Technology,  
Haifa,  
Israel

**Takuya Ueda**

Department of Integrated Biosciences,  
The University of Tokyo,  
Kashiwa,  
Japan

**David Umlauf**

Institute of Molecular Genetics,  
CNRS,  
Montpellier,  
France

**Claus Urbanke**

Medizinische Hochschule Hannover,  
Zentrale Einrichtung  
Biophysikalisch-Biochemische Verfahren,  
Hannover,  
Germany

**Sylvie Urbé**

University of Liverpool,  
Liverpool,  
UK

**Vincent Vanburen**

National Institute on Aging,  
National Institutes of Health,  
Baltimore, MD,  
USA

**Dennis E. Vance**

University of Alberta,  
Edmonton, Alberta,  
Canada

**David L. Vaux**

The Walter and Eliza Hall Institute of  
Medical Research,  
Royal Parade,  
Parkville, Victoria,  
Australia

**Paulo H. Verardi**

International Laboratory of Molecular  
Biology for Tropical Disease Agents,  
University of California,  
Davis, CA,  
USA

**Mukesh Verma**

Cancer Biomarkers Research Group,  
Division of Cancer Prevention,  
National Cancer Institute,  
Bethesda, MD,  
USA

**R. Victor Rebois**

National Institutes of Health,  
Rockville, MD,  
USA

**Peter A. Vincent**

Center for Cardiovascular Sciences,  
Albany Medical College,  
Albany, NY,  
USA

**Christine Vogel**

MRC Laboratory of Molecular Biology,  
Cambridge, MA,  
USA

**Anne B. Vogt**

Roche Center for Medical Genomics,  
F. Hoffman-La Roche Ltd,  
Basel,  
Switzerland

**J. Willem Voncken**

University of Maastricht,  
Maastricht,  
The Netherlands

**Kent E. Vrana**

Penn State University College of Medicine,  
Hershey, PA,  
USA

**Stephen S. Wachtel**

Department of Obstetrics and Gynecology,  
University of Tennessee,  
Memphis, TN,  
USA

**Yoh Wada**

ISIR,  
Osaka University,  
Ibaraki, Osaka,  
Japan

**Roger D. Waigh**

University of Strathclyde,  
Glasgow,  
Scotland

**Edward E. Walsh**

University of Rochester School of  
Medicine and Dentistry,  
Rochester, NY,  
USA

**Denan Wang**

Boston University,  
Boston, MA,  
USA

**Denong Wang**

Columbia Genome Centre,  
Columbia University,  
New York, NY,  
USA

**Jian Wang**

Beijing Genomics Institute,  
Beijing & James D. Watson  
Institute of Genome Sciences,  
Hangzhou,  
China

**Jun Wang**

Department of Psychiatry,  
Washington University School  
of Medicine,  
St. Louis, MO,  
USA

**G. Russell Warnick**

Pacific Biometrics Research Foundation  
Issaquah, WA,  
USA

**Michael P. Washburn**

Stowers Institute for Medical Research,  
Kansas City, MO,  
USA

**Michael R. Waterman**

Department of Biochemistry,  
Vanderbilt University School of Medicine,  
Nashville,  
Tennessee,  
USA

**Hadiya A. Watson**

Department of Biology,  
The Johns Hopkins University,  
Baltimore, MD,  
USA

**Beverly Wendland**

Department of Biology,  
The Johns Hopkins University,  
Baltimore, MD,  
USA

**Paul Wentworth**

The Scripps Research Institute,  
La Jolla, CA,  
USA

and

University of Oxford,  
Oxford,  
UK

**James G. Wetmur**

Department of Microbiology,  
New York, NY,  
USA

**Michael Whitaker**

University of Newcastle upon Tyne,  
Newcastle upon Tyne,  
UK

**David Whitmore**

University College London,  
London,  
UK

**Jerker Widengren**

Department of Physics,  
Royal Institute of Technology,  
Stockholm,  
Sweden

**Ronit Wilk**

Department of Molecular and Medical  
Genetics,  
University of Toronto,  
Toronto,  
Canada

**John Lewis Williams**

Roslin Institute,  
Roslin,  
Midlothian, Scotland,  
UK

**Michael Williams**

Cephalon Incorporated,  
West Chester, PA,  
USA

**R. Anthony Williamson**

Immunology Department,  
The Scripps Research Institute,  
La Jolla, CA,  
USA

**David S. Wilson**

Absalus Inc.,  
Mountain View, CA,  
USA

**John H. Wilson**

Department of Biochemistry and Molecular  
Biology,  
Baylor College of Medicine,  
Houston, TX,  
USA

**J. David Wininger**

Wake Forest University School of Medicine,  
Winston-Salem, NC,  
USA

**Kevin J. Wise**

University of Connecticut,  
Storrs, CT,  
USA

**Tilo Wolf**

Department of Experimental Neurology  
(Charité) Humboldt University,  
Berlin,  
Germany

**Gane Ka-Shu Wong**

Beijing Genomics Institute,  
Beijing & James D. Watson  
Institute of Genome Sciences,  
Hangzhou,  
China

**Todd Charles Wood**

Division of Natural Sciences,  
Bryan College,  
Dayton, TN,  
USA

**Kim C. Worley**

Human Genome Sequencing Center,  
Baylor College of Medicine,  
Houston, TX,  
USA

**Chengang Wu**

Department of Soil and Crop Sciences,  
Texas A&M University,  
College Station, TX,  
USA

**Jane Y. Wu**

Department of Pediatrics and  
Department of Molecular Biology and  
Pharmacology,  
Washington University School  
of Medicine,  
St. Louis, MO,  
USA

**Annette Wysocki**

University of Mississippi  
Medical Center,  
Jackson, MS,  
USA

**Jie Xu**

Evergen Biotechnologies, Inc.,  
Storrs, CT,  
USA

**Zhanyou Xu**

Department of Soil and Crop Sciences,  
Texas A&M University,  
College Station, TX,  
USA

**Huanming Yang**

Beijing Genomics Institute,  
Beijing & James D. Watson  
Institute of Genome Sciences,  
Hangzhou,  
China

**Tilahun D. Yilma**

International Laboratory of Molecular  
Biology for Tropical Disease Agents,  
University of California,  
Davis, CA,  
USA

**Jeannine M. Yon**

Institute for Molecular and Cellular  
Biochemistry and Biophysics,  
University of Paris,  
Orsay,  
France

**Koji Yonekura**

University of California,  
San Francisco, CA,  
USA

and

Osaka University,  
Osaka,  
Japan

and

Dynamic NanoMachine Project,  
Suita, Osaka,  
Japan

**Jun Yu**

Beijing Genomics Institute,  
Beijing & James D. Watson  
Institute of Genome Sciences,  
Hangzhou,  
China

**Liya Yuan**

Department of Pediatrics and  
Department of Molecular Biology  
and Pharmacology,  
Washington University School of Medicine,  
St. Louis, MO,  
USA

**E. J. Yunis**

Dana-Farber Cancer Institute,  
Boston, MA,  
USA

and

Harvard Medical School,  
Boston, MA,  
USA

**Eugene R. Zabarovsky**

Microbiology and Tumor Biology Center,  
Karolinska Institute,  
Stockholm,  
Sweden

**Edward Zanders**

DeNovo Pharmaceuticals Limited,  
Cambridge,  
UK

**Mark Von Zastrow**

University of California San Francisco,  
Department of Psychiatry,  
San Francisco, CA,  
USA

**Yujing Zeng**

Department of Electrical and Computer  
Engineering,  
University of Delaware,  
Newark, DE,  
USA

**Hanswalter Zentgraf**

German Cancer Research Center,  
Applied Tumor Virology,  
Heidelberg,  
Germany

**Hong-Bin Zhang**

Department of Soil and Crop Sciences,  
Texas A&M University,  
College Station, TX,  
USA

**Marian R. Zlomislic**

University of Calgary,  
Alberta,  
Canada

**J. Zuñiga**

Dana-Farber Cancer Institute,  
Boston, MA,  
USA

and

Harvard Medical School,  
Boston, MA,  
USA

and

Instituto Nacional de  
Enfermedades Respiratorias,  
Mexico City,  
Mexico

**Michael B. Zwick**  
Immunology Department,  
The Scripps Research Institute,  
La Jolla, CA,  
USA

**Boris L. Zybailov**  
Stowers Institute for Medical Research,  
Kansas City, MO,  
USA

## Acknowledgements, Cumulative List of Reviewers

**Patricia M. Abad**

Purdue University,  
West Lafayette, IN,  
USA

**Abul K. Abbas**

Harvard Medical School,  
Boston, MA,  
USA

**David Abramson**

Cornell Medical Center,  
New York, NY,  
USA

**Jordi Alcaraz**

Lawrence Berkeley National Laboratory,  
Berkeley, CA,  
USA

**Alan L. Balch**

University of California,  
Davis, CA,  
USA

**Thomas O. Baldwin**

Texas A&M University,  
College Station, TX,  
USA

**Giorgio Bernardi**

Stazione Zoologica Anton Dohrn,  
Napoli,  
Italy

**M. J. Bishop**

University of Cambridge,  
School of Medicine,  
Cambridge,  
UK

**Pamela Bjorkman**

California Institute of Technology,  
Pasadena, CA,  
USA

**Kristina Bostrom**

University of California San Diego,  
San Diego, CA,  
USA

**Lisa Brannon-Peppas**

Eli Lilly and Company,  
Indianapolis,  
USA

**Hans J. Breter**

Johannes Gutenberg-Universität Mainz,  
Mainz,  
Germany

**Anthony Brookes**

Karolinska Institute,  
Stockholm,  
Sweden

**Franz Brümmer**

University of Stuttgart,  
Stuttgart,  
Germany



**Arabinda Chaudhuri**

Indian Institute of Chemical Technology,  
Hyderabad,  
India

**Cyrus Chothia**

MRC Laboratory of Molecular Biology,  
Cambridge,  
UK

**Michael F. Christman**

Boston University,  
Boston, MA,  
USA

**Klaus Cichutek**

Paul Ehrlich-Institut,  
Langen,  
Germany

**Pio Conti**

University of Chieti,  
Chieti,  
Italy

**T. A. Cropp**

University of Maryland,  
Maryland,  
USA

**Peter J. A. Davies**

The University of Texas Health Science  
Center Houston,  
Houston, TX,  
USA

**John H. Dawson**

University of South Carolina,  
Columbia, SC,  
USA

**Arnold L. Demain**

Massachusetts Institute of Technology,  
Cambridge, MA,  
USA

**Thomas Devlin**

Hahnemann University School of Medicine,  
Pennsylvania,  
USA

**Ruth Ann Dewel**

Appalachian State University,  
Boone, NC,  
USA

**H. Dintzis**

John Hopkins School of Medicine,  
Maryland,  
USA

**Tim Donlon**

Kapiolani Medical Center,  
Aiea, Hawaii,  
USA

**William A. Eaton**

National Institutes of Health,  
Bethesda, MD,  
USA

**W. Ross Ellington**

Florida State University,  
Tallahassee, FL,  
USA

**Barbara Engelhardt**

University of California,  
Berkeley, CA,  
USA

**Gadi Fibich**

University of California,  
Los Angeles, CA,  
USA

**Vera Gamulin**

Institute Rudjer Boskovic,  
Zagreb,  
Croatia

**Ian Garner**

Pharmaceutical Proteins, Ltd.,  
Edinburgh, Scotland,  
UK

**James I. Garrels**

Cold Springs Harbor Laboratory,  
Cold Spring Harbor, NY,  
USA

**Jeffrey A. Gelfand**

Harvard Medical School/Massachusetts  
General Hospital,  
Boston, MA,  
USA

**Alison Goate**

University of Washington School of  
Medicine,  
St. Louis, MO,  
USA

**Takashi Gojobori**

National Institute of Genetics Mishima,  
Shizuoka,  
Japan

**I. H. Goldberg**

Harvard Medical School,  
Boston, MA,  
USA

**Paul Goodfellow**

Washington University,  
St. Louis, MO,  
USA

**Jay A. Gottfried**

New York University  
New York, NY  
USA

**Barney Graham**

Vanderbilt University Hospital,  
Nashville, TN,  
USA

**Michael D. Griswold**

Washington State University,  
Pullman, WA,  
USA

**Guoqiang Gu**

Vanderbilt University Medical Center,  
Nashville, TN,  
USA

**George Guilbault**

University of New Orleans,  
New Orleans, LA,  
USA

**Sarah Gurr**

University of Oxford,  
Oxford,  
UK

**Barry Hall**

University of Rochester,  
Rochester, PA,  
USA

**Jung-Hoon Han**

MRC Laboratory of Molecular Biology,  
Cambridge,  
UK

**Gerhard Haszprunar**

Zoologische Staatssammlung München,  
Munich,  
Germany

**Armin Helisch, M. D.**

Dartmouth-Hitchcock Medical Center,  
Hanover, NH,  
USA

**Patrick Hess**

National Health Labs,  
New York, NY,  
USA

**John Hildebrandt**

Medical University of South Carolina,  
Charleston, SC,  
USA

**Gerd Illing**

PSF biotech AG,  
Berlin,  
Germany

**George Alan Jeffrey**

University of Pittsburgh,  
Pittsburgh, PA,  
USA

**Dick Junghans**

Deaconess Hospital,  
Evansville, IN,  
USA

**Jaap A. Kaandorp**

University of Amsterdam,  
Amsterdam,  
The Netherlands

**David Kaplan**

Natick Research, Development and  
Engineering Center,  
Natick, MA,  
USA

**Brian Kay**

University of North Carolina,  
Chapel Hill, NC,  
USA

**M. Kelve**

Laboratory of Molecular Genetics  
Tallinn,  
Estonia

**Roger Keynes**

University of Cambridge,  
Cambridge,  
UK

**Richard A. King**

University of Minnesota  
Minnesota,  
USA

**Claude B. Klee**

National Cancer Institute,  
Bethesda, MD,  
USA

**Ted Klein**

E.I. du Pont de Nemours & Co.,  
Wilmington, Detroit,  
USA

**Dennis Klinmann**

Center for Biologics Evaluation and  
Research,  
Bethesda, MD,  
USA

**Otto Kreyer**

Harvard Medical School,  
Boston, MA,  
USA

**Joseph R. Lakowitz**

University of Maryland School of Medicine,  
Maryland,  
USA

**Ulf Landegren**

Uppsala University,  
Uppsala,  
Sweden

**Charles Langley**

University of California,  
Davis, CA,  
USA

**Laura Lee**

Vanderbilt University Medical Center,  
Nashville, TN,  
USA

**Hans Lehrach**

Max Plack Institute for Molecular Genetics,  
Berlin,  
Germany

**Arthur M. Lesk**

Pennsylvania State University,  
Hershey, PA,  
USA

**Jenifer Levini**

Cornell University,  
Ithaca, NY,  
USA

**Sally Leys**

The University of Alberta,  
Edmonton, Alberta,  
Canada

**Tim Lohman**

Washington University School of Medicine,  
St. Louis, MO,  
USA

**David G. Lowe**

Skyline Ventures,  
Palo Alto, CA,  
USA

**Martin Marinus**

UMass Medical School,  
Worcester, MA,  
USA

**G. Steven Martin**

University of California at Berkeley,  
Berkeley, CA,  
USA

**Mike McKeown**

Salk Institute,  
La Jolla, CA,  
USA

**L. McLaughlin**

Boston College,  
Chestnut Hill, MA,  
USA

**Marie-Louise Michel**

Institut Pasteur/INSERM U370,  
Paris,  
France

**Nina Mitra**

Institute for General Botany,  
Hamburg,  
Germany

**Peter B. Moore**

Yale University,  
New Haven, CN,  
USA

**Veronica Morea**

University La Sapienza,  
Rome,  
Italy

**Krishna Murthy**

Temple University Medical School,  
Philadelphia, PA,  
USA

**Alexey G. Murzin**

MRC Centre for Protein Engineering,  
Cambridge,  
UK

**Kyungjae Myung**

National Institutes of Health,  
Bethesda, MD,  
USA

**Celeste Nelson**

Lawrence Berkeley National Laboratory,  
Berkeley, CA,  
USA

**Barry R. O'Keefe**

National Cancer Institute,  
Maryland,  
USA

**Christine A. Orengo**

University College London,  
London,  
UK

**Hartmut Oschkinat**

Research Institute for Molecular Pharma-  
cology,  
Berlin,  
Germany

**R. H. Pain**

Jozf Stefan Institute,  
Ljubljana,  
Slovenia

**Yong Serk Park**

Yonsei University,  
Wonju,  
Republic of Korea

**Carl A. Pinkert**

University of Alabama at Birmingham,  
Birmingham, AL,  
USA

**Richard Porter**

State University of New York,  
Stony Brook, NY,  
USA

**Thomas Quinn**

John Hopkins University,  
Baltimore, MD,  
USA

**Francesco Ramirez**

Mount Sinai Hospital,  
New York, NY,  
USA

**Andrew Rice**

Baylor College of Medicine,  
Houston, TX,  
USA

**Phoebe A. Rice**

University of Chicago,  
Chicago, IL,  
USA

**S. Rutledge**

MRC Centre for Protein Engineering,  
Cambridge,  
UK

**Noriyuki Satoh**

Kyoto University,  
Kyoto,  
Japan

**Alan L. Schwartz**

Washington University School of Medicine,  
St. Louis, MO,  
USA

**Nobuyoshi Shimizu**

Keio University School of Medicine,  
Tokyo,  
Japan

**Gary Siuzdak**

The Scripps Research Institute,  
La Jolla, CA,  
USA

**Josefine Sprenger**

University of Applied Sciences  
Weihenstephan,  
Freising,  
Germany

**Eva A. Turley**

London Regional Cancer Center,  
London, Ontario,  
Canada

**Veronica van Heyningen**

Western General Hospital,  
Edinburgh,  
UK

**G. Vassart**

Universite Libre de Bruxelles,  
Bruxelles,  
Belgium

**Victor Velculescu**

Johns Hopkins University School  
of Medicine,  
Baltimore, MD,  
USA

**Boris Vyskot**

Academy of Sciences of the Czech Republic,  
Brno,  
Czech Republic

**Allan M. Weissman**

National Cancer Institute,  
Frederick, MD,  
USA

**Akio Yamazaki**

Wayne State University School of Medicine,  
Detroit, MI,  
USA

**Keyi Yang**

Baylor College of Medicine,  
Houston, TX,  
USA



## Cumulative Subject Index Volume 1 to Volume 15

- a**
- A $\beta$  1:190
  - A $\beta$  immunization 1:201
  - A kinase anchoring protein 13:158, 164
  - a master equation 14:140
  - A $\beta$  production 1:189
  - 2-5A synthetase-RNase L 15:407
  - (2–5)A system 13:285
  - AAA ATPases 11:2
  - AAA proteins 2:512
  - AAA superfamily 11:86
  - aadA (aminoglycoside adenylyl transferase) 2:631, 634, 638
  - AAVs, *see* adeno-associated viruses
  - AB1380 3:395
  - ab initio gene-finding software 13:102
  - ab initio modeling 11:134
  - Abbott Laboratories 6:557
  - ABC transport protein 8:150, 154
  - ABC transporter 3:625, 11:152
  - ABC transporter BtuCD 11:147
  - ABC transporter family 2:234
  - ABCA1, *see* ATP-binding cassette transporter A1
  - ABCB4 7:198
  - ABCG5 7:212, 213
  - ABCA7 7:198
  - ABCC8 11:698
  - ABCG8 7:212, 213
  - ABCB11 7:198
  - Abd-B 6:191
  - abdominal 13:301
  - abduction 7:574
  - abductive inference 7:561
  - Abelson tyrosine kinase 13:349
  - aberrant gene expression 9:449
  - ABF
    - common HLA haplotypes 13:208
    - DNA blocks 13:208
  - abiotic and biotic stress responses 10:309
  - abiotic stress
    - regulation during 10:348–349
  - abiotic stress tolerance
    - aluminum toxicity 14:567
    - dehydration-stress tolerance 14:566
    - iron stress 14:567
    - regulatory genes 14:566
    - salt stress 14:566
  - ABL (Abelson murine leukemia virus) 9:440
    - BCR gene 7:136
    - chimeric Bcr-Abl protein 7:136
    - Philadelphia chromosome 7:136
  - ABL1/ABL2 7:135
  - abnormal transcript of c-met 6:11
  - ABO blood group antigens 5:573
  - abortive initiation 3:540
  - Abraham 3:623
  - abrB 1:321, 322
  - abscisic acid
    - regulation by 10:341–342
  - absolute configuration
    - determination 7:438
  - absolute scale
    - intensities 7:425
    - Wilson plot
      - B, overall temperature factor 7:425
      - C, scale factor 7:425
  - Absolv 3:606
  - absorption 10:217
    - absorption coefficient 3:57
  - absorption, distribution, metabolism and excretion (ADME) 3:597, 11:597, 617, 623, 633
  - absorptive endocytosis 1:626
  - AC133 15:219
  - AC, *see* adenylate cyclase
  - accessory factors 4:189
    - amphiphysin 4:187
    - AP180/CALM 4:187
    - auxilin 4:187



- accessory factors (*continued*)
- dynamin 4:187
  - endophilin 4:187
  - Eps15 4:187
  - epsin 4:187
  - Hsc70 4:187
  - synaptojanin 4:187
  - synaptotagmin 4:187
- accessory olfactory bulb (AOB) 12:640
- accessory olfactory system 12:676–677
- structure of 12:656–658
- accessory proteins 1:108–109
- accommodation 12:488
- antidonor antibodies 15:583
- accreditation 3:492
- accuracy 7:449
- accuracy of structure determination
- crystallographic *R*-factor 7:449
  - free *R*-factor 7:450
  - Luzzati or  $\sigma_A$  plot 7:450
  - mean coordinate error 7:450
  - Ramachandran plot 7:450
  - RCSB Protein Data Bank at Rutgers University 7:450
  - real space *R*-factor 7:450
  - stereochemistry of the final model 7:450
- accurate mass tag (AMT) 8:15f
- Accutane (13-*cis*-retinoic acid) 12:387
- AC/DC effects 4:18
- ACE inhibitor 8:98
- acetaminophen 2:62, 67
- acetate 4:371
- acetate fermentation pathway 8:243–244
- acetyl methyl carbinol test 1:518
- acetylated histone H4 6:11
- acetylation 14:268, 444, 15:30ff
- xenobiotic amino groups 2:64
- acetylcholine (ACh) 8:444, 446, 10:283
- motor endplate 11:667
- acetylcholine receptor 4:482, 11:669
- acetylcholinesterase 7:486, 8:97ff, 11:149, 668
- acetyl-CoA 7:101, 8:165, 173
- acetyl-CoA carboxylases 14:637ff
- Achilles' heel strategy 15:562
- Achromatopsia 11:683
- acid–base catalysis 12:499
- acid–base hydrolysis 9:327
- $\alpha$  1-acid glycoprotein 3:629
- acid hydrolases, lysosomal 4:203
- acid hydrolysis
- glycoproteins 2:251
- acid-fast stain 1:511
- acidification, endosomal 4:212
- acid-labile subunit (ALS) 4:401
- acids and bases
- definitions of 1:644
  - hard 1:644–648
  - metal-ion scales 1:645–646
  - soft 1:644–648
  - substitution reactions of 1:644–645
- acinetobacter 8:454
- Acipimox 14:683
- aconitase 2:609, 4:123, 8:213, 216, 217
- acoustic startle reflex 4:605
- AcpA 1:322
- acquired CNS ion channel syndromes 11:683
- acquired immune deficiency syndrome, *see* AIDS
- acquired immunity 1:358
- E. coli* lipopolysaccharide (LPS) 14:43
  - toll-like (Toll) receptors 14:43
- acquired LQT channelopathies 11:666
- acridinium esters 2:522ff
- acridinium sulfonyl 2:522ff
- acrocentric 3:561, 563
- acrosome reaction 14:10–11
- acrylaldehyde 2:68
- acrylamide gel 11:493ff
- actin 2:497, 499, 13:628, 14:2, 15:19ff, 20
- actin cytoskeleton 4:186ff, 309, 9:133
- actin filaments 4:202
  - Arp2/3 4:187
- $\alpha$ -actinin 2:338ff
- Actinobacillus pleuropneumoniae* 6:313
- actinomycete 10:641
- actinomycin D 2:590
- action potential 10:30, 11:649
- initiation by noxious stimuli 10:35–36
- action spectrum 12:414, 424ff, 435, 447, 452, 455
- activated charcoal 1:419
- activated eggs
- chromosomes 2:474
  - c-mos 2:480
  - colocalization 2:475
  - contractile ring closure 2:475
  - cortical granule exocytosis 2:480
  - cyclin B1 2:479
  - cytokinetic ring 2:474
  - MAP kinase 2:479
  - midzone microtubules 2:474
  - nuclear envelope 2:479
  - pronuclei 2:479
  - ubiquitin-dependent 2:479
- “activation function” domain 15:10

- activation of T cells  
 effector T cells 1:371  
 memory T cells 1:372  
 naive T cells 1:371
- $\gamma$ -activation sequences 15:404, *see also* GAS
- activation-induced cell death (AICD) 3:227
- activation-tagging  
 inducible activation-tagging 14:265
- activator RNA 12:45
- activator/dissociation (Ac/Ds) 14:260
- activators 3:538, 4:360, 10:315
- activators of G protein signaling 13:154
- active chromatin movement  
 evidence for 3:8
- active sites of enzymes 7:168
- active targeting  
 to diseased cells 14:178–181
- active transport 8:146  
 antiport 8:153  
 example 8:153  
 measurement 8:155  
 symport 8:153
- actinin 4:385ff, 389ff, 11:588  
 actinin A ( $\beta_A\beta_A$ ) 4:394  
 actinin AB ( $\beta_A\beta_B$ ) 4:394  
 actinin B ( $\beta_B\beta_B$ ) 4:394
- actinin receptor-like kinase 1 15:208
- actinin-like receptor kinases, *see* ALK
- $\sigma^{32}$  activity  
 control of 13:469
- activity coefficients 4:13
- activity-based protein profiling 9:108–109
- acute lymphoblastic leukemia (ALL) 2:174
- acute myelogenous leukemia 4:264
- acute myeloid leukemia (AML) 1:153, 14:191
- acute renal failure 8:453
- acute respiratory distress syndrome (ARDS) 3:150
- acute vascular rejection  
 activated endothelial cells 15:581  
 $\alpha$ 1,3Gal-deficient pigs 15:581  
 Gal $\alpha$ 1-3Gal 15:581  
 xenoreactive antibodies 15:581
- acute-phase proteins 8:447
- acute-phase response 8:448
- acyl CoA: cholesterol acyltransferases 7:218
- acyl derivatives 2:3, 4
- acylation 1:425
- acylation-stimulating protein (ASP) 7:37, 14:682
- acyl-carrier protein (ACP) 9:585, 13:661
- acyl-CoA synthase-1 (ACS1) 14:664
- 1-acyl-glycerol-3-phosphate acyltransferase (AGPAT) 14:640
- ad hoc  
 frequency counts of 10:455–456
- Ad vector  
 with modified fiber proteins 15:347
- ADAM10 15:214
- adaptation 5:315, 347, 10:30, 33, 14:131
- adaptor proteins 7:128  
 GRB2 7:130  
 PLC- $\gamma$  7:130  
 RAS/GTPase activating protein 7:130ff  
 regulatory p85 subunit of PI3K 7:130  
 Shc 7:130
- adaptive immune response 6:384
- adaptive immunity 6:341, 348–353, 407, 435–439, 8:442, 10:86
- adaptive mutagenesis  
 mechanisms proposed for 5:321–322
- adaptive mutation literature  
 critical reading of 5:320–321
- adaptor complex  
 AP-1 4:188  
 AP-2 4:187, 188, 190  
 AP-3 4:190  
 AP-4 4:190  
 appendage 4:189  
 core 4:189  
 hinge 4:189  
 $\alpha$ -subunit 4:190  
 $\beta_2$ -subunit 4:190  
 $\mu_2$  subunit 4:190  
 $\sigma_2$  subunits 4:190
- adaptor molecules 15:347–348
- adaptor protein 4:183, *see also* adaptor complex
- adaptors 8:128
- additive genetic variance 1:589, 596
- adenine nucleotide transporter (ANT) 8:165
- adenine-N6 12:326
- adeno-associated virus genome 15:247
- adeno-associated viruses (AAVs) 13:259, 15:246f
- adenocarcinoma 6:4, 9:101
- adenoma 6:11
- adenomatous polyposis coli (APC) 2:229f, 4:256, 6:15, 18f, 7:328, 9:97, 415, 12:181, 13:352
- adenosine 3',5' monophosphate 13:147ff
- adenosine deaminase (ADA) 14:685, 15:240
- adenosine diphosphate (ADP) 8:164, 169, 9:573
- adenosine triphosphate, *see* ATP
- adenosine-deaminase (ADA)-deficit 15:487
- adenosylcobalamin 4:120, 8:227
- adenosylmethionine (AdoMet) synthetase 7:169

- adenovirus 7:304, 15:241  
   recombinant 3:172  
 adenovirus genome 15:244  
 adenylate cyclase 5:560, 11:570, 573, 14:658  
 adenylyl cyclase 8:87, 325, 331, 12:41, 13:145ff,  
 155ff  
 ADH 11:697  
 adherence 1:555ff  
   nonpilus adhesins 1:565  
   phagocytosis 1:567  
   receptor 1:563–565, 566–568  
 adherens junctions (AJ) 4:279ff, 9:529, 12:184  
 adhesin 1:554ff, 559  
   colonization 1:554  
   quorum sensing 1:554  
 adhesion 10:93  
 adhesion molecules 1:396, 5:212, 219,  
 229–230  
   ICAM-1 1:359  
   integrins 1:372  
   LFA-3 1:359  
   members of the Ig superfamily 1:372  
   mucin-like molecules 1:372  
   selectins 1:372  
 adhesion receptor DC-SIGN, *see* CD209  
 adhesion receptors 13:282  
 adipocere 4:667ff  
 adipocyte 1:1–2, 14  
   antidiabetic PPAR $\gamma$  ligands 1:16–18  
   as therapeutic target for metabolic disease  
   1:15–18  
   developmental origin of 1:9–13  
   metabolism, regulation of 1:3–4  
   physiology of 1:4–9  
   vs. precursor cells 1:11–13  
 adipocyte differentiation 14:640  
 adipocyte lipid-binding protein (ALBP or aP2)  
 14:657, 669  
 adipocyte secreted factor (ADSF) 1:8  
 adipogenesis 1:11  
 adipokines 1:3, 7  
 adiponectin 7:37  
 adipophilin (ADPH) 14:647  
 adipose dysfunction  
   metabolic disease of 1:13–15  
 adipose tissue 1:2, 3  
   as endocrine organ 1:6–9  
   development of 1:9–11  
   plasticity of 1:9–11  
 adipsin 14:682  
 adjacency constraint 12:622  
 adjuvant 3:176, 10:90  
   biological 10:107  
 ADMET properties 6:590  
 adolescent skin 13:235  
 adoptee 1:592  
 adoption agencies 1:593  
 adoption studies 1:591ff  
 adoptive parents 1:593  
 ADP 7:101  
 ADPKD 11:695  
 ADP-ribosylation 14:268  
 ADP-ribosylation factor 1 (ARF1) 14:666  
 adrenaline 8:444, 446, 14:361  
 adrenergic receptor 11:574  
    $\beta$ -adrenergic receptor 8:99, 102  
    $\beta_2$ -adrenergic receptor 10:201ff  
    $\beta$ -adrenergic receptor kinase ( $\beta$ -ARK) 12:672  
    $\beta$ -adrenoceptor blocker 14:361  
 adrenocorticotropin hormone 8:444, 446  
 adrenoleukodystrophy 15:261  
 ADRP 14:643  
 adulimumab 14:459  
 adult (somatic) stem cells 13:340  
 adult stem cells 13:383, 394  
   characteristics of 13:367  
 advanced glycation end products 7:46, 47  
 adventitious agents 15:166ff, 168  
 adverse events 15:267  
 A-enzyme 5:561  
 aequorin 2:528  
 aerobic life 5:493  
 aesculetin production from aesculin 1:520  
 afadin 2:356  
 afferent nerve 10:30, 35  
 affinity 6:366, 8:13, 33, 11:105  
 affinity maturation 6:384, 398  
 affinity NMR 13:584, 592  
 affinity purification 8:13, 26, 31, 33, 34  
 affinity selection 8:411, 10:159  
 affinity tags 11:121  
 affinity-labeling 12:384  
 aflatoxin 2:68, 7:329  
 AFLP (amplified length fragment  
   polymorphism) 1:314, 317, 2:540  
 Afro-American hair 13:694  
 AGAMOUS 14:267  
 Aga1p 8:415  
 Aga2p 8:415  
 agar 1:505  
 agarose gel 1:434  
 age 13:233–237  
 age distribution 1:530, 7:540  
 age of onset 1:182  
 age-related diseases 14:222–223  
 age-related macular degeneration 12:391  
 AGEs 8:64  
 AGG interruptions 4:614

- aggrecan 5:560  
 aggregate block frequency (ABF)  
   measuring genetic diversity 13:201  
 aggregate frequency of DNA blocks (ABF)  
   degree of genetic diversity 13:193  
 aggregates 1:24  
   characterization 1:30  
   detection 1:30  
 aggregation 1:24, 8:310, 311, 321, 326  
   irreversible 1:29  
   transient 1:27  
 aggregation factor 13:279  
 aggregation processes  
   mechanisms 1:25  
 aggregation receptor 13:281  
 aggregation theory 1:531  
 aggresome 11:2, 20  
 aging 1:53ff, 65, 77, 80, 4:335, 634ff, 641, 5:498  
   accumulation of DNA damage 1:92  
   calorie restriction 1:67  
   cause of aging 1:56  
   cockayne syndrome B (CSB) 1:70, 72  
   decline in gene expression 1:57  
   declines in function 1:57, 68  
   DNA damage 1:70  
   DNA damage theory 1:53  
   DNA double-strand breaks 1:68  
   DNA repair pathway's 1:69  
   DNA single-strand breaks 1:68  
   ERCC1 1:70  
   helicase 1:70  
   helicase motifs 1:70  
   homologous recombinational repair (HRR) 1:73  
   loss of neurons 1:69  
   neurons 1:68  
   p53 1:60, 70  
   progressive irreversible deterioration of cell, tissue, and organ function 1:91  
   protein damage 1:60  
   XPD 1:70  
 aging, acceleration of  
   DNA-damaging chemicals 1:67  
   ionizing radiation 1:67  
 aging, DNA repair  
   HRR 1:63  
   NER 1:63  
   NHEJ 1:63  
 aging, enzymes in  
   CSB 1:61  
   ERCC1 1:62  
   Ku-70 1:63  
   Ku-80 1:61, 63  
   Ku-70 helicase 1:61  
   MsrA 1:62  
   p53 1:62  
   RECQ2 helicase 1:61  
   RECQ3 helicase 1:61  
   RECQ4 helicase 1:61  
   topoisomerase III $\beta$  1:61  
   topoisomerases 1:63  
   XPD helicase 1:61  
 aging, syndrome  
   bloom syndrome 1:61, 63  
   cockayne syndrome 1:61, 63  
   Rothmund–Thomson syndrome 1:61, 63  
   trichothiodystrophy 1:61, 63  
   Werner syndrome 1:61, 63  
 aglycon specificities 5:546  
 agnosia 10:116, 119  
 Ago1 14:238ff  
 AGO2 4:611  
   Argonaut 14:238  
 Ago (Cdc4, Fbw7) 12:170, 196  
 agonist 11:594, 597, 13:144ff  
 agonist trafficking 13:172  
*Agrobacterium* 10:366, 368, 436, 14:259, 269  
*Agrobacterium* plasmid Ti 10:438  
*Agrobacterium* transformation 14:549ff  
*Agrobacterium tumefaciens* 6:229  
 agronomic properties  
   generation time, citrus 14:568  
   sprouting time, potato 14:567  
 Ahlquist Jon 8:524  
 AIDS (Acquired Immune Deficiency Syndrome) 1:100, 102, 2:571, 5:305, 6:329, 608, 15:136, 160, 162ff  
 AIDS vaccine 15:163  
 AIDS/HIV  
   cell biology of 1:99–116  
   molecular biology of 1:99–116  
 AIF 10:128  
 AIM1 13:620  
 airborne precautions 10:521  
 ajmalicine 10:660  
 AKT 2:334, 7:29, 15:18  
 AKT2  
   DNA-dependent protein kinase 7:141  
   Integrin-linked kinase 7:141  
   ovarian and pancreatic cancers 7:141  
   pleckstrin homology (PH) domain 7:141  
   protein kinase B beta 7:141  
   PTEN 7:141  
 AKT (PKB) 8:328, 12:178ff  
 albino3 11:295  
 albright hereditary osteodystrophy (AHO) 5:482, 12:692

- albumin 4:212, 8:520, 11:117  
 bovine serum 7:103  
 alcohol 2:57  
 alcohol dehydrogenase 8:222  
 alcohol dehydrogenase stereochemistry 2:609  
 aldehyde 11:115  
 aldehyde dehydrogenases 2:53ff, 57  
 aldehyde oxidase 8:228  
 aldolase 7:106  
 aldosterone 11:690, 697  
 aldosterone disease 4:176  
 ALG-2  
 DAP-kinase 2:143  
 algae 2:626  
 alginate gel 1:434  
 alginic acid 2:591  
 alignment algorithm 2:76, 80  
 alignment domain 14:209  
 alizarin labeled region 13:689  
 ALK 4:397ff  
 glycine-rich patch 7:127  
 GRB2 7:127  
 insulin receptor substrate-1 7:127  
 MAM domain 7:127  
 nucleophosmin 7:127  
 Shc protein 7:127  
 Son of Sevenless 7:127  
 ALK-1 15:217  
 ALK-5 15:217  
 alkali halides 4:654  
 alkaline Bohr effect 5:284  
 alkaline borohydride treatment 5:543  
 alkaline phosphatase 8:224  
 alkanethiolates 11:119  
 alkylating agents 3:431, 436  
 alkylation of bases  
 mispairing by 12:121  
 alkylphosphonates 1:406ff  
 allantoin 4:646  
 allele 4:587, 11:686, 13:192  
 allele-specific ligase detection reaction (LDR)  
 14:432  
 allele-specific oligonucleotide (ASO) probes  
 3:489  
 allele-specific primers in a PCR (ASPCR)  
 7:606  
 allelic ladder 3:493  
 allergens 11:111  
 allergic reactions 14:40  
 degranulation  
 histamine 14:39  
 neurosensitizing molecules 14:39  
 proinflammatory 14:39  
 allergy 8:453, 455, 11:111  
 alloantigens 1:362, 2:280  
 allogeneic bone marrow transplants 15:264  
 allometric scaling 10:224  
 allometry 10:224  
 allosteric 14:2  
 modulation 7:100  
 allosteric binding site 6:156, 162  
 allosteric effects 7:170, 11:120  
 allosteric inhibitors 9:519  
 allosteric ligands 11:605  
 allosteric modulation 11:604–607  
 allosteric site 11:605  
 benzodiazepine (BZ) 11:599  
 allosteric switch  
 conformational changes 11:538  
 Gln194 11:538  
 sensor of ATP binding 11:538  
 allosteric transition 5:397, 11:607  
 allostery 5:266, 269, 6:68ff, 81–84ff, 8:576,  
 11:42  
 allosteric core 6:84  
 allosteric parameters 6:83  
 allosteric protein 6:68  
 allosteric transition 6:81  
 quaternary states 6:82  
 R state 6:82  
 T state 6:82  
*see also* hemoglobin  
 allotransplantation 13:211  
 alloxan 4:643  
 allozymes 5:250, 256  
 allyl alcohol 2:68  
 alphoid DNA 1:488  
 ALS  
 pathological findings of 8:565–566  
*see also* acid-labile subunit  
 alsin mutations 8:544  
 altered recognition specificity 12:332  
 alternate splicing 12:24, 60  
 alternate transcripts, *see* alternative  
 splicing  
 alternative marker systems 14:553  
 alternative pathway 14:448  
 alternative pre-mRNA splicing 1:142–152  
 alternative splice forms  
 identification of 2:80  
 alternative splicing 1:126, 137, 4:594, 9:255,  
 12:102, 716  
 developmentally regulated 1:151–152  
 generating genetic diversity 1:142–144  
 genetic diversity 1:143–144  
 patterns of 1:143  
 regulation in response to extracellular stimuli  
 1:152

- role in regulating gene activities 1:142–144  
 tissue-specific 1:151–152  
 alternative splicing regulation  
   mechanisms of 1:144–151  
 alternatively spliced genes 1:125–162  
 Alu 1:255, 257, 263, 265ff, 285ff, 296, 9:262  
   7SL 1:266  
   *see also* short interspersed repeat element  
 Alu repeat 15:555, 562  
   Alu-PCR 5:456ff  
 Alu sequences 3:37  
 alveolar macrophages 10:88  
 Alzheimer's disease (AD) 1:45, 184, 609,  
   3:562, 4:332, 641, 8:201, 219, 453, 503, 12:693,  
   13:318, 695, 15:13ff, 262, 378  
   A $\beta$ 1–40 1:46  
   A $\beta$ 1–42 1:46  
 amaurosis 10:116  
 amaurosis, ataxia 10:119  
 amber 11:46, 48–50, 12:626  
 amber codons 2:456  
 amber-suppressor tRNA 11:46  
 American Caucasians 13:209  
 American Society for Microbiology (ASM)  
   10:515  
 American Society of Clinical Oncology (ASCO)  
   9:531  
 American Tissue Culture Collection 11:105  
 amidases 2:53, 59  
 amide 11:115, 116  
 amide bands 4:668ff  
 amide I band 13:686, 694  
 amide-exchange 13:524, 535  
 amine oxidase 8:219, 220  
 amino acid 1:651, 4:669ff, 10:7, 17, 18, 14:91,  
   104  
   D-enantiomers 2:589  
   three-letter 3:244ff  
 amino acid analysis 3:253  
 amino acid composition  
   essential amino acids 14:569  
 amino acid conjugates 2:64  
 12 amino acid–long oligopeptide  
   enhanced transfection rates 15:494  
 amino acid symbols  
   common symbols for 3:245  
   one-letter symbol 3:245  
   three-letter symbol 3:245  
 amino acid transport  
   system L 8:152  
 aminoacyl 12:486  
 aminoacyl adenylates 10:19  
 aminoacyl-tRNA synthetase (aaRS) 11:46, 49  
 aminoacyl-tRNAs 12:486  
 $\gamma$ -aminobutyric acid (GABA) 12:653, 15:265  
 aminocarbolines 4:515  
 aminogluthetimide 13:52  
 $\delta$ -aminolevulinate synthase 8:349  
 aminomutase 1:426  
 aminooxy peptides  
    $\alpha$ -aminooxy peptides 14:72  
    $\beta^3$ -aminooxy peptides 14:72  
    $\gamma^4$ -aminooxy peptides 14:73  
 7 $\alpha$ -(4'-amino)-phenylthioandrosta-4,6-diene-  
   3,17-dione 13:55  
 7 $\alpha$ -(4'-amino)phenylthio-4-androstene-  
   3,17-dione 13:54  
 amino-terminal propeptide 1:38  
 aminothiols 11:115  
 AML-ETO 2:233  
 ammonia 10:5, 9  
 ammonia as a morphogenetic signal 8:334  
 ammonia, detection of 1:518  
 ammonium cyanide 10:12  
 amnion 4:404  
 amnioserosa 4:286ff  
 amoebozoa 3:326, 330  
 AMP 7:101  
 AMP kinase (AMPK) 14:637ff  
 AMPA 10:121  
 AMPA receptor 4:620, 11:562, 563  
 amphipathic helix 7:281, 10:294  
 amphiphilic drugs 14:188  
 amphiregulin 5:648  
 amphiregulin (AR) 6:16, 22  
 amplicons 3:481, 11:482ff, 15:252  
 amplification 4:3, 18  
 amplification control element (ACE) 12:194  
 amplification mechanisms 4:14  
 amplification of cyclin D1 and EGFR genes 6:6  
 amplification of the cyclin D1 gene 6:23  
 amplified fragment length polymorphism  
   (AmpFLP) 1:313, 3:481  
 AMPPD® 2:528  
 AMT, *see* accurate mass tag  
 AMV-RT 11:485ff  
 amylase 2:254  
 amyloglucosidase 2:254  
   *A. oryzae* 5:7  
    $\beta$ -amyloid 1:183  
   amyloid 15:25ff  
   amyloid fibrils 1:24, 45  
   amyloid precursor protein (APP) 3:565  
   amyloidoses 1:45  
   amylopectin 2:258  
   amyotrophic lateral sclerosis (ALS) 8:231, 542,  
     560, 562, 15:13ff  
 anabolic 13:2, 3, 31

- anabolic agents 13:30  
 anabolic (myotrophic) 13:6  
 anabolism 11:29  
 anaerobic cultures  
   biochemical examination of 1:520  
   jar 1:509  
   Robertson's cooked meat broth 1:509  
   stab and shake cultures 1:509  
   thioglycolate medium 1:509  
 Anakinra 14:459  
 analog-based design 13:547  
 analysis  
   aging 5:414  
   amplification analysis 5:431  
   cancer 5:414  
   cloned animal 5:436  
   discrimination 5:436  
   identification of individuals 5:431  
   imprinting gene 5:431  
   linkage analysis 5:430  
   loss of heterozygosity 5:431  
   phylogenetic analysis 5:431  
   polymorphism 5:436  
   positional cloning 5:436  
   tumor 5:436  
 analytical chemistry 8:190, 192ff  
 analytical development 15:166ff  
 analytical reverse-phase HPLC 3:252  
 analytical ultracentrifugation 11:406ff  
 analyzers 8:9  
 anandamide 14:331  
 Anandron 13:47  
 anaphase promoting complex (APC) 14:21  
 anaphylatoxin C5a 8:439  
 anaplastic lymphoma kinase 7:126  
   midkine 7:127  
   pleiotrophin 7:127  
 ancestral core 11:448  
 ancestral haplotypes (AHs) 13:197  
 ancestral polymorphism 2:559  
 anchor markers 5:406  
 anchorage dependence 12:184ff  
 anchors 1:365  
 ancient rocks 10:6  
 Andersen syndrome 11:665, 673, 674  
   sugar amino acids 14:71  
 androdioecy 9:56  
 androgen ablation 13:44  
 androgen antagonists 13:3  
 androgen binding protein (ABP) 13:11  
 androgen receptor (AR) 2:208–209, 13:3, 19  
 androgen-deficient diseases 13:3  
 androgen-dependent tissues 13:18  
 androgenetic 5:472, 473  
 androgenetic development 15:613  
 androgen-inducible proteins 13:21  
 androgenote 10:75  
 androgen-responsive elements (AREs) 13:19  
 androgens 13:2–4  
 androisoxazole 13:39, 42  
 androstadiene 3-carboxylic acids 13:51  
 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol 13:11  
 5 $\alpha$ -androstane-3 $\beta$ ,17 $\beta$ -diol 13:11  
 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol 13:13  
 androst-5-ene-3 $\beta$ ,17 $\beta$ -diol 13:8  
 androstenedione 13:11, 15  
 androsterone 13:4, 13, 25  
 anencephaly 9:120, 127  
 anergy 1:373, 3:226, 6:466, 476  
 anesthetics 9:565  
 anesthetics, chiral 2:603  
 aneuploid 6:141  
 aneuploidy 5:370  
 Anfinsen 1:25, 2:498  
 Ang2 15:215  
 Angelman syndrome 5:478, 481  
 angina pectoris 5:212, 232  
 angiogenesis 2:172, 4:338, 406, 5:212, 229,  
   637, 8:68, 69, 444, 9:497, 523, 527–528,  
   13:224, 242, 243, 401, 14:164, 174, 191, 284,  
   15:203, 215, 218  
   blocking through inhibiting HIF1 activity  
   2:182–184  
 angiogenesis inhibitors 15:221  
 angiogenic response 15:266  
 angioplasty 5:212, 229  
 angiopoietin-1 15:206  
 angiopoietin 14:298, 15:203, 210, 215  
 angioperms 14:252  
 angiostatin 15:221  
 angiotensin-converting enzyme (ACE) 8:89,  
   98, 14:106, 360  
 anhydrous reaction 10:19  
 animal 3:410, 6:182, 8:350  
 animal identity 3:495  
 animal models 1:462, 4:603, 7:382, 15:142  
 animal models of disease 8:201  
 animal patent 7:368, 369  
   at EPO 7:380  
   in United States 7:379–380  
 animal species  
   amphibians 1:212  
   cattle 1:212  
   fish 1:212  
   goats 1:212  
   insects 1:212  
   mouse 1:212  
   nematodes 1:212

- poultry 1:212  
 rabbits 1:212  
 rats 1:212  
 ruminants 1:212  
 sheep 1:212  
 swine 1:212  
 animal studies 1:597  
 animal welfare 7:385, 541  
 anion exchange chromatography (AEX) 13:266  
 anion selectivity 8:359  
 anisotropic hyperfine 7:160  
 ankyrin repeats 14:442  
 ankyrin-b 11:665  
 ankyrins 8:422  
 annealing temperature 11:488ff  
 annexins 1:241, 2:155  
 annotation 5:532, 7:480, 12:608, 615  
 annotation of functional RNA 12:595  
 annotation system 12:616  
 ANNs 3:611  
 anomalous difference patterson map  
   peaks of the anomalous scatterers 7:434  
 anomalous scattering  
   classical differential equation of the motion of  
     a particle of mass  $m$  7:431  
   classical treatment 7:431  
   dipole-oscillator 7:431  
   Dirac–Slater wave functions 7:432  
   ejection of a photoelectron 7:431  
   experimental determination  
     absorption coefficient  $\mu_0$  7:432  
     fluorescence 7:433  
     Kramers–Kronig transformation 7:433  
     tunable synchrotron radiation 7:433  
    $\Delta f''$  absorption component in anomalous  
     scattering 7:432  
    $\Delta f'$  dispersion component 7:432  
   natural absorption frequency  $\omega_{kn}$  7:431  
   Thomson scattering 7:431  
   total real part of the atomic scattering factor  
     7:432  
 anomeric configuratic  
    $\alpha$  5:539  
    $\beta$  5:539  
 anomeric linkages 2:269  
 anomeric signals 2:263  
 anonymous genetic markers 2:540  
 anopheles 7:473, 10:542  
*Anopheles gambiae* 10:545  
 A-norprogesterone 13:45  
 anosmia 12:638, 658  
 antagonist 11:594, 600, 601, 604, 607, 608,  
   620, 13:144ff  
 antennapedia 2:101, 6:181ff, 194  
 antennapedia complex 6:190ff  
 antennapedia-class 13:303  
 anterior commissure (AC) 12:656  
 anterior olfactory nucleus (AON) 12:656  
 anterior pituitary  
   gonadotrophs 5:553  
   thyrotrophs 5:554  
 anterior subventricular zone (aSVZ) 12:653  
 anterior visceral endoderm (AVE) 2:89  
 anterograde transport 8:127  
 anteroposterior ends 13:272  
 anthracycline 14:189  
 anthrax 1:309ff, 318, 6:304, 8:230  
 anthrax toxin 1:312, 321  
   antigen 1:319  
   cya 1:320  
   edema factor 1:309, 319  
   lef 1:320  
   lethal factor 1:309, 319  
   pagA 1:320  
   protective 1:319  
   protective antigen 1:309  
 anthrax toxin receptor 1:310  
 anthropocentrism 5:317  
 antiandrogenic effects 13:43  
 antiandrogens 13:3, 44  
 antiapoptotic proteins 9:469  
 antiarrhythmics 11:667  
 antiasthma drugs 14:364  
   Contignasterol 14:366  
   Ephedrine 14:365  
   Isoprenaline 14:365  
   Khellin 14:363  
   Salbutamol 14:365  
   Sodium Cromoglycate 14:363  
 antibiotic inhibition  
   modes of 12:495  
 antibiotic resistance 4:356, 6:228, 10:441,  
   12:495  
 antibiotics 2:628, 11:667, 14:349–353, 357  
   Echinocandins 14:356  
   Erythromycin Macrolides 14:354  
    $\beta$ -Lactams 14:348  
   Streptogramins 14:355  
 antibiotics targeting  
   large subunit of 12:501–502  
 antibody 1:201, 360, 2:38, 4:100, 108, 363,  
   6:363, 8:448, 506, 10:214, 217, 218, 225, 230,  
   231, 660ff, 11:103, 675, 14:190–192  
   AB-3 5:362  
   carrier protein 3:254  
   chain promiscuity 3:88  
   classes of 1:332–334  
   engineering of 1:331–334



- antibody (*continued*)
- Fab 3:79, 80
  - genetic modifications of 1:340–346
  - gold-conjugated 4:106
  - gold-labeled 4:105
  - humanized monoclonal 3:77
  - humanizing 3:77
  - monoclonal 3:76, 77
  - MOPC21 5:362
  - multiple antigen peptide 3:254
  - neutralizing 3:86–88, 89, 90, 91, 162, 177
  - scFv 3:79, 80
  - structure of 1:331–334
  - subclasses of 1:332–334
  - template-assembled synthetic protein 3:254
  - types of carbohydrate epitopes: terminal and internal structures 2:289
- antibody arrays 3:50
- antibody complexation 10:225
- antibody fragments 8:412
- antibody fusion proteins 1:344–346
- antibody labeling method 4:42
- immunogold-labeling 4:40
  - on-section 4:40
  - procedure 4:40
- antibody mimetic libraries 8:421
- antibody mimetics 11:106
- antibody molecules
- expression systems 1:346
  - genetic engineering of 1:329–346
- antibody production 1:338–340
- antibody therapy 6:477–478
- antibody/antigen 1:330
- antibody-based therapeutics 14:155
- antibody-dependent cell-mediated cytotoxicity (ADCC) 1:330, 332, 8:606, 15:410
- antibody-mediated enhancement of infection 15:164
- antibody-secreting cells (ASCs) 2:294
- anticancer agent 15:390
- anticancer drugs 14:338, 341–342, 345–346, 348
- Camptothecin 14:339
  - Catharanthus (Vinca) alkaloids 14:337
  - Docetaxel 14:340
  - Epothilones 14:343
  - Etoposide 14:344
  - marine sources 14:347
  - Paclitaxel 14:340
  - Podophyllotoxin 14:344
  - Teniposide 14:344
- anticancer therapy 13:405
- anticatabolic effect 13:33
- anticentromere antibodies 1:485
- anticipation 15:5ff
- anticoagulants 1:247
- anticoagulation factor 5:559
- anticodon 2:453, 5:390, 12:484
- codon interaction 14:589
  - definition 14:580
  - tRNA loop 14:588
- anticodon triplet 12:488
- antidiuretic hormone (ADH) 11:696
- antiendothelial cell antibodies 1:497
- antifreeze proteins (AFPs) 14:496
- antifungal 4:343
- antifungal activity
- Papaver somniferum* 5:15
  - Peniophora gigantea* 5:15
  - Trichoderma viride* 5:15
- antigen 1:331, 385, 4:363, 370, 6:384, 388, 11:105, 14:454, 15:165, 263
- biochemical nature 1:361
  - entry sites 1:362
  - foreign 1:386
  - origin 1:362
  - presentation of 6:432–435
  - self 1:386
  - types 1:360
- antigen arrays 11:111
- antigen delivery system
- antibody mediated uptake 3:222
  - exosomes 3:222
  - peptide loading 3:220–224
  - protein loading 3:220–224
- antigen detection system
- ELISA 6:449, 450
  - primary antibody 6:449
  - RIA 6:449
  - sandwich assays 6:455
  - secondary antibodies 6:449
- antigen driven theory 1:489
- antigen entry sites 1:362
- antigen pattern recognition receptors (PRRs) 3:218
- antigen presentation 1:368, 385, 3:219
- cross-presentation of 3:220
  - duration of 6:350
  - on CD1 molecules 3:220
- antigen presenting molecules
- CD1 molecules 1:366
  - MHC class I 1:364
  - MHC class II 1:366
- antigen processing 1:367, 395, 3:219–220
- MHC class I 1:368
  - MHC class II 1:370

- antigen receptor  
  B-cell 1:360  
  T-cell 1:360
- antigen recognition receptors 1:376
- antigenic determinants  
  sizes 2:288
- antigenic peptides 1:364, 386
- antigenic variation 15:164
- antigen-presenting cell (APC) 6:349, 392, 429, 432, 13:639, 642  
  cellular immunity 1:358  
  humoral immunity 1:358  
  *see also* APC
- antigen-producing cells 15:246
- antigen-specific immunity  
  antibodies definition 1:357  
  antigens definition 1:357
- antihistamines 11:667
- anti-inflammatory cytokines 8:448
- anti-inflammatory drugs 8:636  
  antiproteinase 8:637  
  lipoxin 8:637
- antimicrobial activity 1:570, 14:370, 15:408, 410
- antimicrobial agents 14:369
- antimicrobial defense 10:88
- antimicrobial peptides 6:424, 10:88
- antimicrobial resistance 1:554
- anti-Müllerian hormone (AMH) 4:396, 5:609
- anti-nRNP 1:464
- antinuclear antibody (ANA) 1:483
- antinutritive factors, reduced 14:570
- anti-oncogene 12:122
- antioxidant 4:634ff, 5:500, 7:166, 175
- antioxidant enzyme  
  superoxide dismutase (SOD) 1:65
- antioxidant responsive element (ARE) 5:502
- antioxidants, dietary 1:67
- antiparasitic drugs 14:367, 369–371, 373–374  
  Artemether 14:366  
  Artemether 14:366  
  Artemisinin 14:366  
  Avermectins 14:372  
  Chloroquine 14:368  
  Mefloquine 14:368  
  Milbemycins 14:372  
  Quinine 14:368
- antiport 8:153
- antiproliferative activity 15:408, 415
- antiproliferative signal 12:166
- antipsychotic drugs 1:599
- antiretroviral drugs 1:100, 114
- antiscorbutic 15:516
- antisense 1:214, 436, 4:335, 8:113, 14:267  
  sense–antisense principle 1:413
- antisense oligonucleotides 2:121, 9:429–430, 10:226, 14:168
- antisense peptides 3:256
- antisense RNA 3:340, 10:412, 415, 418  
  in therapy 10:261
- antisense technology 1:404ff
- anti-smith antigen (Sm) 1:464
- anti-SS-A/Ro 1:464
- anti-SS-B/La 1:464
- anti-topo I 1:485
- $\alpha$ 1-antitrypsin 15:260
- antitumor activity 4:210, 15:410
- antitumor agent 1:415
- antitumor estrogens 1:449–457
- antitumor estrogens, targeting of  
  restrictive conditions for 1:445–449
- antitumor steroids 1:439, 442–457  
  background of 1:440–441
- anti-type II collagen antibodies 5:560
- antiviral activity 15:390, 405, 408, 410
- antiviral compounds  
  hydantoin 5:105, 112  
  ribavirin 5:107  
  ribonucleoside analogs 5:107
- antiviral immunity 15:252
- antiviral protein  
  2-5A synthetase 15:406  
  dsRNA-activatable protein kinase 15:406
- anxiety 4:604
- aorta-gonad-mesonephros region 15:204
- AP-1 10:132
- AP endonuclease 3:433ff, 10:130
- AP lyase activity 9:390
- AP sites 3:434
- Apaf-1 10:129, 621, 622, 625, 627, 628
- AP-1 and AP-2 adaptors 8:128
- APC, *see* adenomatous polyposis coli
- APC, *see* antigen presenting cell
- APC LOH and DCC LOH 6:23
- APC mutation 6:11, 23, 24
- APC, nonprofessional 1:359  
  keratinocytes 1:360  
  myoblasts 1:360  
  thymic cortical epithelial cells (cTECs)  
  1:360  
  thymic medullary epithelial cells 1:360
- APC, professional 1:358  
  B lymphocytes 1:359  
  dendritic cells (DCs) 1:359  
  macrophages 1:359
- APCs 1:361ff
- AP2/EREBP families 14:266

- APETALA1 14:271  
 APETALA3 (AP3) 14:263, 271  
 AP1 (Fos/Jun) 12:176  
 APH-1 1:192ff  
 apical 4:200ff  
 apical–basal axis 13:304  
 apical membrane 5:212, 222, 11:684  
 apical recycling endosomes (ARE) 4:200  
 apicidin 4:269  
 AP1 (Jun/Fos) 12:184  
 ApoA1 5:213, 226  
 ApoA2 5:226  
 ApoA5 5:228  
 ApoA-I 7:198, 211, 214, 225, 226  
   variants 7:227  
 ApoA-II 7:225–228  
 ApoA-IV 7:198, 211, 225, 226, 228  
 ApoA-V 7:198, 211, 225, 226, 228  
 ApoB 7:198, 205, 210, 226, 235  
   ApoB-48 7:229  
   ApoB-100 7:229  
   ApoB48 remnants 7:232  
   hypervariable region 7:230  
   mRNA  
     editing 7:229  
     mutations 7:209  
   polymorphisms 7:230  
 ApoB48 5:213  
 ApoB100 5:213, 224  
 ApoC-I 7:198, 225, 226, 230, 232  
   pseudogene 7:233  
 ApoC-II 7:198, 202, 225, 226, 232, 233  
   deficiency 7:231  
   variants 7:231  
 ApoC-III 7:198, 211, 225, 226, 227, 231, 232  
 ApoC-IV 7:198, 225, 226, 232, 233  
 apocrine sweat glands 13:232  
 ApoD 7:226, 236  
 ApoE 5:213, 228, 7:198, 225, 226, 232  
   Alzheimer disease 7:234  
   common alleles 7:233  
   deficiency 7:234  
   gene inactivation 7:233  
   transgenic mice 7:233  
 apoenzyme 9:571, 576  
 ApoH 7:226, 236  
 ApoJ, *see* clusterin; SP-40/40  
 ApoLI 7:226, 237  
 apolipoprotein 7:40, 226ff, 278  
   genes 7:226  
 apolipoprotein (a) 7:226, 235  
 apolipoprotein assays 7:285  
 apolipoprotein E 1:187ff  
   allele frequency 1:187  
   alleles 1:187, 194  
   functions 1:194  
   gene 1:187  
   genetic risk factor 1:187  
   molecular mechanisms 1:194  
   protein 1:187  
 apolipoproteins 5:213, 221, 7:198ff, 225ff, 280, 281  
   atherosclerosis prevention of 5:227–228  
   evolution 7:225  
   structure 7:225  
 apomicts 1:78  
 apomixis 14:265  
   adventitious embryony 12:290  
   gametophytic apomixis  
     apospory 12:290  
     diplospory 12:290  
   sporophytic apomixis 12:290  
 apoptosis 1:247, 390, 431, 495, 2:142, 197, 228, 3:277, 278, 4:335, 392, 432, 638, 5:213, 232, 637, 6:384, 393, 7:36, 503, 8:361, 440, 444, 9:133, 497, 528, 10:127ff, 178, 182, 247, 289, 618, 619, 622, 623, 626, 627, 628, 630, 12:156, 163, 178, 187, 348, 364–365, 13:285, 317, 690, 14:2, 438, 451, 457, 634ff, 15:266, 293, 513  
   ATM 9:11  
   Bcl2 9:11  
   bcl-2 family 7:505  
   death receptor 7:521  
   DNA damage 9:11  
   extrinsic activation 10:128  
   family of enzymes, p53, p63, and p73 1:64  
   FasL 15:294  
   intrinsic 10:128  
   lymphocytes 15:294  
   p53 1:63, 83, 7:522  
   pathway 7:521  
   poly(ADP-ribose) polymerase, or PARP 1:63  
   protective mechanism 1:82  
   p66<sup>shc</sup> 1:58  
   p66Shc 1:73  
   thyrocytes 15:294  
 apoptosis protein (IAP) family  
   inhibitors of 9:470  
 apoptosis-inducing factor 10:128  
 apoptosis-inhibitory proteins (IAPs) 8:547, 10:622f, 631  
 apoptosome 10:129, 622  
 apoptotic bodies 1:390  
 apoptotic cell death 1:463, 7:330  
 apoptotic cells 3:221–222  
   clearance of 10:182  
 aporepressors 3:513

- APP  
 alternative splicing 1:189  
 FAD mutation 1:185  
 gene 1:184, 189  
 homologs 1:189  
 mRNAs 1:189  
 mutations 1:184  
 normal function 1:189  
 proteolytic processing 1:189ff
- AP-PCR (arbitrary primed polymerase chain reaction) 3:490
- application 4:423, 10:169  
 bioluminescent 2:527  
 chemiluminescent 2:527
- applications of DNA libraries 3:417
- applied biosystems (AB) 6:557
- apposition system 6:376
- appressorium 10:370
- apraxia 10:116, 119
- aptamer 10:242, 11:106
- AQP2 11:696
- AQP2 shuttle 3:311
- aquaporin (AQP) 3:303, 4:637, 8:149ff, 11:150, 696  
 in kidney 3:309–311
- ara C 12:39
- Arabidopsis* 5:506, 10:377–379, 12:455ff
- Arabidopsis thaliana* 2:624, 10:361, 550, 13:619, 14:255  
 chromosomes 14:253  
 Columbia 14:260  
 Landsberg erecta 14:260  
 Wassilewskija 14:260
- 2'-arabino-RNA 9:409
- arabinose 2:249
- arabinose operon 12:39
- arachidonic acid 4:120, 7:98
- archaea 7:249, 251, 8:238f
- archaea lipids 7:252
- archaeal ribosomes 8:249
- archaeobacteria  
 molecular biology of 8:237–257
- archaeocytes 13:277
- Archea 11:51
- architectural signaling 14:401–403
- Arf-family GTPases  
 ARF1 4:199  
 Arf6 4:192
- arginase 8:227, 228
- argininosuccinate lyase 2:629, 634
- ARGONAUTE 14:269
- Arg-vasopressin (AVP) 3:304
- ARH, *see* autosomal recessive hypercholesterolemia
- Aril 1:417
- A-ring 1:446
- A-ring complexon 1:450–451
- Aristaless related homeobox (ARX) protein 15:49
- Aristotle 13:331
- armadillo repeats 15:51
- (aRNA) amplification 8:501
- ARNO 4:200
- Aromasin 13:55
- aromatase 13:14, 17
- aromatase inhibitors 13:53
- aromatic hydroxylation 4:645
- aromatic ring interactions 3:535
- aromatization 13:15
- arrestin 4:390, 13:150ff, 165
- arrestin domain 15:23
- arrhythmia 11:662, 665
- Arteether 14:366–368
- Artemether 14:366–368
- Artemisinin 14:366–368
- arterial 15:207, 216
- arteries 15:208
- arteriogenesis 14:284ff
- arthritis 11:111, 14:47, 48  
 cartilage erosion  
 bone destruction 14:39  
 osteoarthritis (OA)  
 cartilage 14:39  
 degenerative joint disease  
 back 14:39  
 feet 14:39  
 hips 14:39  
 joint space 14:39  
 knees 14:39  
 weight-bearing joints 14:39
- ArthroSoft® 14:50
- arthrosynovitis  
 chemoattractants 14:41  
 MCP-1 14:41  
 RANTES 14:41
- artificial intelligence (AI) 10:472
- aryl hydrocarbon receptor 2:54
- arylsulfatase 2:630
- ascites 7:537
- ascomycin 13:571–572  
 bound to FKBP 13:573
- ascorbate peroxidase (APX) 6:39
- ascorbic acid 4:641, 15:515  
 differentiation of 15:520–521  
 extracellular matrix production 15:518–519  
 noncollagen gene expression 15:519–520  
 transport of 15:516–518
- ascospores 8:312

- asialoglycoprotein receptor 7:309ff, 15:528  
 A-signal 8:309  
 aspartyl protease 10:202  
 aspartylglucosaminuria (AGU)  
   *N*-aspartyl- $\beta$ -glucosaminidase (AGA) 5:590  
*Aspergillus niger* 5:3  
 Asperlicin 14:332–334  
 Aspirin 14:458  
 assay  
   alcohol 2:531  
   glucose 2:531  
 assay design 11:503ff  
 assemblage of polymers 10:4  
 assembly 5:522, 7:304ff  
 assembly process of the flagellum 8:402, 403  
 assembly software package  
   PhrapView 13:99  
   Phred-Phrap-Consed 13:99  
 assignment protocols 13:549  
 assisting protein folding  
   action in 13:490–492  
 association analysis 6:606, 10:656  
 association kinetics 11:403  
 Association of Professionals in Infection  
   Control and Epidemiology (APIC) 10:520  
 association studies 1:599, 601, 602, 609  
 associative expression networks 5:78  
 asteroid 10:8  
 asthma 4:341, 8:453, 10:201  
 astrocytes 2:108, 13:410ff, 418, 421  
   horizontal astrocytes 13:421ff  
   radial astrocytes 13:421ff  
   SGZ astrocytes 13:421ff  
   SVZ astrocytes 13:418ff  
   ultrastructural properties 13:418  
 A-subunit 5:560  
 asymmetric division 13:331, 334, 339  
 ASYMMETRIC LEAVES1 14:264  
 ataxia 10:116, 11:682  
 ataxia telangiectasia (ATM) 9:100  
 ataxia-telangiectasia mutated (ATM)  
   Hodgkin's lymphoma 7:142  
   immunologic deficiency 7:142  
   lymphoid cancers 7:142  
 ataxin-1 15:16  
 ataxin-2 15:19  
 ataxin-3 15:20  
 ataxin-7 15:22ff  
 ataxin-2 binding protein-1 (A2BP1) 15:19  
 Atenolol 14:361  
 atherogenesis 7:239  
 atheroma 7:208, 15:264  
 atherosclerosis 4:338, 634, 5:213, 217–221,  
   226, 7:239, 278, 8:201, 202, 15:217  
 atherosclerotic  
   foam cell formation 7:237  
   foam cells 7:233  
 ATM 12:187  
   cancer 1:82  
   Cdc25C/14-3-3 complex 7:143  
   Chk2 and c-Abl 7:143  
   DNA double-strand breaks 7:143  
   FAT (FRAP, ATM, and TRRAP) domain  
     7:143  
   G2/M checkpoints 7:143  
   G1/S checkpoint 7:143  
   PI-kinase domain 7:143  
   p53 pathway 7:143  
 atomic clash constraint 12:621  
 atomic force microscopy (AFM) 9:20, 35  
 atoms 7:173  
 ATP 2:532, 8:164, 168, 169, 226, 10:43, 11:117  
   turnover of ATP 8:170  
 ATP Cap  
   allosteric effects 11:532  
   Pro307 11:532  
   residues 11:532  
   subunit–subunit interactions 11:533  
 ATP hydrolysis 1:82  
   motor activity 11:533  
   strand exchange 11:533  
 ATP hydrolysis reaction 8:169  
 ATP sensing  
   alternating interfaces 11:540  
   cross-subunit interactions 11:540  
   filament assembly by 11:538  
   hypercooperativity mutant 11:538  
   Phe217 11:538  
   subunit communication 11:540  
 ATP synthase 8:165, 180, 181, 224  
 ATP synthesis 8:171  
 ATP synthetase 2:628  
 ATP1A2 11:682  
 ATP/ADP ratio 8:168  
 ATPase 10:427  
   (Ca<sup>2+</sup>) 8:153  
   (Na<sup>+</sup>, K<sup>+</sup>) 8:153  
   proton translocating 11:334–353  
 ATPase NSF 4:310ff  
 ATP-binding cassette transporter A1 5:212,  
   223, 226, 7:198, 213, 214  
 ATP-dependent motor domain 12:328  
 ATP-dependent protease 2:628  
 ATR 12:187  
   cancer 1:82  
 ATR spectroscopy 13:683  
 Atracurium 14:334–337  
 atrial natriuretic peptide (ANP) 10:218

- AT-rich or GC-rich repeats 13:99  
 atrophin-1 15:15  
 attachment 12:405  
 attachment protein (G) 12:302–303  
 attenuated total reflectance spectroscopy (ATR) 4:652, 654ff, 13:682  
 attenuation 5:370, 397, 6:302, 12:24  
 attenuator 12:35  
 atxA 1:319, 321, 322  
 atypical homeodomains 6:187  
 atypical protein kinase C (aPKC) 12:185  
 AUC 3:616  
 audiogenic seizures 4:606  
 authentication 3:496  
 autism 4:591  
 autoantibodies 1:460, 483, 11:674, 15:413  
 autoantigen  
   degradation 1:497  
   fragmentation 1:496  
 autocatalysis 14:132  
 autoclaving 1:420  
 autocorrelation function 4:463  
 autocrine 5:638, 648  
 autocrine signaling 3:274  
   autocrine loop 3:275  
   placental cytotrophoblast cells 3:275  
   platelet-derived growth factor 3:275  
   transforming growth factor alpha 3:275  
 autofluorescence 15:75  
 autoimmune channelopathies in muscle 11:674  
 autoimmune disease 1:283, 8:455, 11:111, 15:413  
   ethnic variations 13:212  
   paralogous genes 13:212  
   systemic lupus erythematosus (SLE) 1:362  
 autoimmune encephalomyelitis 11:112  
 autoimmune lymphoproliferative syndrome (ALPS) 1:477  
 autoimmune reactions 15:273  
 autoimmune response 11:111  
 autoimmunity 1:393, 399, 460  
   mast cells 14:42  
 autologous adult stem cells 13:356  
 autolysin 2:629  
 automated drug design 10:203  
 automated fitting procedures 13:690  
 automated oligonucleotide synthesis 1:407  
   postsynthetic solution-phase 1:410  
   solid-phase synthesis 1:410  
 automixis 1:77  
 autonomous element 14:260  
 autophagosomes 1:627  
 autophagy 15:24  
 autophosphorylation 7:28ff  
 autoradiography 5:419, 8:124, 11:118, 412, 420, 429  
 autosomal 5:377  
   inheritance 5:370  
   sex-determining genes 5:625  
   SF1 Gene 5:625  
   WNT-4 gene 5:625  
   WT1 gene 5:625  
 autosomal dominant 11:694, 695  
 autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) 11:679  
 autosomal recessive hypercholesterolemia 7:211  
 autosomes 3:561, 563, 12:112, 14:6  
 auxilin  
   auxilin 1 4:194  
   auxilin 2 4:194  
 auxin 1:419, 10:337  
 auxin responsive element (ARE)  
   regulation by 10:337–339  
 auxotroph 13:438ff  
   complementation 13:438  
 average insert size 3:402  
 average linkage 8:525  
 Avermectins 14:372–374  
 Avers 13:614  
 avidin 6:449–452, 456, 15:521–522  
 avidin-affinity purification 8:21  
 avidity effect 3:81  
 Avilamycin 10:647ff  
 avirulence 10:367, 373, 376  
 axin 2:229, 7:328, 330, 12:181  
 axis-pattern formation 13:293  
 axon 11:675  
   collaterals 9:142  
   myelin 9:142  
   Nodes of Ranvier 9:142  
   synaptic boutons or terminals 9:142  
 axon branching and guidance  
   CPG15 9:157  
   critical period 9:155  
   CRMP 9:158  
   electrical activity 9:155  
   ephrins 9:156ff  
   netrin-1 9:155ff  
   semaphorins 9:156ff  
   slits 9:156ff  
 axonal transport 15:261  
 axonemal 2:639  
 axonemal dynein 8:391, 392  
 axoneme 8:389–391  
 axons 2:107  
 axotomy models 8:547

- Ayers, Rupp, and Johnson's medium 1:517  
 5-azacytidine (5-Aza) 4:268  
 5-aza-2'-deoxycytidine 4:268  
 5-azadeoxycytidine 4:620  
 azapeptides 14:68  
   azaamino acid 14:69  
 4-azasteroids 13:49  
 azide 11:64, 123
- b**
- B env (gp41), gag, and protease 15:147  
*B. subtilis* 4:365  
 BabA2 6:14  
 baby machine 1:533, 549  
 BAC (bacterial artificial chromosome) 2:536,  
   540, 620, 624, 3:387ff, 5:119, 528, 10:549,  
   11:434, 12:104, 15:556, 560, 565, 620  
   clone stability 13:79  
   cloning large DNA fragments 13:79  
   plasmids 13:79  
   see also bovine artificial chromosome  
 baccatin III 1:427  
 BACE1 1:189ff  
 BAC-end sequences 5:529  
*Bacillus* 4:365  
*Bacillus anthracis* 1:309ff, 8:230  
*Bacillus cereus* 1:311ff  
*Bacillus subtilis* 1:546, 4:365, 6:227, 8:299ff  
   AbrB 8:302  
   chiral growth patterns 2:613  
   mother–daughter communication in  
     endospore formation 8:304  
   phosphorelay 8:302  
 Bacitracin A 2:590  
 backbone 12:612, 614, 617, 622  
   phosphodiester bond 1:409  
 backbone footprinting 4:529  
   backbone scission 4:533  
   cleavage using hydroxyl radicals 4:532  
   DNase footprinting 4:528  
   Fe(II)-EDTA Fenton chemistry 4:532  
   Fenton–Haber–Weiss reaction 4:525  
   hydroxyl radical footprinting of RNA folding  
     4:539  
   OH radical 4:525  
   radiolysis of water 4:532  
   tethered Fe(II)-EDTA 4:535  
 backtracking 12:621, 622, 626  
 bacteria 1:555ff, 562, 563, 570, 571, 4:679,  
   7:250, 251, 255, 8:229, 230, 238, 9:353, 10:361,  
   366ff  
   arenaviruses 5:597  
   *H. pylori* 5:598  
   Lassa fever virus (LFV) 5:597  
   Lewis<sup>b</sup> (Le<sup>b</sup>) blood group antigen 5:598  
   lymphocytic choriomeningitis virus (LCMV)  
     5:597  
   Mobala 5:597  
   mutagenesis in 12:121–122  
   *Mycobacterium leprae* 5:597  
   Oliveros 5:597  
   sensing of protein misfolding in  
     13:466–476  
   transcriptional regulation in 3:469–470  
 bacteria display  
   FACS 8:415ff  
 bacterial artificial chromosome, see BAC  
 bacterial cell cycle, genetic analysis of 1:549  
 bacterial chromatin 3:541  
 bacterial cloning systems  
   bacteriophages and plasmids 13:77  
   cloned DNA 13:77  
   polylinkers 13:77  
 bacterial conjugation 5:337  
 bacterial display 8:415, 11:106  
 bacterial flagella 8:395, 396  
   rotary motor of 8:594–596  
 bacterial genomes 15:559  
 bacterial growth law 1:548  
 bacterial identity 3:497  
 bacterial intein-like domains 11:250  
 bacterial lipoprotein 7:3  
 bacterial lysis 9:351  
 bacterial nucleoid 3:541  
 bacterial or phage attachment site  
   attB 15:293  
   attP 15:293  
   pseudo-attP 15:293  
 bacterial resistance 14:564  
   antimicrobial peptides 14:565  
   avirulence (AV) genes 14:565  
   resistance gene 14:565  
   T4 lysozyme gene 14:565  
 bacterial restriction point 1:545  
 bacterial superantigens  
   the immune response to 13:641  
 bacterial toxins 8:612  
   DT and DT derivatives 6:504–505  
   PE and PE derivatives 6:505–506  
 bacterial transduction 9:351, 355  
 bacterial transformation  
   adaptive function 1:87  
   *Bacillus subtilis* 1:87  
   competence 1:87  
   *Haemophilus influenzae* 1:87  
   sexual interaction 1:87  
 bacterial vaccines  
   attenuated bacteria 6:300

- bacterial infection 6:299  
 DNA vaccine 6:300  
 innate immune system 6:299  
 mucosae 6:299  
 pathogenic organism 6:299  
 pathogen-specific adaptive immune response 6:299  
   subunit vaccine 6:300  
   whole-cell vaccine 6:300  
 bacteriophage 1:330, 338, 4:105, 106, 356, 363, 13:450ff  
   biology of 9:353–357  
   lambda 3:77  
   *Streptomyces* 13:450  
   tail 9:352, 354  
 bacteriophage  $\lambda$  3:387, 8:414  
 bacteriophage genomics 9:356–357  
 bacteriophage M13 8:411, 412  
 bacteriophage P1-derived artificial chromosome (PAC) 3:387ff  
 bacteriophage plaque 9:351  
 bacteriophage P1 (P1) 3:386ff  
 bacteriophage R17 9:366  
 bacteriophage T4 2:627  
 bacteriophage T7 8:414  
 bacteriophage therapy 9:352, 355  
 bacteriophage-mediated transduction 5:337  
 bacteriorhodopsin 1:576, 577, 582, 583, 7:171, 8:145, 9:566  
   apoprotein 9:559  
   branched photocycle 9:552, 553  
   chemical additives 9:559  
   chromophore analogs 9:559  
   13-desmethyl 9:559  
   *Halobacterium halobium* 8:146  
   M state 9:559, 560  
   main photocycle 9:553  
   O state 9:561  
   photocycle 9:551, 552  
   photophysical optimization 9:560  
   photovoltaic signal 9:564  
   Q state 9:552, 559  
   retinal 9:552  
   sensor 9:564, 565  
   trimer 9:551  
 baculoviral IAP repeat 10:622  
 baculovirus 4:369, 5:294, 11:105  
   human proteins 11:274  
   posttranslational modifications 11:274  
   recombinant 3:166, 167  
 Bad 10:129  
 Bag 10:129  
 baking quality  
   high molecular weight glutenins 14:571  
 balanced growth 1:530  
 balanced lethal stocks 3:574  
 ball and chain 11:651  
 BALT, *see* lymphoid tissues  
 BamHI 12:332  
 band assignments 13:684–686  
 band shift 3:545  
 BAR domain 8:129  
 Bardet–Biedl Syndrome (BBS) 12:691  
 barley (*Hordeum vulgare*)  
   HvBR11 14:257  
   uzu 14:257  
 barnase 11:137  
 Barr body 6:141  
 Barrett's metaplasia 13:371  
 barriers 7:301ff, 10:88  
 barstar 11:137  
 bartter  
   SLC12A1 11:691  
   TAL 11:691  
 Bartter syndrome (BS)  
   sensorineural deafness 11:693  
   SLC12A1 11:692  
   type 1 11:692  
   type 2, KCNJ1 11:692  
   type 3, CLCNKB 11:693  
   type 4, BSND 11:693  
 basal body (eukaryotic flagellum) 2:638, 641, 8:393ff  
 basal cell carcinoma 3:378  
 basal cell nevus syndrome 3:374  
 basal keratinocytes 13:222  
 basal lamina or basement membrane 2:326ff  
 basal layer 13:345  
 basal (nonairway) surface 15:261  
 basal promoter 10:314  
 base 11:2, 12:611–613, 620, 622  
 base analog  
   base replacement by 12:121  
 base calling 5:518  
 base excision repair (BER) 1:56, 3:361, 368, 428, 432ff, 439, 10:130, 12:112  
   apurinic (AP) site 1:71  
   CSB 1:72  
   DNA damage, oxidative 1:73  
   DNA glycosylase 1:71  
   DNA polymerase  $\beta$  1:73  
   8-hydroxy-2'-deoxyguanosine 1:80  
   p53 1:73  
   PARP 1:72, 80  
   ref-1 1:73  
   spontaneous depurinations 1:70  
 base pair 12:614, 616, 618, 619, 625



- base pairing 12:622, 626  
 canonical 12:612, 613  
 Non–Watson–Crick 12:613  
 noncanonical 12:613  
 probabilities 12:590  
 Watson–Crick 12:612, 613, 615, 616  
 wobble 12:614–616, 631
- base stacking 12:612, 617, 626  
 straight upward 12:613
- base triple 12:628, 629
- $\lambda$ -based vectors 5:445ff  
 cosmids 5:447ff  
 diphasmids 5:447  
 hyphages 5:447  
 phasmids 5:447
- baseline 11:388, 482ff, 514ff
- basement membrane (BM) 8:46, 47, 48, 50, 52, 54, 14:386, 15:206
- basement membrane zone (BMZ) 13:223–224
- basic fibroblast growth factor (bFGF) 6:16, 17, 22
- basic helix-loop-helix (bHLH) 12:426ff
- basic membrane properties 11:685
- basolateral early endosomes (BEE) 4:200
- basolateral membrane 5:213, 11:684
- basophils 6:347
- batch culture 5:8
- batched segregant analysis 15:618
- BAT-R11 6:15
- battery 3:272
- Baudhuin 13:609
- Bauduin 13:614
- BAX 8:361, 10:129, 623–625, 629
- Bayesian clustering 9:260
- Bayesian networks 14:138
- Bazooka complex 12:185ff
- BC1 4:598
- BC200 1:296, *see also* short interspersed repeat element
- bc<sub>1</sub> complex 8:176
- bcd 6:204ff
- B-cell 1:363, 370, 381ff, 391, 462, 5:555, 6:340, 341  
 activation 1:381  
 antigen presentation in the germinal center 1:384  
 antigen presentation outside the follicular center 1:382  
 B cell/follicular DC contacts 1:385  
 BCR 2:293  
 CD40–CD40L engagement 1:384  
 HLA-DO 1:385  
 memory 1:385
- B-cell (antibody) responses 15:126
- B-cell antigen receptor (BCR) 1:361, 381, 6:430, 432
- B-cell lineages/subtypes  
 B-1 2:296  
 conventional B-cell 2:296
- B-cell lymphoma 4:263
- B-cell memory  
 generation of 6:399  
 germinal centers (GCs) 6:398  
 signaling lymphocyte activation molecule (SLAM) 6:398  
 SLAM-associated protein (SAP) 6:398  
 X-linked lymphoproliferative syndrome (XLP) 6:398  
 maintenance of 6:399
- B-chains 6:7
- Bcl-2 8:361, 10:129, 623–631
- Bcl-2 family 13:286
- BCL-2 protein family 9:469–470
- Bcl2 rearrangement  
 effect of 12:116
- Bcl-x<sub>L</sub> 10:129
- B<sub>12</sub> coenzymes 9:582–583
- BCR 14:454
- BCR-ABL 2:231, 232, 235, 10:202
- BCR-ABL tyrosine kinase 10:201ff
- B-DNA  
 A-conformation 1:410  
 A-form 1:408  
 B-conformation 1:410
- BDNF, *see* brain-derived neurotrophic factor
- bean pod mottle virus 9:367
- Becker myotonia 11:672
- Beckmann rearrangement 14:354
- Beckwith–Wiedemann syndrome 5:474, 476, 482, 12:167
- Beer–Lambert law 3:57, 4:663, 13:675
- behavior genetics 1:586
- behavior, role of chirality 2:611
- behavioral asymmetries 2:613
- behavioral genomics 1:609
- BEL class 6:217ff
- BEL domain 6:217ff
- Benveniste Raoul 8:523
- benzo[a]pyrene  
 epoxidation of 2:60
- benzodiazepine 8:91, 105
- benzoic acid 1:429
- benz(o)pyrene 13:351
- benzoquinone 11:116
- benzotriazole 13:692
- benzylsuccinate synthase 4:120
- BER, *see* base excision repair
- Bernoulli text 10:453

- Best, Charles 10:282  
 best fit 11:390  
 beta-2 adrenergic G-protein-coupled receptor ( $\beta$ 2AR) 4:210  
 beta-amyloid 4:338  
 beta-glucuronidase, *see* GUS  
 betaglycan 4:399  
 betaine 10:283  
   recombination 1:288ff  
 BFNC1 11:678  
 BglII 12:332  
 B7-H1 6:486  
 bHLH 12:414, 437, 439, 442, 456, 458  
 BH3-only proteins 10:623, 624  
 BHQ 11:489ff  
 Biacore™ 3:552  
 “biallelic” variation 3:482  
 bicalutamide 13:44, 47, 48  
 BICR/M1R<sub>k</sub> cells 7:544  
 bicyclic 11:116  
 bidirectional organization 1:537  
 bidirectional replication 1:527, 537  
 bifurcated hydrogen bond 12:614  
 Big Bang 10:3  
 bilamellar invaginated vesicles (BIVs) 7:302ff  
 bilateral symmetry 2:612, 13:272ff  
 bilayer 10:16  
 bilayer fusion  
   physical principles of 11:72  
 bile acid response elements 7:225  
 bile acids 5:213, 222, 7:219  
 bile salts 7:198  
 biliary excretion 10:220  
 bilirubin 7:98  
 bimolecular association 11:395, 398, 403  
 binary classification scheme 13:690  
 binary code sequence 5:324  
 binary model 14:506, 527  
 binary state (of regulatory molecules) 9:498  
 BIND database 12:103  
 binding  
    $\Delta G_{\text{bind}}$  3:535  
 binding affinity 9:258  
   cluster effect 2:292  
 binding agents 11:108  
 binding data 11:398, 399  
 binding kinetics 13:561  
 binding parameters 13:557  
 binding proteins (BPs) 5:645, 12:358–359  
 binding site 6:186ff, 13:567  
   Antp 6:186  
   identical 11:398, 400  
   independent 11:398, 399  
   nonidentical 11:399  
   number 11:399, 400  
 binning 8:200  
 bioanalytics 10:216  
   DNA-nanoparticle conjugates 9:40–43  
 bioassays 10:216  
 bioavailability 8:212, 10:217, 218, 226  
 bioballistical gene transfer methods 15:490  
 bioballistics  
   biotechnology 15:490  
 biocatalysts 8:426  
 biochemical pathways 9:255  
 biochemical signalling 14:401–403  
 biochemical structure of ion channels 11:650  
 biochemical tests for characterizing bacteria 1:516  
 biochemical validation 14:400  
 biocontainment 1:225  
 biocontrol 5:13  
 biodefense actions  
   chronology of 10:511–512  
 biodegradable polymeric particles 8:611  
 biodistribution 7:301ff, 10:217  
 biodiversity 5:350  
 bioengineered tissue 14:406  
 bioengineering  
   tissue production in 14:406–407  
 biogenetic law  
   ontogeny recapitulates phylogeny 3:265  
 biohazards 7:548ff  
 bioinformatics 6:570  
   database search 11:269  
   homology-based modeling 11:269  
 bioinorganic chemistry 1:635–636, 644–647, 650, 655–656  
   abundances of 1:639  
   Ca<sup>2+</sup> vs. Mg<sup>2+</sup> 1:639–641  
   cooperativity of 1:651  
   dioxxygen 1:653–654  
   essentiality of 1:637–639  
   ionic radii 1:639  
   metal ion binding characteristics of 1:651–653  
   metal-ion hydrolysis 1:643  
   nonaqueous environments 1:648–649  
   stability ruler 1:642–643  
   stability sequences 1:641–642  
 biologic markers  
   susceptibility 4:228  
 biological activities associated with IFNs 15:405  
 biological activity  
   angiotensin-converting enzyme (ACE) inhibitors 14:80

- biological activity (*continued*)
  - antibacterial activity 14:82
  - anti-inflammatory activities 14:82
  - cytotoxicity of  $\beta$ -amyloid peptide 14:81
  - HIV antiretroviral therapy 14:80
  - lung surfactant protein C 14:83
  - proline endopeptidase inhibitor 14:84
  - proteasome inhibitors 14:84
  - redox-active metal chelating activity 14:82
  - superoxide dismutase 14:82
  - thrombin inhibitors 14:85
  - transcriptional activation 14:81
- biological analysis 7:175
- Biological and Toxin Weapons Convention (BWC) 10:508, 511
- biological barriers 14:167
- biological biomarkers 9:113
- biological code words
  - determination of 10:451–453
- biological codes
  - classification of 10:451
  - logical trap 10:451
- biological complexity
  - LPS 2:287
- biological function of logical trap 10:451
- Biological Information System 14:144
- biological markers 4:230, 232
  - effect 4:226
  - exposure 4:226, 227
- biological markers intermediate 4:231
- biological matrices 14:408
- biological membrane fusion
  - extracellular fusions 11:72
  - fusion proteins of enveloped viruses 11:72
  - intracellular fusions 11:72
- biological membranes
  - fusion of 11:71
- biological parents 1:592, 593
- biological peptide library method
  - advantages 10:153
  - disadvantages 10:153
  - phage-display peptide libraries 10:153
- biological regulation 15:96–98
- biological response modifiers (BRMs) 15:415
  - fungal polysaccharides 5:8
  - lentinan 5:8
  - scleroglucan 5:8
- biological structures, role of chirality 2:611
- biological systems
  - convoluted nature of 10:473
  - gene transfer as transduction 15:490
- biological weapons 10:508, 510
- biologically active peptides 14:43
- biologically active proteins 3:258
- biologically (biologically defined-repeat or BDR)
  - sequence-recognizable transposable elements 13:87
- biologicals and antisense 11:632
  - antisense oligonucleotides 11:633
  - RNA interference (RNAi) 11:633
- bioluminescence 2:523ff
- bioluminescent organisms 2:526
- biomarker 9:92, 96, 11:110, 14:152, 157
  - as surrogate end points 9:113
  - validation of 9:113–115
- biomass 2:525
- biomass measurement by
  - dry weight 1:512
  - turbidometric estimations 1:512
- biomaterials 14:407, 408
- biomimetic polymer 14:164
- Biomolecular Electronic Devices 9:558
- biomolecular electronics 9:551
- biomolecular lithography 9:38
- biomolecules 14:423
- biopanning 8:411
- biopharmaceuticals
  - antifungal activity 5:17
  - cyclosporin 5:17
  - lentinan 5:17
  - mevinolin 5:17
  - scleroglucan 5:17
  - Tohyopocladium* 5:17
- biopharming system 10:660
- biophysical probes 11:63–64
- biopolymers 10:10
- bioprocessing 2:36ff
- bioreactor 1:209, 7:547, 10:386, 388
  - domestic animals 1:228
  - hydrodynamics 14:406
  - power of rotation 14:406
  - transgenic 1:228
- biosafety 7:384
- biosensors 2:40
- bioseparations 2:45
- biosurfactant lipids 7:262
- biosynthesis 13:6, 8
- biosynthetic gene cluster 10:645ff
- biosynthetic pathway 4:185
- Biotechnology Industry Organization (BIO) 10:392
- Biotechnology Regulatory Service (BRS) 10:392
- biotemplating 9:20
  - DNA–protein interaction for 9:38–40
- bioterror
  - concept of 10:512–513

- bioterrorism  
   preparedness for 10:507–525  
   recognition 10:517  
   training 10:517  
   vs. biowarfare 10:509–511  
 bioterrorism preparedness 10:508  
   avenues of 10:514–525  
   disease reporting 10:518–519  
   law 10:514–516  
   medical preparedness 10:516  
   national security 10:514–516  
   rationale of 10:513–514  
   scientific preparedness 10:516  
 biotic and abiotic stresses 5:503, 10:341  
 biotic stress  
   regulation during 10:349–350  
 biotin 6:449–450, 15:521–524, 529–530, 550  
   biotin-labeled deoxynucleotide 6:451  
   embryological development 15:526–527  
   requirement for specific functions  
     15:527–528  
   requirement of, by culture cells 15:525–526  
 biotin, effect of  
   regulations of specific proteins 15:528–529  
   synthesis of specific proteins 15:528–529  
 biotin-accepting peptide 11:108  
 biotin-binding proteins 15:523  
 biotinidase 15:522  
   as biotin-carrier protein 15:524–525  
 biotiny functions 9:583–584  
 biotinylation 11:108  
 biotransformations 5:3, 16ff  
   *Curvularia* 5:17  
   *Penicillium raistrickii* 5:17  
   *Rhizopus* 5:17  
   stereospecificity 5:16  
   steroids 5:17  
 biotrophy 10:369, 372  
 biowarfare 10:508  
 BiP 2:501ff, 513  
 bipolar disorder 1:607, 609  
   heritability 1:608  
   linkage studies 1:608  
   studies 1:608  
 bipolar sensory receptor neuron 12:642  
 birefringence 3:56ff  
 bisecting GlcNAc 5:549ff  
 bisite catalysis 11:337  
 bis(monoacylglycerol)phosphate 10:290  
 bispecific antibodies 1:342  
 bisulfite 4:266  
 bisulfite deamination 9:323  
 bithorax complex 6:190ff  
 Bjerrum characteristic length 3:199  
 black lipid bilayer membrane (BLM) 8:363  
 black smokers 10:9  
 B-lactamases 6:559  
 BLAST 5:532  
 blast cells 9:529  
 blastocele 13:384  
 blastocyst 1:213, 10:72, 77, 485, 13:330  
   morula stage 13:384  
 blastomere 13:329, 330  
 blastomere/embryo aggregation 1:212  
*Blastomyces dermatidis* 5:16  
 blastula 13:330  
 blepharophimosis-ptosis-epicanthus inversus  
   syndrome (BPES) 15:49  
 Blk 1:381  
 BLM  
   homologous recombinational repair (HRR)  
     1:75  
 block duplication mechanism 13:206  
 blocking  
   background radioactivity 5:416  
   double strand break 5:417  
   gap 5:417  
   nick 5:417  
   nonspecific-damaged site 5:416  
   signal/noise ratio 5:416  
 blood 4:335, 668  
 blood–brain barrier (BBB) 3:630, 8:156,  
   10:126, 14:48, 174  
 blood coagulation 5:559  
 blood glucose levels 8:170  
 blood group A determinant 5:561  
 blood group B determinant 5:543  
 blood group substances  
   I 2:286  
   Le 2:286  
   Le<sup>a</sup> 2:286  
   Le<sup>b</sup> 2:286  
   Lec-1 2:286  
   Lec-2 2:286  
   Le<sup>x</sup>(SSEA-1) 2:286  
   Sialyl Le<sup>x</sup> 2:286  
 blood islands 15:203  
 blood meal 7:483  
 blood pressure  
   regulators of 5:237  
 blood substitutes 5:280, 6:68, 103  
   nitric oxide 5:281–283  
   96 $\alpha$  Val $\rightarrow$ Trp 5:283  
   see also oxygen carriers  
 blood vessels 15:208  
 blood-group antigen-binding adhesion 6:14  
 bloom syndrome 1:75, 9:393  
   aging 1:73

- bloom syndrome (*continued*)  
 cancer 1:73  
 homologous recombinational repair (HRR)  
 1:73
- blot 9:333, 335
- blotting 2:527ff
- blue–white selection 5:442ff  
 $\beta$ -galactosidase (*lacZ*) gene 5:442
- BM, *see* basement membrane
- bmi-1 2:228
- BMPs, *see* bone morphogenetic proteins
- BMP/TGF $\beta$  signaling 4:289
- BODIPY-dye terminators 9:406
- body axis 6:181ff
- Bohr effect 6:68, *see also* hemoglobin
- bolasterone 13:35
- bombardment 10:5
- bone marrow 3:87, 89, 90, 15:219
- bone marrow–derived cell (BMDC) 10:134,  
 13:363, 366
- bone marrow stem cells 15:261
- bone maturation 13:31
- bone morphogenetic proteins (BMPs) 4:392ff,  
 5:649, 13:420ff  
 self-renewal of ESC 13:389
- bone quality analysis 13:688, 689
- Boolean networks 14:138
- Booroola sheep 4:398
- borate 10:13
- Bordetella* 6:311
- Bordetella pertussis* 1:397, 6:309
- borrelia  
 vaccine 15:160
- Borrelia burgdorferi* 6:559
- borreliosis  
 vaccine 15:164
- Bortezomib 14:459
- bottom-to-top strategy 2:567
- bottom-up modeling 14:134
- botulinum toxin 8:229, 230
- botulism 8:229, 230
- bound water 1:577, 580
- bovine artificial chromosome (BAC) 7:352
- bovine papilloma viruses 4:107
- bovine spongiform encephalopathy (BSE)  
 7:360, 10:590  
 prions 10:591
- Bowman's glands and ducts 12:643
- box C/D 1:474
- BP180 2:343ff
- BP230 2:343ff
- BPH 13:44, 49
- Brachydanio rerio* 10:547
- brachyury 13:276
- bradykinin 10:37
- bradykinin pathway 10:37–39
- brain 14:42  
 loss of neurons 1:69
- brain development 2:87–123
- brain size  
 cellular redundancy 1:69  
 life span 1:69
- brain tumors 15:340–341
- brain-derived neurotrophic factor (BDNF)  
 4:600, 5:647, 8:571, 11:582, 12:646, 15:13
- branch point binding protein, (BBP) 1:139
- branched chain fatty acids 7:258
- branching morphogenesis 4:290
- branching order 2:553
- Brassica oleracea* 14:256
- Brassica rapa* (cabbage and mustard) 14:256
- brassinosteroids (BR) 10:347  
 regulation by 10:345–346
- BRCA1 4:260, 6:15, 9:318  
 breast tumors, AIB1 4:264  
 cancer 1:82
- BRCA2 9:318  
 cancer 1:82
- BRCA1-associated genome surveillance  
 complex (BASC)  
 homologous recombinational repair (HRR)  
 1:73
- BRCT domain 14:232
- breast cancer 8:453, 9:523, 13:53, 352,  
 15:338–339
- breast cancer associated-1, *see* BRCA1
- breast tumors  
 AIB1 4:264
- breeds, of cattle 7:339
- brefeldin A esterase 14:658
- B-ring 1:446
- Britten, R. J. 8:523
- broad heritability 1:596
- broad host range 10:436, 439
- Broca's aphasia 2:613
- 17-bromoacetoxyprogesterone 13:52
- 5-bromodeoxyuridine (BrdUrd) 4:428ff
- bromodomain 4:250
- bronchial airway epithelial cells 15:260
- bronchiectasis 15:260
- bronchiolitis 12:298, 299
- bronchoscopic instillation 15:260
- brown adipose tissue 8:183
- Brownian dynamics calculations 11:148
- Brownian dynamics simulation 11:134
- Brucella spp.* 6:312
- brucellosis*  
*Brucella spp.* 6:312

cell-mediated immunity 6:312  
 live vaccine 6:312  
 vaccination 6:313  
 Brugada syndrome 11:665  
 brush cells 12:643  
 BS, *see* Bartter syndrome  
 B-signal 8:309  
 BT treatment 13:693  
 BtuCD, *E. coli* 8:154  
 budding 15:239  
 buffer 1:505  
   bicarbonate 7:545  
 building blocks 13:684  
 $\pi$ -bulge 1:578  
 bulk flow 8:126, 127  
 $\alpha$ -bungarotoxin 11:659  
 Bv8/prokineticin 10:43  
 BXSb 1:476  
 3.9-bya 10:5  
 bystander activation 1:383

## c

C83 1:189ff  
 C99 1:189ff  
*C. elegans*, *see* *Caenorhabditis elegans*  
   as biological model 9:54–55  
   chromatin 9:61–62  
   chromosome structure of 9:60–61  
   chromosomes 9:60  
   developmental stages of 9:56  
   ecology of 9:55–56  
   evolution of 9:55–56  
   gene expression 9:61–64  
   genetics of 9:56–57  
   genomes 9:57–58  
   genomics of 9:57–59  
   informatics 9:57–58  
   life cycle of 9:56  
   nomenclature of 9:56–57  
   noncoding RNA world 9:58–59  
   nucleus 9:61–64  
   overview of biology 9:54–57  
   protein-coding genes 9:58  
   proteome 9:58  
   recombination of 9:61  
   repetitive elements 9:59  
   sexual system of 9:56  
   taxonomy of 9:55–56  
   transcription 9:61–63  
   transposons 9:59  
 C–H stretching 13:686  
 $\gamma$ C receptor family  
   IL-2 13:135  
   IL-4 13:135

Ca<sup>2+</sup> pump  
   PMCA 2:158, 159  
   SERCA 2:158, 159, 163  
   SERCA pump 2:160, 164  
 CAAT box 12:24  
 CACNA1A 11:675, 680, 682, 15:21ff  
 CACNA1F 11:683  
 CACNA1S 11:673  
 CACNB4 11:680  
 CaCo-2 3:624, 8:156  
 Caco-2 cells 8:149  
 CADASIL 10:118, 15:214  
 cadherin 2:96, 117, 4:279ff, 6:7, 12:184  
   cell adhesion recognition 2:348  
   classification 2:348  
   DE-cadherin 4:283  
   domain structure 2:348  
   families 2:348  
   genomic organization 2:348  
   sequence 2:348  
   shotgun 4:283  
   structural features 2:347  
 cadherin1 (CDH1) 6:8  
 cadherin-related proteins 2:347  
*Caenorhabditis elegans* (*C. elegans*) 4:283ff, 331,  
   6:182ff, 9:54, 70ff, 10:544, 545, 550, 14:511  
   fungi 6:182ff  
   plants 6:182ff  
   ventral enclosure 4:290  
 CagA 6:14  
 CagA+/VacAs1+ strains of *H. pylori* 6:14  
 CAGE 6:11  
 Cairns 5:318–319  
 cairnsian mutation 5:315  
 cajal body 1:466  
 CAK 12:164  
 Calcarea 13:273ff  
 calcifying tissues 2:166  
 calcimedins 1:242  
 calcineurin 4:343  
 calcitonin 10:221  
 calcium 2:134, 138, 142, 165–168, 4:168,  
   8:183, 465, 487ff, 10:300  
   cell cycle checkpoints 14:25  
   cell cycle control 14:23–25  
   transcription 4:172  
 calcium apoptosis  
   apoptosis 2:142  
   apoptotic bodies 2:142  
   death proteins 2:143  
   necrotic cells 2:142  
   programmed cell death 2:142  
 calcium binding EGF-domain  
   cbEGF 2:139

- calcium calmodulin–dependent nitric oxide synthase (NOS) 10:121
- calcium channel 2:157, 10:301, 11:670, 680, 13:157, 15:21ff
- calcium homeostasis 2:137
- calcium imaging 15:79
- calcium ion, intracellular 4:426
- calcium ions 1:639, 2:138, 4:318, 8:133, 329, 14:659
- universal egg activator 14:14
- calcium oscillations
- calcium-induced calcium-release 2:141
- IP<sub>3</sub>–Ca<sup>2+</sup> crosscoupling 2:141
- calcium release 2:162, 11:673
- calcium signaling 14:14–15
- calcium signals
- at fertilization 14:20–22
- calcium uniporter 8:182
- calcium wave
- initiation of 14:18–19
- calcium-binding proteins 1:243
- calcium/calmodulin
- autophosphorylation 2:468
- calcium/calmodulin-dependent protein kinase
- II 2:464
- $\alpha$  2:467
- $\beta$  2:467
- $\delta$  2:467
- $\gamma$  2:467
- molecular weight 2:467
- calcium-dependent activation 11:668
- calcium-responsive RNA element (CaRRE) 1:152
- calcyclin 1:246
- C18 alkyl group 9:302
- Callisto 10:4
- callus 1:416
- calmodulin 2:134, 145, 4:165, 321ff, 8:216, 465, 487ff, 13:156
- CaM-dependent kinases 2:146
- CaM-dependent protein kinase II 4:169
- calmodulin-dependent kinases
- Ca<sup>2+</sup>-dependent gene expression 2:151
- CaMKI 2:150, 151
- CaMKII 2:148–151
- CaMKIV 2:150, 151
- CaMKK 2:150–152
- IV 2:150
- myosin light chain kinase 2:147
- neuronal plasticity 2:149
- calmodulin-like domain protein kinase 2:167
- calnexin 2:513
- calorie restriction
- aging 1:67
- Cu/ZnSOD 1:67
- DNA damage, oxidative 1:67
- life span extension 1:67
- MnSOD 1:67
- oxidative damage 1:68
- calorimetry 1:583
- calpactins 1:242
- calpains 15:32
- calphobindins 1:242
- calreticulin 2:513
- calusterone 13:26
- Calvin cycle 2:631
- CAM, *see* cell adhesion molecule
- CaM KII 2:466
- calmodulin 2:471
- meiotic spindle 2:471
- CaM KII, *see* calcium/calmodulin-dependent protein kinase II
- cAMP 7:101, 8:331, 335, 337, 10:370, 14:658
- protein kinase 4:168
- transcription 4:172
- cAMP phosphodiesterase 8:325, 335
- cAMP receptor (cAR1) 8:325, 326, 331
- cAMP waves 8:331
- cAMP-activated protein kinase 8:315, 324, 335, 337, 12:149, 14:443, 631ff
- cAMP-activated protein kinase A 8:314ff
- campomelic dysplasia 5:624
- camptothecin 10:660, 14:339
- canarypox vector (ALVAC) 15:147
- canarypox virus 3:171
- cancer 2:172, 173, 4:339, 5:470, 483, 638, 645, 7:119ff, 124–128ff, 130ff, 131ff, 134ff, 8:456, 10:201, 629, 11:110, 12:719, 720ff, 13:321, 14:456, 15:217, 298, 415, 416
- accumulation of mutations 1:68
- acute lymphoblastic leukemias 7:130
- acute myelogenous leukemias 7:130
- acute myeloid leukemia 7:124
- anaplastic large-cell lymphomas 7:127
- ATM 1:82
- ATR 1:82
- better surveillance of 9:100–101
- BRCA1 1:82
- BRCA2 1:82
- breast cancer 7:128
- case for early detection of 9:100–102
- chromosome rearrangements in 3:10–11
- chronic myeloid leukemia 7:119
- clonal evolution of 9:501–507
- early-onset multiple endocrine neoplasia types 2A and 2B 7:134
- FANCD2 1:82
- gastrointestinal stromal tumors 7:131

- gliomas 7:128  
hallmark traits of 9:540  
hematopoietic cancers 4:213  
HMLH1 1:82  
homologous recombinational repair (HRR) 1:73  
immunology of cancer 6:429–444  
immunosuppressive factors in 6:465–489  
improved survival of 9:101–102  
juvenile myelomonocytic leukemia 7:124  
key regulatory pathways, disease process of 9:507–515  
late-onset familial medullary thyroid carcinoma 7:134  
lymphomas, leukemia, epithelial neoplasms, and solid tumors 7:126  
mast cell leukemia 7:131  
melanomas 7:125  
molecular evolution of 9:501–507  
molecular mechanism of 9:438–450  
mutations 7:118ff  
myeloid leukemias 4:214  
non-small-cell lung cancer 7:119  
ovarian cancers 7:128  
ovarian dysgerminomas 7:131  
p53 1:82  
papillary thyroid carcinoma 7:134  
stem cells 13:401–402  
discussion of 13:404–406  
methods 13:403–404  
results of 13:404  
targeting chromatin control 2:179–180  
T-cell lymphoma 7:131  
testicular seminomas 7:131  
cancer antigens 11:112  
cancer cell cycle 2:177  
regulation of  
Cdks 2:177–179  
E2F 2:177–179  
cancer cells  
molecular markers of  
cellular and tissue markers 9:515  
circulating cancer markers 9:515–516  
epigenetic markers 9:516–520  
genetic markers 9:515  
pharmacogenetic markers 9:515  
cancer chemotherapy  
theoretical foundations of 2:171–184  
cancer detection  
application of biomarkers in 9:99–102  
cancer diagnostics  
challenges in 9:113–115  
imaging of 9:112–113  
immunoassays 9:104  
laser capture microdissection 9:106  
mass spectrometry 9:105  
matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF) mass spectrometry (MS) 9:105–106  
pattern analysis of 9:102–106  
protein arrays 9:104–105  
surface-enhanced laser desorption/ionization mass spectrometry (SELDI) 9:103–104  
target specific detection 9:106–109  
technologies of 9:109–113  
technology advancement in 9:102–113  
two-dimensional gel electrophoresis 9:104  
cancer gene therapy 15:266  
cancer genes that encode protein kinases 7:115  
Cancer Genome Anatomy Project (CGAP) 14:152  
cancer metastatic to a vertebral body 15:272  
cancer metastatic to bone 15:271  
cancer patients  
clinical studies in 3:229–230  
cancer stem cell 2:223, 226, 228, 230  
better drug selection 2:234  
future implications of 2:235  
implications for diagnosis and treatment 2:233  
recent evidence 2:224  
tumor relapse 2:233  
cancer therapy 2:173  
recombinant immunotoxins in 6:497–520  
*Candida tropicalis* 13:612, 615  
candidate gene positional 7:352  
candidate gene studies 1:188  
candidate genes 1:599  
candidate M3-Mn genes 12:366  
candidate tumor-suppressor gene 6:6  
cannabinoids (CB) 14:326, 330–332  
canonical pathway 14:445  
CAP3 5:522  
capacitation 6:534  
capacity factor 6:246, 248, 9:298  
capillary 5:519, 15:207  
capillary column 6:246  
capillary electrophoresis (CE) 2:256, 8:12  
carbohydrates 2:258  
capillary gel electrophoresis 14:421, 425  
capillary isoelectric focusing, *see* CIEF  
capillary liquid chromatography  
affinity chromatography 6:284  
capillary ion-exchange chromatography 6:284



- capillary liquid chromatography (*continued*)  
 capillary RPC of proteolytic peptides for proteomic analysis 6:282  
 general considerations 6:278  
 multidimensional capillary separations for proteins 6:284  
 SEC 6:284
- capillary-based sequencers 13:78
- capital investments 15:169
- CAPRI protein–protein docking contest 6:591
- capsid 1:103, 15:254
- capsid of bacteriophage 9:352, 357
- Captopril 14:360–361
- capture agent 11:102, 104, 109
- capture antibody 11:104
- capture step 13:266
- carbamate 8:229
- carbanion 12:335
- carbohydrate 1:429, 8:170, 11:120  
 classes 2:247  
 conformation 2:247  
 occurring as both enantiomers 2:591  
 structural types 2:246
- carbohydrate antigens 2:277
- carbohydrate array 11:121
- carbohydrate epitopes  
 terminal and internal structures 2:289  
 types 2:289
- carbohydrate recognition domain (CRD) 5:583
- carbohydrate-protein interactions 2:291
- carbohydrates, absolute configuration 2:585
- carbohydrates utilisation of 1:519
- carbon dioxide 8:210ff, 211, 221, 10:6
- carbon dioxide reduction pathway 8:242–243
- carbon monoxide 8:214
- carbon tetrachloride 4:643
- carbon-centered radicals 7:156
- carbon-fiber amperometry 4:310
- carbonic anhydrase 8:221–223
- carbonyldiimidazole 10:19
- carboxamides 2:522ff
- carboxylesterase 3 14:673
- carboxylesterases 7:485
- carboxymethylated dextran 3:554
- carboxypeptidase 8:216ff, 222, 223
- carboxypeptidase S (CPS) 4:205
- carcinoembryonic antigen (CEA) 6:22, 9:98, 14:403, 15:160
- carcinogenesis 7:551, 9:498, 502  
 DNA damage 1:65  
 missing enzyme 1:64
- carcinogenic *N*-nitrosoamines 6:13
- carcinogenicity 9:440
- carcinogen-induced tumors 5:354
- carcinogens 9:381
- carcinoma sequence 6:11
- carcinomas 13:331
- carcinosarcomas 13:352
- cardiac action potential 11:661
- cardiac electrophysiology 3:634
- cardiac muscle 14:676
- cardiac troponin T (cTNT) 15:41
- cardiac-specific voltage-gated sodium channel 11:663
- cardinal vein 15:209
- cardiolipin 1:361, 477, 10:279, 290
- cardiomyopathy 4:340
- cardiovascular diseases 5:211–238  
 gene therapy of 13:262
- cardiovascular drugs 14:358–359, 363  
 Adrenaline 14:361  
 Atenolol 14:361  
 Captopril 14:360  
 Dicoumarol 14:362  
 Lovastatin 14:357  
 Pravastatin 14:357  
 Propranolol 14:361  
 Simvastatin 14:357  
 Teprotide 14:360  
 Warfarin 14:362
- CARG box 10:352
- cargo selection 8:128
- carnitine palmitoyltransferase I 7:99ff
- carnitine palmitoyltransferase II 7:99ff
- carnitine palmitoyltransferase-1 (CPT1) 14:639
- $\beta$ -carotene 5:495
- carotenoids 2:637
- carrier 1:411ff, 5:379  
 cationic 1:411
- cartilage 5:560
- cartilage matrix–deficient 5:560
- cascade reaction 7:165
- casein (in cattle) 7:356
- Casodex 13:47
- CASP, CAFASP, CAPRI 11:134
- CASP contest 6:582
- caspase 4:432, 638, 10:127ff, 205, 619, 620–622, 625–627, 14:451, 15:11ff
- caspase-3 13:286
- caspase-8 13:286
- caspase activated DNase 10:622
- caspase recruitment domains 10:621
- caspase subfamily  
 CED-3 10:205  
 ICE 10:205
- cassette dosing 3:598
- CAT, *see* catalase

- cat genes 5:498  
 catabolism 11:29  
 catabolite repression 12:40  
 catalase (CAT) 2:531, 4:639, 5:497, 6:34, 44,  
 7:106, 8:217, 218, 13:611, 613, 614, 618, 620  
 catalysis 10:7, 11, 24, 11:30  
 catalytic antibodies 2:21, 11:27, 31, 40  
 catalytic elongation 10:23  
 catalytic proficiency 11:28, 35  
 catalytic reaction cycle 11:35–36, 38–40  
   gear shift mechanism 11:37  
 catalytic RNAs 12:515  
 catalytic strain 11:245  
 catalytic triad 14:658  
 catechol O-methyltransferase 1:606, 2:65  
 catecholamines 14:656  
 $\alpha$ -catenin 2:353, 4:279, 6:7, 12:184  
 $\alpha$ - $\beta$ -catenin 6:19  
 $\beta$ -catenin 2:229, 230, 232, 353, 4:279, 6:7, 19,  
 7:330, 12:181, 184, 15:51  
 $\beta$ -catenin (CTNNB1) gene 7:328  
 $\beta$ - $\gamma$ -catenin mutations 6:13  
 $\beta$ -catenin/TCF-4 complex 6:19  
 catharanthus (vinca) alkaloids 14:337–339  
 cathepsins 1:370, 10:127, 15:32  
 cation-dependent Man-6-P receptor (CD-MPR)  
 5:582  
 cationic formulations 7:300ff  
 cationic gene transfer systems 15:496  
 cationic lipids/liposome/lipid–DNA complex  
   entry in cells 15:302  
   entry in nucleus 15:305  
   fate inside cell 15:304  
   structure of lipids 15:300, 301, 302  
 cationic liposomes (lipoplex)  
   cationic phospholipids 15:491  
 cationic polymer gene transfer systems 15:495  
 cationic polymers 15:494  
 cation-independent Man-6-P receptor (CI-MPR)  
 8:129  
   IGF-II/MPR 5:582  
   insulin-like growth factor II (IGF-II) 5:582  
 cattle 1:227  
 Caucasian Americans  
   high-frequency small blocks 13:198  
   level of genetic diversity 13:209  
 Caucasian human hair 13:694  
 Caucasians  
   lower genetic diversity 13:208  
 Caudal 6:201  
*Caudina arenicola* 6:88  
*Caulobacter* 1:547  
*Caulobacter crescentus* 1:546, 8:292ff  
   cell cycle 8:293, 294  
   cell cycle control 8:292  
   CtrA 8:293, 295, 296  
   morphogenesis 8:292–294  
   subcellular localization of phosphorelay  
     proteins 8:298  
 causal relationships 14:133  
 caveats 14:539  
 caveolae 4:183ff, 14:648  
 caveolin 2:340, 4:194, 7:198, 214, 13:163, 317,  
 14:643  
 C-bands 3:21  
 CBC-SGC 13:92  
 CBC-SGS approach  
   crop plant genome – the rice genome 13:78  
   large-insert clones 13:79  
   map-directed operation 13:92  
   shotgun cloned 13:79  
   shotgun libraries 13:92  
   small-insert clones 13:79  
 CBL2 4:576  
 CBP/p300 14:443  
 CCA transferase 11:59  
 c-Cbl 4:213, 8:135  
 CckA 8:299  
 CcrM MTase 12:338  
 CCT 2:497ff  
 CD1 1:361, 364, 366ff, 370, 390  
   endocytic compartments 1:366  
   glycolipids 1:367  
   ligand-binding cleft 1:367  
   microbial lipids 1:367  
   peptide antigens 1:367  
   structural studies 1:367  
   structure 1:366  
 CD2 1:374  
 CD3 1:374  
 CD4 1:375  
 CD9 1:371  
 CD19 1:382  
 CD24 2:225  
 CD28 1:373, 374, 15:263  
 CD34 15:219, 220  
 CD36 1:377, 390, 7:215, 238, 14:628ff, 674  
 CD40 1:373, 379, 384, 390, 392, 396, 15:263  
 CD43 1:374  
 CD44 2:225, 6:18, 23  
 CD45 1:374  
 CD47 2:340  
 CD63 1:371, 395  
 CD80 1:360, 373, 379, 382, 384, 396, 15:263  
 CD82 1:371  
 CD86 1:360, 373, 379, 384, 395, 396, 15:263  
 CD91 1:390  
 CD133 15:219

- CD151  
    $\alpha_3\beta_1$  2:340  
 CD154 15:263  
 C3d 1:382  
 CD antigen 4:423  
   CD3 4:421  
   CD4 4:421  
   CD8 4:421  
   CD19 4:421  
   CD45 4:421  
 CD4+ T-cell memory 6:397  
   effector differentiation of 6:396  
 CD8+ T-cell memory  
   maintenance of 6:392–393  
 CD8+ T-cell memory generation  
   models of 6:394, 396  
     decreasing-potential model 6:395  
     instructive model 6:395  
     linear differentiation model 6:393  
 CD44 abnormal transcripts 6:11  
 CD11a/CD18 10:124  
 Cdc4 12:155  
 Cdc6 12:190ff  
 Cdc7 12:190  
 Cdc13 14:236  
 Cdc25 12:165ff  
   Cdc25A 12:176, 189  
   String 12:195  
 Cdc42 2:334  
 Cdc45 12:190ff  
 Cdc28 (Cdc2) 12:145ff  
 CD44 gene 6:18  
 CDG-Ia  
   phosphomannomutase 2 (PMM2) 5:594  
 CDG-Ib  
   phosphomannose isomerase, PMI 5:594  
 CDG-Ic  
    $\alpha$ 1,3 glucosyltransferase (ALG6) 5:594  
 CDG-IIa  
   UDP-GlcNAc: $\alpha$ -6-D-mannosidase  
      $\beta$ 1,2-*N*-acetylglucosaminyltransferase II  
     (GlcNAc-TII) 5:595  
 CDG-IIb  
   Bombay (hh) blood type 5:595  
    $\alpha$ 1,2-fucosyltransferase 5:595  
   LAD I 5:595  
   leukocyte adhesion deficiency syndrome II  
     (LAD II) 5:595  
   Lewis blood group antigens 5:595  
   Se loci 5:595  
 c-di-GMP 8:298  
 Cdk (cyclin-dependent kinase) 6:390, 8:314ff,  
   318, 9:508, 12:145ff  
   Cdk1 12:165  
   Cdk2 12:189  
   Cdk2(3) 12:148ff  
   Cdk3 12:154  
   Cdk4 6:5, 7:142, 12:176  
   Cdk4(6) 6:5, 12:153ff  
   Cdk7 12:154, 164  
   Cdk8 12:154  
   Cdk9 12:154  
 Cdk inhibitor (Cki) 6:24, 7:329, 12:155, 172,  
   176, 184, 194  
 CIP (KIP) 12:165ff  
 Cki exchange 12:172ff  
 Cki proteolysis 12:168  
 Dacapo 12:165, 183, 194ff  
 INK4 12:165ff  
 p130 12:155ff  
 p27 12:155ff  
 p21<sup>C</sup>IP1 12:165ff, 176ff, 178ff, 187  
 p16<sup>I</sup>NK4A 12:165ff, 178  
 p15<sup>I</sup>NK4B 12:165ff, 175, 178  
 p18<sup>I</sup>NK4C 12:165ff  
 p19<sup>I</sup>NK4D 12:165ff  
 p27<sup>K</sup>IP1 12:165ff, 172ff, 178  
 p57<sup>K</sup>IP2 12:165ff  
 CDKN2A 7:329  
 CD40L 1:378, 379, 384, 385, 392, 396  
 cDNA and genomic DNA libraries 8:422  
 cDNA clones 10:532ff  
 cDNA (complementary DNA) 1:252, 8:264,  
   268, 500, 9:325, 11:105, 485ff, 12:522, 575,  
   661  
 cDNA expressed sequenced tags 14:262  
 cDNA library (complementary DNA library)  
   3:386, 396ff, 10:531, 533, 536  
 cDNA microarray 3:48  
 cDNA segment 8:412ff  
 cDNA-based (spotted) arrays  
   advantages of 8:270  
   drawbacks of 8:270  
 C<sub>2</sub>-domains 2:156  
 CDP-choline 10:294  
 CDP-choline: 1,2-diacylglycerol 10:285  
 CDP-choline pathway 10:299  
 cdp-diacylglycerol (CDP-DG) 10:280  
 CDP-diacylglycerol synthase 10:292  
 CDP-ethanolamine 10:287  
 CDP-ethanolamine: 1,2-diacylglycerol  
   ethanolaminephosphotransferase 10:288  
 Cdt1 12:192  
 CD44 v9 6:18  
 CED-4 10:624  
 CED-9 10:623, 624  
 CEDIA 6:369, 372, 374

- CEH (conserved extended haplotype) 13:192, 194, 197, 202, 210  
 allotransplantation matching 13:208  
 association with disease 13:203  
 disease gene 13:209  
 immune response genes 13:208  
 mapping disease susceptibility 13:208
- CEH fragments 13:203
- CEH of Caucasians 13:206
- Celera effort 5:59
- cell 5:354ff, 7:536ff, 537ff, 540ff, 542ff, 543ff, 549ff, 10:134  
 A431 cells 5:362  
 A549 lung carcinoma cells 5:361  
 baby hamster kidney (BHK) cells 5:361  
 cloning 7:536  
 continuous line 7:536  
 cycle 7:536  
 epithelial 7:543  
 freezing 7:549  
 growth factors of 9:532–533  
 H460a 5:362  
 H460a cells 5:359ff  
 H322a, H226b, H596b 5:362  
 in vitro 1:411  
 in vivo 1:411  
 individual age 7:540  
 line 7:536  
 mouse brain 7:542  
 mouse tumor 7:537  
 normal rat kidney (NRK) cells 5:361  
 NRK fibroblasts 5:362  
 of origin for lung cancers 5:354  
 SCLC-V 5:356  
 shape 9:529–530  
 stem cell 5:354  
 strain 7:536  
 suicide 10:618  
 Suramin 5:362  
 tumor 7:541ff
- cell adhesion molecule (CAM) 6:3, 8, 344, 8:59, 330
- cell age 1:530
- $\beta$ -cell apoptosis 14:631ff
- cell architecture  
 actin filament 2:470  
 cortical granules 2:470  
 cytoskeletal sheets 2:470  
 intermediate filament 2:470  
 meiotic metaphase II 2:470  
 microtubules 2:470  
 microvilli 2:470  
 spindle microtubules 2:470
- cell biology 3:264
- cell biology of  
 PrP<sup>Sc</sup> formation 10:567
- cell body 9:141
- cell–cell contacts 7:551
- cell–cell interaction  
 cell junctions 3:277  
 cell–matrix interaction 3:278  
 cell signals 3:278  
 communicating junction 3:277  
 gap junctions 3:277  
 tight junctions 3:277
- cell–cell junctions 4:279
- cell coculture 14:392
- cell culture 1:415ff, 11:375  
 large-scale 14:405–407  
 mammalian 7:536
- cell culture system 12:359
- cell cycle 2:142, 172, 176, 4:332, 424ff, 5:502, 7:539, 8:325, 332, 10:284, 296, 12:462, 464, 467, 469, 14:22–23  
 cyclin 7:517  
 cyclin-dependent inhibitors 7:518  
 cyclin-dependent kinase 7:518
- cell cycle and development  
 asymmetric spindle positioning 3:290  
*C. elegans* 3:290  
 cell cycle alteration 3:288  
 cell cycle checkpoints 3:288  
 cell cycle of embryos 3:288  
 cell-intrinsic timing mechanism 3:290  
 cell-type-specific transcriptional enhancers 3:288  
 classic cell cycle 3:288  
 developmental programs 3:288  
*Drosophila* development 3:288  
 heterochronic gene pathway 3:290  
 mammalian oligodendrocyte development 3:290  
 maternal gene products 3:288  
 midblastula transition 3:288  
 mouse embryos 3:288  
 oocyte maturation 3:288  
 signaling pathways 3:288
- cell cycle arrest 8:338
- cell cycle checkpoints 9:498, 529, 14:23
- cell cycle control 10:435, 14:1–25
- cell cycle onset  
 checkpoint at 14:25
- cell cycle progression  
 at fertilization 14:20–22  
 E2F protein families in 12:357–358  
 RB protein families in 12:357–358
- cell cycle regulators 6:8, 12:367

- cell death 2:228, 4:431, 5:501, 7:326, 10:619, 625, 631
- cell differentiation
- apoptosis 3:287
  - cell cycle 3:287
  - cell lines 3:287
  - differentiated phenotype 3:287
  - E2F transcription factors 3:287
  - knockout mice 3:287
  - MyoD 3:287
  - myogenic differentiation 3:287
  - myogenin 3:287
  - pRb protein 3:287
  - retinoblastoma protein 3:287
- cell division
- cytokinesis 8:481
- cell division cycle 14:20–23
- checkpoints 2:389
  - cyclins and cyclin dependent kinases 2:389
  - different stages of 14:19
  - four phases 2:388
- cell entry 7:307ff
- cell entry of an enveloped virus 15:253
- cell fates 6:182
- cell generation
- aspects to 2:107–108
  - molecular aspects of 2:109–113
- cell growth 12:144
- cell intrinsic mechanisms 2:109
- cell junction molecules 13:282
- cell junctions
- adhering junctions 3:277
  - desmosomes 3:278
- cell life span 14:219
- cell mass 1:528
- cell–matrix interaction
- cell movement 3:279
  - integrin signaling 3:279
  - involution of tissue 3:279
  - malignant transformation 3:279
  - microenvironment 3:278
- cell–matrix junctions 2:326ff
- cell membrane 1:527, 4:433, 8:142, 10:4, 14:181
- fluidity 8:144
  - structure 8:143
  - transport across 8:146
- cell movement
- cell shape 3:279
  - convergence 3:280
  - convergent extension 3:280
  - extension 3:280
  - JAK/STAT pathway 3:283
  - morphogenetic movements 3:279
  - polarized cell movements 3:280
  - tubulogenesis 3:284
- cell nonautonomous mechanisms 2:109–112
- cell physiology 14:152
- cell polarity 8:484
- Cell Porator and Voltage Booster System (Life Technologies) 3:406
- cell production 5:638, 651
- cell profiling 7:540ff
- cell proliferation 4:427
- cell replacement 10:133
- cell replacement strategy
- accumulation of mutations 1:68
- cell shape, control of
- extracellular matrix (ECM) 14:388
- cell signaling 12:216
- autocrine signaling 3:274
  - endocrine cells 3:276
  - endocrine disrupters 3:276
  - endocrine glands 3:276
  - endocrine signaling 3:276
  - hormones 3:276
  - juxtacrine signaling 3:274
  - paracrine signaling 3:275
- cell signals 3:278
- cell sorting 4:421
- cell stress 14:455
- cell stress response 14:440
- cell surface 1:531
- cell surface carbohydrate, sialyl-dimeric Le antigens 6:23
- cell surface display 8:414
- cell surface molecules 6:485–487
- Fas/FasL 6:483–484
- cell surface receptors 7:300ff, 8:424
- without tyrosine kinase activity 9:461
- cell survival 14:440
- cell suspension 1:416ff
- cell theory
- cellular pathology 3:264
  - human pathology 3:264
  - humoral pathology 3:264
- cell type choice 8:331
- cell viability 15:74
- cell wall degrading enzymes (CWDEs) 10:366, 370, 371
- cell wall synthesis 1:432
- cell-free assays 8:125
- cell-free expression systems
- isotopes for NMR analysis 11:275
  - selenomethionine 11:275
- cell-free translation system 2:452
- cell-intrinsic factor 12:90

- cell-mediated immunity 1:461, 5:295, 10:86  
 versus antibody mediated immunity  
 6:348–349
- cell-mediated immunity induction of  
 T-cell activation  
 costimulation 6:349–350  
 DC maturation 6:350–351  
 extravasation 6:351
- cell-mediated inflammation 6:419–420
- cellomics 10:132
- cells, dividing  
 DNA damage 1:67
- cells, nondividing  
 accumulate DNA damage 1:57  
 aging 1:68  
 brain 1:68  
 cellular redundancy 1:69  
 declines in function 1:68  
 DNA damage 1:67  
 DNA repair 1:68  
 functional declines with age 1:57  
 liver 1:68  
 muscle 1:68
- cells, proliferating  
 replacement strategy 1:84
- cells, somatic 1:80
- cells, specialized for reproduction  
 egg cell 1:83  
 follicle cells 1:83  
 nurse cells 1:83  
 sperm 1:83  
 yolk proteins 1:83
- cell-to-cell adhesion 13:279
- cell-to-cell spread 14:270
- cell-to-cell viral transmission 15:462  
 dendritic cell to T-cell transmission 15:464  
 nanotubes and viral transmission 15:464  
 the virological synapse 15:463
- cellubrevin 4:199
- cellular adhesion 9:498, 528
- cellular adhesion molecules (CAMs) 9:527
- cellular checkpoints 14:131
- cellular communication 14:269
- cellular compartmentalization 8:121
- cellular control 12:106
- cellular division  
 predictable 12- to 18-h cycle 13:384
- cellular effector mechanisms 6:419–420  
 oxygen-dependent killing 6:421–422
- cellular fusion proteins 11:94
- cellular immunity 12:310–312
- cellular isoform of the prion protein (PrP<sup>C</sup>)  
 10:560
- cellular level 14:175–177
- cellular luminescence 2:533
- cellular mediated immune responses  
 immunologic tolerance  
 microchimerism 15:584  
 mixed hematopoietic chimerism  
 15:584  
 thymic transplantation 15:584
- immunoregulation 15:583
- NK cells 15:584
- “xenoreactive” T cells 15:583
- cellular oncogene activation  
 by viral integration 9:449
- cellular proteins incorporated in the virion  
 15:461
- cellular redundancy  
 brain 1:69  
 cells, nondividing 1:69
- cellular RNA species 9:324
- cellular senescence 14:219
- cellular signaling pathways 13:334
- cellular therapy 13:352
- cellular uptake  
 endosome 1:411  
 liposomes 1:411
- cellulase 1:433, 2:254
- cellulose fibrils 8:337
- cenH 14:238ff
- centenarians (humans who have lived for more  
 than 100 years)  
 PARP 1:63, 72
- Center for Biologics Evaluation and Research  
 (CBER) 13:264
- Centers for Disease Control and Prevention  
 (CDC) 10:515
- centiMorgan (cM) 5:370, 405
- central coiled coil 11:77  
 primary pulling force 11:78
- central core disease (CCD) 11:674
- central diabetes insipidus 3:302  
 animal models of 3:319  
 treatment of 3:317–318
- Central dogma 10:312
- central nervous system (CNS) 8:444, 12:161,  
 13:352, 14:328–334  
 drugs affecting 14:327  
 cannabinoids 14:330  
 conotoxins 14:329  
 excitability 11:684
- central supramolecular activation cluster  
 (c-SMAC) 1:374
- centrioles 2:638
- centromere 3:21, 46, 562, 563, 5:377, 6:139ff,  
 11:441–443, 14:2, 231ff
- CENP-A 1:484

- centromere (*continued*)  
 CENP-B 1:484  
 CENP-C 1:484  
 centromeric satellite, *see* satellite DNA  
 centrosome (microtubule-organizing center, MTOC)  
 centriole 12:189  
 pericentriolar material 12:189  
 cephalosporin 10:656ff  
*Cephalosporium acremonium*  
 cephalosporin 5:19  
 $\beta$ -lactam 5:19  
 ceramide 10:281, 301, 13:311  
 ceramide-1-phosphate 13:313  
 c-erbB2 6:12, 20, 24  
 c-erbB3 6:12  
 c-erbB1 (EGFR) 6:6, 12  
 cerebral palsy 11:111  
 cerebrospinal fluid 3:631  
 Cerenkov counting 11:429  
 cerium 1:431  
 Cerius 3:606  
 ceruloplasmin 8:220  
 cervical cancer 4:675ff  
 CETP, *see* cholesteryl ester transfer protein  
 cetorelix 10:233  
 CF (counting factor) 8:331, *see also* cleavage factor, cystic fibrosis  
 CFTR 6:326, 7:607, 11:687, 15:243  
 ATP-binding cassette (ABC) transporters 8:627  
 cAMP-dependent protein kinase 8:627  
 chaperone proteins 8:629  
 chaperones 8:635  
 class I mutations 8:634  
 crystal structure 8:628  
 domains 8:627  
 function 8:627  
 gene therapy 8:634  
 mutations 8:626  
 structure 8:627  
 tissue location 8:628  
 trafficking 8:628  
 CFTR mutations 12:112–114  
 CGG expanded-repeat mouse 4:613  
 CGG methylation 4:619  
 CGG repeat 4:592  
 CGGBP1 4:612  
 CGG-repeat expansion 4:587  
 CGI-58 14:645  
 cGMP 8:329, 14:680  
 protein kinase G 4:168  
 cGMP phosphodiesterase 8:87, 11:570, 574  
 CH<sub>2</sub> absorptions 13:685  
*Chaenocephalus aceratus* Lonnberg 6:69  
 chalcones  
 cell cycle 3:292  
 differentiating myoblasts 3:292  
 GDF8 3:292  
 myostatin 3:292  
 neurogenesis 3:293  
 olfactory epithelium 3:293  
 organogenesis 3:292  
 skeletal muscle 3:293  
 channel 2:134, 11:697  
 gap junction 7:550ff  
 channel families 11:653  
 channel gating 8:366, 367, 376  
 channelopathies 11:645  
 channelopathy gene families 11:671  
 chaperone 4:343, 8:213, 229, 542, 552, 11:3, 288, 12:385, 14:2  
 BiP 11:294  
 calnexin 5:581  
 calreticulin 5:581  
 contribution to proteasome-mediated degradation 11:16  
 CPX 8:624  
 Djpl 13:624  
 genisteine 8:624  
 glycerol 8:624  
 Hsp70 11:294, 13:624  
 phenylbutyrate 8:624  
 chaperone binding site 14:610  
 chaperone moiety  
 translocation mediated by 13:506–508  
 chaperone protein 8:349, 9:470  
 chaperone-like activity 11:12  
 chaperone-mediated autophagy 1:629  
 chaperone-protease pairs 13:506–509  
 chaperonin 2:488, 494ff, 13:464, 487  
 architecture of 13:488–492  
 chaperonin (Hsp60) system 13:485–492  
 characterization and storage 3:417  
 charge density 7:306ff  
 charge interactions 7:312ff  
 charge state 13:540  
 charge-coupled device 2:522  
 checkpoint 1:545, 8:339, 12:161  
 checkpoint control 10:428, 12:144  
 CHEF gel 3:415ff  
 chelate (from Greek claw) 1:636, 641  
 chelating ligands 1:637  
 chemical complementarity 2:7  
 chemical electric and magnetic field effects 4:2  
 chemical fixation  
 fixation artifacts 4:32  
 fixed 4:43

- glutaraldehyde 4:32, 43  
 mesosome 4:33  
 Os<sub>5</sub>O<sub>4</sub> 4:45  
 OsO<sub>4</sub> 4:33  
 postfixation 4:33  
 chemical gene-transfection systems 15:490  
 chemical genomics 11:616  
 chemical Langevin equation 14:141  
 chemical libraries 8:90, 91ff  
 chemical mechanism  
   protein splicing 11:243  
 chemical mechanism of protein splicing  
   aminosuccinimide formation 11:246  
   asparagine cyclization 11:246  
   branched ester intermediate 11:245  
   conserved penultimate histidine 11:246  
   C-terminal asparagine 11:246  
   C-terminal glutamine 11:247  
   finishing reactions 11:247  
   kinetic studies 11:249  
   linear thioester 11:243  
   N-O or N-S acyl rearrangement 11:247  
   N-O or N-S acyl shifts 11:245  
   N-S (or N-O) acyl rearrangement 11:243  
   N-S or N-O acyl shift 11:243, 244  
   transesterification 11:245, 246  
 chemical microarray  
   chemical ligation 10:158  
   in situ synthesis 10:158  
   physical adsorption 10:158  
 chemical modification 12:621, 629, 631  
 chemical modification method  
   1-cyclohexyl-3-(2-morpholinoethyl)  
   carbodiimide metho-*p*-toluene sulfonate  
   (CMCT) 4:528  
   diethylpyrocarbonate (DEPC) 4:528  
   dimethylsulfate (DMS) 4:528  
   kethoxal [ $\beta$ -ethoxy- $\alpha$ -ketobutyraldehyde]  
   4:528  
 chemical mutagenesis 15:602ff  
   breeding scheme 15:604ff  
 chemical reaction equilibria 4:7  
 chemical shift 11:165, 13:518, 524, 530, 551,  
   553, 567, 572  
   amino acids 13:534  
   <sup>13</sup>C 13:544  
   definition 13:523  
   random-coil 13:533  
   titration 13:540  
 chemical shift index 13:535, 536  
 chemical shift mapping 13:518, 561  
 chemical shift perturbation 13:583, 584  
 chemical space 3:605, 10:203  
 chemical synthesis of peptides 2:38  
 chemical vector technology 15:491  
 chemical weapons convention (CWC) 10:512  
 chemical-exchange 13:570  
 chemical-induced autoimmunity 1:462  
 chemicals 5:339  
 chemiluminescence 2:523ff, 11:109  
 chemiosmotic coupling 1:577, 8:178  
 chemoattractant 8:326  
   microvascular leakage 14:41  
   protease-activated receptor (PAR) 14:41  
   tryptase  
     gelatinase 14:41  
     metalloproteinase 14:41  
 chemokine 5:213, 219, 230–231, 638, 641,  
   6:384, 397, 406, 408, 410, 8:432, 435, 437, 444,  
   445, 449, 454, 10:87, 100, 12:308, 15:399  
   alternatively activated macrophages 1:380  
   AMAC-1 (alternative macrophage  
     activation-associated chemokine-1) 1:380  
   MCP-1 (macrophage chemotactic protein)  
     1:380  
   MIP-3 $\beta$  1:372  
 chemokine receptor 5:230–231, 9:262, 15:339  
 chemokine receptor antagonists 6:170  
 chemometrics 4:664  
 chemoprevention 9:498, 530–531  
 chemosensation 11:467–468  
 chemotaxis 3:326, 327, 14:9–10  
 chemotaxis aggregation 8:326  
 chemotherapeutic 1:412  
 chemotherapeutic agents 9:383  
 chemotherapy 2:13, 233, 234, 9:531, 12:349,  
   14:167  
   AIDS 1:412  
   CMV-retinitis 1:412  
   Crohn's disease 1:412  
   ICAM-1 1:412  
   lung cancer 1:412  
   melanoma 1:412  
 chenodeoxycholic acid 7:219  
 CH<sub>3</sub>-H<sub>4</sub> MPT  
   reactions involved in synthesis of  
     8:242–244  
 chiasmata 14:6  
 chick 3:411  
   embryo 7:537, 551  
 chicken genome 2:535–537, 546–547  
   maps of 2:538–544  
   sequence assembly of 2:544–545  
 chicken genomics  
   importance of 2:537–538  
 chicken karyotype 2:538  
 chickenpox 3:155  
 childhood tumors 13:348



- chimera 10:72, 82  
 generation of transgenics 13:392  
 chimeric Ad vector  
 species fiber 15:346  
 with different serotype 15:346  
 chimeric antibodies 1:336–337  
 chimeric individual 13:336  
 chimeric mouse 14:506, 525  
 chimeric oligonucleotides 1:408ff  
 chimeric transcription factor 15:255  
 chimerism 1:217  
 chimpanzee colony 2:569  
 chimpanzee, culture 2:572  
 chimpanzee genome project  
 finishing phase 2:574  
 sequencing errors 2:575  
 sequencing strategy 2:573  
 shotgun phase 2:574  
 chimpanzee, life span 2:570  
 chimpanzee subspecies 2:560  
 chimpanzees 15:143  
 Chinese hamster ovary cells (CHO) 3:168,  
 10:291, 387  
 Chinese hamster ovary (CHO) mutants 10:289  
 ChIP 14:229ff  
 chiral acetates 2:611  
 chiral centers 10:22  
 chiral drugs 2:600  
 chiral phosphates 2:611  
 chiral phosphorothioates 2:611  
 chiral recognition 2:604  
 chirality 3:56ff, 10:17  
 amino acids 2:587  
 axial 2:585  
 definition 2:582  
 in biology 2:582  
 origin 2:614  
 specification – *D/L* notation 2:584  
 specification – *R/S* notation 2:582  
 chiroptical 3:65  
 chirped pulse 15:69  
 chitinase 2:254  
 chitosan 15:497  
 Chk1 12:189  
 Chk2 12:187  
*Chlamydia trachomatis* 6:555, 558ff  
*Chlamydomonas*  
*C. eugametos* 2:620  
*C. moewusii* 2:620  
*C. monoica* 2:620  
*C. reinhardtii* 2:620, 621  
*C. smithii* 2:620  
 chloramphenicol 11:51, 12:501  
 chlormadinone acetate 13:45  
 Chlorocruorin 6:70  
 4-chloro-17 $\beta$ -hydroxyandrost-4-en-3-one 13:26  
 chloroperoxidase (CPO) 6:49  
 reactions catalyzed by 6:50–51  
 chlorophyll 2:627ff  
 chloroplast 2:621ff, 5:496, 15:368, 369, 371,  
 374  
 cyanobacteria 14:258  
 DNA 2:627ff, 3:483, 5:258  
 genetic system 2:624  
 genome 2:624ff  
 inner envelope 11:291  
 lumen 11:289, 291  
 promoters 2:627  
 ribosomes 2:628, 631  
 stroma 11:291  
 thylakoid 11:289  
 transformation 2:631ff, 634  
 vegetative survival strategy 1:85  
 chloroplast genome 5:244  
 expression of 10:324–327  
 chloroquine 7:472, 14:368–372  
 chlorosis 10:365, 367  
 chlorotestosterone 13:26  
 choanocytes 13:274, 277  
 Chol 7:303ff  
 cholecystokinin (CCK) 14:108  
 cholera 6:304  
*V. cholerae* 6:305  
 cholera toxin 5:560, 13:152, 319  
 cholesterol 1:620, 4:194, 7:278, 279, 283,  
 8:143ff, 362  
 synthesis 7:198, 217  
 cholesterol 7 $\alpha$ -hydroxylase 7:219  
 cholesterol metabolism  
 bile acid metabolism  
 disorders 7:219, 221  
 catabolism  
 bile acid metabolism 7:219, 221  
 disorders  
 cerebrotendinous xanthomatosis 7:221  
 cholesterol 7 $\alpha$ -hydroxylase deficiency  
 7:221  
 cholesteryl-ester storage disease 7:221  
 Niemann–Pick Disease Type C 7:222  
 oxysterol 7 $\alpha$ -hydroxylase deficiency 7:221  
 Smith–Lemli–Opitz Syndrome 7:218  
 wolman disease 7:221  
 intracellular lipoprotein degradation 7:221,  
 222  
 cholesterol side-chain cleavage 13:8  
 cholesteryl ester transfer protein 7:198, 211,  
 213, 216, 230  
 cholic acid 7:219

- choline 8:144, 10:297  
   transporter 8:155  
 choline acetyltransferase (ChAT) 8:544  
 choline kinase 10:283  
 choline transport 10:283  
 choline-deficient 10:286, 295  
 cholinephosphotransferase 10:285  
 chondrocytes 12:162, 167  
 chondroitin sulfate B 2:591  
 chorea 15:12  
 chorion 4:404  
 chorionic gonadotropin 5:554  
 Chp1 14:238  
 CHRNA4 11:678  
 CHRNB2 11:679  
 chromaffin cells 4:311ff  
 chromaffin granules 1:245  
 chromatin 3:20, 4:95, 106, 239, 5:149, 480,  
   6:138ff, 139ff, 12:101, 14:2, 266  
   folding of 9:283  
   nucleolar 4:101  
   nucleosomal 4:101, 102  
   stretching of 9:283  
 chromatin and DNA fiber mapping 5:165  
 chromatin diffusion  
   evidence for 3:7  
 chromatin domains and loops 2:421  
   acetylation 2:422  
   enhancers 2:422  
   LCRs 2:422  
   nucleases sensitivity 2:422  
   S/MARs 2:422  
 chromatin fibers, *see* chromatin  
 chromatin folding  
   diameter of ~30 nm 2:420  
   Histone H1 2:420  
   10-nm chromatin fiber 2:420  
   50 to 80 nm 2:421  
 chromatin immobilization  
   evidence for 3:7  
 chromatin immunoprecipitation 12:100  
 chromatin loops 3:20  
 chromatin organization 12:101  
 chromatin remodeling 4:247, 13:375  
 chromatin structure 2:416  
 chromatin SV40 4:98  
 chromatin-mediated repression 10:484, 490  
 chromatogram 5:516  
 chromatographic 8:13, 21  
 chromatography 2:46, 8:4, 20, 23, 29, 31, 33,  
   35, 194, 195, 9:301  
   carbohydrates 2:255  
 chromobindins 1:242  
 chromodomain 4:253  
 chromophore 1:578, 582, 3:56ff, 12:414, 425,  
   452, 453, 457, 463  
   fluorophore 12:216  
   intrinsic 15:75  
 chromosomal banding  
   C-bands 5:62  
   G-bands 5:62, 67  
   H3<sup>-</sup> R-bands 5:67  
   R-bands 5:62  
   T-bands 5:62, 67  
 chromosomal deletions  
   chromosome 3 (p14–p23) 5:363  
   deletions in 171 5:363  
   loss of heterozygosity 5:363  
   3p deletions 5:363  
   Rb locus 5:363  
 chromosomal deletions in lung cancer 5:362ff  
 chromosomal DNA 3:451  
 chromosomal instability 6:15, 23  
 chromosomal locus 15:560  
 chromosomal segregation  
   aneuploidy 9:10  
   centrosomal anomalies 9:10  
 chromosomal translocation 14:152–153  
   chimeric transcripts 7:126  
   fusion proteins 7:126  
 chromosome 2:538, 3:532, 4:109, 5:325, 375,  
   6:139ff, 11:219, 369ff, 12:111, 406, 14:6  
   analysis sorting 4:434  
   evolution by fluorescence-activated  
     chromosome sorting 5:119–132  
   inactivation 7:506  
   microdissection of 5:125  
   painting 5:124–125  
 chromosome 21  
   pathogenesis of 3:565  
   phenotypic mapping of 3:564  
   structure of 3:563–564  
 chromosome aberrations  
   chromosome painting in diagnosis of  
     5:126–129  
   deletion or deficiency 5:401  
   duplication 5:401  
   inversion 5:401  
   translocation 5:401  
 chromosome abnormalities  
   DNA damage 1:86  
 chromosome banding 2:561, 3:24  
 chromosome bands 3:20  
 chromosome condensation 10:427  
 chromosome forms 7:475  
 chromosome gain or loss 6:15  
 chromosome inversions 7:475  
 chromosome microdissection 5:457

- chromosome organization  
   within nucleus 3:1–11  
 chromosome 17p13 6:4  
 chromosome painting, *see* FISH  
 chromosome positioning 3:3–5  
 chromosome 19q 15:246  
 chromosome rearrangement 5:316  
 chromosome stability 14:207  
 chromosome structure  
   axis or core 2:410  
   chromosome scaffolds 2:410  
   functional 2:410  
   location 2:410  
 chromosome substitution 14:506, 509  
 chromosome, subtelomeric region 2:562ff  
 chromosome territories 2:408  
   chromosome painting 2:409  
   DNA foci 2:409, 410  
   FISH 2:409  
 chromosome translocation 9:449  
 chromosome-specific paint probe 5:120, 122  
 chromosome 14:254ff  
   centromeres 14:254  
   nucleolar organizers 14:254  
   telomeres 14:254  
 chronic external ophthalmoplegia (CEOP)  
   15:377  
 chronic gastritis 6:11  
 chronic granulomatous disease (CGD) 10:189,  
   15:409, 417  
 chronic inflammation  
   lymphoid organ-like structures 6:352–353  
 chronic inflammatory bowel diseases 6:21  
 chronic inflammatory disease 8:455  
 chronic liver disease 7:325  
 chronic myelogenous leukemia (CML) 2:174,  
   3:11, 10:202  
 chronic pain 15:270  
 chronic periodontitis 8:453  
 chronic wasting disease 10:592–593  
 chronic wounds 13:244–245  
 chylomicron particles  
   intestinal lipid exportation on 5:223  
 chylomicron remnants 5:213, 228  
 chylomicrons 5:214, 223, 7:229, 231, 282,  
   14:626ff  
   assembly 7:199  
   catabolism 7:200  
   chylomicron remnant uptake 7:202  
   chylomicronemia 7:201  
 $\alpha$ -chymotrypsin 7:170  
 chymotrypsin catalysis 11:38  
 CIAP1 6:6  
 cICAT 8:20, 21  
 cICAT-labeled 8:21  
 ciclosporin 10:656  
 CID, *see* collision-induced dissociation  
 CIEF (capillary isoelectric focusing) 8:12  
 CIEF-FTICR 8:12  
 cigarette smoke 4:643  
 cigarette smokers  
   active cigarette smokers 5:355  
   heavy smokers 5:355  
 cilia 8:389  
 ciliary dynein  
   dark horse 8:583  
 ciliary dyskinesia 2:640  
 ciliary neurotrophic factor (CNTF) 5:653,  
   8:561, 565, 11:585  
 circadian clock  
   light regulation of 10:332–333  
 circadian control  
   evening element 14:262  
 circadian rhythm 12:414, 419, 420ff, 432ff,  
   439, 444ff, 450, 451, 454, 460, 464ff, 465, 466,  
   467, 468ff  
 circadian rhythm regulation 4:610  
 circadian time (CT) 12:414, 422  
 circannual rhythms 12:420  
 circular causalities 14:128  
 circular dichroism (CD) 3:56, 8:360, 374,  
   11:397, 12:31  
   electronic 3:58  
   instruments 3:63  
   stopped-flow 3:65  
   time-resolved 3:66  
   vibrational circular dichroism 3:61  
 circular DNA 15:498  
 circular pDNA 10:228  
 circularizing probe 7:188  
 circularly polarized light 10:18  
 circulating lipid  
   absorption of 1:4–5  
   storage of 1:4–5  
 circulating proteins 15:258  
 cirrhosis 7:325  
 cis- and trans-splicing reactions 12:57  
 cis–trans isomerization of X-Pro peptide bonds  
   1:40  
 cis-acting elements 5:507  
 cis-acting sequences 10:315  
 cis-element 1:436, 9:258, 10:309, 341  
 cis-etiocholanolone 13:25  
 cis-parinarate 7:100  
 11-cis-retinal 12:376  
 11-cis-retinoids 12:378  
 cisternal maturation 1:621  
 citrate 7:99, 8:216

- citrate synthase 2:609, 610  
     FAs 7:106  
 citric acid cycle 7:106  
 citric acid, prochirality 2:609  
 c-Jun N-terminal kinase (JNK1) 7:133  
 c-Jun terminal kinase–kinase (JNKK) 7:138  
 CKII phosphorylation 4:611  
 c-kit ligand 5:643  
 Cks 12:168  
 Cks (Suc1, p13) 12:155  
 CLA1, *see* SR-BI  
 cladistics 8:529, 530ff  
 class E compartment 4:203  
 class I 15:414  
 class I fusion proteins 11:75  
 class I proteins  
     fusion mechanism of 11:76  
 class II MHC antigen 15:411, 414  
 class II viral fusion proteins  
     E-glycoproteins of flaviviruses,  
     alphaviruses 11:78  
 class III region blocks 13:202  
 class switch recombination (CSR) 12:122  
 classic molecular motors 8:578, 581–585, 590  
     coordination 8:589  
     energy efficiency 8:588  
     fuel economy 8:588  
     kinesin  
         intracellular porter 8:580  
         molecular tug-of-war 8:586  
         motors movements of 8:586–587  
         muscle myosin 8:579–580  
         strokes  
             variation across motor families  
             8:587–588  
 classical growth curve 1:528  
 classifications of proteins 11:205  
 clathrin 4:183ff, 8:127, 128, 13:316  
     clathrin heavy chain 4:188  
     clathrin-coated pits 4:186  
     clathrin-coated vesicles (CCV) 4:188,  
     8:123  
     clathrin-independent endocytosis 4:193  
     clathrin-mediated endocytosis 4:186  
     distal leg 4:189  
     hub region 4:189  
     light chains 4:188  
     proximal leg 4:189  
     terminal domain 4:189  
     triskelion 4:188  
 claudin 2:362  
     barrier properties 2:363  
     diseases 2:363  
     isoforms 2:363  
     knockout animals 2:364  
     selectivity 2:363  
 clavulanic acid (80) 14:349  
 CLCN1 11:670  
 CLCN5 11:697  
 CLCN7 11:697  
 CLDN16 11:694  
 clearance 10:220  
 ClearView® 6:375  
 cleavage and polyadenylation specificity factor  
     (CPSF) 3:467  
 cleavage domain 12:327  
 cleavage factor (CF) 10:319  
 cleidocranial dysplasia (CCD) 15:48  
 clinic  
     adult-onset solid tumors 9:12  
     antiangiogenic therapies 9:12  
     antibody-based therapies 9:12  
     genomic diversity 9:12  
     heterogeneous tumor cell populations and  
     the therapeutic target problem 9:12  
     prevention 9:13  
     surgery 9:13  
     targeted agents 9:12  
 clinical application of xenotransplantation  
     adult and embryonic stem cell culture  
     15:587  
     “bridge” organ transplantation 15:586  
     free tissue xenografting 15:586  
     hepatocytes 15:586  
     in vitro organogenesis 15:587  
     islets of Langerhans 15:586  
 clinical chemistry 4:681  
 clinical development  
     vaccine 15:169  
 clinical gene therapy  
     treatment of diseases 13:263  
 clinical gene therapy trials  
     overview of 13:259  
 clinical pregnancy rate 6:540  
 clinical proteomics 11:313  
 clinical studies 3:230  
 clinical trials 7:45, 8:202, 14:303, 15:157, 390  
     hemophilia B patients 15:259  
     phase I 15:158, 170  
     phase II 15:158, 170  
     phase III 15:158, 162, 163, 169, 170  
     phase IV 15:158, 170  
 clinical uses of IFNs 15:414  
 clinical-phase trials 1:411ff  
 CLIP (class II MHC-associated Ii peptide)  
     1:370, 385  
 clock gene 4:611, 12:414, 423, 425, 427ff,  
     431ff, 437, 439ff, 444ff, 458, 461ff, 468ff

- clock-controlled gene 12:414, 431, 444, 449, 453, 455
- clofibrate 2:62
- CLogP (part of the Daylight suite) 3:602, 606
- clone coverage  
clone libraries proper 13:84  
unbiased 13:84
- clone fingerprints 13:100
- clone gap  
standard Southern techniques 13:88
- clone insert length  
full-length inserts 10:535
- clone linking 15:566
- clone mouse line 12:104
- clone ordering 15:565–566
- clone recovery rate  
measured by colony-PCR 13:92
- clone-by-clone SGS or CBC-SGS 13:73, 75
- cloned mammals 1:53  
cumulina cloned mouse 1:85  
Dolly, cloned lamb 1:85  
low success rate 1:85  
nucleus, sufficiently free of damage 1:85
- cloneless genomic libraries 15:566
- cloneless library 15:556, 561, 567
- cloning 1:226, 5:442ff, 443, 7:369, 9:209, 212, 221–222, 226, 13:337, 363, 367, 369, 14:483  
ability to generate human embryonic stem cells 13:388  
animals 9:203, 204  
amphibians 9:233, 13:370  
companion animals 9:237, 238, 240  
endangered species 9:237  
farm animals  
bovine 9:238  
cattle, bovine 9:235  
goat 9:236  
horse 9:237  
pig 9:236  
sheep 9:235  
fish 9:234  
laboratory animals  
mouse 9:234, 235  
rabbit 9:234, 235, 238  
rat 9:234, 235  
application 9:233, 235–237  
asexual reproduction 3:297  
cellular cloning 3:298  
chromosomal abnormalities 3:298  
clonal analysis 3:299  
clonal restriction 3:299  
clonal selection theory 3:299  
consent for donation 13:388  
efficiency 9:204, 223, 227, 230, 235  
embryonic 9:212ff  
ethical issues 13:388  
founder cell 3:298  
Honolulu Method 1:221  
humans 9:238  
mammalian 13:370  
Minute technique 3:299  
molecular cloning 3:297  
nuclear transfer techniques 3:297  
parthenogenesis 3:297  
pluripotent 3:298  
polymerase chain reaction 3:297  
positional gene cloning 3:297  
reproductive 3:298, 9:205, 238, 239  
restriction of potency 3:298  
serial transplantation 3:298  
somatic 9:212ff, 215  
somatic cell nuclear transfer 3:299  
somatic cell nuclei 3:298  
somatic nuclear transfer 13:388  
syndrome 9:232  
therapeutic 3:298, 9:205, 238, 239, 13:371  
totipotent 3:298  
vegetative propagation 3:297  
*see also* nuclear transfer
- cloning experiments  
altered phenotype of cloned individuals 1:86  
cloned mice 1:86  
DNA damage 1:86  
donor somatic cells 1:86  
gene expression profile 1:86  
low survival rate 1:86  
mice derived from normal mating 1:86  
nonmeiosis-derived conceptions 1:86
- cloning vector 3:387, 390ff
- closed complex 3:538
- closed spina bifida 9:120
- closing sequence gaps  
genomic DNAs as PCR templates 13:99  
isolated YAC 13:99  
physical gaps caused by cloning failures 13:99
- clostridial neurotoxins 8:135  
*Clostridium botulinum* 8:230  
*Clostridium tetani* 8:230
- clotting factor 15:258
- ClpB 2:502, 512
- clpP 2:628
- Clr4 14:237ff  
methyltransferase 14:237
- cluster analysis 9:92, 108
- cluster determinant (CD) 6:430
- clustered lesions 7:152

- clusterin 7:226, 236  
 clustering 14:136  
 clusters of differentiation (CD) 6:384  
 CMAH 2:563  
 C-mannosylation 5:572  
 cmd mouse 5:560  
 c-met 6:12, 24  
 c-met transcripts 6:12  
 CMF (conditioned medium factor)  
   8:326  
 CML 2:174, 15:416  
 CMP domain 6:210ff  
 C-MTase 12:334  
 CMV (cytomegalovirus) 6:559  
 c-myc 2:228, 230, 6:19, 7:331, 9:471  
 c-myc transcription factor (PuF) 6:23  
 CNGA3 11:683  
 CNGB3 11:683  
 Cnidaria 13:275ff  
 CNS, *see* central nervous system  
 CNTF, *see* ciliary neurotrophic factor  
 CO 8:226, 231, 10:6  
 CO<sub>2</sub> 2:621, 631, 8:223, 229, 10:6  
 CoA 7:99  
 coactivators 13:20  
 coalescence temperature 13:544  
 coarse-grain models 11:73  
 coarse-grained simulation 13:653  
 coatamer 8:128  
 coated pit 13:150  
 coated vesicle 8:127  
 coatomer 4:199  
 coatomer protein 1:621  
 coats 8:127  
 cobalt 1:431, 8:226  
 Cobas Amplicor, Roche Diagnostics Systems  
   6:559  
*Coccidioides immitis* 5:16  
   vaccine 15:174  
 cochaperone 2:488, 494  
 cockayne syndrome B, *see* CSB  
 cockayne syndrome (CS) 3:371, 376, 9:393  
 code 10:449  
 coding region 4:356  
 codon 2:453, 624, 630, 4:356, 5:371, 390, 11:46,  
   12:484, 486, 14:580  
   anticodon interaction 14:589  
   4-base 11:49, 50  
   start 14:586, 601  
   stop 11:48, 49  
   termination 14:586, 601  
   usage 14:615  
 codon usage 9:253, 13:445ff, 14:551  
 coenzyme Q10 15:39  
 coenzymes  
   organic cofactors 9:571–587  
   vitamin-derived 9:573–586  
 coevolution, virus–host 2:571  
 coexpression 1:217  
 cofactor 1:192ff, 2:530, 9:572  
 Coffin–Lowry syndrome 4:254  
 cognitive testing 4:604  
 cohesin 14:237  
 coiled phagosome 10:187  
 colcemid 3:23  
 cold sore 15:249  
 colds 15:417  
 ColE1 10:414  
 colinearity 5:386, 14:256  
 collagen 2:326ff, 514ff, 4:279ff, 8:47, 48, 50, 53,  
   55, 56, 66–68, 224, 13:225–226  
   chondrodysplasias 2:329  
   fibril-associated collagens 2:328  
   fibrillar collagens 2:328  
   network-forming collagens 2:328  
   osteogenesis imperfecta 2:329  
 collagen I gels 14:398  
 collagen matrix 1:389  
 collagenase 7:542  
 CollapsinI 2:118  
 collateral 14:288  
 collisional quenching 4:446  
 collision-induced dissociation (CID) 7:571,  
   8:8ff, 10, 16, 28f  
 colloidal gold 4:105, 109  
 colloidal properties 7:301ff  
 colocalization 8:500  
 colon cancer 9:523  
 colony stimulating factor (CSF) 5:638, 643,  
   8:437  
 colony-forming units 13:342  
 color-banding methods 5:128  
 colorectal cancer 6:19  
 colostrum 8:449  
 column 9:301ff  
 column oven 9:303  
 column protection 9:302  
 coma 10:9, 119  
 combinational drug therapy 12:401  
 combinatorial biosynthesis 10:647ff  
 combinatorial chemistry 2:23, 8:90ff, 95, 96,  
   10:199  
 combinatorial libraries 8:96  
 combinatorial peptide libraries  
   disulfide bond 8:420  
   NNK coding scheme 8:420  
   random peptide libraries 8:420  
 combinatorial peptides 8:412

- combinatorial synthesis
  - compound libraries 5:17
  - fumitremorgin 5:17
- combining sites
  - cavity-type 2:290
  - groove-type 2:290
- combustible air 8:239
- comet assay 3:363
- comets 10:9, 11
- CoMFA 3:605
- Committee for Proprietary Medicinal Products (CPMP) 13:264
- common endosome (CE) 4:200
- common environment 1:591
- common environmental variance 1:596
- common fragile sites 4:571ff
- common HLA haplotypes
  - serological specificities for HLA-A, B, and DR 13:201
- commonly ethyl methanesulfonate (EMS) 14:259
- compact genomes 11:366ff
- comparative embryogenomics 10:542
- comparative embryology 3:267
- Comparative Genome Analyses
  - gene families 13:109
  - gene networks 13:109
  - genome annotation 13:109
  - guiding molecular biologists 13:109
  - Mammalian Gene Collection (MGC) 13:109
- comparative genome hybridization (CGH) 2:195, 5:129, 8:278, 9:515, 12:366, 15:556, 567
- comparative genomics 9:259, 10:533, 542, 545, 11:371ff
  - genome sequencing 13:109
  - human-centric to species-focused 13:109
- comparative sequence analysis 12:631
- comparative sequencing 2:545–546
- compartment 12:101, 13:299
- compartmentalization 11:288
- COMPASS (CMP) 6:210ff
- compatibility 4:358
- competence 3:272
- competence factors 3:134
- competition experiments 11:404ff
- competition model 6:236
- complement C3 14:682
- complement membrane complexes 15:164
- complement receptor 1:385, 10:185
- complement system 5:584
- complementarity-determining regions 11:106
- complementary DNA, *see* cDNA
- complementary DNA library, *see* cDNA library
- complementation 1:55, 79, 83, 86ff, 87, 4:330, 13:438ff, 14:260
  - auxotroph 13:438
  - diploid 1:89
  - masking of deleterious recessive mutations 1:89
- complementation test 5:371, 375
- complementing cells 15:241, 250
- complete genome sequences 8:249
- complex alleles 5:25
- complex analysis 4:664ff
- complex inheritance 1:587
- complex mutants 3:342–343
- complex PK/PD models 10:232
- complex polygenic diseases 11:658
- complex systems 8:190, 204
- complex tissues
  - functions in 2:120–123
- complex type 5:579
- complexity 14:129f
- complexity hypothesis 6:236
- complexity of the organism 12:101
- complexity pyramid 14:138
- complex-type sugar chains 5:543ff, 548ff
  - bi 5:549
  - mono 5:549
  - pentaantennary sugar chains 5:549
  - tetra 5:549
  - tri 5:549
- complexus adherens junction 2:360
- compliance 14:409–410
- complotype block 13:202
- component-based approach 14:143
- compositional constraints 5:348
- compound databases 11:624
- compound libraries 8:91ff
- compound properties 11:618
- compound sources
  - new chemical entities (NCEs) 11:595, 626
- compounds 6:50, 11:625
  - ABT-594 11:627
  - epibatidine 11:627
- computational biology 6:569
- computational chemistry 3:601
- computer infrastructure 14:141
- computer modeling 7:118, 12:608
- computer-aided structure prediction 10:203
- computer-assisted diagnosis (CAD) 9:112
- computer-assisted systems biology 10:469–473
- COMT, *see* catechol-O-methyltransferase
- concatemer 9:352, 357, 12:709, 713ff, 714ff
- concentration 4:663ff
- concerted evolution 14:256

- concerted model 11:604  
 concordant hypermethylation of the CDH1 and RAR $\beta$ 2 promoters 6:11  
 condensation 7:303ff  
 conditional gene targeting 14:530–533  
 conditional model 1:216, 14:506  
 “conditional” protein splicing 11:257  
 conditional transgenesis 14:529–530  
 conditionally replicating 15:267  
 conditions on the primitive Earth 10:6  
 cone-rod dystrophy 15:22ff  
 cone-rod homeobox protein (CRX) 15:23  
 configurations  
   absolute 2:583  
   Cahn–Ingold–Prelog system 2:583  
   relative 2:583  
   sequence rules 2:583  
 confocal fluorescence 7:169, 11:109  
 confocal laser scanning microscopy and FCS (LSM-FCS) 4:482  
 confocal microscopy (CM) 7:166, 14:426, 15:62  
 conformation  
   macromolecules 2:259  
   conformational 7:170  
   conformational analysis 2:271  
     NOE 13:539  
   conformational state transition 4:10  
   conformational transitions 7:171  
 congenital central hypoventilation syndrome (CCHS) 15:50  
 congenital disorders of glycosylation (CDGs) 5:593  
 congenital infection 3:159  
   cytomegalovirus 3:156  
 congenital myopathy 11:674  
 Congo red birefringence 15:25  
 conidiation 12:451ff  
 conjugation 5:320, 343, 10:437, 11:108  
   bacterial conjugation 6:228  
   conjugation 1:69  
   homologous recombinational repair (HRR) 1:69  
   plasmid 6:228  
   T-DNA 6:228  
   Ti plasmid 6:228  
 conjugation reactions 2:53  
 Conklin’s method for staining spores 1:512  
 connective tissue 2:326ff  
 connectivity 14:136  
 connector 9:352, 354  
 conotoxin 11:659, 683, 13:532, 546, 14:329  
 consanguineous marriages  
   expression of deleterious mutations 1:91  
   major congenital malformations 1:91  
 Consed 5:522  
 consensus 6:183ff  
 conservation law of robustness 14:130  
 conserved extended haplotypes, *see* CEHs  
 complement genes (complotypes) and TNF 13:193  
 conserved noncoding regulatory elements  
   Sox9 gene 11:375  
 conserved regions  
   identification of 2:545–546  
 conserved sequence blocks (CSB) 15:373  
 conserved sequences 10:542  
 conserved structural element 12:329  
 conserved structure 12:593  
 conserved synteny 15:620  
 constant parameters 11:384  
 constant region 1:330, 343  
 constitutive activity 11:606  
 constitutive defenses 6:408–410  
 constitutive ectopic expression 14:263  
 constitutive exocytosis 4:307  
 constitutive receptor activity 11:606  
 constrained diffusion 3:2, 9–10  
 constraint satisfaction problem 12:618–623ff, 631ff  
   domain 12:619  
   search space 12:618–623  
   search tree 12:622  
   variable 12:619, 620  
 construction of bacteria-based large-insert, ordered genomic DNA libraries 3:409  
 construction of DNA libraries 3:402  
 construction of genomic library  
   partial filling-in 5:451  
 contact effect 7:550  
 contact hypersensitivity 3:377  
 contact inhibition 7:538, 12:184ff  
 contact precautions 10:521  
 contact site 8:361  
 contact-dependent (short range) axon guidance mechanisms 2:116–117  
 contact-independent (long-range) axon guidance mechanisms 2:118–119  
 contaminated culture, purification from 1:507  
 contamination 1:418, 7:548, 11:510  
 contamination control  
   background signals 6:460  
   false-positive signals 6:460  
 context of death 11:662  
 contig (BAC) 5:120, 121, 407, 522, 7:352, 11:434, 13:95  
 contig map 2:536, 542–544, 3:44  
 Contignasterol 14:366



- contigs and scaffolds  
 paired sequence reads 13:96  
 “scaffold” neighboring contigs 13:96
- continuous culture  
 chemostat 5:8
- continuous wave illumination (CW ESR) 7:162
- continuous-exchange cell-free 2:455
- continuous-flow cell-free 2:455
- contractile proteins 11:669
- control 11:512  
 feedback control 14:131, 132  
 feedforward 14:132  
 integral feedback control 14:131  
 negative feedback 14:132  
 positive feedback 14:132
- controlled release 14:164, 167
- controlled release systems 14:168
- conventional far-field microscopy 9:272
- convergent evolution 8:422  
 parallel 11:211
- cooperative binding 11:400
- cooperativity 1:581, 4:2, 3, 16, 5:266, 273, 6:68  
 intrinsic free-energy changes 6:89  
 reaction scheme 6:89  
 subunit interactions 6:88  
*see also* hemoglobin
- coordinate induction 12:27
- coordinate repression 12:28
- coordinately transcribed genes 5:79
- COP1  
 light responses, regulator of 10:331–332
- COPI 4:199, 8:127, 128
- COPII 8:127, 128
- copper 1:67, 2:636, 8:212, 217, 219, 221, 222, 224–226, 231
- copper enzymes 8:213
- copper–zinc superoxide dismutase (CuZn-SOD) 10:123
- coprotease activity  
 autocleavage 11:543  
 LexA 11:543  
 phage  $\lambda$  cI 11:543  
 UmuD 11:543
- COP9 signalosome (CSN) 11:3, 9, 12:171
- copy number polymorphism 9:184
- copyrights 7:371
- core gene 7:327
- corepressor (inducer) 3:507, 12:28
- coronary artery disease 7:278, 292
- coronary disease 8:453
- corpus lutea 4:396ff
- correlation coefficient 11:517
- correlation spectroscopy 11:159, 164
- correlation tables 4:659ff
- correlation time 7:160
- cortex 2:108
- cortical granule exocytosis 2:466
- corticotrope 4:389
- corticotropin-releasing factor (CRF) 8:444, 14:104, 110
- cosmic rays 10:4
- cosmid 2:620, 630, 3:387, 5:120, 121
- cost of goods sold (COGS) 10:389
- Costal2 (Cos2) 12:179
- costimulation 1:382, 10:93
- costimulatory molecules 1:384, 386  
 4-1BBL 1:373  
 CD40 1:373  
 CD80 1:373  
 CD86 1:373  
 CD80 (B7.1) 1:359  
 CD86 (B7.2) 1:359
- cosuppression 12:537
- COSY 2:269, 13:525, 526, 590
- Cot1 3:38
- CoT analysis 7:477
- Cot1 DNA 3:39
- cotranslational folding 12:506–508
- coumarin 11:117
- coumarin anticoagulants 14:362
- counterion condensation theory 3:199
- counting methods  
 counting chambers 1:513  
 dilution-plate/spread plate 1:515  
 dilutions 1:515  
 direct smear 1:514  
 Helber cell 1:513  
 hemocytometer 1:513  
 membrane filter method 1:515  
 most probable number (MPN) method 1:515  
 Thoma chamber 1:514  
 total count 1:513  
 viable counts 1:514
- coupling 8:166ff, 173
- coupling constant 13:524, 531, 535, 549, 553  
 conformational analysis 13:539
- courtship behavior  
 adaptive function 1:91  
 guppy fish 1:91  
 select for fitness 1:91
- covalent attachments 7:308ff
- covalent derivatization of proteins 5:37
- covalent intermediate 12:335
- covalent modification 12:325
- covariation 12:621, 631
- cowpoxvirus 6:559
- COX2, *see* cyclooxygenase 2

- coxsackie/adenovirus receptor 15:254  
 C<sub>p</sub>  
   molar specific heat capacity 3:536  
 CP110 12:189  
 C-peptide 4:482  
 C-period 1:526  
 CpG DNA 10:91  
 CpG dyads 4:239  
 CpG island 4:242, 5:430, 457ff, 11:449, 15:33ff  
   density of CpG islands 5:74  
   DNA methylation 5:72  
   GC suppression 5:72  
   gene silencing 5:73  
   tissue-specific expression patterns 5:74  
 CpG island methylator phenotypes 6:11  
 CpG nucleotides 1:377  
 CpG ODN 8:613  
 CpG oligonucleotides 1:396  
 CpG repeat sequences 15:255  
 CpG-immunostimulatory oligonucleotides 9:431  
 CpNpG 5:433  
 CRAC 8:327  
 C-Raf kinase 8:361  
 cranial mesenchyme 9:131  
 cranial neurulation  
   actin cytoskeleton 9:133  
   cell proliferation 9:134  
   cranial mesenchyme 9:131  
   molecular regulation of 9:131–134  
   neural crest emigration 9:133  
   neuronal differentiation 9:133–134  
   programmed cell death 9:133  
 craniorachischisis 9:120, 127  
 crankshaft effect 12:612  
 CRE expression 14:532–533  
 C-reactive protein (CRP) 6:413  
 create multivesicular bodies (MVBs) 8:123  
 CREB 4:611, 15:26  
 CREB-binding protein (CBP) 15:11ff  
 Cre-lox 4:336, 10:297  
 CRE-LoxP 14:506, 532  
 CREM 15:26  
 CRE-MER 14:506  
 CRH 14:48  
   CRHR-1 14:47  
   CRHR-2 14:47  
   receptor 14:47  
 CRHR-1 antagonist  
   Antalarmin 14:48  
 criminal DNA databases 3:495  
 C-ring 1:446  
 crinophagy 1:627  
 cripto 6:16, 17, 22  
 CrkII 2:335ff  
 Crohn's disease 4:644, 6:21, 8:453, 455  
 cross-bridges 8:579  
 cross-contaminations 7:541  
 cross-fostering 1:593  
 crossing point (Cp) 11:483ff  
 crossing-over 5:371, 404  
 crossing-over, intrachromosomal 2:563  
 cross-linking 7:149, 151, 154–156  
   formaldehyde 4:95  
   glutaraldehyde 4:95, 100, 102  
 cross-presentation  
   MHC Class I 1:394  
   proteasome-independent 1:394  
   TAP-dependent 1:394  
 cross-priming 1:394  
 cross-reactants 6:377ff  
 cross-reacting molecules 6:376  
 cross-reactivity 2:555  
 cross-species reciprocal chromosome painting 5:120  
 CRP  
   cyclic AMP receptor protein 3:538  
 cruciforms 3:545  
 Crumbs complex 12:185  
 Crumbs (CRB) 4:283  
 crust 10:5  
 cryo EM  
   approaches 4:46  
   EM at cold temperatures 4:57  
   high pressure freezing 4:46  
   hydrated cryosections 4:50  
   the cellulose capillary tube 4:47  
   the fine-needle biopsy 4:48  
 cryocrystallography  
   cryoprotectant 7:411  
   cryostat 7:411  
   crist flash-frozen 7:410  
   ice formation 7:410  
   radiation damage 7:410  
   small loop 7:411  
 cryoelectron microscopy 1:577, 4:90, 104, 7:302ff, 11:78, 13:657  
 cryo-EM structural refinement  
   normal-mode-assisted 13:665–666  
 cryogenic electron microscopy 13:654  
 cryoprobe 13:522, 527, 528, 538  
 cryosection 4:37  
 cryostat chamber 13:680  
 cryotherapy 12:349  
 cryptic ECM 8:70  
 cryptic ECM epitope 8:46  
 cryptic splice sites 1:146

- cryptochrome 10:331, 12:425ff, 428ff, 432, 436ff, 447ff, 456ff, 459, 463  
 crystal 7:395, 14:39  
 crystal mounting 7:409  
   goniometer head 7:410  
   quartz capillary 7:410  
   thin-walled 7:410  
 crystal symmetry  
   Bravais-lattice types 7:396  
   crystal lattice 7:395  
   international tables for crystallography 7:396  
   Laue groups 7:396  
   noncrystallographic symmetries 7:397  
   point group symmetry 7:396  
   space groups 7:396  
   unit cell 7:395  
 $\alpha$ -crystallin 2:507  
 crystallization  
   batch 7:404  
   dialysis 7:402  
   free-interface diffusion 11:277  
   high-throughput screening 11:276  
   liquid-handling systems 11:276  
   membrane proteins  
     lipidic mesophases 11:277  
   microfluidic system 11:277  
   nanoliter robotic systems 11:276  
   screening 7:402  
   seeding 7:401  
   vapor diffusion 7:402  
 crystallographic refinement  
   atomic temperature factor *B* 7:448  
   automation 7:449  
   bond 7:448  
   crystallographic *R*-factor 7:448  
   dihedral torsion angle 7:448  
   energy or stereochemistry restraints 7:447, 449  
   individual occupancy 7:449  
   least-squares method 7:449  
   maximum likelihood method 7:449  
   molecular dynamics (MD) 7:449  
   noncrystallographic symmetry 7:448  
   potential energy function *E* 7:448  
   real atomic resolution 7:449  
   simulated annealing (SA) 7:449  
   structural model 7:447  
   structure analysis 7:449  
   unrestrained crystallographic refinement 7:449  
   valence angle 7:448  
 crystallographic structure determination  
   heavy-atom substructure 11:279  
 crystallography 1:577, 11:78  
 cystic fibrosis  
   *Haemophilus influenzae* 8:629  
   Staphylococcus aureus 8:629  
 CSB (cockayne syndrome B)  
   aging 1:70, 73  
   base excision repair (BER) 1:73  
   8-hydroxyguanine 1:72  
   *see also* conserved sequence blocks)  
 C-13 side chain addition 1:426  
 C-signal 8:309–311  
 CSPD 2:524  
 CT, *see* cytidyltransferase  
 ct $\alpha$  10:297  
 CT $\alpha$  gene 10:284, 296  
 CT $\beta$  gene 10:284  
 CT $\alpha$  transcription 10:296  
 C-terminal gateway 11:534  
 C-terminal R-SNARE motifs 11:94  
 CTL (cytotoxic T-cell, cytotoxic T lymphocytes)  
   3:165, 4:208, 6:340, 348, 384, 430, 475, 10:628, 15:293, 409ff  
   Ex vivo generation of 6:443  
 CTL epitopes 15:164  
 CTL escape mutations 15:164  
 CTL response 15:138  
 CTL targets 15:140  
 CTLA-4 1:373, 15:263  
 CTL-eliciting immunogen 15:139  
 CTL-escape mutants 15:139  
 CTP:phosphocholine 10:283  
 CTP:phosphocholine cytidyltransferase 10:293  
 ctp:phosphoethanolamine cytidyltransferase 10:288  
 cubic lipid phase 1:577  
 cubulin 4:212  
 CUG-BP1 and ETR-3-like factors (CELF) 15:42  
 Cul1 12:168ff, 179, 191  
 Cul3 12:170  
 Cul4 12:192  
 culmination 3:327  
 culture 7:536ff, 538ff, 541ff  
   characteristics 1:521  
   deep stab 1:506  
   incubations 1:506  
   liquid 1:505  
   media 1:506  
   organotypic 7:550  
   pH 1:505  
   plate 1:506  
   primary 7:536, 538, 541  
   pure 1:505  
   shake 1:509

- slope 1:506  
 solid 1:505  
 suspension 7:543ff  
 tests 1:516  
 three-dimensional 7:550ff  
 culture conditions setting  
   multiple facets of 14:397–400  
 culture system  
   setting up 14:392–401  
 cumulina cloned mouse  
   rate of successful implantation 1:85  
 curare 11:659, 14:334–337  
 Curran 11:686  
 curve fitting 4:663, 13:688  
 curved DNA 3:534  
 cut 6:208ff  
 cut domain 6:209ff  
 cutaneous lymphocyte-associated antigen (CLA)  
   1:389  
 CUX 6:209ff  
 C-value paradox 9:184, 12:128–129  
 CWDE 10:367, 369  
 CXCL chemokine family 6:17  
 cyanide 8:226  
 cyanoacetylene 10:12  
 cyanobacteria 2:633ff, 12:414, 462ff  
 cyanobacterial cells 13:695  
 cyanobacterial lipids 7:273  
 cybernetic 14:125, 127, 128  
 cycle of life 13:333  
 cycle sequencing 9:398  
 cycle threshold (Ct) 11:483ff  
 cyclic AMP 14:3  
 cyclic AMP receptor protein 12:24  
 cyclic hydroxyamic-acid containing peptide  
   4:269  
 2',3'-cyclic phosphates 10:20  
 cyclic structure building 12:623  
 cyclic structure building approach 12:624  
 cyclin 8:314, 315, 9:508, 12:145ff, 146, 153,  
   154, 164, 169, 176, 177, 186, 189, 194, 356  
   Clb 12:147  
   Cln 12:147  
   cyclin A 12:148, 184, 192  
 cyclin B 2:468  
 cyclin B1 2:466  
   cyclin box 12:146  
   cyclin C 12:154  
   cyclin D 12:153ff, 184  
   cyclin D1 2:335, 6:5, 19, 7:331, 12:176, 177  
   cyclin E 6:20, 12:148ff, 184, 186, 189, 194ff  
   cyclin F 12:154ff  
   cyclin G 12:154ff  
   cyclin H 12:154, 164  
   cyclin K 12:154  
   cyclin proteolysis 12:169  
   cyclin T 12:154  
 cyclin D1 gene amplification 6:13  
 cyclin E gene 6:13  
 cyclin E gene amplification 6:11  
 cyclin E overexpression 6:11  
 cyclin G-associated kinase, *see* auxilin  
 cyclin genes 7:329  
 cyclin/CDK complexes 6:13  
 cyclin-dependent kinase 4, *see* Cdk  
 cyclization 10:23  
 cycloaddition 11:64  
 cyclobutane pyrimidine 9:383  
 cyclobutane pyrimidine dimer (CPD) 3:356,  
   428, 429ff  
 cyclooxygenase 4:120, 6:61  
   mechanism of 6:62–63  
   structure of 6:62–63  
 cyclooxygenase 2 (COX2) 6:5, 14, 21f, 10:126  
 cyclopentadiene 11:116  
 cyclophilins 1:40  
 cyclopropane fatty acids 7:259  
 2 $\alpha$ ,3 $\alpha$ -cyclopropano-5 $\alpha$ -androstan-17 $\beta$ -ol  
   13:39  
 17 $\beta$ -(cyclopropylamino)-5-androsten-3 $\beta$ -ol  
   13:52  
 cyclosporin 4:343, 5:7ff, 13:525, 556,  
   14:374–375  
   immunosuppressants 5:8  
   *Tolypocladium* 5:7  
 cyclosporin A 1:670, 10:656  
   cyclophilin complex 13:572  
 CYFIP1 4:603  
 CYFIP2 4:603  
 cynomolgus macaque 10:77  
 CYP1A1 2:54  
 CYP3A 10:201  
 CYP3A4 3:627  
 CYP7A1, *see* cholesterol 7 $\alpha$ -hydroxylase  
 CYP2D6 2:54  
 cyproterone acetate 13:44, 48  
 CYPs 3:627  
 cytochrome *c* oxidase 8:224  
 cystatin B gene (CSTB) 15:39ff  
 cysteine 11:108, 115  
   cysteine, absolute configuration 2:584  
   cysteine proteases 10:620, 11:120  
   cysteine string protein 4:311  
   cysteine transporter 4:208  
 cystic fibrosis (CF) 6:325, 7:603, 11:686,  
   12:112, 15:260, 487  
   abnormal liver function 8:630  
   animal models 8:637

cystic fibrosis (CF) (*continued*)

- antimicrobial peptides (defensins) 8:632
- basic defect-pathology relations 8:629
- carrier frequency 8:625
- chemoattractants 8:632
- diabetes 8:630
- diagnosis 8:625
- epidemiology 8:625
- exocrine pancreatic insufficiency 8:630
- genotype-phenotype relations 8:626
- hypergammaglobulinaemia 8:632
- immune complexes 8:632
- immunology 8:632
- in African-Americans 6:332
- incidence 8:625
- liver 8:637
- lung infections 8:629
- modifier genes 8:626
- mutations 8:626
- neutrophils 8:632
- pancreatic insufficiency 8:637
- polymorphonuclear leukocytes 8:632
- prevalence 8:625
- prognosis 8:626
- Pseudomonas aeruginosa* 8:629
- reactive oxygen species 8:632
- respiratory tract 8:629
- screening 8:625
- sputum 8:632
- therapy strategies 8:634
- type III hypersensitivity reaction 8:632
- cystic fibrosis transmembrane conductance regulator, *see* CFTR
- F508del 8:624
- misfolding 8:624
- mutation 8:624
- phenylalanine in position 508 8:624
- premature intracellular degradation 8:624
- cystine knot structure 4:389
- cystinosis 1:620
- cytidyltransferase (CT) 10:283, 299, 12:465
- cytochalasin D 4:202
- cytochrome 4:347, 7:170
- cytochrome *b* 2:628, 629
- cytochrome *b*<sub>6</sub>*f* complex 2:631ff, 636
- cytochrome *c* 8:225, 10:129, 622, 625, 626
  - FAs 7:106
- cytochrome *c*<sub>6</sub> 2:624ff, 636
- cytochrome *c* oxidase (CCO) 6:34, 8:213, 218, 224–226
  - electron transfer of 6:58
  - O<sub>2</sub> activation of 6:58–60
  - proton pumping 6:60–61
  - structure of 6:57–58
- cytochrome *c* peroxidase (CCP) 6:39, 8:218
- cytochrome oxidase 2:628, 4:120
- cytochrome P450 2:53ff, 3:102, 6:34, 45, 156, 162, 7:485, 8:210, 216, 217–220, 13:17
  - electron transfer of 6:48–49
  - epoxidation 2:56
  - genetic variability 2:54
  - heteroatom oxidation 2:56
  - hydroxylation 2:56
  - mechanism of 6:46–48
  - nomenclature 2:54
  - reductive reactions 2:57
  - structure of 6:46–48
- cytochrome P<sub>450</sub> isozymes 10:209
- cytochrome P450 reductase 2:55
- cytochrome P450<sub>SCC</sub> 13:8
- cytochrome P450 taxane-10 $\beta$ -hydroxylase 1:426
- cytochrome P450 taxane-13 $\alpha$ -hydroxylase 1:426
- cytoduction 2:622
- cytogenetic expression 4:589
- cytogenetic maps 2:540–541
- cytoglobin 6:70, 97, 98
- cytogram 4:420
- cytokine 1:391, 5:214, 219, 230, 638, 640, 6:384, 389, 391, 406, 408, 410, 8:432, 10:87, 11:110, 368, 552, 578, 12:308, 13:115–138, 14:43, 449, 15:148, 389, 391, 392, 397, 399, 410, 412, 415, 418
  - historical perspective 3:118–121
  - IFN- $\alpha$  15:314, 315
  - IFN- $\beta$  15:310, 314, 315
  - IFN- $\gamma$  15:297, 314, 315
  - IL-1 15:297, 314
  - IL-2 15:311
  - IL-4 15:297
  - IL-6 15:298, 314, 315
  - IL-8 15:314
  - IL-10 15:297, 313
  - IL-12 15:293, 297, 299, 314, 315
  - IL-18 15:293
  - interleukin 3:115–150
  - lectin-like activities 5:588
  - TGF- $\beta$ 1 15:297–299
  - TNF- $\alpha$  15:314, 315
- cytokine genes 15:400
- cytokine monocyte chemoattractant protein-1 11:111
- cytokine network 8:451
- cytokine receptor (CCR5) 5:652, 6:329, 8:438, 439, 15:401
  - hematopoietin family of 13:130–136
- cytokine synthesis inhibitory factor 6:475

- cytokine type II 13:130  
 cytokinesis 14:3  
 cytokinin 1:419, 10:334  
   regulation by 10:339–340  
 cytomegalovirus, *see* CMV  
 cytomegalovirus 3:155, 156, 228–229, 6:389, 559  
   guinea pig 3:177  
   vaccine 15:160  
 cytomegalovirus (CMV)-retinitis 15:488  
 cytoplasm 1:527, 528, 531  
 cytoplasm synthesis during the division cycle 1:532  
 cytoplasmic antigens  
   presentation on MHC I molecules 3:219–220  
 cytoplasmic domain  
   catenin binding domain 2:352  
   cytoskeletal attachment 2:352  
   interaction p120 2:353  
   juxtamembrane domain 2:352  
   lateral clustering 2:352  
 cytoplasmic “dumping” 15:20  
 cytoplasmic factors  
   pattern of cleavage is well coordinated 13:384  
 cytoplasmic fraction 14:217  
 cytoplasmic genomes  
   chloroplasts 1:85  
   mitochondria 1:84  
 cytoplasmic male sterility (CMS) 10:336  
 cytoplasmic repressor 12:30  
 cytoplasmic signals  
   calcium 2:465  
   gap junctions 2:465  
   G-proteins 2:465  
   hormones 2:465  
   kinases 2:465  
   phosphatases 2:465  
   phospholipases 2:465  
   phosphorylated 2:465  
 cytoplasmic streaming 8:485  
 cytoplasm-to-vacuole 1:624  
 cytoplasm 9:204, 223ff, 227  
   activated 9:225, 226  
   non-activated 9:224, 226  
 cytosine deaminase  
   induced activation of 12:116, 122  
 cytosine methylation 9:305  
 cytosine-C5 12:326  
 cytosine-N4 12:326  
 cytoskeleton 2:464, 4:279, 8:463ff, 464ff, 469ff, 473ff, 481ff, 10:178, 182  
   actin 8:469  
   dyneins 8:463  
   intermediate filaments 2:412  
   microfilaments 2:412  
   microtubules 2:412, 8:463  
   phragmoplast 8:464, 473, 481  
 cytosolic heat shock response 13:467–471  
   inducers 13:466  
   sensors 13:466  
   signals 13:466  
 cytotoxic chemotherapy 14:187  
 cytotoxic T cells (CD8+) 6:354  
 cytotoxic T lymphocytes, *see* CTL  
 cytotoxic T-cell, *see* CTL  
 cytotoxicity 6:510
- d**  
 δ1 15:214  
 3-D cell culture  
   additional functions for known proteins  
     discovery of 14:403  
     applications of 14:401–407  
     interactions among signal transduction pathways 14:401  
 D cells 13:421ff  
   D1 cells 13:422ff  
   D2 cells 13:422ff  
   D3 cells 13:422ff  
 3D cocultures  
   additional complexity, need for 14:410  
 3D culture  
   biochemical and imaging 14:398  
   developmental and pathological conditions, recaptulation of 14:403  
   manipulations of imaging 14:398  
   systems that mimic neoplasias 14:404–405  
 3D culture milieu  
   components of 14:397  
 2D electrophoresis 2:556  
 2D ESR technique relies 7:162  
 2-D fluorescence differential gel electrophoresis (DIGE) 7:580  
 2D gel electrophoresis (2-DE) 7:561, 11:313–315  
 2D PAGE 8:2ff, 4, 5, 11–13, 15, 23–28  
 DAAO, *see* D-amino acid oxidase  
 DABSYL 11:489ff  
 DAF (DNA amplification fingerprinting) 3:490  
 D-amino acid oxidase 1:606  
 danazol 13:23, 39  
 danger hypothesis 1:392  
 danger signals 1:392, 393  
*Danio rerio*, *see* zebrafish  
 Danios 10:550  
 data analysis 11:513

- data cleansing 2:80  
 data collection field 13:689  
 data integration  
   basic genomic information 13:89  
   functional annotation, of sequenced genomes 13:89  
   gene-centric or marker-centric 13:89  
   genetic information 13:89  
   markers 13:89  
   sequence polymorphisms 13:89  
 databases 1:298, 6:608, 14:142  
 databases of protein domains  
   Pfam 12:103  
   SMART 12:103  
 date hubs 9:509  
 DAX1 Gene  
   mapping studies 5:621–623  
 Daylight software 3:602  
 Dbf4 12:190  
 DCC 6:18, 20  
 DCC (deleted in colorectal cancer) 2:118  
 DCCD (dicyclohexylcarbodiimide) 11:335  
 Dcr1 14:238ff  
   dicer 14:238  
 DCs 1:361, 363, 364, 370, 372, 375  
   adhesion receptor DC-SIGN 1:391  
   antigen uptake mechanisms 1:389  
   CD34<sup>+</sup> bone marrow–derived precursors 1:388  
   CD14<sup>+</sup> monocyte pathway 1:389  
   CD34<sup>+</sup> precursor pathway 1:388  
   follicular dendritic cells 1:385  
   human DC subtypes 1:388  
   immature 1:390, 10:94  
   immune evasion 1:397  
   immunotherapy 1:398  
   interdigitating dendritic cells (IDCs) 1:362  
   interstitial 1:390  
   macropinocytosis versus phagocytosis 1:390  
   maturation 1:390, 391  
   myeloid 10:94  
   myeloid versus lymphoid 1:387  
   “natural interferon–producing cells” (NIPCs) 10:94  
   plasmacytoid 10:94  
   plasmacytoid cell pathway 1:389  
   plasticity 1:397  
   precursors 10:94  
   pre-DCs 10:94  
   receptors for endocytosis 1:390  
   subsets 1:387  
   T cell priming and polarization 1:395  
   T helper cell polarization 1:396  
   DC-SIGN (DC-specific ICAM-3-grabbing nonintegrin) 1:372, 391  
   DCT 11:693  
   D-cycloserine 2:590  
   ddCt 11:518ff  
   D,D(35)E motif 12:408  
   2D-difference gel electrophoresis  
     applications 5:45ff  
     Cy dye labeling 5:40  
     cysteine thiol labeling 5:47  
     fluorescence detection 5:43, 44  
     image analysis 5:44  
     internal standard 5:40, 41  
     lamp/CCD-based 5:44  
     linear dynamic range of detection 5:40  
     minimal lysine labeling 5:41, 42  
     NHS-cyanine dyes 5:39  
       induced molecular weight shifts 5:42  
     poststaining of dye-labeled proteins 5:42, 43  
     sensitivity 5:40  
   2D-DIGE 8:18  
   ddm1 (decrease in DNA methylation) 14:268  
   DDT 7:472  
   2-DE differential protein expression analysis 5:34ff  
   de Duve 13:609, 614  
   de novo 6:11  
   de novo design 10:206ff  
   de novo gastric carcinoma 6:11  
   de novo methylation 14:269  
   de novo pathway 13:615, 622–624  
   10-deacetyl baccatin III acetyl transferase 1:426  
   10-deacetyl-baccatin III 1:427, 10:659  
   deacylation–reacylation 10:293  
   “dead-on-arrival” (DOA) elements  
     Helena 12:130  
     nonallelic 12:130  
   deafness  
     barttin 11:693  
     CLCNKA 11:693  
     CLCNKB 11:693  
     DFNA2 11:693  
     endolymph fluid 11:693  
     KCNQ4 11:693  
   deamination 9:305, 12:120  
   death domain 8:444  
   death effector domains 10:621  
   death-inducing signaling complex (DISC) 10:129, 622, 14:451  
   death-receptor pathway 10:626  
   7-deaza-GTP 9:402  
   decamethonium 14:334–337  
   decapentaplegic (Dpp) 12:176

- decoding 12:484, 486, 491–495  
 decontamination 10:520–522  
 deconvolution 4:662ff  
 decoy approach 2:177  
 dedifferentiation 2:231, 232, 7:331, 13:335  
 defective interfering particles 15:252  
 defense  
   regulation during 10:349–350  
 defense mechanisms of viruses 15:407  
 $\alpha$ -defensins 10:99  
 defensins 6:343, 8:442, 10:96  
 deficiency mutations 5:24–25  
 deficiency of the enzyme 5 $\alpha$ -reductase 13:24  
 degenerate oligonucleotide-primed PCR (DOP-PCR) 5:124  
 DegP 13:510  
 $\sigma^{32}$  degradation  
   control of 13:468–469  
 degradation 1:405ff, 3:188  
   AS-ODN turnover 1:410  
   enzymatic degradation 1:406  
   5'-exonuclease 1:406  
   3'-exonucleases 1:406  
   glycoproteins 5:590  
   nucleolytic cleavage 1:406  
 degradation signals (degrons)  
   ubiquitin-dependent recognition of 11:14–15  
 degron 11:3  
 DegS 13:512  
 dehydration 11:108  
 dehydroepiandrosterone 13:4  
 dehydrogenase/ $\Delta^{4,5}$ -isomerase 13:10  
 1-dehydrotestolactone 13:26  
 delayed and incomplete inactivation 11:672  
 delayed hypersensitivity (DH) 15:412  
 delayed-type hypersensitivity 8:443  
 2D-ELDOR spectroscopy 7:173  
 deletion 11:225  
   deletion bias (DB) 12:128, 129  
   based on small indels 12:130–131  
   *Drosophila* 12:130  
 delivery 1:405ff, 7:305ff  
   liposomes 1:406  
   nanoparticles 1:406  
 DELSEED loop 11:340  
 Delta 5:557, 12:183  
 delta4 15:215  
 delta ( $\delta$ ) IFNs 15:391  
 demethylation 9:305  
 demographic 5:244, 248  
 Demospongiae 13:273ff  
 denaturant 1:44  
   critical concentration 1:29  
   GdnHCl 1:29  
   urea 1:29  
 denaturation 3:189–190, 9:311  
   thermal 1:25  
 denaturation maps 3:205  
 denaturation process  
   absorbance  
     changes with temperature 3:190–192  
     analytical methods for 3:190–193  
     methods of 3:192–193  
 denaturation studies  
   degradation potential for 3:206  
   hybridization 3:205  
   sequence variances of 3:206  
   simulation of melting 3:203–205  
   stringency 3:206  
   thermodynamic analyses 3:203–205  
   utility of 3:203–207  
 denature 11:107  
 denaturing high performance liquid chromatography 9:300  
 denaturing solvents 3:201–203  
 dendrimer 14:164, 199  
   star- or tree-shaped, structures 15:496  
 dendrite patterning  
   Arc 9:155  
   calcium/calmodulin-dependent protein kinase II 9:154ff  
   CREST 9:155  
   critical period 9:153  
   cypin 9:154ff  
   Dcdc42 9:155  
   electrical activity 9:153  
   enabled 9:155  
   ephrin family 9:153  
   flamingo 9:155  
   immediate early genes 9:154ff  
   kakapo 9:155  
   L1 9:154  
   Narp 9:155  
   neurotrophins 9:153  
   notch, wnt, beta-catenin 9:154  
   semaphorin 3A 9:153  
   the small GTPases 9:154ff  
   thyroid hormone 9:154  
 dendrites 2:107, 8:503, 9:141  
   growth cones 8:505  
   localization 8:504  
   targeted 8:504  
   translation 8:505  
   transport 8:504  
 dendritic cell vaccination  
   in infectious diseases 3:232



- dendritic cells 1:386ff, 2:293, 3:213–215, 221, 6:340, 346, 385, 407, 472, 10:93, 181, 11:675, 13:136
- antigen presentation 3:219–220
- antigen processing 3:219–220
- antigen recognition 3:218–219
- antigen uptake 3:218–219
- as immunostimulators 3:224–225
- as tumor vaccines 3:229–232
- costimulation 3:224–225
- cytokines 3:224–225
- ex vivo generation of 6:443–444
- generation from hematopoietic precursor cells 3:217–218
- genetic manipulation
- DNA 3:222
- RNA 3:222–223
- viral vectors 3:223–224
- interaction with B cells 3:225
- interaction with NK cells 3:225
- maturation of 3:224–225
- migration of 3:224
- primary 3:217
- regulatory T cells induction 3:226–227
- subsets of 3:216–218
- T-cell anergy induction 3:225–226
- tolerance induction 3:225–226
- deletion 3:227
- virus interactions 3:228–229
- HIV-1 3:227
- SIV 3:227
- dendritic spines 9:149
- dendronized polymers 14:199
- deneddylation 12:171
- Dengue 15:164
- Dengue virus 3:229
- dense bodies
- cytomegaloviral 3:165
- density functional model
- quantum mechanical 3:602
- Dent disease 11:697
- dentatorubral-pallidolusian atrophy (DRPLA) 7:607, 15:6ff
- de-nucleated viruses 15:498
- deoxycholic acid 7:219
- 1-deoxy-D-xylulose-5-phosphate 1:425
- deoxyribonucleoside triphosphate (dNTPs) 14:209
- Department of Defense Global Emerging Infections Surveillance and Response System (DOD – GEIS) 10:524
- DEPC 11:509
- dependent kinase II
- metaphase to anaphase 2:468
- dephosphorylation 10:295, 12:357
- depolarization 10:30, 41, 11:646, 14:3, 13
- deprotonation 11:401
- depsipeptide 4:269
- depurination 3:206
- derepressor RNA 12:46
- 17 $\alpha$  derivatives 1:451–452
- 7 $\alpha$ , 11 $\beta$  derivatives 1:451
- derivatized resin 2:22
- derived features 8:530
- dermal dendrocytes 13:230
- dermal papillae 13:224
- dermal vasculature 13:224–225
- dermatitis herpetiformis 13:206
- dermatoheliosis 13:237
- dermis 13:218, 220, 224–227
- dermorphin 2:588
- descriptors 3:601
- desensitization 13:150ff, 14:687
- deshielding 7:308ff
- design of living matter 14:143
- designer therapeutic stem cells 13:356
- designer therapy 13:352
- 13-desmethyl retinal 9:560
- desmoplakin 2:360
- desmosome 2:356, 4:279, 13:243
- cytoplasmic tail 2:358
- extracellular domain 2:357
- functions 2:361
- plaque proteins 2:358
- destabilization to the double helix
- hydrolysis 10:59, 60
- methylation 10:59, 61
- oxidation 10:59, 61
- DET1 13:620
- detection 7:188, 9:304, 11:117
- detection agent 11:109
- detection antibodies 11:106
- detection of gene expression 7:317ff
- detector 7:406, 8:9
- charge-coupled device (CCD) detectors
- fiber-optic faceplate 7:409
- X-ray phosphor 7:409
- image plate
- photostimulable phosphor 7:407
- photographic films 7:407
- proportional detector
- multiwire proportional chamber (MWPC) 7:408
- proportional detectors 7:407
- single-photon counters 7:407
- detergents 1:44
- determination 3:272, 13:331
- determination/differentiation 13:334

- detoxification 3:107, 11:469  
 deuterated chloroform 1:424  
 deuterated triglycine sulfate (DTGS) detector  
 13:680  
 deuteration 13:563  
 deuterium isotope effect 1:579  
 deuterostome 6:187ff  
 deuterostomia 13:272ff  
 development 3:326, 6:182ff, 9:70ff  
   cell fusion 9:85  
   expression patterns 9:75  
   founder cells 9:82  
   heterochronic 9:84  
   life-span 9:87  
   longevity 9:87  
   microRNA 9:84  
   programmed cell death 9:86  
   promoter 9:75  
 development cost  
   pharmaceuticals 15:171  
 developmental biology 10:531, 532  
   biogenetic law 3:265  
   comparative embryology 3:264  
   descriptive 3:264  
   experimental embryology 3:264  
 developmental cell biology 3:263  
 developmental clock  
   reprogramming 1:86  
 developmental genetics 8:517  
 developmental genomics 10:531  
 developmental mechanics 3:266  
 deviation 11:391  
 Dewar pyrimidinone 3:357  
 dFmr1 4:607  
 dFmr1 null mutants 4:609  
 dg 14:238ff  
 DG, *see* dystroglycan  
 D-galactose oxidase 2:590  
 2D-gel-based proteomics  
   quantitative analysis of differential protein  
   expression 5:34  
 DGGE 9:300  
 DH5 $\alpha$  3:395  
 dh 14:238ff  
 DH10B 3:395  
 DHFR 11:56, 13:563, 565, 579  
   trimetrexate complex 13:578  
 DHPLC 9:300ff  
 D-3-hydroxybutyrate 7:102  
 diabetes 4:634ff, 7:102, 8:219,  
   12:163  
   insipidus 4:175  
   mellitus 4:174, 5:482  
   transient neonatal 5:482  
 diabetes insipidus 11:696  
   animal models of 3:319  
   autosomal dominant central 3:313–314  
   autosomal dominant nephrogenic 3:317  
   autosomal recessive central 3:314  
   autosomal recessive nephrogenic  
   3:315–316  
   AVPR2 11:697  
   central 3:312–314  
   molecular biology of 3:301–320  
   nephrogenic 3:314–317  
   treatment of 3:317–319  
   V2 vasopressin receptor 11:697  
   X-linked nephrogenic 3:315  
 Diabetes mellitus 7:26ff  
 DIABLO 10:129  
 diabodies 1:341  
 diacylglycerol acyltransferase (DGAT)  
   14:640  
 diacylglycerol (DAG) 12:670  
 diagnosis 11:662  
 diagnostic kits 5:307  
 diamond anvil cell 4:656  
 DIAP1 10:623  
 diastereoisomers 2:582  
 dibutylphthalate 1:435  
 dicer 10:251, 12:530ff, 14:269  
   PAZ domain 12:532  
 2,6-dichlorobenzonitrile 1:434  
 dichloromethane 1:422  
 2,4-dichlorophenoxyacetic acid 1:419  
 dichroism 3:556  
 dicoumarol 14:362–363  
*Dictyostelium* 4:349, 8:372, 378  
   approaches in proteome 3:336  
   approaches in transcriptome 3:336  
   as model organism 3:327–330  
   cDNA project 3:335–336  
   phylogeny of 3:329–330  
   social amoeba 3:327–328  
*Dictyostelium discoideum* 8:321ff  
   cell types 8:323  
   cellular slime mold 3:325–343  
   culmination 8:334  
   genome of  
     organization of 3:330–331  
     repetitive elements of 3:332  
     sequencing projects 3:333–336  
   germination 8:337  
   multicellular development 8:322  
   selection of 3:337  
   spore maturation 8:337  
   spores 8:334  
   stalk cells 8:334

- Dictyostelium discoideum* (continued)  
 terminal differentiation 8:334  
 transformation of 3:337
- Dictyostelium* genome project 3:333–335
- Dictyostelium* research  
 current focus of 3:330
- 11(12)-dien-5 $\alpha$ -o-acetyl transferase 1:426
- diet 7:27ff
- diethyl pyrocarbonate (DEP) 3:539, 12:567
- 13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one 13:36
- DIF 8:333
- difference Fourier technique  
 difference Fourier map 7:445  
 OMIT maps 7:446  
 weighting schemes  
 read 7:446  
 sim 7:446
- difference spectroscopy 4:661
- differential display 10:538
- differential equations 11:403, 14:138
- differential expression 10:532
- differential scanning calorimetry (DSC) 3:556
- differential staining techniques 1:511
- differentiation 2:88, 113, 326ff, 4:662, 5:638, 6:182ff, 12:101, 160, 162
- differentiation markers 2:224
- differentiation-inducing factor (DIF) 8:332ff
- difficulty susceptibility genes in  
 American Caucasians 13:209
- diffraction data evaluation  
 autoindexing 7:426  
 detector parameters 7:426  
 diffraction spots 7:426  
 indexing of diffraction patterns 7:426  
 integration 7:426  
 merging 7:426  
 refinement crystal 7:426  
 (R-merge) 7:426  
 scaling 7:426  
 statistical analysis 7:426
- diffraction patterns  
 crystal symmetry 7:422  
 diffraction intensities 7:422  
 reciprocal lattice points (hkl) 7:422  
 space group 7:422  
 symmetry 7:422  
 unit cell dimensions 7:422
- diffuse interstellar dust clouds 10:8
- diffuse reflectance 4:655ff
- diffuse reflectance spectroscopy 4:652
- diffuse type gastric carcinoma 6:11
- diffusion 6:366, 8:151  
 coefficient 8:147  
 ion channel 8:150  
 porin 8:149  
 rotational 7:162  
 translational 7:162
- diffusion editing 13:591
- diffusion-filtered NMR screening 13:592
- diffusional 13:588
- digenic syndrome 11:693
- digestion  
 in situ digestion 5:422  
 landmark digestion 5:421  
 second digestion 5:422
- dihedral angle restraints 13:549
- dihydrofolate reductase, *see* DHFR
- 1,4-dihydropyridines (DHP) 8:91, 107, 108, 11:629
- 1,2-dihydropyridono[5,6-g]quinolines 13:47
- dihydrotestosterone 13:3, 4
- dileucine 1:619
- dileucine motif 4:191
- dilution plates 1:515
- dilutions of bacteria 1:515
- DimA 8:334
- dimensional protein gel electrophoresis 3:49
- dimer linkage site (DLS) 1:103
- dimerization 3:352
- dimethyl sulfate (DMS) 3:539
- dimethylbenzanthracene (DMBA) 9:502
- dimethylethanolamine 10:286
- 5,5-dimethylpyrroline-N-oxide 4:645
- 7 $\alpha$ ,17 $\alpha$ -dimethyltestosterone 13:35
- 7 $\beta$ ,17 $\alpha$ -dimethyltestosterone 13:26
- DinI  
 stabilize active RecA 11:542
- 4-dinitrophenol (DNP) 8:177
- dinucleotide 9:252, 253
- dipalmitoyl-phosphatidylcholine 10:279
- dipeptides 10:10
- diphosphatidylglycerol 10:290
- diphtheria toxin (DT) 6:502
- diploblastic animals 13:272ff
- diploblasts 15:192
- diploid 4:335, 5:375, 14:252  
 complementation 1:89
- diploid stage of the sexual cycle 1:88
- diploidy 1:87
- diplopia 10:119
- dipolar interactions 4:118
- dipole–dipole 7:161
- dipole–dipole interaction 7:164
- dipole orientation 4:6
- dipole reaction 4:7
- dipole transitions 4:11
- dipole-pairing 4:10

- dipolophoresis 4:6  
 direct contact 12:332  
 direct gene transfer  
   particle bombardment 14:550  
   protoplast transformation 14:550  
 direct labeling 5:414  
 direct link PK/PD models 10:229  
 direct readout 3:507  
 direct recognition 10:184  
 direct sequencing 7:601–603  
 directed acyclic graphs 9:264  
 directed assembly 9:20, 25  
 directed cloning  
   M13 phage 13:93  
   plasmid cloning system 13:93  
   plasmid-based random cloning system  
     13:93  
   random shotgun protocol 13:93  
 directed mutagenesis 12:631  
 direct-link models 10:228  
 disaccharides  
   analytical method 2:247  
 disaggregases 13:509  
 DISC, *see* death-inducing signal complex  
 discadenine 8:337  
 DiscernArray 11:122  
 discovery 15:537  
 discrete uniform distribution (DUD) 10:453  
   measuring deviations from 10:458–464  
 discriminant analysis 3:618  
 disease 1:285ff, 404ff, 2:168, 4:331  
   disease development 1:405  
   hepatitis C 1:413  
   repetitive element 1:285  
 disease association 11:700  
   genetic markers 13:192  
 disease diagnosis 4:675ff  
   MALDI for 7:606–607  
   base deletion 7:603–605  
 disease genes 13:211  
 disease, human 2:569  
   environmental influences 2:571  
   genetic predispositions 2:571  
 disease models 3:47  
 disease pathogenesis 12:312  
 disease progression 13:695  
 disease resistance 14:257ff  
 disease susceptibility 5:640  
 disease-causing isoform (PrP<sup>Sc</sup>) 10:560  
 diseased alleles 14:513  
 Disheveled 12:182, 13:294  
 disjunction 14:3  
 disomy  
   uniparental 5:471, 474  
 dispensing radioactive solutions 11:419ff  
 displacement from equilibrium 8:166, 170  
 display method  
   mRNA-ribosome-polypeptide complex  
     2:459  
 display technologies 11:106  
 dissociation constant 3:546, 7:100, 11:105, 621,  
   13:557  
 dissociation kinetics 11:397  
 dissociation rates 11:105  
 dissociation temperature 9:334, 335  
 distal 5:266, 267, 269  
 distal regulatory sequences 10:315  
 distal-less 6:202  
 distamycin 2:14, 5:185, 13:566  
 distamycin A 4:572  
 distance chart 10:449  
 distribution 3:629, 10:218  
 distribution of domain families 11:213  
 disulfide bridges 1:30  
 disulfiram 2:59  
 diuretic amiloride 11:691  
 diuretic hormones 7:487  
 diuretics 11:693  
   amiloride 11:691  
   furosemide 11:691  
 divalent cation 12:333  
 “dive bomber” EMG 11:671  
 divergence 11:203, 221, 225, 228  
   hemoglobin  $\beta$ -chain 11:205  
   sequence 11:223  
   single nucleotide substitution 11:205  
 diversity 11:675  
 diversity of carbohydrates  
   composition 2:281  
   heteropolysaccharides 2:282  
   homopolysaccharides 2:282  
   linkages 2:281  
   sequences 2:281  
 divide-and-conquer 12:623  
 division cycle 1:534  
 division site, localization of the 1:541  
 DivJ 8:298  
 DivK 8:298  
 dizygotic 1:590  
 Dlg complex 12:185ff  
 D-loop  
   homologous recombinational repair (HRR)  
     1:74  
 Dlp1 13:615, 622  
 DM2 15:41  
 Dmc1 1:81  
 DMP-323 13:580, 581  
 Dmp68 4:611

- DMPK, *see* dystrophica myotomica protein kinase
- DNA 1:528, 3:485, 4:424ff, 674ff, 5:515, 6:186ff, 9:270, 11:485ff, 13:561, 568ff, 14:255
- degradation 4:432ff
- electroporation into embryos 14:481–482
- electroporation into sperm 14:481–482
- folding of 9:283
- ionizing radiation damage to 7:149–156
- major groove 6:185
- minor groove 6:186, 13:568
- mutagenesis of 12:109–123
- repetitive 6:140, 143, 144
- repressor–operator recognition of 3:507–526
- satellite 6:144, 147, 149
- stretching of 9:283
- structure determination 13:550
- structure of 12:111–114
- zipping of 9:283–284
- DNA acquisition 5:342
- DNA alkylation 2:60
- DNA amplification 12:194
- DNA analysis
- by mapping 9:286–288
  - by restriction fragment sizing 9:286–288
- Matrix-assisted Laser Desorption/Ionization (MALDI) for 7:592–596
- DNA aneuploidy 6:15
- DNA bacteriophage 4:97
- DNA base changes 9:384
- DNA biosynthesis 2:5
- DNA biotemplating 9:36–38
- DNA blocks 13:210
- DNA bovine papillomavirus 4:100
- DNA breaks 6:15
- DNA chip 12:714, 720ff, 14:423, 426–428
- combination with microfluidic device 14:431–432
- DNA chip technologies 14:428
- DNA chromatography 9:297ff
- DNA cloning 13:73
- DNA compaction 3:541
- DNA complexity 2:620, 624
- DNA concentration 3:197–198
- DNA constructs 1:217
- DNA cross-links 1:82
- DNA damage 1:55, 82, 89, 10:130
- abasic sites 1:65
  - aging 1:70
  - breaks 1:65
  - cause of aging 1:56
  - cell cycle checkpoint 12:16
  - cells, dividing 1:67
  - cells, nondividing 1:67
  - chromosome abnormalities 1:86
  - consequences of unrepaired DNA damage 1:56
  - damage 1:70, 79, 80
  - decline in gene expression 1:57
  - donor somatic cells 1:86
  - double-strand damages 1:79
  - master switch 1:60
  - O<sup>6</sup>-methylguanine 1:59
  - 8-oxodeoxyguanine 1:65
  - p53, master switch 1:60
  - progressive irreversible deterioration of cell, tissue, and organ function 1:91
  - sex pheromones 1:88
  - single-strand damages 1:79
  - single-strand DNA 12:16
  - types of damage 1:56ff
- DNA damage accumulation
- fragmentation of nuclear DNA 1:84
- DNA damage checkpoint 12:187ff, 14:24
- DNA damage during meiosis
- ATM 1:82
  - p53 1:82
- DNA damage, mitochondrial 1:65
- DNA damage, oxidative 1:59, 67
- apoptosis 1:73
  - double-strand breaks 1:59
  - endogenous cellular metabolism 1:83
  - fenton reaction 1:59
  - hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) 1:59, 88
  - hydroxyl radical (OH<sup>•</sup>) 1:59
  - reactive oxygen species (ROS) 1:73
  - single-strand breaks 1:59
  - superoxide radical (O<sub>2</sub><sup>•-</sup>) 1:59
- DNA damage removal
- apoptosis 1:83
  - recombinational repair 1:92
  - repair 1:83
  - sex 1:92
- DNA damage tolerance 3:428
- DNA damage, unrepaired
- replacement strategy 1:84
- DNA damages blocking replication
- homologous recombinational repair (HRR) 1:73ff
  - nonhomologous end joining (NHEJ) 1:73ff
- DNA denaturation 3:187–211, 5:254
- DNA deoxyribophosphodiesterase (dRpase) 3:433, 436
- DNA dependent protein kinase (DNA-PK) 1:75, 10:128
- DNA diagnostics 4:617

- DNA double-strand breaks 1:82  
aging 1:68  
homologous recombinational repair (HRR)  
1:73ff  
neurons 1:68  
nonhomologous end joining (NHEJ)  
1:73ff
- DNA endonuclease 2:627
- DNA extraction 5:251–252
- DNA extraction procedures 3:483  
cation-exchange resins 3:484  
magnetic beads 3:484  
organic extraction 3:484  
“preferential lysis” 3:484  
ultrafiltration 3:484
- DNA fibers, *see* fiber FISH
- DNA fingerprinting 5:259
- DNA gain 11:445–448, 12:132
- DNA glycosylase 1:71, 3:437, 10:130
- DNA helicase 3:456–457
- DNA heteroduplex 2:557
- DNA histogram 4:424
- DNA, histone 11:111
- DNA hybridization 7:588, 8:522, 523ff
- DNA hypermethylation 6:11, 9:92, 109
- DNA immunoprecipitation 1:489
- DNA interstrand cross-link  
homologous recombinational repair (HRR)  
1:73ff  
nonhomologous end joining (NHEJ)  
1:73ff
- DNA length 3:197–198
- DNA lesion  
radiation-induced 7:151–152  
vs. mutation 12:114
- DNA libraries 3:385ff
- DNA ligase 3:433, 436, 6:554ff, 9:390
- DNA, long-term storage of  
FTA<sup>®</sup> paper 3:483ff
- DNA loops 2:421
- DNA loss 11:445–448  
due to small indels and genome size 12:131
- DNA mapping 9:284–285
- DNA marker 5:443ff
- DNA melting 9:283f, 311
- DNA melting predictions 9:313
- DNA metabolism 5:323
- DNA methylation 2:206–207, 4:239, 241,  
5:470, 471, 479, 480, 6:11, 145, 150f, 7:505,  
9:323, 10:131, 484  
repression by 10:353
- DNA methylation analysis 9:304
- DNA methyltransferases (DNMT) 4:242,  
5:480, 6:145, 10:131, 14:268
- DNA microarray 3:491, 644, 5:505, 7:188,  
8:264, 268, 272, 10:532, 540, 13:73  
Cy3 10:538  
Cy5 10:538  
glass slide 10:538  
linear-amplified 10:538  
lithographic technique 10:538  
nylon membranes 10:538  
phosphorous-32 10:538
- DNA microinjection 1:209, 212, 216, 217, 224,  
4:480f  
differential interference contrast 1:229  
Nomarski/Smith microscopy 1:229
- DNA mismatch repair gene 6:21
- DNA, mitochondrial  
mtDNA population bottlenecks 1:85
- DNA modification 5:433
- DNA molecules 4:91, 14:207
- DNA MTase 12:323ff, 334  
catalytic mechanism 12:323
- DNA packaging 9:353–356  
energy of compaction 9:357–359  
physical chemistry of 9:357–360
- DNA packaging and chromatin 2:416  
histones 2:417  
the core structure of a nucleosome 2:417
- DNA packaging motor 9:352, 355, 359–360
- DNA pairing 1:81
- DNA photolyase 3:428, 430ff
- DNA polymerase 3:433, 450, 454–456, 5:313,  
319, 6:554ff
- DNA polymerase- $\alpha$  12:190ff
- DNA polymerase  $\eta$  (pol $\eta$ ) 3:440ff
- DNA polymerase  $\zeta$  (pol $\zeta$ ) 1:471, 3:440ff
- DNA polymerase-based sequencing 13:76
- DNA polymerization errors 12:119
- DNA polymorphism 6:8, 14
- DNA primase 3:456–457
- DNA primer 14:208
- DNA probe 7:180ff, 14:422, 432
- DNA profiling 3:479
- DNA–protein conjugates  
as tools in nanofabrication 9:33–36
- DNA radicals  
reaction of 7:152–153
- DNA rearrangement 5:339, 344, 12:115
- DNA recombination 3:532
- DNA repair 1:53ff, 55, 64, 67, 68, 80, 82, 86ff,  
2:380, 386, 3:429ff, 6:3, 9:381, 10:130,  
12:109–123  
genome intact 2:388  
recombinational repair 1:91  
redundant information 1:56, 91

- DNA repair (and complementation) theory of sex 1:77
- DNA repair capacity 1:67
- DNA repair, double-strand breaks  
Dmc1 1:81  
Rad51 1:81
- DNA repair enzyme  
copper/zinc SOD (Cu/ZnSOD) 1:59  
CSB 1:61  
ERCC1 1:62  
excision repair cross complementing 1 (ERCC1) 1:64  
family of enzymes, p53, p63, and p73 1:64  
helicase 1:63  
helicase-motif 1:63  
Ku-80 1:61  
Ku-70 helicase 1:61  
manganese SOD (MnSOD) 1:59  
MGMT 1:58  
O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) 1:59  
p53 1:62  
poly(ADP-ribose) polymerase (PARP) 1:58, 63  
RecQ5 $\beta$  helicase 1:64  
RECQ2 helicase 1:61  
RECQ3 helicase 1:61  
RECQ4 helicase 1:61  
superoxide dismutase (SOD) 1:59  
topoisomerase III $\beta$  1:61  
topoisomerases 1:63  
XPD helicase 1:61
- DNA repair gene 2:200–201, 6:8
- DNA repair pathway 1:53, 56, 70, 77  
aging 1:69  
excision repair cross complementing 1 (ERCC1) 1:64  
interstrand cross-link repair 1:64  
nucleotide excision repair (NER) 1:64  
repair enzyme 1:76
- DNA repair systems 5:339
- DNA replication 1:67, 528, 2:380, 3:449–450, 462–472, 9:284f, 10:414, 11:121  
autonomous replicating sequence 2:384  
biochemistry of 3:453–458  
checkpoint 12:187ff  
checkpoint activation 9:10  
initiation events 2:384  
Okazaki fragments 2:386  
origin recognition complex 2:384  
origins of 3:451  
regulation of 3:458–461  
replication proteins 2:386  
structural aspects of 3:451–452
- DNA restriction–modification systems 5:337
- DNA sequence 2:556ff, 5:245, 8:527  
deletion 2:564ff  
diversity 2:560  
evolutionary rate 2:564  
insertion 2:564ff  
nonfunctional 2:558  
repetitive 2:563  
substitution 2:563ff  
substitution, multiple/parallel 2:566  
human-specific 2:568  
transposable elements 2:563  
variation 2:560
- DNA sequence assembly 13:95  
close the gaps 13:96  
Lander–Waterman gaps 13:96  
Phred–Phrap–Consed package 13:96  
repeat gaps 13:96  
RePS (an assembler, repeat-masked Phrap with scaffolding) 13:96
- DNA sequence comparison 2:556ff  
DNA–DNA hybridization 2:557  
mitochondrial DNA 2:558  
nuclear DNA 2:558ff
- DNA sequence homologies 5:336
- DNA sequencer 3:489
- DNA sequencing 2:530, 5:252–253, 7:588, 597–603, 8:281, 14:426  
basic technology 13:76  
concept and technology of 13:76  
DNA methylation sites 13:73  
sequence polymorphisms 13:73
- DNA single-strand breaks  
neurons 1:68
- DNA sizing  
MALDI 7:596–597
- DNA slippage 5:245
- DNA stability  
counterion type  
melting temperature, dependence of 3:198–200  
denaturing solvents 3:201–203  
extrinsic factors 3:198–201  
factors affecting 3:193–203  
intrinsic factors 3:194–198  
nearest neighbors, distribution of 3:196  
neighboring domains  
conformational states of 3:197  
pH 3:200–201  
sequence complexity 3:197
- DNA strand breakage 7:149, 154–156
- DNA strand exchange 1:81
- DNA synthesis 1:534, 5:322
- DNA targets for FISH mapping 5:146

- DNA topoisomerase I 1:484  
 DNA transcription 3:449–464, 467–468  
   elongation of 3:465–466  
   promoter escape 3:465  
   regulation of 3:469–472  
 DNA transformation 5:337  
 DNA transposon 1:254ff, 262, 285, 296, 297ff,  
   *see also* interspersed repeat  
 DNA triplex 15:37  
 DNA turnover mechanisms  
   amplification 9:184  
   deletion 9:184  
   intrastrand deletion 9:190  
   replication slippage 9:189  
   rolling circle replication 9:190  
   unequal crossing over 9:184  
 DNA typing analysis 3:479ff  
 DNA vaccination 15:113  
 DNA vaccine 3:173, 174, 6:298, 15:162  
 DNA vectors 15:147  
 DNA viruses 9:351–360  
 dnaA 1:537  
 dnaA boxes 1:537  
 DnaA protein 1:537  
 DNA-associated protein 13:384  
 DNA-based nanoparticle assemblies 9:30–43  
 DNA-binding activity 8:348  
 DNA-binding domains  
   helix-hairpin-helix 11:536  
   loop 1 11:534  
   loop 2 11:534  
   primary DNA binding site 11:534  
   secondary DNA binding site 11:534  
 DNA-binding motif 3:508, 513  
 DNA-binding proteins 9:257  
 DNA-binding sites 12:100  
 DNA-damaging agent 12:110, 114  
   increased mating 1:88  
 DNA:DNA hybrid  
   formation of 9:341–346  
   stability of 9:335–341  
 DnaJ 1:35, 2:501, 503  
 DnaJ proteins 13:497–499  
 DnaK 1:35, 2:501, 511ff  
 DNA-ligand binding  
   minor groove binding 13:365, 557ff  
 DNA-modification methyltransferase 12:323  
 DNA-PK, *see* DNA dependent protein kinase  
 DNA:RNA hybrid  
   formation of 9:341–346  
   stability of 9:335–341  
 DNase I 1:477, 4:522, 11:507ff  
 DNaseP<sup>®</sup> 9:298  
 dNTP 14:206  
 Doa4 4:205  
 Dobzhansky, Theodosius 8:522, 534ff  
 Docetaxel 14:340–343  
 Dock180 2:335  
 docking 11:134  
 docking programs 2:29  
 docking proteins  
   IRS 4:400  
   Shc 4:400  
 dolichol-P-mannose 10:302  
 dolicholpyrophosphate 5:577  
 Dolly, cloned lamb 13:338  
   rate of successful implantation 1:85  
 domain 6:181ff, 8:238f, 11:213, 530  
   beads on a string 11:207  
   Cadherin 11:220  
   C2H2 and C2HC zinc-finger 11:227  
   Chothia 11:228  
   combinations 11:225  
   DNA-binding 6:181  
   domain accretion 11:226  
   domain architecture 11:226  
   domain combinations 11:226, 227  
   domain composition 11:217  
   domain definitions 11:209  
   domain geometry 11:227  
   four-helical cytokines 11:222, 226  
   geometry 11:226  
   globins 11:223  
   HisA beta/alpha barrels 11:218  
   hydrophobic core 11:207  
   immunoglobulins 11:220, 222  
   inserted domains 11:211  
   interactions 11:227  
   large 12:337  
   Levitt and Chothia 11:207  
   lysyl-tRNA-synthetases 11:215  
   multidomain proteins 11:217, 225  
   P-loop hydrolase 11:226  
   Rossmann domains 11:227  
   sequence-based domain definitions 11:210  
   serine proteases 11:216  
   supra-domains 11:226  
   three-dimensional structure  
     protein kinases 11:209  
     TIM-barrel 11:216  
   units of protein evolution 11:206  
 domain combination 11:225  
 domain evolutionary unit 11:207  
 domain function  
   substrate specificity 11:222  
 domain fusion 6:603  
 domain prediction  
   ab initio 11:211



- domain prediction (*continued*)
  - genome sequence 11:212
  - genomes 11:210
  - homology 11:212
  - predicting domains 11:211
  - SUPERFAMILY database 11:212
- domain rearranged methyltransferases (DRMs) 14:269
- domain swapping
  - 3D 1:31
- domestic animal 1:209
- domestication, origins of 7:338
- dominance 1:587, 593, 5:371
  - codominant 5:399
  - partial dominance 5:399
  - recessive 5:398
- dominance variance 1:589
- dominant 11:662, 671
- dominant gain-of-function 11:672
- dominant LQT alleles
  - KCNQ1 11:663
  - LQT4 11:665
  - LQT5 11:665
  - LQT6 11:665
- dominant negative 11:657, 15:9
- dominant-negative inhibition 10:582–583
- dominant-negative sheep 10:596–597
- donor plant 1:418
- dopamine 8:220
  - methylation 2:65
- dopamine DRD3 receptor 1:606
- dopamine  $\beta$ -hydroxylase 8:220
- Doppler 14:48
- dorsal closure 4:287ff
  - F-actin 4:288
  - leading edge 4:289
  - myosin 4:288
  - purse string 4:288
- dorsal root ganglia 15:270
- dosage sensitive sex reversal 5:622
- dose-escalation schedule 15:268
- dose-limiting toxicity 6:518
- dot blot analysis 12:572
- dot plot 12:585
- DOTAP 7:303ff
- DOTAP liposomes
  - lamellar structures 15:493
- dot-blot approach 3:489
- dot-bracket notation 12:586
- double helical complexes 10:22
- double-parked (Dup) 12:192
- double-stranded DNA (dsRNA) 7:3, 9:300ff, 10:92, 11:493ff, 15:399, 401, 404, 406f
- double-stranded RNA viruses
  - bacteriophage  $\phi$ 6 9:367
  - yeast virus L-A 9:369
- doubling time 7:540
- dounce homogenizer 14:399
- Down syndrome (DS) 4:591, 12:691
  - animal models 3:565
    - transgenic mice 3:568–569
    - trisomic mice 3:566–568
  - cytogenetics 3:563
  - gene expression analyses 3:569
  - molecular genetics of 3:561–569
  - phenotype of 3:562–563
- downregulation 3:270, 13:150ff
- downstream process 1:429, 15:166
- Dox-induction 4:599
- DP 12:156ff
  - dDP 12:156
  - DP1 12:156
  - DP2 12:156
- D-period 1:527
- DPP 4:289ff
- DQA1\*0102 6:15
- DQF-COSY 13:525, 531, 532
- DRB\*1601 6:15
- DRE binding protein (DREB) 10:348
- D-ring 1:447
- dRNA 12:46
- drop seizure 11:682
- droplet diffusion technique 4:100
- droplet precautions 10:521
- Drosophila* development 3:288
  - asymmetric cell division 3:289
  - cell growth 3:289
  - embryonic cells 3:289
  - endoreplication 3:289
  - growth-sensitive cell cycle checkpoint 3:289
  - imaginal disk cells 3:289
  - larval imaginal cells 3:289
  - larval phase 3:289
  - patterning 3:289
- Drosophila* immune response
  - Imd pathway 7:4
  - Toll pathway 7:4
- Drosophila melanogaster* 3:6, 4:278, 331, 607, 6:141, 182ff, 8:372f, 10:542, 545, 12:415, 421ff, 423ff, 436ff, 446ff, 451, 455, 465, 468, 13:206, 339, 14:511
  - chromosome aberrations 3:579
  - genetic analysis 3:585
  - genetic mapping 3:587
  - mitotic chromosomes 3:576
  - mutagenesis 3:585
  - polytene chromosome 3:577

- the *drosophila* genome project 3:581  
 transposable elements 3:582  
 drosanolone 13:35, 42  
 dRpase, *see* DNA deoxyribosephosphodiesterase  
 drug 4:331, 11:595, 597  
   animal model studies 1:409  
   biological barriers of 14:170–177  
   clinical development 15:173  
   in circulation 14:170–175  
   intracellular delivery of 14:163–199  
   metabolism 10:201  
   preclinical development 15:173  
   registration 15:173  
   targeting delivery of 14:163–199  
 drug absorption  
   computational method 8:157  
   modeling 8:157  
   molecular descriptor 8:157  
   prediction 8:157  
 drug delivery 14:167, 308  
 drug design 2:172, 8:97, 10:198ff, 13:522, 524  
   analog-based 13:547  
   mechanism-based 2:173–174  
   structure-based 13:519, 520  
 drug development 13:521, 528, 532  
 drug discovery 1:404, 11:620, 13:519, 520, 522, 524, 14:357, 359  
   NMR instrumentation 13:526  
   nonpeptide 14:112–119  
   peptide 14:112–119  
   peptidomimetic 14:112–119  
   small-molecule drugs (NCEs) 11:596  
 drug effect biomarkers 9:113  
 drug metabolism 2:52, 3:107  
 drug metabolism, nonnormal effects 2:69  
 drug metabolism studies  
   high-throughput methods 2:70  
 drug reactions 11:658  
 drug–receptor interactions 8:108  
 drug receptors 11:614  
 drug resistance 9:498, 531–532  
 drug screening 6:588  
 drug specificity 11:699  
 drug targeting 14:164  
   controlled release 14:167–168  
   principles of 14:167–168  
 drug testing 14:405  
 drug therapy 6:478  
 drug toxicity 2:533  
 drug-induced systemic autoimmunity 1:462  
 druglike molecule 3:618, 8:91, 94  
 D1S191 6:15  
 DSB 12:3ff, 5  
   DNA helicase 12:11  
   MRN complex 12:11  
   nuclease 12:11  
 Dsba 2:509  
 DsbC 2:509  
 D-signal 8:310  
 DSPA- $\alpha$ 1; desmoteplase 10:127  
 dsRNA, *see* double-stranded DNA  
 dsRNA-dependent protein kinase 15:407f  
 d-tocopherol  
   transport of 15:514  
 dual specificity kinases 7:122  
   MEK 7:123  
 dual targeting  
   transcriptional 15:350–352  
   transductional 15:350–352  
 dual-color cross-correlation fluorescence 7:167  
 duality of genomic information 5:349  
 Duchenne muscular  
   gene size 6:327  
 Duchenne muscular dystrophy 15:262, 487  
 dukes stage 6:22  
 duplex 1:408, 410ff, 12:111  
   DNA–RNA 1:410  
   RNA–RNA 1:410  
 duplicated genes 9:255, 11:377ff  
 duplication 11:203, 207, 210, 217, 221, 228  
   domain family expansions 11:219  
   genes 11:215, 219  
   lineage-specific expansions 11:219  
   whole genome duplication 11:218  
 duplication and recombination 11:215  
 duplication, segmental 2:563  
 dUTP 11:510  
 dyad symmetry 12:33  
 dyes and detectors  
   remarks on 9:272–273  
 dynamic combinatorial chemistry 8:95ff  
 dynamic expression linkages 5:83  
 dynamic libraries 8:96  
 dynamic light scattering (DLS) 9:25  
 dynamic mutation 4:570ff, 592, 7:607  
 dynamic processes 13:570  
 dynamic programming 12:586  
 dynamic quenching 4:446  
 dynamic range 8:4, 12  
 dynamics 4:124, 13:550, 573  
   motion of lipids in membranes 4:125  
 dynamin 8:130, 13:622  
   dyn1 4:202  
   dyn2 4:202  
 dynein 2:638, 640  
   action of 9:280  
 dyskeratosis congenita 14:223  
 dyslexia 10:116, 119

- dysmorphology 11:665  
 dysphasia 10:116, 119  
 dysraphism 9:120  
 dystonia 15:262  
 dystroglycan (DG) 5:557, 10:285, 300  
   arenaviruses 5:597  
   Lassa fever virus (LFV) 5:597  
   lymphocytic choriomeningitis virus (LCMV) 5:597  
   Mobala 5:597  
   *Mycobacterium leprae* 5:597  
   Oliveros 5:597  
 dystrophica myotonica protein kinase (DMPK) 3:597, 15:40ff  
 dystrophin 15:262
- e**
- E**  
 selectin 5:585  
*E. coli* 2:628, 3:395ff, 639, 4:357, 362–364, 371, 679ff, 5:505, 10:414  
   envelope stress responses of 13:466–476  
   ETEC 6:305  
   S30 2:454  
*E. coli* dam 12:339  
*E. coli* genome 3:639, 646  
   as model for systems biology 3:644–645  
   ORF predicted sequence 3:640–641  
   RNA genes of 3:641–643  
   sequence of 3:640, 641–643  
   sites of 3:641–643  
 EA, *see* episodic ataxia  
 early cancer detection  
   current status in diagnostics for 9:95–96  
 early detection 9:92, 109  
 early endosome 8:128  
 early endosome antigen-1 (EEA1) 4:196  
 early endosome fusion 8:130  
 early gastrula organizer (EGO) 2:89  
 early or sorting endosome 8:123  
 early patterning 2:88, 91  
 early sudden death 11:662  
 early T-lymphocyte activation-1 6:18  
 easily shocked (eas) 10:287  
 Easson–Stedman model 2:605  
 Ebola virus 3:91, 229  
 E-box 4:390, 12:415, 427ff, 437ff, 442ff, 448, 458  
 4E-BP1 12:179  
 E-cadherin 4:260, 6:7, 12, 24, 7:551  
 E-cadherin mutations 6:13  
 eccrine sweat glands 13:219  
 E-cell 3:657  
 Echinocandins 14:356–357  
 echinoderms 14:3, 12  
 eclosion 12:415, 421, 424, 426ff, 431  
 ECM29 11:3, 19  
 ECM, *see* extracellular matrix  
 ecmA 8:332  
 ecmB 8:332  
 Eco, Umberto 7:573  
 economic justification  
   investment incentive 7:370–371  
 EcoRI 12:325, 327  
 EcoRI/MunI 12:332  
 ecosystem 5:334  
 ECP, *see* eosinophil cationic protein  
 ectoderm 2:89, 13:219, 330  
 ectomycorrhizal fungi 5:16  
 ectopic expression 14:506, 513, 516  
 $\sigma^E$ -dependent envelope stress response 13:471  
   inducers 13:472–473  
   regulator 13:473–476  
   sensors 13:472–473  
   signals 13:472–473  
 EDTA (ethylene diamine tetraacetic acid) 7:610  
 EEA1 4:315  
 EF 1:310  
 E2F 2:172, 6:13, 21, 12:348  
   dE2F1 12:156  
   dE2F2 12:156  
   E2F1 12:156ff, 194  
   E2F2 12:156ff  
   E2F4 12:156ff, 184  
   E2F5 12:156ff  
   E2F6 12:156ff  
   E2F7 12:156ff  
   E2F3a 12:156ff  
   E2F3b 12:156ff  
 effect modification 4:229, 231  
 effective population size ( $N_e$ ) 5:244, 262, 12:128, 129  
 effector 13:143ff  
 efferent nerve fiber 10:30  
 efficacy 11:603, 618  
   functional antagonism 11:607  
   intrinsic activity 11:602  
   inverse agonist 11:607  
   negative antagonist 11:607  
   neutral antagonist 11:607  
   pharmacological antagonism 11:607  
 efficient delivery 7:299ff  
 EF-G 2:454  
 EF-hand 2:144  
 EF-hand protein 2:134, 138, 144  
 EF-Ts 2:454  
 EF-Tu 2:627

- E2G-3 6:13
- EGF (epidermal growth factor) 2:174, 4:200, 391, 6:16, 17, 22, 499, 7:128, 9:455, 10:134, 13:136, 284, 416ff, 14:108, 397
- EGF family 5:647–648, 6:3, 16
- EGFR (epidermal growth factor receptor) 2:232, 5:640, 6:16, 17, 22, 9:514, 11:581, 582, 12:176, 13:151
- family 9:456–458
- heparin-binding EGF 7:128
- transforming growth factor- $\alpha$  7:128
- EGFR subfamily 7:127
- betacellulin 7:128
- cytoplasmic domain 7:128
- EGF 7:128
- ErbB-2 (HER2) 7:128
- ErbB-3 (HER3) 7:128
- ErbB-4 (HER4) 7:128
- extracellular domain 7:128
- ligand-binding domains 7:128
- EGF/TGF $\alpha$ /receptor system 6:7
- egg
- activation 2:464
- CaM KII 2:473
- cell 1:83, 2:466
- chromosomes 2:466
- interaction of 14:9–14
- intracellular-free calcium 2:466
- meiosis 2:466
- meiotic cell cycle 2:466
- meiotic spindle microtubules 2:473
- sperm 2:465
- egg cylinder stage
- trophoblast giant cells 13:389
- Eh 1:509
- Ehrlich, Paul 8:86
- EIA 6:368
- eIF4E 12:178, 179
- eight-cell stage 10:485, 486
- EKG 11:661
- ELAM-1 6:23
- elastin 8:48, 13:226–227
- elderly skin 13:235–237
- electric and magnetic field strength 4:2
- electric currents 4:6
- electric discharge 10:7
- electric field reception 4:3
- electric signals 13:292
- electrochemical detection system 14:429
- electrochemical detector
- integration of 14:429–430
- electrochemical DNA chip 14:430–431
- electrochemical gradient 2:631
- electrochemiluminescence 2:524
- electrofusion 1:212, 221, 4:136
- applications of electroporation 4:153
- dielectrophoresis 4:142
- mechanism of electrofusion 4:143
- procedure of electroporation 4:146, 147
- production of hybridomas 4:152
- electromobility shift 3:545
- electron and X-ray
- scattering labels 7:168
- electron density equation 7:422
- inverse Fourier transform of the structure factor F(S) 7:423
- electron micrographs (EMs) 11:8
- electron microscopic analysis 8:360, 378
- electron microscopy and atomic force microscopy 3:557
- electron microscopy (EM) 4:53, 58, 67, 91, 12:300
- elastically scattered electrons 4:57
- electron source 4:55
- energy-filtering transmission 4:70
- inelastically scattered electrons 4:57
- interpretation in EM 4:74
- microscopy 4:70
- voltage 4:55
- electron nuclear double resonance (ENDOR) 7:162, 170
- electron spectroscopic imaging 4:109
- electron spin density 4:123
- electron spin resonance 4:635ff, 7:153
- electron transfer 4:123, 8:210ff
- electron transfer flavoprotein (ETF) 8:174
- electron transport chain (ETC) 15:14
- electron transport proteins (ETP) 11:35
- electron transport system 3:103, 7:100
- electronic structure 3:59ff
- electro-olfactogram (EOG) 12:666
- electrooptical relaxation 4:17
- electropermeabilization 4:135, 137
- electrophilic 11 $\beta$  derivative 1:456–457
- electrophoresis 2:46, 5:244, 245, 516, 9:301
- disk agarose gel electrophoreses 5:416
- first dimension (1st-D) electrophoreses 5:416
- horizontal electrophoresis 5:420
- polyacrylamide gel electrophoresis 5:416
- second dimension (2nd-D) electrophoresis 5:416
- two-dimensional electrophoresis 5:414
- vertical electrophoresis 5:419
- electrophoretic mobility 5:261
- electrophysiology 11:687

- electroporation 2:629, 3:337, 406, 4:137, 14:474, 480  
 electroinjection 4:151  
 electropore 4:139, 140  
 gene transfer 4:150  
 in situ electroporation 4:147  
 in vivo electroporation 4:155  
 iontophoresis 15:490  
 irreversible breakdown 4:138  
 mechanism of DNA uptake 4:141  
 membrane breakdown 4:136  
 recovery state 4:138  
 reversible breakdown 4:138  
 transdermal drug application 15:490  
 waveforms 4:144  
 electrospray ionization (ESI) 7:562, 8:6–9, 12, 11:310, 317  
 electrospray mass spectroscopy (ESI-MS) 8:12, 27, 35, 14:432  
 electrostatic adsorption 10:294  
 electrostatic attraction 12:328  
 electrostatic charges 7:161, 169  
 electrostatic interactions 2:8, 7:304  
 electrostatic potential 7:170  
 electrostatics calculations 11:144  
 electrotopological state index 3:604  
 elementary flux modes 6:594  
 elicitation 1:432  
 eliminase 5:543  
   chondroitinase ABC 5:544  
   chondroitinase B 5:544  
   chondroitinase C 5:544  
 elimination 10:219  
 ELISA, *see* enzyme-linked immunosorbent assay  
 ELISPOT 6:374, 8:450  
 ellipticity 3:57  
 Ellis van Creveld syndrome 6:329  
 elongation 2:453  
 elongation factors 2:454, 12:484, 503, *see also* mRNA translation, protein factors  
 eluent 9:301ff  
 EM, *see* electron microscopy  
 EM ARG 4:109  
 EM autoradiography 4:53  
 EM grid 4:96  
   ambient temperature em methods 4:27  
   carbon 4:95  
   carbon-coated 4:90, 92, 93, 94, 97, 102, 105  
   coated 4:95  
   films coated 4:92  
   negative staining of particles 4:27  
   parlodion 4:95  
   parlodion-coated 4:93  
   plastic coated 4:90, 92  
 EM spreading  
   benzyltrimethylammonium chloride 4:94, 95, 100  
   chromatin 4:102  
   cytochrome c 4:93, 95  
   dsDNA 4:95  
   heteroduplex 4:95  
   large chromatin 4:96  
   long DNA molecules 4:96  
   nucleic acids 4:95  
   polyamines 4:96  
   protamines 4:95  
   protein-free 4:93–96, 100  
   RNA 4:95  
   small chromatin units 4:97  
   ssDNA 4:95  
 EM staining  
   phosphotungstic acid 4:96, 102  
   uranyl acetate 4:96, 102  
 EM tomography 4:61  
 embedding  
   laboratory care 4:35  
   Lowicryl HM23 4:51  
   methacrylate-based embedding 4:34  
   toxic 4:35  
 embryo 1:213, 417, 6:533, 7:541ff  
   cryopreservation 9:231, 236  
   ES cell-derived 14:527–529  
   in vitro 9:231  
   transfer 9:231, 232, 235  
 embryo formed 13:332  
 embryogenesis 6:182ff, 8:447, 12:362, 13:319, 370  
   auxin transport  
     auxin accumulation 12:286  
     auxin efflux carrier 12:287  
     auxin influx carrier 12:287  
     PIN proteins 12:287  
     polar auxin transport 12:287  
     polarity of PIN proteins 12:287  
   cotyledons 12:285  
 embryogenesis, embryo development  
   apical cell 12:284  
   basal cell 12:284  
   early heart (triangular) stage 12:284  
   globular embryo 12:284  
   hypophysis 12:284  
   proembryo 12:284  
   protoderm 12:284  
   suspensor 12:284  
   zygote 12:283  
 embryogenomics 10:531ff  
 embryology 1:212  
 embryonal cells and cancer 13:346

- embryonic development 14:265  
   blastocyst formation 13:383  
   blastomeres 13:384  
   series of cleavages 13:384  
   timed completion of meiosis 13:383  
 embryonic stem cell (ESC) 1:209, 4:337, 9:239,  
 10:76, 77, 485, 12:86, 13:335, 364, 383, 393,  
 14:507, 512, 524  
   biology 13:396  
   characteristics of 13:383  
   differentiation of 13:390  
   enriched genes 13:394  
   isolation 13:387  
   properties of 13:388ff  
   random mutagenesis in 14:536–539  
   self renewal 13:389  
   teratocarcinomas 13:383  
   transgenic animals 13:383  
   uses of 13:395  
 embryonic stem cell therapy 13:337  
 embryonic stem cell transfer 1:212  
   chimerism 1:217  
   conditional modeling 1:209  
   gain-of-function 1:209  
   knockin 1:210  
   knockout 1:210  
   loss-of-function 1:209  
   primordial germ cells 1:219  
 embryonic tissues 10:548  
 embryonic transcription 13:384  
 EMEA, *see* European Agency for the Evaluation  
   of Medicinal Products  
 emergent phenomena 14:125  
 emerging properties 14:127  
 emerging therapeutic agents 14:156  
 emetine 2:630  
 emission 11:488ff  
 emission anisotropy 3:557  
 EMIT 6:369, 372, 373, 374ff  
 $\alpha$ -emitting compounds 1:455  
 emphysema 15:260  
 empty-spiracles 6:202  
 emulsification 4:513  
 emulsion 4:504  
 ENaC, *see* epithelial sodium channel  
 enantiomers 2:582, 8:109ff, 10:17  
   insect pheromones 2:599  
   natural products 2:592  
   odor 2:595  
   physiological responses 2:594  
   plant growth regulators 2:600  
   taste 2:595  
 ENase 12:323ff, 325  
   catalytic mechanism 12:323  
 encapsulation 7:303ff  
 encoded library 8:95  
 5'-end capping 10:319–320  
 3',5' end conjugates 1:409  
 5'-end conjugates 1:409ff  
 3'-end formation 10:317–319  
 end product repression 12:28  
 end-labeling reaction 11:422  
 endocrine 5:638  
 endocrine signaling 3:276  
 endocrine systems 5:640  
 endocytic carrier vesicles (ECVs) 4:199  
 endocytic pathway 7:307ff, 8:123  
 endocytic small vesicles (ESVs) 4:199  
 endocytosis 8:146ff, 155, 10:178, 179, 221, 223,  
 13:150, 14:164, 175  
   end genes 8:124  
 endocytosis via clathrin-coated vesicle (CCV)  
 11:91  
 endoderm 2:89, 13:330  
 endo- $\beta$ -galactosidases 5:541ff, 544  
 endogenous fibroblasts 15:259  
 endogenous ligands 14:178  
 endogenous neuroprotection 10:134  
 endogenous proteins  
   overexpression of 3:339  
 endogenous pyrogen 8:434  
 endogenous retroviruses  
   derivatives of 11:466  
 endogenous RNAi  
   invading genetic elements 12:537  
   RITS complex 12:540  
   transcriptional silencing 12:539  
 endogenous substrates 3:104  
 endogenous transposons 14:260ff  
 endoglin 15:208, 217  
 endoglycosidase 2:252, 255  
 endolymph fluid 11:666  
 endomesoderm 10:547  
 endometrial remodeling 4:406  
 endometrium 8:445  
   human 7:551  
 endo- $\beta$ -*N*-acetylglucosaminidases 5:541  
 endonuclease 1:262ff, 269, 3:352, 12:324  
   AP endonuclease 1:252  
 endophyte 1:418  
 endopinacocytes 13:273  
 endoplasmic reticulum channelopathies  
 11:698  
 endoplasmic reticulum (ER) 2:501ff, 513,  
 4:194, 8:121, 10:188, 300, 11:289, 12:645,  
 13:475, 610, 615, 623, 624, 628, 14:15, 642  
 endoprotease 8:230  
 ENDOR, *see* electron nuclear double resonance

- endoreplication 12:152, 161, 164, 171, 194  
 endorphins 14:328  
 endosialidase 5:543  
 endosomal compartments 1:370  
 endosomal sorting complex required for transport (ESCRT) 4:204f  
 endosomal vacuolar ATPase 11:697  
 endosome 1:619, 10:178, 188  
   apical early endosomes (AEE) 4:200  
   early endosomes 4:185  
   late endosomes 4:185  
   multivesicular body 4:183ff  
   recycling endosome 4:185  
   sorting endosome 4:185  
 endosomotropic 14:164  
 endosperm  
   endosperm development 12:280  
     alveolus (ALV) 12:281  
     cellularization 12:281  
     chalazal cyst (ChC) 12:282  
     chalazal endosperm (CZE) 12:281  
     micropylar endosperm (MCE) 12:281  
     multinucleate syncytium 12:281  
     peripheral endosperm (PEN) 12:281  
     radial microtubule system (RMS) 12:282  
     syncytial nuclear division 12:281  
   endosperm types 12:280  
     cellular 12:281  
     helobial 12:281  
     nuclear 12:281  
 endospore formation 8:301  
 endostatin 15:221  
 endosymbiont 13:610, 14:258  
 endosymbiosis 5:346, 8:171  
 endosymbiotic theory 2:624  
 endothelial cell 4:194, 8:441, 444, 446, 451, 452, 13:241, 14:287, 15:164, 203, 212, 215, 217  
 endothelial cell precursors 15:219  
 endothelial cell progenitors 15:218  
 endothelial dysfunction 7:52  
 endothelial lipase 7:216, 217  
 endothelial progenitor cells 14:300  
 endothelin 13:536–538, 14:43  
   ET-1 4:403ff  
   ET-2 4:403ff  
   ET-3 4:403ff  
 endothelin antagonists 13:541  
 endothelin-converting enzymes 4:403  
 endothelium 15:205  
 endotoxin 8:440, 450, 454  
 endo- $\beta$ -xylosidase 5:544  
 end-sequencing 13:98  
 energase 11:28, 33  
 energetic membranes 4:123  
 energy absorption 7:150–151  
 energy coupling  
    $\gamma$ -subunit, role of 11:338–340  
 energy dot plot 6:587  
 energy expenditure 14:680, 698  
 energy landscape 1:27, 2:491  
 energy metabolism 8:171  
 energy parameters 12:588  
 energy transfer 7:171, 174  
 engineered matrices  
   future directions 14:408–409  
 engineering 14:143  
 engineering antibody fragments  
   bivalent scFvs 1:340–341  
   monovalent scFvs 1:340–341  
   multivalent scFvs 1:340–341  
 engrailed 6:185ff, 203  
 enhancer 5:397, 6:146, 580, 10:315, 484  
 enhancer detection 14:260  
 enhancer mutations 5:400  
 enhancer/inhibitor (En/I) 14:260  
 enhancer/promoter 1:227  
 enigmatic vanilloid receptors 14:331  
 ensembl system 5:58  
 entactin, *see* nidogen  
 enterotoxigenic *E. coli*  
   vaccine 15:160  
 enthalpically driven 3:535  
 enthalpy 2:7, 3:535  
 entrain 12:421ff  
 entrainment 12:415, 428ff, 434ff, 446ff, 451ff, 462ff, 466  
 entropic change 3:535  
 entropy 2:7, 13:542  
 entropy–enthalpy compensation 3:536, 537ff  
 entry into the cell  
   arenaviruses 5:597  
   Lassa fever virus (LFV) 5:597  
   lymphocytic choriomeningitis virus (LCMV) 5:597  
   Mobala 5:597  
   *Mycobacterium leprae* 5:597  
   Oliveros 5:597  
 enucleated fertilized eggs  
   compound blastocysts 13:388  
   ES lines 13:388  
 enucleation 9:206, 226–227  
   chemically assisted 9:228  
 Env 15:139  
 envelope variants 1:109–110  
 enveloped viruses 15:252  
 environment 5:315, 491  
 environmental conditions 5:334  
 environmental effects on bacteria 1:517

- environmental variance 1:595  
 enzymatic activity 11:113  
 enzymatic antioxidant defenses 5:495  
 enzymatic photoreaction 3:361, 428  
 enzymatic repair systems 5:339  
 enzymatic site-specific cleavage 9:304  
 enzyme 2:530, 4:508, 8:211, 423, 10:660, 11:28, 14:3  
   as life's actuators 11:29  
   chemical nature  
     biological catalysts 11:30  
   cooperativity 11:29  
   definition of 11:32  
   glycolytic 7:101  
   kinetics 2:39  
   proteolytic 7:542  
   reactor 2:39  
 enzyme activators 11:40  
 enzyme activity profiling 11:102  
 enzyme catalysis 2:18  
 enzyme commission 6:599  
 enzyme electrophoresis 5:249, 250  
 enzyme function 8:423  
   inborn errors in  
     Lou Gehrig's disease 11:43  
 enzyme induction 2:54  
 enzyme inhibition 2:16, 11:40, 13:48  
   noncovalent enzyme inhibitors 2:17  
 enzyme–inhibitor complex structures 7:455  
   cystathione  $\beta$ -lyase 7:452  
     CBL/AVG 7:454  
     CBL/TFA complex 7:454  
     difference Fourier technique 7:454  
     external aldimine 7:454  
     Michael addition 7:454  
     PLP cofactor 7:454  
   L-aminoethoxyvinylglycine (AVG) 7:452  
   Thrombin–Rhodniin Complex  
     cocrySTALLIZATION 7:455  
     efficient blood anticoagulants 7:455  
     Rhodniin 7:455  
     rotational and translational searches 7:456  
      $\alpha$ -thrombin 7:455  
     two KAZAL-type domains 7:456  
      $\beta$ , $\beta$ , $\beta$ -tri-fluoroalanine (TFA) 7:452  
 enzyme kinetic 4:425, 11:41, 384  
 enzyme reaction  
   mechanochemical 11:32–33  
   energase-type enzymes 11:34–35  
 enzyme regulation 11:41, 43  
   Adair–Koshland model 11:42  
   allosteric interactions 11:42  
   cooperativity 11:42  
   feedback inhibition 11:42  
   Monod–Wyman–Changeux concerted transition model 11:42  
 enzyme science  
   history of 11:30–32  
 enzyme specificity chiral substrates 2:606  
 enzyme structure  
   aminotransferases 7:451  
   C-terminal domain 7:451  
   cystathionine  $\beta$ -lyase (CBL) 7:450  
   homotetramer with 222 symmetry 7:451  
   N-terminal domain 7:451  
   PLP 7:451  
   second domain  
      $\alpha/\beta$  structure with a seven-stranded  $\beta$ -sheet 7:451  
     three heavy atom derivatives 7:451  
 enzyme–substrate interactions 13:551  
 enzyme substrate recognition 12:492  
 enzyme-catalyzed reactions  
   classification of 11:32–33  
 enzyme-linked immunosorbent assay (ELISA) 1:317, 466, 483, 6:369, 370ff, 8:414, 450  
 enzymology 11:31  
 E6 onco-protein 12:185  
 eosin isothiocyanate 3:545  
 eosinophil cationic protein (ECP) 6:346, 15:220  
 eosinophil granulocytes 6:346–347  
 eosinophil peroxidase (EPO) 6:346  
 eosinophil-derived neurotoxin (EDN) 6:346  
 eosinophils 4:636  
 Eph 15:216  
 EphB4 15:207, 216  
 Ephedrine 14:365–366  
 ephrin B2 15:207, 216  
 ephrins 15:203, 216  
 epi detection 15:70  
 epiblast cells 13:392  
 epidemics 7:27ff, 12:307  
 epidemiology 1:182ff  
 epidemiology, molecular 4:226  
 epidermal carcinogenesis and stem cells 13:350  
 epidermal growth factor, *see* EGF  
 epidermal growth factor receptor, *see* EGFR  
 epidermis 13:218, 221–224  
 epidermolysis bullosa (EB) 2:344  
 epigenesis 8:532  
 epigenetic 4:239, 5:470, 472, 9:92, 110, 12:44, 14:267  
   modifications 5:471  
 epigenetic inheritance 6:139, 149  
 epigenetic regulation 10:74, 82



- epigenetic regulation of transcription 10:310  
 epigenomics 9:109–111  
 epilepsy 4:344, 11:677  
 epilepsy and neurodegeneration in animals 13:690  
 epilepsy, hereditary 11:677  
 epinephrine 14:658  
 episodic ataxia (EA) 11:681f, 15:22  
 epistasis 1:593, 4:330, 5:371, 394  
 epithelia 11:684, 685  
   blood-brain barrier 8:156  
   intestinal 8:156  
   transport across 8:156  
 epithelial architecture 4:279  
 epithelial cells 4:186ff  
 epithelial sodium channel (ENaC) 8:628, 638, 11:690f  
 epithelial specific antigen 2:225  
 epithelial stem cell  
   *Drosophila* follicle cell 12:81  
   hair follicle 12:77  
   mammalian epidermis 12:77  
   mammalian gut crypt 12:80  
 epithelialization 13:243–244  
 epithelium (basal cells) 4:278ff, 13:345  
 2,3 $\alpha$ -epithio-5 $\alpha$ -androstan17 $\beta$ -ol 13:39  
 2,3 $\alpha$ -epithio-17 $\alpha$ -methyl-5 $\alpha$ -androstan17 $\beta$ -ol 13:39  
 epithionitriles 10:349  
 epitope 1:366, 474, 483, 2:555, 4:363, 6:365, 366ff, 367ff, 8:422, 11:104, 15:139  
   B-cell epitope 1:382  
   conformational epitope 1:486  
   cryptic epitopes 1:494  
   epitope mapping 1:486  
   T-cell epitope 1:382  
 epitope tagging 8:10, 13, 31  
 epothilones 14:343–344  
 epoxide 6:46  
 epoxide hydrolases 2:53, 59  
 epoxomicin 11:3  
 Eppstein–Barr virus (EBV) 1:384, 3:229, 6:389, 8:454, 15:313  
   EBV nuclear antigen-1 (EBNA1) 15:292  
 EPR imaging 7:174  
 EPRI 4:128  
 Epristeride 13:51  
 EPSPs 11:675  
 eptifibatide 10:218  
 equal environments assumption 1:590  
 equilibrium constant 11:398  
 equilibrium denaturation  
   conditions for 3:205  
 equine infectious anemia virus (EIAV) 13:258  
 equipartition 10:425  
 equivalent dose 11:416  
 ER, *see* endoplasmic reticulum  
 ErbB 2:172, 174, 4:213  
 ErbB family 2:174–175  
 ERBB1 (avian erythroblastosis virus) 9:440  
 ERCC1  
   aging 1:70  
   homologous recombinational repair (HRR) 1:75  
 ERGIC 8:127  
 ergodic 10:207  
 ergosterol 8:377  
 ERK 9:464  
   ERK5 7:123  
   MAP kinase phosphatase-1 7:126  
   p38<sup>MAPK</sup> 7:123  
   Raf signaling 7:123  
 ERK MAP kinase 2:334  
 ERK-extracellular signal regulated kinase, *see* MAP kinase  
 ERNA-3D 12:625  
 Ero1p 2:510  
 Erp57 2:514  
 ER-resident aminopeptidase ERAP-1 1:368  
 error catastrophe 5:107  
 error distribution 11:392  
 error estimation 11:393  
 error propagation 11:386  
 error space 11:391  
 error surface 11:391, 392, 394  
 error-prone ribosome 12:495  
*Erwinia stewartii* 6:559, 10:366, 367, 369  
 erythrocrucorins 6:70  
 erythroid cells 12:161ff, 163  
 erythroid lineage  
   differentiation 2:435, 440, 441, 443  
   expansion 2:435  
   expansion pp 9–14 2:437ff  
   genes required for 2:437  
   genes required for pp. 7–17 2:435ff  
   signals required for pp. 9–17 2:436ff  
   specification 2:435, 436, 443  
   survival 2:435, 443  
   survival pp 9–14 2:437ff  
 erythroid-differentiating factor 4:394  
 erythromycin 10:649ff  
 erythromycin macrolides 14:354–355  
 erythropoiesis 13:31, 32  
 erythropoietin (EPO) 10:135, 230, 387  
 ESC, *see* embryonic stem cell  
 escargot 4:291  
 ESCRT, *see* endosomal sorting complex  
   required for transport

- E-selectin 6:23  
 ESI, *see* electrospray ionization  
 E-signal 8:310  
 ESI-MS/MS, *see* electrospray mass spectroscopy  
 ES-like cells 13:392  
 esophageal cancer 6:4  
 esophageal SCC 6:6  
 ESR  
   cwESR 4:117ff  
   pulsed ESR 4:117ff  
 ESR imaging 4:128  
 EST, *see* expressed sequence tag  
 Est1 14:236  
 EST alignments  
   integration of 2:79–80  
   query into database of 2:81  
 EST frequency 10:536  
 EST orientation 2:76, 80  
   resolution by alignments 2:82  
 EST probes 5:143  
 EST sequence clusters 11:374ff  
 ester C=O stretching vibrations 13:686  
 esterases 2:53, 59  
 estradiol binding  
   structural requirements for 1:446–447  
 estradiol-17 $\beta$  (E2) 4:384ff  
 estrenol 13:38, 42  
 estrogen binding capacity  
   ligand-induced regulation of 1:448–449  
 estrogen biosynthesis 13:15  
 estrogen receptor level  
   ligand-induced regulation of 1:449  
 estrogen receptors 4:259, 386ff, 9:472  
   ER $\alpha$  4:387  
   ER $\beta$  4:387  
   nucleocytoplasmic shuttle of 1:447–448  
 estrone 13:15  
 ESTs with human genome  
   efficient computational alignment of  
   2:81–82  
 Eta-1 6:18  
 etanercept 14:459  
 ethanol  
   metabolism of 2:58  
 ethanolamine 8:143, 144, 10:280  
 ethanolamine kinase 10:288  
 ethanolamine P 10:302  
 ether-linked phospholipid 13:621  
 ethidium bromide 11:493  
 ethyldienolone 13:34  
 ethylene 1:432  
   regulation by 10:342–344  
 ethylene responsive factor (ERF) 10:348  
 17 $\alpha$ -ethylestr-4-en-17 $\beta$ -ol 13:38  
 etiocholanolone 13:13  
 etiologic agents  
   asbestos 5:354ff  
   cigarette smoking 5:354ff  
   elimination of tobacco consumption 5:365  
   radon 5:354ff  
 etiologic studies 4:233  
 Etoposide 14:344–347  
 Ets 10:296, 12:176  
 ETS gene family 9:472  
 Eubacteria 7:250, 8:239  
 Eucarya 8:238f  
 euchromatin 3:574, 4:246, 5:527, 6:138ff,  
   12:48, 14:260  
 euglycemic 7:102  
 Eukarya 7:250  
 eukaryotes 11:59  
   initiation mechanisms in 3:460–461  
   noncoding DNA evolution in 12:129–135  
   noncoding DNA, size of 12:129–130  
   transcriptional regulation in 3:470–472  
 eukaryotic algae lipids 7:274  
 eukaryotic cells 1:545, 11:58, 60, 13:663  
   membrane-surrounded organelles 11:71  
 eukaryotic chromosomes 5:328  
 eukaryotic endoplasmic reticulum  
   unfolded protein response (UPR) of  
   13:483–485  
 eukaryotic flagella 8:389  
 eukaryotic genes 5:245  
 eukaryotic genomes 13:82  
   influence of recombination 12:132  
 eukaryotic heat shock response  
   factors of 13:476–483  
   pharmacological regulation of 13:481–483  
 eukaryotic Hsp104  
   disaggregases 13:509  
 eukaryotic proteasome 13:506  
 eukaryotic P450s 6:46  
 eukaryotic translocation machinery 12:507  
*Euplectella aspergillum* 13:290  
 Europa 10:4  
 European Agency for the evaluation of  
   medicinal products (EMA) 10:392, 13:264,  
   15:487  
 European Patent Convention (1973) (EPC)  
   7:375  
 European Patent Office (EPO) 7:378  
 EVA polymer 3:42  
 evanescent wave 3:553  
 Evans Blue 1:420  
 Evans Blue extravasation 14:48  
 even-skipped 6:198, 15:191  
 everninomicin 10:647

- evo-devo 8:517, 532  
 evolution 5:313, 322, 509, 6:182ff, 192ff,  
   11:219, 12:101  
   biological 2:565  
   DNA sequence 2:565ff  
   homeobox genes 6:192, 216  
   male-driven 6:113  
   molecular 2:565  
   of phenotypes 2:565  
   species-specific 2:563  
 evolution and development 8:532  
 evolution genes 5:337, 345  
 evolution study 8:415  
 evolution system 2:460  
 evolutionary change 8:535ff  
 evolutionary fitness 5:345, 346  
 evolutionary function of viruses 5:348  
 evolutionary pressure 12:338  
 evolutionary processes 9:184ff  
   genetic drift 9:184  
   natural selection 9:184  
 evolutionary relationships 6:186  
 evolve 10:4  
 Ewald construction  
   Bragg's law 7:421  
   direct space 7:421  
   Ewald sphere 7:422  
   reciprocal lattice 7:420  
   reciprocal space 7:421  
   scattering vector **S** 7:421  
 EXAFS 8:214  
 exchange interaction 7:161  
 exchange rate 13:567  
 exchange regime 13:553, 556, 559  
   fast 13:552  
   intermediate 13:552  
   slow 13:552  
 exchanger 2:135  
 excitation wavelength 11:488ff  
 excitation-contraction (EC) coupling  
   11:660  
 excitation-secretion (ES) coupling 11:675  
 excited state 4:440f  
 excited triplet state 3:355, 7:164  
 exciton 3:60ff  
 excitotoxicity 10:116, 120, 15:13ff  
 exclusion 3:500  
 exemestane 13:55  
 exencephaly 9:120, 126  
 exit 12:486  
 exit tunnel 12:484, 499–501, 507  
 EXO1 3:435, 440  
 exocrine glands 15:260  
 exocyst complex 4:315  
 exocytosis 4:307ff, 8:133, 146ff, 155  
   constitutive exocytosis 11:70  
   regulated 11:70  
 exogenous matrices 14:407  
 exogenous substrates  
   aromatase cytochrome P450 3:106  
   cholesterol biosynthesis 3:104  
   cytochrome P450cam 3:106  
   fatty acid hydroxylase P450 3:106  
   lanosterol 14 $\alpha$ -demethylase cytochrome P450  
     3:104  
   polycyclic aromatic hydrocarbons (P4501A1)  
     3:106  
 exoglycosidases 2:252, 5:546  
 exon 1:126, 158, 5:371, 9:255, 12:24, 517  
 exon–intron junction 1:137  
 exon recognition 1:146  
 exonic splicing enhancer (ESE) 1:146  
 exonic splicing silencer (ESS) 1:146  
 exons 1:137, 140, 2:635, 5:245, 387, 12:351  
 exonuclease 10:227  
 $\lambda$ -exonuclease 12:329  
 exonuclease III 3:543  
 exopeptidases 10:221, 222  
 exopinacocytes 13:273  
 exopolysaccharides 10:366, 369  
 exosomes 1:399, 494, 3:222, 4:209  
 Expanded Genetic Code 8:112  
 expanding trinucleotide repeats 5:402  
 expansin 14:265  
 expansion 4:592, 11:45–65  
 expansion of the genetic code  
   artificial genetic code 2:457  
 expectation-maximization 9:259  
 experiment 14:133  
 experimental allergic encephalomyelitis (EAE)  
   14:46  
 experimental analysis of the bacterial division  
   cycle 1:549  
 experimental data 11:387, 14:135  
 experimental design 10:538  
 experimental inflammatory arthritis  
   IL-6 –/– mice 14:41  
   TNF –/– mice 14:41  
 experimental results 11:391  
 experimental systems 11:387  
 explant 1:416ff  
 exponential function 10:417, 11:385, 402  
 exponential growth 3:541  
 exportin 11:59  
 exportin1 4:596  
 exposure–response 10:215  
 exposure/response correlations 10:228  
 express neutrophilin-1(NRP-1) 6:17, 22

- expressed protein ligation 11:64  
 expressed-sequence tag (EST) 2:536, 546f, 620,  
 3:48, 5:406, 506, 532, 9:260, 10:533ff, 12:708ff,  
 15:556, 560  
 expression 4:370, 7:305ff  
   microarray 9:76  
   proteomics 9:76  
 expression arrays 3:42  
 expression controls 5:85  
 expression data 6:595, 10:536  
 expression, heterologous 8:362  
 expression libraries 3:49, 386  
 expression pattern 4:593  
 expression profiles 3:49  
 expression profiling 2:78, 3:43, 5:507, 7:315  
 expression profiling arrays 11:103  
 expression systems 1:346  
 expression vectors 8:609ff, 11:121, 15:115  
 expressivity 5:394, 11:658  
 extein 11:242, 245  
 extended shuttle model 13:625  
 external plexiform layer (EPL) 12:648  
 external spawners 14:12  
 extracellular 2:138  
 extracellular calcium sensor  
   CT 2:140  
   PTH 2:140  
   vitamin D<sub>3</sub> 2:140  
 extracellular complementation 8:308  
 extracellular domain  
   cis-dimerization 2:350  
   therapeutic interventions 2:351  
   trans-dimerization 2:351  
 extracellular "Gel"  
   choice of 14:392  
 extracellular matrix 3:278, 8:47, 49, 224,  
 15:206, 207  
   basement membrane 4:280ff  
 extracellular matrix (ECM) 2:114, 326ff,  
 4:278ff, 392, 5:649, 8:46, 54, 64f, 67, 222,  
 12:184ff, 13:222, 14:385, 392  
   cell adhesion triggering in tricellular  
   reorganisation 14:389  
   gels 14:397  
   ligands 8:60  
   modifications 8:62  
   plasticity of 14:386–387  
   provisional matrix 2:330  
   receptors 14:386  
   response elements 14:388  
 extracellular matrix (ECM) signaling  
 14:385–388  
 extracellular matrix proteins 13:225–227  
 extracellular mitogenic signals 9:453  
 extracellular signals 1:152  
 extracellular-signal regulated kinase 13:159ff  
 extrachromosomal arrays 9:60–61  
 extrachromosomal rDNA palindrome 3:332  
 extracytoplasmic stress response 13:472  
 extradenticle 6:214  
 extravasate 7:304ff  
 extravasation 14:174  
 extravascular space 14:174  
 extruded 7:306ff  
 eye lens 2:507  
*Eyg* 12:183
- f**  
 Δ F508 11:686  
<sup>19</sup>F spectrum 13:575  
 F8A 6:113  
 FA transport 14:647  
 FA transport protein (FATP) 14:673  
 Fab 1:330, 346, 6:364  
 Fab1 4:196  
 FABP, *see* fatty acid binding protein  
 fabry 13:321  
 Fabs 11:105  
 facial characteristics 4:590  
 facial weakness 10:119  
 facilitated diffusion 8:146, 12:328  
   examples 8:151  
   kinetic equation 8:151  
   measurement 8:153  
 facilitative transporters (GLUTs) 7:28  
 F-actin 4:279ff, 13:663  
 F-actin cytoskeleton  
   ADF/cofilin 4:285  
   Arp2/3ff 4:285  
   or AC proteins 4:285ff  
   profilin (chickadee) 4:285ff  
   WASP 4:285ff  
 F-actin filaments 13:663–665  
 factor FVIII  
   mRNA 6:114  
   protein domains 6:114  
 factor IX 6:112  
   gene 6:115  
   inhibitor 6:128  
   mRNA 6:115  
   protein domains 6:115  
   tridimensional structure 6:117  
 factor V 6:114  
 factor VII 6:115  
 factor VIII 6:112  
   gene 6:113  
   *see also* FVIII  
 factor X 6:114, 115

- FAD, *see* flavin adenine dinucleotide  
 FADD 10:622, 626, 629  
 failing myocytes 11:666  
 FAK, *see* focal adhesion kinase  
 false discovery rate 10:539  
 false positives 9:257  
 6-FAM 11:489ff  
 FAM11A 4:576  
 familial adenomatous polyposis (FAP) 4:256, 6:19  
 familial amyotrophic lateral sclerosis 8:543  
 familial combined hyperlipidemia (FCH) 7:210  
 familial hemiplegic migraine (FMH) 11:681f, 15:22  
 familial hypercholesterolemia (FH) 1:156, 4:190, 5:214, 225, 7:208  
 familial hypoalphalipoproteinemia (FHA) 5:214, 226  
 familial hypobetalipoproteinemia (FHB) 7:210  
 familial ligand-defective apoB (FLDB) 7:209  
 familial partial lipodystrophy 7:53  
 familial predisposition to lung cancer  
   heritable variation in response to carcinogens 5:355  
   Mendelian codominant inheritance of a rare autosomal gene 5:355  
 family studies 1:589  
 FANCD2  
   cancer 1:82  
 farnesyl pyrophosphate synthase 7:218  
 Fas 1:476, 10:628, 630  
 Fas ligand 15:264  
 FasL  
   sources of 6:483  
 FasL-mediated toxicity  
   tumor evasion of 6:483  
 fast exchange 13:554, 556  
 FASTA 5:532  
 fast-atom bombardment (FAB) 7:593  
 fast-Fourier transform (FFT) 13:675  
 fasting 7:102  
 fat 4:341  
 fat absorption 14:640  
 fatal familial insomnia (FFI) 10:585  
 FAT/CD36 8:152  
 F-ATPase (F-type ATPase) 11:334, 335  
 F-ATPase holoenzyme  
   rotational catalysis of 11:344–350  
 F-ATPase in membranes  
   rotational catalysis of 11:347–350  
 fat-soluble cases 15:537  
 fat-soluble vitamins 15:511  
 fatty acid 7:263  
 fatty acid binding protein (FABP) 1:5, 7:74ff, 96ff, 104, 14:669  
 fatty acid binding protein-1 (FATP1) 14:664  
 fatty acid binding proteins transport function 7:74ff, 76ff, 80ff, 81ff, 83ff  
   equilibrium binding studies 7:74  
   in vitro fatty acid–transfer 7:76  
   knockout mice 7:83  
   protein–protein interactions 7:81  
   transfection studies 7:80  
 fatty acid content, modified 14:554  
   polyunsaturated fatty acids 14:569  
 fatty acid synthase (FAS) 13:660–663, 14:638  
 fatty acids 1:2, 4, 4:667, 7:96, 279  
   fluorescent 7:100  
   long-chain 7:98  
   polyunsaturated 7:98  
 fatty acids clouds 10:3  
 fatty streak 5:214, 219  
 fault tolerance 14:130  
 F8B 6:113  
 F-box 12:155  
 Fc 1:330, 346, 11:108  
 Fc receptor 1:385, 5:556, 10:184  
 Fc $\gamma$  receptors 1:377  
 FCH, *see* familial combined hyperlipidemia  
 fCJD  
   in libyan jews 10:584  
   octarepeat inserts caused by 10:584  
   penetration of 10:584–585  
 FCS, *see* fluorescence correlation spectroscopy  
 aggregates 4:476  
 aggregation processes 4:479  
 applications 4:478  
 autocorrelation function 4:467  
 background fluorescence 4:482  
 calcium 4:491  
 change in the diffusion properties 4:469  
 change in the fluorescence brightness 4:470  
 conformational kinetics 4:492  
 different species 4:469  
 DNA–DNA interaction (DNA sequencing) 4:489  
 DNA molecules 4:489  
 dual-color 4:473  
 first experimental realization 4:463  
 fluorescently labeled ligands 4:484  
 higher order 4:477  
 instrumentation 4:464  
 internalization of receptors 4:485  
 intracellular interactions 4:481  
 labeling 4:484  
 ligand–receptor 4:470, 481, 485  
 limits 4:494

- living cells 4:481  
 observation volume 4:466–468  
 photobleaching 4:484, 494  
 photophysical states 4:490  
 protein–DNA interactions 4:489  
 protein–protein interactions 4:478  
 reaction 4:469, 470  
 receptor–ligand complex 4:481  
 rotational diffusion 4:476  
 saturation 4:494  
 scanning 4:475  
 singlet–triplet transitions 4:491  
 specific interactions 4:478  
 translational diffusion 4:465  
 ultra-HTS (uHTS) 4:494  
 vesicle–peptide interactions 4:486  
 washing of the cells 4:484  
**FDR 10:539**  
 febrile seizures 11:679  
 fed batch culture  
   secondary metabolites 5:8  
 Federal Bureau of Investigation (FBI) 10:520  
 Federman 13:614  
 feedback inhibition 1:433, 14:668  
 feeder cells 13:386  
 feeder layer 7:542ff  
 feline immunodeficiency virus (FIV) 13:258  
 Fellgett's and Jacquinot's advantages 13:675  
 female carriers 4:589  
 female gamete formation  
   megagametogenesis  
     antipodal cells (ACs) 12:273  
     central cell nucleus (CCN) 12:273ff  
     central vacuole 12:273  
     chalazal 12:273  
     egg cell 12:273ff  
     embryo sac 12:273  
     female gamete 12:269ff  
     micropylar 12:273ff  
     molecular nature of 12:273  
     polar nuclei 12:273ff  
     pole 12:273ff  
     synergid cells (SCs) 12:273ff  
   megasporogenesis  
     archesporial cell 12:272  
     functional megaspore 12:272  
     megaspore 12:269ff  
     megasporocyte 12:272  
     MMC 12:272  
 ovule  
   chalaza 12:269  
   embryo sac 12:269ff  
   funiculus 12:269  
   inner integument 12:269  
   integument initiation and growth 12:271  
   micropyle 12:269  
   nucellus 12:269  
   outer integument 12:269  
   ovule patterning 12:271  
 female gametes 14:8–9  
 FEN1 4:614  
 Fenton chemistry 4:522  
 Fenton reagents 8:213  
 fermentation 2:41  
 fermentation process 15:166ff  
 fermentation tests  
   aesculetin production from aesculin 1:520  
   Hugh and Leifson's method 1:519  
   levan production 1:520  
 ferredoxin 3:103  
 ferredoxin reductase  
   microsomal flavoprotein 3:103  
 ferritin 4:644, 8:349  
 ferroportin 8:349  
 fertility 1:80  
 fertilization 2:166, 466, 5:556, 10:485, 13:333,  
   14:19–23  
   cell differentiation 13:384  
   centriole 6:539  
   chromosomes 6:539  
   egg cell 12:278  
   in vitro 13:335, 385  
   in vitro fertilization (IVF) 6:533ff  
   increases in Ca<sup>2+</sup> 6:538  
   karyogamy 12:278  
   mitogen-activated protein kinase (MAP)  
     6:539  
   plasmagamy 12:278  
   pollen tube growth, regulation  
     γ-aminobutyric acid (GABA) 12:277  
     Ca<sup>2+</sup> gradient 12:277  
     Hyp-rich glycoproteins (HRGPs)  
       12:277  
     Rop GTPases 12:277  
     stigma secretory zone 12:277  
     transmitting tissue 12:277  
   primary endosperm nucleus 12:279  
   receptive ovule 12:278  
   receptive synergid 12:278  
   sporophyte–gametophyte interactions  
     filiform structures 12:276  
     micropyle exudates 12:276  
     pollen germination 12:275  
     pollen transfer 12:275  
     pollen tube growth 12:275  
     synergid cell death 12:278  
   zygote 12:279  
 fertilization calcium signals 14:14–19

- fertilization calcium wave 14:15–16  
 signal transduction 14:17–19
- fertilization cone 14:13
- fertilized egg 10:485
- fertilized egg and embryonic development 13:329
- fetal testis  
 Müllerian inhibiting substance (MIS) 7:503  
 sex reversal 7:502  
 SOX9 7:502  
 SRY 7:502
- fever 8:434, 442
- F<sub>0</sub>F<sub>1</sub> 11:334, 346
- FGenesH 5:532
- FGF-2 10:134
- FGF-4 14:294
- FGF, *see* fibroblast growth factors
- FGF signaling  
 BNL (branchless) 4:291  
 BTL (breathless) 4:291ff
- FGFR, *see* fibroblast growth factor receptor
- FHB, *see* familial hypobetalipoproteinemia
- FHM1 11:682
- FHM2 11:682
- fiber diffraction 13:654
- fiber diffraction refinement  
 on long-range normal modes 13:666–667
- fiber FISH (DNA fibers) 5:149f, 7:347  
 chromatin fiber preparation 5:150  
 DNA fiber preparation 5:152  
 target preparation 5:150
- fiber (of viruses) 15:332
- fibrillarlin 1:467, 484
- fibrillates 11:662
- fibrinogen 8:48  
 fibrin 2:330  
 fibronectin-null embryos 2:330
- fibrinogen domains 7:482
- fibroblast growth factor (FGF) 5:642, 650–651, 6:3, 9:455, 527, 12:648, 13:389, 417ff, 14:293ff
- fibroblast growth factor receptor family 9:458
- fibroblast growth factor receptor (FGFR)  
 6:327, 9:455, 11:582  
 constitutive activation 7:129  
 immunoglobulin-like domains 7:129ff  
 STAT5 7:129  
 translocations 7:129  
 ZNF198 7:129  
 ZNF198-FGFR1 7:129
- fibroblast IFN 15:391
- fibroblasts 13:242–243
- fibronectin 2:326ff, 5:560, 8:55, 56, 63, 65, 67–69, 224, 13:241
- fibrosis 8:624, 15:217
- fibrous cap 5:214, 220
- Fick's first law 8:147
- FID, *see* free induction decay
- FIDA/PCH 4:479
- field and molecular motion 4:4
- field carcinogenic events  
 causes of 9:504
- field effect transistors 9:564
- field enhancement 4:14
- field flow chromatography 2:261
- field flow fractionation 2:260
- filamentous fungi 5:3  
 gene fusion 5:12  
 posttranslational modifications 5:12  
 proteolysis 5:12  
 transcription 5:12  
 translation 5:12
- filamin 2:338ff
- filoviruses 3:91
- filters, preprocessing 8:197, 199  
 binning 8:200  
 hierarchical PCA 8:200
- FIMDA (Fluorescence Intensity Multiple Distributions Analysis) 4:478
- finasteride 13:44, 49
- fingerprint 3:603, 5:528
- fingerprint contig, *see* FPC
- fingerprint region 13:686
- fingerprinting 15:620
- finished sequence 11:434
- finishing 5:524
- firefly 2:523
- firefly luciferin  
 membrane-permeable 2:532
- first and second messengers 14:92, 108
- first living system 10:4
- first-pass metabolism 3:616
- FIS 3:541  
 UP element 3:539
- FISH (fluorescence in situ hybridization)  
 2:536, 539, 3:2, 4, 4:440, 456, 5:120, 121, 140, 7:33, 346, 9:515, 14:256, 15:556, 567
- FISH model  
 large-size 14:476–477  
 medium-size 14:476  
 small-size 14:476
- FISH species  
 selection of 14:475–477
- FISH technique 13:100
- FISH transgenesis 14:488
- fission 13:610, 622, 624
- fission pathway 13:615
- fission yeast 14:229ff
- fitness 6:324

- fitting 11:386  
 fitting algorithms 11:385  
 fixation of genetic change in individual organism 5:315  
 Fizzy-related (Fzr, Hec1, Cdh1) 12:196  
 FK506 1:670, 13:556, 571, 572, 585  
 FKBP 13:585, 592  
 flagella 2:621ff, 638ff, 8:389  
   flagellar apparatus 2:624  
   flagellar apparatus 2:638  
   flagellar filament 8:398–401, 404–407  
   flagellin 8:395, 398–401, 404–407, 10:91  
   flagellum biogenesis 8:294, 296  
   flagellum-related genes 1:546  
   flagellar filament cap 8:401, 402, 404–407  
   flares 14:39  
   flavin adenine dinucleotide (FAD) 8:165, 9:575  
   flavin mononucleotide (FMN) 9:575  
   flavocoenzymes 9:575, 577  
     biosynthesis of 9:576  
   flavonoids  
     morin 14:50  
     quercetin  
        $\beta$ -phenolic ring 14:50  
     Rutin 14:50  
   flavoprotein monooxygenases 2:53ff  
 FLD 14:268  
 FLDB, *see* familial ligand-defective apoB  
 flexibility 7:305ff, 13:549  
   HIV protease 13:582  
 FLIP 10:626  
 flip-flop system 5:340  
 flips 12:334  
 Flk-1 15:212  
 floral development 14:263  
 floral organ 14:267  
   development of stages  
   molecular factors 12:263  
   petal 12:255ff  
   pistil 12:255ff  
   sepal 12:255ff  
   stamen 12:255ff  
 flow chamber 4:417ff  
 flow cytometer 4:417  
   data processing 4:420  
   fluidics 4:418  
   optics 4:419  
   signal processing 4:419  
 flow cytometry 1:549, 5:129, 7:167  
   applications to marine biology 4:435  
   applications to microbiology 4:435  
   clinical applications 4:427  
   instrument 4:417  
 flow karyotype 5:120, 123  
 flow NMR 13:528  
 FLOWERING LOCUS C (FLC) 14:268  
 FLOWERING LOCUS D (FLD) 14:268  
 flowering plants 1:84  
   complementation 1:89  
 flowering time  
   light regulation of 10:333–334  
 Flt1 15:212  
 fluctuation analysis 4:463  
 fluctuations 14:140  
 fluid mosaic model 8:144  
 fluid-phase endocytosis 1:626  
 fluorescein isothiocyanate (FITC), in  
   fluorescence microscopy 1:514  
 fluorescence 2:632, 637, 4:420, 439–440,  
   453–454, 7:164, 167, 172, 11:56, 109, 12:216,  
   15:62  
   emission spectrum 4:444–445  
   excitation spectrum of 4:445  
   flow cytometry 4:455–456  
   historical overview 4:441–442  
   lifetime of 4:446–447  
   multiphoton 4:450–452  
   processes in 4:442–446  
     polarization (anisotropy) of emission  
       4:447–450  
   fluorescence anisotropy 3:556  
   fluorescence correlation spectroscopy, *see* FCS  
   fluorescence 2D-difference gel electrophoresis  
     (2D-DIGE) 5:34ff  
   fluorescent cyanine dye derivatives 5:34, 38  
   minimal lysine labeling 5:38  
   NHS-Cy2/Cy3/Cy5 cyanine dyes 5:34  
   sample labeling 5:38  
   fluorescence detection 3:489, 9:304  
   fluorescence emission 15:63  
   fluorescence in situ hybridization, *see* FISH  
   fluorescence intensity 3:556  
   fluorescence intensity distribution analysis  
     (FIDA) 4:477  
   fluorescence lifetime imaging microscopy  
     (FSIM) 4:447, 7:174  
   fluorescence microscopy 1:466, 7:174, 10:426,  
   13:689, 690, 695  
   fluorescence resonance energy transfer, *see*  
   FRET  
   fluorescence signal 14:425  
   fluorescence technique 7:169  
   fluorescence-activated cell sorter (FACS)  
     4:456, 5:122–124, 455, 6:371, 8:416  
   fluorescent dye 11:109  
   fluorescent indicators 15:76  
   fluorescent oligonucleotides 9:424–425  
   fluorescent probes 4:452



- fluorescent recovery 7:164  
 fluorescent scanners 11:109  
 fluorescent signal 11:514  
 9 $\alpha$ -fluoro-11 $\beta$ ,17 $\beta$ -dihydroxy-17 $\alpha$ -  
 methylandrosterone-4-en-3-one 13:26  
 fluorography 11:412, 431  
 fluorometric methods 14:429  
 fluorophore 4:440, 442, 11:64, 15:74  
   endogenous 15:76  
   exogenous 15:76  
 fluorophores and indicators  
   genetically encoded 15:77  
 fluorophore's extinction coefficient 4:444  
 2'-fluoro-RNA 9:409  
 fluors 5:145  
 fluoxetine 4:342  
 fluoxetine (trade name, Prozac) 2:601  
 fluoxymesterone 13:23, 26  
 fluphenazine  
   prodrug of 2:59  
 flushing 13:44, 46, 47, 48, 14:48  
 flux 11:403  
   glycolytic 7:98  
 flux balance analysis 6:593  
 FMN, *see* flavin mononucleotide  
 FMR1 4:576, 587, 592  
 FMR2 4:576, 15:36  
 FMR3 15:36  
 FMR1-EGFP 4:599  
 Fmr1 knockout mice 4:604  
 FMR1 mRNA levels 4:612  
 FMR1 mutation 4:613  
 FMRP 4:587, 592  
 FMRP levels 4:612  
 FMRP-ribosome binding 4:596  
 5-FOA 11:61  
 foam cells 5:214, 219  
 foaming 4:504, 514  
 focal adhesion 2:326ff, 4:281ff  
   actin microfilament cytoskeleton 2:326  
   focal contact 2:341  
 focal adhesion kinase (FAK) 2:333ff, 4:282,  
 12:184  
 Foerster/fluorescence resonance energy  
   transfer 9:273-274  
 folacin 15:548  
 folate-preventable NTDs  
   animal models of 9:134-135  
 fold recognition 6:584, 11:134  
 folding 1:24  
   intermediates 1:26  
   pathway 1:26  
   studies 1:33  
 folding pathways 2:491  
 folding problem  
   theoretical studies 1:26  
 follicles 5:556  
   antral 4:384  
   atretic 4:384  
   Graafian follicles 4:388ff  
   ovulatory 4:384  
   preantral 4:384  
   primordial 4:384  
 follicle-stimulating hormone (FSH) 4:384ff,  
 13:7  
 follicular dendritic cells (FDCs) 1:385  
 follistatin 4:389ff  
 follitropin 5:553  
 Food and Drug Administration (FDA) 6:439,  
 10:392, 522, 13:264  
 food protein interaction 4:504  
 food proteins  
   enzymes of 4:508-509  
   functionality of 4:503-517  
   interactions of 4:503-517  
 footprinting 4:522, 539, 549, 9:308  
   cleavage-based 4:554  
   complexes 4:562  
   differential reactivity of individual sites  
     4:528  
   fundamental features of 4:553  
   HPLC and mass spectrometry 4:557  
   hydroxyl radical-mediated 4:557  
   limited dose 4:528  
   quantitative equilibrium 4:559  
   techniques 4:554  
 force 14:409-410  
 force field 2:27, 12:625, 626  
   parameters 2:28  
 forebrain specification 2:104-107  
 foreign antigenic peptides 1:368  
 foreign antigens 1:362, 364  
 foreign peptides 1:365, 366, 393  
 forensic applications  
   DNA typing for 7:609-616  
   mass spectrometry DNA detection for  
     7:611-616  
 forensic DNA  
   sample preparation of 7:610-611  
 forensic testing 9:262  
 forespore 8:304ff  
 forked junctions 3:534  
 Forkhead 13:276, 296  
 Forkhead (FOX) family  
   (FKHR) 4:391  
 Forkhead L2 (Foxl2) 15:49  
 Forkhead transcription factors 12:176ff  
   FoxO 12:176

- formaldehyde cross-linking 3:547  
 formalin test 15:271  
 formestane 13:53  
 formose 10:13  
 forms of genomic damage 9:4  
   chromosomal instability 9:5  
   intrachromosomal instability 9:5  
   microsatellite instability 9:5  
 formulation development 15:166ff  
 forskolin 13:156, 14:660  
 forward genetic 12:423, 436ff, 446, 455, 463,  
   14:258, 15:602ff  
 FOS and JUN families 9:471  
 fosfomidomycin 1:432  
 Fos(Fra) 12:176  
 fossilized microscopic life 10:6  
 founder effect 6:329–331, 15:20ff  
 four-base codon method 2:457  
 Fourier analysis 9:254  
 Fourier transform 13:523  
   G-matrix 11:169  
 Fourier transform electron spin resonance (2D  
   FT ESR) 7:162  
 Fourier transform infrared (FTIR) microscopes  
   13:676, 687, 692  
 Fourier transform infrared (FTIR)  
   spectrometers 13:675, 679  
 Fourier transform infrared spectroscopy (FTIR)  
   1:579, 4:652, 653  
 Fourier transform ion cyclotron resonance  
   (FTICR) 8:8, 9, 12, 15f, 20  
 Fourier transformation (FT) 4:653, 11:160f  
 four-point attachment model 2:605  
 four-way cruciform 3:534  
 Foxd3/Genesis  
   early embryonic development 13:389  
 FOXP2 2:567  
 FPC (fingerprint contig) 5:529, 530, 11:438  
   assembling of, sequence-ready clones  
   13:100  
 FPIA 6:369, 372, 373, 374ff  
 FRA10B 4:577  
 FRA11B 4:576  
 FRA16B 4:577  
 fractalkine receptor 12:308  
 fractionation 11:182  
 fragile sites 3:46, 4:569ff, 587, 589,  
   15:33  
   cancer 4:582  
   classification 4:571ff  
   clinical significance 4:582  
   cytogenetics 4:577  
   induction 4:579  
   inheritance 4:580  
   molecular genetics 4:571  
   nomenclature 4:571  
 fragile X knockout mice 4:604  
 fragile X mental retardation-1 (FMR1) gene  
   15:33ff  
 fragile X syndrome (FRAXA) 4:570ff, 588f,  
   15:33ff  
   carrier females 4:575  
   molecular basis 4:576  
   premature ovarian failure 4:575  
   tremor/ataxia neurodegenerative syndrome  
   4:575  
 fragile X syndrome of mental retardation  
   15:4ff  
 fragile X tremor-ataxia syndrome (FXTAS)  
   15:9ff, 44ff  
 fragile XE mental retardation (FRAXE) 4:576,  
   15:34ff  
 fragility 14:130, 132  
 fragment assembly 6:572  
 fragment optimization 13:587  
 fragmentation 8:8, 16, 17, 21, 29, 31, 9:406  
   reduction of 9:409  
 fragmentation method 13:587  
 fragment-based screening 13:583  
 fragments of conserved extended haplotypes  
   13:192  
 frame 12:619, 623  
 frameshift mutation 5:371, 400  
 frameshifts 12:115  
*Francisella tularensis* 6:309  
 frataxin 15:36ff  
 FRAXE, *see* fragile XE mental retardation  
 free energy 12:587  
 free fatty acid (FFA) 1:5, 7:34ff  
 free induction decay (FID) 13:523  
 free radical 4:634ff, 5:494, 7:149, 154  
 free 50S ribosomal subunits 13:506  
 free-energy calculations 11:148  
 freely mobile charges 4:6  
 free-radical enzyme intermediates 4:119  
 free-radical theory of aging 5:498  
 free-running 12:415, 420ff, 426, 429ff, 435,  
   438ff, 442, 453ff, 462  
 freeze substitution 4:49, 53  
 freeze-fracture and replica methods  
   simple shadowing methods 4:51  
 FRET (fluorescence resonance energy transfer)  
   3:557, 4:424, 440, 454–455, 9:273, 11:488ff,  
   12:216  
   bioimaging 12:232  
   FLIM 12:232  
   protein–protein interactions 12:230  
 Friedel's Law 7:433

- Friedreich's ataxia, fragile X mental retardation,  
 or Hallervorden-Spatz disease 15:262  
 Friedreich's ataxia (FRDA) 12:691, 15:9ff, 36ff  
 Fringe 5:557  
 frizzled 2:229, 12:181  
 frizzled receptor 13:294  
 frizzled-related protein 13:296  
 frog  
   spinal cord 7:537  
 frogs 7:101  
 frozen accident 10:17  
 FruA 8:310, 311  
 fructan production 14:570  
 fructose 2:249  
 fructose-1,6-bisphosphatase 1:628  
 fructose-1,6-bisphosphate 7:101  
 fructose-2,6-bisphosphate 7:101  
 fructose-6-phosphate 7:101  
 fruit fly 4:330, 6:182ff, 8:372  
 fruit ripening, delayed 14:554  
 fruiting body 8:334  
 Frz 8:310  
 F<sub>0</sub>sector  
   structure of 11:344–345  
 FSH receptor 4:389ff  
 FTDP-17ff 1:193  
 F<sub>1</sub> transgenic fish 14:474  
 F<sub>2</sub> transgenic fish 14:492  
 FtsJ 13:506  
 FtsZ 8:293, 304, 305  
 FtsZ protein 1:541  
 FtsZ ring 1:527  
 fucose 2:249  
 fucosidosis  
    $\alpha$ -fucosidase 5:591  
    $\alpha$ -fucosyltransferases 5:561  
 Fuc- $\alpha$ -Ser/Thr linkage  
   coagulation factors 5:575  
 fuel  
   preference 7:98  
   sensing 7:98  
 Fugu 4:349  
 full genome scans 1:188  
 full mutation 4:587, 592  
 full-site integration 12:407–410  
 fully denaturing mode 9:303  
 fumarase 2:610  
 function 11:221  
   neo-functionalization 11:222  
   pseudogene 11:222  
   reaction chemistry 11:222  
   subfunctionalization 11:222  
 functional annotation, *see* genome annotation  
 functional arrays 11:103  
 functional assays  
   fluorescence imaging plate reader (FLIPR)  
     11:622  
   fluorescence polarization (FP) 11:622  
   fluorescence resonance energy transfer  
     (FRET) 11:622  
   green fluorescent protein (GFP) 11:622  
 functional candidates 11:684, 700  
 functional coordination 5:79  
 functional food 10:657  
 functional genomics 3:51, 640, 644, 5:3, 7:363,  
   8:265–267, 10:543, 11:615, 12:718, 14:157, 258  
 functional group mapping 13:687, 695  
 functional informatics 14:152, 158  
 functional mimicry 12:503  
 functional plasticity model 1:387  
 functional proteomics 11:120  
 functional redundancy 14:258ff, 262ff  
 functional RNA 12:584  
 functional studies 10:534  
 functional validation 14:400  
 fungal homeobox genes 6:216ff  
 fungal identity 3:497  
 fungal prions 10:593  
 fungal resistance  
   hypersensitive reaction 14:548  
   hypersensitive response 14:564  
   pathogenesis-related proteins 14:564  
   phytoalexins 14:564  
 fungi 1:88, 3:412, 4:364, 7:268, 8:372, 10:361,  
   369, 13:614  
 furosemide 11:692  
 fused 12:179  
 fusiogenic peptides 15:494, *see also* peptides  
 fusion 7:307ff, 11:218, 13:344  
   protein–lipid interactions 11:74  
   protein–protein interactions 11:74  
 fusion catalysts 11:75  
 fusion pathway 11:70, 73  
 fusion peptides  
   amphiphilic 11:70  
    $\beta$ -barrel conformation 11:78  
   short loops 11:78  
   virus-mediated fusion 11:75  
 fusion pore 4:310ff, 11:70, 73f  
 fusion proteins 4:356, 10:661, 11:121,  
   12:303–305, 14:190–192  
   diversity of 11:94  
   refolding 11:71  
   role of 11:74  
 fusion sites  
   dirty nanostructures 11:72  
 fusion, telomeric 2:561  
 fusion-inhibiting neutralizing Mabs 12:304

futsch-mRNA 4:610  
 Fv 6:364  
 FVIII and FV  
 combined deficiency 6:114  
 FVIII  
 binding sites for FIX 6:123  
 inactivation by protein C 6:115  
 inhibitors 6:124  
 interaction with vWF 6:123  
 nonrandy-type von willebrand disease  
 6:123  
 tridimensional structure 6:115  
*see also* factor VIII  
 FVIIIa  
 heterotrimer stability 6:122  
 Fv/scFv 1:330  
 FWA locus 14:269  
 FXR 7:199, 215, 220, 225, 228, 231  
 FXR1 4:600  
 FXR2 4:600  
 Fxr1 knockout 4:607  
 Fxr2 knockout mouse 4:607  
 FXR1P 4:602  
 FXR2P 4:602  
 Fyn 1:374, 381, 2:340  
 FYVE 1:625  
 FYVE domain  
 syntaxin-13 4:196  
 t-SNARE 4:196  
 FYXD2 11:694

## **g**

G72 1:606  
 G-C-rich regions 9:318  
 GA ladder 9:308  
 GABA receptors 9:152ff  
 GABA<sub>A</sub> receptor 9:152, 11:560, 564, 680  
 GABA<sub>B</sub> receptor 9:152, 11:572, 577  
 GABRG2 11:680  
 GAG 8:54, 60  
 Gag 15:139  
 gag interactome 15:460  
 gain of cyclin E 6:13  
 gain of function 1:216, 2:121–123, 11:657,  
 15:6ff  
 gain-of-function approaches 3:339–340  
 gain-of-function mutation 5:371, 400  
 GAK 12:155  
 GAL4 4:334, 11:61  
 galactose 2:249  
 galactose oxidase 2:254, 8:225  
 galactosidase 2:254  
 $\beta$ -galactosidase 5:546, 7:550, 12:27  
 $\beta$ -galactoside permease 12:27

$\alpha$ -galactosylceramide 10:95  
 $\beta$ -galactosyltransferases 5:562  
 galacturonic acid 2:249  
 gallstone 4:676ff, 5:214  
 Gal4p 11:124  
 GALT, *see* lymphoid tissues  
 galuran 8:337  
 gametes 2:629, 13:333  
 formation of 14:6–9  
 gametogenesis 2:621, 8:316, 317, 531  
 gametophytes 14:260  
 gamma c chain of the cytokine receptor 15:257  
 ganglion cells 12:363  
 gangliosides 5:549, 560f, 8:567, 13:311  
 gangliotetraose 5:551  
 globotetraose 5:551  
 GM1 5:560  
 isoglobotetraose 5:551  
 lacto-N-neotetraose 5:551  
 lacto-N-tetraose 5:551  
 Ganymede 10:4  
 gap closure  
 pseudogaps 15:568  
 true gaps 15:568  
 gap phases 12:143  
 gapped LCR (G LCR) 6:554ff  
 GARP 10:542  
 gas composition 1:432  
 GAS (gamma activation site) 13:116, 122  
 gastric cancer 6:3, 8  
 gastric inhibitory polypeptide 14:694  
 gastrointestinal absorption 14:345  
 gastrointestinal cancers 15:335–336  
 gastrointestinal carcinomas 6:3  
 gastrointestinal elimination 10:221  
 gastrointestinal (gi) stem cells 13:345  
 gastrointestinal stromal tumors (GIST) 2:174  
 GastroPlus 3:606  
 gastrulation 2:89, 13:330  
 complex, orchestrated cell movements  
 13:384  
 delamination 13:384  
 different germ layers 13:392  
 epiboly 13:384  
 ingression 13:384  
 invagination 13:384  
 involution 13:384  
 gates 11:647  
 gating 4:420  
 gating charges 8:367  
 Gaucher disease 5:23–27  
 Gaucher, Tay-Sachs 13:320  
 Gaussian distribution 11:392  
 gaze palsy 10:119

- GBF (G-box-binding factor) 8:331
- GC  
 carbohydrate analysis 2:256
- G + C content 11:367ff, 449
- (G + C) content 3:194–196
- G/C content 11:504ff
- GC, *see* *Neisseria gonorrhoeae*
- G:C to T:A transversion 6:5
- GC → AT base substitutions 6:13
- GC → AT transitions 6:13
- GC-content 2:557, 5:63, 11:504ff, 13:101  
 problems in cloning, and sequencing  
 procedures 13:102
- GC-MS  
 bias 8:195  
 reproducibility 8:195  
 sensitivity 8:194
- GC-rich templates 9:404
- GC-skew 1:527, 537
- GC<sub>3</sub> values 5:65
- G1 cyclin-dependent kinases  
 Cdk4/6 and Cdk2 2:335
- GDP-Rab proteins  
 GDP-dissociation inhibitor (GDI) 11:81
- gel electrophoresis 7:588, 590, 11:124
- gel filtration (GF) 13:266
- gelatinase B, a matrix degrading enzyme 6:22
- gelation 4:504, 510, 512–513
- geldanamycin 2:180
- gelsolin 2:156
- geminate recombination 6:69, *see also*  
 hemoglobin
- gender  
 determination of 7:615–616
- gene ablation 1:222
- gene amplification 9:449, 14:153
- gene amplification of E1F-1 6:13
- gene chips, *see* microarray
- gene clusters 6:181ff, 13:440ff  
*Streptomyces* 13:440
- gene conversion 2:537, 8:320, 9:256
- gene coverage 10:539
- gene delivery 15:290  
 angiogenesis 15:296  
 anti-PECAM-1 15:314  
 autoimmune diseases 15:297  
 brain creatine kinase (BCK) gene 15:296  
 cancer 15:293, 299, 310–312  
 cardiac troponin C (cTnC) gene 15:295  
 cationic lipid & cationic liposomes  
 15:299–307  
 chylomicron 15:308  
 cystic fibrosis transmembrane conductance  
 regulator (CFTR) gene 15:311
- Duchenne muscular dystrophy 15:294, 295
- electroporation 15:297, 298
- emulsion-mediated 15:308, 309
- epidermal growth factor (EGF) and its  
 receptor 15:299, 307
- experimental allergic encephalomyelitis  
 (EAE) 15:297
- experimental autoimmune thyroiditis (EAT)  
 15:294
- gene gun 15:298, 299
- hypoxia-responsive enhancer (HRE) element  
 15:296
- ischemia 15:296
- medullary thyroid cancer (MTC) 15:293
- microelectroporation 15:298
- myocardial diseases 15:295
- $\alpha$ -myosin heavy chain ( $\alpha$ -MHC) 15:295,  
 296, 310, 314
- nucleic acid vaccines (NAC) 15:298
- SCW arthritis 15:297
- skeletal muscle 15:294, 298
- stealth liposome 15:309
- vascular endothelial growth factor (VEGF)  
 gene 15:297  
 wound healing 15:298, 299
- gene density 5:62
- gene discovery, expression, and function 3:418
- gene duplication 11:219, 456–459, 15:193
- gene engineering and gene therapy 3:422
- gene–environment correlation 1:596  
 active 1:595  
 evocative 1:595  
 passive 1:595
- gene expression 1:2, 15, 405ff, 2:76, 79, 381,  
 568, 3:9, 5:323, 506, 7:314ff, 8:264, 268, 533,  
 9:258, 264, 10:536ff  
 control by proteolytic degradation  
 10:346–347  
 hormonal regulation of 10:337–348  
 in yeast 10:297  
 light regulation of 10:329–337  
 plasticity of 13:367–375  
 promoter enhancer 1:212  
 regulated by GDNF 10:45  
 regulated by NGF 10:44–45  
 sequence-specific inhibition 1:405  
 transcription/regulatory proteins 1:212  
 whole-genome analyses of 9:59
- gene expression patterns  
 association with EST groups on human  
 genome 2:79–80  
 less-frequent subsequences, identification of  
 2:82–83  
 use of human genome for 2:82–83

- gene expression pre- and post blood feeding 7:483
- gene expression profiling 8:281, 12:709, 714ff
- gene family 9:251, 11:654, 14:257ff  
CYP17 (17 $\alpha$ -hydroxylase/17,20-lyase) 3:108
- gene finding 6:578, 12:584
- gene flow 6:332
- gene function analysis 9:428–429
- gene fusion 5:340
- gene gating 3:8–9
- gene gun technology 9:45, 15:490
- gene loss 11:459–460
- gene mapping 5:60  
  evolution by fluorescence-activated chromosome sorting 5:119–132
- gene mapping and cloning 3:419
- gene mapping by FISH 5:139ff  
  applications 5:157  
  counterstaining and banding 5:155  
  denaturation 5:153  
  detection 5:153  
  hybridization 5:153  
  pretreatment 5:153  
  resolution of FISH mapping 5:157ff  
  stringency washes 5:154  
  with CGH and spectral karyotyping (SKY) 5:164  
  ZOO-FISH 5:164
- gene model 5:69
- gene number estimates 5:56
- gene ontology 6:600, 9:263
- gene prediction 5:57, 532
- gene rearrangements 13:349
- gene regulation 3:533, 14:266  
  by PhyA signaling 10:330–331  
  by PhyB signaling 10:331  
  during stress 10:348–351
- gene repertoire 12:639, 674
- gene replacement strategies 3:341
- gene set  
  construction of 11:452–453
- gene signatures 10:534
- gene silencing 8:267, 10:131, 427, 14:265, 268, 269  
  Neurospora 5:4
- gene size 13:103
- gene spaces 13:104  
  empty space 5:65  
  genome core 5:65
- gene structure 4:593, 5:65, 10:533  
  exon length 5:66  
  intron sizes 5:66  
  number of exons 5:66
- gene switch 15:255
- gene tagging 2:630, 14:259
- gene targeting 1:235, 5:175, 14:507, 15:262  
  basics of 14:521–527  
  biotechnological procedures of 14:526–527  
  developments in 14:512–513  
  technology of 14:521–527  
  vector design of 14:521–524
- gene therapy 5:211–216, 219–220, 236–238, 8:112, 425, 449, 14:168, 198, 305, 15:235, 486  
  antioxidant enzymes 5:233–234  
  genetically modified organism 15:487  
  growth factors 5:232–233  
  infectious diseases of 13:262–263  
  inflammatory targets for 5:229–233  
  overview of 5:217–218  
  pro-enzymes 5:233–234  
  receptors 5:232–233  
  targets for cardiovascular disease 5:221–229  
  transcription factors 5:235  
  vascular targets for 5:229–233  
  vector targeting in 15:331–353
- gene therapy of pain 15:270
- gene therapy targets  
  lipoprotein pathways 5:221–222
- gene transcription 3:532, 13:20
- gene transfer 1:210–211, 217, 230, 3:47, 9:252, 15:235  
  blastomere/embryo aggregation 1:212  
  DNA microinjection 1:212  
  electrofusion 1:212  
  embryonic stem (ES) cell transfer 1:212  
  methodology of 14:483–484  
  methods of 13:254–255, 14:480–484  
  naked nucleic acid 13:256–257  
  nonviral vectors 13:256–257  
  viral vectors 13:257–259
- nuclear transplantation 1:212
- primordial germ cells 1:219
- retroviral infection 1:212
- spermatogonial cell transfer 1:212
- spermatozoa-mediated transfer 1:212
- teratocarcinoma cell transfer 1:212
- gene transfer medicinal products  
  clinical use 13:267
- gene transfer methods 15:489  
  cloning 1:209  
  DNA microinjection 1:209  
  embryonic stem cell 1:209  
  methodologies 1:209  
  nuclear transfer 1:209  
  retrovirus-mediated transfer 1:209
- gene transfer systems  
  modern drug delivery 15:490

- gene trap 10:543, 14:260, 507  
 mutagenesis of 14:537–538
- gene tree 2:559
- gene validation 9:428–429
- gene vector 5:343, 15:236
- gene-finding algorithms 13:102
- gene-for-gene resistance 10:367, 376
- general cognitive ability  
 adoption studies 1:603  
 family studies 1:603  
 genes 1:604  
 heritability 1:603  
 twin studies 1:603
- general principles of microbial development 8:338
- general solvation equation 3:623, 632
- generalized epilepsy with febrile seizures plus (GEFS+) 11:679
- generalized transduction 13:438ff  
 lysogeny 13:438
- generation of hydroxyl radical 4:533
- generators of genetic variations 5:347
- gene-regulatory regions  
 conservation of 11:459
- genes 1:476, 586, 599, 2:76, 77–79, 5:354ff, 374, 6:182ff, 578, 9:172–174ff, 176ff, 12:110, 13:192, 14:6, 15:392  
 adjuvant 5:294  
 alternative gene splicing 9:176  
 APC, CDH13, RAR $\beta$ , FHIT, RASSF1A, TIMP3, p16, MGMT 5:364  
 aromatic hydrocarbon-inducible cytochrome P450I A I gene 5:355  
 aryl hydrocarbon hydroxylase gene product 5:355  
 attenuating 5:294  
 BAP1 5:364  
 chimeric 5:294  
 c-myc 5:356  
 coagulation related 5:237–238  
 copy number 9:171  
 DAPK 5:364  
 deleted p53 5:363  
 developmental control 6:182  
 developmental regulation of 10:351–352  
 EGFR 5:361  
 encoding an inhibitor 5:363  
 evolution of 11:452–462  
 flp genes 9:173  
 genetic events in SCLC and NSCLC may differ 5:355  
 genome 9:174ff  
 gpflp genes 9:173  
 homeotic 8:532  
 inactivation 5:362  
 inactivation of the p53 gene 5:364  
 missense mutations 5:363  
 mutations of p53 5:363  
 of the cyclins 5:364  
 overexpression of the p53 protein 5:363  
 p16 5:364  
 PTEN, hOGG1 5:364  
 recA 1:88  
 recessive 5:362  
 regulatory 8:532  
 retinoblastoma (Rb) 5:362  
 structural 8:532  
 tumor suppressor function of p53 5:363  
 tumor suppressor genes 5:362  
 v-erb B 5:361  
 wild-type p53 5:363
- genes as drugs 8:112
- Genescanner (Applied Biosystems) 6:557
- Genesis 5:349
- Genesis RSP 100, Tecan Inc 6:557
- genetic ablation 14:222
- genetic admixtures  
 genetic drift markers 13:210
- genetic algorithms 3:610, 5:314, 324–329, 10:207
- genetic background 1:216
- genetic capsid modification 15:346f  
 coupled with transcriptional targeting 15:351–352  
 with adaptor molecules 15:348–350  
 with incorporation of larger-sized targeting molecules 15:350
- genetic change 5:314, 329  
 dissemination in natural populations 5:247–249
- genetic code 11:45, 47–65, 14:581
- artificial RNA 2:453  
 deviations from 14:586  
 polyuridylic acid 2:453  
 reading frame 14:586  
 standard 14:586  
 triplet-binding experiment 2:453
- genetic computing  
 multiobjective fitness functions 8:199  
 premature convergence problem 8:199
- genetic distance 2:554ff
- genetic diversity 1:143, 2:559ff, 6:226, 7:341, 342
- genetic drift 2:560, 5:247–249, 6:324, 329  
 CEHs 13:210  
 haplotype analysis 6:330  
 mutation analysis 6:330–331

- genetic engineering 1:227, 235, 437, 2:631, 5:350, 10:658, 11:108
- genetic evolution 5:314
- genetic homology 1:597
- genetic improvement 7:354  
*A. nidulans* 5:19  
 breeding 5:18ff  
 fungal incompatibility 5:19  
 mutagenesis 5:18  
 parasexual cycle 5:18, 19  
 selective 5:18  
 transformation 5:19
- genetic information 10:21
- genetic instability 2:42, 6:3, 8, 14:152, 15:6ff
- genetic intelligence  
 evolution of 5:313–329  
 historical context of 5:316–318  
 intellectual context of 5:316–318
- genetic linkage 2:539–540, 10:584
- genetic loci 1:478, 15:560
- genetic male sterility 7:381
- genetic manipulation  
 prohibited by EmbryoschutzGesetz (EschG) 15:486
- genetic map 2:536, 539, 5:371, 404, 13:108f, 15:560  
 assembled, genome sequence map 13:108  
 genetic and functional studies 13:109  
 sequence polymorphism discovery 13:109
- genetic mapping 15:617ff
- genetic marker 5:244, 9:515  
 choice of 5:256–261  
 interpretation of 5:256–261
- genetic modification 1:437
- genetic noise  
 DNA damage 1:79, 80  
 mutation 1:79, 80
- genetic pedigrees 2:538
- genetic polymorphism 1:235, 2:58, 5:336, 8:450, 452  
 elucidation of 13:197
- genetic predisposition 1:461
- genetic profile, *see* genotype
- genetic programing 3:610
- genetic recombination  
 5:326, 13:192, 14:6–7
- genetic restrictions 15:164
- genetic screens 15:602
- genetic selection 5:442ff  
 Spi 5:442  
 supF 5:442
- genetic sequence 9:449, 12:111
- genetic stratification and population admixture 13:193
- genetic systems 8:252–256
- genetic toolkit 15:187
- genetic variation 1:593, 3:107, 480, 5:322, 334, 6:333, 605
- genetically identical 14:509
- genetically modified organisms 5:350  
 lateral gene transfer 6:225  
 transgenic crops 6:235
- genetics 1:184ff, 4:330, 5:314, 324  
 familial Alzheimer's disease 1:184  
 sporadic Alzheimer's disease 1:187
- gene-transfection systems  
 minimal infectivity and immunogenicity 15:489
- Geneva Protocol 10:511
- genital ridge 13:339
- genome 1:531, 537, 2:76–79, 3:3, 639, 7:560, 10:532ff, 11:434, 12:110, 13:440ff  
*Arabidopsis* genome 5:432  
 bread wheat 14:251  
 complexity 5:415  
 diploid 5:414  
 G + C 9:252, 254  
 G + C content 9:251  
 genome size 5:416  
 haploid 5:414  
 human genome 12:100  
 mammalian genome 5:430  
 mapping 5:414  
 plant genome 5:430  
 segmentation 9:251  
*Streptomyces* 13:440, 444  
 vertebrate genome 5:431
- genome annotation 12:709, 717ff, 718ff, 13:102  
 and analysis 13:100  
 compositional and structural dynamics 13:101f  
 heterogeneous distributions of DNA composition 13:101  
 sequence variations 13:104  
 SGS 13:104
- genome, bovine 7:344
- genome databases 5:562
- genome duplication 15:599
- genome evolution  
 gene duplications and deletions 13:107  
 insect genomes 13:105  
 transposons 11:219  
 vertebrate genomes 13:105
- genome human chromosome  
 physical mapping of 15:555–569
- genome instability 12:13



- genome maps 11:371ff
  - fingerprinting 11:371
  - ultracontigs 11:371
- genome markers
  - selection of 2:83
- genome organization 5:336
- genome physical mapping 3:419
- genome plasticity 14:257
- genome projects 10:531
- genome rearrangements 6:581
- genome scanning 5:415, 7:55
- genome segmentation 9:254
  - compositional heterogeneity 9:252
- genome sequence 10:531, 535
  - exon 14:254
  - gene 14:253
  - intron 14:254
- genome sequencing 2:544–546, 3:421, 643
  - BAC clones 15:621
  - ESTs 15:621
  - large genome, maize 13:109
  - large genomes 13:109
  - WG-SGS strategy for, animal genomes 13:109
  - whole-genome shotgun 15:621
- genome size 3:402, 11:441
- genome structure
  - genetic map 14:253ff
  - linkage groups 14:253
  - physical map 14:253
- genome working draft 13:82
- genome-sequencing project 6:571, 13:100
  - ESTs and cDNAs 13:107
  - NIAS 13:107
  - RIKEN 13:107
  - sequencing cDNA clones 13:107
- genome-wide microarrays 8:280
- genomic base distributions
  - profiles of 3:207
- genomic clone libraries 15:565–566
- genomic DNA 13:384
- genomic DNA libraries 3:386, 398ff, 13:90
- genomic features
  - covariation of 11:452
- genomic fluidity 5:510
- genomic gains 12:365–366
- genomic imprinting 5:470, 471, 10:72ff, 74ff, 79–81ff
  - imprinting 10:74
- genomic instability 5:498, 9:7f, 13f, 12:17f
- genomic libraries 5:443ff
  - amplified libraries 5:447
  - construction
    - classical 5:448
    - dephosphorylation 5:448
  - general 5:443
  - jumping 5:451ff
  - linking 5:451ff
  - percentage of recombinants 5:448
  - representativity 5:447ff
  - special 5:443
- genomic losses 12:365–366
- genomic mapping
  - concepts of 15:560–561
- genomic modifications 5:510
- genomic responses 5:491
- genomic restriction maps 15:561–565, 567
- genomic RNA 12:301
- genomic scale 5:505
- genomic sequence
  - human chromosome 9 13:207
- genomics 2:38, 4:331, 5:381, 515, 8:189ff, 190, 264, 266, 9:109, 517, 10:531, 12:101
  - gene–environment 4:234
- genomics, comparative 2:573
- genomics, transcriptomics 10:132
- genotype 1:600, 4:587, 5:247, 8:281, 12:112
- genotype–phenotype correlation 2:567
- Gen-Probe 6:559
- Genscan 5:532
- Geodia cydonium* 13:279ff
- geosmin 2:598
- germ cell 1:85, 5:556
- germ cell niches 13:339
- germ cell tumors 13:394
- germ layer
  - ectoderm, endoderm, and mesoderm 10:76, 78
  - primitive endoderm 10:75
  - trophectoderm 10:74, 75, 77
- germ line 1:77, 85
  - avoid DNA damage 1:83
  - avoid metabolism 1:83
  - cells, dividing 1:80
  - DNA damage 1:80
  - DNA repair 1:80
  - immortality 1:69
  - meiosis, periodic 1:69
- germ stem cells 13:339
- German Gene Technology Regulation 15:486
- germinal center 1:385, 386, 2:294, 13:410ff
  - centroblasts 1:384
  - centrocytes 1:384
- germline stem cell
  - Caenorhabditis Elegans* gonad 12:76
  - Drosophila* ovary 12:74
  - Drosophila* testis 12:73

- mammalian ovary 12:73
- mammalian testis 12:69
- germplasm theory
  - continuity of the germplasm 3:267
  - somatoplasma 3:267
- Gerstmann–Sträussler–Scheinker syndrome (GSS) 10:566, 584
- gestonorone capronate 13:45
- g-factor 4:118
- GFP, *see* Green Fluorescent Protein
- GFP-fusion protein
  - angiogenesis 12:236
  - biomonitoring 12:240
  - cell signaling 12:233
  - cell sorting 12:240
  - developmental analysis 12:240
  - future 12:241
  - gene expression 12:234
  - gene promoters 12:237
  - host-pathogen interactions 12:234
  - imaging cell dynamics 12:233
  - labeling of cells 12:239
  - marker 12:239
  - metastasis 12:236
  - ornamentals 12:241
  - stable transgenic lines 12:237
  - subcellular localization 12:233
  - transgenic 12:236
  - transient transgenic assay 12:237
- GGAs 1:624, 4:190
- GGG trinucleotide 5:75
- G<sub>i</sub> proteins 14:658
- gibberellic acid 1:420
- gibberellins 5:7ff
  - Gibberella fujikuroi* 5:7
  - regulation by 10:340–341
- gibbon 2:553ff
- Gibbs free energy change 8:167
- Gibbs sampling 9:259
- Giemsa bands 3:37
- GimC 2:497
- Gitelman syndrome 11:693
- GJB2 11:683
- glandular stem cells 13:345
- Glanzmann's thrombasthenia 2:332
- glass fiber 1:420
- GlcNAc- $\beta$ -Ser/Thr linkage 5:574
- Glc- $\beta$ -Ser linkage
  - thrombospondin 5:575
- gld 1:476
- Gleevec 2:174
- Gli (Ci) 12:179ff
- glial cell-line derived neurotrophic factor 15:265
- glial-derived neurotrophic factor (GDNF) 8:571
- gliding motility 8:307
- G $\gamma$ -like domain 13:155
- glimepiride 14:689
- glimmer 5:532
- global energy minimum 2:28
- global fitting 11:392
- global genomic repair (GGR) 1:56
- global LD measurement 13:203
- global models 3:615
- global parameters 11:390, 393
- $\beta$ -globin 5:270
- globin gene 6:92ff, 94ff, 95–97ff
  - ancestor globin 6:97
  - $\alpha$ -family gene 6:95, 96
  - $\beta$ -family gene 6:95, 96
  - location in chromosome 6:92
  - mosaic structure 6:94
  - order of expression 6:96
  - regulatory elements 6:95
  - see also* globin subunits
- Globin subunits
  - chaperone,  $\alpha$ -chain 6:96
  - distal histidine 6:75, 86
  - globin fold 6:71, 94
  - heme pocket 6:76
  - primary structures 6:71ff
  - proximal histidine 6:75, 84
  - types during development 6:93
  - see also* hemoglobin, and globin gene
- globose (light) basal cell 12:643
- glomerular filtration 10:221
- glomerular layer (GL) 12:648
- glomeruli 4:212
- glow-discharged 4:102
  - carbon-coated 4:96
- glow-discharging 4:92, 97, 99, 104, 105
- GLRA1 11:682
- GLRB 11:682
- glucagon-like peptide-1 14:681
- glucocerebrosidase 5:23, 24
- glucocerebrosidase gene (GBA) 5:24
- glucocerebroside 5:23, 24
- glucocorticoids 14:458
- glucokinase 7:98ff, 101
- gluconeogenesis 7:41, 101ff
- glucosamine 2:249, 14:49
- glucosamine sulfate or chondroitin sulfate 14:49, 50
- glucosaminoglycan 8:48, 53
- glucose 2:249, 4:681, 7:100, 11:122
  - analysis 2:253
  - oxidation 7:99

- glucose oxidase 2:254  
 glucose paradox 10:123  
 glucose 6-phosphatase 7:98ff  
 glucose tolerant 7:30  
 glucose-galactose malabsorption  
   SLC5A1 11:696  
 glucose-1-phosphate 7:101  
 glucose-6-phosphate 7:100, 10:292  
 glucose-6-phosphate dehydrogenase  
   3:663  
 glucose-stimulated insulin secretion (GSIS)  
   14:632  
 glucosidase 2:254  
 glucosidase I (GI) 5:579  
 glucosidase II (GII) 5:579  
 glucosuria 11:695  
 glucuronic acid 2:249  
 glucuronidase 2:254  
 glucuronyl transferases 2:53, 60, 61  
 GLUT1 8:146, 151ff, 156  
 GLUT4 8:151ff, 14:628, 674  
 GLUT5 8:156  
 glutamate 10:43  
 glutamate receptor 4:600, 9:149, 11:559, 560,  
   563, 577  
    $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole-  
   propionate (AMPA) 9:149ff  
 AMPA receptors  
   ABP 9:151  
   GluR1-4 9:151  
   GluR5-7, KA1, and KA2 9:151  
   GRIP 9:151  
   LIN-10/Mint1-3 9:151  
   MAGUK 9:151  
   PICK1 9:151  
   PSD-95 9:151  
   stargazin 9:151  
 AMPA silent synapses 9:150  
 kainate 9:149ff  
   PSD-3/chapsyn-110 9:151  
   PSD-95/MAGUK 9:151  
 metabotropic receptors 9:149ff  
   homer 9:151  
   shank 9:152  
 NMDA 9:149ff  
   CRIPT 9:150  
   GKAP 9:150  
   MAP1A 9:150  
   membrane-associated guanylate kinase  
   (MAGUK) 9:150  
   spectrin 9:150  
   splice variants 9:150  
 glutamic acid decarboxylase 15:265, 272  
 $\gamma$ -glutamyltranspeptidases 5:557, 563  
 glutathione 1:650, 4:639, 8:184, 11:121  
   depletion of 2:68  
   intracellular 4:426  
 glutathione peroxidases 4:639ff  
 glutathione reductase 4:639, 7:487  
 glutathione transferases 2:53, 66, 7:485  
 gluten-sensitive enteropathy 13:206  
 glycan 2:251, 278, 10:93  
   analysis 2:253  
   detection 2:266  
 glycation nonenzymic 7:104  
 glycemic index 7:28  
 glyceraldehyde, absolute configuration 2:584  
 glycerokinase (GK) 8:361  
 glycerol-3-phosphate acyltransferase (GPAT)  
   14:638  
 glycerol-3-phosphate dehydrogenase (GPDH)  
   14:636  
 glycerol-3-phosphate pathways 14:640  
 glycerophospholipid 8:144  
 glycine 1:429  
 glycine receptor 11:561, 564, 682  
 glycobiology 5:556  
 glycoceramidases 5:543  
 glycoconjugates 2:278  
   analytical method 2:247  
 glycogen 7:30, 101  
 glycogen synthase-3 $\beta$  2:229  
 glycogen synthase kinase-4 14:659  
 glycogen synthase kinase-3 $\beta$  (GSK3 $\beta$ ) 6:19,  
   12:170, 178, 181  
 glycogenolysis 7:41  
 glyco hormones 5:553ff  
   hCGs 5:554  
    $\alpha$ ,  $\beta$ -subunit 5:554  
 glycolaldehyde phosphate 10:13  
 glycolipid antigens 3:220  
 glycolipids 1:364, 2:253, 278, 13:311, 312  
   analytical method 2:247  
 glycolysis 7:98, 8:164, 171  
 glycolytic flux 7:102  
 glycomics 2:297, 11:122  
 glycopeptide 10:642ff  
 glycoprotein hormone family 4:388  
 glycoproteins 2:251, 278, 5:572, 14:3  
   analytical method 2:247  
   bacteria 5:596  
   cytomegalovirus 3:168  
   entry into the cell 5:596  
   glycans 2:252  
   human herpesvirus 6 (HHV-6) 5:597  
   human immunodeficiency virus (HIV)  
   5:597  
   malarial parasite 5:598

- MN blood group system 5:598  
*P. falciparum* 5:598  
*P. vivax* 5:598  
 parasites 5:596  
 techniques for detecting 9:106–108  
 viruses 5:596  
 glycorandomization 10:649ff  
 glycosaminoglycans 2:250, 278, 326ff, 5:543ff, 13:227, 233  
   chondroitin 4-sulfates 5:550  
   chondroitin 6-sulfates 5:550  
   dermatan sulfates 5:550  
   heparan sulfates 5:550  
   hyaluronic acids 5:550  
   keratan sulfates 5:550  
 glycosidases 4:207, 7:171  
 glycosidic bond 12:609, 615  
 glycosidic torsion 12:609  
   anti 12:611  
   syn 12:611  
 glycosome 13:609, 613, 618, 619, 622  
 glycosphingolipid storage diseases 5:592  
 glycosphingolipids 2:278, 3:309, 4:194, 5:549, 560  
 glycosylases 3:432ff  
 glycosylation 1:346, 2:297, 6:114, 8:26–28, 9:263, 10:386, 11:108  
   control of immune responses 5:590  
 glycosylphosphatidylinositol (GPI) 5:575, 10:301  
   acetylcholinesterase 5:576  
   anchored molecule 10:92  
   anchored protein 14:648  
   CD55 (also termed decay accelerating factor, (DAF) 5:576  
   lymphocyte function associated antigen-3, LFA-3 5:576  
   neural cell adhesion molecule, N-CAM 5:576  
   5'-nucleotidase 5:576  
   thymocyte antigen-1, Thy-1 (also identified as CD90) 5:576  
 glycosyltransferases 5:549, 572, 576  
   cloning 5:561  
 glyoxylate cycle 13:612–614, 619  
 glyoxysome 13:609, 619  
 glypiation GPI bridge 5:572  
 G-matrix Fourier Transform (GFT) 11:169  
 GM-CSF (granulocyte macrophage-colony-stimulating factor) 1:330, 389, 8:441–443, 446, 448, 453, 457, 13:136, 15:400, 418  
 GMP (good manufacturing practice) 10:386, 387, 13:264  
 goats 1:227  
 gold 11:119  
 gold nanoparticles 9:28  
 golden rice 10:657ff  
 Goldman–Hodgkin–Katz equation 8:369  
 Goldschmidt Richard 8:534  
 Golgi apparatus 4:188, 10:299, 13:314  
   body 2:513  
   cisternae 8:121, 122  
   stack 8:121, 125  
 gonad 5:608, 609  
 gonad differentiation  
   genetics of 5:607–633  
 gonadotrope 4:389ff  
 gonadotropin-releasing hormone (GnRH) 4:384ff, 12:692, 13:7  
 gonocyte 7:499  
 good clinical practice 15:169  
 good laboratory practice 7:548  
 Goodman 8:521ff  
 Goodman Morris 8:520  
 goodness-of-fit 1:597  
 goose bumps 13:231  
 goosocoid 13:296  
 Gossypol 13:55  
 Gossypolone 13:56  
 Gould 13:615, 629  
 gp120 11:122  
 GPC 11:577  
 GP120-CD4 interactions  
   inhibitors of 6:168  
 GPCR, *see* G protein-coupled receptors  
 Gp130 cytokine family 8:437  
 G6PD deficiency 3:664  
   in Africa 6:332  
   in Mediterranean 6:332  
 GPI lipids 14:648  
 gp80 or contact sites A (csA) 8:330  
 gp130 receptor-like subfamily 13:134  
 gp130-related receptors  
   IL-12 family of 13:134–135  
 G-protein coupled protein 8:99  
 G-protein (GTP-binding regulatory protein) 8:318, 327, 11:552, 565, 572, 575, 584, 14:108  
   disease 4:175, 177  
   heterotrimers 4:166  
   Ras.GDP 4:165  
 G-protein of vesicular stomatitis virus (VSV-G) 13:258  
 G-protein-coupled receptor kinase (GRK) 11:552, 575, 576, 577, 13:150ff

- G-protein-coupled receptors (GPCR) 3:303, 306, 4:332, 7:169, 8:86ff, 317, 326, 10:200, 11:554, 556, 565, 566, 568, 572, 574, 577, 589, 595, 598, 606, 610, 622, 647, 12:661, 14:686  
 G-protein-associated 11:611  
 modulating proteins 11:611  
 G-protein-coupled signaling receptors 4:191  
 G-protein-coupled vasopressin receptors  
 signal transduction of 3:307–309  
 G-protein-linked receptor family 4:389ff  
 G-quartet structure 4:595, 597, 15:34  
 gradient elution 6:246, 9:301  
 gradient gel analysis 5:254–255  
 grafting 1:451  
 graft-versus-host disease (GvHD) 1:474, 6:512  
 grain cultures 13:691  
 grain silage 13:691  
 gramicidins 2:589  
 gram-negative bacteria 13:471  
 Grams method for staining, bacteria 1:511  
 granddaughter design (QTL) study 7:357  
 granulation tissue 13:242  
 granule cell layer (GCL) 12:648  
 granules 14:46  
 granulocyte colony stimulating factor (G-CSF) 5:640, 10:219, 14:196  
 granulocyte-macrophage colony-stimulating factor (GM-CSF) 6:346, 441, 10:104, 13:262  
 granulocytes 1:363, 10:93  
 granulomas 15:413  
 granulosa cells 4:388ff  
 granzymes 1:496, 4:210, 6:354, 10:628  
 graph theory 14:136  
 Grassi, Battista 7:472  
 gratuitous inducer 12:24  
 Graves' disease 1:463  
 gravin 14:697  
 gray zone alleles 4:614  
 grazing angle spectroscopy 13:683  
 Grb7 6:7  
 great apes 2:553ff  
 green fluorescent protein (GFP) 2:523ff, 630, 3:7, 339, 4:334, 452–454, 485, 9:76ff, 10:398, 11:55, 12:217ff, 219–221ff, 223ff, 227–230ff, 14:261, 15:76  
*Aequorea victoria* 12:217  
 applications 12:227  
 beta-can 12:221  
 developmental 12:217  
 FLIP 12:230  
 FRAP 12:230  
 genetically modified GFP 12:223  
 GFP cDNA 12:219  
 natural homologs 12:223  
 ornamentals 12:217  
 photoactivatable fluorescent proteins 12:229  
 photobleaching 12:230  
 physical characteristics 12:220  
 protein-protein interaction 12:217  
 reporter 12:228  
 three-dimensional structure 12:220  
 transgene 12:217  
 G-rich overhang 14:229ff  
 grids  
 glow discharging grids 4:29  
 GRK, *see* G-protein-coupled receptor kinase  
 GroEL 1:35, 490, 2:494, 511ff, 13:488  
 GroEL–GroES 1:36  
 reaction cycle 1:37  
 GroES 2:494, 13:490  
 ground substance 13:227  
 group delay dispersion 15:68  
 group frequencies 4:652  
 group I introns 12:516, 517  
 group II introns 2:635  
 growth  
 exponential 7:540  
 malignant 7:550  
 three-dimensional 7:544  
 growth cone 2:114  
 growth curve 7:539ff  
 growth differentiation factor (GDF) 4:392ff  
 growth factor 5:214, 219, 232–233, 637–641, 8:437, 9:498, 11:552, 578  
 activin 7:504  
 angiogenesis 3:277  
 BMP 7:504  
 c-erb B-2 5:361  
 c-kit 7:503  
 cytotrophoblast cells 3:277  
 discovery of 5:642–645  
 E2F 3:276  
 EGF 7:546  
 epidermal growth factor receptor (EGFR) 5:361  
 families of 5:645–654  
 FGF 7:546  
 follistatin 7:504  
 G<sub>1</sub> checkpoint 3:277  
 GDNF 7:503  
 hematopoietic growth factors 3:277  
 hematopoietic inductive environments 3:277  
 IGF 7:546  
 inhibin 7:512  
 insulin-like 5:645–647

- insulin-like growth factor I (IGF-I) 3:277, 5:361  
 N-CAM 7:503  
 NGF 7:546  
 PDGF 7:503, 546  
 platelet-derived growth factor 3:277, 5:362  
 pro-TGF- $\alpha$  5:361  
 retinoblastoma protein 3:276  
 stem cell factor 7:503  
 TGF- $\beta$  5:361, 7:503  
 transforming growth factor 3:276  
 growth factor receptor 11:579  
 growth factor/cytokine receptor system 6:3  
 growth factors and autocrine–paracrine growth control 5:360ff  
   oncogene products related to 5:360  
   stimulation of SCLC cell growth 5:360  
 growth hormone 1:227, 14:680  
 growth hormone–releasing factor (GRF) 14:96  
 growth of bacterial cultures 1:528  
 growth of the flagellar filament 8:403–407  
 growth rates 1:529  
 growth regulator 1:417  
 growth with preferred attachment 14:137  
 Grp78 2:513  
 GrpE 1:35, 2:504  
   structure of 13:497–499  
 G<sub>s</sub> proteins 14:658  
 Gsc 6:207ff  
 GSK3 $\beta$  12:170, 178, 181  
 GTFs (general transcription factors) 10:315  
 GTG 3:29  
 GTG banding 3:24  
 GTPase factor-binding center 12:503  
 GTPase-activating protein (GAPs) 11:81, 13:154, 158  
 GTP-binding regulatory protein, *see* G-protein  
 guanidinium chloride 3:69  
 guanine nucleotide binding proteins  
   G-proteins 9:466–468  
 guanine nucleotide dissociation inhibitor 13:158  
 guanine nucleotide exchange factor (GEF) 8:542, 544  
 guanine-nucleotide-binding protein-coupled receptors (GPCR) 6:170  
 guanosine-5'-diphosphate, 3'-diphosphate 12:43  
 guanyl cyclases 4:122  
 guanylyl cyclase 8:86, 231, 329  
 guanylyl cyclase activating protein (GCAP) 12:669  
 Guard hypothesis 10:377  
 guided missiles 14:168  
 guidepost/stepping-stone cells 2:114  
 guinea pigs 15:143  
 guluronic acid 2:249  
 GUS 2:631, 14:261  
 gut epithelium 4:202  
 gynecological cancers 15:340  
 gynogenetic development 15:613
- h**
- H-2 1:474  
 H<sub>2</sub> 10:6  
 H<sup>+</sup> ATP synthase 7:169  
*H. pylori* 6:11, 14  
 HAART, *see* highly active antiretroviral therapy  
 haematopoietic 10:134  
*Haemophilus influenzae* 6:227  
 Hagelberg, Erika 8:526  
 hair follicle 13:345  
 hair sections 13:693  
 hairpin polyamides 2:15  
 hairpin ribozyme 9:327, 12:518, 519, 628  
 hairy cell leukemia (HCL) 6:513, 8:456, 15:416  
 hairy roots 10:661  
 half-life in the circulation 7:303ff  
 halorhodopsin 1:583  
 Halotestin 13:26  
 halothane 11:673  
 HAMA, *see* human antimouse antibody  
 hammerhead ribozyme 12:519  
 handcuffing 10:423  
 handedness 2:613  
 hand-foot-genital syndrome (HFGS) 15:49  
 hanging drop method for microscopic observations of unstained bacteria 1:510  
 Hansch 3:620  
*Hansenula polymorpha* 13:610, 611, 615  
 haploinsufficiency 11:657, 15:40ff  
 haplotypes 6:324, 326, 7:479  
 haptens 6:365  
   ivy 1:361  
   penicillins 1:361  
   poison 1:360  
 haptens for FISH 5:145  
 hardware and automation 13:598  
 Hardy–Weinberg equilibrium 1:587  
 Hardy–Weinberg rule 5:262  
 Harlequin approach 5:128  
 harnessing tobacco roots  
   secrete proteins 10:398–399  
 Harvard Institute of Proteomics 11:105  
 haustoria 10:372, 373, 376  
 HBV, *see* hepatitis B virus  
 HCC-specific codon 249 mutation 7:329  
 HCN 10:12

- HCR 12:63  
 HCV, *see* hepatitis C virus  
 HDAC, *see* histone deacetylase  
 HDL2 15:52ff  
 HDL (high-density lipoprotein) 4:212, 5:214, 222, 7:210, 213, 215–217, 226, 227, 231, 232, 237, 8:152  
 HDL-C assays 7:286–287  
 HD-ZIP 6:216ff  
 head and neck cancer 6:4  
 head and neck squamous cell carcinoma (HNSCC) 9:503  
 headache 10:119  
 hearing 11:683  
 hearing loss 11:662  
 heart 4:335, 13:355  
   bovine 7:99  
   porcine 7:104  
 heat shock 2:488, 13:466–476  
 heat shock elements (HSEs) 13:477  
 heat shock factor 13:464  
   activation of 13:479–481  
 heat shock promoters 13:466  
 heat shock protein effectors  
   action of 13:463–512  
 heat shock protein family 1:35  
 heat shock protein, *see* HSP  
 heat shock proteins, small 2:507, 511ff  
 heat shock regulon 13:466  
 heat shock response 8:535  
   chaperone effectors of 13:485–502  
 heat stress 1:392  
 heat-inducible components 13:503–506  
 heat-inducible genes 13:477  
 heavy-strand promoter (HSP) 15:372  
 hedgehog (Hh) 12:179ff  
 hedgehog proteins 11:242  
   groundhog 11:251  
   HINT domains 11:251  
   warthog 11:251  
 hedgehog signaling (HH) 4:293  
 HeLa 7:538, 541, 543, 546, 547  
 helicase 1:64  
 helicity 3:68  
*Helicobacter pylori* 6:8, 8:229  
   vaccine 15:160  
 3<sub>1</sub> helix 3:70  
 3<sub>10</sub>-helix 3:68  
 $\alpha$ -helix 3:59ff, 15:47, 395, 396, 397  
 helix–coil equilibrium 3:190  
 helix–coil transition 3:188, 190  
 helix-turn helix 3:533  
 helix-turn-helix (hth) motif 3:511, 6:185ff  
 helper CD4+ T cell (Th cells) 6:385  
 helper functions 15:247  
 helper phage 3:81, 83  
 hemangioblasts 15:203  
 hemarthrosis 15:258  
 hematological disease 15:257  
 hematopoiesis 3:117, 134, 8:441, 447, 12:163, 170, 13:365, 14:300, 15:217  
   cell–cell interactionsff pp. 15,16 2:442  
   definitive 2:444  
   definitive hematopoiesis 2:430, 440  
   embryonic  
     definitive 2:431  
     primitive 2:431  
   microenvironment 2:444  
   primitive hematopoiesisff pp. 2–17 2:430  
 hematopoietic cell 15:204, 212  
 hematopoietic cell lineage 13:342  
 hematopoietic factors 8:437  
 hematopoietic growth factors 5:651–654, 9:455, 14:297  
 hematopoietic stem cell 2:429, 444, 12:84, 167, 13:342, 15:268  
   properties 2:226  
 hematopoietin 3:116, 122, 5:642, 13:117, 123, 130, 15:393, 401  
 hematopoietin receptors (HR) 3:116, 122  
 heme 5:266, 268, 6:34, 35, 8:216, 218, 224–226, 228, 231, *see also* hemoglobin  
 heme enzyme 6:33–64, 8:214  
 heme oxygenase 6:35, 54  
   mechanism of 6:56–57  
   structure of 6:55–56  
 heme peroxidases 6:36  
 heme proteins 5:276  
 hemiacetal 7:103  
 hemianopia 10:116, 119  
 hemicellulase 1:433  
 hemichrome 6:77  
 hemidesmosomes 2:326ff  
   BP230-null mice 2:344  
   intermediate filament cytoskeleton 2:326  
   intermediate filaments 2:343  
   keratin filament cytoskeleton 2:343  
   plectin-null mice 2:344  
 hemifusion  
   bilayer fusion 11:70  
 hemihypaesthesia 10:119  
 hemiketal 7:103  
 hemin controlled repressor 12:63  
 hemiparesis 10:116, 119  
 hemizygous 5:379  
 hemochorial placentation 8:521  
 hemochromatosis in Europe 6:331  
 hemochrome 6:77

- hemodynamic 15:207
- hemoglobin 6:54, 7:170, 8:225, 231, 519, 523ff  
 assembly of globin monomers 6:86ff, 87ff  
 association-dissociation scheme 6:87  
 variations across species 6:87ff
- bisphosphoglycerate (or BPG) 6:79, 83
- C7 mutants 5:278
- components in erythrocyte  
 adult Hb or HbA 6:76  
 fetal Hb or HbF 6:76  
 glycated Hb 6:76
- concentration in erythrocyte 6:70
- constants 6:87
- dimensions 6:70
- distal residues of 5:272–277
- equilibrium with heme ligands 6:77–80ff, 84ff  
 Bohr effect 6:79, 84  
 Hill equation 6:79  
 Hill plot 6:78  
 O<sub>2</sub> affinity 6:78  
 $p_{1/2}$  6:79  
 values of binding parameters 6:80
- evolutionary considerations 5:286, 6:97–100ff  
 duplication events 6:98  
 evolutionary rates 6:99, 100  
 genealogical tree 6:99, 100  
 positions invariant in sequence 6:98
- expression systems of 5:270–272
- ferric derivatives 6:77
- ferrous derivatives 6:77
- genetic engineering of 5:265–288
- kinetic 6:87
- kinetics with ligands 6:80ff, 81ff  
 four-state scheme 6:80, 81  
 geminate process 6:80, 81  
 values of binding parameters 6:80
- KNF model 6:81, 82
- ligand-binding pathways 6:85ff
- molecular mass 6:70
- MWC model 6:81–82  
 four states 6:84  
 general features 6:83  
 two states 6:83
- N-terminal mutants 5:278–279
- O<sub>2</sub> affinity 6:79
- of animals  
 crocodiles 5:285–286  
 fish 5:284–285  
 geese 5:283–284
- optical absorption spectra 6:78
- oxyhemoglobin 4:122
- proximal histidine mutants 5:277–278
- S-nitrosyl hemoglobin 4:122
- structural changes, ligand-linked 6:84, 85
- subunit contacts 6:75, 76
- Trp37(C3) $\beta$  5:279–280
- truncated Hbs 6:70
- variants  
 databases 6:101  
 nature of mutants 6:101  
 selected list 6:102  
*see also* molecular disease  
*see also* globin subunits; allostery
- hemophilia 15:258, 273
- A 6:111
- B 6:111
- genetic counseling 6:130
- genetics 6:111
- gonadal mosaicism 6:130
- incidence 6:112
- missense mutation 6:129
- mutation at CpG sites 6:129
- treatment, gene therapy 6:131  
 clinical trial 6:132
- hemophilia A 6:112  
 gross gene deletions 6:118  
 inhibitors 6:129  
 inversions 6:118  
 large insertions 6:118  
 mutation 6:112, 117, 119ff
- hemophilia B 6:124  
 inhibitors 6:129  
 mutation 6:125, 127  
 mutation affecting 6:125f  
 mutation rate 6:112
- hemorrhage 5:214, 220
- hemostasis 13:239–241
- hemozoin 14:367
- heparan sulfate 5:559
- heparin 5:559
- heparin binding (HB)-EGF, PDGF, IGF II 6:16
- heparin binding-EGF (HBEGF) 5:648
- heparinase 5:559
- hepatic elimination 10:221
- hepatic lipase 7:205, 208
- hepatic nuclear factor 7:42
- hepatitis 2:571
- hepatitis B virus (HBV) 4:107, 108, 6:559
- hepatitis C vaccine 8:456, 15:160, 164, 418
- hepatitis C virus (HCV) 6:389, 555, 559, 7:327, 15:418
- hepatitis delta ribozyme 12:519
- hepatoblasts 7:325
- hepatocellular carcinoma (HCC) 7:324, 9:107, 11:110, 15:336
- hepatocyte cell lines 3:627



- hepatocyte growth factor (HGF) 5:651  
 hepatocyte growth factor/scatter factor (HGF/SF) 6:12  
 hepatocytes 7:101, 10:295, 15:268  
 hepatogenesis 7:325  
 HEPES 7:545  
 heptahelical receptors 13:143ff  
 herbicide resistance genes 14:548, 554  
 hereditary diffuse gastric cancer (HDGC) 6:13  
 hereditary hemorrhagic telangiectasia 15:208  
 hereditary non-polyposis colon carcinoma (HNPCC) 4:260, 6:21, 9:97  
 hereditary vascular anomalies 15:214  
 heritability 1:590, 596, 5:371, 380  
 heritable human prion diseases 10:583–586  
 HER-2/neu 9:458  
 herpes simplex virus type 1 (HSV-1) 1:397, 3:228, 15:249  
 herpes simplex viruses (HSV) 3:91, 4:107, 6:392, 555, 559, 15:248  
   DNA 4:94  
   vaccine 15:160  
 herpes viruses vaccine 15:164  
 herpes zoster 3:156  
 HERV 1:269, 283, 292ff, 296, *see also* endogenous retrovirus  
 hESCs  
   basic biology of early developmental events 13:395  
 heteroatom 7:150, 153  
 heterobifunctional cross-linking reagents 3:257  
 heterochromatic knob 14:258  
 heterochromatin 1:491, 3:2, 8, 574, 4:246, 5:527, 6:138ff, 12:48, 14:232ff, 260  
   satellite 5:190  
 heterocyclic aromatic amines (HAAs) 4:515  
 heterodimer 5:642  
 heterodisulfide 8:242  
 heteroduplex 4:91, 99, 9:311ff  
 heterogeneity 14:207  
 heterokaryons 13:363, 366, 370  
   binucleate 13:373  
 heterologous 14:507, 516  
 heterologous protein  
   *A. nidulans* 5:10  
   *A. niger* var. *awamori* 5:9  
   *Achlya bisexualis* 5:9  
   Aspartyl protease 5:9  
   aspergillopepsin A 5:11  
   *Aspergillus oryzae* 5:9  
   chymosin 5:9  
   expression of 3:339–340  
   glycosylation 5:10  
   GRAS status 5:10  
   interferon 5:9  
   *N. crassa* 5:10  
   proteases 5:11  
   regulatory approval 5:11  
   transformation 5:10  
 heterologous transposons 14:260ff  
 heterolysis 6:35  
 heteromeric complexes 6:186ff  
 heteromultimers 11:654  
 heteroplasmicity 2:637  
 heteroplasmy 5:258, 15:368, 374, 375  
 heterosis 5:256  
 heterotetrameric adaptor protein 1:623  
 heterotrimeric G protein 3:303, 306, 13:143ff  
   activation 13:151  
   G $\beta$  13:152  
   G $\gamma$  13:152  
   G<sub>12/13</sub> 13:152  
   G<sub>i/o</sub> 13:152  
   G<sub>q/11</sub> 13:152  
   G<sub>s</sub> 13:152  
   G<sub>t</sub> 13:154  
   structure 13:151  
 heterotropic ligands 6:79, 83, 84  
 heterotypic fusion 4:195  
 heterozygosity 5:248  
 heterozygote 5:247, 11:657  
 heterozygote advantage 6:324  
 [1-<sup>2</sup>H]-ethanol, enantiomers 2:608  
 heuristic reasoning  
   logic of 10:472  
 Hex 6:203  
 hexachlorinated biphenyls  
   metabolism of 2:56  
 Hexactinellida 13:273ff  
 hexahistidine tag 11:108  
 hexane 1:422  
 hexapeptide motif 6:187  
 hexokinase (HK) 2:254, 7:98ff, 8:361  
   porin 7:99  
 hexosamine 7:48  
 hexosamine flux 7:46  
 Hex1p 13:616  
 HEY ovarian cancer cells 13:403  
 HgA1C 7:35  
 HGF, *see* hematopoietic growth factor  
 HGF/SF 6:17  
 HGMD (Human Gene Mutation Database) 1:153  
 HGT  
   barriers 6:226, 234, 237  
   measurements of 6:226  
 HhaI 12:334

- hidden markov models (neural network)  
 6:575, 601, 9:253, 254, 260  
 sequence composition 13:103  
 signal to weight 13:103
- hierarchical cluster analysis 8:199
- hierarchical organization 14:133
- hierarchical synthesis scheme (HSS) 13:664
- HIF-1 (hypoxia-inducible-factor-1) 10:132, 135
- high blood pressure 11:690
- high cell density 8:338
- high density lipoprotein cholesterol 7:40
- high mobility group (HMG) 15:372
- high performance liquid chromatography (HPLC) 1:422, 6:246, 8:12f, 25, 32, 9:108, 298, 386  
 carbohydrates 2:256f  
 theoretical considerations 6:248
- high pressure freezing  
 the bare-grid method for particulate specimens 4:46
- high repetitive sequence content  
 genomes with 13:110
- high-affinity nerve growth factor (NGF) 12:646
- high-density lipoprotein, *see* HDL
- higher order autocorrelation functions 4:477
- highest current (1 A) 13:678
- high-frequency ESR 4:121ff
- high-frequency ESR spectroscopy 7:162
- highly active antiretroviral therapy (HAART) 6:156f, 608, 12:411
- highly optimized tolerance 14:130
- high-mannose type 5:548ff, 579
- high-melting domain 9:316
- high-molecular-weight (HMW) 3:389
- high-resolution autoradiography 4:102, 106
- high-resolution autoradiography (EM ARG) 4:90, 107
- high-throughput  
 drug testing 14:405
- high-throughput analysis 3:491, 12:104
- high-throughput genomics approaches 14:156–157
- high-throughput genotyping 7:180
- high-throughput protein production 2:460
- high-throughput screening (HTS) 3:600, 4:492f, 8:90, 94, 11:616, 622, 625
- hindbrain specification 2:99–103
- HindII 12:325
- hindsight (HNT) 4:292ff
- HINT domain 11:242
- hippocampus 11:251, 13:410ff
- hippuric acid 1:429
- HIS3 11:61
- Hispanic Americans  
 frequent HLA-Cw/B blocks 13:199
- his-tag 4:362
- histamine 14:48
- histamine H3  
 antagonists 10:208  
 receptor 10:208
- histidine kinases 8:297ff, 298, 310, 335, 337
- histidine operon 12:33
- histidine protein kinases 8:293, 308, 335
- histidine tag 11:348
- histocompatibility markers 13:337
- histogram matching 7:444
- histologies  
 non-SCLC 5:355  
 SCLC 5:355
- histone acetylase (HAT1, Hbo1) 12:193
- histone acetylation 4:248, 5:480, 15:14
- histone acetyltransferase (HAT) 3:470, 9:519
- histone deacetylase (HDAC) 9:519, 10:131, 12:156ff, 193ff, 14:268, 15:18
- histone deacetylase inhibitors (HDAC Is) 4:268, 15:14
- histone H3 14:237ff
- histone H4 6:11
- histone methylation 4:251, 5:480
- histone methyltransferase (HMT) 12:156
- histone modifications 10:131  
 ATP-dependent chromatin remodeling machines 2:419  
 fluid properties 2:420  
 heterochromatin proteins 2:419  
 histone acetylation 2:418
- histone phosphorylation 4:254
- histones 7:505, 12:101, 14:3, 255, 268, 15:13ff  
 biotinylation of 15:529–530
- HIV antigen 15:147
- HIV entry inhibitors 6:168
- HIV (human immunodeficiency virus) 1:377, 4:205, 6:389, 555, 559, 608, 8:454, 11:122, 12:411  
 drug therapy of 1:114–115  
 immune response to 1:112–114  
 life cycle of 1:103–108  
 molecular biology of 1:102–110  
 natural selection 6:329  
 origins of 1:100–102  
 virus structure of 1:102–103
- HIV protease 2:606, 8:98, 101, 13:549, 565, 577ff  
 flexibility 13:582  
 inhibitor complexes 13:579
- HIV reverse transcriptase 10:200ff
- HIV therapeutics 6:155–171

- HIV-1 genome 15:241  
 HIV-1 (human immunodeficiency virus 1)  
   1:391, 3:88, 90, 91, 93, 12:402, 404, 410,  
   13:258, 15:148  
 HIV-1 nucleocapsid protein 6:171  
 HIV-1 replication 15:418  
 HIV-1 RNA genome 15:140  
 HLA alleles  
   DNA methods 13:196  
 HLA blocks 13:198  
 HLA class IIDQ and DR alleles 6:15  
 HLA haplotypes  
   allelic variants 13:207  
   nonrandom association 13:207  
 HLA polymorphism 13:193  
 HLA restrictions 15:164  
 HLA segregation  
   specific parental haplotypes 13:207  
 HLA-A  
   allele-level typing of 13:209  
 HLA-Cw 13:211  
 HLA-Cw/B block 13:198  
   extension of 13:203  
 HLA-DM 1:385, 395  
   molecular chaperone 1:371  
   peptide editor 1:371  
   peptide loading 1:371  
   x-ray analysis 1:370  
 HLA-DO 1:385  
   CLIP removal 1:386  
   cochaperone 1:386  
   HLA-DM–HLA-DO complexes 1:386  
   lysosomal MIICs 1:386  
 HLA-DQB1 13:211  
 HLA-DR/DQ block  
   HLA-DPB1 13:203  
   HLA-DRB1, -DQB1 haplotypes 13:199  
 HLA-G 6:485–486  
 HL-60 cells  
   GM3 5:561  
   neolacto-series gangliosides 5:561  
 Hlx 6:203  
 H2-M 1:370  
 HM74 14:686  
 HMBC 13:531  
 HMG-CoA reductase 7:198, 217, 218  
 HMG-CoA synthase 7:198, 217, 218  
 HMLH1  
   cancer 1:82  
 hMLH1 6:11, 15, 21, 24  
 HMM 9:255, 256, 263  
 HMQC-NOESY 13:572  
 hMSH2 6:15, 21  
 HMW genomic DNA 3:408  
 [<sup>3</sup>H]NaBH<sub>4</sub> 5:540  
 HNF1 $\alpha$  6:185ff  
 HNF4- $\alpha$  7:220  
 HNF 6:207ff  
 HnRNA 12:24  
 H-NS 3:541  
 HO endonuclease 8:320  
 Hoechst 33:258 13:562, 565, 566, 569  
 HOKPP 11:673  
 hok/sok system 10:430  
 holism 14:125  
 holistic experiments 8:204  
 Holliday junction-RuvA complexes 9:309  
 Holliday junctions 3:545, 9:308ff  
   BLM 1:74  
   WRN 1:74  
 hollow fiber 7:547  
 holocentric 9:54, 60  
 holoenzyme 9:572, 583  
 holographic memories 9:560  
 holokinetic 9:54, 60  
 holoprosencephaly (HPE) 15:48ff  
 holorepressors 3:513  
 homeobox 6:181ff  
 homeobox gene 6:189ff, 14:267, 15:182, 187  
   sine oculis (SO) 6:189  
 homeodomain 2:100, 6:181ff, 186ff, 15:49ff  
   class 6:187  
   family 6:187  
   superclass 6:187  
 homeodomain protein 13:298  
 homeodomain-containing proteins 9:472  
 homeostasis 6:385, 399, 8:212, 448, 449, 531,  
   536ff, 11:597, 14:130, 132  
 homeotic gene 6:181ff, 190ff  
 homeotic selector 13:301  
 homeotic selector genes 13:273ff  
 homing endonucleases 11:242, 243, 247  
   intein homing 11:250  
   LAGLI-DAG 11:250  
 hominoids 2:553ff  
 homo sapiens 10:542, 548  
 homochiral 10:18  
 homocysteine 8:226  
 homodimer 5:642, 6:186ff  
 homodimeric ENase 12:327  
 homoduplex 9:311ff  
 homogeneous assays 4:493  
 homogeneous transformation matrix 12:619  
 homologous 3:117, 5:314  
 homologous chromosomes 1:77  
 homologous recombination 1:217, 219, 5:175,  
   297, 7:316, 12:3ff, 14:521  
   break-induced replication 12:7

- D-loop 12:7
- DNA ligase 12:11
- DNA repair 11:528
- double-strand break repair 12:5
- endonuclease 12:11
- gene conversion 12:4
- gene disruption by 3:340–341
- Holliday junctions 12:5
- insert foreign DNA 13:395
- insertion of reporter molecule 13:395
- nonreciprocal recombination 12:4
- Rad52 12:11
- reciprocal recombination 12:3
- RPA protein 12:11
- single-strand annealing 12:8
- steps in 11:529
- synthesis-dependent strand annealing 12:7
- transformation 12:5
- homologous recombination gene targeting 1:214
- homologous recombinational repair (HRR) 1:56, 73ff, 77
  - ATM 1:82
  - ATR 1:82
  - BRCA1 1:82
  - BRCA2 1:82
  - conjugation 1:69
  - FANCD2 1:82
  - HMLH1 1:82
  - p53 1:82
  - Rad51 1:82
  - self-fertilization 1:69
  - sexual reproduction 1:69
- homologous signal transduction pathways 3:271
- homologs 3:141, 14:3
- homology 11:213, 225, 227
  - analogs 11:218
  - ancestral sequence 11:210
  - common ancestor 11:211
  - common evolutionary ancestor 11:208
  - convergent evolution 11:208
  - evolutionary relationship 11:205, 210
  - families 11:205
  - fold 11:211
  - four-helical cytokine superfamily 11:205
  - homologous proteins 11:204
  - inference 11:211
  - modeling 11:134
  - nonorthologous displacement 11:218
  - phylogenetic profile 11:217
  - phylogenetic relationships 11:205
  - protein classification
    - families 11:208
    - superfamilies 11:205, 208, 211, 213
    - protein evolution 11:205
    - searching 5:532
    - sequence similarities 11:204ff, 210
    - structural similarity 11:205
    - superfamilies
    - xenologs 11:218, 220
- homolysis 6:35
- homothorax (hth) 6:214ff
- homotypic fusion 4:195
- homozygous 11:657, 14:509
- homozygous mutation 9:311
- homunculus 13:332
- hook 8:397
- hopping 12:331
  - intersegment transfer 3:538
- horizontal (dark) basal cell 12:643
- horizontal gene transfer 5:337, 343, 344, 6:225, 10:436, 11:218f
- horizontal spread 10:436
- horizontal transfer 10:412
- hormonal replacement therapy 3:318
- hormone 4:161, 5:638, 640, 8:436, 450, 13:8, 145ff
  - androgen 7:509
  - disease 4:174
  - estrogen 7:512
  - FSH 7:503
  - NT3 7:503
  - nuclear 7:107
  - receptors family 7:107
  - retinoic acid 7:503
  - testosterone 7:512
  - thyroid hormone 7:505, 513
- hormone binding domains (HBD) 1:448
  - conformation of 1:441–442
  - structure of 1:441–442
- hormone response elements (HREs) 15:510
- hormone-sensitive lipase (HSL) 1:5, 14:627ff
- horseradish peroxidase (HRP) 6:40, 8:214
- horsetail 14:232ff
  - homologous chromosomes 14:232
  - homologous recombination 14:232
- host immune response
  - antibodies 1:566
  - complement 1:566
  - evasion 1:566
  - serum resistance 1:566
- host–pathogen interactions 13:320
- host preference 7:485
- host range 15:241
- host resistance 10:373
- host systems 3:395ff

- host–vector system 2:41  
 hotspots 13:192, 208  
   hypothetical chromosomal regions 13:193  
 hot-start 11:487ff  
 housekeeping genes 11:516ff  
 HOX 10:542, 15:48  
 HOX cluster 6:181ff, 13:302  
 Hox family 2:228  
 Hox genes 6:181ff, 12:160, 15:188  
 HOX homeotic gene family 14:252ff  
 HoxA9 2:232  
 HP1 14:237  
   HP1<sup>H5α</sup> 1:492  
   HP1<sup>H5β</sup> 1:492  
   HP1<sup>H5γ</sup> 1:492  
 HPAEC  
   carbohydrate analysis 2:256, 257  
 hpg mouse 4:407  
 HPLC, *see* high performance liquid chromatography  
 hPot1 14:236  
 HPV, *see* human papillomavirus  
 HR genes  
   BRCA1 12:10  
   Rad54 12:10  
   Rad51 paralogs 12:10  
 hRap1 14:232ff  
 HSA 13:587  
   diffusinal brady 13:588  
 HSC  
   hierarchy of the hematopoietic system 2:227  
   targets for malignant transformation 2:232  
 HslO 2:510  
 HslU–HslV 13:508–509  
 Hsp10 2:494  
 Hsp15 13:506  
 Hsp33 2:510, 13:505–506  
 Hsp40 2:501  
 Hsp47 2:514ff  
 Hsp60 2:494  
 hsp60 6:14  
 Hsp70 1:35, 2:501ff, 511ff, 13:497–498  
 Hsp90 1:35, 2:172, 180, 504, 511, 13:503–504  
   regulation of 2:180–182  
   structure of 13:497–499  
 Hsp100 1:35  
 Hsp104 2:502  
 HSP (heat shock protein) 1:390, 393, 394, 620, 6:14, 8:450, 531, 535ff, 10:92, 15:10ff  
   stress-induced expression of 13:463–512  
 Hsp70 system 13:492–500  
 HSQC 13:518, 525, 526, 530, 555, 583, 587, 589, 598  
   chemical-shift mapping 13:561  
 HSR 3:46  
 hst-1 and int-2 genes 6:5  
 HSV, *see* herpes simplex virus  
 HSV-TK 15:266  
 [<sup>3</sup>H]thymidine 13:412ff  
 HTLV 8:454  
 HtrA proteases 13:509  
 HtrA2/Omi 10:623, 625  
 5HT<sub>3</sub> receptor 11:564  
 hTRF1 14:231ff  
 hTRF2 14:231ff  
 HTS, *see* high-throughput screening  
 HU 3:541  
 Hugh and Leifson's method 1:519  
 HuIFN-α<sub>2</sub> 15:393  
 HuIFN-γ 15:401  
 HuIFN-β 15:401  
 HuIFN-α subtypes 15:401  
 human f  
   porin 31HL 8:372f  
   VDAC1/porin1 8:372f  
 human annulus  
   modeling of 14:400  
 human antichimeric antibody (HACA) 1:337  
 human antimouse antibody (HAMA) 1:335, 10:224  
 human bacterial diseases  
   anthrax 6:304  
   cholera 6:304  
   enterotoxigenic *Escherichia coli* 6:305  
   plague 6:306  
   shigellosis 6:306  
   tuberculosis 6:307  
   tularemia 6:309  
   typhoid fever 6:308  
   whooping cough 6:309  
 human blastocysts 13:387  
 human blood group  
   A 2:282  
   B 2:282  
   dextrans 2:283  
   diheteroglycans 2:283  
   H 2:282  
   triheteroglycans 2:283  
 human blood plasma 7:166  
 human cancer gene 7:118  
 human–chimpanzee comparison  
   biomedical differences 2:570ff  
   cytogenetic differences 2:561  
   DNA sequence differences 2:575  
   ethical considerations 2:572

- human rights 2:572ff
- infectious diseases 2:571
- qualitative difference 2:572
- human conception fail
  - natural meiosis-based 1:86
  - spontaneous and induced abortions 1:86
- human diseases
  - genetic defects in 12:690
  - smell dysfunction in 12:690–695
- human EGF 5:643
- human embryonic stem cells (hESC) 13:401, 403
- human factor IX (hFIX) 15:292
- human gene therapy 12:410
- human genetic disease 6:323–333
- human genetic diversity 13:193
- human genetic information 14:6
- human genetic variation 6:323–325, 329–333
  - mutation 6:326–328
  - natural selection
    - heterozygote advantage 6:328–329
    - sickle cell disease 6:328–329
- human genome 4:331, 6:572, 10:548, 11:596, 13:194
  - body expression map of 2:75–83
  - body-map data 2:79
  - computational methods of 2:80–82
  - MHC loci 13:207
  - overview of 2:77–79
- human genome project (HGP) 2:77, 8:266, 13:77
  - BAC (bacterium artificial chromosome)-based STS (sequence-tagged site) 13:75, 78
  - cosmids 13:78
  - gene transfer vehicles 15:491
  - genome-scale physical mapping effort 13:78
  - large-insert clones 13:78
  - minimal tiling path (MTP) 13:75
  - physical mapping 13:75
  - YAC (yeast artificial chromosome)-based 13:75
- human growth hormone 10:586
- human HepG2 cell 13:695
- human (Hu) prions 10:563
- human identity 3:492
- human immunodeficiency virus, *see* HIV
- human immunodeficiency virus/acquired immunodeficiency syndrome 15:136, *see also* HIV
- human IVF 6:540
- human leukocyte antigen (HLA) 6:516
- human lung fibroblast cells 13:695
- human MHC CEHs 13:192
- human monoclonal antibodies
  - in mice 1:337–338
- human motor neuron diseases 8:542–543
- human papillomavirus (HPV) 3:228, 6:555, 559, 12:185
- human pathologies 8:134
- human plasma 2:37
- human PrP gene polymorphisms 10:585–586
- human serum albumin, *see* HSA
- human studies 5:358
- human telomerase reverse transcriptase (hTERT) 2:201
- human telomerase RNA 9:322
- human therapeutics 7:305ff
- human transcriptome map (HTM) 5:79
- human trials 15:142
- humanized antibodies 1:337
- humidity control
  - crystal quality improvement 7:412
  - free mounting system
    - cryo-loop 7:413
    - humidifier unit 7:413
    - patch-clamp pipette 7:413
- humoral effector mechanisms 6:422–427
- humoral immunity 1:461, 10:86, 12:309–310
- huntingtin 15:12
- Huntington 4:332
- Huntington's disease (HD) 7:607, 10:260, 12:693, 15:6ff
  - inherited prion diseases 15:262
  - like 2ff 15:52
- husbandry 1:222
- hyaloid vessels 15:207
- Hyalonema sieboldi* 13:291
- hyaluronidase 2:254
- hybrid 9:334, 335
- hybrid cell lines
  - radiation hybrids 5:456
- hybrid organelle 4:206
- hybrid proteasome 11:3, 5, 19
- hybrid selection 3:45
- hybrid simulation 14:141
- hybrid state 12:505
- hybrid state model 12:504
- hybrid type 5:548ff, 579
- hybrid vigor 1:84
- hybridization 3:574, 6:226, 7:346, 478, 8:500, 9:334, 10:534, 14:255, 422, 426
  - hybrid-bridge 6:231, 234
- hybridization assays 2:527
- hybridization probes 11:498
- hybridized DNA 14:431
- hybridoma 1:331, 334, 472, 3:76, 77, 11:105
- hydration 13:237–238

- hydrazinolysis 5:540  
 hydrazone 11:64  
 hydrocarbons 10:9  
 hydrocephalus 9:120  
 hydrocephaly 12:163  
 hydrocephaly with hop gait 8:135  
 hydrodynamic stress 1:434  
 hydrogel 11:108, 14:386, 392  
 hydrogen 10:5  
 hydrogen bond 1:579, 4:504, 506, 10:204,  
 12:612, 615, 625, 626  
 hydrogen bonding 2:6ff, 9, 3:533, 13:524, 571,  
 573, 581  
 hydrogen bonding interactions 3:535  
 hydrogen out-of-plane 1:579, 581  
 hydrogen peroxide 5:494, 505, 8:210ff, 211,  
 217ff, 220, 221, 227, 231  
 hydrogen sulfide production, detection of  
 1:518  
 $\alpha/\beta$ -hydrolase 14:645  
 hydrolases 1:619  
 hydrolyze 10:18  
 hydronephrosis 3:312  
 hydrophobic effect 2:6ff, 10, 3:535  
 hydrophobic interaction chromatography (HIC)  
 6:248, 9:323  
     basic principles 6:260  
     mobile phase 6:262  
     stationary phase 6:261  
 hydrophobic interactions 1:29, 4:504, 509,  
 10:294  
 hydrops 9:232  
 hydrotalcite 10:11  
 hydrothermal 10:16  
 hydrothermal systems 10:7, 9  
 hydroxo complexes 1:643  
 $\alpha$ -hydroxy acid 11:55  
 hydroxy fatty acids 7:259  
 17 $\beta$ -hydroxyandrost-1,4-dien-3-one 13:34  
 17 $\beta$ -hydroxy-5 $\beta$ -androst-3-one 13:25  
 3 $\beta$ -hydroxy-5 $\alpha$ -androst-17-one 13:11  
 19-hydroxyandrostenedione 13:15  
 4-hydroxy-androstenedione 13:53, 55  
 hydroxyapatite (HTP) 8:361  
 6-hydroxydopa quinone 8:219  
 6-hydroxydopamine 4:643  
 17 $\beta$ -hydroxyestr-4-en-3-one 13:33  
 8-hydroxyguanine 4:638ff  
 hydroxyl radical 3:543, 4:522, 635ff, 5:494  
 hydroxylamine oxidoreductase (HAO) 6:63–64  
 hydroxylapatite 10:11, 19  
 17 $\alpha$ -hydroxylase 13:9  
 hydroxylated products  
     benzo(a)pyrene 3:107  
      $\beta$ -hydroxylation 6:116  
     hydroxylation 1:425, 6:56  
     17 $\beta$ -hydroxy-17 $\alpha$ -methylandrostan[3,2-c]  
         pyrazole 13:39  
     2-hydroxymethylene-17 $\alpha$ -methyl-5 $\alpha$ -androst-  
         17 $\beta$ -ol-3-one 13:37  
     17 $\beta$ -hydroxy-17 $\alpha$ -methyl-2-oxa-5 $\alpha$ -androst-  
         3-one 13:37  
     11 $\beta$ -hydroxy-17 $\alpha$ -methyltestosterone 13:36  
     4-hydroxy-17 $\alpha$ -methyltestosterone 13:36  
     17 $\alpha$ -hydroxypregnenolone 13:8  
     17 $\alpha$ -hydroxyprogesterone 13:8  
     3 $\beta$ -hydroxysteroid 13:10  
     17 $\beta$ -hydroxysteroid dehydrogenase 13:10  
     3 $\beta$ -hydroxysteroid dehydrogenase 13:56  
     11 $\beta$ -hydroxytestosterone 13:11  
     hyperactivity 4:590  
     hyperalgesia 10:30, 33  
     hyerammonemia 15:267  
     hyperbolic function 10:417  
     hyper-branched rolling circle amplification  
         7:189  
     hypercalcemia 3:314  
     hypercholesterolemia 4:212  
     hypereplexia 11:682  
     hyperexcitability 11:672  
     hyperextensible joints 4:590  
     hyperfine splitting 4:119, 7:172  
     hyperglycemia  
         glycemic control 7:27  
         microvascular complications 7:45  
     hyperinsulinemia 14:635ff  
     hyperinsulinism in infancy (HI) 11:698  
     hyperkalemic periodic paralysis (HYPP)  
         11:672  
     hyperlipidemia 14:625  
     hyper-metabolic state 11:673  
     hypermethylation 2:206, 6:11  
     hyperoxaluria type I 13:628  
     hyperplasia 12:351  
     hyperpolarization 11:646  
     hypersensitive response (HR) 10:375  
     hypersensitive sites 12:47  
     hypersensitivity reaction  
         delayed type 6:351–352  
     hypertension 4:338, 10:201, 11:694  
     hypertriglyceridemia 5:225, 7:201, 14:630ff,  
         635ff  
     hypocholesterolemia, autosomal recessive  
         (ARH) 4:212  
     hypodermis 13:227  
     hypogonadism 13:22  
     hypokalemia 3:314

- hypokalemic periodic paralysis (HOKPP) 11:672
- hypolipidemic effect 13:32
- hypomagnesemia  
autosomal recessive 11:694  
TRPM6 11:694
- hypomethylation 2:206
- hypothalamic-pituitary-ovarian-uterine axis 4:383
- hypothalamus 12:416, 433, 14:48, 638
- hypothesis  
calming signals 1:393  
endogenous mediators 1:393  
Hsps 1:393
- hypovolemia 11:690
- hypoxia 6:23, 8:446, 14:301, 15:213
- hypoxia response element 15:11
- hypoxia-inducible factor-1 $\alpha$ , (HIF1 $\alpha$ ) 15:264
- HYPP alleles 11:672
- hysteresis 10:229
- i**
- <sup>123</sup>I and <sup>125</sup>I labeled compounds 1:454–455
- I $\kappa$ B 14:438, 441–443, 447
- IBD (identical-by-descent) fragments  
CIS (cloning of identical sequences) 5:460  
GMS (genomic mismatch scanning) 5:460
- ibuprofen 2:601, 14:49
- ICAM-2 1:372, 373, 391
- ICAM-3 1:372, 375, 391
- ICAM-1 (intracellular adhesion molecule) 1:372–375, 391, 2:333, 10:124, 125, 15:410
- ICAT, *see* isotope coded affinity tag
- ICCR, *see* ion channel-coupled receptors
- I-cell disease 1:622  
mucopolidosis II, ML-II 5:582
- ICH E4 10:215
- ICM (inner cell mass) 10:75, 77f, 13:335  
cultured ESC 13:386  
embryo proper 13:384  
embryonic stem cells (ESCs) 13:383, 385  
harvested from 13:385  
pluripotency in culture 13:386
- ICM-derived pluripotent ESC line  
germ cells and embryoid body 13:395
- ICOS 1:373
- ICUMSA 2:249
- IC<sub>50</sub> value 11:621
- IDAT 8:507
- iDEA 3:606
- ideal solution 4:468
- idebenone 15:39
- identity element 11:46, 51
- idiopathic disease 1:476
- idiopathic epilepsy 11:677
- IDL (intermediate density lipoprotein) 5:215, 224, 7:210, 226, 229
- iduronic acid 2:249
- IEMA 6:369, 374
- IFMA 6:369
- IFN- $\alpha_2$  15:415
- IFN- $\delta$  15:395
- IFN- $\epsilon$  15:391, 395
- IFN- $\kappa$  15:391, 396, 400, 412
- IFN- $\lambda_1$  15:392, 397, 401–404
- IFN- $\lambda_2$  15:392, 397, 401–404
- IFN- $\lambda_3$  15:392
- IFN- $\omega$  15:391, 395, 396, 400, 401, 412, 414
- IFN- $\tau$  15:395, 400, 412  
ovine trophoblastic protein-1 (OTP-1) 15:396  
Ruminantia suborder Artiodactyla 15:396
- IFN gene regulatory elements (IREs) 15:399
- IFN- $\alpha$  (interferon- $\alpha$ ) 1:389, 8:435, 437, 453, 456, 10:221, 15:392, 395–399, 401, 412–414, 416–418  
 $\alpha$ -helical 15:393  
structure 15:393  
subtypes 15:390, 391, 393
- IFN- $\beta$  (interferon- $\beta$ ) 1:389, 5:557, 6:13, 8:456, 15:265, 391, 393, 396f, 400, 401, 412, 414, 416, 418
- IFN- $\gamma$  (interferon- $\gamma$ ) 1:378, 379, 477, 5:231f, 6:17, 8:441, 445, 446, 451, 453, 10:102, 221, 15:390, 391, 396, 397, 400, 404, 412–414, 416, 417
- IFN (interferon) 8:433f, 13:115ff, 138, 14:453, 15:389f, 399, 405, 411, 415, *see also* interferon
- IFN producer cells (IPC) 15:398
- IFN protein 15:393
- IFN- $\gamma$  receptor 5:307
- IFN- $\lambda$  receptor 13:132
- IFN receptor family 13:130
- IFN receptors  
accessory factor (AF) 15:401  
IFN binding proteins 15:401  
type II cytokine receptor family (CRF2) 15:401
- IFNA 15:392, 400, 405
- IFNA genes 15:399, 414
- IFNB 15:405
- IFNB genes 15:392, 399, 400
- IFNE1 15:392
- IFNG 15:400
- IFNG gene 15:392
- IFN-inducible genes 15:404
- IFN-inducible proteins 15:404, 405
- IFNK gene 15:392, 400



- IFN- $\alpha_2, \dots, \alpha_n$  15:412  
 IFN-response gene sequences 15:404  
 IFNs and pathogenesis 15:412  
 IFNs and pathophysiological phenomena 15:412  
 IFN-stimulated genes (ISGs) 13:120  
 IFN-stimulated response element (ISRE) 13:117, 120, 15:404  
 IFNT gene 15:392  
 IFNW 15:405  
 IFNW gene 15:392, 400  
 Ig superfamily molecules 2:116–117  
 IgA 8:229  
 IgA deficiency 13:203  
 IGF-1 10:219  
 IGF-2 6:21  
 IGF, *see* insulin-like growth factor  
 IGFBP, *see* insulin-like growth factor binding protein  
 IGFBP proteases 4:399  
 IGFBP-related proteins (IGFBPrP) 4:399  
 IGF/INS pathway 5:474, 476  
 IGF-receptor 4:399ff  
 IgG 5:556  
 Ig-like transcript (ILT)-3 1:390  
 IHF 3:541  
 IKK 14:438, 448, 451, 452, 456  
 IKK $\beta$  inhibitors 14:458  
 I<sub>Kr</sub> potassium channels 11:667  
 I<sub>Ks</sub> 11:663  
 IL, *see* interleukin  
 IL-1 $\alpha$ , *see* interleukin-1 $\alpha$   
 IL-1 $\beta$ , *see* interleukin-1 $\beta$   
 IL-1, *see* interleukin-1  
 IL-2, *see* interleukin-2  
 IL-4, *see* interleukin-4  
 IL-6, *see* interleukin-6  
 IL-8, *see* interleukin-8  
 IL-10, *see* interleukin-10  
 IL-12, *see* interleukin-12  
 illicit anabolic use 13:33  
 illite 10:11  
 IMAC, *see* immobilized metal affinity chromatography  
 image analysis 5:156  
   cooled charged-couple device (CCD) cameras 5:157  
 IMAGE Consortium 11:105  
 image correlation spectroscopy (ICS) 4:475  
 image reconstruction  
   crystalline arrays 4:110  
   protein filaments 4:110  
 imaging  
   ESR 4:122  
   imaging probe (IP) 9:112  
   IME1 8:315  
   imidazole 10:21  
   immature spines 4:606  
   immediate early functions 15:250  
   immediate hypersensitivity 8:443  
   immobilization 1:420, 11:104  
   immobilized cells 10:661  
   immobilized lectin columns 5:545  
   immobilized metal affinity chromatography (IMAC) 8:27f  
   immobilized-biomembrane affinity chromatography 8:157  
   immobilized-biomembrane chromatography 8:148ff  
   immobilized-liposome chromatography 8:148ff  
 immortal 1:77  
   attrition due to DNA damage 1:84  
   mutation 1:84  
 immortality  
   germ line 1:69  
   immortality 1:69  
   meiosis, periodic 1:69  
 immune defence, cell mediated 6:339–356  
 immune escape mechanisms 1:380  
 immune exclusion 8:606  
 immune rejection of stem cells 13:355  
 immune response 6:396, 518, 7:299ff, 15:125, 137, 142, 164  
   antibodies 1:556, 567  
   antigenic variation 1:567  
   anti-polysaccharide 2:293  
   complement 1:556, 567  
   complexity of anticarbohydrate responses 2:294  
   delayed maturation of anticarbohydrate responses 2:295  
   evasion 1:555  
   molecular mimicry 1:567  
   phagocytosis 1:556  
   silencing of 6:354–355  
 immune synapse 2:333  
 immune system 1:460, 14:47, 440, 454  
   essential components of 6:407–410  
   functions of 6:407–410  
   innate 10:86, 88  
 immune therapy 2:235  
 immune-enhancement 15:164  
 immune-mediated disease 15:164  
 immune-mediated neuropathology 15:164  
 immune-response genes 7:488  
 immunity 3:221, 6:385, 399, 13:285, 15:412  
 immunization, *see* vaccination

- immunoadhesins 1:345  
 immunoaffinity purification 8:10  
 immunoassays 2:527ff, 528, 10:216, 225  
 immunoblotting 1:483, 3:49  
 immunoconjugates 14:164, 170  
 immunocytochemistry 8:124  
 immunodeficiency centromeric instability and facial anomalies 4:243  
 immunodeficient SCID/beige mouse 13:402  
 immunodominant 1:338  
 immunoelectron microscopy 4:90, 108  
 immunofluorescence 4:423, 10:426  
 immunofluorescence assay 7:175  
 immunogenicity 10:224, 12:314, 15:117  
 immunoglobulin (antibody) synthesis 15:410  
 immunoglobulin (Ig) 1:331, 6:363, 385, 398, 8:443  
   dimeric IgA (dIgA) 4:202  
   IgA 1:384, 4:202  
   IgE 1:384  
   IgG 1:384, 4:202, 5:555, 6:363, 449  
   IgM 1:384, 4:202  
 immunogold labeling 4:105  
   accessibility problem 4:44  
   colloidal gold 4:42  
   nanogold 4:45  
   preembedding labeling 4:43, 44  
 immunohistochemical approaches  
   cytochemistry 4:45  
   horseradish peroxidase 4:45  
 immunohistochemistry 8:506  
 immunoligands 1:344  
 immunoliposomes  
   target-specific monoclonal antibodies 15:494  
 immunologic memory 6:383–399  
 immunological distance 8:520  
 immunological memory 10:87, 95  
 immunological sensors 3:218  
 immunological synapse 1:384  
   central supramolecular activation cluster (c-SMAC) 1:374  
   peripheral supramolecular activation cluster (p-SMAC) 1:374  
 immunological tolerance 10:126  
 immunology 6:405–427  
 immuno-PCR 6:450, 455  
   antibody 6:448  
   antigen 6:448  
   antigen–antibody complex 6:448  
   applications 6:461  
   cell surface immuno-PCR 6:458  
   clinical diagnostics 6:461  
   gel electrophoresis 6:459  
   in situ immuno-PCR 6:458  
   mass spectrometry 6:460  
   microtiter plate 6:452  
   molecular linker 6:448  
   paramagnetic microbeads 6:458  
   PCR 6:452  
   PCR products 6:452  
   perspectives 6:461  
   preconjugation 6:456  
   primers 6:448  
   sandwich assay 6:454  
 immunophilin 4:343  
 immunoproteasome 1:368, 394, 399, 11:3, 6–7  
 immunoreceptor tyrosine-based activation motifs (ITAMs) 1:381  
 immunoregulatory activity  
   MHC antigens 15:409  
 immunosuppressant drugs 14:376  
   Cyclosporin 14:374  
   Mycophenolate Mofetil 14:375  
   mycophenolic acid 14:375  
   Sirolimus 14:374  
   Tacrolimus 14:374  
 immunosuppressants 13:571  
 immunosuppression 3:377  
 immunosuppressive agents 1:247  
 immunotherapy 6:444, 14:167, 15:266  
   active 6:441–443  
   passive 6:439–441  
 immunotoxin activity  
   display technologies for improvement of 6:514–517  
 immunotoxin therapy 6:499  
 immunotoxins 6:497–501, 504–520  
   first-generation of 6:502–503  
   second-generation of 6:502–503  
 impact 10:8  
 implantation  
   compact zonula thinning, blastocyst released 13:384  
 implanted embryo 13:385  
 imprint 5:471f  
 imprinted genes 5:476  
 imprinting 4:265, 14:3  
 imprinting-control region 5:470, 478, 479, 480, 481  
 improvement of a biological function 5:344  
 improves DNA as therapeutic agent 15:488  
 in analysis  
   enzymes 2:253  
 in miniature swine 1:230  
 inactivated vaccine 6:298, 300, 301  
 inactivated virus 15:144

- inactivation  
   bacterial ghost 6:301  
   ghost 6:301  
   inactivated vaccine 6:302  
   killed vaccine 6:302  
   live attenuated vaccine 6:302  
   live vaccine 6:301, 302  
   subunit vaccine 6:301  
   whole-cell vaccine 6:301  
 “inactive” nonexcitable conformation 11:672  
 “inactive” nonexcitable state 11:662  
 inbred strain 14:507, 524  
 inbreeding 1:79, 80, 86, 597, 7:338  
   avoided 1:88, 89  
 inbreeding, avoidance  
   bird 1:90  
   major histocompatibility complex (MHC)  
     1:90  
   mouse 1:90  
   primate 1:90  
   smell 1:90  
 inbreeding depression  
   deleterious recessive mutations 1:84  
 include SP 14:43  
 inclusion 3:493, 15:14ff  
 inclusion bodies 1:24, 11:182  
   characteristics 1:41  
   formation 1:40  
   occurrence 1:40  
 inclusion body proteins  
   strategies for refolding 1:43  
 incompatibility 4:358, 10:412, 434  
   cross-incompatibility 12:279  
   interspecific 12:279  
   intraspecific 12:279  
   self-incompatibility  
     heteromorphic SI  
       gametophytic SI 12:279  
       sporophytic SI 12:279  
     S-gene (STERILITY) 12:279  
 incompletely inactivating 11:672  
 indels 12:129  
   polymorphic 12:131  
 independent assortment 5:372, 403  
 independent variables 11:383, 387  
 index cases 1:592  
 indirect link PK/PD models 10:229  
 indirect readout 3:508  
 indirect recognition 10:184–185  
 indirect-link 10:228  
 indirect-response models 10:228  
 indirect-response PK/PD models 10:230  
 indium 14:111  
 individual coenzymes 9:573–587  
 individual DNA molecules  
   as construction material 9:282–283  
   as electric wires 9:282–283  
 individual molecules  
   DNA 9:282–288  
   RNA 9:282–288  
 individual nanoscaled particle assemblies  
   9:32–33  
 individual organism  
   fixation of genetic change in 5:315  
 individuality 13:285  
 indole 3 acetic acid–glycine 1:429  
 indole 3 acetic acid–phenylalanine 1:429  
 indole test 1:517  
 indoleamine 2,3-dioxygenase (IDO) 6:466,  
   481, 15:409  
   effects on immune cells 6:482  
   implications for therapy 6:482–483  
   sources of 6:482  
 indolethylamine *N*-methyltransferase 2:65  
 INDs (investigative new drug applications)  
   11:633  
 induced fit model 11:603  
 induced mutations 12:120–121  
 induced resistance 10:375, 376  
 induced systemic resistance (ISR) 10:375  
 inducers 12:25, 13:466  
 inducible defenses 6:408–410  
 inducible ectopic expression  
   chemical induction 14:265  
   heat shock 14:265  
 inducible mutator systems 5:319  
 inducible nitric oxide synthase (iNOS) 4:639,  
   6:14, 10:126, 15:411  
 inducible promoters 7:315  
 induction 3:266, 7:574, 12:25  
   inducible enzymes 5:396  
   inducible genes 5:396  
 inductive signals 3:276, 277  
 industrial property rights 7:371  
 inexcitability 11:672  
 infant leukemias 4:263  
 infection  
   *Bordetella bronchiseptica* 6:311  
   history of 1:110–112  
   *Pasteurella haemolytica* 6:311  
   *Pasteurella multocida* 6:311  
   *Pasteurella pneumonia* 6:311  
 infection-control procedures 10:520–522  
 infectious human prion diseases 10:586  
 infertility 6:544, 11:687  
 infidelities of DNA replication 5:338  
 in-filling reaction 11:422

- inflammation 4:344, 5:555, 6:406, 410, 419,  
7:326, 8:445, 11:111, 14:299, 15:211, 412  
carrageenan-induced aseptic 14:48  
chemoattraction  
  endothelial molecule 14:44  
IL-6 14:44  
mast cells 14:50  
microvascular leakage 14:44  
proinflammatory neurosensitizing mediators  
  14:44  
  TNF- $\alpha$  14:44
- inflammation-associated cancers 14:458
- inflammatory 14:47  
  adhesion 14:49  
  bacterial  
    infection 14:49  
  invasion 14:49  
  synovial pouch 14:49
- inflammatory arthritis 14:39, 41f, 48
- inflammatory conditions 14:46f
- inflammatory disorders 14:47
- inflammatory mediators  
  sensitization by 10:37
- inflammatory pain 15:270
- inflammatory phase 13:241–242
- inflammatory response 14:451
- infliximab 14:459
- influenza hemagglutinin (HA) fusion protein  
  metastable prefusion state 11:76  
  relaxed postfusion state 11:76
- influenza virus 3:229
- informatics 9:356–357
- information 14:126
- information storage 10:23
- information theory 9:257, 14:129
- informed consent 15:169
- infrared 1:580
- infrared beamlines 13:676
- infrared imaging 4:656ff
- infrared microscopes 13:676
- infrared microscopic maps and images 4:652,  
  13:686, 689
- infrared microscopy (IR microscopy) 13:673,  
  679
- infrared microspectroscopy (IR  
  microspectroscopy) 13:674, 676, 679, 684,  
  691, 694
- infrared spectroscopy, *see* IR spectroscopy
- ING1 6:6
- inhalation anesthetic 11:673
- inherited metabolic diseases 13:317
- inhibin 4:389ff, 11:588  
  inhibin A ( $\alpha\beta_A$ ) 4:393  
  inhibin B ( $\alpha\beta_B$ ) 4:393
- inhibition 8:370
- inhibitor complexes  
  HIV protease 13:581
- inhibitor of caspase-activated DNase (ICAD)  
  10:128, 622
- inhibitor of cyclin D1/cyclin-dependent kinase  
  6:5
- inhibitor of folate metabolism 4:579
- inhibitors 5:598, 11:114, 117, 12:411, 13:51
- inhibitors, amplification 6:554, 560
- inhibitors of androgen biosynthesis 13:3
- inhibitors of thymidylate synthase 4:579
- initiation 2:453, 13:351
- initiation factors, *see* mRNA translation, protein  
  factors
- initiation of DNA replication 1:537
- initiation of RNA synthesis  
  abortive initiation 9:401
- initiator 1:536
- Ink4a/Arf 2:232
- in-line attack 12:333
- innate cellular response to virus infection  
  15:434ff
- innate immune system 1:377, 2:292, 7:488
- innate immunity 1:358, 6:345–348, 406, 407,  
  438–439, 7:1–3, 16–17, 8:441, 10:86, 12:308f
- affinity 6:411
- Drosophila* immune response 7:4
- epithelial cells 6:343f
- evolution of 6:410f
- LAK cells 6:437
- lectin-complement pathway 7:5
- molecular basis of 6:410f
- monocytes/macrophages 6:437
- NK cells 6:437
- PAMPs  
  intracellular recognition of 7:14
- pathways activating IFN response 7:15
- recognition of 6:412–419
- specificity 6:411
- TLR signaling pathway 7:10–14
- Toll-like Receptors (TLRs) 7:5–10
- inner cell mass, *see* ICM
- inner nuclear layer (INL) 12:363
- INO2 10:297
- INO4 10:297
- iNOS 6:21
- inositol 10:291, 292, 297  
  adjunct therapy 9:135
- inositol 1,4,5-triphosphate (IP3) 8:338, 10:121,  
  15:14
- inositol-1,4,5-P<sub>3</sub> 10:292, 300
- inositol-1-P synthase 10:297
- inositol-3-phosphate 10:292

- insect resistance 14:549  
 avidin gene 14:563  
*Bacillus thuringiensis* 14:548  
 proteinase inhibitors 14:563
- insecticide resistance 7:485
- insects 3:411
- insertion 11:225
- insertion sequences (IS) 3:642
- insertional mutagenesis 12:410, 14:507, 536, 15:240, 272  
 plasmid DNA 15:604ff  
 pseudotyped retroviral vectors 15:604ff  
 rate of mutagenesis 15:606  
 retroviral vector 15:604ff  
 transposon 15:604ff
- insertional oncogenesis 13:261
- inside-out integrin signaling 2:335
- InsP<sub>3</sub> receptor 14:18
- insulator elements 15:254
- insulators 3:9
- insulin 4:212, 338, 399, 5:645, 7:26ff, 8:151ff, 10:216, 11:579
- insulin receptor family 9:460
- insulin receptor (Inr) 12:178ff, 15:41
- insulin receptor substrate 7:28, 11:580
- insulin receptor substrate protein-1 (IRS-1) 14:678
- insulin receptor tyrosine kinase (IR) 14:678
- insulin resistance 7:27ff, 8:135, 14:630ff
- insulin secretion 14:631ff
- insulin sensitivity 14:49, 633
- insulin-dependent diabetes mellitus (IDDM) 15:414
- insulin-like growth factor binding protein (IGFBP)  
 IGFBP-1 4:401ff  
 IGFBP-2 4:401ff  
 IGFBP-3 4:401ff  
 IGFBP-4 4:401ff  
 IGFBP-5 4:401ff  
 IGFBP-6 4:401ff
- insulin-like growth factor (IGF) 4:385ff, 6:3, 8:571  
 IGF-I 4:399ff  
 IGF-IB 4:400  
 IGF-II 1:622, 4:399ff  
 preproIGF-IA 4:400
- insulin-like growth factor (IGF)2 receptor 6:21
- insulin-like growth factor (IGF)2 receptor gene 1:604
- integral membrane proteins, lysosomal  
 Igps 4:203  
 LAMPs 4:203  
 LIMPs 4:203
- integrase 12:408–410
- integrase inhibitors  
 strand transfer 6:167–168
- integrated intensity 13:687
- absorption factor 7:424  
 Darwin's equation 7:424  
 Lorentz factor 7:424  
 mosaic crystal 7:424  
 mosaicity 7:425  
 polarization factor 7:424  
 total energy,  $E(h)$  7:424
- integration 4:369, 7:315, 12:401–411, 15:241
- integration of the data 12:105
- integrator gene 12:45
- integrin–ECM interactions 8:66
- integrin LFA-1 15:410
- integrin outside-in signaling 2:333
- integrin signaling 14:387  
 actin filaments 3:279  
 adaptor proteins 3:279  
 adherent cells 3:279  
 anchorage requirement 3:279  
 cell cycle regulation 3:279  
 cytoskeleton 3:279  
 ECM contacts 3:279  
 focal adhesions 3:279  
 integrins 3:279  
 stress fibers 3:279  
 $\alpha V\beta 5$  15:254
- integrin-associated protein-1 (ICAP-1) 2:339ff
- integrin-linked kinase (ILK) 2:339ff
- integrins 1:377, 390, 2:117, 326ff, 4:279ff, 8:50, 12:184ff, 13:282, 15:207  
 $\alpha 2\beta 1$  2:335  
 $\alpha 4\beta 1$  2:333  
 $\alpha 4\beta 7$  2:333  
 $\alpha 6\beta 4$  2:332  
 $\alpha 5\beta 1$  integrin 2:331  
 $\alpha 7\beta 1$  integrin 2:331  
 $\alpha 11\beta 3$  integrin 2:331  
 $\alpha L\beta 2$  integrin 2:333  
 LFA-1 (lymphocyte function-associated antigen-1) 1:372  
 $\beta$ -subunit cytoplasmic domain ( $\beta$ -tail) 2:336  
 VLA-4 (very late activation antigen-4) 1:372
- $\beta 2$ -integrins CD11b/CD18 10:124
- intein structures 11:247f
- inteins 5:391, 11:242, 245, 248, 250, 251, 254  
 screening systems 11:259
- inteins in biotechnology 11:255ff

- Intellectual Property Rights (IPR) 7:368  
 forms of 7:373–374  
 patents 7:371–372  
 origin of 7:369–370  
 purpose of 7:370–371
- intensity factor 11:388, 390
- interactions 4:234, 7:161, 165, 11:222  
 complementary 10:204  
 electrostatic 10:204  
 hydrophobic 10:204  
 steric 10:204
- interactive computer graphics 12:615, 618, 624
- interactome 9:508, 11:124
- interactome analysis 3:644
- inter-Alu PCR 15:556, 568
- intercalation 2:13ff
- intercellular adhesion molecule 1, *see* ICAM-1
- intercellular transport 8:486
- intercept 11:390
- interchromosomal rearrangement 5:120, 124
- interfacial electric polarization 4:2
- interfacial polarization 4:3
- interference 5:327, 6:377
- interferogram 13:674
- interferometric spectrometers 13:674
- interferon genes 15:392
- interferon proteins 15:393
- interferon regulatory factors, *see* IRF
- interferon, *see* IFN
- interferon- $\alpha$ , *see* IFN- $\alpha$
- interferon- $\beta$ , *see* IFN- $\beta$
- interferon- $\gamma$ , *see* IFN- $\gamma$
- interferon-stimulated gene factor-3 (ISGF-3)  
 15:402
- intergenic noncomplementation 5:395
- interleukin-1 1:379, 3:134f, 6:14, 8:434f, 442,  
 445ff, 10:125, 14:453
- interleukin-7 3:139
- interleukin-9 3:140
- interleukin-11 3:141
- interleukin-13 3:142, 10:105
- interleukin-14 3:142
- interleukin-15 3:142, 10:103
- interleukin-16 3:142
- interleukin-17 3:142
- interleukin-18 3:143, 10:102
- interleukin-19 3:143
- interleukin-20 3:143
- interleukin-21 3:143
- interleukin-22 3:143
- interleukin-23 3:144, 10:103
- interleukin-24 3:144
- interleukin-25 3:144
- interleukin-26 3:144
- interleukin-27 3:144, 10:104
- interleukin-28 3:144–145, 15:392
- interleukin-29 3:145, 15:392
- interleukin genes 3:123–127
- interleukin (IL) 3:116, 5:231–232, 638, 640,  
 6:385, 8:433, 435, 437, 10:219, 221, 11:585,  
 14:453  
 biological activities of 3:133–145  
 clinical uses of 3:148–150  
 disease correlates 3:147–148  
 historical perspective 3:118–121  
 pathophysiology of 3:147–148  
 physiology of 3:145–147
- interleukin-1 $\alpha$  (IL-1 $\alpha$ ) 6:3, 16f, 8:438
- interleukin-1 $\beta$  (IL-1 $\beta$ ) 1:392, 5:555, 6:14, 8:449
- interleukin-2 (IL-2) 1:384, 3:135, 5:306, 555,  
 8:435, 443f, 10:103, 15:400
- interleukin-3 (IL-3) 1:380, 3:135–137
- interleukin-4 (IL-4) 1:380, 384, 389,  
 3:137–138, 10:105, 15:272
- interleukin-5 (IL-5) 1:384, 3:138–139, 15:400
- interleukin-6 (IL-6) 1:379, 384, 3:139, 4:405,  
 6:3, 14, 16f, 8:438, 441–445, 447ff, 451ff,  
 10:104, 125
- interleukin-8 (IL-8) 3:140, 6:3, 14ff, 8:438, 451
- interleukin-10 (IL-10) 1:380, 3:140–141, 6:14,  
 8:438, 443, 446, 451ff, 10:106, 223, 229,  
 15:263, 397, 401f  
 complications of 6:478  
 effects on DCs 6:476–477  
 effects on monocytes/macrophages 6:475  
 effects on NK cells 6:476  
 effects on T lymphocytes 6:475–476  
 inhibition of 6:477  
 removal of source 6:478  
 sources of 6:474–477
- interleukin-12 (IL-12) 1:378f, 3:141, 10:103
- interleukin proteins 3:121–127
- interleukin receptors 1:389, 6:17, 8:441, 446,  
 448, 13:132f, 136, 349, 15:401f  
 intracellular signaling pathways 3:131–133  
 structure of 3:127–131
- intermediate density lipoprotein, *see* IDL
- intermediate exchange 13:554, 558, 559
- intermediate filaments 4:99, 104
- intermediate-filament proteins 14:654
- internal and external fields 4:4
- internal DNA standard 3:493
- internal globus pallidus 15:265
- internal heat 10:7
- internal plexiform layer (IPL) 12:648
- internal ribosomal entry site, *see* IRES
- internalization 7:300ff, 10:186–187
- international agreements 7:377

- international intraocular retinoblastoma  
 classification (IIRC) 12:349
- International Regulome Consortium 12:102
- internet 6:610, 14:133
- interphase 6:139ff, 12:143, 14:4
- interphase arrest 14:21–22
- interphase chromatin  
 movement of 3:7–8
- interphase FISH mapping 5:165
- interphase nuclei 5:148ff  
 preparation 5:149
- intersegment transfer 3:518
- intersegmental transfer 12:331
- interspersed repeat 2:630, 9:262  
 autonomous 1:252  
 DNA transposon 1:252  
 endogenous retrovirus 1:269, 271ff, 282f,  
 285, 294, 296, 299  
 LINE, *see* long interspersed repeat  
 long interspersed repeat element 1:252ff  
 mobile elements 1:254  
 nonautonomous 1:252  
 non-LTR retrotransposon 1:253ff  
 processed pseudogene 1:253ff  
 retroposon 1:254ff  
 retroseudogene 1:253ff  
 retrotransposon 1:254ff  
 short interspersed repeat element 1:254ff  
 SINE 1:254  
 transposable elements 1:254  
 transposase 1:254ff  
 transposition 1:254  
 transposons 1:254  
*see also* transposable elements; transposition;  
 transposons
- interspersed repeat repetitive element 1:252ff
- interspersed simple sequence repeats (SSRs)  
 11:466
- interstellar medium 10:3
- interstellar organic molecules 10:7
- interstitial cell-stimulating hormone (ICSH)  
 13:7
- interstitial matrix 8:46–48, 54, 58
- interstitial water molecule 12:331
- interstium, testis 7:499
- interstrand cross-links 3:357
- intersystem crossing 4:491
- intertwined complementary strands 12:111
- intestinal absorption 3:621
- intestinal epithelium 3:616
- intestinal metaplasia 6:11
- intestinal type gastric carcinoma 6:11
- intestine  
 lipid absorption in 5:222–223
- intima 5:215, 219
- intrabodies 3:93, 8:424
- intracellular delivery 14:167
- intracellular detectors 8:422
- intracellular environment 1:34
- intracellular fusion reactions  
 topology and specificity of SNAREs 11:89
- intracellular immunization 1:340
- intracellular organelle compartmentation  
 14:175
- intracellular organelles 5:495
- intracellular protein degradation 1:619
- intracellular receptors 11:613
- intracellular signal transduction  
 AP-1 transcription factor 3:271  
 basal transcription factors 3:272  
 basic helix–loop–helix 3:272  
 basic leucine zipper 3:272  
 CBFA1 3:274  
 combinatorial regulation 3:272  
 competence 3:272  
 cross-talk 3:271  
 deep homology 3:271  
 DNA binding sites 3:274  
 enhancers 3:272  
 family 3:272  
 hedgehog signal transduction pathway  
 3:271  
 homeobox genes 3:273  
 homeodomain family 3:272  
 homologous signal transduction pathways  
 3:271  
 Nieuwkoop center 3:274  
 Pax genes 3:273  
 phytochromes 3:271  
 promoters 3:272  
 receptor tyrosine kinase 3:271  
 receptors 3:268  
 signal transduction 3:270  
 Smad signal transduction pathway 3:271  
 Tbx4 3:273  
 Tbx5 3:273  
 trans-activating domain 3:271  
 transcription 3:271, 272  
 transcriptional regulation 3:272  
 trans-regulatory factor 3:272  
 Wnt-signal transduction pathway 3:271  
 zinc finger family 3:273
- intracellular signaling 5:501, 13:317
- intracellular signaling pathways 3:131–133
- intracellular targeting 14:181–185
- intracellular trafficking pathways 11:80
- intracellular-free calcium 2:464
- intrachromosomal rearrangement 5:120, 126

- intracoronary administration 15:264  
 intracytoplasmic sperm injection (ICSI) 6:538  
 intradermal 14:48  
 intraepithelial neoplasia 9:498, 533  
 intraflagellar transport (IFT) 8:394  
 intragenic complementation 5:395  
 intramyocellular TAG 14:674  
 intranuclear inclusions 4:613  
 intravenous 7:301ff  
 intrinsic clearance 3:626  
 introgression 6:226, 238  
 intron 1:126, 127, 137, 2:620, 624ff, 5:245, 372,  
   387, 11:250, 12:24, 132, 351, 514, 517, 14:4  
   group I 2:627  
   group II 2:627  
   intron homing 2:627  
   splicing of 10:320f  
 intron or intervening sequence 12:24  
 intron retention 1:158  
 intron/exon junction 11:507ff  
 intronic splice signals  
   conservation of 11:456  
 intronic splicing enhancers (ISEs) 1:146  
 intronic splicing silencers (ISSs) 1:146  
 intuitive understanding 14:145  
 intussusception 15:218, 220  
 invagination 1:541  
 invariant chain 1:370  
 invasion 1:558, 563, 565, 2:561ff  
   extracellular 1:568  
   intracellular 1:568  
   intracellular survival 1:567  
   invasins 1:568  
   survival 1:569  
 inverse hexagonal micelles 15:493  
 inversus viscerum 2:612  
 invertase 2:254  
 invertebrate 4:332, 9:175, 177  
   arthropod 9:174  
   cnidarian 9:168, 171ff  
     *Hydra* 9:170  
   cnidarianhydra 9:171ff  
   genome 9:173  
   insects 9:168  
     *Drosophila* 9:174  
     *Helicoverpa* 9:174  
   molluscs 9:168  
     *Aplysia* 9:176  
   nematode  
     *Ascaris suum* 9:173  
     *C. elegans* 9:173ff  
     *Caenorhabditis elegans* 9:172  
     *Globodera pallida* 9:173  
     nonparasitic 9:172  
     parasitic 9:172  
     roundworm 9:172  
 investor 15:174  
 inwardly rectifying potassium channel 11:665  
 ion channel 4:332, 8:86, 91ff, 100, 103, 105,  
   10:30, 11:595, 13:145ff  
   calcium (Ca<sup>2+</sup>) 8:150  
   chloride (Cl<sup>-</sup>) 8:150  
   diffusion 8:150  
   gated by acid 10:33–34  
   gated by ATP 10:34–35  
   gated by mechanical stimuli 10:35  
   gated by noxious cold 10:33  
   gated by noxious heat 10:32–33  
   gated by noxious stimuli 10:32–37  
   potassium (K<sup>+</sup>) 8:150  
   sodium (Na<sup>+</sup>) 8:150  
 ion channel–binding peptides 14:107  
 ion channel, cardiac 11:660  
 ion channel, epithelia 11:685  
 ion channel, muscle 11:667  
 ion channel, nerve 11:675  
 ion channel proteins 11:647  
 ion channel-coupled receptor (ICCR)  
   11:554–556, 569, 577f  
 ion equilibrium 4:12  
 ion flows 4:13  
 ion indicators 15:76  
 ion pairing, reverse phase chromatography  
   9:298  
 ion trap (IT) 8:8  
 ion trap mass spectrometer 6:246  
 ion-exchange 6:248  
 ion-exchange chromatography  
   basic principles 6:266  
   mobile phases 6:271  
   operating parameters 6:271  
   peptide separation in IEC 6:273  
   stationary phases 6:269  
 ionic interactions 3:535, 7:308ff  
 ionic strength 7:397  
 ionization monitors 11:427  
 ionizing radiation 7:150, 151, 13:321, 14:456  
 IP<sub>3</sub> receptor 2:161  
 IPSPs 11:675  
 IPTG 12:29  
 IQ motif 8:477  
 IR microscopy, *see* infrared microscopy  
 IR microspectroscopy, *see* infrared microscopy  
 IR spectrometers 13:674  
 IR spectroscopic data 13:695  
 IR spectroscopy (infrared spectroscopy) 1:577,  
   8:195f, 13:673, 695  
 IR spectrum 13:684



- IR synchrotron 13:676f, *see also* synchrotron  
 IR window 13:681  
 IRAK family 7:12  
 IRES (internal ribosomal entry site) 12:584, 15:399  
 Iressa 2:175  
 IRF-1 15:399, 404, 408, 411  
 IRF-2 15:399, 400, 408  
 IRF-3 15:399, 400, 418  
 IRF-5 15:400  
 IRF-7 15:399f  
 IRF-9 15:402–404  
 IRF (interferon regulatory factor) 13:121, 15:399, 411  
 IRFs (interferon response factors) 13:117  
 IRMA 6:369  
 IRO 6:215  
 IRO box 6:215  
 iron 7:169, 8:211ff, 216, 217, 219, 226, 231, 9:328  
 iron level, increased  
   ferritin 14:569  
   iron absorption 14:569  
 iron sulfide 10:9  
 iron–sulfur cluster-containing proteins 15:37  
 iron–sulfur clusters (ISCs) 15:37  
 iron–sulfur enzymes 8:216  
 iron transporter DMT-1 8:349  
 iron-responsive element (IRE) 8:343, 15:404  
 iron-sulfur proteins 4:123  
 Iroquois 13:279  
 IR-reflective coating 13:682  
 IS elements 5:341  
 ischemia 4:129, 5:215, 220, 229, 8:446, 14:284ff  
 ischemic heart disease 10:201, 15:264  
 ischemic myocardium 15:264  
 ischemic preconditioning 10:134  
 ischemic tolerance 10:117, 134  
 ISCOMS 8:614  
 ISGF-3 13:117, 120, 15:402–404  
 ISH 10:540ff  
   various developmental stages 10:541  
 isochores 5:64, 9:251, 252  
 isocitrate dehydrogenase 2:606  
 isocratic elution 6:247  
 isoforms 4:587, 594, 14:48  
 isogenic DNA 14:507  
 isolation 5:335  
 isolation and culture 13:335  
 isolation, methods of bacterial 1:507  
   from natural sources 1:508  
 isolation, reproductive 2:562  
 isoluminol 2:522ff  
 isomerases, peptidyl–prolyl cis–trans 2:505  
 isomerohydrolase 12:380  
 isomers 2:582, 10:22  
 isomorphous differences  
   square of the isomorphous differences 7:428  
 isomorphous replacement 7:427ff  
 isoniazid 2:64  
 Isoprenaline 14:365–366  
 isopropyl- $\beta$ -thiogalactoside 12:29  
 isoproterenol 14:660  
 isosteric base pair 12:616  
 isosteric family 12:616, 618  
 isostericity 12:616, 628  
 isotherm 2:46  
 isothermal process 9:404  
 isothermal titration calorimetry (ITC) 3:556  
 isotope 4:122ff  
 isotope coded affinity tag (ICAT) 5:47, 7:580, 8:20f, 28, 35, 11:310, 318  
 isotope coding 11:318–319  
 isotope editing 13:563, 564, 574  
 isotope filtering 13:563, 574  
 isotope labeling 4:120, 11:63, 13:519, 527  
 isotropic hyperfine splitting ( $A_{iso}$ ) 7:159  
 isozymes 5:498  
 ISRE, *see* IFN-stimulated response element  
 ISSR-PCR (inter simple sequence repeat polymerase chain reaction) 3:490  
 issued patents 7:378–380  
 Isua 10:5  
 IT 8:9  
 iterative 11:391  
 iterative deconvolution 2:24  
 iterons 10:412, 422  
 ITs 8:9  
 IVF  
   epigenetic effects 6:540  
   superovulation 6:540  
   technology 13:385
- j**  
 J domain 2:501  
 JA signaling 10:344  
 jackknife model  
   fusion as a two-step process 11:76  
 Jacobsen syndrome 4:570ff  
 jagged 15:214f  
 JAK1 15:402, 403  
 JAK2 10:137, 15:402  
   acute lymphocytic leukemia 7:137  
   acute myeloid leukemia 7:137  
   atypical chronic myeloid leukemia 7:137  
   cytokine induced signals 7:136  
   cytokine receptor 7:136

- hematopoietic cells 7:137  
 IL-3 7:136  
 IL-5 7:136  
 IL-6 7:136  
 JH domains 7:136  
 STAT proteins 7:136  
 T-cell childhood acute lymphocytic leukemia 7:137  
 Tel-JAK-2 fusion protein 7:137  
 Tel-JAK-2 translocation 7:137  
 JAK (janus kinase) 1:663ff, 11:585, 588, 589, 12:183ff, 13:117, 119, 15:411  
   family members of 13:124–129  
   family of 13:123–125  
   Jak1 13:124  
   Jak2 13:124  
   Jak3 13:124  
   JAK structure of 13:123–124  
   Tyk2 13:125  
 JAK-STAT signaling 3:283f, 9:468–469, 14:680  
   regulation of 13:136–138  
 JAK-STAT signaling cascade 13:115–138  
 jasmonate 1:431  
 jasmonic acid 2:586  
   regulation by 10:344–345  
 jasplakinolide 4:202  
 jaundice, neonatal 2:62  
 JAW locus 14:265  
 Jervell and Lange-Nielsen syndrome (JLN) 11:662, 665, 683  
 jet lag 12:421  
 jetting technologies 8:274  
 jigsaw puzzle 1:27  
 JLN, *see* Jervell and Lange-Nielsen syndrome  
 JNKK  
   MAPK kinase–kinase 7:138  
   prostate cancer 7:138  
   Ubiquitination 7:138ff  
 joints 14:42  
 josephin domain 15:21  
 J-proteins 13:498–499  
 JUMNA 12:615, 626  
 jumping libraries 5:452ff, 15:556  
 Jun 12:171, 176  
 Jun kinase 12:184  
 jun N-terminal kinase (JNK) 4:286ff, 14:451, 15:15  
 junctophilin-3 (JPH3) 15:52ff  
 juvenile laryngeal papilloma (JLP) 15:417  
 juvenile RA 14:40  
   proinflammatory molecules 14:51  
 juxtacrine signaling  
   Eph receptors 3:274  
   ephrins 3:274
- k**  
 K<sup>+</sup> and H<sup>+</sup> wasting 11:690  
 kainic acid 13:690  
 kallikrein-kinin system (KKS)  
   human tissue kallikrein gene (CHK) 15:294  
   kinin 15:294  
   kininogen 15:294  
 Kallmann syndrome (KS) 4:407, 12:692  
 KANADI 14:263  
 kanadi1 14:262  
 Kaposi's sarcoma 15:418  
 Kar2p 2:513  
 Karplus relationship 2:265  
 karyogamy 14:235ff  
 karyoplast 9:210, 227  
 karyotype 3:20  
 karyotype evolution 5:129–131  
 karyotypic analysis 12:366  
 K/BxN mouse 14:42  
*k<sub>cat</sub>* 11:396  
 KCBP (kinesin-like calmodulin-binding protein)  
   calmodulin-binding domain 8:465, 469  
   coiled-coil stalk 8:465  
   motor domain 8:465  
   myosin tail homology 8:465  
   talin-like region 8:465  
 KCNA1 11:682  
 KCND2 potassium channel 11:683  
 KCNE1 11:663, 665, 666  
 KCNE2 11:663, 665  
 KCNE3 11:673  
 KCNH2 11:663  
 KCNJ11 11:698  
 KCNJ2 11:665  
 KCNQ1 11:666  
 KCNQ2 11:678  
 KCNQ3 11:678  
 KCNQ2/KCNQ3 11:699  
*K<sub>d</sub>* 7:100  
 Kdo 2:249  
 KDR 15:212  
 Kearns–Sayre syndrome (KSS) 15:377  
 KELCH 15:44  
 Kelch-like 1 (KLHL1) 15:44  
 Kennedy, Eugene 10:282  
 Kennedy's syndrome 2:208  
 keratinocyte 12:359, 13:52  
 keratinocyte growth factor (KGF) 2:203, 5:650, 6:12, 17, 9:455  
 keratinocytes 1:363, 12:162, 13:221  
 4-keto retinal 9:560  
 α-ketoglutarate dehydrogenase 7:106  
 ketone 11:64  
 ketone body 7:102

- key-based approaches 3:603  
 keyhole limpet hemocyanin, (KLH) 6:441  
 k-GRAM (k-tuple) 10:448, 453  
 KH domains 4:594  
 Khellin 14:363–365  
 kidney 11:688, 12:719, 720ff  
 kidney glomerulus 14:174  
 kidney stones 4:677ff  
 killer inhibitory receptor (KIR) 6:438  
 kinase 2:637, 4:333, 11:113, 14:4  
   calcium/calmodulin-dependent protein  
   kinase II (CaM KII) 2:467  
   cAMP-protein 7:99  
   chimeric proteins 7:127  
   MPF 2:467  
   oligomerization domain 7:127ff  
   protein kinase C 2:467  
   pyruvate dehydrogenase 7:99  
 kinase domain 4:397  
 kinase, protein  
   CaM-dependent protein kinase II 4:169  
   casein kinase 2 4:170  
   mitogen-activated protein 4:166  
   p21-activated kinase 4:166  
   protein kinase B 4:170  
   protein kinase C 4:168  
   Rho-associated, coiled-coil forming protein  
   kinase 4:166  
 kinesin 2:638  
   intracellular porter 8:580  
   processivity 8:584  
 kinesin cycle 8:590  
 kinetic information 13:556  
 kinetics 13:551, 552, 566  
   ligand exchange 1:655–656  
   metal ion complexation 1:654–656  
   substitution reactions of 1:654–655  
 kinetin 1:420  
 kinetochore 1:487, 6:144  
 King 8:537ff  
 King Mary-Claire 8:531ff  
 kiss and run 4:206  
 kiss-and-run exocytosis 4:311ff  
 KIT  
   constitutively active 7:131  
   E3 ubiquitin ligase c-Cbl 7:131  
   GRB2 7:131  
   immunoglobulin-like domains 7:130  
   SHP-1 (a protein-tyrosine phosphatase  
   7:131  
   Src family 7:131  
*Klebsiella aerogenes* 8:229  
*K<sub>m</sub>* 11:396  
 K-means clustering 9:260  
 knob 15:345  
 knockdown 15:608ff  
 knockin 14:507  
 knockin mutant 2:569  
 knockout 1:214, 476, 4:335, 15:610ff  
 knockout (KO) mice 8:447  
 knockout mice 1:598, 670, 7:33, 15:411  
 knockout mutant 2:569  
 KNOTTED 14:270  
 Knotted-class homeobox gene 14:264  
 knowledge generation 14:133  
 KNOX  
   class 6:217ff  
   domain 6:217ff  
 Kohne, D. E. 8:523  
 Koshland Nemethy Filmer sequential model  
   11:605  
 Kpn repeat 15:556, 562  
 krabbe 13:321  
 K-ras mutation 6:6, 18, 23  
 krebs cycle 7:99, 8:216  
 K-region 14:237ff  
   mat2 14:237  
   mat3 14:237  
 kringles 7:235  
 K-sam 6:12, 24  
 Ku70  
   nonhomologous end joining 1:75  
 Ku86  
   nonhomologous end joining 1:75  
 Kunau 13:614  
 Kupffer cells 1:358, 15:268  
 Kuzbanian 15:214  
  
*I*  
*L*  
   selectin 5:585  
 L1 1:255, 263ff, 285, 287  
   CR1 1:268  
 L2 1:268ff  
   CR1 1:263  
   MIR3 1:269  
 L3  
   CR1 1:268  
   esterase 1:268ff  
   MIR3 1:269  
 label retaining cells 13:222  
 labeled DNA 7:169  
 labels 6:637  
   enzyme 2:530  
 labial 6:191ff  
 lab-on-a-chip 3:501, 9:409, 14:423  
 laboratory strains 15:599ff  
 lac A<sup>+</sup> 12:29

- lac i<sup>+</sup> 12:29  
 Lac Operon 12:29  
 lac Y<sup>+</sup> 12:29  
 lac Z<sup>+</sup> 12:29  
 lactacystin 11:3  
 $\beta$ -lactam antibiotics 10:656  
 $\beta$ -lactams 14:348–354  
 lactate dehydrogenase (LDH) 7:106, 9:281  
 lactate-acidosis hypothesis 10:123  
 lactic acid 2:592  
 lactoferrin 4:121  
 lactoperoxidase 8:218  
 lactose permease  
   *E. coli* 8:146, 155  
 lactotrope 4:389  
 LACZ 11:61  
 lagging chromosomes 14:237  
 lagging strand synthesis 10:437  
 lag-phase 1:528, 530, 7:540  
 Laibach, Friedrich 14:252  
 lamarckian inheritance 5:321  
 lamarckian interpretations 5:316  
 lambda repressor (cI) 3:511  
 Lambert-Eaton myasthenia syndrome (LEMS)  
   11:674  
 lamin A/C gene 7:53  
 lamina  
   nuclear 6:144  
 lamina propria 1:363  
 laminin-1 14:396  
 laminins 2:326ff, 4:279ff, 5:557, 8:47, 48,  
   50–52, 65, 67, 224  
   laminin-1 ( $\alpha_1\beta_1\gamma_1$ ) 2:329  
   laminin-2 ( $\alpha_2\beta_1\gamma_1$ ) 2:329  
   laminin-4 ( $\alpha_2\beta_2\gamma_1$ ) 2:329  
   laminin-5 ( $\alpha_3\beta_3\gamma_2$ ) 2:329  
   laminin-8 ( $\alpha_4\beta_1\gamma_1$ ) 2:329  
   laminin-9 ( $\alpha_4\beta_2\gamma_1$ ) 2:329  
   laminin-10 ( $\alpha_5\beta_1\gamma_1$ ) 2:329  
   laminin-11 ( $\alpha_5\beta_2\gamma_1$ ) 2:329  
    $\alpha_5$  laminin-null 2:329  
 LAMP-1 4:208  
 LAMP-2 4:208  
 LAMP2a 1:620  
 LAMP2b 1:620  
 lamp/charge-coupled device (CCD)-based 5:43  
*Lampetra planerii* 6:88  
 land plants 2:625  
 Lander–Waterman curves  
   clone coverage 13:86  
 Langerhans cells (LCs) 13:221, 230, 361–364  
   Birbeck granules 1:358  
   CD1a 1:389  
   CD11c 1:389  
   dendritic cell family 1:358  
   E-cadherin 1:389  
 langerin (CD207) 1:389, 390  
 Langley, John Newton 8:86  
 Langmuir–Blodgett technique 9:563  
 lanthanide fluorescence 7:175  
 lanthanum 1:431  
 lantibiotics 2:588  
 LAP proteins  
   display DLG 4:283  
 large conformational change 13:654  
 large genome-sequencing projects 13:75  
 large molecular assembly  
   20S proteasome from yeast 7:462  
   eukaryotic proteasome 7:463  
   lactacystin inhibitor 7:463  
   octa- or nonapeptides 7:464  
   subunits 7:463  
   symmetry 7:463  
 large terminase subunit 9:354  
 large-insert clones  
   BAC 13:78  
   BACs or YACs 13:72  
   BCAs and cosmids/fosmids 13:100  
   YAC 13:78  
 large-scale analysis 10:536  
 large-scale production 1:435  
 large-scale sequencing era 13:76  
 large-scale sequencing (LSS) 13:78  
 large-scale sequencing (LSS) technique 13:73  
 lariat 12:25  
 laser 4:418, 11:490ff  
 laser capture microdissection (LCM) 3:25, 40,  
   8:268, 499, 9:106, 10:541, 11:110  
 laser microbeam 3:29  
 laser pulse 3:41  
 laser surgery 13:386  
 laser UV cross-linking and photofootprinting  
   3:548  
 laser-based fluorescence scanner 14:430  
 laser/photomultiplier tube (PMT) scanning  
   5:43  
 laser-scanning microscopy 15:62ff  
 late endosomes 8:123, 10:290  
 latency 15:239, 249  
 latency associated peptide; (LAP) 6:469  
 latency promoter 15:250  
 latency-associated transcript 15:249  
 latent TGF $\beta$  binding protein 6:469  
 lateral gene transfer 9:261, 14:258  
 lateral inhibition 2:110  
 lateral ventricles 13:410ff  
 Laveran, Charles 7:472  
 law of large numbers 8:517, 525ff, 536ff, 537ff

- law of mass action 14:139  
law of requisite variety 14:131  
layer formation 2:112–113  
 $\alpha,7\alpha$ -bis(acetylthio)-17 $\alpha$ -methyl-  
17 $\beta$ -hydroxyandrost-4-en-3-one 13:37  
Lbx 6:201  
LC, *see* Langerhans cells  
LCAT, *see* lecithin cholesterol acyl transferase  
L-cells 7:538  
LCK 1:374  
    adaptive immunity 7:137  
    T-cell acute lymphoblastic leukemia 7:138  
    T-cell receptors (TCR) CD4 and CD8 7:137  
     $\beta$ TCR:LCK 7:138  
LC-MS 6:286, 10:216, 11:310  
    bias 8:195  
    capillary RPC-MS 6:288  
    general considerations 6:287  
    LC/MS for protein analysis 6:289  
    reproducibility 8:195  
    sensitivity 8:194  
LC-MS/MS 9:105, 12:104  
LC-NMR 13:527, 528, 538  
LCx, Abbott 6:557  
LD analysis  
    gene mapping 13:196  
    susceptibility markers 13:196  
LD (lipid droplets) 14:624ff  
LDL  
    as targets for gene therapy 5:225  
    catabolism 7:207  
    half-life 7:208  
    modified 7:237  
    mutations 7:209  
    receptor 1:156, 4:191, 212, 5:215,  
    7:205–208, 210–213, 226, 229, 233, 235,  
    237, 8:129  
    structure 7:206  
LDL-C assays  
    lipid panel 7:287–288  
Le<sup>a</sup> 5:546  
lead 1:647–648, 10:11  
lead compound discovery 11:625  
lead compounds 14:327  
lead generation 8:84  
lead optimization 8:84  
lead structure 8:89  
leader sequence 12:36  
leadzyme 12:628–630  
leaf development 14:264  
LEAFY 14:266  
LEAFY (LFY) 14:271  
least-squares fitting 11:386, 390, 391  
Le<sup>b</sup> determinant 5:561  
Leber's hereditary optic neuropathy (LHON)  
15:377  
lecithin 10:282  
lecithin cholesterol acyl transferase 5:227,  
7:198, 211, 213, 216, 227, 228, 230  
    mutations 7:215  
lecithin-retinol acyltransferase (LRAT) 12:378  
    family 12:382  
lectin 2:271, 278, 5:581, 582, 10:93  
    agglutination 2:291  
    complete-antigens 2:279  
    C-reactive protein (CRP) 5:587  
    C-type 5:583  
    C-type (calcium-dependent) 2:291  
    electrostatic interactions 2:292  
    endothelial–leukocyte adhesion molecule-1  
    (ELAM-1) 5:585  
    galectins 5:585  
    haptens 2:279  
    H-bonds 2:292  
    I-type 2:291, 5:586  
    ligands 2:292  
    Mannan-binding lectin, MBL 5:584  
    mannose-binding protein 5:584  
    murine lymph node homing receptor 5:585  
    pentraxin 2:291, 5:587  
    platelet granule membrane protein-140  
    5:585  
    polyamphiphilic 2:292  
    P-type 2:291  
    serum amyloid P component (SAP) 5:587  
    siglecs 5:586  
    specificity 2:270  
    S-type 2:291, 5:585  
    van der Waals 2:292  
lectin–carbohydrate interactions 2:292  
lectin-complement pathway 7:3, 5  
LEDGF 12:407  
Le-enzyme 5:561  
left isomerism 2:612  
*Legionella pneumophila* 8:135  
legitimate 5:314  
*Leishmania* 1:379  
    vaccine 15:160  
*Leishmania major*  
    vaccine 15:174  
L1 element  
    X inactivation 1:296ff  
lentiviral vectors 14:540  
lentiviruses 1:100, 15:240  
leptin 7:34ff, 38, 14:680  
Leptospirosis *leptospira* spp. 6:315, 11:436  
    *Bacteroides nodosus* 6:316  
    *Chlamydia psittaci* 6:316

- Edwardsiella ictaluri* 6:316  
*Ehrlichia risticii* 6:316  
*Fusobacterium necrophorum* 6:316  
*Haemophilus paragallinarum* 6:316  
*Streptococcus suis* 6:316  
lethal environmental selection 5:315  
lethal mutations 5:342  
leucine zipper  
  coiled coil 3:533  
leucine-rich repeat (LRR) 6:413  
leukemia 4:340, 13:349, 15:269  
leukemia exception 9:8  
leukemia inhibitory factor (LIF) 4:405, 5:640,  
  8:561, 11:585  
  growth of mESC 13:388  
leukocyte adhesion deficiency-1 (LAD1)  
  2:331  
leukocyte counter receptors 5:229–230  
leukocyte IFN 15:391  
leukocytes 6:406, 13:240, 15:211  
  adrenocorticotrophic hormone (ACTH)  
  14:47  
   $\alpha$ -melanocyte stimulating hormone ( $\alpha$ -MSH)  
  14:47  
  see also MSH2-6  
  produce  $\beta$ -endorphin 14:47  
leukotrienes 8:211  
LEUNIG 14:267  
levan production 1:520  
Levinthal paradox 1:26  
Lewis<sup>x</sup> antigen  
  neutrophil adherence 5:595  
Lewy bodies 8:506  
Le<sup>x</sup> 5:546  
Leydig 4:399  
Leydig cell 7:499, 8:445  
LF 1:310  
LFA-1 1:373, 374, 379  
 $\alpha$ -L-Fucosidase 5:546  
L-galactose 2:590  
lgl 12:185  
L-glucose 2:590  
LHCII proteins 2:637  
LH-RH 10:218  
LH-RH antagonist 10:233, 235  
liability threshold model 1:588  
liarazole 13:52  
libido 1:216  
library 5:520, 8:420, 11:46, 51, 106  
  deconvolution 2:23  
  library design 13:596  
  library methods requiring deconvolution  
  dual recursive deconvolution 10:161  
  iterative process 10:160  
  libraries from libraries method 10:161  
  orthogonal partition approach 10:161  
  positional scanning methodology 10:161  
  recursive deconvolution strategy 10:161  
  synthetic peptide combinatorial libraries  
  10:160  
  library of ligands 13:583  
  licencing factor 12:192  
  license-to-kill model 1:373, 396  
  LICOS 1:373  
  lid 11:3  
  Liddle syndrome 11:691  
  LIF, see leukemia inhibitory factor  
  life cycle 1:88  
  of adeno-associated virus 15:248  
  of adenovirus 15:245  
  of HSV 15:250  
  of lentiviruses 15:242  
  life span 1:67, 4:340  
  brain size 1:69  
  mitochondria 1:65  
  life span extension 1:53  
  cell suicide (apoptosis), reduce 1:57  
  Cu/ZnSOD 1:59  
  DNA repair, increased 1:57  
  methionine sulfoxide reductase (MsrA)  
  1:60  
  MGMT 1:58  
  MnSOD 1:59  
  MsrA 1:58  
  O<sup>6</sup>-methylguanine-DNA methyltransferase  
  (MGMT) 1:59, 77  
  oxidative damage, reduce 1:57  
  paramecia 1:69  
  PARP 1:58, 63  
  protein damage 1:60  
  p66<sup>shc</sup> 1:58  
  p66Shc 1:60, 73  
  SOD 1:58  
  lifestyle 7:31  
  Lig4 14:232  
  ligand 1:636, 641, 4:346, 6:367, 11:595, 598,  
  603, 604, 608, 616, 13:117, 125, 145ff  
  discrimination between 5:276–277  
  ligand binding 4:10  
  rates of 5:274–276  
  ligand docking 11:145  
  ligand dynamics 13:542  
  ligand exchange 1:655  
  ligand for both EGFR and c-erbB2 6:7  
  ligand library 13:586  
  ligand scale 1:646–647  
  ligand-based design 13:529  
  ligand-based drug design 10:198ff

- ligand-binding domain (LBD) 13:20f, 14:533  
 conformational changes of 1:442–445
- ligand-binding proteins 11:455
- ligand-coated complexes 7:308ff
- ligand-DNA binding 13:560
- ligand-exchange reactions 8:347
- ligand-gated channels 11:682
- ligand-gated ion channels (LGICs) f8:36f, 11:647  
 GABA<sub>A</sub> 11:606  
 GABA<sub>A</sub> ion channel 11:615  
 GABA<sub>A</sub> receptor 11:599  
 GABA<sub>A</sub>/benzodiazepine (BZ) receptor 11:611  
 5HT<sub>3</sub> 11:606  
 nicotine 11:605  
 nicotinic cholinergic 11:606  
 P2X<sub>7</sub> receptor 11:599  
 the nicotinic cholinergic receptor, nAChR 11:612  
 the NMDA receptor 11:612  
 the P2X receptor 11:612
- ligand/receptor complexes  
 identification of 12:665–666
- ligase 7:181
- ligase chain reaction (LCR) 6:555ff, 7:187
- ligase, DNA 6:554ff
- ligase-mediated molecular analysis 7:179
- ligation 3:416, 6:554ff, 7:180ff  
 chemical 7:184  
 enzymatic 7:182  
 reaction 7:183  
 substrate requirements 7:184
- light 1:430, 10:7
- light emission measurement 2:525
- light emitting diodes (LED) 11:490ff
- light microscopy 13:674
- light scattering 2:259, 4:420
- light signal  
 interaction with hormonal pathways 10:334–335
- light-harvesting chlorophyll a/b binding protein 2:630
- light-strand promoter (LSP) 15:372
- Lignac-de Toni-Debre-Fanconi 4:212
- LIM 6:210  
 class genes 13:303  
 domain 6:211ff  
 homeobox protein 13:296  
 homeodomain protein 13:298
- limb regeneration 13:335
- limitations of 2-DE-based approaches 5:46
- limitin 15:391
- linalool, odor 2:598
- linalyl acetate, odor 2:598
- LINE, *see* long interspersed repeat element
- line shape 13:524, 542
- line width 13:530, 556
- lineage 13:411ff, 427  
 glial-restricted 13:427ff  
 neural stem cells 13:425
- lineage sorting 2:559
- linear accelerator 13:678
- linear pDNA 10:228
- linear regression 11:390, 396
- linearization 11:384
- linearization procedures 11:390
- Lineweaver–Burk 11:384, 390, 396
- linkage 1:600, 5:404, 9:421, 10:20, 13:193
- linkage analysis, *see* linkage groups
- linkage disequilibrium (LD) 1:602, 11:700, 13:193f, 15:375  
 measurement of 13:194
- linkage groups 2:620, 624, 6:606
- linkage mapping, *see* genetic mapping
- linkage studies 1:599
- linker adapter 3:34
- linker lipids 7:309ff
- linking library 5:452, 15:556, 564
- lipase 2 of *Moraxella* TA144 14:657
- lipases 4:207, 7:98ff  
 endothelial lipase 7:198  
 hepatic triglyceride lipase 7:198  
 hormone-sensitive 7:98  
 lipoprotein lipase 7:198
- lipid A 7:260
- lipid analogs 4:198
- lipid bilayer 14:4  
 membrane 8:374, 378  
 transition temperature 8:144
- lipid binding sites 1:244
- lipid biochemistry 7:278–280
- lipid biophysics 11:74
- lipid droplets, *see* LD
- lipid panel 7:287
- lipid peroxidation 4:635ff
- lipid raft 1:621, 7:29ff
- lipid storage, balance of  
 regulatory mechanisms 1:6
- lipid transport 7:198  
 disorders 7:234  
 abetalipoproteinemia 7:207  
 Anderson disease 7:212  
 chylomicron retention disease 7:212  
 familial combined hyperlipidemia 7:210  
 familial hypercholesterolemia 7:208  
 familial hypobetalipoproteinemia 7:210  
 familial ligand-defective 7:209

- hepatic lipase deficiency 7:208
- hypercholesterolemia 7:211
- sitosterolemia 7:212
- tangier disease 7:214
- dysbetalipoproteinemia
  - type III hyperlipidemia 7:234
- endogenous 7:204
- exogenous 7:199
- reverse cholesterol transport 7:213
- lipid-absorption 14:639
- lipid-linked oligosaccharide 5:577
- lipids 1:2f, 4:665ff, 7:102, 278, 11:120, 13:685, 686
- Lipinski 3:617
- Lipinski's "Rule of 5" 11:624
- Lipoarabinomannans (LAMs) 1:366, 10:92
- lipocortins 1:242
- lipodystrophy 1:15, 6:156f, 167, 7:34ff, 14:640
- Lipofectin
  - DOTMA and DOPE 15:492
  - transfection agent 15:492
- lipofuscin fluorophores 12:391
- lipogenesis 14:637ff
  - triglycerides 7:33
- lipolysis 14:624ff
  - triglycerides 7:33
- lipopeptides 1:391, 10:91
- lipoplex 15:288, 292, 300–305
  - antisense plasmid 15:311
  - cancer 15:309, 310, 312
  - CFTR 15:311ff
  - major histocompatibility complex (MHC) gene 15:311
  - sigma receptor 15:309
- lipopolyplex 15:288, 300, 305–306, 315
  - cancer vaccine 15:310
  - folate 15:307
  - immunoglobulin receptor (IgR) 15:314
  - oligonucleotides (ODN) 15:307
  - polylysines (PLL) 15:312
- lipopolysaccharide (LPS) 6:412, 7:3, 10:91, 11:111
- lipoprotein 4:338, 5:215, 219, 7:198ff, 10:91
  - analysis of 7:277–292
  - assay results, interpretation of 7:291–292
  - electrophoresis of 7:288–289
  - fractionation of 7:285–289
  - function of 7:280–283
  - overview of 7:278–283
  - proatherogenic 7:285
  - structure of 7:280–283
  - subfractionation of 7:289
- lipoprotein analysis
  - diagnostic application of 7:289–292
  - standardization of 7:289–291
- lipoprotein components
  - analysis of 7:283–285
- lipoprotein lipase deficiency 7:201
- lipoprotein lipase (LPL) 1:4, 5:215, 223, 7:200ff, 206, 14:626ff
- lipoprotein receptors
  - ApoB48 receptor 7:203
  - as a target for gene therapy 5:224–225
  - LDL receptor 7:202, 203
  - LDL-receptor-related protein 7:202, 203
  - VLDL receptor 7:203
- liposome 4:192, 7:300ff, 8:129, 133, 142, 14:164, 174, 187–190
  - enhanced metabolic degradation 15:493
  - immobilized-liposome chromatography 8:148
  - low endocytosis rates 15:493
- lipoteichoic acid (LTA) 7:3, 10:91
- lipotoxicity 1:3, 7:34ff, 14:627ff
- lipoxigenase 7:98, 8:217
- lipoyl functions 9:586
- liquid array 11:112
- liquid chromatograph (LC)–mass spectrometry (MS), *see* LC-MS
- liquid–liquid extraction 2:47
- liquid-phase separation 8:12
- Listeria monocytogenes* 1:371, 4:208, 6:559, 8:449
- live attenuated RSV vaccines 12:316–317
- live bacterial vaccines 6:303
  - live attenuated organism 6:298
- live recombinant subunit vaccines 12:316
- live vaccines 6:298, 302, 303
- live-attenuated vaccine
  - cytomegalovirus 3:175
- live-attenuated virus 15:146
- liver 4:341
- liver tissue slices 3:627
- liver X receptor 7:43
- living organism (animal) patents 7:367–388
- LMO2 12:410, 15:269
- load-bearing layer 1:539
- local changes in the DNA sequences 5:338, 344
- local compositional complexity
  - entropy principle of 10:466–469
- local minima 3:608, 11:392
- local model 3:615
- local parameters 11:390, 393
- localized detection 7:188
- locally multiply damaged sites (LMDS) 7:152



- lock and key 11:598  
 locked nucleic acids 1:408ff  
 locus 1:600, 5:574, 15:557, 568  
 locus control region (LCR) 12:688, 15:254  
   transcription factor 2:383  
 LOD (log-odds) score 1:600, 6:606  
 LogD 3:602  
 logical circuits 14:143  
 logical trap 10:451  
 log-odds complexity distribution 10:468  
 LogP 3:602  
 LogPcyc 3:602  
 log-phase 1:528, 7:540  
 LOH 6:4, 11, 12:348  
   and mutations of the APC gene 6:19  
   at 13q 33–34 6:6  
   of 18q 6:20  
   of the APC, DCC 6:5  
   of the p53 6:20  
   on chromosome 17q21 6:15  
 Lon 13:509  
 long interspersed repeat element (LINE)  
   1:263, 318, 3:21, 36, 9:262, 15:557, 562  
 long term depression (LTD) 4:607, 11:563,  
   578, 15:34  
 long terminal repeat (LTR) 13:253  
 long-chain acyl-CoA 14:632ff  
 long-chain fatty acids (FA) 7:74ff  
 long-range jumps 12:331  
 long-range repetitive element-polymorphism  
   PCR 1:314, 315  
 long-term gene expression 7:315  
 long-term potentiation 4:607, 11:563, 578,  
   14:459  
 long-term sensitization 10:44–45  
 lophine 2:524  
 L-ornithine 8:227  
 loss of imprinting (LOI) of IGF2 6:21  
 loss of neurons  
   brain 1:69  
 loss of p27 expression 6:13  
 loss of RUNX3 6:11  
 loss-of-function 1:216, 2:120–121, 4:398,  
   11:657, 690, 15:9ff  
 loss-of-function mutations 3:341, 5:372, 400  
   dominant negative effects 3:340  
 loss-of-heterozygosity (LOH) 11:695, 12:367  
 lovastatin 10:655ff, 14:357–360  
 Løvtrup Søren 8:532  
 low DNA transfer rates 15:498  
 low temperature 1:431  
 low transfection rates 15:493  
 low-abundance 8:12, 34  
 low-complexity repeats (LCR) 13:95  
 low-density lipoprotein receptor, *see* LDL  
   receptor  
 low-density lipoproteins, *see* LDL  
 lower-body obesity 14:690  
 Lowicryl resins 4:51  
 low-melting domain 9:315  
 low-melting-point (LMP) agarose 3:389ff  
 LOX1, *see* OLR1  
 Lp(a), *see* apolipoprotein (a)  
 LPL 7:216  
   cofactor 7:231  
 lpr 1:476  
 LPS 1:378, 380, 396, 14:452  
 LPS recognition system  
   CD14 1:377  
   LPS-binding protein (LBP) 1:377  
   TLR-4 1:377  
 LQT1 11:663, 666  
 LQT2 11:663  
 LQT3 11:663  
 LQT5 11:666  
 LQT7 11:665  
 LQT genes 11:664  
 LQT mutations 11:663  
 LQT syndromes 11:662  
 Lrp 3:541  
 LR-resins 4:34  
 L-shape 12:626  
 LSS 13:93  
 LTD, *see* long-term depression  
 LTP, *see* long-term potentiation  
 LTR retrotransposon, *see* retrovirus  
 LTR, *see* long terminal repeat  
*Lubomirskia baicalensis* 13:290  
 luciferase 2:523ff, 13:292  
 luciferin  
   firefly 2:523  
 lucigenin 2:524  
*Lumbricus terrestris* 6:88  
 luminal vesicles 4:186  
 luminescent reporter 12:456, 464  
 luminol 2:523ff  
 luminometer 2:522ff  
 lung cancer 5:354ff, 11:112  
   metastases 5:365  
   non-small-cell lung cancer (NSCLC)  
     5:354  
   pre malignancy and second primary cancers  
     5:364  
   primary cancer 5:365  
   recurrent cancers 5:365  
   second primary cancers 5:365  
   small-cell lung cancer (SCLC) 5:354  
   small-cell/large-cell carcinoma 5:357

- lung cancer families  
 in young individuals (50 or less) 5:355
- lung infections 8:632  
 airway surface liquid (ASL) 8:630  
 anaerobic growth conditions 8:630  
 antimicrobial peptides 8:630  
 ASL 8:638  
 cytokines 8:633f  
 defensins 8:630  
 emphysema 8:633  
 fibrosis 8:633  
 growth hormones 8:633  
*Haemophilus influenzae* 8:629  
 hypertonic saline 8:635  
 inflammation 8:630  
 mucociliary clearance 8:635  
 mucus hypersecretion 8:633  
 mucus viscosity 8:630  
 neutrophils 8:633  
 nitric oxide 8:633  
 NO 8:634  
*Pseudomonas aeruginosa* 8:629, 630  
 reactive oxygen species 8:633  
 sputum 8:636  
*Staphylococcus aureus* 8:629, 630
- lung surfactant 10:279
- LUNX3 loss 6:11
- lupus 1:477, 11:111
- lupus erythematosus 8:455
- lupus nephritis 8:453
- luteinizing hormone (LH) 4:384ff, 13:7
- luteinizing hormone receptor 4:389
- lutropin 5:553
- LUX primers 11:493
- LXR 7:215, 233
- LXR $\alpha$  7:199, 220, 224, 225
- LXR $\beta$  7:199, 224, 225
- $\beta$ -lyase 2:67
- 17,20-lyase inhibitors 13:52
- lyme arthritis 14:39
- lyme neuroborreliosis 15:164
- lymph nodes 1:362, 376, 387, 390
- lymphangiogenesis 5:638
- lymphatic system 6:385, 395
- lymphatic vessels 15:208, 210
- lymphedema 15:209
- lymphocytes 6:385, 388, 411, 8:441–443, 451  
 IL-2 14:47
- lymphocytic choriomeningitis virus (LCMV)  
 3:228, 6:391
- lymphoid DCs 1:388
- lymphoid tissues 1:363f, 371, 390, 391  
 bronchial-associated lymphoid tissues (BALT)  
 1:362
- gut-associated lymphoid tissues (GALT)  
 1:362
- mucosal-associated lymphoid tissues (MALT)  
 1:362
- Peyer's patches (PP) 1:362
- lymphokine-activated killer (LAK) cells 3:135,  
 6:437, 472, 8:456
- lymphokines 5:306, 639, 651, 8:434, 13:118
- lymphoma 1:399, 4:214
- lymphotoxin 6:398, 8:438, 447
- Lyn 1:381
- lyonization 4:619, 5:612
- lysine 11:108
- lysine 2,3-aminomutase 4:120
- lysobis-PA 10:290
- lysobisphosphatidic acid (LBPA) 1:620, 4:203
- lysogenic bacteriophage 9:352, 354
- lysogeny 13:438ff  
 generalized transduction 13:438
- lysophosphatidic acid 4:193
- lysosomal channelopathies 11:698
- lysosomal enzymes  
 Man-6-P 5:581, 582
- lysosomal storage 5:592
- lysosomal storage diseases 1:629
- lysosome-related organelles 1:621
- lysosomes 1:619, 4:401, 8:123, 10:188  
 biogenesis 4:206  
 lysosomal storage diseases (LSDs) 4:213  
 secretory 4:208
- lysosomotropic 14:165
- lysozyme 1:46, 2:254, 4:670ff, 7:170f
- lytic bacteriophage 9:352, 354
- lytic infection 9:354
- m**
- M13 5:521
- M1000, Abbott 6:557
- M cell 1:363, 8:607
- M current 11:678
- M. genitalium* 3:661
- macaques 15:143
- Mac-1 (CD11b/CD18) 1:377
- Machado–Joseph disease (MJD) 15:19ff
- machine learning 9:260
- macroautophagy 1:620, 627
- macrocyt formation 3:327
- macrolide antibiotics 12:501
- macromolecular NMR 13:522
- macromolecular phasing  
 anomalous scatterers 11:279  
 heavy-atom labels 11:279  
 isomorphous replacement 11:279  
 molecular replacement 11:279

- macromolecular phasing (*continued*)  
 SAD and MAD phasing 11:279  
 selenomethionine 11:279
- macromolecule–ligand interactions 13:551, 552
- macronucleus paramecia 1:69
- macroorchidism 4:588, 604
- macrophage mannose receptor (MMR) 6:414, 10:90
- macrophage migration inhibitory factor (MIF) 6:479–480, 8:434
- macrophage proliferation 6:470
- macrophage scavenger receptors (MSR) 6:414, 10:90
- macrophages 1:358, 361, 363, 375ff, 377, 389, 391, 394, 2:293, 3:117, 126, 4:193, 208, 636, 6:22, 345, 10:93, 180, 295, 297, 15:164  
 activation 1:378  
 alveolar 1:364  
 antigen recognition receptors 1:376  
 bone marrow–derived monocytes 1:376  
 cellular origin 1:375  
 cross talk 1:375  
 effector functions 1:379  
 endocytic pathway of 10:188  
 innate immune response 1:375  
 Kupffer cells 1:376  
 phagosome maturation in 10:188–189
- macropinocytosis 1:390, 3:218  
 macropinosomes 4:193
- mad cow disease 3:91
- MAD technique 7:435  
 basic equations 7:436  
 dispersive differences 7:437
- MadCAM-1 2:333
- Madin–Darby canine kidney (MDCK) cells 2:362, 4:200
- MADS 10:542  
 box gene 10:310, 351  
 box proteins 14:264  
 transcription factors 14:266
- magainin 4:488
- MAGI 13:283
- magma 10:9
- Magnaporthe grisea* 10:370
- magnesium 12:333
- magnesium–lead catalyst 10:13
- magnetic field 4:3, 117
- magnetic fluid hyperthermia (MFH) 9:43
- magnetic induction of electric fields 4:2
- magnetic nanoparticle  
 conjugates of 9:43–45  
 in biomedical sciences 9:43–44
- magnetic resonance spectroscopy 4:117, 13:674
- magnetization transfer experiments 13:589
- magnetosomes 4:2
- Maillard reactions 4:511
- main olfactory system  
 basic structure of 12:642–656
- maintenance of genomic integrity  
 DNA damage repair 9:9  
 homologous recombinational repair 9:9  
 mismatch repair 9:9  
 nonhomologous end joining 9:9
- maize 5:499, 10:361, 14:257, 260
- major basic protein-2 (MBP-2) 6:346
- major grooves 2:13
- major histocompatibility complex, *see* MHC
- major transitions 15:183
- malaria 7:472, 8:453  
 vaccine 15:160, 164
- malate–aspartate shuttle 8:173
- malate dehydrogenase 7:106
- malate synthase 2:610
- MALDI 7:596, 8:8, 9, *see also* Matrix-assisted laser desorption and ionization
- MALDI-MS 2:262, 8:11, 13, 24, 27, 32, 34, 10:541
- MALDI-TOF (matrix assisted laser desorption ionization time of flight) 8:9, 15, 18, 10:402
- MALDI-TOF MS 2:262, 8:12, 24, 12:104  
 advantageous for TS using 9:406
- male gamete formation  
 cytoplasmic male sterility (CMS) 12:268  
 fertility restorers 12:268  
 microgametogenesis 12:266ff  
 bicellular pollen 12:267  
 generative cell 12:267  
 male germ unit (MGU) 12:267ff  
 pollen grain 12:267  
 pollen mitosis 12:267  
 pollen wall  
 columella 12:267  
 exine 12:267  
 intine 12:267  
 nexine 12:267  
 sexine 12:267  
 sporopollenin 12:267  
 tectum 12:267  
 sperm cells 12:267  
 vegetative cell 12:267
- microsporogenesis  
 archesporial cell 12:264ff  
 cell wall formation 12:266  
 endothecium 12:265  
 microsporangium 12:265

- microspore 12:265ff
- middle layer 12:265
- pollen mother cells (PMCs) 12:265
- primary parietal cell 12:265
- primary sporogenous cell 12:265
- tapetum 12:265
- male gametes 14:7–8
- male pseudohermaphroditism 13:24
- male sterile plants 14:554
- maleimide 11:108
- malignancies
  - hematological 3:231–232
  - virus-associated 3:231
- malignant, *see* cancer
- malignant diseases 15:415
- malignant hyperthermia 11:670, 673
- malignant melanoma 1:399, 15:341–342
- MALLS 2:260
- malonyl-CoA 7:99ff, 14:637ff
- MALT, *see* lymphoid tissues
- malting quality 14:571
- MAM 10:286, 289, 300
- mammalian 4:367, 368, 5:498
- mammalian cell 2:42, 401
- Mammalian Gene Collection 11:105
- mammalian prions 10:594
- mammalian stem cells 1:225
- mammals
  - carcinogenesis in 12:121–122
- mammary acini
  - functional integrity and structural accuracy, relationship between 14:400
- manganese 8:217, 227, 228, 231
- manganese superoxide 8:227
- manganese superoxide dismutase (Mn-SOD) 10:123
- mania 1:607
- MANIP 12:618, 624–626, 628, 633
  - comparative sequence analysis 12:632
  - group II intron 12:631, 632
  - hammerhead ribozyme 12:632
- mannan-binding lectin (MBL) 6:413
- mannose 2:249
- mannose 6-phosphate 1:619
- mannose receptor (MR) 1:377
- mannose-binding lectin-associated serine proteases (MASPs) 5:585
- mannose-6-phosphate receptors (MPR) 4:203
- mannose-6-phosphate/insulin-like factor 2 receptor (M6P/IGF2R) 7:328
- $\alpha$ -mannosidases 5:546, 556
- mannosidases 2:254
  - N-linked glycoproteins 5:579
- $\alpha$ -mannosidosis 5:591
- $\beta$ -mannosidosis 5:591
- mannuronic acid 2:249
- Man-Ser/Thr linkage
  - $\alpha$ -dystroglycans 5:575
  - nervous system 5:575
- mantle 10:5
- manufacture of AAV 15:247
- MAP kinase (mitogen-activated protein kinase) 2:464, 466, 4:390ff, 5:503, 6:389, 7:31, 118ff, 8:314ff, 315, 318, 440, 9:462, 10:370, 378, 11:553, 583, 584, 589, 13:146ff, 159ff, 165, 14:451, 15:294
  - active form 2:473
  - c-mos 2:472
  - ERK 1/2 2:472
  - ERK 5 2:472
  - JNK/SAPK 2:472
  - MEK 1/2 2:472
  - p38 2:472
  - phosphorylation 2:472
  - Raf 2:472
- MAP1B 4:598
- MAPK and MPF
  - Cyclin B1 2:471
- MAPKK 8:230
- maps and pathways 3:653
- maps, genomic 7:345
- margination 6:344
- marine bacterial luciferase 2:528
- marine sources 14:347–348
- marked retention of nitrogen 13:31
- marker chromosomes 3:46
- marker DNA 6:449, 450
- marker expression 2:225, 231
- marker genes 14:548, 551
  - antibiotic resistance genes 14:552
  - excision of marker genes 14:553
  - herbicide resistance genes 14:552
- marker rescue 5:197
- markers 2:536, 539, 5:443, 15:618
  - anonymous markers 5:444
  - polymorphic
    - microsatellites 5:444ff
    - minisatellites 5:444
    - single-nucleotide polymorphism (SNP) 5:444
- Markov chains 9:253
- Markov process 9:250
- Marks Jonathan 8:527, 536ff
- Mars 10:4
- Martin–Bell syndrome 4:588
- masking 12:415
- masking of mutation 1:86
- mass action ratio 8:169

- mass analyzers 8:8
- mass increase 1:547
- mass spectrometry (MS) 3:252, 7:559, 8:3, 5, 10, 18, 20, 21, 25, 31, 33, 194f, 508, 9:93, 104, 307, 10:541, 11:110, 310, 318
  - DNA fragment sizing of 7:587–616
  - DNA sequencing of 7:596–603
  - DNA sizing of 7:596–603
  - electrospray ionization 2:261, 5:35
  - glycans 2:261
  - glycopeptides 2:253
  - in-gel tryptic digestion 5:39
  - liquid chromatography, *see* LC-MS
  - of proteomics 11:315ff
  - peptide mass fingerprinting 5:36
  - protein identification from gels 5:35, 42
  - sequence information 2:268
- massive parallel signature sequencing 12:715
- massively parallel hybridization, *see* DNA chip
- MAST® 6:375
- mast cells 6:347, 10:93, 94
  - activation 14:46
  - bone marrow progenitor 14:42
  - C3a and C5a 14:40
  - chemokine receptor
    - CXCR3 14:41
  - chondroitin sulfate
    - activation 14:50
  - c-kit 14:42
  - CRH 14:48
  - cytokines 14:50
  - degranulation 14:46
  - disodium cromoglycate (cromolyn) 14:49
  - epidermal growth factor (EGF) 14:41
  - flavonoids 14:49
    - quercetin 14:50
  - histamine-releasing peptide (HRP) 14:43
  - HPA
    - IL-6 and IL-1 14:48
  - HRP 14:43
  - IL 14:41, 50
  - immunoglobulin E (FcεRI) 14:42
  - intragranular activation 14:46
  - juvenile RA
    - IL-6 14:40
  - mediators 14:48
    - biogenic amines 14:46
    - de novo synthesized molecules
      - chemokines 14:45
      - cytokines 14:45
      - growth factors 14:45
    - eicosanoids 14:46
    - histamine 14:46
    - IL-6 14:46
  - major actions 14:45
  - molecules 14:45
  - prestored molecules
    - biogenic amines 14:45
    - enzymes 14:45
    - peptides 14:45
    - proteoglycans 14:45
    - tryptase 14:46
  - metalloproteinases 14:40
  - neurohormonal 14:47
  - neurons 14:47
    - CRH 14:48
  - neuropeptides 14:42
  - perivascular 14:47
  - pheochromocytoma cells 14:42
  - piecemeal degranulation 14:46
  - platelet-derived growth factor (PDGF) 14:41
  - proteolytic enzyme 14:42
  - selective secretion 14:45
  - stem cell factor 14:42
  - TNF 14:41
  - TNF-α 14:40, 50
  - triggers
    - anaphylatoxins 14:44
    - antigens 14:44
    - cytokines 14:43, 44
    - drugs 14:44
    - enzymes 14:44
    - free radicals 14:44
    - growth factors 14:44
    - histamine-releasing factors 14:43
    - hormones 14:43, 44
    - neuropeptides 14:43
    - neurotransmitters 14:44
    - peptides 14:44
  - vascular endothelial growth factor (VEGF) 14:41
  - vesicles 14:46
  - Master Cell Banks 15:166
  - master gene 2:568
  - master mix 11:511ff
  - master regulator
    - Spo0A 8:300
  - master switch 1:60
    - BRCA1-associated genome surveillance complex (BASC) 1:73
    - poly(ADP-ribose) polymerase, or PARP 1:63
  - Master Working Cell Bank (MWCB) 13:266
  - mastitis (in cattle) 7:360
  - mastoparan 13:154
  - MATα2 6:185ff
  - Mat1 12:164
  - mated model 12:46

- maternal antibody  
transplacentally acquired 12:307–308
- maternal genes 3:272, 10:484
- maternal IgG 4:202
- maternal inherited mRNA  
regulates initial developmental events  
13:384
- maternal mRNA 10:489
- maternal to zygotic gene transition 10:486
- maternal uterus  
endometrial lining of 13:384  
undergoes decidual reaction 13:384
- mathematical growth law 1:548
- mathematically (mathematically defined-repeat  
or MDR 13:87
- mating 14:232ff
- mating factors 12:144
- mating type 2:621ff, 8:316
- mating type locus (MAT) 6:216ff, 8:317, 319
- matricellular proteins 8:46, 48, 58, 63
- matrigel 14:393, 398
- matrigel technique 14:398
- matrix 13:624  
core 13:610  
crystalloid 13:610, 611
- matrix attachment functions 15:254
- matrix metalloproteases 8:224
- matrix metalloproteinases (MMP) 1:380,  
4:385ff, 6:19, 8:64, 10:127, 13:565, 574, 14:302
- matrix protein (M) 12:305
- matrix-assisted laser desorption and ionization  
(MALDI) 7:562, 588, 592, 8:6, 11:110, 310,  
316, *see also* MALDI
- matrix-attached regions 6:580
- maturation arrest 13:347
- mature CPS mCPS 4:205
- mature oocyte 13:384
- maturity-onset diabetes of the young 7:52
- Max 12:178
- Maxam–Gilbert sequencing 9:308
- maxi chloride channel 8:379
- maximum likelihood 8:529, 9:250, 254, 256
- MC-Annotate 12:615–617
- m*-carboxy cinnamic bishydroxamic acid 4:269
- McCune–Albright syndrome 4:408
- MCM 12:190ff
- MCP 8:311
- MCP-1 14:299
- MC-Search 12:617
- M-CSF 10:221, 223
- MC-Sym 12:612, 618, 620–623, 626–628, 631,  
633
- MDCK 3:624
- MDL 18,962 13:54
- Mdm2 12:187
- MDS 3:46
- MEA/FIE Polycomb Group 14:262
- measles virus 3:227–228
- measurement in biology 10:472–473
- measurement of bacteria 1:510
- mechanical stress 14:409
- mechanism of CGG-repeat expansion 4:613
- mechanisms of genetic variation 5:335
- mechanistic models 3:607
- mechanoenzyme 8:576, 577
- mechanosensation 10:34
- mechanotransduction 2:343, 14:387
- MeCP2 10:131
- medications 13:239
- medium 7:542ff, 545ff  
conditioned 7:542  
serum-free 7:545
- medrogestosterone 13:45, 48
- medroxyprogesterone acetate 13:45
- Mefloquine 14:368–372
- megabase-size DNA 3:389ff
- megagametophyte 1:417
- megakaryocytes 12:152, 161
- megalín 4:212
- megaloblastic anemia 12:163
- MEIA, (microparticle enzyme immunoassay)  
6:557
- MEIDOS 14:262
- MEINOX 6:217
- meiosis 1:77, 80, 82, 89, 91, 2:391, 622, 3:562,  
563, 5:318, 372, 7:499, 9:61, 13:192, 14:6–7  
maturation promoting factor 14:19–20  
sporulation 1:88
- meiosis, adaptation for removing DNA damage  
1:69, 77
- meiosis, periodic  
germ line 1:69  
immortality 1:69
- meiosis, plant  
differences of 12:265  
genes affecting of 12:265
- meiosis, vertebrates  
recombinational repair 1:90  
sexual signals 1:90
- meiotic arrest 14:19–20
- meiotic HR  
programmed DSBs 12:13  
Spo11 12:13  
synaptonemal complex 12:13
- meiotic recombination 1:81, 13:196
- MEIS 6:214ff
- Meis1 2:232
- MEIS or HM domain 6:214ff

- MEK1  
 constitutive activity 7:123  
 dominant-negative 7:123  
 knock out 7:123  
 PD98:59 7:123  
 U0126 7:123
- Mek 7:122
- melanocyte stimulating hormone (MSH)  
 14:181
- melanocytes 13:219, 223
- melanoma 3:230, 378, 4:338, 8:456
- melanoma inhibitory activity (MIA) 15:341
- melanopsin 12:435ff
- MELAS 10:118
- melatonin 12:418, 446, 449ff
- melittin 4:488
- mellibiose 12:29
- melting curve 3:188, 190
- melting temperature 2:557, 3:190, 9:334, 335, 414
- membrane 2:47, 7:172, 8:12, 31, 34, 10:15, 13:312  
 bacterial outer 8:376  
 mitochondrial inner 8:359ff, 370, 377  
 mitochondrial outer 8:359ff, 376f, 379  
 model 8:361, 362  
 nuclear 6:140, 144
- membrane association 12:388
- membrane compartment channelopathies 11:698
- membrane curvature 4:192
- membrane dynamics 7:172
- membrane filtration 1:515
- membrane fission 4:192, 11:71
- membrane fusion 4:307ff, 11:72
- membrane insertion 12:507–508
- membrane potential 4:425
- membrane potential ( $\Delta\psi$ ) 8:165
- membrane protein 3:70, 4:672ff, 13:551  
 integral membrane protein 8:142  
 peripheral membrane protein 8:142, 145  
 transmembrane protein 8:142ff
- membrane translocation 14:182
- membrane tubulation 4:192
- membrane-associated adaptor proteins 9:462
- membrane-associated nonreceptor tyrosine kinases 9:461–462
- membrane-associated phospholipase 9:462
- membrane-bound fusion proteins (SNAREs) 11:81
- membrane-elution 1:533
- memory 4:338, 14:459
- memory CD4+ T cells  
 generation of 6:390–392  
 maintenance of 6:397  
 memory generation of 6:397  
 phenotype of 6:396–397  
 phenotyping 6:388–389  
 trafficking of 6:397
- memory cd8+ T cells  
 enhanced responsiveness of 6:389–390
- memory cells  
 characteristics of 6:388
- Mendelian 5:260, 380, 11:657
- Mendelian traits 5:380
- meninges 15:265
- meningococcus B  
 vaccine 15:174
- mental retardation 4:588
- MEPPs 11:668
- 3-mercaptop-2-methylpentanol, odor 2:597
- mercuric chloride 1:494
- mercury 1:474
- mercury cadmium telluride (MCT) 13:676, 680
- meristem 1:417, 3:296
- merkel cells 13:221, 232
- mesenchymal stem cell-like protein 13:277
- mesial temporal sclerosis 13:690
- mesoderm 2:89, 13:219, 296, 330
- mesothelioma 12:122
- messenger RNA (mRNA) 2:380, 8:247–248, 264, 265, 9:324, 12:301, 13:19, 254
- messenger RNP(mRNPs) complexes 15:34
- Met (HGF receptor)  
 $\alpha$ -chain 7:131  
 $\beta$ -chain 7:131  
 hepatocyte growth factor/scatter factor 7:131  
 mesothelioma 7:132  
 MET precursor protein 7:131  
 MET-binding domain 7:132  
 osteosarcoma 7:132  
 pancreatic cancer 7:132
- meta genomes  
 portions of ruminant stomach 13:110
- metabolic end products  
 acetyl methyl carbinol detection of 1:518  
 aesculetin production from aesculin 1:520  
 hydrogen sulfide 1:518  
 indole 1:517  
 levan production 1:520  
 methyl red test 1:518  
 nitrates, reduction of 1:518
- metabolic engineering 10:658
- metabolic inhibitor 1:431
- metabolic labeling 8:18, 20, 28
- metabolic networks 6:591, 592
- metabolic NMR 13:522

- metabolic oxidation 14:371  
 metabolic pathways 9:251, 12:719  
 metabolic profiles 8:191ff  
   bias 8:193  
   completeness 8:192  
   cost 8:193  
   temporal stability 8:203  
   time series 8:200  
 metabolic regulation 11:3, 21  
 metabolic resistance 7:485  
 metabolic syndrome 7:51  
 metabolic trajectory 8:201, 203  
 metabolic transformations of androgens 13:11  
 metabolism 1:2, 3, 3:626, 4:335, 10:220, 12:106  
   bacterial 8:201  
   human 8:200  
 MetabolismExpert 3:606  
 metabolites 11:120  
   carriers 8:179  
   glycolytic 7:100  
   nitrogen 10:96  
   regulation by 10:350–351  
   transporters 8:182  
 metabolome 3:643  
 metabonomics 8:189ff  
 metabotropic glutamate receptor 7:487,  
   13:282, 15:34  
 metal chelator 8:214  
 metal cofactor 8:215, 216, 218  
 metal contamination 9:300  
 metal ion binding characteristics  
   amino acids 1:651  
   nucleic acids 1:653  
   nucleosides 1:652–653  
   peptides 1:651–652  
   proteins 1:652  
 metal ions 10:10, 24  
   control of 2:636  
   hydrolysis 1:643  
 metal shadowing 4:101, 104, 105  
   platinum–palladium 4:90  
 metal sulfides 10:9  
 metalloprotease 8:210ff, 230  
 metalloproteins 7:456  
   cytochrome-c nitrite reductase  
     anomalous difference Patterson maps  
       7:460  
     anomalous dispersion contributions  
       7:460  
     biological nitrogen cycle 7:460  
     Ca<sup>2+</sup> 7:462  
     catalytic 20S particle 7:462  
     dimer formation 7:461  
     five hemes 7:461  
   MAD technique 7:458  
   molecular replacement 7:462  
   one compact domain with  $\alpha$ -helices  
     7:461  
   proteolytic chamber 7:462  
   19S cap 7:462  
   26S proteasome 7:462  
   site of nitrite reduction heme 1 7:462  
   six-electron reduction of nitrite to  
     ammonia 7:460  
   ubiquitin-labeled target proteins 7:462  
   X-ray fluorescence spectrum 7:460  
 multicopper enzyme ascorbate oxidase  
   azurin 7:457  
   “blue” oxidases 7:457  
   functional derivatives 7:458  
   homotetramer 7:457  
   intramolecular electron transfer 7:458  
   MIR technique 7:457  
   mononuclear centers 7:457  
   plastocyanin 7:457  
   similar  $\beta$ -barrel type 7:457  
   three-domain structure 7:457  
   trinuclear copper centers 7:457  
 metalloregulatory proteins 8:347  
 metallothionein (MT) 1:227, 8:347  
 metal-responsive element (MRE) 8:344, 345  
 metal-responsive transcription factor (MTF)  
   8:344  
 metaphase 6:139ff  
 metaphase arrest 14:20–21  
 metaphase chromosome 3:20, 5:146ff  
   preparation 5:147  
 metaphase I oocyte, *see* oocyte  
 metaphase mapping  
   chromosome breakpoint 5:162  
   quantitative FISH (Q-FISH) 5:163  
   relational mapping 5:161  
   segmental duplications 5:161  
   single-copy genes 5:160  
 metaphosphate 12:324, 333  
 metaplasia 3:272, 13:366  
 metastasis 4:260, 338, 15:210  
 metastasis suppressor genes 2:203  
 metastatic ovarian carcinoma 14:190  
 metazoa 13:272ff, 15:368  
 metazoan organism 6:341  
 metazoan pattern formation 13:276  
 Metchnikoff, Elie 1:375  
 Meteor 3:606  
 meteorites 10:8, 11, 12  
   amino acids 2:614  
 methacrylate polymers  
   microencapsulation 15:497



- methandienone 13:42  
methandriol 13:25  
methandrostenolone 13:34, 42  
methane 10:5  
  genetics 8:244  
  methanoarchaea 8:240  
methanococcus 8:252–254  
methanogenesis  
  biochemistry of 8:239–244  
  two major pathways, steps to 8:241–242  
Methanogens  
  coenzymes 9:587  
  molecular biology of 8:237–257  
methanol 1:422  
methanosarcina 8:254  
methenolone acetate 13:35  
MET/HGF receptor family 9:460  
methionine sulfoxide reductase 4:643  
methionine synthase 8:226  
methotrexate 13:577, 579  
2'-methoxy oligonucleotides 9:421  
methyl cytosine amplification (MCA) 9:111  
methyl jasmonate 1:431  
methyl red test 1:518  
7 $\alpha$ -methyl  
  1,4-seco-2,3-bisnor-5 $\alpha$ -androstan-17 $\beta$ -ol  
  13:28  
methyl transferases 2:65, 12:324  
1-methyladenine 10:21  
3-methyladenine 1:625  
1-methyl-1,4-androstadiene-3,17-dione 13:54  
17 $\alpha$ -methyl-5 $\alpha$ -androstan-17 $\alpha$ -ol 13:38, 43  
17 $\alpha$ -methylandrostan-17 $\beta$ -ol[2,3-*d*]isoxazole  
  13:39  
2 $\alpha$ -methyl-5 $\alpha$ -androstan-17 $\beta$ -ol-3-one 13:35  
17 $\alpha$ -methylandrostan-5-ene-3 $\beta$ ,17 $\beta$ -diol 13:25  
17 $\alpha$ -methyl-5 $\alpha$ -androstan-2-en-17 $\beta$ -ol 13:38  
methylases 2:53  
methylated DNA binding proteins 4:261  
methylation 3:358, 431, 439, 8:535, 9:304,  
  14:237ff, 239ff, 268, 15:33ff  
  cytosine methylation of 5-position (5MeC)  
  5:431  
  methylated state 5:414  
  methylation analysis 2:266ff, 5:547  
  methylation-sensitive enzyme 4:617, 5:414  
17 $\alpha$ -methyl-B-nortestosterone 13:45  
methyl-CpG-binding domain (MBD) proteins  
  10:131, 14:268  
5-methylcytosine 4:241  
7 $\alpha$ -methyl-14-dehydro-19-nortestosterone  
  13:36  
6-methyleneandrost-4-ene-3,17-dione 13:55  
17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one  
  13:34  
1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one  
  13:35  
17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9,11-trien-3-one  
  13:35  
methylmalonyl-CoA mutase 8:227  
methylphosphonate linkages 9:420  
17 $\alpha$ -methyltestosterone 13:5, 10, 25, 29, 39  
methyltetrahydrofolate 8:226  
methyl- $\beta$ -thiogalactoside 12:29  
MetJ-regulated genes 3:525  
metkephamid 10:219  
metalloproteins 7:457  
mevalonate 1:425  
mevastatin 10:655  
MF59 8:615  
mfold 12:591  
MGDF (megakaryocyte growth and  
  differentiation factor) 9:532  
MHC antigen 13:355, 15:415  
MHC blocks 13:198, 209  
  frequency distribution of 13:203  
MHC class I 1:368, 15:148  
  classical receptors 6:484–486  
  hydrogen-bonding network 1:365  
  nonclassical receptors 6:484–486  
  self-peptide repertoire of 1:366  
  specificity pockets 1:365  
  x-ray structure 1:365  
MHC class I loading complex  
  calnexin 1:369  
  calreticulin 1:370  
  ERp57 1:370  
  ( $\beta_{2m}$ ) 1:369  
   $\alpha$ : $\beta_{2m}$ -peptide complexes 1:370  
  TAP 1:370  
MHC class I molecules 1:364ff, 368, 394, 7:464  
  immunoglobulin domains 1:364  
  peptide ligands 1:364  
MHC class I processing  
  ER-resident aminopeptidase ERAP-1 1:368  
  immunoproteasome 1:368  
  proteasome 1:368  
  TAP 1:368  
MHC class II 1:370, 390, 13:642  
  self-peptides 1:367  
MHC class II molecules 1:360, 363, 366ff, 381,  
  383–385  
  class II binding cleft 1:366  
  crystallographic structure 1:366  
  naturally processed peptides 1:366  
  peptide ligand motifs 1:366  
  specificity pockets 1:366

- MHC class II processing  
 CLIP 1:370  
 invariant chain 1:370
- MHC class III region 13:197
- MHC disease genes  
 mapping of 13:206
- MHC genes  
 class I, II, and III 13:195
- MHC haplotypes  
 ethnic specificity 13:209  
 structural analysis of 13:208  
 variants 13:209
- MHC (major histocompatibility complex)  
 1:359ff, 461, 2:571, 4:209, 6:385, 392, 430,  
 433, 13:193, 641, 14:454  
 bovine 7:359  
 chromosomal region 13:195  
 class III region 13:207  
 genetic fixity 13:198  
 three chromosomal regions paralogous to the  
 MHC 13:206
- MHC paralogous genes  
 classical MHC class I and class II regions  
 13:207
- MHC restriction 1:368, 383
- MHS1 11:673
- MHS2 11:674
- MHS5 11:673
- MIAME 10:536
- MIAME standard 6:596
- mice 15:143  
 history of 14:508–513  
 knockins of 14:533–536
- micellar electrokinetic chromatography (MEKC)  
 14:433
- micelle 14:165, 178
- Michaelis–Menten equation 8:151, 11:41
- Michaelis–Menten kinetics 11:396
- Michaelis–Menten model 8:214, 11:390
- Michelson interferometer 13:680
- micro total analysis systems 14:421–427  
 applications of 14:428–433  
 perspectives of 14:433–434
- microaggregates 15:26
- microarray data  
 normalization of 8:278–279
- microarray experiment – crucial points  
 design of 8:275–278  
 hybridization 8:276–278  
 labeling 8:276–278  
 reference (control) source, choice of  
 8:275–276
- microarray experiments  
 reproducibility 10:539
- microarray expression analysis 3:48
- microarray (gene chips) 3:19, 4:340, 6:596,  
 8:268ff, 501, 9:258, 12:103, 431ff, 441, 444,  
 449, 455, 461, 708, 714ff, 718–721ff,  
 14:262  
 applications 8:281–282  
 data validation of 8:279  
*streptomyces* 13:440
- microarray hybridization 15:617
- microarray technique 12:44  
 historical background of 8:267–269  
 principles of 8:267–269
- microarray-based technology 12:44  
 advantages of 8:263–282  
 array platforms 8:269  
 data 8:278–280  
 fabrication of 8:269  
 interpretation of 8:278–280  
 limitations of 8:263–282  
 principles of 8:263–282  
 statistical data analysis of 8:279  
 technical restrictions of 8:280  
 validation of 8:278–280
- microautophagy 1:628
- microbe hunting 9:355–356
- microbead technology 4:435
- microbial antigens 2:280
- microbial cells 4:678ff
- microbial genome sequencing 13:77
- microbicidal molecules  
 production within phagosomes 10:189
- microbore column 1:424
- Microcal Origin 5.0 13:689
- microcalorimetry 3:555
- microcarrier 7:547
- microchannel 14:428
- microchannel plates (MCP) 7:590
- microcloning 3:33
- microcomplement fixation 8:519
- microculture 3:22
- microdeletion 11:449
- microdiffusion technique 4:93–95, 97
- microdissection libraries 3:44
- microenvironment 13:357
- microevolution 15:183
- micro-FISH 3:44
- microfluidic device 14:423–426, 434
- microfluidics technology 14:406
- microglial cells 10:125
- $\beta_2$ -microglobulin 1:364
- microgravity 2:304–314, 316, 317, 14:406
- microgravity analog culture system (MACS)  
 2:307ff, 312, 316
- microheterogeneity 2:288

- microinjection 1:211, 3:47, 15:616  
   Cyclin A 15:294  
 micromanipulators 3:25  
 micronucleus  
   germ line DNA 1:69  
 micronutrient 8:345  
 microparticle enzyme immunoassay (MEIA)  
   6:557  
 micropipettes 3:25  
 micropolarity 7:160, 163  
 microreactor 14:428  
 microRNA target 12:596  
 microRNAs 9:58, 12:540, 545, 14:265, 267,  
   15:34  
   biogenesis of 12:543  
   cloning of 12:541  
   Drosha 12:543  
   Exportin 5 12:543  
   HOXB8 gene 12:543  
   lin-4 12:541  
   lin-14 12:541  
   mechanism of 12:542  
   miR-196 12:543  
   PAZ domain 12:543  
   stRNA 12:542  
 microsampling methods 4:656ff  
 microsatellite 1:283, 3:46, 480, 5:407,  
   15:4  
   expansion 1:283ff  
   loci 5:249, 7:349  
   markers 15:617  
   polymorphisms 13:209  
   sequences 2:540  
 microsatellite DNA 5:260–261  
 microsatellite instability (MSI) 6:15  
 microscopic examination of bacteria  
   hanging drop 1:510  
   unstained bacteria 1:510  
 microscopy 4:656, 7:167  
   differential interference contrast  
     1:229  
   electron microscopy 8:124  
   epifluorescence microscope 5:156  
   fluorescence microscopy 8:124  
   interference filters 5:156  
 microscopy Nomarski/Smith microscopy  
   1:229  
 microsomal  
   microsomal transfer protein 7:42ff  
   microsomal triglyceride transfer protein  
     7:199, 207  
 microsomes 3:104, 627  
 Microsporidia 6:216ff  
 microtubule 2:638, 640, 4:186ff, 6:144, 8:390,  
   583, 13:627, 628  
 microtubule dynamics and organization 8:485  
 microvillar cell 12:643  
 microvilli 11:684  
 microviscosity 7:161, 165  
 microwells 11:117  
 midbrain specification 2:103–104  
 mid-infrared 4:652, 658ff  
 Migfilin 2:342  
 migration inhibitory factor (MIF) 8:449, 455,  
   9:99  
 milbemycins 14:372–374  
 milk lipid granules 14:651  
 Miller 10:7  
 Miller spreads 4:90, 96, 102  
   C-terminal domain (CTD) 2:382  
   transcription factors 2:381  
 Miller technique 4:101  
 Milroy's disease 15:209  
 mimosa 12:420  
 minerals 10:7, 24  
   catalysts 10:19  
   surfaces 10:10  
 miniature endplate potentials 11:668  
 miniaturization 4:492  
 minichromosome replication 1:542  
 minichromosomes 1:542, 4:98  
   SV40 4:102  
 minimal information about a microarray  
   experiment (MIAME) 10:539  
 minimal tiling path (MTP) 13:72, 75  
 minimum free energy (MFE) structure 12:589  
 minisatellite DNA 5:259–260  
 minisatellites 3:480, 15:4  
 Minnesota Patriots Council 10:513  
 minor groove 13:568  
 minority allele populations 9:318  
 minoxidil 2:64  
 Mip130 12:194  
 MIPS Functional Catalog 6:599  
 miR172 14:267  
 miRNP  
   Ago-2 12:543  
   FMRP 12:545  
   Gemin 3 12:544  
   Gemin 4 12:544  
 misclassification 4:227, 229  
 mismatch repair (MMR) 3:428, 432, 439ff,  
   6:228, 9:388, 10:130  
 mismatch repair proteins MSH3 6:21  
 mispair thermodynamics 3:206–207  
 Mithramycin 10:648ff

- mitochondria 2:627ff, 3:377, 5:496, 6:540–543ff, 8:226, 359ff, 364, 376, 377, 379, 10:300, 623, 624, 626, 13:610, 612, 618–620, 622, 14:13, 15:368  
 destruction 6:543  
 development of embryos 6:541  
 genes 2:628ff  
 genome 2:628, 6:541  
 manganese SOD (MnSOD) 1:59  
 MnSOD 1:59  
 mtDNA 6:541  
 mutations 2:622  
 origin of 15:373–374  
 $\alpha$ -proteobacteria 14:258  
 ROS leakage 1:65  
 sperm-derived 6:538ff  
 TFAM 6:541  
 transmission 6:542ff  
 vegetative survival strategy 1:84
- mitochondria-associated membrane MAM 10:281
- mitochondrial 5:244  
 ATP content 6:542  
 disease 6:542, 543  
 distribution 6:542  
 heteroplasmy 6:542  
 inheritance 6:544  
 mtDNA defects 6:542  
 paternal mtDNA 6:542  
 transmission 6:543, 544
- mitochondrial calcium transporting systems 2:165
- mitochondrial channelopathies 11:698
- mitochondrial DNA 5:257–258, 9:391, 13:210, 384  
 evolutionary studies 15:379–381  
 genetics of 15:376  
   heteroplasmy and segregation 15:374–375  
   inheritance 15:374  
 human migration patterns 15:382–383  
 natural selection in 15:383  
 recombination of 15:375–376  
 tracing human history 15:379
- mitochondrial dysfunction 15:376, 378–379  
 mutations 15:377
- mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms (MELAS) 15:377
- mitochondrial fusion 11:79
- mitochondrial genome 3:331, 12:716  
 evolution of 15:367–383  
 expression of 10:327–329  
 function of 15:367–383  
   gene content of 15:369  
   gene organization of 15:370–371  
   genetic code 15:371–372  
   replication 15:372–373  
   structure of 15:367–383  
   substitution rate 15:376  
   transcription 15:372–373
- mitochondrial genomics 15:381–382
- mitochondrial inner membrane 10:291
- mitochondrial lineages 15:383
- mitochondrial membranes 4:432, 8:359ff
- mitochondrial mutations  
   contribution to aging 15:378–379
- mitochondrial myopathy 15:383
- mitochondrial permeability transition pore (MPTP) 8:361, 10:123, 129
- mitochondrial P450s 3:111
- mitochondrion 8:171  
   inner membrane 11:289
- mitofusins  
   role of 11:79
- mitogen 3:276, 12:153, 166
- mitogen-activated protein kinase, *see* MAP kinase
- mitosis 2:389, 5:372, 6:141, 7:499, 12:143, 14:4  
   chromosome condensation 2:391  
   exit checkpoint 14:24  
   promoting factor 12:145
- mitotic cell cycle 13:384
- mitotic chromosome geometry 3:5
- mitotic clock 2:201
- mitral cell layer (MCL) 12:648
- mixed connective tissue disease 1:464
- mixed gels 14:398
- mixed genomes 13:110
- mixture design 13:597
- Miz1 12:178
- MLCKA (myosin light chain kinase A) 8:329
- MLH 6:8
- MLH1 3:435
- MLH2 3:435
- MLH3 3:435
- MLN1 11:698
- MLVA 1:318
- MMLV-RT 11:485ff
- MMP 8:64
- MMP-2 10:127
- MMP-9 6:17, 10:127
- MMPs 8:66, 69
- MMR mutators 6:234
- MND  
   animal models, identification of 8:562–565  
   axonal transport, disintegration of 8:569–571

MND (*continued*)

- disease mechanisms, identification of 8:562–565
- gene defects, identification of 8:562–565
- treatment of 8:571–573
- Mnk 12:178
- MnSOD 1:67
- mobile DNA elements 12:410–411
- mobile elements, *see* interspersed repeat
- mobile genetic elements 5:337, 341
- mobile introns 11:243
- mobile phase 6:247, 9:301
- mobility pattern 2:556
- model 3:651, 11:387, 14:133
  - predictive power 11:389
  - quality 11:389
  - selection 11:389
  - validity 11:389
- model abstraction 14:135
- model building 14:142
  - atomic model 7:447
  - automatic chain-tracing 7:447
  - computer graphics system 7:447
  - model-building cycle 7:447
  - modeling programs 7:447
  - trace of the polypeptide chain 7:447
- model organisms 2:569ff, 3:326, 330, 4:331, 10:544, 14:251, 252
  - Arabidopsis* 14:266
  - C. elegans* 14:266
  - Caenorhabditis elegans* 14:266
  - Drosophila* 14:261, 266
  - maize 14:255
  - Physcomitrella patens* 14:261
  - rice 14:254–256, 266
  - tobacco 14:254
  - yeast 14:266
- modeling 11:139, 12:106, 14:133
- modeling human annulus 14:400
- modeling package
  - Sybyl, Spartan, or Hyper-Chem 2:28
- modeling tools 3:653
- modified posttranslationally 8:10
- modified vaccinia ancara (MVA) 13:254
- modular design 14:132
- modulators 13:469–471
- modules 14:132
- moiety – recombinant antibody fragments
  - targeting of 6:506–507
- molar absorption coefficient
  - extinction coefficient 3:556
- Molconn-Z 3:606
- molds
  - Ascomycetes* 5:3
  - Basidiomycetes* 5:3
  - Fungi Imperfecti* 5:3
  - Hyphae* 5:3ff
  - hyphal tip 5:3ff
  - mycelium 5:3ff
- molecular anthropology 8:517
- molecular architecture 13:640
- molecular arms race 12:326
- molecular assumption 8:519, 525ff, 526ff, 529–531ff
- molecular beacons 8:505, 11:497
- molecular biology 8:250–257
  - features of 8:244–245
  - promoters 8:246
  - terminators 8:246
  - transcription of 8:245–248
  - translation
    - elongation factors 8:248–249
    - initiation 8:248–249
- molecular cell biology
  - era of 9:271–272
- molecular change 8:517, 520, 521ff, 523ff, 529–531ff
- molecular chaperones 1:25, 34, 371, 620, 629, 10:423, 12:484, 506, 13:465
  - dependence of yeast prions on 10:593–594
- molecular chaperonin GroEL 13:658–660
- molecular characteristics 15:401
- molecular clocks 5:244, 248, 8:517, 519–521ff, 524ff, 531ff
- molecular cloning 10:532, 13:76
- molecular crowding 1:34
- molecular descriptors 6:589
- molecular diffusion 13:591
- molecular disease
  - HbS 6:103
  - hemoglobin, variants 6:69, 101, 103
  - met Hb (or M) mutants 6:103
  - molecular basis of Hb diseases 6:101ff
  - unstable Hbs 6:101
  - see also* hemoglobin variants
- molecular diversity 8:94
- molecular dynamics (MD) 2:28, 7:163, 168, 170, 12:625, 626, 13:657
- molecular dynamics simulation 1:33, 11:134, 146, 13:654
- molecular epidemiology 4:227, 229
  - interaction 4:226
- molecular events
  - c-myc oncogene was amplified in a subgroup of SCLC cell lines 5:356
  - development 5:354ff
  - DNA repair 5:363
  - genesis 5:354

- inactivation of expression by promoter
  - methylation 5:364
- inactivation of Rb 5:363
- 3p allele loss 5:364
- 9p (p16 locus) 5:364
- pause at both the G1 and G checkpoints 5:363
- phosphorylation of the Rb protein 5:363
- premature entry of cells into the next phase 5:363
- progression 5:354ff
- regulation of progression through the cell cycle 5:363
- reversal of a single genetic abnormality 5:360
- molecular evolution 3:499, 5:334, 349, 6:69, 8:425, *see also* hemoglobin
- molecular farming 10:660
- molecular genetics 5:317
- molecular graphics 11:135, 143
- molecular interactions 11:183
  - hydrogen bonds 11:184
  - hydrophobic interactions 11:184
  - ionic interactions 11:184
- molecular manipulation
  - pathways of 3:338–342
  - tools for 3:336–343
- molecular marker
  - associated with the development of the cancer 5:364
  - clonally preserved 5:364
  - occur early in the development of the cancer 5:364
- molecular mechanics 1:789, 2:27, 3:601, 12:615, 618, 15:405
- molecular medicine 7:580
  - era of 9:271–272
- molecular mimicry 1:495
- molecular modeling 2:27, 266
- molecular motors 9:278–280
- molecular oncogenesis
  - models of 9:445–446
- molecular oncology 9:497–544
- molecular oxygen 10:6
- molecular paleontology
  - molecular archaeology 10:55, 64
  - molecular forensics 10:55
- molecular pharming 1:212
- molecular phylogenetics 15:185
- molecular replacement
  - homologous probe structure 11:280
  - maximum likelihood 11:280
- molecular scaffold 2:464, 480
  - advantages 2:469
  - CaM KII 2:469
  - ERK1/2 2:469
  - JNK pathway 2:469
  - MAP kinase 2:468, 469
  - microtubules 2:468
  - roles for molecular scaffolds 2:469
  - spindle 2:469
  - Ste5 protein 2:468
- molecular scissors 10:248
- molecular sequence analysis 6:573
- molecular signals 13:334
- molecular switches 12:388
- molecular systematics 8:517, 518, 523ff, 526ff
- molecules 10:93
  - DNA 4:92
  - RNA 4:92
- moloney murine leukemia virus (MoMLV) 14:482
- molten globule state
  - properties of 4:516
- molybdenum 8:228
- molybdoenzymes 8:213ff
- moment difference 4:9
- Mongolian gerbil model of stomach carcinogenesis 6:14
- 2-monoacylglycerol 14:639, 668
- monoacylglycerol acyltransferase (MGAT) 14:639
- 2-monoacylglycerol lipase (2-MAGL) 14:628ff, 668
- monoamine oxidases 1:595, 2:53ff, 57
- monocarboxylic acid transporters 3:626
- monochromators 4:440, 443
  - double mirror system 7:405
  - graphite crystal 7:405
  - nickel filter 7:405
- monoclonal antibody (mAb) 1:472, 4:618, 6:365, 430, 439, 502, 512, 10:225, 11:105, 12:301
- monocyte-attractant protein 1 (MCP-1) 10:126
- monocytes 1:366, 376, 389, 390, 4:347, 636, 5:555, 6:345, 8:452
  - interleukin-1 14:47
- monocytes/macrophages 13:241–242
- Monod 2:43
- Monod, Wyman, Changeux concerted model 11:605
- monogenic congenital diseases
  - gene therapy of 13:259
- monogenic diseases 8:112
- monogenic ion channel disease 11:656
- monogenic seizure syndrome 11:678
- monokine 8:434, 13:118
- monolayer 7:542ff

- monolith columns 9:300  
 monomeric antibodies  
   polymers of 1:343–344  
 monooxygenases  
   carbon monoxide 3:102  
   heme iron 3:102  
   hemoprotein 3:102  
   (xenobiotics) 3:102  
 2-monopalmitoylglycerol 14:668  
 monophyletic 15:373  
 monosaccharides 2:249, 278, 5:539  
   analytical method 2:247  
 monozygotic 1:589, 14:6  
 Monte Carlo searching 2:28  
 Monte Carlo simulation 3:607  
 montmorillonite 10:11, 16, 18, 19, 21  
 mood disorders 1:607ff  
 moral justification 7:371  
 morbillivirus 12:300  
 Morgan, Thomas Hunt 8:534  
 morphine alkaloids 14:327–328  
   Straub tail 14:329  
 morphogen 3:273, 13:282, 283  
   morphogen receptor gradient 3:270  
   retinoic acid 3:269  
   signal transduction 3:270  
 morphogen gradients 3:273, 4:210  
 morphogenesis 3:278, 565, 4:278ff, 292, 8:334,  
   335, 484, 13:286, 14:139  
 morphogenetic fields 8:533  
 morpholino 15:608ff  
 morpholino oligonucleotides 2:121  
 morpholino phosphorodiamidate  
   oligonucleotides (MOs) 14:480  
 morphology 5:9, 7:302ff  
 Morris water-maze 4:619  
 morula 1:213, 13:329, 330, 384, 14:524  
 MOS 9:469  
 mosaic analysis 14:271  
 mosaic embryos  
   genesis of 14:524–526  
 mosaic or chimeric mice 13:340  
 mosaicism 1:217  
 mosquitoes 3:411, 7:471  
 moss glycosylation 10:401–404  
 Mössbauer 7:173  
 Mössbauer labeling 7:167  
 Mössbauer labels 7:170  
 Mössbauer spectroscopy 7:171  
 most probable number (MPN) 1:515  
 motif 10:448, 451, 12:324, 616–618, 620, 624,  
   14:137  
 motif descriptor 10:449  
 motif searching 12:617, 623  
 motility 13:627  
 motility assays 8:580  
   with cytoskeletal filaments 8:597–598  
 motoneuron degeneration  
   enzyme superoxide dismutase 8:568–569  
 motoneuron disease  
   autoimmune hypothesis of 8:567  
 motor (bacterial flagellum) 8:397  
 motor neuron  
   anatomical aspects of 8:561–562  
   cultures of 8:545  
   functions of 8:571  
   toxic lesions of 8:567–568  
 motor neuron degeneration  
   animal models of 8:547–550  
   culture models of 8:544–547  
 motor neuron diseases (MND)  
   animal models of 8:541–553  
   cellular models 8:541–553  
   clinical appearance of 8:562–566  
   concepts of 8:552  
   genetics of 8:543–544  
   molecular mechanism of 8:559–573  
   pathology of 8:562–566  
   pathophysiology of 8:559–573  
   therapeutic, approaches of 8:550  
   treatments of 8:559–573  
 motor proteins 8:575–595, 598–599  
   dynamic instability 8:597  
   microtubule ends 8:597  
   polymers 8:596–597  
 motors 8:475, 477, 481  
   dyneins 8:475ff  
   kinesins 8:463, 481ff  
   myosins 8:477ff  
 mountain representation 12:585  
 mouse 1:223, 4:330, 10:484  
   colocalization of SINEs in 11:465–466  
   genetics of 14:508–509  
   molecular genetics of 14:510–513  
   shift in substitution spectra 11:449–450  
 mouse embryonic fibroblasts (MEFs) 12:153ff  
 mouse genome 10:549, 11:449  
 mouse lineage  
   different activity of SINEs in 11:464–465  
 mouse Moloney leukemia virus 15:239  
 Mox 6:199  
 MP2  
   quantum mechanical 3:602  
 M6P receptor 1:622  
 MPF (maturation promotion factor) 2:466, 468,  
   9:508  
   cyclin degradation 2:472  
 Mpk1 14:237

- M2 proteins (M2-1, M2-2) 12:305–306  
 MPSS, *see* massive parallel signature sequencing  
 MR 1:390  
 MRE 8:345  
 MRI 4:128  
 MRL-lpr/lpr 1:476  
 mRNA 1:405ff, 2:452, 9:319  
   ribosome 1:410  
   target RNA 1:406  
 mRNA display 8:419, 11:106  
   psoralen 8:417  
   3' puromycin 8:417  
 mRNA polarity 14:581–582  
 mRNA processing 9:62  
 mRNA structure 14:584  
   5' cap 14:585  
   eukaryote 14:585  
   ferritin 14:611, 612  
   frameshift 14:582  
   histone 14:583  
   internal RNA entry site 14:614, 615  
   polarity 14:582  
   polyadenylation 14:585  
   polycistronic 14:612, 613  
   prokaryote 14:585  
   pseudoknot 14:612  
   Shine–Dalgarno sequence 14:585, 615  
   stability 14:609  
   translational control 14:612  
 mRNA surveillance 9:63  
 mRNA targets 4:597  
 mRNA translation, control 14:608, 610, 613, 617  
   amino acid abundance 14:615  
   antisense polynucleotide 14:615  
   codon usage 14:615  
   elongation factor activity 14:612  
   frameshift 14:612  
   initiation factor activity 14:612  
   internal RNA entry sites 14:614, 615  
   mRNA stability 14:609  
   mRNA structure 14:612  
   mRNA/protein interactions 14:611  
   ribosome activity, modulation 14:615  
   ribosome inactivation 14:616  
 mRNA translation mechanism 14:580–583, 585–593, 600, 602, 609–617  
   initiation of translation 14:594–599  
   peptide bond formation 14:584, 604–607  
   peptide chain elongation 14:599  
   peptide chain elongation/translocation cycle 14:601  
   termination 14:601, 603  
   translocation 14:607, 608ff  
 mRNA translation, protein factors 12:484, 495–496  
   elongation factors, eukaryotic 14:601, 603  
   elongation factors, prokaryotic 14:599, 601  
   IF-1 2:454  
   IF-2 2:454  
   IF-3 2:454  
   initiation factors, eukaryotic 14:595, 597  
   initiation factors, prokaryotic 14:594–596  
   termination factors 14:599, 603  
 mRNA transport 4:599  
 mRNA-binding proteins 4:597  
 mRPE65 12:381  
 MsbA 11:153  
 MSH2 3:435, 439ff  
 MSH3 3:435, 439ff  
 MSH6 3:435, 439ff, 6:21  
 MSI 6:23  
 MS/MS 2:268, 8:2, 8f, 13, 15–17, 24, 25, 27–29, 31, 33–35, 11:311  
 MSR1 7:238  
 M.SssI 12:338  
 Msx 6:202  
 mt DNA  
   hypervariable zone 8:526  
 MTase 12:325  
 Mtb, (*Mycobacterium tuberculosis*) 6:555, 558ff  
 mtDNA analysis 3:482  
 MTF-1/MRE system 8:348  
 MTP, *see* microsomal triglyceride transfer protein  
 MTS1 7:329  
 MUC1 6:14  
 mucidin 2:629  
 mucins 6:488  
 mucolytic drugs  
   ibuprofen 8:636  
   inhaled steroids 8:636  
   prednisone 8:636  
   recombinant human DNase 8:637  
 mucor  
   linoleic 5:8  
   unsaturated fatty acids 5:8  
 mucosa 1:363  
 mucosa-associated lymphoid tissue (MALT)  
   lymphoma 6:14  
 mucosal 8:606ff, 608ff  
   adjuvants 8:611  
   common immune system 8:606  
   delivery systems 8:609



- mucosal (*continued*)  
 DNA vaccine 8:608  
 vaccination 8:606, 608
- mucosal immune mechanisms 12:309  
 mucosal secretions 4:202
- Müllerian ducts 5:609  
 Müllerian-inhibiting factor (MIF) 4:396  
 Müllerian-inhibiting substance (MIS) 4:385ff, 5:649
- MultiCASE 3:603, 606  
 multicellular organisms 5:640  
 multicellular spheroids 14:405  
 multicolor banding (MCB) 5:126  
 multidimensional 8:4, 12, 24, 25, 31  
 multidimensional chromatographic peptide separation 5:47  
 multidimensional chromatography 8:18  
 multidimensional NMR 13:519, 524–526, 573  
 multidimensional protein identification technology (MudPIT) 8:2, 13, 23–25, 31, 11:318  
 multidimensional protein NMR spectroscopy aspects of 11:161–165  
 multidrug resistance genes 3:625  
 multidrug resistance (MDR) 12:366, 14:192  
 multidrug-resistant HIV strains 6:156, 157  
 multienzyme complex 12:390  
 multifactorial inheritance 1:587  
 multifactorial regulation 3:111  
 multilamellar 14:188  
 multilamellar vesicles (MLVs) 7:302ff  
 multimer resolution 10:432  
 multi-omics descriptor 8:192, 204  
 multiphoton absorption (MPA) 15:62  
 multiphoton microscopy (MPM) 15:62ff, 67  
 multiple alignment 9:254  
 multiple carboxylase deficiency (MCD) 15:525  
 multiple data set 11:392  
 multiple elements 14:409–410  
 multiple forks 1:527  
 multiple internal reflectance 4:655  
 multiple isomorphous replacement anomalous scattering (MIRAS) 7:435  
 multiple organ failure 15:267  
 multiple quantum ESR 7:162  
 multiple sclerosis (MS) 8:453, 456, 11:112, 12:693, 13:206, 15:265, 416  
 multiple-locus variable-number tandem repeat analysis (MLVA) 1:315  
 multiplex analysis 15:557, 565  
 “multiplex PCR” approach, defined 3:489  
 multiplexed 11:103, 486ff  
 multiplexed arrays 4:435  
 multiplexed protein assay 11:102  
 multiplexing 7:188  
 multi/pluripotent cells 13:334  
 multipotent adult progenitor cell (MAPC) 13:393  
 multipotential 13:334  
 multiprotein complexes 11:124  
 multisite catalysis 11:337  
 multistep mode 10:417  
 multistep tumorigenesis 9:445  
 multisystem autoimmune diseases 1:464  
 multi-target DNA assay panel (MTAP) 9:99  
 multitargeting 9:539–544  
 multivalent display 8:414  
 multivariate analysis 8:196ff  
   colinearity in 8:196  
   conventional 8:196, 197  
   genetic computing methods 8:199  
   hierarchical cluster analysis 8:199  
   model validation 8:198  
   neural network methods 8:199  
   non-linear methods 8:199  
   overfitting 8:198  
   projection methods 8:198  
   “short-and-fat” datasets in 8:196  
   supervised methods 8:198  
   variable selection 8:197  
 multivesicular bodies 1:619, 8:135  
 multiwavelength anomalous diffraction technique  
   exact isomorphism 7:435  
   selenomethionyl proteins 7:435  
 multiwell plate 7:546  
 Munc-13 4:310  
 Munc18 4:311  
 Murchison 10:12  
 Murchison meteorite 10:14, 17  
 murine development  
   E2F 12:362  
   p107 in 12:360–362  
   p130 in 12:360–362  
   RB family regulation of 12:360–362  
   RB1 in 12:360  
 murine leukemia 12:404, 410  
 murine leukemia virus (MLV) 13:257  
 murine monoclonal antibodies 1:334–336, 12:308  
 murine *N*-acetylglucosaminyltransferase V (MGAT5) 5:590  
 Mus musculus 4:331, 10:542, 548ff  
 muscarinic receptor 8:87ff, 11:575, 577  
 muscle 4:335  
 muscle differentiation 12:167  
 muscle growth 13:31  
 muscle stiffness 11:671

- muscleblind 15:42ff  
 muscleblind-like proteins (MBNL) 15:42  
 muscular dystrophy 4:340, 14:391  
 mushrooms  
   *Agaricus campestris* 5:7  
   *Lentinus edodes* 5:7  
 musk odor 2:596  
 mutagenesis 5:337, 9:553, 555, 12:110, 14:211, 15:602ff  
   chemical mutagenesis 10:543  
   chlorambucil (CHL) 10:543  
   directed evolution 9:557  
   ethylnitrosourea (ENU) 10:543  
   random 9:554, 556, 557  
   semirandom 9:554, 556, 557  
   site-directed 6:39, 9:554, 556  
   to produce immunity repertoire 12:122–123  
   X-ray 10:543  
 mutagenic 5:339  
 mutagenic conditions 5:339  
 mutagens 5:339, 12:110, 114, 15:602ff  
 mutant cells 5:316  
 mutant enzyme 9:399  
 mutant screens 12:423, 426ff, 431, 446, 451, 459, 463, 465, 469  
 mutant VEGF mice 8:550  
 mutants 2:621ff, 638, 8:124, 9:74ff  
   herbicide-resistant mutants 2:632  
   nonsense mutations 2:637  
   site-directed mutagenesis 2:634  
   transposons 9:74  
 mutation 1:55, 4:330, 5:314, 316, 336, 372, 398, 9:499, 534–535, 11:217, 12:110, 15:378, 602ff  
   advantageous 11:221  
   at regulatory sequences 12:116  
   auxotrophic mutations 2:624  
   chromosomal rearrangement 8:534  
   classical mutants 14:259  
   deleterious 11:221  
   drug-resistant markers 2:624  
   error in DNA 1:92  
   fast neutron 5:435  
   gain-of-function mutations 14:262  
   gene duplication 8:534  
   insertional mutants 14:259  
   ion beam 5:435  
   load 6:113  
   loss-of-function 14:258  
   macromutation 8:534, 535ff, 536ff  
   masked 1:89, 92  
   micromutation 8:534  
   mutagenesis experiments 11:223  
   mutation 1:79, 5:435  
   nature of 5:245–247  
   negative 11:221  
   neutral 11:221  
   nonsynonymous substitutions 11:221  
   physical mutagen 5:435  
   point 8:534  
   point mutations 11:221  
   positive 11:221  
   synonymous substitutions 11:221  
   transitions 11:221  
   transversions 11:221  
   types of 12:114–117  
   X-ray 5:435  
   mutation hotspots 12:116  
   mutation of K-ras 6:20  
   mutation or LOH of p53 6:11  
   mutation or loss of E-cadherin 6:11  
   mutation rate 5:245–247, 323  
     germ line-specific 2:566  
   mutation reversions 12:116  
   mutations of the Tp53 6:4  
 MutH 12:329  
 MutL 3:435, 439  
 MutL $\alpha$  3:435, 439ff  
 MutL $\beta$  3:435, 439  
 MutS 3:435, 439  
 MutS $\alpha$  3:435, 439ff  
 MutS $\beta$  3:435, 439  
 mutually induced fit 12:331  
 MVIIA 13:532, 535, 537  
 Mx 15:406  
 myasthenia gravis (MG) 1:463, 11:674  
 MYB 12:194, 14:266  
 Myb domain 14:231ff  
 MYB family 9:472  
 MYB transcription factor 14:264  
 MYC (avian myelocytomatosis virus) 9:440, 12:171ff, 176, 178, 184, 196  
*Mycobacteria leprae* 1:379, 6:233  
   vaccine 15:174  
 mycobacterial lipids 1:364, 366  
 mycobacterium tuberculosis (Mtb) 1:379, 6:233, 307, 555, 558ff  
 mycoherbicides  
   *Colletotrichum gleosporoides* 5:15  
   *Phytophthora palmivora* 5:15  
 mycoinsecticides 5:13ff  
   *Beauveria bassiana* 5:14ff  
   beauvericin 5:14  
   biotrophic 5:13  
   blastospores 5:14  
   chitinase 5:14  
   conidia 5:14

mycoinsecticides (*continued*)

- destruxins 5:14
- enhiantin 5:14
- lipases 5:14
- Metarhizium anisopliae* 5:14
- proteases 5:14
- Verticillium lecanii* 5:14
- mycolic acids 1:366, 7:259
- mycophenolate mofetil 14:375–376
- mycophenolic acid 14:375–376
- Mycoplasma arthritidis* 13:639
- mycoplasma lipoproteins 1:391
- Mycoplasma* spp.
  - Mycoplasma agalactiae* 6:314
  - Mycoplasma gallisepticum* 6:314
  - Mycoplasma hyopneumoniae* 6:314
  - Mycoplasma-induced respiratory disease (MIRD) 6:314
- mycoprotein 5:7ff
  - Fusarium venenatum* 5:7, 8
- mycorrhiza 5:13
- MyD88 10:98
- myelin 11:112
- myelin basic protein 4:673ff
- myeloid cells 6:419
- myeloid DCs 1:388
- myeloid hyperplasia 12:360
- myeloma 1:399
- myelomeningocele 9:120
- myeloperoxidase 8:218
- myocardial infarction 5:215, 220, 7:51, 208, 14:284ff
- myocardium 15:264
- myoclonic epilepsy type 1ff 15:9
- myoclonic epilepsy with red-ragged fibers (MERRF) 15:377
- MyoD 12:167
- myoglobin (Mb) 4:122, 5:267, 6:70, 72, 97, 7:171, 8:231, 521, 11:56
  - concentration in muscles 6:90
  - evolutionary considerations 6:98ff
  - FAs 7:106
  - primary structure 6:71ff
  - reaction with O<sub>2</sub> and NO 6:90
- Myo2p 13:628
- myosin V molecules 9:280
- myosins 2:342ff, 4:195, 315
- myotonia 11:670, 673
- myotonic dystrophy 15:5ff
  - type 1 (DM1) 15:40ff
  - type 2 (DM2) 15:42ff
- myotrophic 13:32
- myotrophic effect 13:5
- myotrophin 13:284

- Myxococcus xanthus*
  - extracellular signals 8:308
  - morphogenesis 8:307, 309
- myxoma virus 8:454
- myxothiazol 2:629

**n**

- N<sub>2</sub> 10:6
- N. tabacum* 10:660ff
- NAA 6:555ff
- NAA, nucleic-acid amplification 6:555
- NAC (nascent-polypeptide association complex) 2:502, 14:266
- N-acetylgalactosaminyltransferase 5:561
  - T1 5:562
  - T2 5:562
  - T3 5:562
  - T4 5:562
  - T5 5:562
  - T7 5:562
  - T9 5:562
- N-acetyl-glucosamine 10:302
- nAChR 11:674
- N-acyl transferases 2:53, 64
- NAD<sup>+</sup> 7:101
- NADH 4:208, 7:101, 8:218
- NADH dehydrogenase 2:627, 628
- NADP<sup>+</sup> 7:101
- NADPH 7:101, 14:4
- NAD(P)H oxidase 7:49ff
- NADPH P450 reductase 3:104
- NADPH-cytochrome P-450 reductase 13:17
- Na<sup>+</sup>/glucose transporter, *see* sodium/glucose transporter
- naive libraries 3:93
- Na/K-ATPase 11:682, 694
- naked rodent antibodies 14:155
- naloxone 15:271
- naltrexone 15:271
- nandrolone 13:33, 42
- nandrolone decanonate 13:31
- nanoarrays 8:507
- nanobiotechnology 9:19–20, 24–44
  - applications of 9:45–46
  - concepts of 9:21–23
  - inorganic nanoparticles 9:22–23
  - topics of 9:21–22
  - transfection 9:45
- nanocrystals 8:427
- Nanog
  - proper self-renewal of ES cells 13:389
  - recently identified homeodomain 13:389
- nanomedicine, the discipline 14:165

- nanomedicines 14:165, 167, 185–186  
 importance of 14:198–199
- nanometer accuracy laser  
 manipulation of 9:276
- nanometry 9:352, 358
- nanoparticle devices  
 magnetic switching of 9:44–45
- nanoparticle-protein conjugates  
 as biolabels 9:26–28
- nanoparticles 9:20, 14:165, 192–193  
 as model systems 9:45–46  
 DNA-directed oligomerization of 9:30–32  
 protein-directed organization of 9:24–25  
 protein-functionalized 9:24–29
- nanosensors 8:195
- nanotechnology 8:426
- nanowell 11:114
- NAP22 4:598
- narrow heritability 1:596
- nasal epithelium 15:260
- nascent peptide 12:484
- National Cancer Institute (NCI) 9:100
- National Synchrotron Light Source (NSLS)  
 13:678
- National Synchrotron Light Source-Upton, USA  
 13:677
- natriuretic peptide 11:589
- natural fields 4:3  
 definition of field 4:4
- natural habitats 15:599
- natural killer (NK) cells, *see* NK cells
- natural killing 6:345
- natural medicines 8:84
- natural product sources 11:626
- natural products 8:84, 89, 94, 13:530, 14:343,  
 346, 368
- natural selection 1:79, 5:247, 334, 6:324, 8:521,  
 13:210  
 functional competence 1:85  
 replicative capacity 1:85
- natural strategies of genetic variation 5:344
- NBD-Cl  
 (7-chloro-4-nitrobenzo-2-oxa-1,3-diazole)  
 11:335
- N-benzoylation 1:426
- NBS-LRR (nucleotide binding site-leucine rich  
 repeat) 10:349
- NC1 8:51
- NC domain 8:66
- N-CAM (neural cell adhesion molecule) 2:116
- NCBI 10:533
- ncRNA search 12:594
- NDI  
 aquaporins 11:696
- nearest-neighbor joining 8:529
- near-field microscopy 9:275–276
- near-infrared 4:652, 660ff
- necklace glomeruli 12:670
- necrosis 1:390, 392, 4:431, 13:690
- necrotic cells 3:221–222
- necrotic zones 5:215, 220, 236
- necrotrophy 10:369, 371
- nectins 2:356
- Nedd4 4:205
- Nedd8 12:171, 179
- needle 1:417
- negative control 12:30
- negative feedback 1:430
- negative feedback loop 14:445
- negative regulator of splicing (NRS) 1:150
- negative screen 11:55
- negative selection 11:55
- negative staining 4:103  
 methylcellulose embedding 4:30  
 phosphotungstic acid 4:90, 99, 104, 105,  
 107  
 uranyl acetate 4:90, 97, 99, 104–108
- Neisseria gonorrhoeae* (GC) 6:227, 555, 558ff
- nematode (*C. elegans*)  
 molecular biology of 9:53–64
- nematode resistance 14:565
- nematodes 4:331, 9:70–72ff  
*Ascaris* 9:76ff  
 dauer 9:73  
 hermaphrodite 9:73  
 larval 9:72  
 parasite 9:70, 71ff  
 pharynx 9:72
- NEM-sensitive factor (NSF) 8:126
- neocentromeres 1:260ff
- neodymium laser 3:548
- neointimal hyperplasia 13:322
- neomycin cassette 4:604
- neonatal dehydration 11:696
- neonatal skin 13:234–235
- neoplastic disease diagnosis  
 DNA in 9:91–115
- neopterin 10:232
- neovascularization 5:216, 15:264
- neoxanthin 2:586
- nephroblastoma 13:348
- nephrogenic diabetes insipidus 3:302, 11:696  
 animal models of 3:319  
 treatment of 3:318–319
- nephrolithiasis  
 kidney stone 11:697
- nephron 12:720
- Nernst equilibrium 11:646

- nerve cells into functional circuits, wiring of  
 cellular aspects to 2:113–114  
 molecular aspects to 2:114–120
- nerve growth factor (NGF) 5:642, 647, 6:399,  
 14:41, 108
- nerve receptors 13:232
- nervous system 9:171, 172ff, 173–175,  
 174ff  
 ladderlike 9:172  
 nerve net 9:168  
 neuron 9:169ff, 170ff, 176ff
- NES 4:595
- Nessler's reagent, testfor ammonia 1:519
- nested models 1:597
- nestin 10:78ff, 79ff
- netrin 2:118
- netropsin 5:185, 13:566
- network 14:136  
 models 11:228  
 power law 11:220, 226, 228  
 preferential attachment 11:228  
 random mode 11:228
- network biology 14:136
- network topology 14:136
- N-ethylmaleimide sensitive factor (NSF)  
 4:195, 8:133
- N-ethyl-N-nitrosourea 15:602ff  
 mechanism of mutagenesis 15:603  
 rate of mutagenesis 15:603
- neural cell adhesion molecule (NCAM) 4:407
- neural crest 2:94
- neural crest emigration 9:133
- neural induction 2:88, 89
- neural network analysis 8:199
- neural networks 3:62ff, 610, 9:263
- neural plate 2:91, 9:120, 122
- neural plate bending  
 regulation of 9:129–131
- neural plate/tube  
 A–P patterning in 2:98–107  
 D–V patterning in 2:91–98
- neural precursor cell 10:79
- neural ridge 2:92
- neural stem cells 12:82, 13:410ff, 411ff
- neural tissue  
 formation of 2:89–91  
 patterning of 2:91–107
- neural tube 2:91, 9:120, 122
- neural tube defects  
 molecular biology of 9:119–135
- neuraminic acid 2:249
- neuraminidase 2:254, 5:592
- neuregulins 1:606, 5:648
- neuroanatomy 4:591, 606
- neurobiology 4:335, 9:76ff  
 acetylcholine 9:78  
 amyloid 9:81  
 dopamine 9:79  
 GABA  $\gamma$ -aminobutyric acid 9:78  
 neurodegeneration 9:81  
 neuropeptides 9:79  
 neurotransmission 9:78  
 serotonin 9:79
- neuroblastoma 13:348
- neuroblasts 13:418ff
- neurodegeneration 4:338
- neurodegenerative diseases 15:378  
 implications for 10:597  
 olfactory disorders 12:692
- neurodegenerative pathologies 1:45
- neuroectoderm 2:91, 94, 13:219
- neuroendocrine markers  
 calcitonin 5:354  
 creatine kinase isoenzyme BB 5:354  
 gastrin-releasing peptide 5:354  
 L-dopa decarboxylase 5:354  
 neuron-specific enolase 5:354
- neuroepithelial cells 13:411ff
- neurofibrillary tangles 1:193, 8:503
- neurogenesis 8:508, 13:410ff  
 adult neurogenesis 13:410
- neurogenic phenotype 2:111
- neuroglobin 6:70, 97, 98
- neurological disease 15:261, 265
- neuromediators 8:442
- neuromeres 2:99
- neuromuscular blocking drugs 14:335–337  
 Atracurium 14:334  
 Curare 14:334  
 Decamethonium 14:334
- neuromuscular junction (NMJ) 2:107, 4:610,  
 11:668
- neuron 2:107ff, 4:334, 9:76ff, 10:79–80ff,  
 14:48ff  
 dopaminergic 10:78  
 generation of 2:109–112  
 serotonergic 10:78
- neuron structure 11:676
- neuronal calcium sensors  
 guanylate cyclase-activating proteins 2:152  
 recoverins 2:152
- neuronal cell death  
 motoneuron disease, implications for  
 8:560–561
- neuronal cell lines 8:544
- neuronal cells 12:161
- neuronal channels 11:677
- neuronal differentiation 9:133

- neuronal maturation 4:609  
 neuronal receptors 13:292  
 neuronal sheaths 5:651  
 neuronal stem cells 10:133, 13:345  
 neuronal voltage-gated calcium channel  
   mouse mutants 11:680  
 neurogenesis 10:133  
 neuropathic pain 10:30, 44, 15:270,  
   271  
 neuropeptide 9:168, 169, 177ff  
   adipokinetic hormone 9:174, 175  
   ecdysiotropin 9:174, 175  
   egg-laying hormone 9:176  
   FaRP 9:172, 173ff, 175, 176  
   FMRFamide 9:172, 175, 176  
   Hym-355 9:171  
   metamorphosin A 9:171  
   pheromone biosynthesis-activating  
     neuropeptide (PBAN) 9:174  
     antagonist 9:175  
     peptide mimic 9:175  
   precursor 9:170ff, 171ff, 176ff  
   processing 9:171ff, 176ff  
     carboxypeptidase 9:170  
     peptidylglycine  $\alpha$ -amidating  
       monooxygenase 9:170  
     propeptide convertase 9:170  
 neurophysin 1 4:404  
 neuropilin 14:290, 15:206, 212, 213  
 neuropilin 1 15:207, 211, 214  
 neuropilin 2 15:207, 211, 214  
 neuropore 9:121, 129  
 neuropsychiatric disorders 11:684  
 neurosecretion 9:168  
   invertebrate 9:169ff  
   neuroendocrine 9:169  
   neurohormone 9:169  
   neurotransmitter 9:169  
 neurospheres 13:346, 416ff  
*Neurospora crassa* 8:360, 362f, 372ff, 377,  
   12:415, 451ff, 13:616  
 neurotensin (NT) 14:43  
 neurotransmission 4:319ff  
 neurotransmitter release 9:146  
 neurotransmitters 4:307, 9:141, 13:145ff,  
   14:15, 329, 332, 430, 15:21ff  
   acetylcholine  
     alzheimer's disease 9:145  
     neuromuscular junction  
       9:145  
   catecholamines  
     dopamine 9:144ff  
     epinephrine 9:144ff  
     huntington's disease 9:145  
     norepinephrine 9:144ff  
     parkinson's disease 9:145  
     schizophrenia 9:145  
   classical 9:143ff  
   D-aspartate 2:588  
   D-serine 2:588  
   gamma-aminobutyric acid  
     inhibitory 9:146  
   gaseous neurotransmitters 9:144  
   glutamate  
     excitatory 9:145  
     ischemia, anoxia, or stroke 9:146  
     learning 9:146  
     memory 9:146  
   nonclassical 9:143ff  
   peptide neurotransmitters 9:144  
   serotonin  
     depression 9:145  
 neurotrophic factors 8:560  
   identification of 8:571  
 neurotrophin (NT)-3 8:571, 12:646  
 neurotrophin receptor 5:647, 11:582, 585  
 neurotrophin receptor family 9:461  
 neurotrophin tyrosine receptor kinases  
   Cdc-42/Rac/Rho 7:132  
   ETV6/Tel transcription factor 7:133  
   immunoglobulin-like domains 7:132  
   neurotrophin 3 7:132  
   NTRK1 7:132  
   NTRK3 7:132  
   Rap-1 7:132  
   Ras 7:132  
   TPR-Ntrk1 translocation 7:132  
 neurotrophins 5:647  
 neurulation 2:94, 9:121  
   multiphase embryonic event 9:122–124  
   rostro-caudal sequence of 9:123–124  
 neurulation initiation  
   planar cell polarity signaling, role of  
     9:127–129  
 neuraceuticals 10:657ff  
 neutral endopeptidase (NEP) 14:112  
 neutral lipids 7:305  
 neutral substitution rate 11:457  
 neutral theory 5:248  
 neutralizing antibody 15:138  
 neutropenia 8:457  
 neutrophils 1:380, 4:208, 636, 5:555, 640,  
   6:344–345, 13:241  
   elastase 8:633  
   metalloproteinases 8:633  
 new chemical entities (NCEs)  
   ABT-594 11:627  
   epibatidine 11:627

- new synthetic vectors 15:488  
 new world monkeys 2:554  
 New Zealand Black (NZB) mice 15:413  
 newborns 4:202  
 NFAT 14:441, 455  
 NF- $\kappa$ B 1:381, 384, 4:638, 5:501, 6:14, 17, 21, 24, 10:125, 132, 626, 11:590, 12:178, 14:437, 15:399, 400  
   p50 14:440  
   p65 (RelA) 14:440  
 NF- $\kappa$ B activation 6:3, 22  
 NGF 11:582  
   *N*-acetylgalactosamine (GalNAc) 5:572  
   *N*-glycanases 5:541  
   *N*-glycosylation 5:572  
 NgoMIV 12:332  
 NH<sub>3</sub> 10:6  
 NHEJ 14:232ff  
   DNA repair 14:232  
   DSBs 14:232  
   *N*-hydroxysuccinimide 11:108  
 NIA Mouse 7.4K 10:548  
 NIA Mouse 15K 10:548  
 niacin and niacinamide 14:683, 15:547  
 nicastrin 1:192  
 nickel 8:229, 231  
 nickel sulfides 10:10  
 nick-translation reaction 11:422  
 Nicolet NicPlan IR microscope 13:680  
*Nicotiana benthamiana* 14:270  
 nicotinamide adenine dinucleotide (NADH) 8:164  
 nicotinamide adenine dinucleotide phosphate (NADPH) 9:575  
 nicotinic acetylcholine receptor 11:557, 558, 559, 560, 668  
 nicotinic acid 14:683  
 nicotinic receptor, *see* nicotinic acetylcholine receptor  
 NicPlan IR microscope 13:680, 681  
 nidogen 8:47, 48, 50, 52, 53  
 Niemann Pick A and B diseases 13:320  
 Nieuwkoop center 13:273ff  
 NIH rearrangement 2:56  
 Nijmegen breakage 9:393  
 nilutamide 13:44, 47  
 Ni-NTA 11:121  
 nisin 2:588  
 nitrate reductase 2:629, 630  
 nitric oxide 4:118ff, 636ff, 6:80ff, 89–91ff, 7:166, 8:86, 228, 231, 446, 10:121, 375, 378, 15:293  
   kinetic constants 6:80  
   physiological implications 6:91ff  
   reactions with Hb derivatives  
     kinetic constants 6:90  
     role in defense 10:350  
 nitric oxide radicals 1:379  
 nitric oxide synthase 4:129, 6:35, 51–52, 8:218, 228  
   active site structure of 6:54  
   structure of 6:53–54  
 nitric oxide synthesis 15:413  
 nitric oxide traps 7:165  
 nitrile 1:519, 10:9  
 nitrocellulose 11:107  
 nitrogen 10:6  
 nitrogen base 12:609  
 nitrogen oxides 10:7  
 nitrogen starvation 14:232ff  
 nitrogenase 7:169  
 nitrogenous base 12:609, 610  
 3-nitrotyrosine 4:639  
 nitroxide spin probe 7:172  
 NK-1 6:201  
 NK-2 6:202  
 NK-3 6:202  
 NK-4 6:202  
 NK cells (natural killer cells) 1:379, 6:444, 13:117, 129, 15:409, 411, 415  
 NK cluster 6:189ff  
 NK (natural killer) cells 6:345, 407, 430, 469, 8:607, 10:93, 13:124–346, 15:293  
   Ex vivo generation of 6:444  
 NKT 10:93  
 NKT cells 10:95  
 NLS 4:595  
 nm23 6:23  
*N*-methyl-D-aspartate (NMDA) 2:588  
*N*-methyltransferase 10:285  
 NMDA 10:121  
 NMDA receptor 2:588, 11:562, 563  
 NMDAR1 receptor 10:201  
*N*-mers 2:81  
 NMR 1:577, 580, 671, 2:253  
*N*-Mtase 12:334  
*N,N'*-diacetylchitobiose  
   endo C<sub>II</sub> 5:541ff  
   endo D 5:541ff  
   endo H 5:541ff  
 NO 8:227, 231  
 no amplification control 11:512  
 NO synthase II (NOS II) 15:293  
 NO synthetase (iNOS) 1:379  
 nociceptor 10:30, 32  
 nociceptor sensitivity  
   modulators of 10:42–44

- nodal 4:397ff  
 NOD-LRR family 7:2  
 NOE docking 13:530, 564  
 NOE (nuclear overhauser effect) 11:164,  
 13:519, 535, 551, 567, 593  
 conformational analysis 13:539  
 flexibility 13:543  
 intermolecular 13:568, 574, 577  
 structure determination 13:549  
 NOE pumping 13:584  
 NOESY 2:269, 13:526, 531, 532, 574, 590, 593  
 chemical-exchange cross peaks 13:567  
 noggin 13:277, 278, 420ff  
 noise 14:140  
 in the transmission of genetic information  
 DNA damage 1:79  
 mutation 1:79  
 nomenclature 15:537  
 amino acid deletion 3:246  
 amino acid insertion 3:246  
 amino acid, sequence 3:244  
 amino acid substitution 3:246  
 cyclic peptides 3:246  
 disulfide bond 3:246  
 free termini 3:245  
 linear polypeptides 3:244  
 side chain lactam 3:246  
 synthetic analogs 3:246  
 nonadditive genetic variance 1:596  
 nonadoptees 1:593  
 nonallergic triggers 14:40  
 nonautonomous element 14:260  
 nonavidin biotin-binding proteins 15:522–524  
 noncoding DNA 12:129, 133  
 noncoding lesions 12:121  
 noncoding RNA 3:333, 9:254, 258, 12:583  
 noncoding RNA genes 11:462  
 noncoding RNA world 9:58  
 noncoding, tandemly repeated DNA  
 satellite DNA 9:184  
 noncollagenous (NC1) 8:50  
 noncovalent biotin-binding proteins  
 15:521–524  
 noncovalent interactions 2:6  
 noncytokine receptors 13:136  
 nondenaturing mode 9:303  
 nondisjunction 5:372  
 monosomy 5:401  
 trisomy 5:401  
 nonenzymatic defenses 5:495  
 non-Hodgkin's lymphoma (NHL) 4:263,  
 14:190  
 nonhomologous end joining (NHEJ) 1:56, 73ff  
 BLM 1:75  
 DNA damages blocking replication 1:75  
 DNA-PK<sub>cs</sub> 1:75  
 double-strand breaks 1:75  
 DSB repair 12:9  
 interstrand cross-links 1:75  
 Ku70 1:75, 12:9  
 Ku80 12:9  
 Ku86 1:75  
 ligase IV 1:76  
 microhomology 1:75  
 WRN 1:75  
 XRCC4 (X-ray repair cross complementing  
 protein 4) 1:75  
 nonhost resistance 10:373, 376  
 nonhuman primates  
 in vitro fertilization 6:540  
 noninflammatory gene targets 5:237–238  
 cell death 5:236  
 noninsulin-dependent diabetes mellitus  
 14:624ff  
 nonlethal environmental selection 5:315  
 nonlinear fiber microscopy 15:83  
 nonlinear modelling 3:609  
 nonlinear optical microscope 15:64  
 non-LTR retrotransposon  
 esterase 1:268ff  
 MIR 1:269  
 non-Mendelian inheritance 15:5  
 nonnucleoside reverse transcriptase inhibitors  
 (NNRTIs) 6:162–163  
 nonnucleotidic modifications 9:424  
 nonoverlapping  
 frequency counts of 10:453–455  
 nonparametric linkage 1:601  
 nonpeptide 14:104  
 nonpeptide libraries, encoding and decoding  
 branch coding 10:167  
 chemical encoding 10:166  
 MS-encoded small molecule library 10:168  
 peptide-encoded small molecule library  
 10:168  
 sequential coding 10:167  
 spatial separation of testing and coding  
 molecules 10:167  
 nonpeptide oligomer or small molecule libraries  
 10:165  
 nonphotochemical quenching 2:637  
 nonprofessional phagocytes 10:181–182  
 nonproofreading 9:317  
 nonradiative transitions 4:446  
 nonreplicating subunit vaccines 12:315–316  
 nonselective cation channels 11:694  
 nonsense mediated decay (NMD) 9:63  
 nonshared environment 1:595, 596



- nonsmokers 5:355  
 nonspecific binding 11:108  
 nonspecific ionic charge 7:307ff  
 non-steroidal anti-inflammatory drugs  
   (NSAIDs) 13:239, 481  
 nonsteroidal 5 $\alpha$ -reductase 13:51  
 nonstructural proteins 12:306  
 nonsubjective cluster analysis 13:695  
 nonsynonymous mutation 12:118  
 nontraditional molecular motors  
   ATP synthase 8:593  
   nucleic acid enzymes 8:591  
   RNA polymerase  
     multitasking 8:591–592  
 nontumorigenic 2:225, 233–235  
 nonviral gene-transfection strategies  
   15:487  
 nonviral gene-transfection systems 15:498  
 nonviral system  
   chemical and physical systems 15:486  
   gene transfer as transfection 15:490  
   higher DNA-loading rates 15:498  
   noninfectious 15:498  
 nonviral vectors 7:299ff, 14:198, 15:236, 255  
 nonvirion associated proteins 1:108–109  
 nonvisual ( $\beta$ -) arrestins 4:191  
 noradrenaline 8:444  
 norbolethone 13:36  
 norepinephrine 8:220, 10:43  
 norethandrolone 13:33, 42  
 normal distribution 1:587  
 normal mode analysis (NMA) 13:654, 657  
 normal rat kidney (NRK) 5:648  
 normal tissue formation  
   control of 14:403  
 normal tissue renewal 13:340  
 normal transmitting male 4:587, 589  
 normalization of expression data 6:597  
 normalization of the cDNA library 3:406  
   large-insert genomic 3:407  
   small-insert genomic 3:407  
 normethandrone 13:33, 42  
 19-nortestosterone 13:33, 42  
 Northern blot analysis 5:562, 12:567, 568  
 notch 2:228, 229, 4:291ff, 12:170ff, 183ff, 186,  
   195, 13:334, 427ff, 15:203, 207, 214, 215  
 notch genes 13:210  
 notch signaling 5:557  
 no-template control 11:512  
 novel bases  
   difluorotoluene 2:13  
 novel biomarkers 9:114  
 novobiocin 2:627  
 NPC 8:32, 33  
 N3'-P5'-phosphoramidates  
   morpholino oligonucleotides 1:409  
 N-Ras  
   guanine nucleotide exchange factors 7:120  
 NSAID 14:458  
 NSF, *see* N-ethylmaleimide sensitive factor  
 NLS VUV-IR ring 13:679  
 NS-1 retrovirus 4:213  
 NT, *see* nuclear transfer  
 NTDs (neural tube defects) 9:122  
   causation of 9:124–126  
   developmental mechanisms of 9:126–134  
   environmental factors of 9:125–126  
   folate-resistant 9:135  
   genetic factors of 9:124–125  
 NTDs prevention  
   folic acid 9:134–135  
   vitamins 9:134–135  
 N-terminal nucleophile hydrolases  
   glutamine PRPP amidotransferase 11:254  
   glycosylasparaginase 11:254  
   penicillin acylase 11:254  
   proteosome 11:254  
 N-terminal polymerization motif  
   BRC repeats 11:537  
   conserved region 11:536  
   filament assembly 11:536  
    $\beta$ -strand 11:536  
 nuclear 10:295  
   efficiencies 1:221  
   nuclear mutations 2:634  
 nuclear architecture  
   and nuclear compartments 2:400  
   molecular interactions 3:6–7  
   regulation of gene expression 3:8–9  
   role in chromosome interactions 3:9–11  
 nuclear biotin-binding protein 15:525  
 nuclear bodies (NBs) 15:24ff  
   coiled or Cajal bodies 2:402  
   Pc-G bodies 2:403  
   PML bodies 2:403  
 nuclear compartmentalization 3:9  
 nuclear DNA 8:527, 11:366ff  
 nuclear entry 12:428ff, 443, 456ff, 465  
 nuclear envelope 3:2  
   biogenesis 2:397  
   interactions with 3:4–5  
 nuclear envelope interactions  
   role in gene silencing 3:8  
 nuclear envelope (NE) 3:3  
 nuclear export 13:137, 14:445  
 nuclear export sequence (NES) 13:137  
 nuclear export signals (NESs) 1:448  
 nuclear factor (NF1) 15:532

- nuclear genes 5:256–257  
nuclear genome 2:624, 5:256  
nuclear hormone receptor 4:332  
nuclear import 14:445  
nuclear inclusions 15:10ff  
nuclear lamina 3:6  
    Emery Dreifus muscular dystrophy 2:396  
    lamin function 2:395  
    lamin mutants 2:396  
    lamin proteins 2:393  
    lamin-associated proteins 2:396  
    the lamin genes 2:395  
nuclear localization 14:445  
nuclear localization signals (NLSs) 1:448  
nuclear magnetic moments (NMM) 11:160, 161, 166  
    NMR imaging (NMRI) 13:522  
nuclear magnetic resonance spectroscopy (NMR) 1:424, 3:520, 5:286–288, 8:202, 11:160, 280  
    bias 8:193  
    chemical shift anisotropy (CSA) 11:167  
    chemical shift perturbation 11:281  
    cryogenic probes 11:165, 281  
    experimental protein parameters 11:165–167  
    for drug discovery 13:526  
    glycans 2:263ff  
    high-field magnets 11:281  
    instrumentation 11:165, 13:538  
    nuclear matrix 3:2, 6  
    parameters 13:524, 553  
    probes 7:168  
    protein NMR 11:161  
    rapid acquisition, methodology of 11:169  
    relaxation data 13:550  
    reproducibility 8:193  
    sampling problem 11:162  
    screening by NMR 13:519, 520, 522, 527, 529, 582, 598  
    sensitivity 8:194  
    solid-state NMR 11:281  
    structural genomics 11:176–177  
    structure determination 11:170–174  
    structures of recPrP 10:575–577  
    techniques 10:199  
    timescales 13:551, 552  
    titrations 13:563  
    ultrafast 11:170  
nuclear oncogenes 9:471–473  
nuclear organelle genome interaction 10:309  
nuclear Overhauser effect, *see* NOE  
nuclear Overhauser enhancement spectroscopy 11:160, 166  
nuclear plasmids 3:333  
nuclear plasticity 13:365  
nuclear pore 3:6  
    nucleoporins 2:393  
    pore function 2:393  
    structure of the core 2:392  
nuclear pore complex (NPC) 8:30–32  
nuclear pyridoxal phosphate binding 15:531  
nuclear receptors 1:2, 440, 441, 7:220  
    LXR $\alpha$  7:224  
    LXR $\beta$  7:224  
    PPAR $\alpha$  7:224  
    PPAR $\beta$  7:224  
    PPAR $\gamma$  7:224  
    SREBP 7:223  
nuclear runoff assay 12:568  
nuclear speckles 2:403  
nuclear speckles/interchromatin granule clusters 2:403  
nuclear spin 11:160, 161  
    relaxation parameters 11:167  
nuclear splicing 12:53  
nuclear structure and function 2:392, 411, 415  
nuclear transcriptional factors 13:20  
nuclear transfer (cloning) 1:220, 9:204–206  
nuclear transfer (NT) 1:225  
    adult phenotype 9:219, 232  
    animal welfare 9:239, 240  
    artificial activation 9:230  
    cell cycle 9:217, 218, 223ff, 225  
    cloning 1:221  
    DNA methylation 9:209ff  
    dolly 9:206, 216, 220, 240  
    donor cell  
        cycle stage  
            G0 9:224  
            G1 9:220, 223  
            G2 9:223ff  
            G0/G1-phase 9:224ff  
            G2/M-phase 9:224  
            M-phase 9:224  
            S-phase 9:224, 225, 227  
    differentiation status 9:212ff, 239  
    adult stem cells 9:204, 216  
    blastomeres 9:213  
    embryonic germ cells 9:215  
    embryonic stem cells 9:214, 238  
    fibroblasts 9:216ff  
    primordial germ cells 9:215  
    progenitor cells 9:216  
    terminally differentiated cells 9:216  
epigenetic 9:205  
gene damage 9:218

- nuclear transfer (NT) (*continued*)  
 donor cell (*continued*)  
   genetic differences 9:217  
   genomic non-equivalence 9:217  
 electrofusion 1:221  
 ethical aspects 9:239  
 genetic background 9:219  
 Honolulu Method 1:221  
 method  
   fusion 9:229  
   injection 9:229  
 mitochondrial heteroplasmy 9:205, 218, 237  
 serial 9:205  
 telomeres 9:205, 219  
 X chromosome  
   inactivation 9:221  
   *see also* cloning
- nuclear transformation 2:629ff
- nuclear transplantation 1:212, 13:337, 367, 14:483
- nuclear transport  
 FG-repeats 2:400  
 importins 2:399  
 karyopherins 2:398  
 nuclear localization sequence 2:398  
 nuclear transport – facilitated diffusion 2:400  
 RanGTP 2:398, 399  
 RNA export pathways 2:399  
 selectivity – gating 2:400
- nuclear-encoded RNA polymerases (NEP) 10:325
- nuclear-organelle interactions 10:335–337
- 5' nuclease assay 1:316
- nuclease protection assay 12:568, 569
- nucleases 9:304, 14:175
- nucleation 3:542
- nuclei 2:622ff
- nuclei formation 2:112
- nucleic acid 1:653, 2:527ff, 4:674ff, 5:374, 7:173, 175, 10:18, 13:686  
 characterization of 9:269–288
- nucleic acid analysis 4:489
- nucleic acid bases 10:12
- nucleic acid detection 7:180ff
- nucleic acid enzymes 11:27–43
- nucleic acid footprinting 4:523
- nucleic acid hybridization assays  
 immunoassay labels 2:528
- nucleic acid hybrids  
 formation of 9:333–346  
 structure of 9:333–346
- nucleic acid labeling 11:412, 422
- nucleic acid packaging 9:364ff
- nucleic acid structures 13:550
- nucleic acid-liposome complexes 7:300ff
- nucleic base  
 loss of 12:120
- nucleic-acid amplification, *see* NAA
- nucleocapsid protein (N) 12:305–306
- nucleoid 2:624, 5:375
- nucleolar organizer 11:369
- nucleolar organizer region (NOR) 3:10, 563
- nucleolin 4:596
- nucleolus 1:466, 2:401, 6:140, 144, 14:256  
 dense fibrillar component (DFC) 2:402  
 fibrillar center (FC) 2:402  
 granular component (GC) 2:402  
 ribosomal RNA genes 2:402
- nucleophile 2:5, 12:324
- nucleophilic catalysis 2:18
- nucleophosmin (NPM/B23) 12:189
- nucleoplasmin 2:489ff
- nucleoporins 11:254
- nucleoprotein complexes 4:91, 92
- nucleoside 6:156, 160
- nucleoside reverse transcriptase inhibitors (NRTIs) 6:157–161
- nucleoside triphosphates (NTPs) 3:465
- nucleosides 1:652
- nucleoskeleton  
 functions at the matrix 2:415  
 nuclear architecture and the nucleoskeleton 2:414  
 proteins of the nuclear matrix 2:413
- nucleosomes 2:417, 3:3, 4:91, 6:138ff, 9:46, 261, 14:268  
 euchromatin 2:418  
 heterochromatin 2:418  
 small chromatin units 4:98
- nucleotide 6:156, 160, 10:14  
 base stacking 9:251  
 purine 9:257  
 pyrimidine 9:257  
 transition probabilities 9:254
- nucleotide conformation 12:609, 622
- nucleotide conformer 12:612
- nucleotide cycle 13:491–492
- nucleotide exchange factors 11:32
- nucleotide excision repair (NER) 1:56, 3:352, 369, 428, 432, 437ff, 9:383, 10:130, 12:112  
 DNA repair pathway's 1:69  
 oxidative damages 1:70  
 subpathways  
   global genomic repair (GGR) 1:70  
   transcription coupled repair (TCR) 1:70

- nucleotide hydrolysis 11:12  
nucleotide interaction 12:612  
  annotation 12:617, 620  
  cis 12:617  
  LG 12:615  
  LW 12:614–617, 620  
  LW+ 12:614, 615, 617  
  LW edge 12:614, 617  
  LW+face 12:614, 615  
  nomenclature 12:613–616  
  noncanonical 12:633  
  reverse 12:614, 615  
  Saenger 12:613  
  straight 12:614, 615  
  trans 12:617  
nucleotide release factors 13:499  
nucleotide reverse transcriptase inhibitors (NtRTIs) 6:157–161  
nucleotide sequences  
  entropy of 10:458–460  
  redundancy of 10:458–460  
nucleotide substitution 2:557, 5:338  
nucleotide triphosphates 2:5  
nucleus 1:466, 2:108, 165, 5:375, 6:139ff  
NUCLIN–NUCLSQ 12:625  
NUFIP 4:602  
Numb 12:186  
Numblike 12:186  
numerical integration 11:394, 395, 403  
nutrient transfer 5:470, 483, 484  
nutrition 8:345, 13:238–239  
  liver cancer 4:245  
nutritional stress 8:338  
nutritional studies 1:517  
Nuttall, George H. F. 8:518  
(NZB × NZW) F1 1:476
- o**  
OA  
  WOMAC 14:49  
obesity 1:14–15, 4:338, 7:27ff, 14:624ff  
ob/ob mice 14:631ff  
OBOC library method  
  advantages 10:164  
  cell-based lawn format 10:164  
  in situ solution-phase releasable assay 10:164  
  “ladder sequencing” method 10:165  
  on-bead binding assays 10:162  
  “one-aggregate one-compound” method 10:164  
  “one-bead two-compounds” approach 10:163  
  protease substrates and inhibitors, identification 10:163  
  solution-phase assays 10:163  
  split-mix synthesis 10:162  
  whole-cell binding assay 10:163  
observable quantities 11:383  
Occam’s razor 14:134  
occludin  
  plaque proteins 2:365  
  tight junctions 2:365  
occlusive thrombi 5:220  
Oct-1, Oct-2 6:185ff, 207ff  
octanol-water partition data, *see*  $P_{\text{Oct}}$   
Oct-4 (Oct-3) 10:487, 13:334  
octreotid 10:218–220  
oculopharyngeal muscular dystrophy (OPMD) 15:9ff, 46ff  
odor coding 12:639  
odor representation  
  combinatorial system of 12:683  
odorant binding proteins (OBPs) 7:485, 12:660  
odorant receptor (OR) 7:482, 485, 12:661  
O-GlcNAc transferase (OGT)  
  corepressor Sin3 5:580  
  GlcNAc- $\beta$ -Ser/Thr linkage 5:580  
O-glycanase 5:541  
O-glycosylation  
  hydroxylysine (Hyl) 5:572  
  hydroxyproline (Hyp) 5:572  
  N-acetylgalactosamine (GalNAc) 5:574  
  serine (Ser) 5:572  
  threonine (Thr) 5:572  
3’ OH 12:333, 409  
OH X-ray footprinting 3:546  
oil chamber 3:26  
Okazaki fragments 3:452, 4:615, 5:383  
old world monkeys 2:554  
oleaginicity 7:265  
oleamide 7:98  
oleate 7:101  
olfaction 12:639, 640  
olfactory bulb (OB) 12:652, 13:410ff  
  afferent signals, tuning of 12:651  
  centrifugal inputs 12:650  
  glomeruli 12:648–650  
  neurogenesis in 12:653–654  
olfactory cortex 12:654–656  
olfactory dysfunction  
  congenital disorders associated with 12:690–692  
olfactory epithelium 14:10  
olfactory fila 12:648  
olfactory nerve layer (ONL) 12:648

- olfactory neuroepithelium  
   cell types 12:642–645  
   neurogenesis in 12:645  
   receptor cell cilia 12:645  
 olfactory receptor 12:661–666  
   regulatory elements of 12:687–690  
 olfactory receptor genes  
   families of 13:207  
   monogenic expression of 12:677–678  
 olfactory receptor-expressing neurons  
   convergences of 12:680–683  
 olfactory signal transduction  
   concepts of 12:658  
   modern era of 12:658–673  
 olfactory system 12:674–676  
   receptor gene repertoires in vertebrates 12:673  
 olfactory system organization  
   principles of 12:677–683  
 oligo(A)s 10:20, 23  
 oligocarbamate and oligourea peptidomimetics 14:74  
 oligo(C)s 10:20  
 oligodendrocyte precursors 5:647  
 oligodendrocytes 5:650  
 oligodeoxynucleotide 9:414  
   synthesis of 9:416–417  
 oligodeoxynucleotides (ODN) 1:406ff, 15:119  
 oligo-dT 11:486ff  
 oligo(ethylene glycol) 11:117  
 oligo(G)s 10:23  
 oligomer design 2:76  
 oligomeric fusion proteins  
   closed, ringlike oligomeric structure 11:74  
 oligomeric interface 11:536  
 oligomers 15:26  
   selection of 2:83  
 oligonucleotide 8:113ff, 270, 9:413–414, 432, 10:226, 13:557, 14:157, 427  
   2'-amino 9:422  
   applications in cell culture 9:425–428  
   applications in man (“Drugs”) 9:429–431  
   applications of 9:425–429  
   chemically modified 9:419–425  
   2'-fluoro 9:422  
   hybridization with 9:345–346  
   2'-methoxy 9:421–422  
   morpholino 9:422  
   oligonucleotide synthesis 2:11  
   perspectives of 9:425–429  
   phosphorothioate DNA 2:11  
   stability of 9:337–341  
   synthesis of 9:415–419  
 oligonucleotide dissociation 9:346  
 oligonucleotide duplexes 9:337–341  
 oligonucleotide ligation assay (OLA) 7:186  
 oligonucleotide probe 6:554ff, 7:180ff  
 oligonucleotide synthesis 2:12  
 oligonucleotide-based approaches  
   antisense 1:161  
   chimeric molecules 1:161  
   RNAi 1:161  
 oligonucleotide-based arrays (GeneChips and Codelink)  
   advantages of 8:270–271  
   drawbacks of 8:270–271  
 oligonucleotide-based DNA arrays 8:265, 270  
 oligonucleotide-based drugs 1:413  
 oligoribonucleotide 9:414  
   synthesis of 9:417–419  
 oligosaccharide alcohols 5:540  
 oligosaccharides 2:250, 278  
   analytical method 2:247  
   asparagine-linked 3:164, 167  
 oligo(U)s 10:20  
 oligreen 11:500ff  
 OLR1 7:238  
 omentum 15:259  
 O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) 1:56, 76, 3:428, 431  
 Omi 13:512  
 oncogene 2:198–200, 4:177, 338, 6:3, 8:135, 9:96, 435–437, 442–445, 448–449, 499, 533–534, 12:148, 154, 176, 14:152  
   activation 5:356  
   amplification of K-ras 5:358  
   amplification of N-myc and myb 5:356  
   amplification of N-myc RNA 5:356  
   biochemical properties of 9:450–473  
   cancer 9:473  
   categories of 9:446–447  
   cellular functions of 9:450–473  
   clinical implications of 9:473–476  
   c-myc 5:355, 356  
   c-myc and L-myc mRNA showed loss of transcriptional attenuation 5:357  
   c-myc mRNA levels 5:356  
   c-myc protein 5:356  
   c-raf1 protein 5:356  
   erb 13-2 5:361  
   expression of AS RNA 5:359  
   extracellular mitogenic signals of 9:453–455  
   from cell surface receptors 9:456–462  
   growth factors of 9:453–455  
   high levels of a v-fms-related transcript 5:356

- historical perspective of 9:438–441  
 H-ras 5:355  
 identification of 9:473  
 in cytoplasmic signal transduction pathways 9:462–471  
 increased c-myc expression 5:358  
 increased expression 5:357  
 inhibition of K-ras 5:360  
 k-ras mutations 5:358  
 L-myc 5:357  
 membrane-associated nonreceptor 9:461–462  
 mutations 5:363  
 myc family 5:356  
 neu/erb B-2 5:361  
 prognosis of 9:473  
 ras activation as a progression factor in lung cancer 5:359  
 ras family 5:358  
 ras in carcinogen-induced tumors 5:358  
 rearrangement of myc genes 5:357  
 regulation of N-myc expression 5:357  
 responsiveness to bombesin 5:357  
 sporadic alterations in a variety of other oncogenes 5:360  
 the N-myc gene 5:357  
 transcription factors of 9:471–473  
 uptake of ras AS oligonucleotides 5:359  
 with cancer cell adhesion and motility 9:470–471  
 oncogene perturbation  
   mechanisms of 9:448–450  
 oncogenes promoting cell cycle  
   cell division of 9:451–453  
   progression of 9:451–453  
 oncogenesis 9:469–470  
 oncogene-targeted  
   chemotherapy 9:473–474  
   immunotherapy 9:474–476  
 oncogenic kinase 7:118ff  
 oncolysis 15:342  
 oncoproteins 9:437, 448  
   loss of control of cell cycle checkpoints 9:453  
 oncotoxins 6:502  
 one-cell embryo 10:485  
 ONECUT 6:210ff  
 one-dimensional random movement 12:338  
 one-hit kinetics 4:522  
 one-photon 15:64  
 O-nitrophenyl  $\beta$ -D-fucoside 12:31  
 ontology 6:599  
 oocyte 1:225, 5:556, 6:533–535ff, 538ff, 540ff, 13:383, 14:9  
   activation 6:538  
   age 6:540  
   CaMKII 6:538  
   cumulus cells 6:535  
   mtDNA population bottlenecks 1:85  
   zona pellucida 6:534, 535  
 oocyte activation  
   maturation promoting factor (MPF) 6:537  
 oocyte-derived factor 4:395  
 oogenesis 10:74  
 oomycetes 10:361  
 ooplasmic transfer 6:544  
 open reading frame 2:620  
 open reading frames 11:121  
 “Open sandwich” (OS) immunoassay 6:376  
 open spina bifida 9:121  
 operator RNA (oRNA) 12:46  
 operon fusion 5:340  
 operon hypothesis 3:508–511  
 operon induction 5:316  
 operons 5:397, 9:254, 12:28, 101  
 OPI1 10:297  
 opiate drugs 15:270  
 opioid receptors 15:270  
 OPN 6:16, 18  
 opsin 12:415, 428ff, 447  
 opsin shift 1:578  
 opsin/vitamin A 12:424ff, 426, 435  
 opsonins 1:377, 10:178, 184  
 opsonization 6:342, 14:174  
 optical biopsy 15:82  
 optical fibers 13:291  
 optical rotation 3:56ff  
 optical rotatory dispersion 12:31  
 optical sectioning 15:64  
   confocal 15:66  
   excitation-based 15:66  
 optical stethoscope 9:275  
 optimization method 10:207  
 optimized strategy 7:308ff  
 optoelectronic integrated circuits 9:564  
 oral–aboral polarity 13:272  
 oral bioavailability 3:616  
   model animals 3:599  
 oral vaccination 10:660  
 orbital 4:635  
 ORC 12:190ff  
 ORCA family of transcription factor 1:437  
 order of binding 12:339  
 ORF 9:258, 11:435  
 organ  
   bioartificial 7:552

- organelle 11:289  
 organellar genomes 2:623  
 organic acid utilization 1:517  
 organizers 13:287, 295  
 organizing the cytoplasm 2:411  
 organogenesis 5:640, 8:447  
 cis-regulatory systems 3:291  
 differentiation gene battery 3:291  
 field-specific genes 3:290  
 morphogenetic pattern formation 3:290  
 organ-identity genes 3:290  
 organ-identity transcription factors 3:290  
 Pax6/eyeless 3:291  
 PHA-4 3:291, 292  
 pharyngeal organogenesis 3:292  
 regulation of organogenesis 3:290  
 regulatory fields 3:290  
 selector genes 3:290  
 stem cells 3:290  
 organometallic estradiol derivatives 1:450–452  
 oriC 1:536, 537  
 orientation function 4:17  
 orientation-dependent instability 4:614  
 origin of cancer 13:335  
 origin of replication 1:536, 15:252  
 origin of transfer 10:437  
 origin (ori) 3:450  
 orlistat 14:632ff  
 ornithine transcarbamylase 15:267  
 orphan receptors 8:89, 11:595, 609, 613, 614  
 orthogonal  
 aaRS 11:49  
 aminoacyl-tRNA synthetase 11:50–56,  
 58–62  
 pair 11:46, 51  
 tRNA 11:62  
 orthogonal signal correction 8:200, 202  
 orthologous chromosomal segments  
 large-scale rearrangements 11:443  
 orthologous genes 3:641, 9:256  
 properties of 11:453–454  
 orthologs 7:481, 11:218, 220  
 orthology 6:600, 11:217  
 determination of 11:452–453  
 orthology and paralogy 11:217  
 speciation 11:218  
 orthopoxviruses 6:555, 559  
 orthosomycin 10:647ff  
 orthosteric site 11:605  
*Orzo sativa* 10:550  
 Oscillator 12:415, 423, 426, 433ff, 436ff, 448ff,  
 451, 453ff, 456, 459ff, 463  
 oscule 13:275ff  
 OSMAC 10:646  
 osmium tetroxide 3:544  
 osmotic effect 1:429  
 osmotic gradient  
 osmotic lysis 15:497  
 release of complex into cytosol 15:497  
 osteoarthritis 4:341, 14:48  
 osteoblast transcription factor 12:359  
 osteogenic proteins 5:238  
 osteopetrosis 11:697  
 osteopontin (OPN) 6:3  
 osteoporosis 8:201, 13:687, 14:222  
 OTC (ornithine transcarbamylase) 13:258  
 otd/Otx 6:207ff  
 ototoxic aminoglycoside 13:234  
 otr 14:238  
 Otto 5:59  
 outbreeding 1:86  
 outcrossing 1:77, 79, 80  
 avoid inbreeding 1:90  
 masking mutations 1:92  
 outer membrane general import complex, *see*  
 TOM  
 outer membranes 8:377  
 outer nuclear layer (ONL) 12:363  
 outer trophoectoderm 13:386  
 outgroup 2:575  
 outlicensing 15:169  
 outsourcing 15:169  
 “oval” cells 7:331  
 ovarian cancer 9:100  
 ovarian folliculogenesis 4:383  
 ovarian teratoma 10:75ff, 76ff, 82ff  
 ovary ecdysteroids 7:487  
 overall similarity 8:519  
 overdominance 5:247  
 overexpression of genes 1:40  
 overfitting 3:608, 612  
 overlapping  
 frequency counts of 10:453–455  
 overproducing recombinant proteins  
 BL21(DE3) 11:194  
 coexpression 11:195  
 expression host 11:194  
 expression vector 11:194  
 poor recombinant protein expression  
 11:195  
 rare *E. coli* codons 11:195  
 overt rhythm 12:416, 423  
 ovotestis 5:628  
 ovotransferrin 2:261  
 ovulation 8:445, 13:383, 384  
 oxamflatin 4:269  
 oxandrolone 13:31, 37, 41, 42  
 Oxa1p 11:295

- oxendolone 13:46  
 oxetane ring 1:425  
 oxidase 13:611, 613, 614, 620, 621  
 $\beta$ -oxidation 7:34ff, 99, 8:164, 173, 13:612, 614,  
   619–621, 629  
   fatty acid 13:613  
 oxidation 14:455  
   mitochondria 7:99  
 oxidation level 10:5  
 oxidation/reduction, hydrolysis 2:53  
 oxidative burst 5:502, 10:375  
 oxidative damage 1:59, 68, 4:634ff  
 oxidative DNA damage 9:384  
 oxidative metabolism  
   aging 1:69  
   brain 1:69  
 oxidative organisms 1:519  
 oxidative phosphorylation (OXPHOS) 8:165,  
   166, 359, 15:368, 383  
 oxidative species 4:426  
 oxidative stress 4:634ff, 5:499, 7:46, 326,  
   8:568–569, 13:505–506  
 oxidized base  
   incorporation of 12:120  
 oximes 11:64, 115  
 oximetry probes 7:175  
 8-oxodeoxyguanosine 3:361  
 oxygen 4:371, 5:493, 8:21, 22, 210ff, 210–212,  
   217, 218, 220, 221, 226–228, 231, 10:6  
   labeling 8:23, 27  
   linked 5:551  
 oxygen carriers 6:68  
   adverse outcomes 6:104ff  
   alternative sources 6:104  
   first generation 6:104  
   second generation 6:105  
   unsuitability of unprocessed Hb 6:103  
 oxygen equilibrium curves 5:273–274  
 oxygen paradox 5:509  
 oxygen radicals 1:379  
 oxygen toxicity 5:494  
 oxygenic photosynthesis 5:511  
 oxymetholone 13:31, 37, 42  
 oxyR 4:642  
 OxyR regulatory protein 5:503  
 oxytocin 3:302, 304, 4:385ff  
 oxytocin precursor 3:304
- p**
- P  
   selectin 5:585  
 p50 5:266, 282  
 p16 6:5, 8, 11, 24  
 p27 6:13, 20  
 p38 14:451  
 p50 14:442  
 p53 1:64, 2:172, 176, 228, 4:245, 6:4, 18, 7:328,  
   330, 10:131, 625, 629, 12:155, 187ff, 15:14  
   aging 1:70, 73  
   cancer 1:82  
   cell cycle arrest 1:83  
   homologous recombinational repair (HRR)  
     1:75  
   premeiotic delay 1:83  
 p65 14:441, 442  
 p107 12:162, 184  
 p130 12:162, 168  
 P450 3:627  
*P. aeruginosa*  
   antibiotic therapy 8:636  
   antibody production 8:632  
   bacterial microcolonies 8:630  
   bacterial microcolony 8:632  
   cross-infection 8:636  
   early antibiotic therapy 8:636  
   immune complexes 8:632  
   mucoid cell types 8:630  
   mutator strains 8:636  
   (sputum) plugs 8:630  
   vaccination 8:636  
 P element 4:334  
 3p, 5q, 9p, 9q, 13q, 17p, 17q, and 18q 6:4  
 PA 1:310, 317  
 PA200 11:4, 19  
 PAC (P1 artificial chromosomes) 5:141ff,  
   15:565  
 pacemaker 11:660, 12:416, 425, 432ff, 446,  
   449ff, 459, 462  
 “packaging” cell lines 15:239  
 paclitaxel 10:659, 14:340–343  
 padlock probe 7:188  
 pagA 1:321  
 pagR 1:321  
 pain 4:344, 14:39  
 pain and polyneuropathy 15:272  
 pain transduction  
   gating of ion channels 10:29–45  
   modulation of ion channels 10:29–45  
 paired-class homeobox 13:303  
 pair-rule genes 13:273ff, 299  
 PAKa 8:328  
 PAL 1:431  
 palmitate 7:99  
 palmitoyl transferase 12:388  
 palmitoylated 12:388  
 palmitoylcarnitine translocase 7:99ff  
 PAM 11:296



- PAMP, *see* pathogen-associated molecular patterns
- pancreas 15:260
- pancreatic cancer 9:102
- pancreatic  $\beta$ -cell endocrine channelopathies 11:698
- pancreatic  $\beta$ -cells 7:27ff, 14:631ff
- pancreatic insufficiency 11:687
- panning 3:84, 85
- Pantoea 10:366, 369
- pantothenic acid 15:550
- PapD 2:515ff
- papillary dermis 13:224
- ParA 10:425
- ParA oscillation 10:428
- Paracellin-1 11:694
- paracellular 3:622
- paracellular pathways 11:685, 694
- paracellular route 8:146
- paracrine 5:639
- paracrine signaling  
   inducing factors 3:276  
   keratinocyte growth factor 3:276  
   paracrine factors 3:275  
   spermatogenesis 3:276  
   stem cell factor 3:276
- parahormones 4:170
- ParaHox cluster 6:189ff
- parainfluenza 12:316  
   vaccine 15:160, 164
- paralogous chromosomal regions  
   common genetic origin 13:206
- paralogous genes 9:256
- paralogs 3:117, 143, 11:220, 225
- paralogue groups 1 to 13 6:191ff
- paralogy 6:600, 11:217
- paralysis 11:670
- paramagnetic 4:122
- paramagnetic metal ions  
   cobalt<sup>2+</sup> 4:121  
   copper<sup>2+</sup> 4:120  
   iron<sup>3+</sup> 4:120  
   manganese<sup>2+</sup> 4:120  
   nickel<sup>3+</sup> 4:121  
   vanadyl 4:121
- paramagnetic nanoparticles 9:43
- paramecia  
   micronucleus 1:69  
*Paramecium tetraurelia* 8:359, 364ff, 369, 378  
   macronucleus 1:69  
   micronucleus 1:69
- parameters 11:387, 391–393  
   global 11:389, 390  
   initial value 11:390  
   local 11:389, 390
- parametric linkage 1:600
- paramyotonia congenita 11:672
- paramyxovirus 12:298, 300, 304
- paraphyletic 15:373
- paraquat 4:643
- parasegments 13:299
- parasite 4:208, 6:229  
   arenaviruses 5:597  
   *H. pylori*s 5:598  
   Lassa fever virus (LFV) 5:597  
   Lewis<sup>b</sup> (Le<sup>b</sup>) blood group antigen 5:598  
   lymphocytic choriomeningitis virus (LCMV) 5:597  
   malarial parasite 5:598  
   MN blood group system 5:598  
   Mobala 5:597  
   *Mycobacterium leprae* 5:597  
   Oliveros 5:597  
   *P. falciparum* 5:598  
   *P. vivax* 5:598  
   parasitic plants 6:230
- parasitophorous vacuole 4:208
- parathormone  
   disease 4:175, 176
- parathyroid hormone (PTH) 14:108
- paratope 6:365, 366ff
- paraventricular nuclei 4:404
- ParB 4:358, 359, 10:425
- parenchyma 1:417
- p19<sup>ARF</sup> 12:187
- Parkin gene 15:261
- Parkinson 4:332
- parkinsonism 15:19
- Parkinson's disease (PD) 4:643, 8:453, 12:693, 694, 14:491, 15:13ff, 261, 265  
   dopaminergic neurons 13:395
- paromomycin 2:630
- paroxysmal nocturnal hemoglobinuria (PNH) 5:576
- PARP 1:80  
   aging 1:73  
   base excision repair (BER) 1:71  
   nick surveillance protein 1:71
- parsimony 1:597
- Parthenogenesis 10:72ff, 73ff, 80ff  
   sparse populations 1:90, 15:612
- parthenogenetic 5:472, 473, 483
- parthenogenetic stem cells 10:71ff, 76ff, 82ff
- parthenotes 10:72, 74ff, 82
- partial differential equations 14:139
- partial digestion 3:414
- partial familial lipodystrophy (PFLD) 1:15
- partial transgenesis 14:540–542

- partially denaturing mode 9:303  
 partially folded proteins 4:515–516  
 particle organization  
   genetic approaches to 9:25–26  
 P1 artificial chromosomes (PACs) 15:560  
 Partington syndrome (PRTS) 15:49  
 partition 4:356, 10:412, 425  
 partition coefficient 8:147ff  
 partition-diffusion 8:146ff  
   example 8:147  
   measurement 8:148  
   theory 8:147  
 partition-mediated incompatibility 10:425  
 party hubs 9:509  
 PAS 12:426ff, 437, 439ff, 442, 448, 452, 462  
 PA28s 11:18  
 PA28s (aka 11S REGs) 11:4  
 PAS domain 12:416  
 passive immunization 3:157, 6:387  
 passive targeting 14:174  
   diseased tissue 14:177–178  
 Pasteur Louis 13:331  
*Pasteurella* 6:311  
 PAT 14:647  
 patch electrode 11:647  
 patch-clamp capacitance 4:308ff  
 Patched (Ptc) 12:179ff  
 patchy complexity 10:468–469  
 patent 7:368  
   concept of 7:369–374  
   operation of 7:369–374  
   public attitudes  
     in Europe 7:388  
     in United States 7:386–388  
 patent and trademark office (PTO) 7:374  
 patent law 7:370  
 patented animals  
   access to 7:383  
   applications of 7:382  
   compounds, production of 7:382  
   environmental safety of 7:383–384  
   ethics of 7:385–386  
   food safety 7:384–385  
   health 7:384  
   issues with 7:383–386  
     benefits of 7:381–382  
     technology status 7:380–381  
 paternal homologs 14:6  
 path analysis 1:596  
 path length 14:136  
 pathogen 1:554ff, 555ff, 557, 561, 562, 563,  
 564, 565, 566, 567, 568, 570, 571, 6:229, 342,  
 385, 396, 607  
*Leishmania* 1:371  
*Listeria monocytogenes* 1:371  
 mycobacteria 1:371  
 oxygen-independent destruction of  
   6:420–421  
 pathogen-associated molecular patterns (PAMP)  
 1:376, 6:341, 412–413, 7:2, 6, 8:440, 450,  
 10:86, 184, 14:452  
 pathogenesis 1:560, 571, 11:659  
   adhesion 1:556  
   colonization 1:555  
   dissemination 1:556, 569  
   entry 1:562, 563  
   host susceptibility 1:562  
   transmission 1:562  
 pathogenesis-related (PR) protein 10:375  
 pathogenic gene family 11:700  
 pathogenic microorganisms 13:228  
 pathogenicity factors 10:366, 371  
 pathogenicity islands 1:311, 6:230  
 pathologic biomarkers 9:113  
 pathological gain of function 15:262  
 pathological gene expression  
   suppression of 9:429  
 pathology 1:182ff, 3:532  
 pathophysiological mechanisms 11:659  
 pathophysiology 8:201, 11:670, 673  
 pathway engineering 5:4  
   *Acremonium chrysogenum* 5:20  
   expandase 5:20  
   isopenicillin N 5:20  
   *Penicillium chrysogenum* 5:19  
   *Streptomyces clavuligerus* 5:20  
 pathways 4:344, 11:214, 218  
   BER 1:63  
   “Horowitz” model 11:215  
   signaling molecules 11:215  
   small-molecular metabolism 11:215  
   TCR 1:63  
 pathways activating IFN response 7:15  
 patient-isolation precautions 10:521  
 pattern 10:448, 472  
 pattern formation 3:278, 6:182ff, 14:139  
 patterned tissue  
   cellular organization 2:107–108  
 pattern-recognition receptors (PRR) 1:376,  
 6:341, 413–415, 8:450, 606, 10:86, 184  
 patterson function  
   Fourier transform of the intensities 7:424  
   interatomic vectors as maxima 7:424  
 patterson search methods  
   computer programs 7:440  
   intramolecular vectors 7:439  
   molecular replacement 7:438  
   molecule orientation 7:439

- patterson search methods (*continued*)  
 patterson function 7:438  
 rotation function  
 Rossmann and Blow 7:439  
 search model 7:438  
 translation function  
 Crowther and Blow 7:439  
 translation of the molecule(s) 7:439
- PAU family 14:237ff  
 Pauling Linus 8:519  
 PAUP 8:529  
 Pax genes 6:206ff  
 paxillin 2:333ff  
 PBC 6:214ff  
 pBeloBAC11 (top) 3:399  
 P450 biotransformation 3:107  
 pBluescript II KS+ 3:404  
 PBX1 6:185ff  
 PCA (principal components analysis) 3:609  
 P-cadherin 6:7  
 p130Cas 2:333  
 p300(CBP) 12:156  
 p300/CBP-associated factor (PCAF) 15:30  
 PC12 cell line 4:599  
 p21<sup>cip1</sup> 2:228, 230  
 PCR amplification analysis 4:617  
 PCR efficiency 11:501ff  
 PCR fidelity 9:317  
 PCR optimization 9:314  
 PCR (polymerase chain reaction) 1:215, 3:77,  
 206, 451, 4:490, 5:120, 122, 525, 6:450, 451,  
 514, 555, 7:596, 9:334, 427, 10:538, 11:314,  
 12:514, 522, 713ff, 13:73, 14:422, 474, 484,  
 15:557, 561  
 analysis of 5:254  
 combination 14:428f  
 PCR primer optimization 9:314  
 PCR process, defined 3:489  
 PCR technology  
 new physical mapping concept of STS  
 13:78
- PCR-based protocols  
 preparation of sequencing templates 13:81
- PD. . . (D/E)XK amino acid sequence motif  
 12:329
- P1-derived artificial chromosomes (PAC)  
 15:557
- PDGF (platelet-derived growth factor) 1:380,  
 5:649–650, 6:3, 9:455, 458–460, 13:136,  
 14:41, 294ff, 15:203  
 $\beta$  15:218  
 A- 6:7  
 BB 15:218  
 B-receptor 6:7  
 C 15:218  
 D 15:218  
 FGH receptors 11:581
- PDGFR  
 $\alpha$  15:218  
 family 7:130  
 FL (Flt3 ligand) 7:130  
 FMS-like tyrosine kinase 3 7:129  
 immunoglobulin-like (Ig) domains 7:130ff  
 KIT 7:130  
 PDGFRA 7:130, 133  
 PDGFRB 7:130, 133  
 point mutations 7:130  
 small tandem duplications 7:130
- PDI, *see* protein disulfide isomerase  
 peak capacity 6:247  
 peak intensities 13:524  
 peak intensity 13:687  
 pectin lyase 1:433  
 pedigree 11:662  
 PEG (polyethylene glycol) 1:430, 7:303ff, 11:64  
 PEGylation 7:303ff, 14:195  
 and pharmacokinetics 15:493
- PEI-based gene transfer systems  
 dendrimers 15:496
- Peltier thermocycler 11:491
- PEM1/CHO2 10:287  
 PEM2/OPI3 10:287
- pemphigus vulgaris (PV) 13:206  
 Pemt<sup>-/-</sup> mice 10:286
- penetrance 1:600, 5:394, 11:658  
 penetrate 7:301ff  
 PEN-2ff 1:192
- penicillin 2:589, 10:656ff, 14:348  
 penicillin G  
 fed batch processes 5:7  
 penicillin V 5:7ff  
*Penicillium chrysogenum* 5:7ff
- penta EF-hand  
 ALG-2 2:153, 155  
 calpain 2:153, 154  
 grancalcin 2:153  
 peflin 2:153  
 sorcin 2:153
- pentose phosphate cycle 7:106
- penumbras 10:117, 120  
 multiple 10:133
- peptide 4:668ff, 6:204ff, 11:114  
 action mechanisms of 14:106–110  
 antifungal 1:377  
 biological functions of 14:106–110  
 biosynthesis 14:104  
 chemical synthesis of 14:102–104  
 chemistry of 14:94

- drug design of 14:110  
 metabolism of 14:104  
 molecular diversity of 14:102–104  
 Octa 6:204  
 pathophysiology of 14:110–112  
 structure of 14:94–102  
 therapeutic targets of 14:110–112  
 three-dimensional properties of 14:94–102  
 peptide backbone  
   angles 3:243  
   cis–trans isomerization 3:243  
   resonance properties 3:243  
 peptide biology  
   biology of 14:104–110  
 peptide bond 3:59ff, 8:224  
 peptide bond, formation 14:584, 604–607  
 peptide fragmentation in MS/MS 8:15  
 peptide libraries 3:257, 14:104  
 peptide loading 1:369, 3:220–221  
 peptide localization signals 14:185  
 peptide mapping 6:247, 8:11  
 peptide mass fingerprinting 7:564, 8:15, 24  
 peptide mass matching method 8:32  
 peptide motifs 1:619  
 peptide nucleic acid hybrid molecule 11:123  
 peptide nucleic acids, *see* PNA  
 peptide–receptor complex 14:108  
 peptide receptors 1:364  
 peptide signal 8:303  
 peptide synthesis  
   macroscopic view of 12:486–488  
 peptide synthetase 10:656ff  
 peptide-binding cleft 1:364  
 peptides 4:668ff  
    $\beta$ -peptides 14:71  
    $\gamma$ -peptides 14:71  
 peptidoglycan (PGN) 1:391, 527, 531, 540,  
   2:589, 6:413, 7:3, 10:90  
 peptidoglycan synthesis, during the division  
   cycle 1:538  
 peptidomimetics 3:257, 6:156, 164, 8:101ff,  
   102, 14:104  
 peptidomimetics and nonpeptides 14:92  
 peptidyl 12:486  
 peptidyl–prolyl cis–trans isomerases 1:38, 40  
 peptidyl transfer  
   molecular mechanism of 12:497–499  
 peptidyl transferase 12:520  
 peptidyl transferase center 12:488  
 peptidyl transferase reaction 12:484  
 peptoids  
   N-alkylglycine oligomers 14:75  
 perfluorocarbons 6:103  
 perforin 4:210  
 perfusion–diffusion mismatch 10:124  
 perhydroxyl radical 5:494  
 pericentric inversion 2:562  
 pericentric region 14:237ff  
 pericytes 14:288, 15:220  
 periderm 13:220  
 peri-infarct depolarizations 10:124  
 period 12:416, 420ff, 430ff, 433, 435, 438ff,  
   445, 451, 453ff, 458ff, 465, 467ff, 470  
 periodic paralysis syndromes 11:672  
 peripheral clocks 12:431ff, 444, 449ff  
 peripheral ischemic vascular disease 14:285  
 peripheral neuropathies 13:322  
 peripheral oscillators 12:416, 425  
 peripheral rhythmicity 12:434  
 peripheral supramolecular activation cluster  
   (p-SMAC) 1:374  
 peripheral vascular disease (PVD) 14:284ff  
 periplasm 3:82  
 periplasmic proteolytic system 13:509–512  
 periplasmic space 11:289  
 peritonitis 4:347  
 peritubular myoid cell 7:500  
 perlecan 8:47, 50, 53, 54, 68  
 permanent neonatal diabetes (PND) 11:698  
 permeability 8:142, 148, 15:212  
   coefficient 8:147ff  
   measurement 8:149  
 permeability barrier 11:289  
 permeability pore 11:647  
 permeability transition pore (PTP; MPTP)  
   8:361  
 peroxidases 5:496, 6:35–36, 7:482, 8:231  
   active site structures of 6:39  
   catalase 6:44  
   catalytic cycle 6:37–38  
   catalytic mechanism of 6:39–41  
   crystal structures of 6:38–39  
   di-heme 6:41–44  
   enzyme substrate complexes 6:41  
 peroxidation 7:98  
 peroxins 11:299, 13:616, 618, 625  
 peroxisomal proliferator-activated receptors  
   7:106  
 peroxisomal reticulum 13:610  
 peroxisomal targeting signal 13:612, 618–620  
 peroxisome 4:639, 7:98ff, 11:289, 298  
   matrix proteins 11:299  
   membrane proteins 11:299  
   proliferator–activated receptors 7:98  
   PTS1 11:291  
   PTS2 11:291  
 peroxisome biogenesis disorder 13:628  
   infantile Refsum’s disease 13:629

- peroxisome biogenesis disorder (*continued*)  
  neonatal adrenoleukodystrophy 13:629  
  rhizomelic chondrodysplasia punctata  
  13:630  
  Zellweger syndrome 13:629, 630
- peroxisome proliferator-activated receptor  
  (PPAR) 6:19, 7:35, 106, 199, 215, 224, 228,  
  238, 13:620f, 630, 15:14
- peroxisome targeting signal 13:610  
  mPTS 13:623  
  PTS1 13:612, 616, 623, 624, 625, 627, 628  
  PTS2 13:617, 624–626, 630
- peroxyl radical 4:635ff, 7:150, 153
- peroxynitrite radical 7:49, 10:121
- Perrin equation 4:449
- persistent generalized lymphadenopathy 1:111
- personal dosimeters 11:431
- personalized medicines 10:209
- “perturbed expression” profiling 5:78
- pertussis toxin 13:152ff
- PEST (Pink Eye STandard) strain 7:475
- peste-des-petits-ruminants virus 5:299
- petri dishes 7:546
- Petrozole 9:524
- PEX 11:299, 13:628
- PEX2 13:627, 630
- PEX5 13:630
- PEX6 13:629
- PEX7 13:630
- PEX11 13:630
- PEX13 13:630
- PEX14 13:618
- PEX16 13:623
- PEX gene 13:618, 629
- pexophagy  
  macro 13:616  
  micro 13:616
- Pex1p 13:616, 626, 627
- Pex2p 13:616, 617, 620, 623, 625
- Pex3p 13:615, 616, 623
- Pex4p 13:616, 617, 626
- Pex5p 13:616, 617, 625–627
- Pex6p 13:616, 617, 626, 627
- Pex7p 13:616, 625
- Pex8p 13:617, 625, 626
- Pex9p 13:617
- Pex10p 13:616, 617, 625–627
- Pex11p 13:615, 617, 622, 623
- Pex12p 13:617, 625, 627
- Pex13p 13:617, 625, 627
- Pex14p 13:617, 625, 627
- Pex15p 13:616, 617, 626
- Pex16p 13:615, 617, 623
- Pex17p 13:617, 625, 627
- Pex18p 13:617
- Pex19p 13:616, 617, 623
- Pex20p 13:617
- Pex21p 13:617
- Pex22p 13:616, 617, 626
- Pex23p 13:617, 622
- Pex24p 13:617
- Pex25p 13:617, 622
- Pex26p 13:617, 626
- Pex27p 13:617, 622
- Pex28p 13:617
- Pex29p 13:617
- Pex30p 13:617
- Pex31p 13:617
- Pex32p 13:617, 622
- Peyer’s patches 1:363
- Pfam 12:103
- P450 fold 3:110
- p53 gene  
  master switch 1:60  
  p66Shc 1:60
- p73 gene 6:11
- P-glycoprotein 3:625, 8:147, 154, 156, 11:153
- PGN-recognition proteins (PGRP) 7:4
- P-gp 3:631
- pH  
  dependence 11:401  
  dependent stabilities 1:649–650  
  domain 8:328  
  intracellular 4:426
- pH and counterions 7:399
- PH (pleckstrin homology) domain 8:327
- phage  
  filamentous 3:79, 80  
  phage display 8:97, 411, 11:106  
  phage libraries 1:338  
  phage receptors 5:318  
  phage T4 lysozyme 4:125  
  phagemid 3:81, 83  
  phagocytes 1:359, 10:178, 184  
  intracellular survival 10:191  
  types of 10:180–182
- phagocytic signaling  
  models of 10:183
- phagocytic target  
  recognition of 10:183–185
- phagocytosis 1:390, 4:193, 6:406, 413, 420,  
  10:90, 95, 177–178, 181  
  cell biology of 10:182–189  
  cytoskeleton in 10:187–188  
  early signaling events in 10:185–186  
  evasion of 10:190  
  induction of 10:190–191  
  microbes 10:190–191

- pathogens 10:182
- physiology of 10:179–180
- phagolysosomes 1:379, 15:517
- phagosome 10:95, 178, 182, 184
- phagosome maturation
  - membrane traffic in 10:188–189
- PHANTASTICA 14:264
- pharma algorithms 3:606
- pharmaceutical industry 10:198ff
- pharmaceutical production in plants
  - serum proteins 14:573
  - single-chain antibody 14:573
- pharmaceutical readiness 10:522–523
- pharmaceuticals 14:376
  - success rates 15:172ff
- pharmacochaperones 3:320
- pharmacodynamics 9:522, 10:214
- pharmacogenetic 6:607, 8:264, 266, 10:198ff, 11:658, 662, 684
- pharmacogenetic and polygenic arrhythmia syndromes 11:666
- pharmacogenetic ion channel disease 11:658
- pharmacogenomics 6:607, 8:264, 266, 10:198ff, 13:173, 14:433
- pharmacokinetics 7:176, 10:214, 242, 256
- pharmacokinetics of DNA 10:227
- pharmacokinetics of peptides and proteins 10:217
- pharmacologic uses 15:552
- pharmacological receptors 8:100
- pharmacometabonomics 8:202, 203
- pharmacophore-based ligand libraries
  - benzodiazepines 11:628
  - molecular modeling 11:628
  - privileged pharmacophores 11:628
- pharmacophores 8:91, 10:205, 14:110
- pharmacophore modeling 13:546
- pharmokinetics 7:175
- phase calculation
  - best Fourier 7:443
  - figure of merit 7:442
  - individual probabilities 7:442
  - protein phases 7:441
  - refinement of heavy atom parameters
    - lack of closure 7:440
    - method of least squares Rossmann 7:440
  - total probability curves  $P(\alpha)$  7:442
- phase contrast microscopy 1:510
- phase I, II, and III trials 15:142
- phase I/II safety/dose-escalation trial 15:271
- phase improvement
  - histogram matching
  - image processing 7:444
  - molecular averaging
    - additional symmetries 7:444
    - local symmetry operations 7:444
    - molecular envelope 7:444
    - noncrystallographic or local 7:444
    - virus structures 7:444
- phase combination
  - Hendrickson and Lattman coefficients 7:445
  - solvent flattening
    - Fourier back-transforming 7:443
    - molecular boundaries 7:443
    - solvent corrected map 7:443
    - solvent region 7:443
- phase problem 7:422, 424
- phase response curve 12:422, 452, 458
- phase shifts 12:416, 425, 463
- phase transition 4:16
- phenacetin
  - oxidation of 2:55
- 7 $\alpha$ -phenethylandrosta-4-ene-3,17-dione 13:54
- phenocopy 11:699
- phenolics 1:418
- phenotype 1:586ff, 4:336, 590, 5:247, 334, 9:74ff, 10:287, 12:112
  - analysis 14:539–540
  - emergence of new 2:567
- phenotypic covariance 1:588
- phenotypic effect 4:612
- phenotypic values 1:587
- phenotypic variance 1:593, 595, 596
- 7 $\alpha$ -phen-propylandrosta-1,4-diene-3,17-dione 13:55
- phenylalanine 1:419, 426, 8:217
- phenylalanine ammonia lyase 1:431, 2:606
- phenylalanine hydroxylase 8:217
- phenylisoserine 1:426
- phenylketonuria 8:217
- $\alpha$ -phenyl-tert-butyl nitron 4:645
- PHRES1 14:262
- pheromones 8:317, 318
  - adaptive function 1:87
- pheromones, sex 1:88ff
  - adaptive advantage 1:88
  - mating type 1:88
  - outcrossing 1:89
  - Saccharomyces cerevisiae* 1:88
  - Schizosaccharomyces pombe* 1:88
  - sexual communication 1:88
- Philadelphia chromosome 14:153
- phleomycin 2:630
- phosphoenol pyruvate carboxykinase (PEPCK) 15:529
- phosphane 11:123
- phosphatase, protein 4:171

- phosphatases 13:137  
 phosphate 7:101, 8:165, 10:14, 11:117, 12:333  
 phosphate backbone  
   internucleoside linkage 1:406  
   neutral backbone 1:407  
 phosphate group 12:609, 610, 622  
 phosphate linkage  
   modifications of 9:419–421  
 phosphate starvation 1:431  
 phosphatidylcholine 8:143  
 phosphatidylmethylethanolamine 10:286  
 phosphatidylethanolamine 10:285, 287  
 phosphatidylethanolamine *N*-methyltransferase (PEMT) 10:280  
 phosphatidylglycerol 10:290  
 phosphatidylinositol 10:291  
 phosphatidylinositol 3-kinase (PI3K) 7:28ff, 8:327, 328, 10:137, 293, 11:583, 584, 589  
 phosphatidylinositol synthase 10:292  
 phosphatidylserine 10:627  
 phosphatidylserine synthase 10:288  
 3-phosphoadenosine-5'-phosphosulfate 2:63  
 phosphoamidate linkages 9:421  
 phosphoamidite 9:414, 415  
 phosphodiester bond formation 3:540  
 phosphodiester linkage 9:414, 415  
 phosphodiesterase 2:5, 8:329, 10:11, 118, 13:155, 14:668  
 phosphoenol pyruvate 7:101  
 phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS) 8:155  
 phosphofructokinase-fructose 1,6-phosphatase 7:98ff  
 phosphoglycation 5:572  
 phosphoglycerate kinase (PGK) 14:517  
 phosphoinositide  
   phosphatidylinositol-3 kinase 4:170  
   transcription 4:173  
 phosphoinositide 3-kinase 2:333, 4:196, 13:156  
 phosphoinositolglycans 14:689  
 phospholipase 8:227, 14:4  
   phospholipase A<sub>2</sub> 4:170  
   phospholipase C 4:168  
   PLC 4:168  
 phospholipase A<sub>2</sub> 1:247  
 phospholipase C 8:87, 222, 338, 10:121, 11:571, 574, 583, 13:156  
 phospholipase D 10:302, 14:666  
 phospholipid 4:504, 665ff, 7:257, 10:16  
   bilayer 8:142  
 phospholipid assay 7:285  
 phospholipid hydroperoxide glutathione peroxidase 4:643  
 phospholipid metabolism 7:222  
 phospholipid transfer protein 7:198, 215, 225, 10:299  
 phospholipid transport 10:298  
 phosphopantetheinyl coenzymes 9:585–586  
 phosphopeptides 8:22, 27  
 phosphoprotein (P) 8:22, 12:305–306  
 phosphoramidite 1:409ff, 2:12  
 phosphorelay 8:296ff, 301  
 phosphoric acid  
   condensation products 2:5  
 phosphorimaging 11:118  
 phosphorimidazolides 10:20  
 phosphorothioate 1:405ff, 406ff  
 phosphorothioate linkages 9:419–420  
 phosphorylated 8:22, 27, 9:307  
 phosphorylation 8:26–28, 10:14, 284, 295, 11:114, 117, 12:356, 14:268, 443  
 phosphorylation analysis 9:306  
 phosphorylation regulates cell–cell adhesion 2:355  
 phosphothioate oligonucleotides (PONs) 10:226  
 phosphotidylinositol (PI) lipids 1:625  
 phosphotransferase 1:621  
*Photinus pyralis* 2:523  
 photoactivation 15:80  
 photoaffinity labeling 11:63, 123  
 photoaging 3:377  
 photoaptamers 11:106  
*Photobacterium fischeri*  
   dark mutants 2:533  
 photobleaching (FRAP) 7:164, 15:67, 74  
 photocaged cysteine 11:63  
 photocarcinogenesis 3:378  
 photochemical generation 15:80  
 photochromism 7:165  
 photo-crosslink 11:106  
 photocycle 1:577, 579, 582  
 photodamage 15:67, 74  
 photodiode array detector 1:424  
 photodynamic therapy 15:82  
 photoelectric reaction 13:292  
 photoenzymatic repair (PER) 3:352, 366  
 photohydrate 3:352  
 photoisomerization 12:376  
 photolithography 11:117  
 photolyase 9:388  
 photomultiplier 4:440, 443  
 photon antibunching 4:476  
 photon counting histograms 4:477  
 photonic devices 9:566  
 photooxidative damage 2:637  
 photoperiod 12:416, 459, 461

- photopigment 12:416, 424, 432, 435ff, 447, 452ff, 457ff, 463, 466  
 photoproducts 3:352, 429ff, 9:383  
 photoprotection 3:365  
 photoreception system 13:292  
 photoreceptors 10:309, 330, 12:393  
 photoreduction 7:166  
 photorespiration 13:613, 619  
 photosensitizer 5:494  
 photosynthesis 2:621ff, 12:455, 461, 467ff  
   activity 2:621  
   apparatus 2:631  
   bacterial reaction centers 4:123  
   chlorophylls 4:123  
   function 2:621  
   mutants 2:632  
   oxygen-evolving complex 4:124  
   quinones 4:123  
 photosynthetic electron transfer chain 2:627  
 photosynthetic proteins 9:566  
 photosystem I 2:631ff  
 photosystem II 2:631ff  
 phototransduction 13:167  
 phototropins 10:331  
 PHOX-2B 15:50  
 Phrap 5:522  
 Phred 5:519  
 Phred-Phrap-Consed 13:81  
 phycoerythrin 11:109  
 phyla 9:177ff  
 phylogenetic analysis 8:469ff, 12:519  
   classes 8:478  
   myosins 8:478  
   subfamilies 8:469  
   using parsimony 8:529  
 phylogenetic footprinting 9:259  
 phylogenetic inferences 9:250, 256  
 phylogenetic methods 9:256  
 phylogenetic profiles 6:603  
 phylogenetic tree 9:250  
 phylogeny 11:219, 14:256, 15:599ff  
   construction 6:576  
   evolutionary pathway 11:220  
   evolutionary relationships 11:220  
   human and great ape 2:553ff  
   phylogenetic trees 11:220  
   phylogenomic-type 11:220  
   sequence alignments 11:220  
   vertebrate lineages 15:601  
 phylogeography 5:263  
 phylum 6:187ff  
   platyhelminthes 9:172ff  
   flatworms 9:171  
*Physarum* 2:627  
 physical adsorption 11:107  
 physical colocation and dislocation 5:81  
 physical gaps 13:72, 86, 88  
 physical gene-transfection systems 15:490  
 physical mapping 2:536, 5:406, 529, 13:72, 108, 15:561, 620  
   approaches for 15:561  
   radiation hybrid mapping 13:100  
   restriction-digest fingerprints 13:100  
   STSs 13:100  
 physical mapping methods  
   clone fingerprinting 13:108  
   hybridization-based 13:108  
   large-insert clones 13:108  
   sequence-tagged connectors 13:108  
 physical parameters 11:387  
 physical transfection systems  
   electroporation and bioballistics 15:490  
 physiologic and infectious hurdles to xenotransplantation  
   interspecies challenges 15:584  
   metabolic and physiologic functions 15:585  
   zoonosis 15:585  
 physiological clotting function 15:259  
 physiological models 3:600  
 phytoalexins 10:371, 375  
 phytoanticipins 10:370, 375  
 phytochromes 10:330–331  
 phytohormones 10:309, 337  
   cross talk between 10:347–348  
 phytoremediation 13:692  
*P<sub>i</sub>* 8:164  
 PI bisphosphate (PI-P<sub>2</sub>) 10:291  
 PI phosphate (PI-P) 10:291  
*Pichia pastoris* 4:366, 13:615  
 picogreen 11:500ff  
 picornaviruses  
   capsid proteins 5:97  
   cis-acting replication elements 5:108  
   coxsackievirus 5:95  
   features of the picornavirus virion 5:97  
   foot-and-mouth disease virus 5:95  
   genome organization 5:96  
   hepatitis A virus 5:95  
   immune evasion 5:98, 104, 105  
   initiation of viral RNA synthesis 5:96  
   internal ribosome entry 5:99  
   packaging 5:103  
   parechoviruses 5:96  
   poliovirus 5:95  
   receptors and virus adsorption 5:98  
   replication proteins pp 12–15 5:104  
   rhinovirus 5:95  
   RNA encapsidation 5:112



- picornaviruses (*continued*)  
 viral RNA replication 5:103  
 viral RNA synthesis 5:106  
 viral-encoded proteinases 5:101  
 virion assembly 5:112, 113  
 virus uncoating 5:99
- picrotoxin 11:659
- piecemeal autophagy of the nucleus 1:628
- pig as a source of tissues and organs 15:576
- pigment epithelial-derived factor 15:221
- pigment epithelium-derived factor (PEDF)  
 13:243
- pigs 1:209, 230
- PI3K 12:176, 178ff, 184, 14:660
- PI3K-AKT pathway 9:464–466, 10:129
- PI-4-kinase 10:300
- PI5-kinase 4:192
- PI3 kinase, *see* phosphatidyl inositol 3 kinase
- pili, bacterial 2:515
- pilosebaceous glands 13:219
- pilosebaceous unit 13:228
- pilus 10:437
- PIM 7:138
- PIM1  
 Burkitt's lymphoma 7:139  
 hematopoiesis 7:139  
 HPI, a 7:139  
 IL-2 7:139  
 IL-3 7:139  
 mitosis 7:139
- pinacocytes 13:277
- p53 inactivation 6:20, 23
- pin-and-ring technology 8:272
- p16<sup>INK4A</sup> 7:328–330
- p16<sup>I</sup>NK4A 12:187
- pin-to-pin technology 8:271
- pioneer neurons 2:114
- PI-4,5-P<sub>2</sub> 10:292, 300
- PIP1 14:236
- PIP3 8:327, 328
- PI/PC transfer protein 10:299
- PI-specific phospholipase C 10:300
- PISTILLATA (PI) 14:263
- Pit-1 6:207ff
- pituitary adenylate cyclase-activating  
 polypeptide 8:444
- pituitary tumors 12:363
- pK<sub>a</sub> 3:621
- PKA, *see* cAMP-activated protein kinase
- pK<sub>a</sub> value 11:401
- PKB 7:28
- PKC pathway 10:37–39
- PKC (protein kinase C) 2:464, 466, 9:469  
 $\alpha$  2:467
- $\delta$  2:467
- $\eta$  2:467
- $\gamma$  2:467
- $\lambda$  2:467
- $\mu$  2:467
- $\theta$  1:374, 2:467
- $\varepsilon$  2:467
- $\zeta$  2:467
- activated PKC 2:477
- atypical 2:467
- calcium oscillations 2:467
- cofactor 2:471
- conventional 2:467
- conventional isotypes 2:471
- cortical granule exocytosis 2:477
- DAG signals 2:467
- diacylglycerol 2:479
- germinal vesicle 2:471
- $\beta$ I 2:467
- $\beta$ II 2:467
- isotypes 2:467
- MPF 2:479
- novel 2:467
- PKM 2:478
- second polar body 2:478
- sperm 2:477
- PKCR, *see* protein kinase-coupled receptors
- PKD1 11:695
- PKD2 11:695
- p27<sup>K</sup>IP1 12:191
- PKM 2:466
- PK/PD modeling 10:214, 228
- PKR 15:406, 408
- pKu70 14:232ff
- pKu80 14:234ff
- placebo 14:49
- placenta 8:445
- placental trophoblasts 5:554
- plague  
 biological weapon 6:306  
 live attenuated bacterial/strain 6:306  
 Yersinia pestis 6:306
- plakoglobin 2:353
- plakophilins 2:359
- planar waveguide technology 11:110
- Plant Alternative Splicing Database (PASDB)  
 10:322
- plant biotechnology 14:271
- plant breeders' rights 7:372–374
- plant cells 2:42
- plant defense  
 general elicitors of 6:410
- plant development  
 epigenetic regulation of 10:352–353

- role of miRNAs 10:352–353
- plant embryo mutants
  - auxin resistant6 (axr6) 12:286
  - bodenlos (bdl) 12:286
  - fass mutant 12:285
  - gnom (gn) 12:286
  - monopteros (mp) 12:286
  - piiz 12:285
  - titan 12:285
- plant embryology 10:549
- plant expression
  - history of 10:389–390
  - systems used for 10:404–405
- plant expression systems
  - SWOT analysis of 10:390–392
- plant galls 5:510
- plant gene expression
  - basic mechanism of 10:312–329
  - motifs of 10:317
  - regulation of 10:307–353
  - transcription factors of 10:317
  - translation 10:322–324
- plant genomes 13:82
  - diploid species 13:110
  - polyploid crop 13:110
- plant homeobox domain 4:263
- plant homeobox genes 6:216ff
- plant identity 3:496
- plant life cycle
  - gametophyte 12:252ff
    - female 12:253
    - male 12:253
  - gametophytic generation 12:252
  - sporophytic generation 12:252
- plant mitochondrial genomes 10:327
- plant organelle genome
  - expression of 10:324–329
- plant reproduction
  - apomixis 12:252
  - propagation 12:252
  - sexual reproduction
    - embryo formation 12:252ff
    - fertilization 12:252ff
    - gamete fusion 12:252ff
  - sporophyte 12:252ff
  - vegetative 12:252
- plant sexual organs structure
  - ABCE model 12:255ff
    - cadasteral activity 12:262
    - quartet model 12:262
  - bolting 12:253
  - floral meristems 12:253
  - induction of flowering 12:253
    - autonomous pathway 12:256
    - floral organ identity genes 12:255ff
    - floral pathway integrators 12:259
    - flowering time genes 12:255
    - hormone-dependent pathway 12:256
      - abscisic acid (ABA) 12:259ff
      - gibberellic acid (GA) 2:258
    - long-day photoperiod/light quality pathway 12:256
      - light receptor 12:257
    - MADS transcription factor 12:258
    - meristem identity genes 12:255
    - vernalization 12:256, 258
  - inflorescence apical meristem 12:253
  - shoot apical meristem (SAM) 12:253
- plant toxins 6:503–504
- plant variety protection (PVP) 7:372
- plant-based expression
  - analytical characterization of 10:405–406
  - biopharmaceuticals of 10:385–406
  - contingency measures of 10:392–396
  - humanlike glycosylation 10:396–398
  - moss glycosylation 10:398–404
  - risk assessment of 10:392–396
  - status of 10:390–396
  - tobacco rhizosecretion 10:398–404
  - tobacco transfection 10:398–404
- plant-based expression systems 10:387–389
- plants 2:167, 3:408, 5:510, 8:372, 378
  - DNA typing in 3:483
  - sexual signals 1:90
- plant-transformation-competent binary BAC (BIBAC) 3:387ff
- plaques 1:183
- plasma cells 1:381, 6:386, 398
- plasma lipoproteins
  - liver as major producer of 5:223–224
- plasma membrane, *see* cell membrane
- plasma potassium 11:672, 673
- plasma protein binding 3:629
- plasmacytoid DCs 1:388
- plasmalogen 13:621, 629
- plasmanyl 10:280
- plasmenyl 10:280
- plasmid 1:528, 2:37, 3:387, 4:358, 359, 5:521, 10:413, 439, 13:449ff
  - complementary DNA (cDNA) 15:291
  - CpG cytotoxicity 15:314, 315
  - high-copy 1:542
  - low-copy 1:542
  - polyadenylation (poly A) 15:291
  - promoter 15:291
  - size 15:291
  - Streptomyces* 13:449
  - vector 5:120

- plasmid addiction 10:429  
 plasmid apartheid 10:433  
 plasmid digest 9:298  
 plasmid DNA 7:316ff, 10:227, 13:253  
 plasmid DNA preparation methods  
   absorbent-based 13:80  
   alkaline lysis protocols 13:80  
   centrifugation steps 13:81  
   isothermal amplification protocols 13:80  
 plasmid modifications 7:315  
 plasmid R1 10:418  
 plasmid-based clone (PBC) 3:387ff  
 plasminogen 7:235  
 plasminogen activators 10:127  
 plasmodesmata 10:364, 14:269, 270  
*Plasmodium falciparum* 10:545  
   vaccine 15:174  
 plastic sectioning  
   block trimming 4:36  
 plasticity 13:366  
 plasticity of adult stem cells 13:341  
 plastids 2:624  
   light mediated changes in 10:332  
 plastocyanin 2:636  
 plastoquinone 2:627  
 plastoquinone pool 2:637  
 plate tectonics 10:5  
 plateau phase 11:661  
 platelet factor 15:221  
 platelet-activating factor (PAF) 6:345, 8:446,  
   10:301  
 platelet-derived growth factor, *see* PEG  
 platelets 4:208, 6:348  
 platinum-based chemotherapy 2:235  
 PLC 11:584, 589  
    $\beta$ -pleated sheets 15:25  
 PleC 8:298  
 plectin 2:343ff  
 PleD 8:298  
 pleiotropic effects 5:507  
 pleiotropy 5:394  
 pleoplasticity 13:341  
 pleoplasticity of hematopoietic stem cells  
   13:343  
 pleopotency controversies 13:344  
 pleopotency or fusion 13:355  
 pleopotent stem cells 13:334  
 plexin D1 15:206  
 PlGF 14:289, 15:211  
 PLH/DNA complexes  
   high transfection rates 15:495  
 ploidy  
   aneuploidy 5:401  
   euploidy 5:401  
   polyploid 5:401  
 p27 loss 6:11  
 PLS (partial least squares) 3:609  
 PLTP, *see* phospholipid transfer protein  
 pluripotent cells 14:507  
   therapeutic applications 13:393  
 pluripotentiality 5:640, 13:334  
 PMF 7:564  
 pmn mice 8:549–550  
 PMPs 13:623  
 PMS1 3:435  
 PM/Scf 1:484  
 p53 mutation 6:13  
 PNA (peptide nucleic acid) 1:409ff, 2:11,  
   3:257, 5:198, 9:422, 10:22, 23, 242  
   in therapy 10:262–263  
 PNA (polyamide (“peptide”) nucleic acid)  
   10:253  
 pneumonia 10:137, 12:298, 306  
 pneumovirus 12:298, 300  
 P/O ratios 8:182  
 pockets 1:366, 366ff  
*P<sub>oct</sub>* 8:157  
 podophyllotoxins 10:660, 14:344–347  
 point mutations 7:606–607, 8:530, 12:114  
   identification of 3:206–207  
 Poisson–Boltzmann 11:144  
 Poisson–Boltzmann equation 11:135  
 Poisson process 4:468  
 polarity of cells  
   genetic encoding of the three-dimensional  
     form 3:281  
   planar cell polarity (PCP) pathway 3:281  
   polarized cell behavior 3:281  
 polarization 13:384  
 polarized cells 11:684  
   embryonic blastomeres 3:278  
   neurons 3:278  
 polarized light  
   circularly polarized light 3:56ff  
 polarizer 4:440, 447  
 political preparedness 10:523  
 polonies 15:557, 568  
 PolV  
   error-prone DNA polymerases 11:543  
   SOS mutagenesis 11:543  
   translesion bypass 11:543  
   UmuD<sub>2</sub>C 11:543  
 polyA 9:325  
 poly(A)<sup>+</sup> RNA 12:560  
 poly(A) tail 2:384  
 polyacrylamide 11:108  
 polyadenine-binding protein 2 (PABP2)  
   15:46ff

- polyadenylated transcripts, *see* polyadenylation  
polyadenylation 2:624, 12:25, 716  
poly-(ADP-ribose)-polymerase (PARP) 10:128  
“master switch” 1:63  
polyalanine 15:9ff  
polyamides  
imidazole 5:186  
pyrrole 5:185  
polyamine biosynthesis 6:487  
inhibition of 6:488  
polyamines 6:467, 9:402, 14:4  
effects on monocytes/macrophages 6:488  
effects on NK cells 6:488  
effects on T lymphocytes 6:488  
sources of 6:487  
polyanion 8:360, 370ff, 378  
polycistronic mRNA 12:25  
polyclonal antibodies 1:334, 6:365, 11:105, 106  
Polycomb 12:163, 193, 14:268  
polycyclic aromatic hydrocarbons 2:68  
polycystic kidney disease 2:640, 4:344  
nonselective cation channels 11:695  
polycystin 11:695  
poly(2-dimethylamino) ethylmethacrylate  
15:497  
polyelectrolyte effect 3:535  
polyesters (bacteria) 7:260  
polyethylene glycol, *see* PCR  
polyethyleneimine (PEI)  
cationic polymerization 15:496  
high transfection efficacy 15:496  
intrinsic buffer capacity 15:496  
polygalacturonase 1:433  
polygenic 7:27, 11:684  
polygenic ion channel disease 11:658  
polyglutamine 15:4ff  
polyglutamine binding protein 1 (PQBP-1)  
15:18  
polyglutamine expansion 11:681  
polyglutamine repeat 11:681  
polyhalogenated hydrocarbons  
metabolism of 2:56  
polyketide 10:642ff  
polylinker 5:442  
poly-L-lysine (PLL)  
N-carboxyanhydrid of lysine 15:495  
polymer conjugates 14:193–197  
polymer–drug conjugates 14:196–197  
polymer particles (polyplex) 15:494  
polymer–protein conjugates 14:195–196  
polymer therapeutics 14:165, 193  
polymerase chain reaction, *see* PCR  
polymerase, DNA 6:554ff  
polymerase (L) 12:305–306  
polymerase replication errors 5:325  
polymeric gene transfer system 15:495  
polymeric Ig receptor 4:202  
polymeric micelles 14:197–198  
polymers 7:303ff, 10:22  
polymorphic  
microsatellites 5:444ff  
minisatellites 5:444  
single-nucleotide polymorphism (SNP)  
5:444  
polymorphic variants 11:657  
polymorphism 1:364, 4:340, 5:23, 244, 249,  
6:324, 12:708, 14:4  
length 3:481  
sequence 3:482  
single-nucleotide polymorphism (SNPs), *see*  
“biallelic” variation  
polymorphism link-up 15:557, 564  
polymorphisms 1:599, 3:479ff, 482ff, 5:24–25,  
6:326, 8:266, 12:717ff  
polymorphonuclear cells 13:342  
polymorphonuclear leukocytes 10:181  
polymorphonuclear leukocytes (PMNs) 10:180  
polymorphonuclear neutrophils 2:533, 6:420  
polynucleotide 9:337–341  
polynucleotide duplexes  
stability of 9:335–337  
polynucleotide hybridization 9:343  
polynucleotides 9:337–340, 10:19  
hybridization with 9:341–345  
polyol pathway 7:46  
polyol pathway flux 7:47  
polyomavirus enhancer-binding protein 2  
(PEBP2)/core-binding factor (CBF) 6:12  
polypeptide chain  
elongation of 10:323–324  
polypeptide chain fold 7:426  
polypeptide chain, polarity 14:584  
polypeptide  $\alpha$ -N-acetylgalactosaminyl-  
transferases  
T1~T9 5:562  
polypeptide synthesis, *see* mRNA translation  
polypeptides 10:18, 14:94  
synthesis 10:324  
termination of 10:324  
polyplex 14:166, 174, 15:289, 300  
dendrimer 15:312, 313  
polyethyleneimines (PEI) 15:312–314  
polyploidy 5:372  
poly(Pro) I 3:70  
poly(Pro)II helix 3:70  
polypurine (or polypyrimidine) 5:191, 11:467  
polysaccharides 2:250, 278  
analytical method 2:247

- polysaccharides (*continued*)  
 chondroitin sulfate 14:49  
 decoy 14:49  
*Polysphondylium pallidum* 3:327  
 polytene chromosomes 3:574, 7:475  
 analysis of 3:3–4  
 polyubiquitin 15:21  
 polyunsaturated fatty acids 7:43, 258, 268, 274  
 polyvinylpyrrolidone 1:419  
 POMC, (pro-opiomelanocortin promoter)  
 14:529  
 population genetic theory 12:129, 130  
 population genetics 5:25–27, 13:193  
 population size  
 bacterial biomass measurement 1:512  
 effective 2:561  
 estimation of 1:512  
 logarithmic growth 1:513  
 poured plate 1:507  
 theory of bacterial growth 1:513  
 turbidometric estimations 1:512  
 populations  
 genetic analysis of 5:243–248, 256–263  
 collection of 5:249–250  
 methods of 5:249–255  
 statistical analysis of 5:261–263  
 variations in 5:261–263  
 porcine pleuropneumonia  
*Actinobacillus pleuropneumoniae* 6:313  
 subunit vaccine 6:314  
 pore domain 11:651  
 Porifera 13:272ff  
 porin 8:359  
 aquaporin 8:149  
 bacterial 8:360, 362, 374, 377ff  
 diffusion 8:149  
 eukaryotic 8:362ff, 363, 364, 368, 372ff,  
 377ff  
 general diffusion 8:377f  
 31HL 8:369, 379  
 human 8:369, 372, 378  
 mitochondrial 8:359ff, 361, 369ff, 377ff  
 mouse 8:372  
 pig heart 8:378  
 potato 8:372f  
 rat brain 8:368, 379  
 rat liver 8:362, 369ff  
 root plastid 8:374  
 water-soluble 8:362, 377f  
 yeast 8:368, 372, 375f, 377  
 porphyrin 8:216, 218  
 position effect variegation (PEV) 3:9, 6:141ff  
 positional candidate approach 1:603  
 positional cloning 1:599, 609, 5:407, 7:55,  
 14:259  
 map disease or protection genes 13:211  
 positional information  
 regulatory gene 8:533ff  
 positional scanning 2:23  
 position-specific scoring matrix 9:259  
 positive control 12:38  
 post sequence genome project 3:643–644  
 postgenome era 14:433  
 postjunctional 11:668  
 postsegregational killing genes 10:428  
 suicide genes 6:237  
 postsource decay (PSD) 7:571  
 postsynaptic density 9:149  
 postsynaptic potentials 11:675  
 posttetanic potentiation 2:120  
 posttranscriptional gene silencing (PTGS)  
 5:397, 10:365, 14:270, 541–542  
 posttranslational autoprocesing 11:242  
 posttranslational modification states 8:12  
 posttranslational modifications 1:660, 8:3, 5,  
 13, 17, 24, 28–30, 9:111–112, 11:64–65, 103,  
 311, 14:443, 15:18  
 Pot1 14:236ff  
 potassium channel 13:157  
 potassium-activated myotonia 11:672  
 potato 8:372f  
 potential drug targets  
 HIV-1 nucleocapsid protein 6:171  
 HIV-1 proteins Vif 6:171  
 Rev 6:171  
 Tat 6:171  
 Potential Physiological and Pathophysiological  
 Roles of IFNs 15:410  
 potential therapeutic  
 approaches to 1:161–162  
 POU 6:181ff, 207ff  
 POU-specific domain 6:207ff  
 powers of discrimination 3:482  
 poxvirus 15:147  
 avian 3:171  
 vaccinia 3:169  
 p65/p50 14:442  
 PP, *see* lymphoid tissues  
 p53 pathway 7:330  
 PPIases, *see* isomerases, peptidyl–prolyl  
 cis–trans  
 pp<sup>59</sup>Lyn 14:689  
 (p)ppGpp 8:308  
 PPP2R2B 15:51ff  
 p53 protein 4:489  
 PPRs 1:391  
 pp60src 6:23

- Prader–Willi syndrome 5:478, 481
- pragmatic computational biology  
 biological systems description of 10:447–473  
 distance charts of 10:464  
 frequency counts of 10:453–457  
 noncontiguous patterns of 10:464  
 preliminaries of 10:451–453  
 sequence analysis of 10:447–473  
 statistical modeling of 10:453–457
- pragmatic inference 10:451
- pragmatic theories 10:471
- p21 ras 4:121
- pravastatin 10:655, 14:357–360
- p16/Rb pathway 6:6
- prd domain 6:204ff
- PR0DH2, *see* proline dehydrogenase
- prd-like 6:204ff
- prebiotic evolution 12:515
- prebiotic synthesis 10:12, 13, 23
- p75 receptor 11:582
- precession method  
 Ewald sphere 7:416  
 precession angle 7:415  
 precession motion 7:415  
 reciprocal lattice 7:415  
 undistorted image 7:415
- precipitation 1:25
- preclinical development 15:158, 166
- precursor CPS (pCPS) 4:205
- precursor lesions  
 genetic alterations in 2:194–195
- precursor molecules 5:648
- precursor pool PK/PD models 10:232
- predictive value 4:230
- predisposing genotype 11:673
- preembryo 13:385  
 propagated indefinitely in culture 13:383
- preexisting immunity 8:609
- prefoldin 2:497
- pregnancy monitoring 9:232
- pregnenolone 13:8
- pre-IFN- $\alpha$  15:393
- preimplantation development 10:484
- preimplantation embryo  
 inner cell mass 13:386
- preintegration complex (PIC) 1:105,  
 12:403–408
- premature ovarian failure (POF) 4:612, 15:33
- pre-mRNA 1:126, 127
- pre-mRNA splicing 1:126–140, 471,  
 10:320  
 biochemical mechanisms of 1:141–142  
 human diseases 1:152–160
- pre-mRNA splicing defects  
 diseases caused by 1:160  
 perspectives on diagnosis of 1:160–162  
 treatment of 1:160–162
- premutagenic lesions 5:319
- premutation 4:587, 592, 15:4ff
- prenatal diagnosis 4:617
- preneoplasia  
 examples of diagnostic markers for 9:96–99
- preneoplastic lesions of 13:352
- prenylation 7:217
- preparation of vectors 3:413
- preprocessing filters  
 noise filters 8:200  
 wavelet transformation 8:200
- preprophase band 8:481
- prereplicative complex (pre-RC) 12:190
- pre-RNAs 10:12
- presenilin 1:191ff, 610  
 CTF 1:192  
 endocleavage 1:186  
 endoproteolysis 1:185, 192  
 gene 1:185, 191  
 homologs 1:191  
 mutations 1:185f  
 NTF 1:192  
 structure 1:191
- prespore 8:332
- prespore vesicles (PSVs) 8:337
- prestalk 8:332
- prestarvation factor (PSF) 8:325
- pre-steady state kinetics 11:402
- presynaptic 11:667
- prevalence 1:592
- prevention 7:31
- preventive vaccination  
 infectious diseases of 13:262–263
- prezygotic model 4:615
- Prialt 13:532, 540, 546
- primary active transport 11:691
- primary auxin response genes 10:337
- primary granules 10:188
- primary liver cancer 7:324
- primary precursors 13:410ff
- primary sensory neurons 10:31, 32
- primary structure 14:92, 95
- primate phylogeny 2:555
- primate-rodent ancestor 11:448
- primer extension 4:522, 530
- primer walking 5:524, 13:98
- primers 9:426–428, 11:492ff
- primitive atmosphere 10:6
- primitive features 8:530
- primmorph 13:275ff

- primordial germ cells 1:219, 13:384, 392  
   precursor of the sperm, oocyte and epiblast cells 13:394  
 principal cell 11:697  
 principle component analysis (PCA) 8:198, 200, 13:687  
 principle components 13:687  
 principle of parsimony 11:389, 393  
 prion 3:88, 91, 92, 10:557–560, 567–588, 590–597  
   disease paradigms 10:562–563  
   interplay between species and strains of 10:589  
   nomenclature 10:563–566  
   vs. viruses 10:561–562  
 prion biology  
   principles of 10:597  
 prion disease 10:594, 15:13  
   of animals 10:589  
   prevention of 10:595  
   rodent models of 10:568  
   therapeutics for 10:595  
 prion formation  
   template-assisted 10:580–581  
 prion propagation 10:580  
 prion protein 1:46, 4:122  
   discovery of 10:566  
 prion protein isoforms 10:567  
 prion replication 10:579–583  
 prion therapeutics  
   acridine derivatives 10:595–596  
   anti-PrP antibodies 10:596  
   quinacrine 10:595–596  
 prions, strains  
   isolation of 10:588–589  
 prior RSV vaccine trials 12:312–315  
 Priori 11:666  
 pristane 1:476  
 Pristinamycin 10:647ff  
 privileged structure 8:92ff  
 proapoptotic protein 6:21  
 probabilistic search 12:623  
 proband 12:348, 351  
 probe labeling  
   Direct labeling 5:145  
   Indirect labeling 5:146  
   methods 5:144  
   postlabeling purification 5:146  
   purification 5:144  
 probe-based assays 11:495  
 probes 9:428, 11:492ff  
   probes for FISH mapping  
     bacterial artificial chromosome (BAC) 5:141ff  
     genomic DNA probes 5:142  
     identification of probes from genomic databases 5:141  
     P1 artificial chromosome, *see* PAC  
     synthetic oligonucleotides 5:143  
     unique sequence cDNA 5:143  
     yeast artificial chromosome, *see* YAC  
   proboscipedia 6:192ff  
   procapsid 9:352, 354  
   process biomarkers 9:113  
   process contaminants 15:168  
   process control 13:93f  
     data tracking mistakes 13:93  
     equipment-related errors 13:93  
     failures in DNA preparation 13:93  
     managerial challenges for 13:93  
     scales, automation, and robust protocols 13:94  
     throughput and efficiency 13:94  
   processed pseudogene, *see* interspersed repeat  
   processive mechanoenzymes 8:588  
   processivity 8:576, 584  
   prochiral structure 2:608  
   prodrugs 2:59, 6:157  
   product inhibition 10:295  
   production  
     cellular 7:551  
     proenkephalin 15:270  
   professional antigen-presenting cells 3:215f  
   professional phagocytes 10:180f  
   profilaggrin 13:222  
   profiling 7:541  
   progenitor cells 2:231  
   progenitor strains 1:598  
   progenitors 13:366  
   programmed cell death 5:502, 8:307, 9:133, 10:127ff, 367, 375, 379  
     protective mechanism 1:82  
   programmed death ligand 1 (PD-L1) 6:486  
   programming 13:364, 366, 367  
   programs 1:298  
     BLAST 9:255  
     FASTA 9:255  
     GeneMark 9:255  
     Glimmer 9:255  
   progression factors 3:134  
   progressive motoneuron disease (pmn) 8:549, 565  
   progressive myoclonus epilepsy type 1 (EPM1) 15:39ff  
   progressive supranuclear palsy (PSP) 12:694  
   projection formula 2:584  
   projection, statistical 8:198  
   projection to latent structures (PLS) 8:198

- prokaryotes 1:654, 2:624, 8:238, 239, 10:312  
   initiation mechanisms in 3:458–460  
 prokaryotic ClpB  
   disaggregases 13:509  
 prokaryotic genes 9:257  
 proliferating cell nuclear antigen 1:467  
 proliferation 2:227, 228, 230, 231, 326ff, 7:539,  
   13:317  
 proliferative phase 13:242–244  
 proline 8:201  
 proline dehydrogenase 1:607  
 proline substitutes 14:80  
 prolyl hydroxylase domain containing protein  
   (PHD) 10:137  
 promegestone 13:52  
 prominent ears 4:590  
 promoter 3:450, 461, 537, 4:336, 356, 362, 366,  
   367, 6:147, 149, 150, 579, 10:244, 314, 12:25,  
   30, 14:551, 15:332, 339  
   cis-acting sequences 10:315  
   distal regulatory sequences 10:315  
   T7 4:360, 361  
   trans-acting factors 10:315  
 promoter hypermethylation 4:256, 6:23  
 promoter identification 11:374ff  
 promoter methylation 14:215  
 promoter regions 11:376ff  
   C1170Box123 11:376  
   CRABP-1 11:376  
   Ick 11:376  
   Mx protein 11:376  
   Pax 6 11:376  
   SCL 11:376  
   tyrosinase 11:376  
 promoter sequence 1:436  
 promoter traps 3:341–342  
 promoter/enhancer elements  
   functional analysis of 14:488f  
 promoter-enhancers 7:314ff  
 promotion 13:351  
 promyelocytic 13:349  
 promyelocytic leukemia 4:264  
 promyelocytic leukemia (PML) protein 15:24  
 pronase 7:542  
 pronuclear 2:466  
 pronuclear zygotes 1:213  
 proofreading 5:319, 382, 9:317  
 proopiomelanocortin 14:105  
 propagated AP 11:675  
 propagation 3:542  
 10-propargyl-4-estrene-3,17-dione 13:54  
 propensity functions 14:141  
 prophage 9:352, 354  
 propoxyphene 2:602  
 propranolol 2:602, 14:361, 662  
 Proserid 14:346  
 pros domain 6:214ff  
 Proscar 13:49  
 prosimians 2:554  
 prospective  
   case–case studies 4:233  
   case–control studies 4:233  
   prospective cohort studies 4:234  
 prospective study 4:230  
 Prospero (Pros) 6:213  
 prostaglandin E1 (PGE1) 7:98  
 prostaglandin E2 (PGE2) 1:392, 8:444  
   effects on DCs 6:481  
   effects on monocytes/macrophages 6:480  
   effects on NK and LAK cell activity 6:481  
   effects on T lymphocytes 6:480  
   inhibition of 6:481  
   sources of 6:480–481  
 prostaglandin F2 $\alpha$  4:404  
 prostaglandin H synthase 8:218, 231  
 prostaglandins 6:61, 8:211, 231, 446, 10:39  
 prostate 1:399  
 prostate cancer 13:44, 352  
   genetic alterations in 2:195–196  
   growth factors 2:202–203  
   hereditary factors of 2:192–194  
   metastasis suppressor genes 2:203–206  
   molecular genetics of 2:191–209  
   telomerase 2:201–202  
 prostate-specific antigen, *see* PSA  
 prostereoisomerism 2:607  
 protamine 7:505  
 protease inhibitors 6:163–164, 166  
   Kaletra 6:165  
   nuclear sterol regulatory element binding  
     proteins (nSERBP) 6:167  
 proteases 4:333, 356, 364, 5:236–237, 10:43,  
   11:110, 117, 14:175  
 proteasome 1:368, 2:184, 4:643ff, 6:19, 9:499,  
   535–536, 10:309, 339, 11:1–4, 6–12, 17,  
   12:168, 192, 14:459, 15:32ff, 90–105  
   activators of 11:4, 12, 18–19  
   biogenesis of 11:13–14  
   physiological aspects of 11:20–21  
   physiological importance of 11:20  
   presumed mechanism of 11:16f  
   processing by 11:18  
   protein inhibitors of 11:19–20  
   proteolysis by 11:16f  
   regulatory complex 11:81  
   role of 10:346–347  
   20S 11:41  
   26S 11:4f



- proteasome (*continued*)  
   structure of 11:5f  
   subcellular distribution of 11:20  
   substrate recognition by 11:14–16  
   substrate selection independent of ubiquitin 11:15–16  
   subunit synthesis of 11:13  
   summary of 11:5  
   tissue distribution of 11:20  
   ultrastructure of 11:8f
- proteasome inhibitors  
   enzyme mechanism 11:6
- proteasome subunits  
   posttranslational modification of 11:13–14
- proteasome system  
   ubiquitin 11:7–8, 20–21
- protecting living organisms  
   Europe, developments in 7:375–376  
   issues in 7:374–378  
   leading countries, legislation in 7:376–377  
   United States, developments in 7:374–375
- protection against pathogens 13:228–229
- protection against ultraviolet radiation 13:229–230
- protection group 9:414, 416
- protein 1:405ff, 652, 4:356, 357, 668ff, 6:182ff, 8:2ff, 12, 9:270, 276–282, 11:103, 182, 14:94, 190–192
- protein A 6:449, 11:56
- protein aggregation 2:491, 13:465
- protein analysis  
   application in 14:432–433
- protein and domain function  
   biological process 11:216  
   COGs 11:218  
   co-localize on the genome 11:216  
   EC-numbers 11:216  
   function prediction 11:216  
   functional annotation 11:217  
   functional classification 11:217  
   functional convergence 11:216  
   gene ontology (GO) 11:216  
   GeneOntology 11:217  
   molecular function 11:216  
   operon 11:216  
   Rosetta Stone principle 11:217  
   TIM-barrel 11:216
- protein arrays 6:599, 8:507, 11:311
- protein autoprocessing  
   bacterial intein-like domains 11:250  
   N-terminal nucleophile hydrolases 11:254  
   nucleoporins 11:254  
   pyruvoyl enzyme autoprocessing 11:252
- protein binding 3:629, 10:219
- protein biochips 11:105
- protein biomarkers  
   in clinical research 11:325–327  
   in preclinical research 11:325–327
- protein C 5:559ff, 6:115
- protein carbonyls 4:647
- protein catabolism 13:31
- protein classification  
   CATH 11:209, 211  
   Classification Architecture Topology and Homology (CATH) 11:209  
   classification systems 11:212  
   domains  
     evolutionary domain definition 11:207  
   Families of Structurally Similar Proteins (FSSP) 11:209  
   fold 11:208, 211  
   Hierarchical Domain Classification (SCOP) 11:207ff  
   HMMs 11:209  
   Interpro 11:209  
   Margaret Dayhoff 11:205  
   metasites 11:209  
   Pfam 11:209  
   protein classes 11:207  
   ProtoMap 11:209  
   SCOP 11:209, 210, 217  
   SMART 11:209  
   structural classification of proteins database (SCOP) 11:207  
   superfamilies 11:211, 213  
   TRIBE-MCL 11:209
- protein comparison  
   amino acid sequence comparison 2:556  
   electrophoretic comparison 2:555  
   immunological comparison 2:555
- protein complexes 8:13, 30, 31, 33, 34, 35
- protein concentration 1:34
- protein conformation 4:506–509  
   disorders of 10:594
- protein conformation change 1:581
- protein crystal structures 10:202
- protein cyclization 11:258  
   SICLOPPS 11:259
- protein damage  
   aging 1:64
- protein data bank (PDB) 10:199
- protein degradation  
   inhibition of 13:481
- protein detection 7:190
- protein disorder  
   inherently flexible regions 11:272  
   protein stability 11:272
- protein disulfide isomerase (PDI) 2:510

- protein disulfide isomerases 1:38  
 protein–DNA  
   binding 6:182  
   docking 6:591  
 protein domains 7:482, 12:103  
 protein dynamics 11:175  
   “model-free” approach 11:174  
 protein efficiency ratio (PER) 4:509  
 protein emulsification 4:513f  
 protein energy of 4:509  
 protein engineering 8:425  
 protein enzymes 11:27–43  
 protein evolution 11:217  
   Conery 11:229  
   domain-swapping 11:225  
   evolutionary history 11:220  
   evolutionary pathway 11:220  
   gene fusion 11:226  
   Lynch 11:229  
   mutagenesis experiments 11:223  
   phylogenetic relationships 11:203  
   selection pressure 11:218  
   speciation 11:203  
 protein expression profiling 11:102, 106  
 protein family expansions 7:482  
 protein filaments 4:99, 103  
 protein folding 2:490ff, 3:56, 11:175f  
   degradation 5:581  
 protein footprinting  
   background & history 4:551  
   modification-based 4:556  
   principle 4:551  
 protein functions 6:599, 8:422, 11:218  
   biological validation of 11:328  
 protein gel electrophoresis 5:245  
 protein homology model 10:199  
 protein hydration 11:175  
 protein hydrophobic 9:254  
 protein inactivation 11:191, 193  
   adsorption 11:192  
   heavy-metal ions 11:192  
   oxidation 11:192  
   proteolytic degradation 11:192  
 protein interactions 4:509, 512–515, 11:226  
   arrays 11:103  
   carbohydrates 4:510f  
   complexes 11:214  
   genome-scale protein interaction data 11:215  
   hydration 4:512  
   lipids 4:511–512  
   maps 11:124  
   networks 6:602, 11:215  
   profiling 11:102, 120  
   protein–protein 4:510  
   Rosetta Stone principle 11:217  
   scale-free 11:215  
   soluble ions 4:512  
 protein intracellular 7:97  
 protein kinase  
   activators 1:669  
   ATP 1:660  
   calmodulin 1:663, 665  
   cAMP 1:665  
   cAMP-dependent protein kinase 1:667  
   catalytic core 1:661  
   catalytic loop 1:662  
   cGMP 1:665  
   consensus sequences 1:662  
   crystal structure 1:661  
   Gleevec 1:670  
   glycogen phosphorylase 1:667  
   glycogen synthase kinase 3ff 1:661  
   inhibitors 1:669  
   Iressa 1:670  
   kinase domain 1:661  
   MAPK 1:668  
   phorbol esters 1:669  
   phosphorylase kinase 1:667  
   protein kinase C 1:669  
   recognition motifs 1:662  
   serine 1:661  
   threonine 1:661  
   tyrosine 1:661, 663  
   viral oncogenes 1:663  
 protein kinase A 10:370, 13:156, 164  
 protein kinase B (PKB) 14:678  
 protein kinase C 4:310ff, 7:47, 10:289, 301, 13:157, 15:404  
   agonists 2:476  
   antagonists 2:476  
   Golgi apparatus 2:476  
   pronuclei 2:476  
 protein kinase cascades 8:338  
 protein kinase–coupled receptors (PKCR) 11:555, 556, 578, 589  
 protein kinases 1:659ff, 7:116ff, 117ff, 130ff  
   catalytic loop 7:116  
   dual specificity protein kinases 7:116  
   protein Ser/Thr kinases 7:116  
   protein-tyrosine kinases 7:116  
   pseudosubstrate 7:116  
   receptor PTKs (RTK) 7:117  
   *see also* protein phosphorylation  
 protein kinases encoded by cancer genes  
   calcium/calmodulin-dependent protein kinase subfamily 7:138

- protein kinases encoded by cancer genes  
(*continued*)  
containing Cdk, Mapk, Gsk3, Clk subfamilies 7:142  
containing Pka, Pkg, Pkc subfamilies 7:141  
cytoplasmic protein-tyrosine kinase subfamily 7:135  
homologs of Yeast Sterile 7, Sterile 11, Sterile 7:138  
kinase subfamily 7:138  
phosphatidylinositol kinase (Pik)-related subfamily 7:142  
protein-serine/threonine kinase family 7:138  
protein-tyrosine kinase family 7:126  
Ras 7:119  
receptor protein-tyrosine kinase subfamily 7:126  
tyrosine kinase-like subfamily 7:138
- protein labeling 11:412, 424ff  
protein–ligand docking 6:588  
protein–ligand interactions 13:551  
protein loading 3:220–221  
protein micelle 4:504  
protein microarrays 11:102, 103  
protein misfolding 1:24, 2:491, 8:106  
protein modifications 8:25, 9:263  
protein monomeric 1:29  
protein multidomain 1:29  
protein mutant 10:203  
protein nutritive value of 4:509  
protein oligomeric 1:29  
protein pathways  
functional redundancy 11:215  
nonorthologous replacement 11:215  
pathway evolution 11:216  
recruitment 11:216
- protein phosphatase 1:659ff, 14:661, 15:51ff  
calcineurin 1:667  
cantharidin 1:669  
Cdc25 1:667  
dual-specificity phosphatases 1:666  
MAPK phosphatases 1:667  
okadaic acid 1:669  
PP1 1:667  
PP2A 1:667  
PP2B 1:667  
PP2C 1:667  
pyruvate dehydrogenase phosphatase 1:667  
signature motif 1:667  
Spanish Fly 1:670  
synthetic molecules 1:669  
*see also* protein phosphorylation
- protein phosphorylation 1:660ff, 8:488  
cascades 1:667ff  
multisite 1:667ff
- protein posttranslational modification 12:102  
protein production  
codon usage 11:274  
*Escherichia coli* 11:274  
eukaryotic genes 11:274  
high-throughput 11:273  
*Leishmania tarentolae* 11:274  
*Pichia pastoris* 11:274  
polymerase chain reaction (PCR) 11:273  
*Saccharomyces cerevisiae* 11:274  
wheat germ system 11:274
- protein properties handles for purification 11:185  
amino acid sequence 11:190  
charge 11:186  
density 11:188  
genetically engineered purification handles 11:190  
hydrophobicity 11:187  
isoelectric point 11:187  
ligand binding 11:189  
metal binding 11:189  
posttranslational modifications 11:189  
reversible association 11:189  
shape 11:186  
size 11:186  
solubility 11:188  
specific sequence or structure 11:189  
unusual properties 11:189
- protein–protein docking 6:590  
protein–protein interaction 4:341, 6:212ff, 8:3, 13, 30, 33, 34, 105ff, 422, 11:107, 124, 146, 325, 12:102  
LIM 6:212
- protein purification 11:182  
affinity column purification 11:276  
affinity tags 11:275  
folding and stability 11:276  
metal-affinity chromatography 11:276  
purification tag 11:276
- protein purification strategy 11:194  
protein quality control 15:91, 98  
protein refolding 11:182  
protein repair, enzyme  
MsrA 1:58, 62, 64
- protein repertoire 11:205, 206, 210, 215, 219, 229  
domain composition 11:213, 217  
inserted domains 11:211  
modularity of proteins 11:203  
modules 11:203

- protein secretion 12:507–508
- protein semisynthesis  
 conformationally assisted protein ligation 11:257  
 expressed protein ligation 11:255, 257  
 native chemical ligation 11:255  
 protein splicing in trans 11:257ff
- protein serine-threonine kinases 9:469
- protein single molecule  
 characterization of 9:269–288  
 detection, techniques for 9:272–276  
 preparation, techniques for 9:272–276
- protein solubility 7:397  
 temperature 7:399
- protein sorting 10:293
- protein splicing 11:242, 246, 259  
 chemical mechanism 11:243  
 discovery of protein splicing 11:243
- protein splicing in trans 11:248  
 reassociation 11:249
- protein SRY 5:619f, *see also* SRY
- protein staining 5:35  
 acidic silver nitrate 5:36  
 alkaline silver diamine staining of gels 5:36  
 colloidal CBB G-250, amido black 5:36  
 colloidal gold staining 5:36  
 coomassie brilliant blue (CBB) R-250 5:36  
 fluorescent stains 5:37  
 Nile Red 5:36  
 silver staining 5:36  
 SYPRO Orange 5:36  
 SYPRO Red 5:36  
 SYPRO Rose 5:36  
 SYPRO Ruby 5:36, 37, 40, 42, 43  
 SYPRO Tangerine 5:36
- protein structure 4:506ff, 11:135, 229  
 prediction 6:582  
 tertiar 10:200  
 three-dimensional 10:199
- protein subunit vaccine  
 cytomegalovirus 3:176
- protein synthesis 13:238
- protein synthesis, *see* mRNA translation
- protein test 4:618
- protein thermodynamic control 1:26
- protein threading 6:583
- protein translation 2:380
- protein turnover  
 regulation of 2:184
- protein tyrosine kinase (PTK) 3:132, 13:117
- protein universe 11:229  
 genomes 11:212  
 multicellularity 11:220  
 organisms' complexity 11:212  
 superfolds 11:212  
 unfolds 11:212
- protein X  
 evidence for 10:581–582
- protein yield 4:371, 11:65
- protein-binding sites 1:648, 14:207
- protein-capture agents 11:104
- ProteinChip Array 3:50
- protein-coding genes 9:58
- protein-coding sequences  
 indels in 11:454–455  
 repeats in 11:454–455
- protein-folding problem 11:139
- protein-fusion 4:362
- protein-immobilization 11:107
- protein-ligand complexes  
 biological function 11:272  
 catalytic mechanism 11:273  
 catalytic residue 11:273
- protein-mediated fusion  
 fusion pore flickering 11:75  
 transition states of 11:74
- proteins induced by IFNs 15:404
- proteoglycan chondroitin sulfate 14:49
- proteoglycans (PG) 2:250, 278, 5:543ff, 8:47, 53, 60, 13:226, 227, 242, 14:5, 50  
 analytical method 2:247  
 chondroitin 14:48  
 chondroitin sulfates 5:576  
 dermatan sulfates 5:576  
 glucosamine sulfate 14:48  
 heparins 5:576  
 hyaluronates 5:576  
 keratin sulfates 5:576
- proteoliposome 8:143
- proteolysis 1:441, 10:220, 11:469, 12:168, 14:5, 15:11ff, 90–96
- proteolytic activation 11:78
- proteolytic cascade derepresses 13:475
- proteolytic components 13:508
- proteome 3:533, 643, 4:332, 7:481, 560, 8:3, 5, 10, 18, 23, 24, 28, 30, 33, 34, 9:58, 11:102, 311, 12:100, 13:440ff, 14:432  
*Streptomyces* 13:440
- proteome analysis 3:644
- proteome map 11:327–328
- proteomic 8:21
- proteomic analyses 5:509
- proteomic profiling 3:50
- proteomics 3:19, 49, 5:33ff, 7:560, 8:2ff, 3, 4, 5, 7, 10, 18, 20, 24, 25, 30, 31, 35, 189ff, 190, 264–267, 9:93, 104, 250, 264, 356–357, 517, 10:132, 11:309–312, 12:100, 101  
 applications of 11:323–327

- proteomics (*continued*)  
   bioinformatics of 11:322–323  
   clinical applications of 11:328–329  
   2-D gels 10:541  
   definitions of 11:313  
   diagnostic applications of 11:328–329  
   expression of 11:313  
   future perspectives of 11:327–329  
   interaction of 11:313  
   MALDI MS 10:541  
   mass spectrometry (MS) of 11:315–318  
   protein arrays 11:321–322  
   protein-chip 10:541  
   target identification of 11:323–325  
   technologies of 11:313–323  
   validation of 11:323–325  
 proteorhodopsin 9:566  
 prothrombin 6:114  
 protochlorophyllide 2:627  
 protocols 5:318, 14:132f  
 protofilaments 8:580  
 protoheme 3:111  
   endoplasmic reticulum 3:103  
   reduced pyridine nucleotides 3:103  
   thiolate group 3:103  
 protomutations 4:614  
 proton pumping 6:60, 8:226  
 proton release 1:579, 580, 582  
 proton sponge  
   chemical structure of PEI 15:496  
 proton sponge hypothesis 14:183  
 proton transport pathway 11:344  
 proton uptake 1:582  
 protonation 11:401  
 protonmotive force 8:164, 165ff, 180  
 proton-translocating ATPase 11:335  
 proton-translocating F-ATPase  
   catalytic mechanism of 11:337–338  
 protooncogenes 6:12, 9:437, 441,  
   15:269  
 protoplanetary disk 10:4  
 protoplast 13:439ff  
 protoplast culture 1:432  
 protostome 6:187ff  
 protostomia 13:272ff  
 protozoan genomes 15:559  
 proviral integration of the moloney murine  
   leukemia virus, *see also* PIM  
 provirus 1:100, 105, 12:403  
 provisional wound matrix 13:240–241  
 prox-1 15:208  
 proximal 5:266, 267  
 proximal promoter sequences 10:314  
 proximity ligation 7:190  
 PrP gene  
   expression of 10:569  
   organization of 10:568ff  
   structure of 10:568ff  
 PrP gene dosage  
   incubation time control 10:570  
 PrP gene structure  
   conserved ala-gly region 10:574  
   N-terminal sequence repeats 10:571–574  
 PrP isoforms  
   structures of 10:574  
 PrP polymorphisms  
   in cattle 10:589–590  
   in elk 10:589–590  
   in sheep 10:589–590  
 PrP sequence  
   species variations in 10:571  
 PrP<sup>C</sup> 10:559  
 PrP-deficient mice 10:570f  
 PrP<sup>Sc</sup> 10:559  
   electron crystallography of 10:577  
 PRRs 1:393  
   pruned 4:291  
 PS 10:289  
 PS1 1:184  
 PS2 1:184  
 pS2 6:11, 24  
 PS decarboxylase 10:289, 291  
 PS decarboxylation 10:287  
 PS synthase 1 10:289  
 PS synthase 2 10:289  
 PSA 3:603, 622, 9:98, 13:21  
 psbA 2:627  
 PSD1 10:290  
 PSD2 10:290  
 “pseudo” SNAREs  
   tomosyn and amisyn 11:94  
 pseudogenes 5:23, 24, 76, 9:262, 11:459f,  
   506ff, 12:131  
 pseudogenetic intelligence 5:324  
 pseudo-Hurler polydystrophy  
   mucopolidiosis III, ML-III 5:582  
 pseudohyphae 8:312, 314  
 pseudohypoaldosteronism  
   SCNN1G 11:690  
 pseudohypoparathyroidism (PHP) 12:692  
 pseudoknot 6:587, 12:585, 588, 631  
 pseudoknot core element 14:211  
*Pseudomonas aeruginosa* 8:454, 10:366, 367,  
   377, 13:229  
   asialo-GM1 8:629  
   CFTR 8:629  
*Pseudomonas* exotoxin (PE) 6:502  
 pseudopattern 5:25

pseudopod 10:179, 186  
 pseudopodium activation 8:328  
 pseudopodium inhibition 8:328  
 pseudopregnant 1:216  
 pseudopseudohypoparathyroidism (PPHP)  
   12:692  
 pseudoreverse translation 2:458  
 pseudorotation 12:609, 610  
 pseudouridine synthases 2:636  
 PSF (prestarvation factor) 8:324  
 p66Shc 1:75  
   aging 1:73  
   apoptosis 1:73  
   base excision repair (BER) 1:73  
   reactive oxygen species (ROS) 1:73  
 p53 signaling 15:266  
 psoralen 5:194  
 psychiatric disorders 1:156  
 PTC (points to consider) 10:392  
 PtdIns(4,5)P<sub>2</sub> 4:192  
 PtdIns4P 4:195  
 pterin coenzymes 9:580ff  
 PTOP 14:236  
 P53 (TP53) gene 7:329  
 PTP1b 14:691  
 PTP-PEST 2:341  
 P<sub>1</sub> transgenic fish 14:474, 485  
 p53 tumor suppressor  
   activity manipulation 2:176f  
 P-type ATPase 11:334  
 public consortium 5:58  
 public health 4:234f  
 public health preparedness  
   planning of 10:519f  
   readiness of 10:519f  
 Puerto Rican population  
   high genetic diversity 13:202  
 PufA 8:324  
 pufferfish 4:349  
 pulmonary surfactant 10:290  
 pulse radiolysis 7:150, 154  
 pulse sequence 13:519  
 pulse-chase 8:124, 504  
 pulsed amperometric detection 2:257  
 pulsed field gel electrophoresis (PFGE) 15:557,  
   559  
 pulsed-field gradients 13:527ff  
 pump 2:135  
 purification process 15:166ff  
 purine modifications 9:424  
 purinergic receptor 11:561, 565  
 Purkinje cells 15:16ff  
 Purkinje neurons 12:360, 13:373  
 puromycin 2:459

purple membrane 1:577, 581  
 purpose 14:128  
*p*-value 6:575, 612, 9:257  
 P2X receptor 11:565  
 pXO1 1:309, 311, 312, 318, 320, 322, 323  
 pXO2 1:309, 311, 312, 318, 322  
 PXR 7:225  
 pYAC4 3:399  
 pyridine nucleotide coenzymes 9:577ff  
 pyridoxal phosphate 9:579–580  
   function of 15:531–532  
 pyridoxal phosphate-binding proteins  
   15:530–531  
 pyridoxamine 5'-phosphate 9:579–580  
 pyrimidine dimers 3:549  
 pyrimidine modifications 9:423–424  
 pyrimidine nucleotide biosynthesis 9:582  
 pyrimidine(6-4)pyrimidone dimer 3:356  
 pyrophosphatase 9:402  
 pyrroloquinoline quinone 9:587  
 pyrrolysine 2:587, 8:256, 11:47  
 pyruvate 7:99, 8:164, 173, 10:10  
 pyruvate formate-lyase 4:120  
 pyruvate kinase 5:23  
 pyruvate kinase gene (PKLR) 5:24  
 pyruvate transporter 8:173  
 pyruvoyl enzyme 11:253  
   aspartate decarboxylase 11:252  
 pyruvoyl functions 9:586  
*Pytium insidiosum*  
   vaccine 15:174

## q

1q21-25 13:207  
 7q LOH 6:11  
 QikProp 3:606  
 QM/MM simulation 11:135  
 QRNA 12:595  
 qRT-PCR 8:501  
 QSAR 8:107ff, 11:619  
 Q-switching mode 3:548  
 QT interval 11:661  
 QT prolongation 4:347  
 QTL (quantitative trait loci mapping)  
   2:547  
 quadrupole (QD) 8:8f  
 quality assessment  
   quality of SGS clone library 13:91  
 quality assurance 3:491  
 quality control 2:47, 3:491, 11:504ff, 15:120,  
   121  
 quantal 11:668  
 quantification  
   fluorimeter 3:486

- quantification (*continued*)  
   spectrophotometry 3:485  
   yield gels 3:485  
 quantitation 8:28  
 quantitation of antigen (epitope) 6:460  
 quantitative analysis 4:661ff  
 quantitative data 11:384  
 quantitative equilibrium and time-resolved  
   footprinting 4:536  
 quantitative genetics 1:588  
 quantitative mapping 13:690  
 quantitative modeling 14:135  
 quantitative proteomics 7:561, 8:2, 18, 20, 23,  
   30  
 quantitative structure–activity relationships  
   8:106ff  
 quantitative structure–property relationship  
   (QSPR) mapping 3:608  
 quantitative trait loci 1:588, 7:355  
 quantitative traits 5:380, 7:355  
 quantum dots (QDs) 9:23, 15:82  
 quantum mechanical methods 2:29  
 quantum mechanics 3:602  
 quantum yield 2:523, 3:551, 4:445–446  
 quartz halogen-tungsten lamps 11:490ff  
 quasi-racemates 2:593  
 quasi-species 10:245  
 quasi-vitamins 15:552  
 8-queen 12:619  
 quencher dyes 11:489ff  
 quenchers 4:446  
 quenching 7:164, 172, 11:412  
 quercetin 14:51  
   cytokine secretion 14:50  
   the glycoside 14:50  
 quiescence 12:144  
 quiescent cells 12:354  
 quills 8:273  
 quinine 14:368–372  
 quinol oxidase (QOX) 4:124  
 quinone oxidoreductase 10:201  
 quinoproteins 9:587  
 quorum sensing 10:366, 369
- r**
- R genes 10:376, 377  
 RA 14:48  
   Cedars–Sinai Health Related Quality of Life  
   Instrument (CSHQ-RA) 14:49  
   secretion  
     CRH receptor 14:51  
     IL-6 14:51  
 Rab3 4:316ff  
 rab5 8:130  
 Rab GTPases 4:184, 315ff  
   Rab4 4:185  
   Rab5 4:185  
   Rab7 4:185  
   Rab9 4:185  
   Rab11 4:185  
   Rab15 4:185  
 Rab proteins 4:315ff, 8:130  
   active GTP-bound 11:81  
   inactive GDP-bound conformation 11:81  
 Rab proteins and their effectors  
   role of 11:81  
   tethering and docking 11:81  
 Rabaptin-5 4:196  
 rabbit reticulocyte lysate 2:454  
 rabbits 1:223, 15:143  
 Rabex-5 4:196  
 Rab-interacting lysosomal protein (RILP)  
   4:207  
 Rab1 configuration 3:2, 5  
 Rabphilin 3A 4:316ff  
 Rac 2:334  
 Rac GTPase 12:184  
 racemases 2:607  
 racemates 8:109  
 racemic drugs 8:108  
 racemization, posttranslational 2:587  
 Rac1 protein 4:603  
 RAD1 3:434, 437  
 RAD2 3:434, 437  
 Rad3 3:437ff  
 Rad4 3:438  
 Rad7 3:438  
 Rad10 3:434  
 Rad23 3:438  
 Rad25 3:437ff  
 RAD27 3:436  
 Rad51  
   BRCA2 11:544  
   homologous recombinational repair (HRR)  
     1:73  
   proteins that interact with 11:543  
   Rad51 1:81  
   Rad52 11:544  
 radial glia 13:410ff, 412ff, 415ff  
   as neuronal progenitors 13:415  
   in adult birds 13:415  
   in the embryonic and postnatal mammalian  
     brain 13:423  
 radial glial cells 2:108  
 radial spokes 2:640  
 radiation 5:493, 14:259  
 radiation hybrid mapping 15:619ff

- radiation hybrid maps 2:542, 7:350, 15:557, 561
- radiation hybrids 5:456
- radiation mutagenesis  
 ionising radiation 15:607  
 mechanism of 15:607  
 $\gamma$ -radiation 15:607  
 rate of 15:607
- radiation protection 11:416ff
- radicals 7:150, 8:231
- radio frequency magnetic field (RFMF) 9:44
- radio frequency (rf) pulses 11:161
- radioactive 11:117
- radioactive decay 11:413ff  
 alpha decay 11:413  
 beta decay 11:413  
 electron capture 11:413  
 gamma rays 11:413  
 kinetics of 11:413
- radioactivity 10:7, 11:412, 413
- radioisotopes 11:412ff
- radiolabeled estradiol derivatives 1:453–455
- radiolysis 4:522
- radionuclide 11:412, 420f  
 choice of 11:420  
 relative merits of 11:421
- radiosensitization 15:266
- radiotherapy 9:531
- radius of 2:260
- Radl4 3:438
- Radl6 3:438
- RAD10 3:437
- Raf  
 A-Raf 7:120  
 B-Raf 7:120  
 coumermycin 7:126  
 CR1, CR2, and CR3 7:120  
 geldanamycin 7:126  
 14-3-3 proteins 7:125  
 Raf-1 7:120
- raft 13:312
- ragweed allergy  
 associated with multiple sclerosis (MS)  
 13:206
- Rajneeshee Cult 10:513
- Ral GTPase 12:176
- Ralstonia* 10:366
- Rana catesbeiana* 6:88
- Rana pipens* 7:101
- Rana sylvatica* 7:101
- randle cycle 7:98
- random amplified polymorphic DNA (RAPD)  
 analysis 5:255
- random coil 3:59ff
- random combinatorial libraries 10:149
- random Enu mutation 14:539
- random insertion type 14:524
- random mating 1:591
- random mutagenesis 3:341f, 5:315, 325  
 retroviruses elements of 14:538  
 transposable elements of 14:538
- random networks 14:136
- random primer labeling 11:422
- random primers 11:486ff
- Random SGS 13:93
- random synthesis 10:22
- Rap1 14:230ff
- rap1-17 14:232ff
- rapamycin 4:343, 13:571, 572
- rapamycin–FKBP complexes 13:572
- RAPD (randomly amplified polymorphic DNA)  
 2:540, 3:490, 5:255
- rapid electrophoresis 13:91
- rapid microbiology 2:532
- rapid test device (RTD) 6:374
- rapid testing methods  
 Analytical Profile Index (API) 1:520  
 Enterotube II system 1:520
- rapidly activating delayed rectifier 11:663
- rapidly releasable pool (RRP) 11:89
- RAR $\beta$  6:5, 11, 24
- rare fragile sites 4:571
- RARE (RecA-assisted restriction endonuclease)  
 cleavage 15:558, 562
- Ras 2:334, 8:328, 9:463  
 farnesyl transferase 7:124  
 GTPase activating proteins 7:120  
 Ha-Ras 7:120  
 Ki-Ras 7:120  
 N-Ras 7:120  
 RalEGF/Ral 7:119  
 switch regions 7:119
- Ras GTPase 12:176, 184
- RAS (rat sarcoma virus) 9:440
- rasraf-map kinase 5:642
- RAS-RAF-MEK-MAPK (ERK) pathway  
 9:462–464
- rat 11:436–437  
 colocalization of SINEs in 11:465f  
 different activity of SINEs in 11:464f  
 shift in substitution spectra 11:449f
- rat genes  
 in situ loss of 11:460–462
- rat genome 11:433–436, 453–454, 457–468, 475  
 assembly strategy 11:437–440  
 evolutionary hotspots of 11:450–452  
 features of 11:441–452



- rat genome (*continued*)
  - human disease gene orthologs 11:469–474
  - substitution rates 11:448–449
  - transcription-associated substitution 11:455–456
- rat genome-sequencing project 11:436
- rat lineage 11:449
  - LINE-1 activity in 11:462–464
- rat liver 8:364, 378
- rate constants 4:11, 11:403
- rate of cytoplasm increase
  - rate of cytoplasm increase 1:533
- rate of the reaction 10:11
- rate theory 11:604
- rate-limiting step 12:329, 387
- rates of evolution
  - heterogeneity 9:256
- rat-specific biology 11:467–469
- Rattus norvegicus* 4:331, 10:548ff
- RB1 12:348
- RB family members 12:354–355
- Rb genes 6:5
- RB protein 12:364–365
  - structure of 12:353–354
- RB protein phosphorylation 12:355–357
- R-bands 3:21
- RBF1 12:194ff
- RB1 mutant alleles
  - prediction of 12:351–352
  - spectrum of 12:351–352
- RBPJ-k 15:214
- Rbx1 12:168
- RC
  - biogenesis of 11:13
- RCAS1 6:486
- RCT domain 14:232ff
- Rcy1 4:199
- Rdp1 14:238ff
- reaction centers 9:566
- reaction diffusion waves 14:17–18
- reaction dipole moment 4:8
- reactive nitrogen species 4:634ff
- reactive oxygen 10:96
  - role in stress 10:350–351
- reactive oxygen intermediates (ROI) 15:409
- reactive oxygen, response 1:77
  - SOD 1:58
- reactive oxygen species (ROS) 1:59, 496, 3:352, 433, 4:634ff, 5:493, 7:50, 10:378, 14:634, 15:38
  - p66Shc 1:73
- reactive species
  - defense against 2:66
- reagents 11:510
- real-time detection 3:489
- real-time instruments 11:490
- real-time kinetic PCR-based techniques (RT-PCR) 9:515, 11:483ff, 12:44
- rearrangement, chromosomal 2:562, 6:141
- rearrangement, subchromosomal 2:562ff
- RecA 1:81, 82
- RecA filament 11:529
- RecA homologs 1:89
  - adaptive function 1:82
  - Dmc1 1:81, 82
  - Lim15 1:82
  - Rad51 1:81, 82
- recalcitrant cell culture 1:421
- RecBCD
  - processive helicase 11:540
- receptor 2:45, 4:332, 5:639f, 8:86ff, 433, 9:174–176ff, 10:121, 11:288, 595ff, 606, 608, 609, 619, 621, 12:639, 673, 13:117, 123, 132, 15:506, 509
- receptor activity modifying protein 13:166
- receptor cell-surface receptors 3:270
- receptor channels 4:164
- receptor classes
  - non-GPCR-linked cytokine receptors 11:613
- receptor concepts
  - law of mass action 11:600
  - occupancy theory 11:600
  - Schild regression relationship 11:601
- receptor cytokine 4:163
- receptor disease 4:175
- receptor dynamics 11:608
- receptor enzyme-linked receptors 3:269
- receptor ephrin proteins 3:269
- receptor extended gp130 13:133
- receptor G-protein coupled 4:164, 9:168, 175ff
- receptor homeotic changes 3:269
- receptor hormone receptors 3:270
- receptor JAK/STAT signal transduction pathway 3:270
- receptor ligand-gated 4:164
- receptor nomenclature 11:609
- receptor nuclear 4:161
- receptor nuclear receptor superfamily 3:270
- receptor osteoclastogenesis inhibitory factor 3:269
- receptor osteoprotegerin 3:269
- receptor phosphoinositol pathway 3:270
- receptor progesterone receptor 3:270
- receptor proteins 3:268
- receptor protein-tyrosine phosphatase 13:282
- receptor retinoic acid 3:269
- receptor signaling 15:402
- receptor structure–function 13:20

- receptor theory 11:603  
 receptor toll 3:269  
 receptor torso 3:269  
 receptor tyrosine kinase (RTK) 4:163, 213,  
   7:127ff, 13:146ff, 159ff, 281  
   domain 7:127  
 receptor-based design 13:529, 548  
 receptor-binding assays 11:620  
 receptor-mediated 10:219  
 receptor-mediated elimination 10:223  
 receptor-mediated endocytosis 1:626, 10:222  
 receptor-mediated internalization 14:181  
 recessive 11:662, 671  
 recessive dystrophic epidermolysis bullosa  
   (RDEB) 15:293  
 recessive LQT alleles 11:665  
 RecF, O, and R  
   repair of gapped DNA lesions 11:542  
 recipient 9:213, 233  
   cell 9:205  
   oocyte 9:235–237  
 reciprocal cross-species chromosome painting  
   5:126  
 reciprocal of the affinity constant 11:621  
 recognition domain 12:327  
 recognition helix 6:185ff  
 recognition sequence 12:326  
 recombinant 5:294  
 recombinant antibodies 6:498  
 recombinant *Desmodus rotundus* salivary  
   plasminogen activator 10:127  
 recombinant DNA revolution 12:327  
 recombinant DNA technologies 3:389  
 recombinant DNA-based immunotoxins  
   development of 6:503–507  
 recombinant immunotoxins 6:499  
   against leukemias and lymphomas  
     6:512–514  
   against solid tumors 6:511–512  
   application of 6:511–514  
   construction of 6:507–510  
   design of 6:503–507  
   improving therapeutic window of  
     6:517–520  
   preclinical development of 6:510–511  
   production of 6:507–510  
 recombinant inbred (RI) 14:509  
 recombinant inbred strain 1:598, 14:507  
 recombinant peptides 14:92  
 recombinant proteins 1:41, 483, 2:37ff  
 recombinant tissue plasminogen activator  
   10:119  
 recombinant vaccines 5:296  
 recombinant viruses 15:236  
 recombinase-activating genes (RAGs) 6:411  
 recombination 1:77, 600, 2:630ff, 631, 4:335,  
   5:314, 318, 372, 402, 11:203, 210, 219, 221,  
   228, 14:253, 257  
   biochemistry of 1:81  
   eukaryotes 1:81  
   meiotic 1:81  
   nonhomologous 11:225  
   prokaryotes 1:81  
   RecQ5 $\beta$  helicase 1:64  
   topoisomerases 1:63  
 recombination, adaptive function 1:82  
 recombination rate 2:566  
 recombinational repair 1:80, 89  
   bacterial transformation 1:87  
   dmc1 1:88  
   rad51 1:88  
 recombinational repair, meiotic  
   masking of deleterious mutations 1:89  
   outcrossing 1:89  
 recombinational variation 1:87  
   by-product of recombinational repair 1:88  
 reconstitution 8:361ff  
 recPrP  
   NMR structures of 10:575–577  
 RecQ helicase 14:238  
 recursive partitioning 3:610  
 RecX  
   end-capping mechanism 11:542  
   negative modulator of RecA 11:542  
 recycling 4:198  
 recycling pathway 8:123  
   exocytosis and fusion 11:91  
 red blood cells 4:209, 13:342  
 redox cycling 5:501, 15:516  
 redox potential ( $E_h$ ) 8:179  
 redox probes 7:165  
 reduced organics 10:9  
 reduced penetrance 15:43  
 reduced p27 expression 6:11  
 reducing atmosphere 10:5  
 5 $\alpha$ -reductase 13:14  
 5 $\alpha$ -reductase inhibitors 13:3, 49  
 reductionist approach 14:125, 127  
 reductive metabolism of testosterone 13:11  
 reesterification 14:629ff  
 Ref-1 (also called apurinic/aprimidinic  
   endonuclease or APE)  
   base excision repair (BER) 1:71  
 reference dyes 11:490ff  
 reference mapping populations 2:536, 540  
 reflectance methods 4:654ff  
 reflection spectroscopy 13:682  
 refolding 1:24, 11:105

- refolding proteins solubilized from inclusion bodies
  - aggregation 11:196
  - protein denaturant 11:196
  - wash the inclusion bodies 11:196
- refractive index 3:554
- regional cerebral blood flow 10:119
- regions of increased gene expression (RIDGE) domains 5:79
- regression modeling 8:197
- REGs 11:18
- regularization 11:385, 406ff
- regulated exocytosis 4:307
- regulation of cellular gene expression by IFNs 15:401
- regulation of development 8:532
- regulation of HSV-1 gene expression 15:251
- regulation of IFN Synthesis 15:397
  - regulation of initiation of DNA replication 1:536
- regulation transcriptional level
  - development, tissue-specific, constitutive 3:111
  - inducible 3:111
  - regulatory components 3:111
- regulator 13:466–469
- regulator genes 1:437, 5:396, 12:25, 28
  - corepressors 5:397
  - inducers 5:397
- regulator of G-protein signaling (RGS) 11:553, 575–577, 13:146ff, 169
- regulatory cascades 5:508
- regulatory complex (RC)
  - ATPases of 11:9ff
  - biochemical properties of 11:12–13
  - non-ATPases subunits of 11:4f, 11ff, 195
- regulatory isoforms (RI $\alpha$ , RI $\beta$ , RII $\alpha$ , and RII $\beta$ ) 14:696
- regulatory molecules, binary state of 9:528
- regulatory nascent chains 12:502–503
- regulatory networks 6:594, 9:257, 12:105
- regulatory peptides 7:487
- regulatory proteins 6:185ff, 9:257
- regulatory regions 6:579, 598, 9:255, 257, 261
- regulatory responses 9:257
- regulatory T cells 8:606, 10:106
- regulome 12:100
- regulons 3:510, 12:100
- reinfections 12:306
- Rel 14:438, 441
- REL oncogene 9:471
- relative transformation 12:619, 620
- relaxation 4:128, 11:670, 13:592
- relaxation data 13:542, 544, 553
- relaxation parameters 13:524, 550, 551
- relaxation times 13:524
- release factor 12:484, 503
  - RF-1 2:454
  - RF-2 2:454
  - RF-3 2:454
- reliability 4:232
- remissions 14:39
- remodeling 10:484, 13:244
- renal cancer 1:399
- renal cell cancer (RCC) 6:438
- renal channelopathies 11:688
- renal dipeptidase 8:224
- renal elimination 10:221
- renal epithelia 11:689
- renal glucosuria 11:696
- renal K<sup>+</sup> and H<sup>+</sup> wasting 11:691
- renal salt wasting 11:692
- renaturation 3:206
- Renilla luciferase 2:528
- Renin 11:690, 14:106
- Renkin equation 8:362
- reorientation switch 1:580
- REP (repetitive extragenic palindromic) 3:643
- repair patch 9:390
- repeat finding 6:580
- repeat-derived exon
  - alternative splicing 1:285
  - nonsense-mediated RNA decay 1:285ff
- repeated DNA 8:524
- repeated sequences
  - centromeres 5:433
  - ribosomal RNA 5:433
  - telomeres 5:433
- repeatedly administered 7:309ff
- RepeatMasker 13:87
- repeats 6:580, 9:261
- reperfusion 14:284ff
- repetitive element 1:253ff, 283, 288, 298
  - chromosomal aberration 1:295
  - chromosomal translocation 1:295
  - consensus sequence 1:252
  - diseases 1:285
  - family 1:252
  - genetic rearrangement 1:283ff
  - recombination 1:288ff
  - subfamily 1:252
  - superfamily 1:254
- repetitive fertilization calcium transients 14:16–17
- repetitive sequences 3:480, 5:430
  - classification of 13:94
  - eukaryotic genomes 13:94
  - simple and complex 13:95

- replacement type vectors 14:521  
 replica casting 4:90, 95, 101, 104  
 replicase 15:246  
 replication 6:139, 145, 146, 150, 7:315, 10:4, 23, 11:219  
     RecQ5 $\beta$  helicase 1:64  
     topoisomerases 1:63  
 replication control 10:414  
 replication, error of  
     cancer 1:68  
     mutations 1:68  
 replication factory 10:426  
 replication forks 1:537, 3:450, 452, 453, 5:177  
 replication proteins 3:457–458  
 replication-competent adenovirus (RCA) 13:254  
 replication-competent lentivirus (RCL) 13:258  
 replication-competent plasmid 7:315  
 replication-competent retrovirus (RCR) 13:257  
 replication-defective lentivirus vectors 15:243  
 replication-defective pantropic retroviral vectors infection with 14:482–483  
 replication-induced transcription 10:423  
 replicon 10:412  
     replication, unit of 3:451–452  
 replisome 3:453, 5:385  
 reporter dyes 11:489ff  
 reporter genes 2:531, 4:337, 14:552, 15:236  
 reporter proteins  
     expression of 3:339  
 reporter-function transgenes 14:479  
 repression 5:396, 12:25  
 repressor 4:360, 10:315  
 repressor–operator  
     complexes of 3:513–515  
 repressor–operator interactions  
     general principles of 3:516–519  
     direct readout 3:515  
     indirect readout 3:515  
     of vitro techniques 3:519–523  
     of vivo techniques 3:523–526  
 repressor–operator recognition  
     perspectives of 3:526  
     principles of 3:508–519  
     techniques of 3:519–526  
 repressor–operator recognition of 3:507–526  
 repressor proteins  
     structures of 3:511–513  
 reproduction 4:335, 8:444  
 reproduction strategies  
     apomixis 1:78  
     cross-fertilized 1:78  
     partially cross-fertilized 1:78  
     self-fertilized 1:78  
 reproductive cloning 3:298, 13:338  
 reprogramming 13:339, 364, 366, 367, 376  
 rescue mouse 4:619  
 research, biomedical 2:569  
 reservoir 14:424  
 reshuffling of DNA segments 5:344  
 residual dipolar couplings (RDCs) 11:167  
 resistance to antimicrobials 1:569, 571  
 resolution 6:247, 14:6  
     Abbe theory 7:425  
     nominal resolution 7:425  
     Rad51 paralogs 12:12  
     RusA 12:12  
     RuvC 12:12  
 resonance energy transfer 7:164  
 resonance units 3:554  
 resorptive epithelium 11:687  
 respiration 2:622  
 respiratory chain 8:164  
 respiratory control 8:182  
 respiratory disease 15:260  
 respiratory enzymes 4:124  
 respiratory epithelium 8:607  
 respiratory failure 11:687  
 respiratory syncytial virus (RSV) 12:298, 299, 15:165  
     vaccine 15:164  
 respiratory syncytial virus vaccine 12:297–298, 300–317  
     history of 12:299  
 respiratory tract 1:364  
 response element 15:506, 512  
 response regulator 8:297ff, 298, 301, 310, 335  
 responsive genes 15:399  
 restenosis 5:216, 229, 15:264  
 restricted number of reaction products 10:11  
 restriction 4:359  
 restriction endonucleases 4:361, 362, 5:252, 343, 9:304, 12:323ff, 324ff  
 restriction enzyme 5:442, 9:304  
     cleavage 15:565  
     mediated integration 3:342  
 restriction fragment length polymorphism (RFLP) 2:641, 3:481, 5:252, 341, 406, 6:326, 7:596, 609, 9:304, 15:381  
 restriction landmark 5:414  
     labeling 5:421  
 restriction landmark genomic screening (RLGS) 9:111  
 restriction phenotype 12:325  
 restriction points 1:545, 12:144ff, 156  
 restriction-modification (RM) system 12:323ff, 325  
     type I and III systems 12:323

- restriction-modification (RM) system  
(*continued*)  
type II system 12:323
- Resveratrol 10:658ff
- RET (rearranged in transformation)  
artemin 7:134  
GDNF 7:134  
GFR $\alpha$ 1-RET heterodimer 7:134  
GFR $\alpha$ -1 to -4 7:134  
glycosyl-phosphatidyl-inositol-anchored  
proteins 7:134  
neurturin 7:134  
persephin 7:134
- retargeting of viral vectors 15:254
- rete pegs 13:222
- rete ridges 13:222
- reticular dermis 13:224
- reticular formation 2:108
- retigabine 11:699
- retina  
cone cell 4:293ff  
equator 4:294  
morphogenetic furrow 4:293ff  
ommatidium 4:292  
pigment cell 4:293ff  
R-cell 4:293ff
- retinal 1:576–583, 9:560
- retinal degeneration 15:22ff
- retinal ganglion cells 12:434ff
- retinal lesions 12:351
- retinal pigmented epithelium (RPE) 10:181,  
12:376
- retinitis pigmentosa 2:640
- retinoblast 12:348
- retinoblastoma 7:330  
cancer of infants 12:349–350  
causes of drug resistance in 12:366–367  
chimeric knockout 12:363  
genetic principles of 12:350–351  
genomic changes in 12:365–367  
importance of 12:367–368  
in mice 12:362–364  
molecular genetics of 12:347–368  
targeted RB1<sup>-/-</sup> knockout 12:363–364  
viral oncoprotein-induced 12:362–363
- retinoblastoma gene 12:352–359  
genetic locus of 12:350–351
- retinoblastoma pathway 7:330
- retinoblastoma protein (Rb) 6:149, 12:352–359
- retinoblastoma (Rb) family 7:328  
p107 12:155, 156ff  
RBF1 12:155ff  
RBF2 12:155ff
- retinoblastoma tumor suppressor protein (pRb)  
2:177
- retinocytoma 12:351
- retinohypothalamic tract 12:423, 433ff, 436
- retinoic acid receptors 6:5, 15:509–511
- retinoic acids 12:393
- retinoid receptors  
cellular binding proteins 15:509
- retinoid X receptor 7:107, 13:285
- retinoids 15:508
- retinol-binding protein (RBP) 15:509
- retinoma 12:351
- retroelements 14:255
- retroposition 9:262
- retroposon 1:254, 15:558, *see also* interspersed  
repeat
- retroseudogene, *see* interspersed repeat
- retrotransposition 1:253, 254, 2:630, 12:406,  
*see also* interspersed repeat
- retroviral infection 1:212, 225
- retroviral integration 15:269
- retrovirus 1:100, 102, 254ff, 269ff, 271, 286,  
6:234, 12:401–411, 15:136, 239  
endogenous retrovirus 1:269, 282, 283, 285,  
294, 296, 299  
endogenous retroviruses 1:271ff  
long terminal repeat 1:252ff  
provirus 1:253ff  
RNase H 1:253ff
- retrovirus-mediated transfer 1:209
- Rev 1ff 3:440
- Rev Responsive Element (RRE) 1:107
- revascularization 14:284ff, 285  
procedures 15:264
- reverse arrays 11:111
- reverse cholesterol transport 7:213
- reverse dot-blot approach 3:490
- reverse engineering 14:136
- reverse genetics 9:74, 12:436, 438, 14:261,  
15:607
- reverse NOE pumping 13:594
- reverse transcriptase inhibitors 6:157
- reverse transcriptase polymerase chain reaction  
(RT-PCR) 8:450, 9:319, 10:402, 11:486ff,  
12:559, 568, 575, 678, 14:206
- reverse transcriptase (RT) 1:254ff, 2:628,  
3:403, 403ff, 4:522, 6:157, 10:202, 243, 12:522
- reverse transcription 1:260, 3:403, 12:402,  
15:239  
telomerase 1:260ff
- reversed phase 1:424, 13:266
- reversed phase chromatography 6:248–249  
basic principles 6:250  
C4 6:253

- C18 6:253  
 column geometry 6:255  
 mobile phases 6:255  
 operating parameters 6:256  
 stationary phases 6:252  
 reverse-painting 3:46  
 reverse-transcription polymerase chain reaction 8:500  
 reversible masking 7:313ff  
 RFLP (restriction fragment length polymorphism) 2:540, 624, 13:209  
 analysis 5:252, 7:611–612  
 limitations of 3:486  
 RGD sequence 4:402  
 RGG box 4:595, 15:34  
 RGS, *see* regulator of G protein–signaling  
 RH mapping panel 2:536, 547  
 RH (radiation hybrid) 2:539  
 rhamnose 2:249  
 Rheb GTPase 12:179  
 rheology 4:504, 512–513  
 rhesus macaques (*Macaca mulatta*), cynomolgus macaques (*Macaca fascicularis*), pigtailed macaques (*Macaca nemestrina*) 15:143  
 rheumatoid arthritis (RA) 4:641ff, 5:556, 8:453, 455, 11:112  
 autoimmune response  
   bacterial, viral antigens 14:39  
   infection 14:39  
 inflammation  
   reactive hyperplasia 14:39  
 rhinoviruses 15:417  
 Rho family of GTP-binding proteins 2:334  
 Rho GTPase 2:355, 4:603, 12:178, 184  
   CDC42 4:283  
   RAC1 4:283  
   RHO 4:283  
 Rho guanine nucleotide exchange factor 13:158  
 rhodamine-dye terminators 9:406  
 rhodamine-entrapped vesicles (REV) 4:486  
 rhodamine-labeled phospholipid vesicles (RLV) 4:486  
 rhodanase 7:169  
 Rhodin 13:609  
*Rhodobacter sphaeroides* 10:287  
 rhodopsin 5:549, 9:566, 11:567, 570, 574, 576, 12:376, 13:148  
 rhodopsin kinase 11:576, 13:150  
 rhombomeres 2:99  
 Rhp51 14:235  
 RIA 6:368, 372  
 riboflavin 4:641, 15:545  
 ribogreen 11:500ff  
 ribonuclease 1:25, 8:222  
 ribonuclease A 2:18  
 ribonuclease H, *see* RNase H  
 ribonuclease P 12:60, 519  
 ribonucleic acid, *see* RNA  
 ribonucleoprotein 12:514  
 ribonucleoprotein enzyme 6:6  
 ribonucleoprotein (RNP) complexes 12:519  
 ribonucleoside triphosphate (rNTPs) 14:209  
 ribonucleotide reductases 4:119  
 ribose 1:408, 10:13, 12:609, 610, 622  
 ribose pucker mode  
   endo 12:610  
   envelope 12:610, 611  
   exo 12:611  
   twist 12:610, 611  
 ribosomal DNA (rDNA), *see* nucleolar organizers  
 ribosomal protein 9:253, 12:711, 712ff  
 ribosomal RNA 2:628, 631, 12:515, 709, 716ff  
 ribosomal stalling 12:38, 502  
 ribosomal subunits 12:488  
 ribosome 2:452, 459, 621, 4:361, 587, 8:508, 14:255ff  
   cellular location 14:590  
   function of 12:483–508  
   high resolution structure of 12:483–508  
   ribosomal proteins 2:627  
 ribosome display 3:84, 8:417ff, 11:106  
 ribosome function  
   aminoacyl tRNA binding 14:601, 606  
   chaperone binding 14:610  
   decoding mRNA 14:580–608  
   elongation factor-G binding 14:608  
   elongation factor-Tu binding 14:607  
   fidelity 14:580, 582, 588–590  
   GTP hydrolysis 14:607, 608  
   internal RNA entry site 14:614, 615  
   peptide bond formation 14:604–607  
   peptide chain elongation 14:599–604  
   peptidyl-tRNA binding 14:601, 606  
   proof reading 14:605  
   ribosome inactivating proteins 14:616  
   translocation 14:607, 608ff  
   tRNA binding 14:601, 606  
 ribosome inactivating proteins  
   ricin 2:455  
 ribosome nascent chain complex 11:294  
 ribosome recycling factor 2:454  
 ribosome structure 14:580  
   aminoacyl-tRNA binding site 14:606  
   conformational change 14:607ff  
   elongation factor-G binding site 14:608  
   elongation factor-Tu binding site 14:608

- ribosome structure (*continued*)
  - peptidyl-tRNA binding site 14:606
  - 30S 12:489ff
  - 50S 12:496ff
  - 70S 12:503ff
  - tunnel 14:610
- riboswitches 12:516
- ribozymes 1:161–162, 413ff, 9:430, 10:23, 242, 11:48, 12:25, 514, 518
  - vs. cellular disorders 10:257–258
  - vs. infectious agents 10:255–257
- ribulose 1,5-bisphosphate
  - carboxylase/oxygenase 2:637
- rice 10:361, 380
  - BRI1 14:257
  - D61 14:257
- rice genomic data 13:89
- Richardson's ground squirrel 7:101
- Rieske iron-sulfur center 8:177
- right isomerism 2:612
- Rik1 14:237ff
- RIM proteins
  - effectors of the Rab3 11:82
- Rinderpest 5:298
- ring chromosomes 3:46
- ring of Waldeyer 1:364
- ring-current effect 13:569
- Ringer's solution 1:515
- RISC 14:269
  - argonaute family of proteins 12:535
  - cleavage 12:535
  - FMRP 12:545
  - target selection 12:535
- risk analysis 14:144
- risk assessments 4:229
- risk factors 1:182
  - ability to metabolize debrisoquine 5:355
  - accidents 14:39
  - age 14:39
  - cigarette smoking 5:355
  - field cancerization 5:364
  - joint injuries 14:39
  - lung cancer in relatives 5:355
  - obesity 14:39
  - primary epithelial cancer of the upper aerodigestive 5:364
  - respiratory diseases 5:355
  - work-related activity 14:39
- ritonavir 10:202ff
- rITP 9:402
- RITS 14:238ff
- RK2 10:439
- RLGS 5:414
  - real RLGS 5:433
  - RLGS-M 5:430
  - virtual RLGS (Vi-RLGS) 5:432
- R-loop 10:415
- RME1 4:198
- RMSD 11:386, 12:611, 617, 618, 626, 627
- RNA analog sugar
  - bridged nucleic acid 5:193
  - locked nucleic acid, LNA 5:193
  - 2'-O-(2-aminoethyl) (AE) 5:193
  - 2'-O-Methyl (2'-OMe) 5:193
- RNA aptamers 10:261–262
- RNA chromatography 9:319
- RNA drug 10:242, 245
  - design of 10:264–265
  - synthesis of 10:264–265
- RNA editing 5:388
- RNA energy model 12:587
- RNA enzymes 11:28, 32
- RNA fingerprinting 10:538
- RNA footprinting 9:327
- RNA genomes
  - replication of 10:245–246
  - transcription of 10:245–246
- RNA graph 12:617, 618, 620–622, 624
- RNA interference (RNAi) 1:222, 412ff, 436, 3:340, 4:255, 334, 611, 5:397, 8:113, 114, 552, 9:63–64, 74ff, 10:242, 547ff, 549, 11:311, 12:576, 14:238ff, 507, 541–542, 15:262, 612
  - as antiparasitic approach 10:259
  - dicer 10:544
  - methods of triggering 12:546
  - miRNA 10:251–252
  - overlap with miRNAs 12:545
  - potential therapeutic 12:547
  - RISC 10:544
  - RNAi-induced silencing complex 10:544
  - shRNA 12:547
  - single-stranded hairpin RNAs (hpRNAs) 14:269
  - Sirna 10:251–252
  - vs. cancer 10:259–260
  - vs. genetic disorders 10:259–260
  - vs. viruses 10:258–259
- RNA isolation
  - gentle lysis buffers 12:563
  - harsh lysis buffers 12:564
- RNA ladder 9:303
- RNA molecules 4:91
- RNA packaging
  - in animal viruses
    - Hepadnaviruses 9:372
    - Human Immunodeficiency Virus 9:373
    - Influenza Virus 9:372

- RNA packaging in animal viruses  
 mouse hepatitis virus 9:372  
 Sindbis virus 9:371
- RNA polymerase I and III 10:488
- RNA polymerase II 3:437ff, 10:488, 489, 12:103
- RNA polymerase II transcription factor D (TFIID) complex 15:25
- RNA Polymerase III 11:59
- RNA polymerase mutant  
 homology analysis with Klenow fragments 9:400
- RNA polymerase (RNAP) 2:627, 3:450, 537, 4:359, 6:147, 8:222, 246, 9:399, 10:243, 313f  
 architecture of 3:461–463  
 RNA polymerase I 2:381  
 RNA polymerase II 2:381  
 structure of 8:592  
 T7 4:360  
 transcriptional apparatus 3:461–466  
 T7 RNA polymerase 4:361
- RNA processing 2:635ff, 10:317, 12:514  
 5' cap structure 2:383
- RNA pseudoknot 10:420
- RNA (ribonucleic acid) 4:674, 10:11, 11:120, 485ff, 487ff, 12:559, 14:255  
 as protein antagonist  
 aptamers 10:252–253  
 SELEX 10:252–253  
 spiegelmers 10:252–253  
 clinical application of 10:241–267  
 clinical features 10:243–255  
 delivery of 10:265–266  
 denaturation of 3:207–211  
 emerging clinical applications of 10:255–263  
 folding of 9:283  
 goals in the purification of RNA 12:561  
 immunotherapy by 10:263  
 in Central Dogma 10:243–245  
 interference 6:151  
 metabolism of 10:243–255  
 noncanonical base pairs in 10:246  
 pharmaceutical advantages of 10:254–255  
 pharmacokinetics of 10:265–266  
 pharmacology 10:241–267  
 steady state RNA 12:558  
 stretching of 9:283
- RNA secondary structure 9:303
- RNA splicing 2:383, 12:24, 514, 15:19  
 regulation by antisense RNA 10:246–248
- RNA stability 2:627
- RNA stabilization 9:321
- RNA structure 9:319ff, 328
- RNA structure design 12:597
- RNA structure prediction 6:585, 12:589
- RNA switches 12:597
- RNA tertiary structure 12:496
- RNA transcription 2:380
- RNA virus 12:298
- RNA world 10:22
- RNAalifold 12:594
- RNA-based assays 9:111
- RNA-binding proteins 8:345
- RNA-dependent RNA polymerases 12:536  
 oligomerization 5:107  
 picornavirus 3D polymerase 5:107  
 three-dimensional structure 5:107  
 transitive RNAi 12:537
- RNA-directed DNA methylation (RdDM) 14:269
- RNA:DNA hybridization 14:209
- RNA-induced silencing complex (RISC) 10:251, 12:535, 545, 14:269, 15:35
- RNA:RNA hybrid  
 formation of 9:341–346  
 stability of 9:335–341
- RNase 1:405, 9:322  
 inhibition of ribonuclease activity 12:565
- RNase H 1:405ff  
 gap 1:408
- RNase L 15:406
- RNase mitochondrial RNA processing 12:628
- RNase P RNA 12:628
- RNasin® 12:566
- RNAView 12:616
- RNAz 12:595
- RNP motif 15:19
- rNTP 14:206
- Robertsonian fusion chromosome 3:563
- Robertsonian translocations 3:10
- Robertson's cooked meat medium 1:509
- Robo-4 15:208
- robotics 14:157
- robust fitting 11:387
- robustness 14:130
- Roche Diagnostics Systems 6:559
- rod monochromacy 11:683
- rodents 14:219  
 medium-length duplications in 11:467
- rods and cones 12:434ff
- ROESY 13:531
- ROESY spectrum 2:264
- ROI 15:409, 411, 413, 417
- roller culture 7:547
- rolling circle amplification 11:109
- rolling circle replication 7:189
- Romano–Ward syndrome (RW) 11:662



- ROMK channel 11:692  
 roof plate 2:96  
 root effect 6:79  
 root mean square deviation (RMSD) 11:386  
 roots, biotransformation of pollutants 13:692  
 ROS 14:455  
 ROS-responsive genes 5:505  
 Ross Ronald 7:472  
 rostral migratory stream (RMS) 12:653, 13:418ff  
 rotary-shadowing 4:95–97, 99, 100, 101, 102  
 platinum–palladium 4:93  
 rotating wall vessels 7:547  
 rotation method  
 beam collimation 7:415  
 blind region 7:413  
 crystal mosaicity 7:415  
 Ewald sphere 7:413  
 reciprocal lattice 7:413  
 rotational catalysis 11:334, 344  
 rotational diffusion 7:163  
 luminescent labels 7:162  
 nitroxide 7:172  
 rotational relaxation time 3:557  
 rotational/translational entropy 2:10  
 rotavirus 11:113  
 vaccine 15:160, 174  
 ROUGH SHEATH2 14:264  
 Rous sarcoma virus (RSV) 1:150, 9:440, 12:407  
 rowers  
 vs. porters 8:584–586  
 ROX 11:490  
 RPE65 12:381  
 RP<sub>O</sub>  
 open complex 3:539  
 rRNA 6:144  
 rRNAs 9:321  
 Rsp5 4:205  
 RST microarrays 5:462ff  
 CpG-Island 5:462  
 RSV 3:91  
 molecular biology of 12:299–306  
 physical structure of 12:300  
 RSV infection  
 clinical disease of 12:306–307  
 epidemiology of 12:306–307  
 immunology of 12:307–312  
 RSV isolates  
 antigenic diversity 12:301–302  
 genetic diversity 12:301–302  
 RSV proteins  
 function of 12:302–306  
 structure of 12:302–306  
 RSV vaccine  
 approaches to 12:315–317  
 RT-PCR (reverse transcriptase PCR) 9:319, 10:402, 11:486ff, 12:559, 568, 575, 14:206  
 Rubenstein–Taybi syndrome 4:264  
 rule-of-five 3:617, 8:90, 13:596  
 run-off transcript 9:403, 12:43  
 RUNX2 6:12, 15:48  
 RUNX3 6:11, 12  
 RUNX1/AML1 6:12  
 RUNX3 loss 6:23  
 Ruthenium(II) tris(bipyridyl) 2:524  
 Ruvo Maryellen 8:529  
 RXR 7:107  
 ryanodine receptor 11:670  
 RYR1 11:673, 698
- s**  
 S6 12:179  
 16S rRNA 1:315, 316  
 30S–50S interface 12:504  
 30S subunit  
 interactions with tRNA 12:491  
 path of the mRNA 12:489–491  
*Saccharomyces cerevisiae* 3:395ff, 429f, 4:331, 366, 6:216ff, 8:372f, 11:119, 13:614–617  
 cell cycle 8:312  
 differentiation 8:312, 313  
 gametes 8:313  
 life cycle 8:313  
 mating-type 8:317  
 mating-type switching 8:313, 319  
 pseudohyphae 8:313  
 RE 8:321  
 recombination enhancer 8:321  
 sporulation 8:313  
 S-adenosyl-L-methionine (AdoMet) 4:120, 245, 8:226, 12:325  
 SAGA 15:23  
 SAGE 3:50, 10:117, 537  
 SAHA (suberoylanilide hydroxamic acid) 2:179  
 Salbutamol 14:365–366  
 salicylate 4:645, 14:50  
 salicylic acid 10:365, 375, 378  
 saliva 8:449  
 Salmonella 4:208, 15:160  
*Salmonella enterica* serovar typhi 6:308  
 salmonellosis  
*S. enteritidis* 6:315  
*S. typhimurium* 6:315  
*salmonella choleraesuis* 6:315  
*salmonella gallinarum* 6:315  
*salmonella pullorum* 6:315

- salt and water balance  
   hormones 11:697  
 salt bridges 2:9  
 salt wasting 11:690  
 salting-in 7:398  
 salting-out 7:398  
 SAM 11:295  
 SAM binding domains 4:251  
 sample preparation 13:683  
 sample requirements 13:549  
 sandwich pair 11:104  
 Sanger reaction 9:398  
 Sankoff algorithm 12:594  
 saponins 8:613  
 SAR-by-NMR 13:520, 528, 583–586, 588, 595, 597  
 sarcin–ricin loop 12:503  
 sarcoglycanopathies 15:262  
 sarcolemma 11:667, 15:262  
 sarcolemmal endplate 11:668  
 sarcomas 13:331  
 sarcoplasmic reticulum (SR) 11:670, 14:15  
 Sarich 8:520ff, 521ff  
 SATB 6:210ff  
 satellite DNA 1:254, 259ff, *see also* tandem repeat  
 satellite DNA sequences 3:21  
 saturable active Na<sup>+</sup> cotransporter (SVCT) 15:517  
 saturated fatty acids 7:40  
 saturation transfer 13:591  
 saturation transfer difference, *see* STD  
 saxitoxin 11:659  
 scaffold 11:435, 13:72  
 scaffolding protein 13:163  
 scaffolds 8:91, 13:95  
 scalar nuclear spin–spin couplings 11:166  
 Scale-free networks 14:136  
 Scandinavian Wood Lemming 5:620–621  
 scanning EM 4:60, 65  
   coating techniques 4:67  
 scanning SEM 4:63  
 scanning TEM 4:67  
 scanning tunneling microscope (STM) 9:275  
 scanning-FCS 4:475  
 SCAP, *see* SREBP-cleavage-activating protein  
*Scapharca inaequivalvis* 6:88  
*Scaphiopus couchii* 7:102  
 scarification 5:297  
 Scatchard analysis 11:384  
 Scatchard plot 11:390  
 scatter factor 5:651  
 scattering of X-rays  
   atomic form factor 7:418  
   by atom 7:416  
   crystal 7:418  
   dipole oscillator 7:417  
   electric field component 7:417  
   electron density  $\rho$  (r) 7:418  
   Laue equations 7:419  
   phase factor 7:419  
   structure factor F(hkl) 7:420  
   the amplitude of the scattered wave 7:417  
   unit cell 7:418  
   wave vector 7:417  
 scavenger receptor 5:216, 219, 234–235  
   CD36 7:237, 238  
   LIMP-2 7:238  
   LOX1 7:237  
   MSR1 7:237, 238  
   SR-BI 7:237, 238  
 scavenger receptor (CD36), *see* CD36...  
 scavenger receptor-B1 (SR-B1) 5:228  
 scEst1 14:237ff  
 SCF 5:651, 12:155ff, 161, 168ff, 170, 179, 189, 191ff, 196, 14:41  
 scFv 8:416  
 scFv and Fab libraries 8:420  
   antibody therapeutics 8:421  
   naïve antibody library 8:421  
   semisynthetic 8:421  
 schemata 5:327  
 Schiff base 1:577–583, 7:103  
 Schiff base complex 8:221  
 Schindler disease  
    $\alpha$ -N-acetylgalactosaminidase 5:593  
 schistosoma 15:160  
 schizophrenia 1:593, 605ff, 4:341, 8:453, 502, 10:201  
   adoption studies 1:605  
   concordance 1:605  
   genes 1:605  
   heritability 1:605  
   lifetime risk 1:605  
   twin studies 1:605  
*Schizosaccharomyces pombe* 4:331, 14:230  
 Schwartz 11:667  
 SCID 15:268  
 SCID/beige mice 13:404  
 SCID-X1 (severe combined immunodeficiency disease) 13:258  
 scintillation counters 11:427  
 scissile phosphodiester 12:333  
 sclerenchyma 1:417  
 scleroderma 1:465, 483, 14:47  
 sclerosis 11:112  
*Sclerotium glaucanicum* 5:7  
 SCN 12:416, 423

- SCN1A 11:679  
 SCN2A 11:679  
 SCN4A 11:673  
 SCN5A 11:663  
 SCN4A alleles 11:672  
 SCN1B 11:679  
 SCNN1A 11:690  
 SCNN1B 11:690, 691  
 SCNN1G 11:691  
 SCOR 12:618  
 scoring functions 6:589  
 scorpion primers 11:493  
 scRap1 14:230ff  
 scrapie 3:91  
 screening 14:329, 376  
     fluorescence polarization 8:425  
     microtiter plates 8:425  
 screening bacteria 14:353  
 screening biomarkers 9:113  
 scrib 12:185  
 scRif1 14:232ff  
 scRif2 14:232ff  
 SDF2 8:335  
 sebaceous glands 13:235  
 SEC14 10:299  
 Sec 11:292  
 Sec17 4:314ff  
 Sec18 4:312ff, 314ff  
 sec gene 8:124  
 Sec1/Munc18 8:134  
 second affinity purification 8:33  
 second messengers 1:660, 2:135, 10:300,  
     12:639, 642, 671–672, 14:108  
     adenosine 3',5'-cyclic phosphate  
         12:666–669  
     guanosine 3',5'-cyclic monophosphate (cyclic  
         GMP or cGMP) of 12:669–670  
 second polar body 2:466  
 second site modifiers 14:259  
 secondary active transport 11:691, 695  
 secondary crossover site 5:340  
 secondary hypogonadism 13:24  
 secondary metabolites 14:325  
     gibberellins 5:4  
     penicillins 5:4  
 secondary neurulation 2:94  
 secondary sex characteristics of the male 13:5  
 secondary structure 3:59ff, 4:668ff, 8:360, 372f,  
     374, 375, 379, 11:397, 12:613, 621, 629, 631,  
     14:92, 95  
     positioning 1:410  
 secondary structure graph 12:585  
 second-order selection 5:345, 346  
 Sec1 proteins 4:314ff  
      $\alpha$ -secretase 1:185, 189  
      $\beta$ -secretase 1:185, 189ff  
         active site motifs 1:190  
         structure 1:190  
      $\gamma$ -secretase 1:185, 189ff  
     secretase inhibitors 1:200  
     secretion 4:357, 11:289, 14:50  
     secretor 5:574  
     secretory epithelium 11:687  
     secretory granules 4:208  
     secretory IgA 8:604  
     secretory pathway 8:121  
         fusion reactions in the 11:79  
         regulated exocytosis 11:79  
         vesicular trafficking routes 11:79  
     secretory vesicles 4:307ff  
     sedimentary rocks 10:5  
     seed and soil hypothesis 13:356  
     seed development 10:352  
     seed germination 13:619  
     seedless fruits 14:570  
     segmental duplications 11:443–445  
     segmental polarity genes 13:273ff, 299  
     segmentation 13:273  
     segments 13:299  
     segments, chromosomal 2:561  
     segregation 1:527, 5:373, 402, 11:658  
     segregation of cell components at division  
         1:542  
     segregation of cytoplasm 1:542  
     segregation of DNA 1:543  
     segregation of the cell wall 1:544  
     seizure drug 11:699  
     seizures 11:676  
     SELDI 3:50, 9:103, 11:110, 311, 327  
     SELDI-TOF 9:93, 104  
     select for fitness  
         optimize reproductive success 1:91  
         select for fitness 1:91  
         sexual communication 1:91  
     selected 7:263  
     selectins  
         E-selectin 5:555  
         force spectroscopy on 9:277–278  
         L-selectin 5:555  
         P-selectin 5:555  
     selection 1:597, 7:337, 12:520, 522, 15:257, 258  
         positive, negative, or neutral effect 11:221  
         random mode 11:228  
         random processes 11:229  
         selective pressure to 11:221  
         truncating 6:113  
     selection among potential mating partners  
         1:86

- selection for fitness 1:86ff  
 selective advantage 1:80, 11:657  
 selective androgen receptor modulators 13:3, 47  
 selective antibody system 6:376  
 selective breeding 7:337  
 selective estrogen receptor modulators (SERMs) 1:444  
 selective growth advantage 15:258  
 selective media 1:508  
 selective placement 1:593  
 selective release  
   cytokines 14:39  
 selectivity 8:369f, 372, 10:22  
 selectivity filter 11:647  
 selenium 4:639  
 selenocysteine 2:587, 4:639, 11:47  
 self–nonself 13:285  
 self–self 13:285  
 self-antigens 1:362, 370, 385, 386, 395  
 self-assembled monolayer 11:119  
 self-cleaving RNA 12:514  
 self-fertilization 1:77, 79, 90  
   homologous recombinational repair (HRR) 1:69  
 selfish DNA 9:184ff  
 self/nonself discrimination 2:292  
 self-organization 5:348, 10:10  
 self-organized criticality 14:129  
 self-peptide 1:393  
 self-peptide repertoire 1:366  
 self-proteins 1:376  
 self-renewal 13:388  
 self-splicing RNA 12:517  
 SEM 4:60, 63  
   freeze-drying 4:64  
 semantic theories  
   information of 10:471–472  
 semaphorins 2:118, 15:206, 213  
 semiconductor nanoparticles 9:28  
 semiconservative replication 5:381  
 semiempirical methods  
   quantum mechanical 3:602  
 seminal fluid 8:449  
 seminiferous epithelium, testis 7:499  
   cycle within epithelium 7:501  
   gap junction 7:500  
   stages 7:501  
   tight junction 7:500  
 semisynthesis 1:428  
 semisynthetic libraries 3:94  
 Semliki forest virus 11:78  
 senescence 5:498, 7:326, 330, 14:235ff  
 sensation 13:232–233  
 sense of smell 12:637–695  
 sensitivity 9:93, 105, 10:540  
 sensitization 10:31, 34, 37  
 sensor site 12:45  
 sensorineural hearing loss 11:665  
 sensors 13:466  
 sensory ganglia 15:249  
 sensory kinase 8:297ff  
 sensory nerve terminals 15:249  
 sensory retina  
   renewal of 10:181–182  
 sensory rhodopsins 1:583  
 SEP 14:267  
 separation 8:10–12, 25, 31, 32, 34, 35  
 separation methods 11:191  
 separation process  
   centrifugation 11:191  
   chromatography 11:191  
   electrophoresis 11:191  
   phase partition 11:191  
   precipitation 11:191  
   ultrafiltration 11:191  
 sepsis 8:453, 455, 456  
 septate junctions 12:185  
 septic shock 8:449, 454  
 septum formation 8:304ff  
 sequence 4:331, 11:221  
   consensus 5:524  
 sequence alignment 6:573  
 sequence analysis  
   use of, in coincidence indices 10:460–464  
 sequence assembly  
   assembly process 13:96  
   base caller 13:95  
   computational filters 13:94  
   contaminated reads 13:94  
   electrophoresis-based instrument 13:95  
   Lander-Waterman model 13:94  
   low-quality reads 13:94  
   (MDRs) 13:96  
   multiple estimators 13:88  
   operating teams 13:94  
   phred-phrap-consed 13:95  
   repeats 13:96  
   repetitive sequences 13:94  
   software packages for 13:95  
   validation of 13:88  
 sequence assembly software  
   identifying different reads, and detect overlaps 13:95  
 sequence compilation 6:183ff  
 sequence conservation 6:192ff  
 sequence contigs 13:73, 92  
 sequence covariation 12:592

- sequence finishing  
 better contiguity of a target sequence 13:96  
 clone fingerprinting 13:100  
 end-sequencing 13:98  
 high-copy repeats 13:98  
 low-copy repeats 13:98  
 PCR-sequencing 13:98  
 physical mapping 13:100  
 primer-walking 13:98  
 quality-related contig-breakers 13:98  
 sequence contigs 13:98  
 single-read coverage 13:98
- sequence gap 13:73, 86, 88
- sequence heterogeneity 13:102
- sequence homogenization 9:196
- sequence homology comparison 13:102
- sequence motif 6:214ff
- sequence pattern 10:449
- sequence, primary 8:374, 377
- sequence quality control 13:86  
 poor DNA preparation 13:87  
 poor signal-to-noise ratio 13:87  
 system contamination and malfunction 13:87  
 wet-bench operation 13:87
- sequence similarity 6:183ff
- sequence slippage 11:454
- sequence space 8:416
- sequence specificity of DNA MTase 12:338
- sequence, structure, and function 11:203
- sequenced tagged sites, *see* STS
- sequence-specific contacts 6:185, 12:330
- sequence-specific effects 9:328
- sequence-tagged connectors 5:529
- sequence-tagged restriction site (STAR) 15:558, 566
- sequence-tagged site (STS) 3:44, 5:406, 15:558
- sequencing  
 DNA 5:516  
 genome 5:515  
 shotgun 5:515, 520
- sequencing data acquisition  
 engine of SGS 13:92
- sequencing of complete genomes 12:105
- sequencing reads  
 a parallel subcloning strategy 13:75  
 stepwise primer-directed "walking" strategy 13:74
- sequential exoglycosidase digestion 5:545
- sequential or induced fit 11:604
- SEQUEST 8:13, 17, 26, 27, 29–31, 35
- sequester intracellular calcium 11:670
- serial analysis of gene expression 10:537
- serial module 13:304
- serial transplantation 13:344
- serine 1:429, 8:143, 144
- serine, absolute configuration 2:584
- serine protease 6:116, 7:169, 482, 13:241
- serine protease inhibitors 5:307
- serine racemase 2:588
- serine–threonine kinase 11 (STK11)  
 LKB1 7:139
- serine/threonine kinase receptors 4:397
- seronegative infants 12:314
- serotonin 4:341
- serotonin 5HT2A receptor 1:605
- serotonin receptor 11:561
- serotypes 3:256, 15:164
- serpins 5:307
- Serrate/Jagged 5:557
- Sertoli cells 4:396, 5:556, 7:499, 8:445
- serum 4:680ff, 7:536ff, 539ff, 543ff, 545ff, 8:25, 444, 11:111  
 suspension 7:536  
 tissue 7:536
- serum amyloid P component (SAP) 6:413
- serum stability 7:310ff
- SET domains 4:251, 261
- seven-transmembrane helical protein 1:576
- severe combined immunodeficiency disease (SCID) 13:124, 14:198, 15:240
- severe myoclonic epilepsy of infancy (SMEI) 11:679
- sex 1:53ff, 55  
 adaptation for dealing with DNA damage 1:80  
 benefits of sex 1:53, 79  
 costs of sex 1:53  
 DNA repair 1:53  
 masking of mutations 1:92  
 recombinational repair 1:92
- sex, bacterial  
*Bacillus subtilis* 1:87  
 genes necessary 1:87  
*Haemophilus influenzae* 1:87
- sex chromosome 7:510
- sex, costs of 1:78ff
- sex determination 5:608
- sex differentiation 5:609
- sex reversal 5:608, 610
- sex steroid binding  $\beta$ -globulin (SBG) 13:10
- sex-combs-reduced 6:193
- sex-determining genes  
 autosomal 5:624  
 genealogical evidence in human 5:624  
 X-linked 5:620, 622–623  
 genealogical evidence in human 5:621

- sex-determining region Y gene (SRY)  
 in human 5:615–620
- sex-limited 15:11
- sex-linked inheritance 5:373, 377
- sex-reversing gene 5:622
- sexual communication 1:53, 86ff, 89ff  
 bacteria 1:87  
 complementation 1:88, 92  
 DNA repair 1:87, 88  
 higher eukaryotes 1:89  
 mate selection for fitness 1:92  
*Neurospora crassa* 1:89  
 recombinational repair 1:92  
 select for fitness 1:91
- sexual communication, bird  
 outcrossing 1:90
- sexual communication, human  
 avoid inbreeding 1:91  
 body odor preferences 1:91  
 incest taboo 1:91
- sexual communication, mouse  
 smell 1:90
- sexual communication, plants 1:90
- sexual communication, primate  
 avoid inbreeding 1:90  
 chimpanzees 1:90  
 gorillas 1:90  
 rhesus monkey 1:90
- sexual communication, vertebrates  
 outcrossing 1:90
- sexual reproduction 1:77  
 frequency 1:78  
 homologous recombinational repair (HRR)  
 1:69  
 promotion of efficient DNA repair 1:91  
 sexual reproduction 1:69, 84
- sexual selection  
 animal behavior 1:91  
 guppy fish 1:91
- sexual signals  
 plants 1:90  
 vertebrates 1:90
- sFlt1 15:213
- SGS 13:93  
 clone library 13:83  
 cloning 13:79  
 computing techniques 13:79  
 data analysis 13:83  
 sequence annotation 13:83  
 sequence assembly 13:83  
 wet-bench operators 13:83
- SGS libraries 13:90  
 size-selection 13:90  
 small-insert libraries 13:90  
 sonication and nebulization 13:90  
 subcloning of, large-insert clones 13:90
- SGS methodology  
 overview of 13:79
- SGS sequencing  
 plasmids 13:79
- SGS-related technologies  
 biocomputing 13:81  
 bioinformatics 13:81  
 gene-finding algorithms 13:81  
 sequence assembly 13:81
- SH2 11:583, 588
- shadowing rotary  
 platinum/palladium 4:106
- shaker 11:682
- SHAPES 13:588, 596, 597
- shared environment 1:595
- SH2 domain 1:664, 11:553
- SH3 domains 15:23
- shear stress 1:421, 15:220
- sheep 1:226, 227  
 $\beta$ -sheet 3:59ff
- $\beta$ -sheet structure 8:374
- Sherman paradox 4:576, 590, 15:5
- shibire 4:193
- shielding/deshielding compounds 7:313ff
- shift-downs 1:530
- shift-up 1:529, 530
- Shiga toxin 13:319
- Shigella*  
 vaccine 15:160
- shigellosis 6:306  
*Shigella dysenteriae* 6:307  
*Shigella flexneri* 6:307  
*Shigella sonnei* 6:307
- Shine–Dalgarno sequences 2:628
- shine-dalgarno sequence 12:489
- shock 14:452
- shoot apical meristem (SAM) 14:264
- Short, interfering RNA (siRNA) 1:222, 10:544
- short interspersed repeat element (SINE) 3:21,  
 36, 5:456, 9:262, 15:558, 562  
 MIR 1:269  
 MIR3 1:269
- short tandem repeat–based DNA typing process  
 3:489
- short tandem repeat polymorphisms (STRPs)  
 6:326
- short tandem repeat (STR) 3:481, 7:541, 609,  
 612–613, 13:210
- short-term sensitization  
 mediators 10:37–44  
 nerve growth factor 10:41–42  
 pathways 10:37–44

- short-term sensitization (*continued*)  
 PKA pathway 10:39–41  
 prostaglandins 10:39–41
- shotgun antisense 3:342
- shotgun (HS) sequencing 6:573
- Shotgun sequencing (SGS) 13:73
- SHP, *see* small heterodimer partner
- SHRs, *see* steroid hormone receptors
- sHSPs, *see* heat shock proteins, small
- SH2 (Src homology 2) 13:117, 121
- shuttle vectors 10:440
- shuttling 14:446
- sialidosis  
 $\beta$ -galactosidase-2 5:592  
 neuraminidase (sialidase) 5:592  
 protective protein/cathepsin A (PPCA) 5:592
- sialyl Lea (SLA or Ca 19-9) 6:23
- sialyl Lex (SLX) 6:23
- sialylation  
 leukocyte function 5:589
- Sibley, Charles 8:524
- sickle cell anemia  
 substitution of single gene 15:487
- sickle cell disease 6:325
- side effects 11:699, 15:412, 415, 416
- siglecs  
 immunoreceptor tyrosine-based inhibitory motif (ITIM) 5:587
- sigma factor 8:304–306, 308
- sigmoid  $E_{\max}$ -model 10:229
- signal anchor sequence 3:110
- signal desensitization 12:672
- signal hypothesis 11:289
- signal receptor 11:294
- signal recognition particle (SRP) 11:294, 12:502
- signal sequences 11:288, 12:507  
 export 11:290  
 import 11:290
- signal termination 12:672
- signal transducer and activator of transcription 3:132, 7:129, 11:588, 13:119, 15:402  
 proteins (STAT1, STAT3, STAT5) 10:137  
*see also* STAT
- signal transduction 2:464, 4:349, 5:511, 639, 653, 11:113, 13:143ff, 14:401  
 across the membrane – control of  $\sigma^E$  activity 13:473–475  
 carbon monoxide 2:140  
 cyclic nucleotides 2:140  
 NAADP 2:140  
 nitric oxide 2:140  
 phosphatidylinositol 2:140
- signal transduction cascade  
 inducing/inhibiting transcription in genes 15:489
- signal transduction pathways 8:532, 536ff
- signaling 8:439  
 between nucleus and organelles 10:336–337  
 receptor downregulation 4:210  
 signaling, endosomes 4:211  
 signaling receptors 4:210
- signaling cascades  
 TLR-initiat 10:97
- signaling lymphocyte activation molecule (SLAM) 6:398
- signaling pathway 2:480, 7:119ff, 9:261, 12:719, 15:399  
 Jak/STAT 7:119  
 MAP kinase pathway 7:119  
 PI3K/AKT 7:117ff  
 Raf/MEK/ERK 7:117ff  
 Ras/Raf/Mek/Erk pathway 7:119
- signals 11:388, 13:466
- signal-to-noise ratio (S/N) 13:679
- silencers 5:397, 6:580
- silencing 3:542
- silent base substitutions 12:117–119
- silent carriers 11:666
- silent mating-type locus 14:237ff
- silica 13:289
- silica gel 1:506
- silicon bolometer 13:680
- siloxene 2:524
- silver 1:431
- simian immunodeficiency virus (SIV) 5:298, 13:258, 15:148
- simian-human immunodeficiency virus (SHIV) 11:111
- simple analysis 4:664
- simple shuttle model 13:625
- simpler precursors 10:12
- simulated annealing 10:207, 13:535, 549
- simulation 14:133  
 simulation 5:432
- simulation packages 14:142
- simulations of protein dynamics 11:146
- simultaneous multiple mutation detection (SMMD) method 14:431
- Simvastatin 14:357–360
- SINE, *see* short interspersed repeat element
- single biomolecules  
 spectroscopy on 9:276–277
- single cell oils 7:264, 269
- single Hsp70  
 multiple physiological roles of 13:499–500

- single isomorphous replacement anomalous scattering (SIRAS) 7:434
- single molecular measurement 7:167
- single molecule biochemistry 9:270, 271
- single molecule biophysics 9:270
- single molecule detection (SMD) 4:494
- single molecule DNA  
sequencing of 9:285–286
- single molecule enzyme  
kinetics 9:280–281
- single molecule immunology  
antibodies 9:278  
antigens 9:278
- single molecule research  
reviews of 9:271–272  
seminal work 9:271–272
- single molecules 7:169  
issues on 9:271
- single nucleotide polymorphism, *see* SNP
- single protein molecules  
in living cells 9:281–282  
in viruses 9:281–282
- single whole-chromosome paints (WCP) 5:128
- single-band analysis 4:539
- single-beam IR spectrum 13:674
- single-beam spectrum 13:675
- single-cell 8:497
- single-chain receptor family 13:136
- single-chain variable region 11:106
- single-channel analysis 8:363, 364  
conductance 8:364f, 365, 369, 371, 374
- single-copy DNA 8:523, 524
- single-molecule fluorescence 7:174
- single-strand conformation polymorphism analysis (SSCP) 5:254, 6:326
- single-stranded DNA 9:300ff, 10:92, 11:493ff
- singular olfactory receptor gene activation 12:684–687
- sinoatrial (SA) node 11:660
- Sinorhizobium meliloti* 10:287
- SIPK (salicylic acid induced protein kinase) 10:349
- Sir2  
histone deacetylase 14:232
- Sir3 14:232ff
- Sir4 14:232ff
- Sir proteins 8:320
- siRNA 10:544, 12:532, 14:238ff  
asymmetry of siRNAs 12:533  
off-target effects 12:536
- Sirolimus 14:374–375
- sirtuins 8:320
- SIS oncogene 9:455
- sister chromatid recombination 12:15ff  
harlequin assay 12:16  
stalled replication forks 12:16
- site points 10:206ff
- site-directed mutagenesis 7:171, 12:621
- site-directed spin 7:173
- site-directed spin labeling 7:169
- site-specific attachment 11:108
- site-specific DNA inversion 5:340
- site-specific recombination 5:340
- situs inversus 2:612
- SIV, *see* simian immunodeficiency virus
- SIX5 15:40ff
- Six/so 6:212
- Six/so domain 6:213
- size exclusion 6:248
- size exclusion chromatography 2:260  
basic principles 6:276  
experimental conditions 6:276
- size selection 3:415ff
- size-based RNA separation 9:322
- Sjogrens syndrome 1:464, 11:112
- skeletal mineralization 13:31
- skeletal muscles 7:29ff, 30, 14:635ff  
endurance exercise training 7:32
- skeletogenesis 14:386
- skeleton 13:286
- skin  
embryology of 13:219–221  
human 7:537  
molecular cell biology of 13:217–247  
transplantation 7:552
- skin barrier function 13:228
- skin characteristics  
factors altering 13:233–239
- skin elasticity 13:235
- skin functions 13:227–233
- skin immune system 13:230–231
- skin stem cells 13:345
- S6 kinase (S6K) 12:178ff
- Skp1 12:168ff, 191
- Skp2 12:168ff, 179, 192
- SkpA 12:189
- SLA 6:23
- slab-gel-based sequencers 13:78
- SLAM-associated protein (SAP) 6:398
- SLATE 10:207
- slaving-principle 14:129
- SLC12A3 11:693
- SLC5A2 11:696
- SLC12A1 mutations 11:692
- sliding 12:331
- sliding clamp 3:541
- slimb 12:161, 179



- slime mold 4:349  
 slippage model 4:615  
 slipped-strand mispairing 12:120  
 slope 11:390, 509ff  
 slow delayed rectifier 11:663  
 slow exchange 13:553, 554, 555  
 slow-channel congenital myasthenic syndrome (SCCMS)  
   CHRNA1 11:674  
   CHRNA1 11:674  
   CHRND 11:674  
   CHRNE 11:674  
 slowly releasable pool (SRP) 11:89  
 SLX 6:23  
 SM proteins  
   conserved cytoplasmic proteins 11:91  
 SMAC (second mitochondria-derived activator of caspase) 9:444  
 Smac/Diablo 10:623, 625, 626  
 SMAD 11:588  
   copartner SMADs (Co-Smads) 4:397ff  
   inhibitory SMADs (I-Smads) 4:397  
   receptor-regulated SMADs 4:397ff  
 Smad 12:174  
 Smad2 6:20  
 Smad4 6:20  
 Smad1/5 15:217  
 Smads 6:469  
 Small accessory chromosomes (SACs) 3:47  
 small dense low-density lipoproteins 7:40  
 small fragment homologous replacement, SFHR 5:197  
 small heat shock proteins 13:500–502  
 small heterodimer partner 7:220  
 small Hsp 1:35  
 small hydrophobic (SH) protein 12:305  
 small indels 12:130  
 small interfering RNAs (siRNA) 8:113, 14:269  
 small nuclear ribonucleoprotein 1:460  
 small RNAs 12:102  
 small RNAs – siRNA 9:431  
 small ubiquitinlike modifier (SUMO) 15:15  
 small unilamellar vesicles (SUVs) 7:302ff  
 small-cell carcinoma 11:674  
 small-molecule microarrays 11:122  
 small-molecule mimics 2:18  
 smallpox 5:295  
 SMART 12:103  
 SMaRT 1:162  
 smears 4:617  
 smell 12:639  
 smg mutations 9:63  
 Smith–Lemli–Opitz Syndrome 7:218  
 smooth muscle 15:207, 219, 220  
 Smoothened (Smo) 12:179ff  
 smoothing 4:661  
 SMRT (silencing mediator of retinoid and thyroid hormone receptors) 15:18  
 SMRTER 15:18  
 SN-6999 13:562  
 Snakes 15:194  
 $\alpha$ -SNAP 4:310ff, 8:126  
 SNAP-25ff 4:311  
 SNARE acceptor complexes 11:87  
 SNARE assembly 11:84  
 SNARE complex 4:312ff, 11:86  
 SNARE motif 11:92  
 SNARE proteins 4:310ff, 11:81  
   assembly–disassembly cycle 11:84  
   fusion catalysts 11:83  
   importance of 11:83  
   NSF acceptor protein receptors 11:83  
   SNARE hypothesis 8:132  
   SNAREpin 8:132  
   t-SNAREs 8:132  
   v-SNARE 8:132  
 SNARE transmembrane domains  
   contribution of 11:89  
 SNARE-mediated membrane fusion 11:86  
 SNAREs 4:195, 8:126, 133, 134, 11:70, 79, 84  
   conformational intermediates of 11:87  
   exogenous and endogenous 11:87  
   Q-SNAREs and R-SNAREs 11:85  
   regulators of 11:91  
   v-SNARE 4:199  
 Snf7/Vps20 4:205  
 $S_N1$ -like dissociative mechanism 12:333  
 $S_N2$ -like in-line attack 12:333  
 SNOM (scanning near-field optical microscope) 9:275  
 SNP 11:498, 12:44  
 SNP analysis 13:209  
 SNP blocks  
   and disease genes 13:211  
   SNP classification 2:76, 80  
 SNP (single-nucleotide polymorphisms) 2:77, 540, 3:482, 6:326, 606, 7:478, 609, 613–615, 8:452, 9:56, 260, 10:198ff, 12:44, 13:173, 194, 14:422, 430, 15:618  
   RFLP markers 5:444  
 SNPs (short tandem repeats) 13:210  
 SNP-typed MHC haplotypes  
   integrated haplotype map 13:198  
 SnRNAs 12:26  
 [ $\alpha$ -S]NTPs [nucleoside 5'-O-(1-thio-triphosphate)] 9:408  
 soaps 13:238  
 social communication 13:233

- SOCS (suppressors of cytokine signaling)  
13:118, 120, 138  
  feedback loop 13:137
- sod genes 5:498
- sodium bisulfite (Bis) mediated deamination  
9:305
- sodium channels 11:665
- sodium cromoglycate 14:363–365
- sodium dodecylsulfate polyacrylamide gel  
  electrophoresis (SDSPAGE) 8:32, 9:352,  
  356, 12:104
- sodium exchanger 2:161
- sodium resorption 11:690
- sodium retention 11:691
- sodium wasting 11:693
- sodium-Cl cotransporter 11:693
- sodium-coupled transport 11:695
- sodium/glucose transporter 8:155
- SOD1 mutations 8:544
- software 11:503ff
- solar radiation 10:7, 12:114
- solar system 10:3
- solid phase method  
  Boc 3:249–251  
  deletion sequences 3:252  
  9-fluorenylmethyloxycarbonyl 3:250  
  Fmoc 3:249–251  
  incomplete deprotection 3:252  
  tert-butylloxycarbonyl 3:250
- solid resin 1:435
- solid substrate fermentation 5:4ff  
  *A. oryzae* 5:5  
  *A. soyae* 5:5  
  *Agaricus bisporus* 5:5ff  
  *Aspergillus soyae* 5:5  
  *P. camembertii* 5:5  
  *Penicillium roquefortii* 5:5  
  *R. oligosporus* 5:5  
  *Rhizopus* 5:5
- solid tumors 3:230–231
- solid-phase method 3:247ff  
  permanent protecting groups 3:247  
  temporary protecting groups 3:247
- solid-phase peptide synthesis 2:22
- solid-state deuterium NMR 7:171
- solubility 3:619
- solubilizing reagents 1:44
- soluble receptors 8:440
- soluble VEGFR1 15:212
- solvation energy 2:29
- solvent content  
  Matthews parameter  $V_M$  7:427
- solvent extraction 1:431
- soma 2:107, 9:141
- somatic cell hybrids 7:346
- somatic cell nuclear transfer (SCNT)  
  cloning of mice, sheep, cows 13:395
- somatic gene therapy 13:251, 253–258, 267  
  clinical use of 13:259–263  
  homologous recombination 13:252  
  manufacture of 13:263–266  
  nucleic acid in somatic cells 15:486  
  regulatory aspects of 13:263–266
- somatic mosaicism 4:616
- somatomedin 5:645
- somatostatin 10:218
- somatotrope 4:389
- somatotropin (growth hormone) 10:216, 219,  
  224, 230–232, 14:107, *see also* GH
- somitogenesis 12:170
- sonic hedgehog 2:228, 13:334
- sorghum 14:257
- sorting signal 8:128
- SOS mutagenic repair 12:110
- source DNA  
  genetic heterogeneity of samples 13:91  
  using pulse-field gel electrophoresis 13:91
- Southern blot analysis 1:215, 2:529, 3:487f
- Southern blot hybridization 4:616, 14:484
- Sox 10:549
- Sox-2  
  activate key ES cell-enriched genes 13:389  
  transcription factor 13:389
- sox locus 4:642
- SOX9 gene  
  mapping studies 5:624
- SoxRS regulon 5:505
- SP-40/40 7:236
- SP 14:47
- Sp1 10:296, 15:14
- Sp3 10:296
- spacious phagosome 10:187
- spadefoot toad 7:102
- spaghetti effect 13:266
- spanning tree 12:620–623
- SPARC 8:56, 63, 67
- spatial resolution 10:540
- spatially addressable parallel library method  
  chemical microarray 10:157  
  multipin technology 10:156  
  NanoKan technique  
    advantages 10:157  
    Encore 10:157  
    IRORI NanoKan™ 10:157  
    tea bag method 10:157  
  SPOT synthesis 10:156
- spatio-temporal expression pattern 14:507
- spatiotemporal modeling 14:142

- special senses 11:683
- specialized lineage model 1:387
- speciation 5:131
- species 1:379, 11:387, 388
- species barrier 10:562
- species differences
  - in drug metabolism 2:69
- species identification 3:496
- species tree 2:559
- specific activity 11:108, 412, 415
- specific growth 1:427
- specific intramolecular associations 1:30
- specification 3:272
- specificity 6:376, 9:93, 105
- specificity may 6:377ff
- specimen preparation 4:27, 32, 53
  - critical point drying 4:62
  - cryo em 4:46
    - hydrated cryosectioning 4:49
    - vitrification 4:49
  - dehydration 4:33
  - EM at cold temperatures 4:57
  - embedding 4:33
  - hydrated cryosections 4:50
  - Kleinschmidt method 4:52
  - Lowicryl HM23 4:51
  - microwave technology 4:45
  - positive-negative staining approaches 4:29
  - resin embedding 4:31
  - simple shadowing methods 4:51
  - the cellulose capillary tube 4:47
  - the fine-needle biopsy 4:48
- spectinomycin 2:630, 631, 634, 638
- spectral assignment 13:532
- spectral karyotyping (SKY) 5:125
- spectrin
  - $\alpha$  4:283
  - $\beta$  4:283
  - $\beta_{\text{Heavy}}$  4:283
  - karst 4:283
- spectroscopy 3:56, 7:169
- spectrum manipulation 4:661ff
- specular reflectance 4:655
- speech impairment 2:567
- Spemann organizer 13:273ff
- sperm
  - fertilin 6:537
  - interaction of 14:9–14
- sperm activation 14:9–10
- sperm centrosome 13:384
- sperm–egg
  - fusion 14:11–13
  - interaction of 14:11
    - speciation of 14:11
    - sperm incorporation 14:11–13
- sperm–egg binding
  - $\beta$ 1,4-galactosyltransferase 6:536
  - integrin 6:537
  - metalloprotease 6:537
  - receptor–ligand interaction 6:536
- sperm–egg fusion 14:12
- sperm or pollen cells
  - avoid metabolism 1:83
  - DNA damage 1:83
- sperm recombination studies 13:197
- spermatid 7:499
- spermatocyte 7:499
- spermatogenesis 8:445, 12:168
- spermatogonial cell transfer 1:212
- spermatogonium 7:499
- spermatozoa 6:535ff, 536ff
  - acrosin 6:536
  - acrosome 6:534ff
  - acrosome reaction 6:536
  - chemotaxis 6:533
  - hyaluronidase 6:535
  - hyperactivation 6:535
  - olfactory receptors 6:534
  - sperm capacitation 6:533ff
  - sperm plasma membrane 6:534
- spermatozoa-mediated transfer 1:212
- spermatozoan 7:499
- spermiogenesis 7:499
- Spermophilus richardsonii* 7:101
- spEst1 14:237ff
- S-phase 14:5
- Sphenodon punctatus* 6:78
- spheroids 7:544, 550
- sphinganine 13:314
- sphingoid long-chain base 13:313
- sphingolipid 4:170, 13:311
- sphingolipid/cholesterol-rich micro-domains (DIGs) 14:643
- sphingomyelin (SM) 1:620, 3:309, 8:143, 10:281, 13:312
- sphingosine 13:314
- sphingosine kinase 13:314
- sphingosine-1-phosphate 13:312
- spicule network 13:289
- spicules 13:273ff
- spiegelmers 10:242, 253
  - in therapy 10:262
- spin 7:165
- spin labeling 4:118ff, 13:584
  - nitroxide molecules 4:124

- site-directed spin labeling (SDSL) 4:124ff
- spin labels 1:581, 4:124, 13:594
- spin–lattice relaxation 7:161
- spin trapping 4:127, 645
  - hydroxyl radical 4:128
  - lipoprotein oxidation 4:128
  - superoxide 4:128
  - xenobiotic radicals 4:128
- spina bifida
  - causation of 9:124–126
  - developmental mechanisms of 9:126–134
  - mechanisms of 9:129–131
- spina bifida aperta 9:121
- spinal and bulbar muscular atrophy 15:4ff
- spinal cord slice
  - cultures of 8:545–547
- spinal muscular atrophy (SMA) 1:159, 8:560
- spinal muscular atrophy with respiratory distress (SMARD) 8:562
- spindle 14:5
- spindle apparatus 2:638
- spindle pole body (centrosome, microtubule-organizing center) 12:147
- spine morphology 4:591
- spin- $\frac{1}{2}$  nuclei 11:161
- spinobulbar muscular atrophy (SBMA) 10:260
- spinocerebellar ataxias 15:6ff, 262
  - type 1 (SCA1) 15:16ff
  - type 2 (SCA2) 15:18ff
  - type 3 (SCA3) 15:19ff
  - type 6 (SCA6) 11:681, 15:21ff
  - type 7 (SCA7) 15:22ff
  - type 8 (SCA8) 15:43ff
  - type 10 (SCA10) 15:50ff
  - type 12 (SCA12) 15:51ff
  - type 17 (SCA17) 15:25ff
- spleen 14:47
- spleen cell 14:48
- 5',3' splice sites 1:126
- spliceosomal UsnRNP biogenesis 1:137–138
- spliceosome 1:126, 127, 138, 10:246, 320, 12:54, 518
- spliceosome assembly 1:138–141
- spliceosome cycle 10:321
- spliceosome-mediated RNA trans-splicing (SMaRT) 1:162, 10:249
- splice-variant 11:654
- splicing 2:620, 627, 9:62, 10:246
  - cis-splicing 2:627ff
  - protein splicing 2:628
  - trans-splicing 2:627ff, 635ff
- splicing control elements (SCEs) 5:75
- splicing defects 1:153
  - molecular mechanisms of 1:157–160
- splicing defects, human diseases 1:153–157
  - diagnosis of 1:160–161
- splicing enhancers 1:144
- splicing machinery 1:129–142
  - spliceosome 1:127–128
- splicing regulators 1:127, 150, 157
- splicing regulatory elements 1:127, 145–148
- splicing repressors 1:149, 150
- splicing signals 1:128–137, 145–148
- split and mix synthesis 2:26
- splitting 7:160
- Spo0A 8:300, 301, 303
- sponges 13:273ff
- spongiform encephalopathies 1:45
- spontaneous generation 13:331
- spontaneous mutations 5:336
  - generation mechanisms 12:119–120
- sporadic human prion diseases 10:583
- sporadic LQT 11:666
- sporadic MND
  - pathophysiological mechanisms of 8:566–568
- sporadic osteosarcomas 12:359
- spore differentiation factors 1 and 2 SDF1 8:335
- spore stain 1:512
- spores 14:232ff
- sporogenic developmental cycle 7:473
- sporulation 1:323, 8:299ff, 310, 314, 316
- SPOT 11:117
- spot intensity 5:414
- spotted arrays 8:270
  - fabrication of 8:271–275
- spotted DNA arrays 8:264
- spRap1 14:232ff
- spread plate 1:515
- spreading cytochrome c 4:94
- spRif1 14:232ff
  - ultrastructure of 11:8–9
- S100 proteins
  - 1q21 2:152
  - S100A1–S100A13 2:152
- squalene synthase 7:218
- squamous cell carcinoma (SCC) 3:378, 6:4, 11:110
- SR-BI 7:198, 215, 237
  - scavenger receptor 7:213
- SR-B1 receptor
  - protection against atherosclerosis 5:228–229
- Src 11:583, 12:184

- Src family of cytoplasmic tyrosine kinases 2:333
- src homology domain 2, *see* SH2 domains
- SREBP 7:36, 199, 201  
cleavage-activating protein 7:223
- S-RNA 9:409
- SRY 10:549  
in mouse 5:617–618  
species in 5:618–619
- SSCP 5:254–255
- Ssl1 3:438
- Ssl2 3:437ff
- SSSCA1 1:492
- stab and shake cultures  
for anaerobes 1:509
- stability analysis 14:131
- stability ruler 1:642
- stable elongation complex, RP<sub>E</sub> 3:538
- stable isotopic amino acids in cell culture (SILAC) 8:20, 36
- stacking forces 3:188, 189
- STAGA 15:23
- staining for microscopic analysis  
acid fast 1:511  
differential 1:511  
general principles 1:511  
Gram's method 1:511  
preparation of films 1:510  
spore 1:512
- stains  
ammonium molybdate 4:29  
uranyl acetate 4:29, 30, 33, 36
- stalk cells 8:334
- stalk hypothesis 11:72
- standard 11:484ff
- standard curve 11:516ff
- standard free energy of binding 2:6
- standard genetic sequence 12:112
- standard "wet" chemistry 13:692
- standardization 6:377
- stanazolol 13:31, 39, 41, 42
- staphylococcal enterotoxins (SEs) 8:454, 13:639
- staphylococcal food poisoning (SFP) 13:648
- Staphylococcus aureus* 8:454
- starburst – dendrimers  
dendritic symmetry 15:496
- Stargardt's disease 12:391
- start 12:144ff
- START domain 6:216ff
- Startle syndrome 11:682
- starvation 7:102
- STAT 1:663ff, 8:333, 11:589, 12:183ff, 13:118  
evolution of 13:125–126
- family members of 13:128  
stat2 13:129  
stat3 13:129  
stat4 13:129  
stat6 13:130  
stat5a 13:129–130  
stat5b 13:129–130
- stat1 13:128–129
- structure of  
coiled-coil domain 13:127  
DNA binding domain 13:127  
linker domain 13:127  
NH<sub>2</sub> domain 13:126–127  
SH2 and tyrosine activation domain 13:127–128  
transcription activation domain 13:128  
*see also* signal transducers and activators of transcription
- STAT1 15:402, 403, 404
- STAT2 15:402, 403
- state  
closed 8:360, 368ff, 369, 370, 378  
open 8:360, 363, 370
- state transition 2:637
- state-of-the-art  
simulation methods 13:656–658
- statins 5:216
- stationary night blindness 11:683
- stationary phase 1:427, 529, 3:541, 6:247, 7:540, 9:301
- statistical analysis 11:393
- statistical models 3:608
- Staudinger ligation 11:123
- STD 13:584, 589, 590, 595, 598
- stealth delivery systems 14:168
- steered molecular dynamics (SMD) 13:657
- stem 1:417
- stem cell differentiation 10:79
- stem cell factor, *see* SCF
- stem cell–like phenotype 7:331
- stem cell niche 12:88
- stem cell origin 7:331
- stem cell origin of leukemia 13:349
- stem cell therapy 10:81
- stem cells 2:233, 5:639, 654, 6:11, 10:72ff, 73ff, 76ff, 12:101, 13:276, 393  
adult 13:363–376  
and Adenocarcinomas 13:352  
apical meristems 3:296  
as targets for malignant transformation 2:230  
basic FGF2 3:295  
cell differentiation 3:294  
chimeras 3:295

- cord blood 3:295  
 embryonic stem cells 3:295, 10:72, 12:103  
 environmental cues 3:296  
 ES cells 3:295  
 fundamental properties 2:227  
 genetic regulation 2:228, 231  
 ground meristem 3:296  
 hemangioblasts 3:294  
 hematopoietic 3:294, 13:365  
 inner mass cells 3:295  
 lateral meristems 3:296  
 leukemia inhibition factor 3:295  
 lineage-restricted stem cells 3:294  
 lymphoid precursor cell 3:295  
 meristem 3:296  
 multilineage priming model 3:296  
 myeloid precursor cell 3:295  
 neural crest cells 3:294  
 oncogenes implicated in self-renewal 2:228  
 oogonia 3:295  
 osteoclastogenesis inhibitory factor 3:295  
 osteoprotegerin 3:295  
 parthenogenetic stem cells 10:73  
 pluripotent 3:294, 295  
 primary tissues 3:296  
 primordial germ cell (PGC)-derived cells 3:295  
 procambium 3:296  
 properties of normal stem cells 2:226  
 protoderm 3:296  
 self-renewal 2:223, 224, 226, 227, 229, 230, 231  
 spermatogonia 3:295  
 stem cell factor 3:295  
 stemness 3:296  
 stem loop 9:320  
 stepwise mutation model 5:261  
 stepwise regression 9:261  
 stereochemistry 8:108ff  
   chiral phosphorus 1:406  
   conformation 1:410  
   diastereomers 1:406  
   synthesis stereospecific 1:406  
 stereoisomers 2:582  
 stereology 4:70  
   absolute volume 4:72  
   Cavalieri principle 4:72  
   fractionator method 4:73  
   relative area and volume 4:71  
 stereoselectivity 8:89  
 steric complementarity 2:7  
 steric hindrance 7:303ff  
 sterilization 1:418  
   autoclave 1:507  
   dry heat 1:507  
   filter 1:507  
   steaming 1:507  
 steroid hormone action 13:18  
 steroid hormone receptors (SHRs) 1:441–445, 2:504ff, 8:86, 9:472  
 steroid hormones 1:440  
 steroid–receptor complexes 13:19  
 steroid receptor superfamily 11:613  
 steroidogenesis 13:7  
 steroidogenic cells 14:641  
 steroidogenic enzymes  
   aromatase (P450arom) 4:385ff  
   cholesterol side-chain cleavage cytochrome P450 (P450sc) 4:385ff  
   17 $\alpha$ -hydroxylase (P450c17) 4:385ff  
 steroids 13:8, 31  
 sterol 8:360, 362, 374, 377  
 sterol O-acyltransferases, *see* acyl CoA: cholesterol acyltransferases  
 sterol response element binding proteins (SREBPs) 7:33, 10:296  
 STI-571 10:202  
 Stickleback 15:194  
 sticky proteins 9:509  
 stimulated peripheral blood mononuclear cells 11:113  
 stimulus/secretion-coupling 14:631ff  
 stirred-tank reactor 5:5ff  
 STK11  
   AMP-activated kinase 7:140  
   ataxia-telangiectasia mutated kinase 7:140  
   axis induction 7:140  
   gastrointestinal, pancreatic, ovarian, testicular, uterine, and breast carcinomas 7:140  
   microtubules 7:140  
   PAR1 7:140  
   Peutz-Jeghers syndrome 7:140ff  
   SL26 mutant 7:140  
   STRAD 7:140  
   Wnt signaling 7:140  
 stochastic effects 14:140  
 stochastic focusing 14:140  
 stochastic resonance 14:140  
 stochastic simulation algorithm 14:140  
 stoichiometric titration 11:399  
 stoichiometry 11:399, 13:530, 551, 555, 566  
 Stoke's shift 4:440, 441, 11:488  
 stomatitis vesicular virus 8:449  
 stop-transfer 11:290, 291  
 storage 5:146

- stored lipid
  - mobilization of 1:5–6
  - release into circulation 1:5–6
- strain 3:535
- strand separation 9:335
- strand separation temperature 9:334, 335
- strand transfer 6:167, 12:409
- $\beta$ -strands 3:60ff, 8:375ff, 376, 379
- strands 9:335
- strategies of genetic variation 5:335
- strategies to map and sequence genomes 5:460ff
  - hierarchical 5:460
  - slalom 5:460
  - whole-genome 5:460
- stratospheric ozone 3:379
- stratum basale 13:222–223
- stratum compactum 13:221
- stratum corneum 13:221
- stratum dysjunctum 13:221
- stratum germinativum 13:222–223, 345
- stratum granulosum 13:222
- stratum lucidum 13:221–222
- stratum spinosum 13:222, 345
- streak gonads 5:621
- streak plate method 1:507
- strengths, weaknesses, opportunities, and threats (SWOT) 10:390
- streptavidin 6:449–452, 456, 11:108
- streptavidin-protein A chimera 6:449–451, 453–455, 458
- streptococcal growth 1:547
- streptococcal pyrogenic exotoxins (SPEs) 13:639
- Streptococcus*
  - vaccine 15:160, 174
- Streptococcus pneumoniae* 1:398, 6:227
- streptogramins 14:355–356
- Streptomyces*
  - antibiotic selection 13:455
  - antibiotics 13:440ff
  - bacteriophages 13:450
  - chromosome 13:443ff
  - circularity 13:443ff
  - differentiation 13:440ff
  - gene bank 13:448
  - gene clusters 13:440
  - gene expression 13:458
  - genetic instability 13:444ff
  - genetic manipulation 13:448
  - genetic tools 13:448
  - genome 13:440, 444
  - life cycle 13:441
  - linear 13:443ff
  - metabolites 13:440
  - microarrays 13:440
  - morphological development 13:456
  - PCR-targeted mutagenesis 13:455
  - plasmids 13:449
  - proteome 13:440
  - restriction barrier 13:449ff
  - secondary metabolites 13:441
  - synteny 13:445
  - transposons 13:451
- Streptomyces coelicolor* A3(2)
  - actinorhodin 13:442
  - “calcium-dependent” antibiotic 13:442
  - methylenomycin 13:442
  - undecylprodigiosin 13:442
- streptomycete 10:641
- streptomycin 2:631, 12:495
- stress 5:314
  - acute 14:47
  - contact dermatitis 14:48
  - corticotropin-releasing hormone or CRH 14:47
  - CRH 14:41
  - hormones 14:39
  - HPA axis 14:47
  - hypothalamic-pituitary adrenal (HPA) axis 14:47
  - IL-6 levels 14:41
  - immune system 14:47
  - parathyroid hormone 14:43
  - proteins 15:119
  - somatostatin 14:43
  - urocortin (Ucn) 14:47
- stress response 13:465
- stress signal by DegS
  - recognition of 13:475–476
- stressor 5:492
- stress-responsive genes 5:492
- stroke-induced immune depression (SIDS) 10:137
- stroma 11:110
- stromal cells and cancer 9:499, 536
- stromelysin 8:216, 222, 13:575, 586
- Strongylocentrotus purpuratus* 10:547
- structural classification
  - superfamilies 11:220
- structural domains 4:594
- structural equation modeling 1:597
- structural genomics 6:585, 11:135, 13:522
- structural genomics initiative 10:203
- structural mimicry 12:503
- structural proteins 9:257
- structural refinement 13:654
- structural reporter groups 2:263

- structural RNA 9:255
- structural validation 14:400
- structure 6:183ff, 186ff, 8:375, 11:205, 212, 221, 223
  - 3-D, crystal, secondary 8:372ff, 376, 379
  - homeodomain 6:183, 185, 186
  - NMR 6:185ff
  - primary structure 3:243ff, 8:372, 374
  - secondary structure 3:243ff
  - tertiary structure 3:243ff
  - X-ray 6:185ff
- structure building 12:618
- structure classification
  - superfamilies 11:226
- structure determination 7:449
  - overview 13:549
- structure determination methods
  - electron microscopy is a third method 11:138
  - nuclear magnetic resonance 11:138
  - X-ray crystallography 11:138
- structure elucidation 13:530
- structure evolution
  - circular permutations 11:225
  - domain-swapping 11:225
  - hairpin flips and swaps 11:225
  - strand invasion 11:225
  - strand withdrawal 11:225
- structure of ion channels
  - selectivity filter 11:651
- structure of proteins
  - primary, secondary, tertiary, and quaternary 11:136
- structure prediction methods 11:139
  - De Novo/Ab Initio Methods 11:140
  - fold recognition methods 11:141
  - homology modeling 11:142
- structure-activity relationship (SAR) 8:86, 89, 11:596, 618, 623
  - computer-assisted molecular design (CAMD) 11:619
  - for anabolic agents 13:41
  - for androgens 13:29
  - for 5 $\alpha$ -reductase inhibitors 13:50
  - high-throughput screening 11:595, 597
  - quantitative SAR, *see* QSAR
- structure-based design 13:519, 528–530, 551, 576
- structure-based drug design 8:89, 98, 10:198ff
  - lead compound 11:280
  - virtual ligand screening 11:280
- structure-based modeling 11:143
- structured treatment interruptions (STI) 1:115
- structure-to-function approaches 11:269
  - biochemical function 11:271
  - biological function 11:271
  - enzymes
    - active sites 11:271
    - active-site templates 11:271
    - key functional residues 11:271
    - Ser-His-Asp catalytic triad 11:271
    - serine proteases 11:271
  - surface properties 11:272
  - vector machine-learning 11:272
- STS (sequenced tagged sites) 5:442ff, 15:560
- studies
  - absorption 14:49
  - bioavailability 14:49
  - double-blind 14:49
  - placebo-controlled trial 14:49
- studies in mice 5:358
- subapical compartment (SAC) 4:200
- subcellular compartments 11:697
- subcellular fractionation
  - biochemical analysis 8:124
  - centrifugation 8:124
  - proteomic analysis 8:124
- subcomponent C1q 5:556
- subcutaneous 14:690
- subcutaneous fat 7:35
- Suberites domuncula* 13:275ff
- suberoylanilide hydroxyamic acid 4:269
- subfunctionalization 9:255
- subgenomic RNAs 10:362
- subgranular zone 13:410ff
- subjective day 12:445, 460ff, 466ff
- subjective night 12:422, 429
- subjective night/early dawn 12:456
- submerged liquid fermentation (SLF) 5:5ff
  - A. niger* 5:5
  - citric acid 5:5
- suboptimal structure 12:590
- substance P 8:444
- substantia nigra pars reticulata 15:265
- substitution 11:225
- substitution matrix
  - PAM1 9:260
- substitutions 11:221
- substrate 4:345, 8:576, 11:288
  - cycles 7:98
- substrate binding 13:501
- substrate cycling 14:629ff, 698
- substrate orientation 12:497
- substrate phages 8:424
- substrate polypeptide interaction cycle 13:499
- substrate recognition sequences
  - CYP102A1 3:110



substrate recognition sequences (*continued*)

- SRS2 in 3:110
- SRS3 in 3:110
- SRS4 in 3:110
- SRS5 in 3:110
- SRS6 in 3:110
- SRS1 is 3:110
- substrate access channel 3:110
- substrate sink 13:245
- substrate utilization tests 1:517
- substrates 2:530, 11:113
- substructure synthesis method (SSM) 13:664
- subtelomeric region 14:231ff
- subthalamic nucleus 15:265
- subtraction
  - NotI-CODE 5:459
- subtraction procedures 5:458ff
  - NotI linking libraries 5:458
- subtractive cloning 3:50
  - driver 10:538
  - tester 10:537
- subtypes 15:393, 395–397, 398, 399
- $\beta$ -subunit 11:335, 665
- $\gamma$ -subunit, role of 11:334, 335
  - energy coupling by mechanical rotation 11:338–344
- $\gamma$ -subunit rotation
  - mutational analysis of 11:342–344
- subunit  $\gamma$ -rotation 11:340–342
- subunit vaccine 6:298
- subventricular zone 13:410ff
- succinyl-CoA 8:227
- sudden infant death syndrome (SIDS) 11:667
- sugar
  - modifications of 9:421–422
- sugar chain
  - as antigenic determinants 2:288
  - N-linked 5:540ff
  - O-linked 5:540ff, 562
- sugar-phosphate backbone 3:533
- Su(H) 12:183
- suicide gene therapy 15:266
- suicide inhibitors 11:120
- sulcus limitans 2:94
- sulfamethazine 2:64
- sulfatide 13:322
- sulfation 6:114
- sulfide 10:9
- sulfite 8:228
- sulfite oxidase 8:227, 228
- sulfite oxidase and NADH-cytochrome b<sub>5</sub> reductase 8:177
- sulfonamide antibiotics 14:50
- sulfonylurea receptor/channel 11:698

- sulfotransferase 2:53, 63, 5:549, 10:201
- sum of squared deviations 11:391
- sumoylation 14:268
- sun 13:237
- super shift 3:545
- superantigens (SAGs) 13:639
- supercoiled pDNA 10:228
- superconducting magnets 13:527
- SUPERMAN 14:267
- supermolecular complex 12:328
- supermolecular protein complexes 13:653–657, 666–668
  - biological applications 13:658–665
- supernova 10:3
- superoxide 7:166, 8:210ff, 211
- superoxide anion 7:49ff, 8:221ff, 446
- superoxide dismutase (SOD) 4:639ff, 5:496, 7:171, 8:210ff, 213ff, 219, 220–222, 227, 231, 11:62
  - FAs 7:106
- superoxide dismutase 1 (SOD1) 8:542, 544
- superoxide radical 4:636ff, 5:494
- supervised
  - modeling 3:608
- supF mutation reporter 5:194
- support machines 9:263
- support vector machines (SVM) 3:610
- supporting (sustentacular) cell 12:643
- suppressor 2:638
  - amber 11:51
  - four base 11:65
- suppressor frameshift 11:50
- suppressor genes 9:96
- suppressor mutation 5:373, 400
- suppressor of fused (Su(Fu)) 12:179
- suppressor tRNA 2:456
- suppressor-mutator (Spm),
  - see* enhancer/inhibitor
- Suprachiasmatic nuclei (SCN) 12:433ff
- supramolecular complexes 9:46
  - architectural characteristics of 13:655–656
  - motional characteristics of 13:655–656
  - multilength scales 13:656–665
  - multiresolution 13:656–665
  - refining at multiresolution 13:665–667
  - refining multilength scales 13:665–667
- supramolecular protein complexes 13:655
- supramolecular structure 9:20, 39
- supramolecular structures 9:35
- supraoptic nuclei 4:404
- surface display 8:415
- surface plasmon resonance (SPR) 3:522, 551, 9:28, 11:119, 404

- surface-enhanced laser desorption–ionization,  
*see* SELDI  
 surprisal 10:467–468  
 surrogate haplotypes 13:195  
 surveillance, epidemiology, and end results  
 (SEER) program 9:100  
 survival factors 14:452  
 survival motoneuron (SMN1) 8:563  
 susceptibility 4:17  
 susceptibility genes 1:188  
 SV40 12:348  
 SV40 DNA 4:93, 100  
 SV40 virus 4:194  
 sweat chloride test 11:687  
 Swi6 14:237ff  
 swine 1:227  
 SWI(SNF) 12:156ff, 194  
 SW12/SNF2 chromatin-remodeling  
 14:268  
 Swyer syndrome 5:629  
 SYBR Green I 11:489ff  
 Sybyl 3:606  
 symbionts 6:229  
 symbiosis islands 6:230  
 symbiotic associations 5:346  
 symbol, one-letter 3:244  
 symmetric division 13:331, 340  
 symmetry 7:395  
 sympatric 14:5  
 symport 8:153  
 synapse 4:307ff, 8:230, 11:675  
   asymmetric 9:143  
   postsynaptic 9:143  
   presynaptic 9:142  
   symmetric 9:143  
 synaptic 5:404, 12:407–410  
 synaptic cleft 11:667  
 synaptic overgrowth 4:609  
 synaptic plasticity 4:620, 14:459  
 synaptic transmission 4:308ff, 11:668  
 synaptic transmission neuronal  
   circuit-potential of  
   plasticity 2:119–120  
 synaptic vesicles 4:308, 8:132, 11:667  
   docking 9:146ff  
     nsec1/Munc13 9:147ff  
     RIM1 9:147  
     SNAP-25 9:147  
     SNAREs 9:147ff  
     synaptobrevin 9:147  
     syntaxin 9:147  
     VAMP 9:147  
     v-SNARE 9:147  
   priming 9:146ff  
   recycling/endocytosis 9:146ff  
     AP-2 and AP180 9:148  
     clathrin-mediated endocytosis 9:148  
     kiss and run endocytosis 9:148  
     SNARE 9:148  
   reloading 9:146ff  
   triggering/exocytosis 9:146ff  
     Rab3A 9:148  
     rabphilin 9:148  
     synaptotagmin 9:147ff  
 synaptobrevin 8:230  
 synaptonemes 14:6  
 synaptoneuroosomes 4:600  
 synaptosomal-associated protein 8:230  
 synaptotagmin 4:320f  
   membrane protein of synaptic vesicles  
   11:92  
   phospholipid binding 11:93  
 synaptotagmin and complexin  
   regulators of Ca<sup>2+</sup>-dependent exocytosis  
   11:92  
 synchrotron beam fluctuations 13:687  
 synchrotron FTIR microspectroscopy 13:690,  
   694  
 synchrotron FTIR spectroscopy 13:695  
 synchrotron infrared 13:674, 676, 677  
 synchrotron infrared beam 13:679  
 synchrotron infrared light 13:676, 689  
 synchrotron infrared microspectroscopy  
   13:673, 688, 695  
 synchrotron infrared radiation 13:678  
 synchrotron radiation 3:66, 13:674, 676  
 synchrotron source 13:678  
 synchrotrons 13:676  
 syncytin 1:296ff  
   retrovirus 1:296  
 syndecans 8:60  
 syneresis 4:505  
 synergistic actions 14:50  
 synergistic effects 14:50  
 synergy 8:451  
 synexins 1:242  
 syn-expression 12:45  
 syngamy 14:1–25  
 synonymous mutations 12:118–119  
 synpolydactyly (SPD) 15:48  
 syntaxin 4:313ff, 8:230  
 synteny 4:335, 7:481, 11:372–374ff,  
   14:256  
   conservation 11:372  
   ecore 11:374  
   gene order 11:373  
   Hox complexes 11:374  
   X chromosome 11:374

- $\sigma^{32}$  synthesis
    - control of 13:468
  - synthesis during the division cycle 1:531
  - synthetic androgens 13:22
  - synthetic biology 14:143
  - synthetic chemistry 14:166
  - synthetic cholesterol 7:305
  - synthetic dyes 15:76
  - synthetic nonpeptide oligomer or small molecule libraries 10:151
    - basic principle 10:152
    - permutations 10:152
    - subunits 10:152
  - synthetic oligoribonucleotides 9:326
  - synthetic peptide
    - biology 14:91–119
    - chemistry 14:91–119
    - drug design 14:91–119
  - synthetic peptide libraries
    - cyclization 10:150
    - direct binding assays 10:151
    - direct functional assays 10:151
    - mixed synthesis 10:150
    - solution-phase assay 10:151
    - split-mix synthesis 10:150
    - synthesis and screening 10:149–151
  - synthetic peptides 14:93
  - synuclein 4:340
  - system 2:455, 14:126
    - biological systems 14:128, 130
    - complex systems 14:129
    - dynamics 14:128
    - organization 14:129
    - structure 14:127, 131
  - systematic conformational searching 2:28
  - systematic evolution of ligands by exponential enrichment (SELEX) 11:106
  - systemic acquired resistance (SAR) 10:375
  - systemic glycobiology 2:297
  - systemic inflammatory response syndrome (SIRS) 6:412
  - systemic injections 7:300ff
  - systemic lupus 1:477
  - systemic lupus erythematosus (SLE) 1:464, 8:453, 15:413
  - systemic RNAi 9:54, 64
  - systems biology 7:118, 10:533, 14:125
  - systems biology markup language (SBML) 9:510
  - systems biology workbench 14:142
  - systems engineering 14:125
  - systems theory 14:126, 127
  - systems thinking 14:126
  - systeme project 14:144
- t**
    - T cell activation 1:371, 385, 2:311–313
      - effector T cell 1:373
    - T cell priming 1:395
    - $\gamma\delta$ T cells 10:93
    - T cells 1:372, 381, 385, 392, 462, 2:293, 4:343, 5:555, 6:340, 341, 13:118, 124, 639
      - CD4<sup>+</sup> 1:371, 375, 379, 383, 395, 396, 15:555
      - CD8<sup>+</sup> 1:371, 375, 378, 394–396
      - cytotoxic 1:359, 367, 3:164, 178
      - helper 1:359, 3:178
      - naive 1:358
      - priming 1:395
    - T cytolytic 1 (Tc1) cells 10:86
    - T helper cell polarization 1:396, 397
    - T helper cells 6:340, 346
      - T<sub>H2</sub> 1:379
      - T<sub>H1</sub> cells 1:379, 10:86
    - T lymphocytes 3:117, 118, 14:48
    - tachykinin neuropeptide substance 12:309
    - tacrolimus 14:374–375
    - Tag 12:348
    - Tag1 14:260
    - TAG hydrolase [TGH] 14:673
    - TAL 11:692
    - TALE homeobox genes 6:182ff
    - talin 2:337ff
    - tal-1/SCL 2:228
    - tamoxifen 4:336
    - TAMRA 11:489ff
    - tandem 6:580
    - tandem affinity purification (TAP) 6:602, 8:33
    - tandem mass spectrometry, *see* MS/MS
    - tandem repeat 1:253, 254ff, 256, 257, 260
      - microsatellite 1:253ff
      - minisatellite 1:253ff
      - satellite DNA 1:254
      - simple sequence repeat 1:256ff
      - subtelomeric repeat 1:260ff
      - telomeric repeats 1:257ff
      - variable number of tandem repeat 1:256ff
        - see also* repetitive element; satellite DNA
    - tangier disease 5:216, 226, 7:214
    - tangles 1:183
    - TAP 6:436, 8:33–35
    - TAP method 12:105
    - Tapasin 1:370
    - Taq polymerase 9:399, 11:486ff
    - Taqman<sup>®</sup> 11:496ff
    - target confidence building 11:617
    - target delivery 7:300ff, 8:424
    - target of a specific trace element–containing therapeutic or sequestering agent 8:352
    - target proteins 8:412, 11:104

- target tissue 7:301ff  
target validation 8:84, 89, 422, 426, 11:615, 617  
target-accelerated synthesis 8:96  
targeted cancer therapy 6:499  
targeted gene disruptions 14:261  
targeted induced local lesions in genomes (TILLING) 14:261, 15:610ff  
targeted molecular dynamics (TMD) 13:657  
targeted therapies 6:498  
  era of 9:520  
  genomic approaches to 14:151–158  
  integrated clinical strategies for 14:156  
  integrative approaches to 14:157–158  
  molecular basis 14:152  
  opportunities of 9:520–544  
  principals of 14:152–154  
  technological approaches to 14:156–158  
  threats of 9:520–525  
targeted, transduction 15:252  
targeting 1:440, 15:266  
  challenges for 14:167  
  opportunities for 14:177–185  
targeting enzymatic cascades 14:154  
targeting moiety  
  specificity of 6:519–520  
targeting sequence 11:288  
target-primed reverse transcription 1:254ff,  
  264, *see also* long interspersed repeat element  
targets for drug therapy 11:699  
target-site location 12:328  
tartaric acid 2:592  
 $\mu$ -TAS  
  principle of 14:423–428  
TAS 14:231ff  
Tas3 14:238  
TAS rearrangement 14:234ff  
T-associated sex reversal  
  in mouse 5:631  
Tat 11:302, 15:140  
TAT protein 8:153  
Tat Response Element (TAR) 1:107  
TATA box 2:624, 12:26  
TATA-binding protein (TBP) 8:247, 10:315,  
  15:25  
Tau 12:417  
tau 1:183, 4:339  
  biological role 1:193  
  hyperphosphorylation 1:193  
  isoforms 1:193  
tautomeric equilibria 13:541  
tautomerization 13:541  
taxa-4(20) 1:426  
taxadiene synthase 1:425  
taxane 1:415ff  
taxane immunoassay 1:430  
taxol 1:415ff, 10:659, 13:531, 539  
  extraction 1:423  
Taxol™ biosynthesis 1:424  
Taxotere™ 1:428  
taxus 1:416ff  
Tay–Sachs disease 6:325  
  in French Canadians 6:332–333  
taz1 14:230ff  
T-box family 13:295  
TBP-associated factors (TAFs) 15:26  
TCA cycle 8:173  
T-cell effector cytokine 13:133  
T-cell factor (TCF)-4 6:19  
T-cell growth factor (TCGF) 3:119  
T-cell helper 1 6:14  
T-cell mediated immunity  
  mechanisms of 6:353–354  
T-cell memory 6:355  
  CD8+ 6:388–396  
T-cell proliferation 6:480  
  control of 6:436–437  
T-cell receptor (TCR) 1:361, 373, 374, 6:345,  
  386, 393, 407, 430–432, 12:688, 13:639  
  binding to the 13:645  
T-cell responses 15:125  
T-cell zones 1:382  
TCF-4 2:230  
TCIRG1 11:697  
TCP-1 2:497  
TCP domain transcription factors 14:265  
TCR 2:293, 14:454  
TCR binding sites 13:645  
T-cycles 12:454, 468  
T-dependent (TD) 2:279, 280  
T-DNA 14:259ff  
T4 DNA ligase 3:403ff  
T-DNA (transfer DNA) 14:258  
TEAA 9:299  
Tead2(TEF-4) 10:487  
tears 8:449  
technique  
  polymerase chain reaction (PCR) 5:415  
  Southern hybridization 5:415  
  spot cloning 5:436  
techniques for single molecule studies 9:270  
TED3 13:620  
teleonomic 14:128  
telomerase 2:201, 5:499, 6:6, 12:26,  
  14:205–206, 218, 230ff, 254  
  biochemistry 14:207–217  
  cancer 14:219–222  
  catalytic activity of 14:208–210  
  components of 14:210–217

- telomerase (*continued*)  
 functional sites of 14:208–210  
 human disease 14:219–223  
 protein component 14:213–215  
 RNA component of 14:210–212  
 RNA-dependent DNA polymerase  
 14:207–208
- telomerase activation 6:3, 8, 23, 14:222
- telomerase assays  
 biochemical assays 14:217–219  
 expression assays 14:219  
 standard assay 14:217
- telomerase primer 14:206
- telomerase protein (TERT) 14:213
- telomerase reverse transcriptase (hTERT)  
 6:6
- telomerase-associated proteins 14:215–217
- telomere clustering 14:231ff  
 meiotic prophase 14:231  
 SPB 14:231
- telomere fusion 14:232
- telomere maintenance 14:207
- telomere reduction 6:23
- telomere shortening 5:498
- telomere silencing 14:231ff  
 chromatin structure 14:231
- telomeres 2:624, 3:21, 46, 5:377, 6:139ff, 386,  
 11:441–443, 12:26, 14:206, 207, 216, 219  
 bridge-breakage-fusion 9:11  
 dicentric chromosome 9:11  
 telomerase 9:11
- telomeric repeat 1:257, 9:354, 14:229ff
- temperature 1:430  
 fully denaturing 9:303  
 nondenaturing mode 9:303  
 partially denaturing 9:303
- temperature compensation 12:417, 421ff, 431,  
 454
- temperature factor  
 atomic scattering factor *f* 7:422  
 thermal motion of the atoms  
 anisotropic temperature factors 7:422  
 isotropic temperature factor 7:422
- temperature shift 1:430
- temperature studies 4:657
- template domain 14:208
- template-directed synthesis 10:23
- Templeton, Alan 8:525
- TEMPO 13:595
- temporal lobe epilepsy 11:683
- temporal variation 1:546
- tendamistat 13:543
- tenecteplase 10:218
- Teniposide 14:344–347
- tension 14:409–410
- Teprotide 14:360–361
- teratocarcinoma 13:340, 347
- teratocarcinoma cell transfer 1:212
- teratoma 13:402
- terephthalamides 13:562
- terminal duct cells 13:345
- terminase 9:352, 355
- termination 2:453
- termination codons 2:454
- terminator  
 human prepro-parathyroid hormone (PTH)  
 9:402
- terminus 1:527
- ternary complex models 11:606
- territorial stroke syndromes 10:119
- TERT 14:206
- tertiary interaction 12:621
- tertiary structure 12:515, 14:95
- test gene set 13:103
- test set 3:612
- testicular feminization 13:24
- testis-determining gene 5:608  
 Bkm Satellite DNA 5:611–612  
 H-Y antigen gene (HYA) 5:610–611  
 zinc finger Y gene (ZFY) 5:612–615
- Testlac 13:26
- testosterone 13:3, 4, 23, 29, 42
- testosterone cypionate 13:23
- testosterone enanthate 13:23
- testosterone gel 13:23
- testosterone metabolism 13:13
- testosterone transdermal 13:23
- tetanus 8:230
- tetanus toxin 8:229
- tethering molecules  
 COG complex 8:131  
 EEA1 8:131  
 GARP complex 8:131  
 quatrefoil complexes 8:131  
 Uso1 8:131
- Tet-On 4:599
- tetrabutylammonium bromide 9:327
- tetracycline 4:336
- tetrad 2:622
- tetrahydrobiopterin 8:217–219
- tetrahydrofolate 8:227
- tetrahydrogestrinone 13:33, 36
- tetrameric enzymes 12:331
- tetramers 12:327
- tetraodontidae 11:366ff  
 canthigastrinae 11:364ff  
 cariotetraodon, chonerhinos 11:364  
 diodontidae 11:366

- tetraodon 11:364  
 tetraodontinae 11:364ff  
 tetraodotoxin 11:365ff  
 tetraploid 14:507, 527  
 tetraploid embryo aggregation 12:105  
 tetraploid embryo complementation 9:205, 214  
 tetrasodium EDTA 9:303  
 tetraspan microdomains 1:395  
 tetraspan network  
   CD9 1:371  
   CD37 1:371  
   CD53 1:371  
   CD63 1:371  
   CD81 1:371  
   CD82 1:371  
   T-cell activation 1:371  
   tetraspanins 1:371  
 tetraspanin 1:371, 382, 389, 395, 2:340, 13:283  
 tetrodotoxin 11:659  
 text mining 6:604  
 TFA-HPLC 8:32  
 Tfb1 3:438  
 Tfb2 3:438  
 Tfb3 3:438  
 Tfb4 3:438  
 TFIIF 3:437ff  
   aging 1:70  
 T-flask 7:546  
 TGA family of transcription factors 14:262  
 TGF $\alpha$  6:6, 16, 17, 22, 9:455  
 TGF $\beta$  1:380, 6:16, 17, 22, 23, 8:443–446, 10:125, 11:589, 12:172ff, 15:208, 216, 217, 264  
 TGF- $\beta$  family 14:296ff  
 TGF- $\beta$ , heparin binding (HB)-EGF 6:3  
 TGF $\beta$ , IGF II 6:16  
 TGF $\beta$  receptor 6:11, 11:587, 588  
 TGF- $\beta$  signal transduction pathway 6:20  
 TGF $\beta$  signaling pathway 6:12  
 TGF- $\beta$  superfamily receptors 4:396ff  
 TGF $\beta$  type II receptor 6:21  
 TGFR 12:172  
 TGIF 6:215  
 TH1 8:455, 11:111  
 TH2 8:443, 11:111  
 Th cells (CD4+) 6:353–354  
 Thalassemia 6:96  
 Thale Cress, *see Arabidopsis thaliana*  
 Thalidomide 2:602  
 Th1 and Th2 cytokines 8:443  
 T<sub>H1</sub> cells 1:379, 380  
 T<sub>H2</sub> cells 1:379, 380  
 Th1 cells 6:340, 351  
 Th2 cells 6:340, 351  
 thecal cell 4:391ff  
 theodicy 5:349  
 theory of molecular evolution 5:335, 346, 347  
 therapeutic agents  
   small molecules 14:154–155  
   used in targeted approaches 14:154–156  
 therapeutic angiogenesis 14:284ff  
 therapeutic antibodies 14:155  
 therapeutic approaches 1:201  
 therapeutic cloning 3:296, 13:396  
 therapeutic compounds in nature  
   as leads for new pharmaceuticals 14:323–381  
 therapeutic DNA  
   nucleus localizing sequences 15:494  
 therapeutic gene or DNA-sequence 15:487  
 therapeutic gene transfer  
   regularly repeated 15:498  
 therapeutic index 2:64, 11:596  
 therapeutic options 4:619  
 therapies based on virus–cell interactions  
   inhibition of assembly 15:473  
   inhibition of viral gene expression 15:472  
   interferons 15:471  
   virus entry 15:471  
   viruses as therapeutic agents 15:474  
 therapy 2:172, 174  
   cyclooxygenase 2 (COX-2) inhibitors 14:48  
   immune modifying drugs  
     gold salts 14:48  
     methotrexate 14:48  
     penicillamine 14:48  
     steroids 14:48  
   TNF blockers 14:48  
   immunosuppressant 14:48  
   nonsteroidal anti-inflammatory drugs (NSAIDs) 14:48  
 therapy strategies  
   amiloride 8:635  
   antibiotic therapy 8:636  
   anti-inflammatory and mucolytic drugs 8:636  
   anti-staphylococcal treatment 8:636  
   chaperones 8:635  
   gene replacement therapy 8:634  
   genistein 8:635  
   high-throughput screening 8:635  
   hygienic measures 8:636  
   ibuprofen 8:636  
   inhaled steroids 8:636  
   liver 8:637  
   microspheric pancreatic enzyme preparations 8:637  
   nutrition 8:637

- therapy strategies (*continued*)
- pancreatic insufficiency 8:637
  - pharmacological chaperones 8:635
  - pharmacological treatment of CFTR 8:634
  - prednisone 8:636
  - prevention of infection 8:635
  - separation regimes 8:636
  - transplantation 8:637
  - treatment of infection 8:636
  - UTP 8:635
  - vaccination 8:636
- thermal motion 4:5
- Thermal Optimization 9:561
- thermal processing 4:514–515
- thermally induced mutagens 4:515
- thermodynamic constants 13:557
- thermogenesis 8:183
- thermolabile intermediate 1:41
- thermoplastic membrane 3:41
- thermoplastic polymer membrane 3:41
- thermoregulation 13:231–232
- thermoregulatory 13:231
- Thermus thermophilus* 9:561
- thiamine 15:542
- thiamine pyrophosphate (TPP) 9:572, 573–575
- thiazide 11:693
- thiazolidenediones 7:37ff
- thiazolidine 11:115
- thioester 11:115
- $\beta$ -thiogalactoside transacetylase 12:27
- thioglycollate medium 1:509
- thiol 11:108
- thiomesterone 13:37
- thiopurine S-methyltransferase 10:201
- thioredoxin 4:364, 639, 8:184
- thioredoxin reductase 4:639
- Thomsen myotonia 11:672
- T<sub>H1</sub> phenotype 1:397
- T<sub>H2</sub> phenotype 1:397
- threat of bioterrorism
- global preparedness 10:523–525
- three-dimensional cell culture
- function regulation 14:383
- three-dimensional (3-D) cell culture
- biochemical signaling 14:385–392
  - cell shape 14:385–392
  - tissue structure 14:385–392
- three-dimensional diffusion 3:538
- three-dimensional growth 2:304ff
- three-dimensional memories 9:561
- three-dimensional structure 11:216, 13:548
- ab initio protein fold prediction 11:207
  - accessibility 11:223
  - alpha helices 11:205, 223
  - alpha-helix caps, beta-bulges, conserved turns 11:210
  - beta-sheet 11:225
  - beta-strands 11:205
  - Chothia and Lesk 11:224
  - designability 11:227
  - domains 11:206
  - fibrous proteins 11:206
  - folding kinetics 11:227
  - globin 11:207
  - globular structure 11:205, 210
  - helix packing 11:223
  - helix-turn-helix motifs 11:207
  - hydrophilic 11:223
  - hydrophobic 11:223, 224
  - insulin 11:207
  - isomers 11:224
  - NMR 11:205
  - oligomeric state 11:225
  - protein data bank (PDB) 11:205
  - secondary structures 11:225
  - structural features 11:210
  - structural similarity 11:210
  - superposing 11:224
  - TIM-barrels 11:207
  - unstructured or disordered proteins 11:206
  - X-ray crystallography 11:205
- three-point attachment model 2:608
- threshold 11:483ff, 514ff, 668
- Th1 response 15:263
- Th2 response 15:263
- thrombin–rhodniin complex 7:455
- thrombomodulin 5:559
- thrombosis 5:216, 7:51
- thrombospondin 8:48, 55, 58, 63, 67, 15:216, 221
- thromboxane synthase 8:218
- Thudichum 10:287
- thylakoid 2:631ff
- thymic leukemia (TL) antigen 6:390
- thymidine kinase 5:297
- thymus 1:371, 387, 14:47
- thyroid hormones 13:543
- thyroid peroxidase 4:638
- thyroid tumors 15:341
- thyroid-stimulating hormone (TSH) 14:107
- thyrotrope 4:389
- thyrotropin (TSH) 5:553, 14:111
- thyrotropin-releasing hormone (TRH) 14:117
- thyroxine 13:543
- TIA 10:135
- TIC 11:297
- Tie2 15:206, 210, 215, 216

- tie 15:215
- tight junction 4:201, 279ff, 11:685, 13:283  
 assembly/disassembly 2:366  
 formation 2:367  
 freeze fracture 2:362  
 PKC isoforms 2:367  
 transepithelial electrical resistance 2:362  
 ultrastructure 2:362  
 ZO-proteins 4:280
- TIGR 3:48
- TILLING, *see* targeted induced local lesions in genomes
- TIM22 11:295
- TIM23 11:295
- time constant 11:402
- time imaging 7:167
- time-of-flight 8:25
- time-of-flight mass spectrometer (TOFMS)  
 3:50, 7:588, 590–592, 8:8, 25, 11:317
- timing of CGG-repeat expansion 4:615
- TIMPS (tissue inhibitors of metalloproteinases)  
 4:406
- TIN2 14:236
- T-independent antigens 2:280  
 capsular polysaccharides 2:281  
 exopolysaccharides 2:281
- T-independent (TI) 2:279
- TIP47 14:644
- TIR Domain 7:2, 6
- TIR domain-containing adaptor molecules  
 MyD88 7:11  
 Sterile  $\alpha$  and HEAT-Armadillo motifs (SARM) 7:12  
 TIRAP/Mal 7:12  
 TRAM/TICAM-2 7:12  
 TRIF/TICAM-1 7:11–12
- TIRF (total internal reflection fluorescence-excitation) 9:274
- tissue acidosis 10:123
- tissue architecture 12:184ff
- tissue biopsy 14:399
- tissue cells 6:347
- tissue culture 3:277
- tissue determination 13:334
- tissue macrophages 13:230, 241
- tissue microarrays 11:110
- tissue morphogenesis 14:388
- tissue plasminogen activator (tPA) 10:127, 14:112
- tissue progenitor cell 13:340
- tissue remodeling 1:380
- tissue tropism 14:198
- tissue-determined stem cells 13:340
- tissue-extrinsic factor 12:90
- tissue-specific promoters 15:254, 335  
 development of 15:488
- titin  
 force spectroscopy on 9:277–278  
 titration analysis 13:530
- TLR signaling pathway 7:10  
 IRAK family 7:12–13  
 TAB1 7:13–14  
 TAB2 7:13–14  
 TAB3 7:13–14  
 TAK1 7:13–14  
 TNF receptor-associated factor 6 (TRAF6)  
 7:13
- TLRs, *see also* toll-like receptors
- Tlx 6:201
- T-lymphocyte protein-tyrosine kinase (LCK)  
 7:137
- $T_m$  11:504ff
- $T_M$  3:188
- TMA, Transcription-mediated Amplification  
 6:559
- TNF 8:442, 444, 447, 451–453, 455, *see also*  
 tumor necrosis factor receptor
- TNF $\alpha$  1:378, 379, 392, 6:14, 8:445, 449, 10:125, 128, 14:449
- TNF block 13:202
- TNF blockers  
 etanercept or infliximab 14:48
- TNF- $\alpha$  family 5:231–232
- TNF receptor 1:379, 10:125, 11:587
- TNF receptor-associated factor 6 (TRAF6) 7:13
- TNF region  
 stretch of fixed DNA 13:211
- TNF superfamily 8:437
- TNFR, *see* tumor necrosis factor receptor
- Tobacco mosaic virus* 10:364, 394  
 nucleation of 9:365  
 particle 9:365
- tobacco mosaic virus RNA 4:97
- TOC 11:297
- $\alpha$ -tocopherol 4:640  
 atherogenesis 15:514–515  
 binding to erythrocyte membranes 15:514  
 in cell signaling 15:514
- tocopherols 15:513
- tocotrienols 15:513
- TOCSY 13:531, 532, 590
- Todaro, George 8:523
- Tokuyasu method  
 cryosectionery 4:37
- TolC, *E. coli* 8:150
- tolerance 3:221, 6:467, 472, 8:606ff, 609
- toll-like receptor (TLR) pathway 7:3



- toll-like receptors (TLRs) 1:376, 386, 393, 396, 6:414, 415–419, 7:2, 5, 8:440, 450, 10:86, 90, 184, 14:452  
 TLR1 7:7  
 TLR2 1:377, 391, 7:7  
 TLR3 1:378, 391, 7:7  
 TLR4 1:377, 391, 7:7  
 TLR5 1:378, 7:8f  
 TLR6 7:7  
 TLR7 7:9  
 TLR8 7:9  
 TLR9 1:378, 391, 7:9  
 TLR11 7:9–10
- TOM (outer membrane general import pathway) 8:360, 379, 11:295  
 tomography 4:58
- TOP mRNAs 12:179
- topa quinone 8:221
- top-down modeling 14:135
- topoisomerases 1:64, 2:627  
 aging 1:63  
 topoisomerases 1:63
- top-to-bottom strategy 2:567
- Tor 12:178ff
- torsion 12:609, 610, 612
- total cholesterol assay 7:283–284
- totipotent 13:334
- totipotent stem cells 13:334
- touch genes 2:167
- toxic channelopathies 11:659
- toxic shock syndrome (TSS) 13:639
- toxicity 4:336
- toxicity testing 2:533
- toxicology 4:335, 8:191, 203
- toxicoproteomics 11:313
- toxin moiety  
 plant toxins 6:503–504
- toxins 10:366, 367, 369, 371, 11:659, 13:319
- Toxoplasma  
 vaccine 15:160
- TP 7:101
- t-PA 10:218, 219, 223, 224
- T1 phage-resistant cells 5:316
- TPR (tetratricopeptide) repeats 2:635
- T7 promoter 11:501
- TR 14:206
- Tr1 8:443
- trace element micronutrient 8:344, 350
- trace elements 8:345
- tracheal system 4:290
- trade secrets 7:374
- trademarks 7:371
- training data sets 13:102
- training set 3:612
- trans activating factor 1:436
- trans heterozygote 5:375
- trans-acting factors 10:309, 315
- trans-acting splicing regulators 1:148–151
- transcellular 3:622
- transcellular pathway 11:685
- trans-cleaving ribozymes  
 undesired RNA, destruction of 10:248
- transcript densities 5:60
- transcript processing 10:309, 335
- transcription 1:413ff, 3:533ff, 538, 5:386, 6:142, 147, 152, 9:353, 356, 10:308, 312, 11:121, 13:19, 15:332, 333, 506, 518  
 promoter 1:413
- transcription activators 5:503
- transcription bubble 8:591
- transcription control regions 9:258
- transcription coupled repair (TCR) 1:56, 9:391
- transcription DNA repair 9:284–285
- transcription dysregulation 15:13ff
- transcription enhancer factor 4 (TEF4) 10:296
- transcription factor 1:2, 13, 436, 3:271, 450, 461, 5:397, 506, 6:186ff, 579, 7:506, 11:122, 12:100, 406, 14:266, 15:399, 506, 520  
 AP1 7:508  
 binding sites 9:257  
 CREB 7:508  
 CREM 7:508  
 Ets, Elk, Jun, Fos, CREB 7:124  
 Oct-4 7:508  
 SP1 7:508  
 ZFY 7:508
- transcription factor II H  
 aging 1:70  
 nucleotide excision repair (NER) 1:70
- transcription factor recognition sequences 15:254
- transcription factories 2:404  
 GFP-PCNA 2:406  
 laser scanning confocal microscope 2:405  
 nucleoskeleton 2:405  
 S-phase program 2:406, 407  
 transcription 2:405  
 transcription cycle 2:405
- transcription initiation 3:463–465  
 by addition of GMP 9:403
- transcription initiation complex  
 assembly of 10:315–316
- transcription interference 15:11ff
- transcription rate assays 12:573
- transcription unit 3:466  
 bacterial 3:467  
 eukaryotic 3:467–469
- transcriptional autoregulation 10:423

- transcriptional complexes 12:102  
transcriptional control 15:254  
transcriptional gene silencing (TGS) 14:268  
transcriptional network 5:503  
transcriptional regulation 8:346, 12:100  
transcriptional regulation of  
  odor receptor genes 12:683–690  
transcriptional sequencing 9:406  
  based on the chain termination method  
  9:398  
  direct sequencing without purification  
  9:408  
  promoter 9:398  
  standard protocol 9:407  
transcriptional slippage 9:402  
transcriptional targeting 15:332, 334, 343–345  
  brain tumors 15:340–341  
  breast cancer 15:338–339  
  gastrointestinal cancers 15:335–336  
  gynecological cancers 15:340  
  hepatocellular carcinoma 15:336  
  lung cancers 15:337–338  
  malignant melanoma 15:341–342  
  mesothelioma 15:337–338  
  normal tissue 15:342  
  pancreas 15:336–337  
  pancreatic carcinoma 15:336–337  
  thyroid tumors 15:341  
  urological cancers 15:339–340  
  with adaptor molecule 15:351  
transcription-mediated amplification (TMA)  
6:559  
transcriptome 3:533, 643, 9:250, 10:532ff,  
  11:311, 326, 12:100, 101, 708, 714ff, 717–721ff  
transcriptome analysis 3:644  
transcytosis 4:200, 202, 8:155  
transdetection 15:70  
transdifferentiation 3:272, 13:341, 366  
transducin 11:574, 576, 13:154  
transduction 3:223, 10:31, 34  
  bacteriophage 6:229  
  generalized 6:229  
  specialized 6:229  
transduction proteins 14:108  
transductional targeting 15:332, 345–346,  
  349–350  
  adaptor molecules 15:347–348  
trans-endothelial migration 1:391  
transepithelial flow 11:686  
transepithelial gradients 11:686  
transepithelial transport 11:686  
TRANSFAC 9:260, 12:103  
transfection 7:548, 9:45  
transfer effect 1:428  
transfer RNA, *see* tRNA  
transferred NOE 13:547, *see also* TrNOE  
transferrin 4:198  
transferrin receptor (TfR) 1:344, 4:198, 8:129,  
  349  
transformation 2:634, 3:326, 337, 394ff, 416,  
  5:343, 6:181ff, 14:259  
  competence 6:227  
  homeotic 6:181  
transformation/transformant 13:439ff  
  protoplast 13:439  
transforming growth factor  $\beta$  (TGF $\beta$ ) 1:380,  
  4:389ff, 8:438, 10:106, 15:203  
  effects of monocytes/macrophages 6:470  
  effects on dendritic cells (DCs) 6:472  
  effects on NK and lymphokine activated killer  
  (LAK) activity 6:472  
  effects on T lymphocytes 6:470–472  
  inhibition of 6:473–474  
  sources of 6:469–472  
transforming growth factor (TGF- $\beta$ ) family  
5:648–649  
transgene 3:47, 5:617, 6:386, 14:474, 507, 511,  
  15:235  
  design of 14:513–518  
  expression of 14:485  
  gain-of-function 14:477–479  
  germ line transmission 1:211  
  inheritance of 14:485  
  loss-of-function 14:480  
  mRNA expression 1:210  
  origin of 14:513–515  
  protein expression 1:210  
  reporter-function 14:479  
  species-specific 1:235  
  structure of 14:513–515  
  targeted integration of 14:536  
  transgene integration 1:209  
  types of 14:477–480  
transgene and/or transgene integration  
  mosaicism 1:219  
transgene donor 14:514  
transgene expression 14:485  
  immunoblotting 1:233  
  mRNA 1:232  
  Northern blot 1:233  
  phenotypic screening 1:232  
  protein 1:232  
  protein expression 1:233  
  reverse transcription-PCR (RT-PCR) 1:233  
  RNA slot-blot 1:232  
transgene integration  
  germ-line 1:218  
  mosaicism 1:217, 229

- transgene integration (*continued*)
  - pattern of 14:484–485
  - PCR 1:231
  - Southern blot 1:231
- transgene recipient 14:514
- transgenesis
  - basics of 14:513–521
  - biotechnological procedures in 14:518–521
  - developments in 14:511–512
  - pronuclear injection 14:518
  - rates of integration 15:616
  - refinements of 14:527–536
  - regulatory elements of 14:515–518
  - stable expression 15:616
  - technology of 14:513–521
  - transient expression 15:616
- transgenic 1:476, 4:332, 369, 370, 5:498, 8:350, 10:386, 387, 12:216, 425, 439, 450, 456ff
  - HD 11:376
  - isotocin 11:376
  - oxytocin 11:376
  - Wt1 genes 11:376
- transgenic animal 1:209, 2:43, 7:368, 379, 380
  - commercialization 1:214
  - efficiency 1:229
  - environmental impact 1:214
  - heritability 1:211
  - homozygous 1:231
  - transgenic founder 1:211
  - transgenic line 1:211
  - transmitochondrial animals 1:222
- transgenic domestic animals 1:223
- transgenic fish 14:473–483, 497–498
  - application of 14:485–496
  - as environmental biomonitorers 14:494–496
  - characterization of 14:484–485
  - examples of 14:496
  - growth hormone 14:492
  - human disease modeling 14:490–492
  - identification of 14:484
  - in basic research 14:486–492
  - signaling pathways 14:489–490
  - vertebrate developmental biology 14:487–488
  - with different body color 14:493–494
  - with resistance to pathogen infection 14:492–493
- transgenic mice 1:213, 215, 598, 3:568
  - in biomedical research 14:505–542
- transgenic mosquitoes 7:489
- transgenic mouse models 1:195ff
  - apolipoprotein E transgenic mice 1:198
  - APP transgenic mice 1:195
  - presenilin 1/2 transgenic mice 1:196ff
  - tau transgenic mice 1:197ff
  - transgenic crosses 1:198ff
- transgenic mutant SOD1 mice 8:547–549
- transgenic mutant SOD1 rats 8:547–549
- transgenic plant 2:44, 8:608ff, 10:657
- transgenic rats 1:223
- transglycosylation activity 5:541
- trans-Golgi network (TGN) 8:121, 11:80
- transient amplifying cell 13:223
- transient ischemic attack 10:135
- transit peptide 2:631
- transit-amplifying cells 13:342, 345
- transition 5:373, 399
- transition dipole moment 3:58
- transition proteins 7:505
- transition state 6:156, 164
- transition-state analogs 2:20
- transition-state stabilization 2:18, 12:499
- translation 1:404ff, 2:628ff, 636ff, 5:389, 8:505, 9:353, 356, 10:309, 335, 12:578
  - postranscriptional gene silencing 1:412
  - translation interference 1:405
- translational coupler 5:271
- translational regulation 7:510, 8:349
  - poly(A) tail 7:511
  - RNA binding protein 7:511
  - UTR 7:511
- translational repression
  - lin-4:lin-14 12:542
  - 3' UTR 12:542
- translational research 12:106
- translational/rotational entropy 2:6ff
- translesion DNA synthesis (TLS) 3:428, 440ff, 12:114
- translocase 11:288
- translocating binding proteins 1:447
- translocation 5:474, 12:484, 488, 14:446, 662
- translocation channel 11:288
- translocation machinery 12:484
  - binding of 12:508
- translocation motor 11:288, 289
- translocation mRNA
  - concerted movement of 12:504–506
- translocation tRNA
  - concerted movement of 12:504–506
- translocon
  - protein 11:288
  - signal-assembled 11:290
  - signal-gated 11:290
- transmembrane contact (TMC)
  - fusion pore
    - hemifusion diaphragm 11:73
  - transmembrane glycoproteins 12:300
  - transmembrane  $\alpha$ -helix 3:71

- transmembrane protein 8:151, 11:291  
transmembrane regions 11:455  
transmembrane (TM) 12:661  
7-transmembrane (7-TM) GPCR 11:609  
transmissible mink encephalopathy (TME) 10:563  
transmissible spongiform encephalopathies 10:391  
transmission  
  routes of 1:110  
transmission disequilibrium test 1:602  
transmission electron microscopy (TEM) 4:91, 9:25  
transmission methods 4:653ff  
transmission mode 13:682  
transmission of bovine prions to humans  
  compelling evidence of 10:591–592  
transmission spectroscopy 13:680, 681  
transmitochondrial animals 1:222  
transmittance spectrum 13:674  
transplant tissue survival 15:273  
transplantable tissues 15:575  
transplantation 8:453, 456, 15:263  
transport  
  cycle 1:576  
  mechanism 1:576  
transport and adhesion of cells  
  chemotaxis 2:44  
transporter 3:626, 4:341  
transporter associated with antigen processing (TAP) 1:368  
transporters associated with antigen processing 6:436  
transposable elements 3:332, 5:77, 6:143–145, 151, 152, 11:366ff, 367ff, 12:130, 132  
  evolution of 11:462–467  
  satellite sequences 11:367  
  Ty3-gypsy, Tyl-copia, LINES, DNA  
  transposons, and retroviruses 11:366  
  *see also* interspersed repeat  
transposable genetic elements 5:373, 405  
  insertion of 12:116  
transposases 1:254, 6:204ff  
  prd domain resemblance 6:204  
  *see also* DNA transposon  
transposition 1:254, 5:316, 340, 341, 6:141, 13:439, 439ff, *see also* interspersed repeat  
transposons 5:405, 9:59, 262, 11:219, 13:439, 439ff, 14:255ff  
  germinal excision 14:260  
  somatic excision 14:260  
  *Streptomyces* 13:451  
  *see also* interspersed repeat  
trans-splicing 11:242, 248  
trans-splicing ribozymes  
  defective RNA, repair of 10:248–251  
transthyretin 1:46  
transversion 5:373, 399, 12:115  
TRAP: (telomere repeat amplification protocol) 14:217–219  
Trapoxin A 4:269  
trastuzumab (Herceptin) 1:337  
trauma 8:446  
 $\beta$ -TrCP 14:447  
 $\beta$ -Trcp 6:19  
treatment of disease  
  carbohydrate recognition 5:598  
  glycosylation 5:598  
treatments 1:199ff  
tree, genealogical 2:560  
tree, longevity  
  clone of cells 1:84  
  replacement strategy 1:84  
tree, phylogenetic 2:560  
trehalose 8:337  
tremor/ataxia syndrome 4:613  
*Treponema pallidum* 1:361  
TRF family 14:231ff  
TRFH 14:231ff  
triacsin C 14:632ff  
triacylglycerides 8:170  
triacylglycerol (TG) 4:667ff, 10:285, 14:624  
trial by ordeal 8:84  
TRiC 2:497  
TriC 1:35  
tricarboxylic acid pathways (TCA) 5:81  
tricarboxylic acid (TCA) cycle 8:164, *see also* Krebscycle  
  citric acid cycle  
  trichomes 8:484  
trichostatin A (TSA) 10:132  
trichothiodystrophy (TTD) 3:371, 376  
triethylammonium acetate 9:299  
2,2,2-trifluoroethanol 3:65  
trigeminal system  
  submucosal neurons  
  calcitonin gene-related peptide (CGRP)-containing neurons 14:41  
trigger factor 2:502, 12:506  
triggers  
  anaphylatoxins 14:42  
  bacterial or viral superantigens aggregated 14:42  
  C3a 14:42  
  C5a 14:42  
  IgE and antigen 14:42  
  light chains 14:42  
triglyceride  
  hydrolysis 7:200

- triglyceride assay 7:284–285  
 triglyceride metabolism 7:222  
 trilaminar embryo 13:392  
 trisate 14:50  
 trimannosyl core 5:548ff  
 trimetrexate 13:576, 577  
 trinucleotide repeat 4:570ff  
 trinucleotide repeat expansion 15:4ff  
 trinucleotides 9:253  
 triosephosphate isomerase  
   FAs 7:106  
 triple helical DNA 5:191  
 triple helix-forming oligonucleotides 5:191  
 triple-QD ESI 8:9  
 triple resonance NMR experiment 11:160, 164  
 triple resonance spectra 13:526  
 triplet codon 2:453  
 triplet states 4:491  
 triplet-triplet (T–T) energy transfer 7:165  
 triploblasts 15:192  
 TRIPs (Trade-Related Aspects of Intellectual  
   Property Rights) 7:377  
 trisite catalysis 11:337  
 trisomic mice 3:566  
 trisomy 3:562, 563, 566  
 Trisomy 21 (Down syndrome) 15:487  
 TritonX-100 11:197  
 trityl (triphenylmethyl) radicals  
   tumor 4:128  
 Trk 11:582  
 tRNA 2:452, 628, 8:248, 9:320, 325, 12:515,  
   14:580  
   abundance 14:615  
   adaptor molecule 2:453  
   aminoacylation 14:588–590  
   anticodon loop 14:587ff  
   elongation factor Tu•GTP complex 14:590,  
   605  
   movements through the ribosome 12:506  
   nomenclature 14:587  
   structure 14:587ff  
 T3 RNA polymerase mutant 9:401  
 T7 RNA polymerase mutant 9:399  
 T7 RNA polymerase termination  
   T7-Tf terminator 9:401  
 tRNA splicing 12:57  
 tRNA-Phe 12:613, 626–628  
 TrNOE 13:530, 547, 548, 576, 584  
   in screening 13:593  
 trojan gene effect 14:497  
 trophectoderm 10:485  
 trophoblasts 12:152, 161, 164, 167, 170, 195,  
   15:391  
 tropism 15:332, 345  
 tropocollagen 13:225  
 tropomyosin-related tyrosine kinase (Trk)  
   12:646  
 troponin C 2:141  
 TROSY 13:527, 528, 530, 548, 550  
 TRP channels  
   Mg<sup>++</sup> channel 11:694  
   TRPM6 11:694  
   TRPM7 11:694  
 TRP family 11:695  
 TRPV1  
   direct modulation by protons 10:42  
 Trt1 14:230ff  
*Trypanosoma* 4:209, 10:302  
   vaccine 15:160, 164, 174  
 trypanosomatid 13:618  
 trypanosomatidae 11:274, 275  
 trypsin 7:542, 543  
 tryptophan 8:217  
 tryptophan hydroxylase 8:217  
 tryptophan operon 12:34  
 tryptophan oxygenase 8:218  
 Tsix 4:255  
 T-tubules 11:668  
 tuberculosis 8:456  
   *Mycobacterium tuberculosis* 6:307  
 tubulin 2:497, 499, 630, 639, 640, 8:390  
 tubulin-specific chaperone E (TBCE) 8:570  
 tubulogenesis  
   apical membrane biogenesis 3:284, 285  
   blood vessel development 3:286  
   budding 3:286  
   cell culture systems 3:284  
   common pathway of tubulogenesis  
   3:284  
   cord hollowing mechanism 3:286  
   cytoplasmic vesicles 3:284  
   epithelial morphogenesis 3:284  
   general tubulogenesis process 3:286  
   human diseases 3:287  
   mammalian kidney 3:286  
   mechanistic framework for tubulogenesis  
   3:285  
   neural tube formation 3:284  
   respiratory and renal organs 3:284  
   secretion 3:285  
   tracheal system 3:286  
 tufA 2:627  
 Tul1 4:205  
 tularemia  
   attenuated strains 6:309  
   *Francisella tularensis* 6:309  
 tumor 4:338, 11:674, 15:210, 221  
   gene therapy of 13:261

- invasion 7:551  
 vaccine 15:160  
 tumor antigen markers  
   techniques to detect autoantibodies 9:106  
 tumor antigens 1:394, 6:431–432, 9:499, 537  
 tumor cells 1:390  
 tumor chemosensitivity 2:533  
 tumor counterattack 6:439  
 tumor escape mechanisms 6:437–439  
 tumor microenvironment 13:402  
 tumor necrosis factor (TNF) 5:230, 6:390, 436,  
   7:37, 10:227, 622, 11:111, 12:308, 13:263, 317,  
   14:665, *see also* TNF  
 tumor necrosis factor (TNF) receptor 1:345,  
   11:590  
 tumor promoter 9:534, 14:457  
 tumor rejection antigens 1:399  
 tumor shed immunosuppressive molecules  
   6:488  
 tumor stem cells 13:346  
 tumor suppression 12:354  
 tumor suppressor 4:338, 12:348, 14:457  
 tumor suppressor genes 2:196–198, 6:3,  
   9:437, 438, 499, 537–539  
 tumor susceptibility gene 101 (tsg101) 4:204  
 tumor therapy  
   tumor therapy replication-competent  
     adenoviruses 13:253  
 tumor vaccination 13:254  
 tumor-associated antigens (TAA) 3:92, 6:430,  
   431, 499  
   immune response to 6:435–439  
 tumor-derived FasL 6:483  
 tumorigenesis 2:196, 4:240, 338, 9:438, 12:148,  
   153, 154, 162ff, 167, 171, 176, 178, 184ff,  
   187ff, 13:402, 403, 14:219  
   histone modifications 4:261  
   mouse models 4:265  
 tumorigenic 2:223–226, 234, 235  
 tumorigenic lesions 5:642  
 tumor-infiltrating lymphocytes (TIL) 6:467,  
   470, 8:456  
 tumor-specific markers 8:424  
 tumor-specific receptor expression  
   14:153–154  
 Tunguska 10:8  
 tunnel 12:488  
 turbidity 7:307ff  
 turbidometric estimations of bacterial growth  
   1:512  
 $\beta$ -turn 3:62ff  
 Turner syndrome 5:629  
 turnip crinkle virus 9:367  
 turtle (*Chrysemus picta belli*) 7:101  
 twin studies 1:589ff  
 twin-arginine translocation (Tat) 11:291  
 two cell, two gonadotropin 4:391  
 two-cell embryo 10:486  
 two-color cross-correlation FCS 4:486  
 two-dimensional (2D) cultures 14:389  
 two-dimensional difference gel electrophoresis  
   (2D-DIGE) 8:18  
 two-dimensional gel electrophoresis 5:33ff,  
   9:104, 11:312  
   fluorescence detection 5:37  
   gel bonding to glass plates 5:43  
   isoelectric focusing (IEF) 5:35ff  
   NHS-cyanine dyes 5:41  
   prefractionation of samples 5:46  
   second dimension polyacrylamide gel 5:35  
   separation of protein mixtures 5:33  
 two-dimensional polyacrylamide  
   gel-electrophoresis (2D PAGE) separations  
   8:4  
 two-hit hypothesis 4:239, 9:445  
 two-hybrid system 11:120  
 two-phase culture 1:431, 435  
 two-photon absorption 15:64  
 two-photon excitation 4:485  
 two-photon excited 7:169  
 two-photon excited fluorescence 15:64  
 two-photon laser-scanning microscopy (TPLSM)  
   4:485  
 two-photon microscopy (2PM) 15:62ff  
 two-photon molecular excitation 7:167  
 TYK2 15:402, 403  
 type A cells 13:418ff  
 type B cells 13:418ff  
 type C cells 13:418ff  
 type C viral gene 8:523  
 type I diabetes 13:203  
 type I 15:405, 406  
 type I (acid-stable) IFN 15:391  
 type I chain 5:561  
 type I Diabetes 13:354  
 type I IFN 15:399, 410, 411, 413, 414, 418  
 type I IFN receptor 13:130–132  
 type I IFNs 15:397, 404  
 type I IFNs ( $\alpha$ ,  $\beta$ ,  $\kappa$ ,  $\omega$ , or  $\tau$ ) 15:397  
 type I Interferons (IFNs) 10:101  
 type II (acid-labile) IFN 15:391  
 type II chain 5:561  
 type II IFN 15:400, 409–411, 417  
 type II IFN (IFN- $\gamma$ ) 15:403, 404  
 type II IFN receptor 13:132, 15:404  
 type II IFNs 15:405, 406  
 type III IFNs 15:392, 393, 401, 403, 404, 406

- type III protein export apparatus 8:402, 403, 406  
 type IIS 12:327  
 type IV pili 8:307  
 type IV protein secretion 6:229  
 type IV secretion systems 10:437  
 types of decomposition  
   biological 10:56  
   chemical 10:56  
   mechanical 10:56  
 types of mineralization  
   distillation 10:56  
   incrustation 10:56  
   leached 10:56  
   metasomatism 10:56  
   mineral film 10:56  
   permineralization 10:56  
 typhoid fever  
   *Salmonella enterica* 6:308  
 tyrosine 1:619, 8:217, 221  
 tyrosine kinase 8:86, 11:118, 579  
   nonreceptor tyrosine kinases 15:402  
 tyrosine kinase domain 10:202  
 tyrosine kinases 8:106, 439, 11:583  
 tyrosine motif 13:118, 128, 133  
 tyrosine phosphatase SHP-2 6:14  
 tyrosine radicals 4:120  
 tyrosine sulfate 5:555
- u**
- UAR 8:524, 525ff, 531ff  
 UAS (upstream activating sequence) 3:470  
 U2B beamline 13:679, 680  
 UBC12 12:171  
 ubiquinones 9:586–587  
 ubiquitin 1:626, 8:135, 9:535, 11:4, 12:168, 15:90–105  
   deubiquitylated 4:205  
   ubiquitin conjugating (UBC)-like domain 4:204  
   ubiquitin isopeptidase 4:205  
   ubiquitin-interacting motifs (UIMs) 4:191  
   ubiquitylation 4:185  
 ubiquitin interaction motifs (UIMs) 15:21  
 ubiquitin isopeptide hydrolysis 11:12–13  
 ubiquitin mediated proteosomal degradation 6:13  
 ubiquitinated  $\beta$ -catenin 6:19  
 ubiquitination 8:26, 27, 29, 30, 14:444  
 ubiquitin-proteasome pathways 9:535, 10:296  
 ubiquitin-proteasome proteolytic pathway 1:620  
 UCP3 11:699  
 $\alpha_{2u}$  globulin pheromones 11:468–469  
 ulcerative colitis 4:641, 644, 6:21  
 ultrabithorax 13:301, 15:191  
 ultrashort thermal cycling times 14:428  
 ultrasound 1:431  
 ultrastructure 2:356  
   desmocollins 2:357  
   desmogleins 2:357  
 unc-86 6:207ff  
 uncaging 15:80  
 uncoating 4:194, 15:236  
 uncouplers  
   2,4-dinitrophenol 8:182  
 uncoupling proteins (UCPs) 14:637ff  
 unfolded protein response (UPR) 13:465, 475, 483  
 unicellular algae lipids 7:273  
 unicellular organisms 9:257  
 uniform average rate of genomic change 8:524  
 UniGene 3:48  
 unilamellar 14:188  
 uniparental disomy 10:72, 74  
 uniparental inheritance 2:634, 637  
 unipolar depression 1:607  
   heritability 1:608  
 unisite catalysis 11:337  
 United States Army Medical Research Institute for Infectious Diseases (USAMRIID) 10:511  
 unity of biochemistry 1:550  
 unity of cell biology 1:550  
 universal primers 3:33  
 universality of the genetic code 5:343  
 unmasking 7:308ff  
 unnatural amino acids 2:452, 11:47–49, 52–65  
 unnatural nucleobases 2:457  
 unpaired electrons 4:634ff  
 unsaturated fatty acids (bacteria) 7:256  
 upper aerodigestive tract (UADT) 9:504  
 upper-body obesity 14:690  
 upregulation 3:270  
 uptake 10:219  
 URA3 11:61  
 uracil *N*-glycosylase 11:510  
 uracil-DNA-glycosylase (UDG) 3:433ff, 10:130  
 uranyl 10:11, 20  
 urate oxidase 4:646  
 urea 3:69, 8:211, 228  
 urea cycle 8:228, 15:267  
 urease 8:210ff, 211ff, 229  
   *Urechis caupo* 6:88  
 uric acid 4:646  
 uridine 10:14  
 uridine-5'-diphospho- $\alpha$ -D-glucuronic acid 2:61  
 urinary incontinence 10:119  
 urmetazoa 13:275ff

- urocanic acid 3:377  
urocortin (Ucn II) 14:47  
urocortin (Ucn III) 14:47  
urogastrone 5:643  
urological cancers 15:339–340  
US Food and Drug Administration 10:215, 216, 228  
UsnRNPs 1:126, 137  
Ussing 11:686  
5'UTR-site  
  mRNA translation efficiency 15:488  
UV detection 9:304  
UV endonuclease V 3:361  
UV irradiation 8:65  
UV laser photofootprinting 3:546  
UV light 10:5, 14:456  
UV radiation 8:531, 13:227, 352  
UV (ultraviolet) 10:7  
UvrABC exinuclease 3:361
- v**  
Vac1 4:196  
Vaccination 1:398, 472, 5:295, 6:298, 386, 387, 8:606ff, 615, 617  
  DNA 15:113  
  genetic 15:111  
vaccine 1:116, 201, 3:254, 4:365, 6:298, 8:608ff, 10:107, 660ff, 15:137  
  adjuvants 15:158  
  antigens 15:165  
  attenuated 15:158, 168, 170  
  candidates 15:159  
  classical 5:295  
  conjugate vaccines 15:158  
  DNA 8:611  
  DNA vaccines 15:158  
  edible 8:608, 617  
  inactivated 5:295  
  inactivated vaccines 15:158  
  licensing 15:166, 170  
  live attenuated 3:155, 158, 5:295  
  live-recombinant 3:169, 170  
  mucosal 8:606, 608, 611  
  multivalent 8:608  
  nasal 8:615  
  oligopeptide 15:165  
  phase I 15:173  
  phase II 15:173  
  phase III 15:173  
  preclinical development 15:158, 166, 173  
  production facilities 15:169  
  protein subunit 3:165, 169  
  purified whole virus 15:165  
  research project 15:159, 160, 165  
  safety studies 15:168  
  scientific challenges 15:161ff  
  subunits 15:158, 165  
  toxicological testing 15:168  
  toxoid vaccines 15:158  
  varicella 3:157, 158  
  viral safety 15:168  
vaccine approaches 15:144  
vaccine development 15:139, 157ff, 162ff, 163, 165, 167ff  
  capital investments 15:172  
  cost 15:171  
  duration 15:161  
  economic aspects 15:171  
  success rates 15:161, 172ff  
vaccine production in plants 14:571  
  *E. coli* enterotoxin 14:572  
  hepatitis B surface antigen 14:572  
  oral immunization 14:572  
vaccine research and development 15:157ff  
vaccinia virus 1:379, 397, 3:169–171, 5:294, 8:449, 454  
vacuolar H<sup>+</sup>-ATPase 4:200  
vacuolar import and degradation 1:628  
vacuolar inheritance 1:625  
vacuolar protein sorting (vps) 1:624, 4:203, 8:124  
vacuolar proton-pumping ATPase 1:620  
vacuolar-type ATPase (V-ATPase) 11:336  
vacuole 1:428, 620, 4:207  
vagal nerve 8:444  
validation 4:230–232  
VAMP/synaptobrevin 4:313ff  
Vam3/Vam7 4:207  
van der Waals 3:534  
van der Waals force 2:6ff, 4:505  
van der Waals' interactions 2:10, 6:426  
vanadyl ribonucleoside complexes 12:566  
van't Hoff 3:555  
Vargula luciferase 2:528, 532  
variable numbers of tandem repeats (VNTR) 1:315, 318, 609, 3:481, 5:407, 7:609, 611f  
variable region 1:331, 334  
variable surface glycoprotein (VSG) 12:685  
variant Creutzfeldt–Jakob disease (vCJD) 10:586–587  
variation generator 5:340, 342  
variations on the peptoid theme  
  aminoxypeptoids 14:79  
  aza- $\beta^3$ -peptides 14:79  
  hydrazinoazapeptoids 14:78  
   $\beta$ -peptoids 14:78  
  retropeptoids 14:77  
  ureapeptoid 14:77



- varicella vaccine 3:156, 175, 176, 178  
   recombinant 3:173  
 varicella-zoster virus (VZV) 3:155  
 vascular leak syndrome (VLS) 6:518  
 vascular permeability factor (VPF) 13:225  
 vascular plexus 15:203, 205  
 vascular smooth muscle 14:288  
 vascular tone regulators 5:237  
 vascular-endothelial growth factor (VEGF)  
   1:380, 5:649–650, 6:439, 478, 8:550, 13:225,  
   14:191, 15:11, 203  
 vasculature 15:203  
 vasculogenesis 13:224, 402, 14:285ff, 15:203,  
   217  
 vasoactive intestinal peptide 8:444  
 vasodilation 14:48  
 vasopressin 3:302, 10:221, 11:696  
   release of 3:304–306  
   structure of 3:304–306  
   synthesis of 3:304–306  
 vasopressin receptors 3:308–309  
   expression of 3:306–307  
   structure of 3:306–307  
 vasospasm 5:216, 237  
 V-ATPase 11:334  
   catalytic site 11:350–351  
   proton pathway 11:350–351  
   rotational catalysis of 11:350–353  
   subunit rotation during catalysis  
     11:351–353  
 VCAM-1 2:333, 10:124  
 vCJD prions, transmission  
   by blood transfusion 10:587  
 VCP (valosin-containing protein) 11:4  
   conspicuous hole in the middle 11:86  
   double barrel structure 11:86  
 $V_d$  3:629  
 VDAC 8:359  
 V(D)J recombinase 1:296ff  
   transposases 1:296  
 VDR 15:511  
 VE-cadherin 2:360  
   heterophilic binding 2:352  
   homophilic binding 2:351  
 vector 4:357, 358, 359, 361, 362, 363, 364,  
   366–368, 5:294, 6:229, 10:364, 365  
   applications of 14:186–198  
   BAC 5:445, 461  
   clinical status of 14:186–198  
   design of 14:186–198  
   PAC 5:445, 461  
   parental vector 5:443  
   recombinant vector 5:443  
   YAC 5:445  
 vector targeting 15:252, 273  
 Veenhuis 13:614  
 vegetative survival strategies 1:84ff  
   replacement strategy 1:84  
 VEGF-165 6:17  
 VEGF receptor 2 6:17  
 VEGF (vascular endothelial growth factors)  
   6:17, 22, 9:527, 14:289ff, 15:211, 212, 216  
 VEGF-A 15:211  
 VEGF-B 15:211  
 VEGF-C 6:17, 23, 15:209–211  
 VEGF-D 6:23, 15:209, 211  
 VEGF-E 15:211  
 VEGFR 14:292  
 VEGFR1 15:211–213  
 VEGFR2 15:210–213, 219  
 VEGFR3 15:209–211  
 VEGR 6:23  
 veiled cells 1:362  
 veins 15:208, 210, 216  
 Velcade 2:184, 11:4  
 venous 15:207  
 ventricular zone (VZ) 13:412ff  
 venular 15:216  
 Venus flytrap 14:251  
 Verhulst–Pearl equation 7:540  
 vernalization 14:268  
 vertebrates  
   HOX clusters 6:190  
   sexual cycle is obligatory 1:90  
 vertical gene transfer 6:226  
 vertigo 10:119  
 very low-density lipoproteins (VLDL) 5:222,  
   14:626ff  
 vesicle 10:15, 24, 14:5  
 vesicle fusion 8:131  
   attractive force 8:132  
   repulsive force 8:132  
   specificity of fusion 8:125  
   stalk 8:132  
 vesicle scission 8:130  
 vesicle targeting 8:130  
 vesicle tethering 8:132  
 vesicles, clathrin coated 2:501  
 vesicular stomatitis virus 5:300, 6:350, 14:482,  
   15:240  
 vesicular stomatitis virus glycoprotein (VSVG  
   protein) 8:125  
 vesicular stomatitis virus (VSV) infection  
   6:391  
 vesicular transport 4:199, 206, 10:299  
   anterograde 8:122  
   principle steps of 8:123  
   retrograde 8:122

- vessels 15:203
- veterinary bacterial vaccines  
*Bordetella* 6:311  
*Brucellosis* 6:312  
*Leptospirosis* 6:315  
*Mycoplasma* 6:314  
*Pasteurella* 6:311  
 porcine pleuropneumonia 6:313  
 salmonellosis 6:315  
 zoonotic disease 6:310
- viable counts of bacteria 1:514
- vibrational optical activity 3:58ff
- Vibrio cholerae*  
 vaccine 15:174
- Vid vesicle 1:628
- videomicroscope 3:27
- Vienna RNA Package 12:591
- Vif 15:140
- vimentin 14:643
- vinblastine 10:660, 14:337
- vinca alkaloids 12:366
- Vincent 8:519
- vincristine 10:660
- vinculin 2:337ff
- 17 $\beta$ -vinylprogesterone 13:52
- viral and bacterial vectors 15:146
- viral antigen 12:315
- viral att sequence 12:408
- viral egress  
 ribonucleoprotein transport 15:457  
 vesicular trafficking 15:459  
 virion assembly 15:459
- viral envelope 15:145
- viral epitopes 15:140
- viral escape 1:115–116
- viral fusion inhibitors 6:170
- viral fusion proteins  
 class I and class II fusion proteins 11:71  
 class I and class II proteins 11:75  
 docking and fusion 11:80  
 efficient fusogens 11:76  
 SNAREs 11:94
- viral gene expression  
 DNA virus, transcription 15:448  
 nuclear export of viral RNA 15:452  
 nuclear export shut-off 15:454  
 RNA viruses 15:450  
 transcription 15:450  
 transcription shut-off 15:452  
 translation initiation 15:455  
 translation shut-off 15:456  
 translational regulation by cellular factors 15:455
- viral gene transfer systems  
 deficits of 15:498
- viral genome 3:160  
 CMV 3:161  
 VZV 3:161
- viral glycoprotein 3:155, 160, 162–164, 166, 168, 174
- viral hepatitis  
 hepatitis-B and -C virus infections 15:413
- viral identity 3:497
- viral infection 3:532
- viral LTR promoter 15:269
- viral oncogenes 9:448–449
- viral oncoproteins 12:357
- viral pathogenesis  
 anti-apoptotic viral genes 15:467  
 cytokine and cytokine receptor homologs 15:468  
 downregulation of CD4 15:469  
 inhibitors of MHC/HLA molecules 15:469  
 oncogenicity 15:465  
 proapoptotic viral genes 15:468  
 viral oncoproteins 15:465  
 viral proteins contributing to cell death 15:467  
 viral proteins that affect host immunity 15:468  
 viral-induced neurotoxicity 15:470
- viral protein 15:145
- viral proteinases  
 2A 5:100  
 2A proteinase 5:102  
 3C proteinase 5:102  
 host 5:103  
 host shut-off 5:100, 102  
 L proteinase 5:100, 102  
 shutoff 5:103
- viral receptors  
 angiotensin converting enzyme 2 15:433  
 CCR5 15:433  
 CD4 15:431  
 CD8 15:433  
 CXCR4 15:433
- viral shuttles 14:540–542
- viral transfection  
 yielding high protein 10:399–401
- viral vectors 3:223–224, 14:198, 15:236  
 AAV (adeno-associated viral) vectors 13:259  
 adenoviral vectors 13:258  
 lentiviral vectors 13:258  
 poxvirus vectors 13:259  
 retroviral vectors 13:257–258
- viral-Cbl (v-Cbl) 4:213
- Virchow Rudolph 13:331, 347

- virilizing actions 13:43
- virion associated proteins 1:108
- virosomes 8:610
  - viral proteins or fusiogenic peptides 15:494
- virtual cell 3:651, 6:595
- virtual library 3:614
- virulence 1:319, 320, 322, 554ff, 555, 558–561, 571, 3:542, 9:252
  - infectious dose 1:557
- virulence, evolution of
  - bacteriophages 1:558, 559
  - evolution 1:559
  - mutations 1:559
  - pathogenicity islands 1:558
  - plasmid 1:558, 565
  - plasmids 1:559
  - suppressors 1:558
- virulence factors 1:559, 561, 571
  - adhesins 1:563, 565
  - capsule 1:556, 564, 566, 567
  - cytotoxins 1:558
  - exotoxins 1:556
  - lipopolysaccharides 1:556, 566
  - motility 1:556
  - nonpilus adhesins 1:556
  - pili 1:556, 560, 563–567
  - polysaccharide-based 1:566
  - proteases 1:556, 557, 558
  - survival 1:556
  - toxins 1:555, 557, 560, 563, 565, 569
- virulence, regulation of 1:558f
  - environmental 1:558, 559
  - other regulatory factor 1:561
  - promoter elements 1:560
  - quorum sensing 1:561
  - sigma factors 1:560
  - two-component systems 1:560, 561
- virus 3:229, 4:357, 363, 365, 370, 8:434, 10:361, 364, 365
  - arenaviruses 5:597
  - H. pylori*s 5:598
  - Lassa fever virus (LFV) 5:597
  - Lewis<sup>b</sup> (Le<sup>b</sup>) blood group antigen 5:598
  - lymphocytic choriomeningitis virus (LCMV) 5:597
  - Mobala 5:597
  - movement 10:362
  - Mycobacterium leprae* 5:597
  - Oliveros 5:597
  - polyhedrosis 4:369
  - replication 10:362
  - transmission 10:362
  - vaccinia 4:369
- virus capsid 9:364
- Virus entry 15:430
  - DC-SIGN 15:431
  - heparan sulfate proteoglycans 15:431
- virus fusion 15:433
- virus genome 9:364
- virus infections 15:390
- virus particles 4:91, 107
- virus replication, early events
  - APOBECs 15:444
  - decapsulation 15:442
  - integration 15:447
  - intracellular replication and trafficking 15:445
  - nuclear import 15:446
  - trafficking to the nucleus 15:446
  - TRIMs 15:442
  - uncoating 15:442
- virus resistance 14:554
  - ribosome-inactivating proteins 14:564
  - satellite RNA 14:563
  - viral coat proteins 14:563
  - viral replicase 14:563
- virus subunit 15:145
- virus-mediated gene transfer 15:236
- virus-mediated transduction 5:343
- visceral 14:635ff, 690
- visceral obesity 7:35
- visible 10:7
- vision 11:683
- visual cycle 12:387
- vitamer 15:506, 516
- vitamin 9:572, 15:505–532
- vitamin A 15:510–511, 537
  - absorption of 15:508–509
  - transport of 15:508–509
- vitamin B<sub>12</sub> 8:213ff, 226, 227, 15:549
- vitamin B<sub>6</sub> 15:530, 532, 546
  - nuclear pyridoxal phosphate binding 15:531
- vitamin C 2:592, 4:641, 5:495, 14:569, 15:551
- vitamin content 14:569
  - provitamin A 14:568
- vitamin D 15:539
  - receptors 15:511–512
  - responsive genes 15:512
  - target cells 15:512–513
- vitamin E 11:111, 15:513–515, 541
- vitamin K 15:541
- vitamin metabolism 13:233
- vitamins 9:572, 15:506, 507
- vitelline envelope 14:13
- vitronectin 8:47, 55, 57
- viviparity 10:550
- VLDL 5:216, 7:198, 210, 213, 226, 229, 231, 232
  - assembly 7:204

- catabolism 7:205  
 remnants 5:228, 7:205, 208  
 VLDL receptor 7:205, 206  
   as targets for gene therapy 5:225  
 VNTR analysis 7:611–612  
 VNTR, *see* variable number of tandem repeat  
 volcanic eruptions 10:7  
 Volsurf 3:606  
 Volta experiment 8:239  
 voltage clamp 11:647  
 voltage dependence 8:359, 365ff, 370, 372, 374,  
   376  
 voltage sensor 11:651  
 voltage-dependent anion channel (VDAC)  
   8:361ff, 362, 375  
 voltage-gated channels 8:86, 364, 378, 11:649,  
   651  
 voltage-sensitive dyes 15:76  
 volume of distribution 3:629, 10:218  
 volumetric total production 1:428  
 Volvox 2:620  
 vomeronasal organ (VNO) 12:640, 656  
 vomeronasal receptors 11:467  
 von Neumann systems 11:175  
 von Willebrandt factor  
   force spectroscopy on 9:277–278  
 Vosges–Proskauer test 1:518  
 Vpr 15:140  
 Vps22 4:205  
 Vps23 4:203  
 Vps25 4:205  
 Vps27 4:205  
 Vps28 4:203  
 Vps36 4:205  
 Vps37 4:203  
 VPS34 gene 10:293  
 Vps1p 13:615, 622  
 Vps34p 4:196ff  
 Vps2/Vps24 4:205  
 Vpu 15:140  
 Vsr 12:329
- w**
- Walker A motif  
   ATP binding 11:531  
   Lys72 11:531  
   P-loop 11:531  
   sequence of 11:531  
 Walker B motif  
   ATP-mediated DNA binding 11:531  
   sequence of 11:531  
 wall shear stress 14:301  
 warfarin 2:601, 14:362–363  
 water 10:4, 6, 18  
 water channel proteins  
   requirements for 3:309  
 water channels 11:696  
 water selectivity  
   structural features responsible for 3:309  
 water-mediated contact 12:332  
 water-soluble cases 15:542  
 Watson–Crick 1:404  
 Watson–Crick base-pair geometry 12:492  
 wavelet analysis 9:254  
 wavelets 9:261  
 ways of studying IFN “physiology” 15:411  
 weak-field approximation 4:9  
 weakness 11:672–674  
 WECARE (Women’s Environment, Cancer and  
   Radiation Epidemiology) 9:101  
 Wee1 12:165ff  
 weight 11:393  
 weight training 13:32  
 weighting factors 11:393  
 well-defined structures 12:591  
 Werner syndrome 1:75, 9:393  
   aging 1:73  
   cancer 1:73  
   homologous recombinational repair (HRR)  
     1:73  
 w/ESR  
   electronic structures 4:123  
   ENDOR 4:119  
   ESEEM 4:119  
 West syndrome (WS) 15:49  
 Western blot 2:529, 6:371  
 Western Sandpipers 7:97  
 WG (whole-genome) 13:73  
 WGS approach 11:370ff  
   scaffolds 11:370  
   working draft 11:370  
 WGS (whole-genome shotgun) 2:544, 11:435,  
   437  
 WG-SGS approach  
   microbial genome, *H. influenzae* 13:77  
 WG-SGS method  
   *Drosophila* genome 13:77  
   insect genomes 13:77  
   mouse genome 13:78  
   rat genome 13:78  
 WG-SGS (whole-genome SGS) 13:75  
   contigs 13:92  
   genome survey sequence 13:81  
   ordered within scaffolds 13:92  
   targeted genome sequences 13:81  
   working draft 13:81  
 WG/WNT signaling  
   DSH 4:284

WG/WNT signaling (*continued*)

FZ 4:284  
 TCF 4:284  
 wheat germ extracts 2:454  
 whiskey lactone 2:597  
 white rot fungi  
   lignin peroxidases 5:18  
   *Phanerochaete chrysosporium* 5:18  
   xenobiotics 5:18  
 white smokers 10:9  
 whole genome amplification 3:501  
 whole organism level 14:170  
 whole-cell bioreactors 2:40ff  
 whole-cell vaccine 6:298  
 whole-field detection 15:62  
 whole-genome shotgun 7:476  
 whole-genome shotgun sequencing 2:573ff  
 whooping cough 6:309  
 whooping cough *bordetella pertussis* 6:309  
   filamentous hemagglutinin 6:310  
   pertactin 6:310  
   pertussis toxoid 6:310  
 wide-field imaging 15:62  
 wild-type 9:311  
 wild-type mice 1:598  
 wild-type PrP transgenes  
   overexpression of 10:569–570  
 Wilms 13:348  
 Wilms' tumor gene 4:264  
 Wilson 8:520ff, 537ff  
 Wilson, Allan 8:519, 531ff  
 WIPK (wound induced protein kinase) 10:349  
 wiring 2:88  
 WNT gene family 9:455  
 Wnt pathway 13:294  
 Wnt (Wingless) 12:181  
 Wnt/ $\beta$ -catenin 2:228, 13:334  
 Wnt- $\beta$ -catenin pathway 2:230, 7:330  
 Wnt/ $\beta$ -catenin signaling 2:229  
 Wolffian ducts 5:609  
 Wolpert Lewis 8:532  
 Working Cell Banks 15:166  
 working seeds 15:166  
 working stroke 8:576, 584, 590  
 World Health Organization-directed worldwide  
   Malaria Eradication Campaign 7:472  
 worldview 5:349  
 worms 3:412, 4:330  
 Woronin body 13:616  
 wortmannin 1:625  
 wound bed preparation 13:245  
 wound healing 13:219, 239–245  
 wrapping 7:305ff  
 WRKY 14:266

## WRN

homologous recombinational repair (HRR)  
 1:75  
 WUSCHEL 14:265, 266

## x

X chromosome 5:377, 13:19  
 X chromosome inactivation 13:395  
 X gene 7:327  
*X. tropicalis* 10:547  
 xanthine oxidase 4:638, 8:227, 228  
 xanthomas 7:208  
*Xanthomonas* 10:366, 369, 380  
 xanthophyll cycle 2:637  
 X-chromosome-linked IAP (XIAP) 10:129  
 xenoantigens 2:280  
 xenobiotics 2:52, 4:229, 230, 5:493  
   carcinogenicity 2:68  
   susceptibility 4:226  
   toxicity 2:68  
 xenograft 15:339  
*Xenopus* 10:547, 550  
 xenotransplantation 1:230, 9:205, 208, 237  
 xeroderma pigmentosum (XP) 3:352, 371, 440  
   nucleotide excision repair (NER) 1:70  
 XIAP 10:622, 629  
 Xist 4:255  
 X-linked adrenoleukodystrophy 13:628  
 X-linked defect 4:407  
 X-linked lymphoproliferative syndrome (XLP)  
 6:398  
 X-linked mental retardation (XLMR) 15:49ff  
 X-linked nephrogenic diabetes 3:315  
 XPD aging 1:70  
 X-ray 11:63  
 X-ray crystallography 1:670, 2:290, 12:353, 13:531, 548, 567, 583  
 X-ray data collection  
   flash-freezing techniques 11:278  
   microcrystals 11:278  
   microfocus beamlines 11:278  
   radiation damage 11:278  
   robotic sample changers 11:278  
   tabletop X-ray source 11:278  
   third-generation synchrotrons 11:278  
 X-ray diffraction 1:577, 579, 580, 10:199  
 X-ray diffraction experiment 7:406  
 X-ray elemental microanalysis by EM 4:67  
 X-ray sources  
   rotating anode 7:403  
   sealed X-ray tubes 7:403  
   synchrotron radiation  
     beamlines 7:404

bending magnets 7:404  
 insertion devices 7:404  
 XX male syndrome 5:612  
 XX males  
   human in 5:626  
   in dog 5:628  
   in goat 5:627–628  
   mouse in 5:627  
 XX sex reversal 5:626  
 XX true hermaphrodites  
   in human 5:628  
 XX true hermaphroditism 5:612  
 XY females  
   in human 5:629–630  
   in mouse 5:630, 631–632  
 XY gonadal dysgenesis 5:621  
 XY sex reversal 5:629  
   in mouse 5:630  
 X-Y translocation 5:612  
 XY true hermaphrodites  
   in human 5:632  
 XYd sex reversal  
   in mouse 5:630–631  
 xylem 1:417  
 xylose 2:249

**Y**

Y chromosome 5:377  
 Yaa 1:476  
 YABBY 10:542  
 YAC transgenics 4:619  
 YAC (yeast artificial chromosome) 2:536, 540,  
   5:141ff, 15:565  
 Yaka 8:324  
 YAMMP 12:618  
*Yarrowia lipolytica* 13:615, 617, 623, 626  
 yeast 1:88, 3:429, 4:332, 364, 365, 366, 367,  
   5:503, 557, 6:141, 145, 150, 151, 7:263, 8:361,  
   364, 368f, 372, 375, 11:124, 12:718  
   genomic integration 11:274  
   posttranslational modifications 11:274  
   promoter system 11:274  
   recombinant proteins 11:274  
 yeast artificial chromosome (YAC) 3:387ff,  
   15:558, 559  
 yeast display 3:84, 11:106  
   fluorescently labeled target 8:415  
 yeast genetics 8:124  
 yeast mutants 10:300  
 yeast prion domains 10:593  
 yeast two-hybrid assay 4:602  
 yeast two-hybrid systems 11:319–321  
 yeast two-hybrid (Y2H) 6:602, 8:30, 34, 11:312  
 yeasts fatty acids 7:263

*Yersinia enterocolitica* 8:454  
*Yersinia pestis* 6:306, 13:639  
*Yersinia pseudotuberculosis* 13:639  
 yew 1:415ff  
 YidC 11:294  
 yield 4:371  
 $\gamma$ -intercept 11:517  
 yKu70 14:236  
 yKu80 14:236  
 YOTB 4:196  
 Ypt7 4:207  
 Yule distribution  
   oligonucleotide frequencies of 10:456–457

**z**

zanoterone 13:46  
 ZASC1 6:6  
*Zea mays* 10:550  
 zebrafish (*Danio rerio*) 4:331, 12:432, 437,  
   446ff  
 zebrafish development 15:596ff  
   external development 15:597ff  
   generation time 15:597  
   numbers of offspring 15:598  
   speed of development 15:596  
   transparency 15:597ff  
 Zeitgeber 12:417, 421, 445  
 Zeitnehmer 12:417, 453, 459  
 Zellweger's syndrome 11:299  
 zero-current membrane potential 8:369  
 zeta potential 15:493  
 ZF 6:210  
 ZGA 10:487  
 ZIC2 15:48ff  
 Ziehl–Neilsen stain 1:511  
 Zimm plot 2:260  
 zinc 8:211ff, 221, 222, 224–226, 229, 230  
 zinc enzymes 8:215ff  
 zinc finger 4:387, 8:344, 425, 13:20  
 zinc finger 9 protein (ZNF9) 15:41  
 zinc-binding domains 6:210ff  
 Zipf distribution 10:456  
 zona limitans intertelencephalica 2:106  
 zona limitans interthalamica (ZLI) 2:104  
 zona pellucida 5:556, 13:384, 14:524  
 zona pellucida proteins 4:385ff  
   ZP1 4:405  
   ZP2 4:405  
   ZP3 4:405  
 zonula occluding proteins 2:366  
 Zoolblots 3:39  
 ZOO-FISH 7:347  
 Zuckerkandl, Emile 8:519  
 zygosity 1:590

zygotes 1:215, 225, 2:622ff

zygotic clock 10:484, 488

zygotic gene activation 10:484

zygotic gene expression 10:484

zygotic genes 3:272, 274, 10:485

zygotic nucleus 10:485

## Glossary of Basic Terms

The most basic terms in molecular cell biology are defined below. These, in combination with the key words listed at the head of each article, provide definitions of all essential terms in this Encyclopedia.

### Alleles

Alternative forms of a given gene, inherited separately from each parent, differing in nucleotide base sequence and located in a specific position on each homologous chromosome, affecting the functioning of a single product (RNA and/or protein).

### Amino Acid

An organic compound containing at least one amino group and one carboxyl group. In the 20 different amino acids that compose proteins, an amino group and carboxyl group are linked to a central carbon atom, the  $\alpha$ -carbon, to which a variable side chain is bound (see pages at the back of each volume).

### Amplification

The process of replication of specific DNA sequences in disproportionately greater amounts than are present in the parent genetic material, for example, PCR is an *in vitro* amplification technique.

### Apoptosis

Regulated process leading to nonpathological animal cell death via a series of

well-defined morphological changes; also called *programmed cell death*.

### Bacteriophage (phage)

Any virus (containing DNA or RNA) that infects bacterial cells. Some bacteriophages are widely used as cloning vectors.

### Base Pair

Association of two complementary nucleotides in a DNA or RNA molecule stabilized by hydrogen bonding between their base components. Adenine pairs with thymine or uracil (A–T; A–U) and guanine pairs with cytosine (G–C) (see pages at the back of each volume).

### Bioinformatics

Computational approaches to answer biological questions and enhance the ability of researchers to manipulate, collect, and analyze data more quickly and in new ways. Experts predict that more biologists will do their work *in silico*, using the computer to synthesize, analyze, and interpret the many terabytes of data now being generated.



**cDNA (complementary DNA)**

A DNA copy of an RNA molecule synthesized from an mRNA template *in vitro* using an enzyme called *reverse transcriptase*; often used as a probe.

**Cell Cycle**

Ordered sequence of events in which a cell duplicates its chromosomes and divides itself into two. Most eukaryotic cell cycles can be commonly divided into four phases: G<sub>1</sub> (G1) period after mitosis but before DNA synthesis occurs; S-phase when most DNA replication occurs; G<sub>2</sub> (G2) phase period of cell cycle when cells contain twice the G1 complement of DNA; and M-phase when cell division occurs, yielding two daughter cells (mitosis) each with one complete genome.

**Cell Differentiation**

Progressive restriction of the developmental potential and increasing specialization of function that takes place during the development of the embryo and leads to the formation of specialized cells, tissues, and organs.

**Cell Division**

Separation of a cell into two daughter cells. In higher eukaryotes, it involves division of the nucleus (mitosis) and of the cytoplasm (cytokinesis); mitosis often is used to refer to both nuclear and cytoplasmic division.

**Cell Line**

A defined unique population of cells obtained by culture from a primary implant through numerous generations.

**Chromatin**

The complex of nucleic acids (DNA and RNA) and proteins (histones) comprising eukaryotic chromosomes.

**Chromosome**

In prokaryotes, the usually circular duplex DNA molecule constituting the genome; in eukaryotes, a threadlike structure consisting of chromatin and carrying genomic information on a DNA double helix molecule. A viral chromosome may be composed of DNA or RNA.

**Cloning**

Asexual reproduction of cells, organisms, genes, or segments of DNA identical to the original.

**Cloning Vector *see* Vector****Codon**

Sequence of three nucleotides in DNA or mRNA that specifies a particular amino acid during protein synthesis; also called *triplet*. Of the 64 possible codons, three are stop codons, which do not specify amino acids (see pages at the back of each volume).

**Complementary Base Pairing**

Nucleic acid sequences on paired polymers with opposing hydrogen-bonded bases adenine (designated A) bonded to thymine (T), guanine (G) to cytosine (C) in DNA and adenine to uracil (U) replacing adenine to thymine in RNA (see pages at the back of each volume).

**Complementary DNA *see* cDNA****Dalton**

Unit of molecular mass approximately equal to the mass of a hydrogen atom ( $1.66 \times 10^{-24}$  g).

**Deoxyribonucleic Acid** *see* DNA**Diploid**

The number of chromosomes in most cells except the gametes. In humans, the diploid number is 46.

**DNA (Deoxyribonucleic Acid)**

The molecular basis of the genetic code consisting of a poly-sugar phosphate backbone from which thymine, adenine, guanine, and cytosine bases project. Usually found as two complementary chains (duplex) forming a double helix associated by hydrogen bonds between complementary bases.

**DNA Cloning (Gene Cloning)**

Recombinant DNA technique in which specific cDNAs or fragments of genomic DNA are inserted into a cloning vector, which then is incorporated into cultured host cells (e.g., *E. coli* cells) and maintained during growth of the host cells.

**DNA Library**

Collection of cloned DNA molecules consisting of fragments of the entire genome (genomic library) or of DNA copies of all the mRNAs produced by a cell type (cDNA library) inserted into a suitable cloning vector.

**DNA Polymerase**

Enzymes that catalyze the replication of DNA from the deoxyribonucleotide triphosphates using single- or double-stranded DNA as a template.

**DNA Transcription** *see* Transcription***E. coli* (*Escherichia coli*)**

A colon bacillus, which is the most studied of all forms of life.

**Embryonic Stem Cells (ES)**

Cultured cells derived from the pluripotent inner cell mass of blastocyst-stage embryos.

**Epigenetics**

Mechanisms of storing and transmitting cellular information additional to those based on DNA sequences.

***Escherichia coli*** *see* *E. coli***Eukaryotes**

Organisms whose cells have their genetic material packed in a membrane-surrounded, structurally discrete nucleus and with well-developed cell organelles. Eukaryotes include all organisms except *archaebacteria* and *eubacteria*.

**Expression**

The process of making the product of a gene, which is either a specific protein giving rise to a specific trait or RNA forms not translated into proteins (e.g. transfer ribosomal RNAs).

**Functional Genomics**

A discipline that aims to understand how genes are regulated and what they do, largely through massive parallel studies of gene expression over time and in a variety of tissues.

**Gamete**

Specialized haploid cell (in animals either a sperm or an egg) produced by meiosis of germ cells; in sexual reproduction, the union of a sperm and an egg initiates the development of a new diploid individual.

**Gene Cloning** *see* DNA Cloning**Gene**

A DNA sequence, located in a particular position on a particular chromosome,

which encodes a specific protein or RNA molecule.

### **Genomics**

Comparative analysis of the complete genomic sequences from different organisms; used to assess evolutionary relations between species and to predict the number and general types of proteins produced by an organism.

### **Genotype**

Entire genetic constitution of an individual cell or organism; also, the alleles at one or more specific loci.

### **Haploid**

The number of chromosomes in a sperm or egg cell, half the diploid number.

### **Heterozygous**

Having two different alleles for a given trait in the homologous chromosomes.

### **Homologies**

Similarities in DNA or protein sequences between individuals of the same species or among different species.

### **Homologous Chromosomes**

Chromosome pairs, each derived from one parent, containing the same linear sequence of genes, and as a consequence, each gene is present in duplicate (e.g., humans have 23 homologous chromosome pairs, but the toad has 11 pairs, the mosquito has three pairs, and so on).

### **Homozygous**

Having two identical alleles for a given trait in the homologous chromosomes.

### **Hybridization**

The formation of a double-stranded polynucleotide molecule when two complementary strands are brought together

at moderate temperature. The strands can be DNA or RNA or one of each; a technique for assessing the extent of sequence homology between single strands of nucleic acids.

### **Ligation**

The formation of a phosphodiester bond to join adjacent terminal nucleotides (nicks) to form a longer nucleic acid chain (DNA or RNA); catalyzed by ligase.

### **Marker**

A gene or a restriction enzyme cutting site with a known location on a chromosome and a clear-cut phenotype (expression), or pattern of inheritance, used as a point of reference when mapping a new mutant.

### **Meiosis**

In eukaryotes, a special type of cell division that occurs during maturation of germ cells; comprises two successive nuclear and cellular divisions, with only one round of DNA replication resulting in production of four genetically nonequivalent haploid cells (gametes) from an initial diploid cell.

### **Messenger RNA *see* mRNA**

### **Mitosis**

In eukaryotic cells, the process whereby the nucleus is divided, involving condensation of the DNA into visible chromosomes, to produce two genetically equivalent daughter nuclei with the diploid number of chromosomes.

### **mRNA (messenger RNA)**

RNA used to translate information from DNA to ribosome where the information is used to make one or several proteins.

**Mutation**

The heritable change in the nucleotide sequence of a chromosome.

**Nucleotide**

The monomer which, when polymerized, forms DNA or RNA. It is composed of a nitrogenous base bonded to a sugar (ribose or deoxyribose), bonded to a phosphate.

**Oligonucleotide**

A polynucleotide 2 to 20 nucleotide units in length.

**Operon**

A series of prokaryote genes encoding enzymes of a specific biosynthesis pathway and transcribed into a single RNA molecule.

**Organelle**

Any membrane-limited structure found in the cytoplasm of eukaryotic cells.

**Phage *see* Bacteriophage****Phenotype**

The observable characteristics of a cell or organism as distinct from its genotype.

**Plasmid**

An extrachromosomal circular DNA molecule found in a variety of bacteria encoding “dispensable functions,” such as resistance to antibiotics. Often found in multiple copies per cell and reproduces every time the bacterial cell reproduces. May be used as a cloning vector.

**Polymorphism**

Difference in DNA sequence among individuals expressed as different forms of a protein in individuals of the same interbreeding population.

**Polynucleotide**

The polymer formed by condensation of nucleotides.

**Probe**

A radioactively fluorescent or immunologically labeled oligonucleotide (RNA or DNA) used to detect complementary sequences in a hybridization experiment, for example, identify bacterial colonies that contain cloned genes or detect specific nucleic acids following separation by gel electrophoresis.

**Prokaryotes (Prokaryotes)**

Typically unicellular or filamentous with DNA not located within a nuclear envelope. Prokaryotes include archaeobacteria, eubacteria, cyanobacteria, prochlorophytes and mycoplasmas.

**Programmed Cell Death *see* Apoptosis****Prokaryotes *see* Prokaryotes****Protein**

A linear polymer of amino acids linked together in a specific sequence and usually containing more than 50 residues. Proteins form the key structure elements in cells and participate in nearly all cellular activities.

**Proteomics**

A discipline that promises to determine the identity, function, and structure of each protein in an organelle or cell and to elucidate protein–protein interactions.

**Replication**

The copying of a DNA molecule duplex yielding two new DNA duplex molecules, each with one strand from the original DNA duplex. Single-stranded DNA

replication results in a single-stranded DNA molecule.

### **Repressor**

A protein that binds to a specific location (operator) on DNA and prevents RNA transcription from a specific gene or operon.

### **Restriction Fragment Length Polymorphism *see* RFLP**

### **Restriction Mapping**

Uses restriction endonuclease enzymes to produce specific cuts (cleavage) in DNA, allowing preparation of a genome map describing the order and distance between cleavage sites.

### **Reverse Transcription**

The synthesis of cDNA from an RNA template as catalyzed by reverse transcriptase.

### **RFLP (Restriction Fragment Length Polymorphism)**

DNA fragment cut by enzymes specific to a base sequence (restriction endonuclease) generating a DNA fragment whose size varies from one individual to another. Used as markers on genome maps and for screening for mutations and genetic diseases.

### **Ribonucleic Acid *see* RNA**

### **Ribosomes**

Small cellular components composed of proteins plus ribosomal RNA that translate the genetic code into synthesis of specific proteins.

### **RNA (Ribonucleic Acid)**

A single-stranded polynucleotide with a phosphate oxyribose backbone and four bases that are identical to those in DNA,

with the exception that the base uracil is substituted for thymine.

### **RNA Interference (RNAi)**

Intracellular degradation of RNA that removes foreign RNAs such as those from viruses. These fragments (small, micro, or mini RNA) cleaved from free double-stranded RNA (dsRNA) direct the degradative mechanism to other similar RNA sequences. Used as a technique to silence the expression of targeted genes in a sequence-dependent mode.

### **RNA Polymerase**

The enzyme (peptide) that binds at specific nucleotide sequences, called promoters, in front of genes in DNA, which catalyze transcription of DNA to RNA.

### **RNA Translation *see* Translation**

### **Stem Cell**

A self-renewing cell that divides to give rise to a cell with an identical developmental potential and/or one with a more restricted developmental potential.

### **Structural Biology**

The discovery, analysis and dissemination of three-dimensional structures of protein, DNA, RNA, and other biological macromolecules representing the entire range of structural diversity found in nature.

### **Transcription (DNA transcription)**

Synthesis of an RNA molecule from a DNA template (gene) catalyzed by RNA polymerase.

### **Transfer RNA *see* tRNA**

### **Translation (RNA translation)**

The process on a ribosome by which the sequence of nucleotides in a mRNA

molecule directs the incorporation of amino acids into protein.

**tRNA (transfer RNA)**

RNA molecules that transport specific amino acids to ribosomes into position in the correct order during protein synthesis.

**Vector**

A DNA molecule originating from a virus, a plasmid, or a cell of a higher organism into which another DNA fragment can be integrated without loss of the vector's capacity for self-replication. Vectors introduce foreign DNA into host cells where it can be reproduced in large quantities.

**Virus**

A small parasite consisting of nucleic acid (RNA or DNA) enclosed in a protein coat that can replicate only in a susceptible host cell; widely used in cell biology research.

**Wild type**

Normal, nonmutant form of a macromolecule, cell or organism.

**Zygote**

A fertilized egg; a diploid cell resulting from fusion of a male and female gamete.




## The Twenty Amino Acids that are Combined to Form Proteins in Living Things

### Amino acids with nonpolar side chains


Glycine

Gly  
G




Alanine

Ala  
A




Valine

Val  
V




Leucine

Leu  
L




Isoleucine

Ile  
I




Methionine

Met  
M





Proline

Pro  
P












*Amino acids with nonpolar side chains (continued)*



*Amino acids with uncharged polar side chains*



*Amino acids with charged polar side chains*




## Amino acids with charged polar side chains (continued)

Arginine

Arg


R



Histidine

His


H



Aspartic acid

Asp


D



Glutamic acid

Glu

E



(Figures with kind permission from Voet, D., Voet, J.G., Pratt, C.W. (2001) *Fundamentals of Biochemistry*, Wiley, New York)




## The Twenty Amino Acids with Abbreviations and Messenger RNA Code Designations

<i>Amino acid</i>	<i>One letter symbol</i>	<i>Three letter symbol</i>	<i>mRNA code designation</i>
alanine	A	ala	GCU, GCC, GCA, GCG
arginine	R	arg	CGU, CGC, CGA, CCG, AGA, AGG
asparagine	P	asn	AAU, AAC
aspartic acid	D	asp	GAU, GAC
cysteine	C	cys	UGU, UGC
glutamic acid	E	glu	GAA, GAG
glutamine	Q	gln	CAA, CAG
glycine	G	gly	GGU, GGC, GGA, GGG
histidine	H	his	CAU, CAC
isoleucine	I	ile	AUU, AUC, AUA
leucine	L	leu	UUA, UUG, CUU, CUC, CUA, CUG
lysine	K	lys	AAA, AAG
methionine	M	met	AUG
phenylalanine	F	phe	UUU, UUC
proline	P	pro	CCU, CCC, CCA, CCG
serine	S	ser	UCU, UCC, UCA, UCG, AGU, AGC
threonine	T	thr	ACU, ACC, ACA, ACG
tryptophan	W	trp	UGG
tyrosine	Y	tyr	UAU, UAC
valine	V	val	GUU, GUC, GUA, GUG



## Complementary Strands of DNA with Base Pairing



Two nucleotide chains associate by base pairing to form double-stranded DNA. A (Adenine) pairs with T (Thymine), and G (Guanine) pairs with C (Cytosine) by forming specific hydrogen bonds. (Figure with kind permission from Voet, D., Voet, J.G., Pratt, C.W. [2001]: *Fundamentals of Biochemistry*. Wiley: New York.)